PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Zareba, W; Moss, AJ; Schwartz, PJ; Vincent, GM; Robinson, JL; Priori, SG; Benhorin, J; Locati, EH; Towbin, JA; Keating, MT; Lehmann, MH; Hall, WJ				Zareba, W; Moss, AJ; Schwartz, PJ; Vincent, GM; Robinson, JL; Priori, SG; Benhorin, J; Locati, EH; Towbin, JA; Keating, MT; Lehmann, MH; Hall, WJ		Int Long-QT Syndrome Registry Res Grp	Influence of the genotype on the clinical course of the long-QT syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIAC POTASSIUM CURRENT; HEART-RATE; MUTATIONS; GENE; ARRHYTHMIAS; INTERVAL; PATTERNS; FAMILIES; MODELS; SCN5A	Background The congenital long-QT syndrome, caused by mutations in cardiac potassium-channel genes (KVLQT1 at the LOT1 locus and HERG at the LQT2 locus) and the sodium-channel gene (SCN5A at the LQT3 locus), has distinct repolarization patterns on electrocardiography, but it is not known whether the genotype influences the clinical course of the disease. Methods We determined the genotypes of 541 of 1378 members of 38 families enrolled in the International Long-QT Syndrome Registry: 112 had mutations at the LOT1 locus, 72 had mutations at the LQT2 locus, and 62 had mutations at the LQT3 locus. We determined the cumulative probability and lethality of cardiac events (syncope, aborted cardiac arrest, or sudden death) occurring from birth through the age of 40 years according to genotype in the 246 gene carriers and in all 1378 members of the families studied. Results The frequency of cardiac events was higher among subjects with mutations at the LQT1 locus (63 percent) or the LQT2 locus (46 percent) than among subjects with mutations at the LQT3 locus (18 percent) (P<0.001 for the comparison of all three groups). In a multivariate Cox analysis, the genotype and the QT interval corrected for heart rate were significant independent predictors of a first cardiac event. The cumulative mortality through the age of 40 among members of the three groups of families studied was similar; however, the likelihood of dying during a cardiac event was significantly higher (P<0.001) among families with mutations at the LQT3 locus (20 percent) than among those with mutations at the LQT1 locus (4 percent) or the LQT2 locus (4 percent). Conclusions The genotype of the long-QT syndrome influences the clinical course. The risk of cardiac events is significantly higher among subjects with mutations at the LQT1 or LQT2 locus than among those with mutations at the LQT3 locus. Although cumulative mortality is similar regardless of the genotype, the percentage of cardiac events that are lethal is significantly higher in families with mutations at the LQT3 locus. (N Engl J Med 1998;339: 960-5.) (C)1998, Massachusetts Medical Society.	Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Community & Prevent Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biostat, Rochester, NY 14642 USA; Univ Milan, Ctr Fisiol Clin & Ipertens, Milan, Italy; Osped Maggiore, Ist Ricovero & Cura Carattene Sci, Milan, Italy; Univ Pavia, Dept Cardiol, I-27100 Pavia, Italy; Policlin San Matteo, Ist Ricovero & Cura Carattene Sci, I-27100 Pavia, Italy; LDS Hosp, Salt Lake City, UT USA; Mol Cardiol Fdn S Maugeri, Pavia, Italy; Univ Perugia, Dept Cardiol, I-06100 Perugia, Italy; Hebrew Univ Jerusalem, Bikur Cholim Hosp, Jerusalem, Israel; Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT USA; Sinai Hosp, Arrhythmia Ctr, Detroit, MI 48235 USA	University of Rochester; University of Rochester; University of Rochester; University of Milan; University of Pavia; IRCCS Fondazione San Matteo; University of Perugia; Hebrew University of Jerusalem; Baylor College of Medicine; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Zareba, W (corresponding author), Univ Rochester, Med Ctr, Heart Res Follow Up Program, Box 653, Rochester, NY 14642 USA.		Priori, Silvia G/ABH-6894-2020; napolitano, carlo/ABI-4608-2020; Locati, Emanuela Teresina/AAW-3821-2020; Napolitano, Carlo/K-4760-2016; Towbin, Jeffrey A./J-5595-2019; Schwartz, Peter J/J-4267-2016; Priori, Silvia G G/A-6116-2014	Priori, Silvia G/0000-0001-6877-0288; napolitano, carlo/0000-0002-7643-4628; Locati, Emanuela Teresina/0000-0002-4488-0455; Napolitano, Carlo/0000-0002-7643-4628; Towbin, Jeffrey A./0000-0002-6585-714X; Schwartz, Peter J/0000-0003-0367-1048; Priori, Silvia G G/0000-0001-6877-0288; Medina, Aharon/0000-0002-0274-1406	NHLBI NIH HHS [HL-51618, HL-33843] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033843, R01HL051618] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALI RH, 1997, PACING CLIN ELECTROP, V20, P1072; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BOYLE MB, 1987, NATURE, V330, P373, DOI 10.1038/330373a0; COX DR, 1972, J R STAT SOC B, V34, P187; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Drici MD, 1996, CIRCULATION, V94, P1471, DOI 10.1161/01.CIR.94.6.1471; ElSherif N, 1996, CIRC RES, V79, P474, DOI 10.1161/01.RES.79.3.474; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lehmann MH, 1997, J AM COLL CARDIOL, V29, P93, DOI 10.1016/S0735-1097(96)00454-8; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; MOSS AJ, 1995, CIRCULATION, V92, P2929, DOI 10.1161/01.CIR.92.10.2929; ROMANO C, 1963, Clin Pediatr (Bologna), V45, P656; ROSERO SZ, 1997, ANN NONINVAS ELECTRO, V2, P274, DOI DOI 10.1111/j.1542-474X.1997.tb00336.x; SCHOTT JJ, 1995, AM J HUM GENET, V57, P1114; SCHWARTZ PJ, 1975, AM HEART J, V89, P378, DOI 10.1016/0002-8703(75)90089-7; SCHWARTZ PJ, 1995, CIRCULATION, V92, P3381, DOI 10.1161/01.CIR.92.12.3381; SCHWARTZ PJ, 1993, CIRCULATION, V88, P782, DOI 10.1161/01.CIR.88.2.782; SCHWARTZ PJ, 1997, CIRCULATION S1, V96, P212; Shimizu W, 1997, CIRCULATION, V96, P2038, DOI 10.1161/01.CIR.96.6.2038; SHIMIZU W, 1997, CIRCULATION, V96, P554; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WARD O C, 1964, J Ir Med Assoc, V54, P103; ZAREBA W, 1995, J AM COLL CARDIOL, V26, P1685, DOI 10.1016/0735-1097(95)60383-2	29	528	548	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1998	339	14					960	965		10.1056/NEJM199810013391404	http://dx.doi.org/10.1056/NEJM199810013391404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124MW	9753711				2022-12-28	WOS:000076186900004
J	Grol, R; Dalhuijsen, J; Thomas, S; in't Veld, C; Rutten, G; Mokkink, H				Grol, R; Dalhuijsen, J; Thomas, S; in't Veld, C; Rutten, G; Mokkink, H			Attributes of clinical guidelines that influence use of guidelines in general practice: observational study	BRITISH MEDICAL JOURNAL			English	Article							PROCEDURAL ISSUES; IMPLEMENTATION; NETHERLANDS	Objective: To determine which attributes of clinical practice guidelines influence the use of guidelines in decision making in clinical practice. Design: Observational study relating the use of 47 different recommendations from 10 national clinical guidelines to 12 different attributes of clinical guidelines-for example, evidence based, controversial, concrete. Setting: General practice in the Netherlands. Subjects: 61 general practitioners who made 12 880 decisions in their contacts with patients. Main outcome measures: Compliance of decisions with clinical guidelines according to the attribute of the guideline. Results: Recommendations were followed in, on average, 61% (7915/12 880) of the decisions. Controversial recommendations were followed in 35% (886/2497) of decisions and non-controversial recommendations in 68% (7029/10 383) of decisions. Vague and non-specific recommendations were followed in 36% (826/2280) of decisions and clear recommendations in 67% (7089/10 600) of decisions. Recommendations that demanded a change in existing practice routines were followed in 44% (1 278/29 12) of decisions and those that did not in 67% (6637/9968) of decisions. Evidence based recommendations were used more than recommendations for practice that were not based on research evidence (71% (2745/3841) v 57% (5170/9039)). Conclusions: People and organisations setting evidence based clinical practice guidelines should take into account some of the other important attributes of effective recommendations for clinical practice.	Catholic Univ Nijmegen, Univ Maastricht, Ctr Qual Care Res, NL-6500 HB Nijmegen, Netherlands; Dutch Coll Gen Pratitioners, NL-3502 GE Utrecht, Netherlands; Univ Utrecht, Dept Gen Practice, NL-3508 TA Utrecht, Netherlands	Maastricht University; Radboud University Nijmegen; Utrecht University	Grol, R (corresponding author), Catholic Univ Nijmegen, Univ Maastricht, Ctr Qual Care Res, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Grol, Richard/C-8523-2013; Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285				*AM MED ASS, 1994, ATTR GUID DEV PRACT; [Anonymous], 1992, MANUAL ASSESSING HLT; CLUZEAU F, 1995, J INTERPROF CARE, V9, P227; Duff LA, 1996, J ADV NURS, V23, P887, DOI 10.1046/j.1365-2648.1996.00875.x; Eccles M, 1996, QUAL HEALTH CARE, V5, P44, DOI 10.1136/qshc.5.1.44; Field MJ., 1992, GUIDELINES CLIN PRAC; Field MJ, 1995, SETTING PRIORITIES C; GRILLI R, 1994, MED CARE, V32, P202, DOI 10.1097/00005650-199403000-00002; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; Grimshaw J, 1995, QUAL HEALTH CARE, V4, P53; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GROL R, 1993, BRIT J GEN PRACT, V43, P146; GROL R, 1995, J FAM PRACTICE, V40, P435; Grol R, 1992, Qual Health Care, V1, P184, DOI 10.1136/qshc.1.3.184; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; HADORN DC, 1994, JOINT COMM J QUAL IM, V20, P539, DOI 10.1016/S1070-3241(16)30099-2; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; HAYWARD RSA, 1993, CAN MED ASSOC J, V148, P507; Kahan J P, 1988, Int J Technol Assess Health Care, V4, P289; Kanouse D E, 1988, Int J Technol Assess Health Care, V4, P27; Kanouse DE, 1995, HEALTH POLICY, V34, P167, DOI 10.1016/0168-8510(95)00760-1; LEAPE L, 1990, QUAL REV B, V17, P42; LOHR KN, 1998, GUIDELINES HLTH CARE; *NAT HLTH MRC AUST, 1995, GUID DEV IMPL CLIN P; Rogers EM., 1983, DIFFUSION INNOVATION; *ROYAL COLL GEN PR, 1995, DEV IMPL CLIN GUID; THOMAS S, 1994, BRIT J GEN PRACT, V44, P242; WINKLER JD, 1985, ARCH INTERN MED, V145, P314, DOI 10.1001/archinte.145.2.314; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946	29	593	607	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1998	317	7162					858	861		10.1136/bmj.317.7162.858	http://dx.doi.org/10.1136/bmj.317.7162.858			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	125DN	9748183	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000076222300021
J	Le Good, JA; Ziegler, WH; Parekh, DB; Alessi, DR; Cohen, P; Parker, PJ				Le Good, JA; Ziegler, WH; Parekh, DB; Alessi, DR; Cohen, P; Parker, PJ			Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1	SCIENCE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; PKC-DELTA; EXPRESSION; ALPHA; ACTIVATION	Phosphorylation sites in members of the protein kinase A (PKA), PKG, and PKC kinase subfamily are conserved. Thus, the PKB kinase PDK1 may be responsible for the phosphorylation of PKC isotypes. PDK1 phosphorylated the activation Loop sites of PKC zeta and PKC delta in vitro and in a phosphoinositide 3-kinase (PI 3-kinase)-dependent manner in vivo in human embryonic kidney (293) cells. All members of the PKC family tested formed complexes with PDK1, PDK1-dependent phosphorylation of PKC delta in vitro was stimulated by combined PKC and PDK1 activators. The activation Loop phosphorylation of PKC delta in response to serum stimulation of cells was PI 3-kinase-dependent and was enhanced by PDK1 coexpression.	Imperial Canc Res Fund, Prot Phosphorylat Lab, London WC2A 3PX, England; Univ Dundee, Inst Med Sci, Dept Biochem, Dundee DD1 4HN, Scotland	Cancer Research UK; University of Dundee	Parker, PJ (corresponding author), Imperial Canc Res Fund, Prot Phosphorylat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933; Ziegler, Wolfgang H./0000-0003-4529-1916; Le Good, Jessie/0000-0002-6332-9239; Alessi, Dario/0000-0002-2140-9185				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; Garcia-Paramio P, 1998, BIOCHEM J, V333, P631, DOI 10.1042/bj3330631; GOODE NT, 1994, FEBS LETT, V340, P145, DOI 10.1016/0014-5793(94)80190-8; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGOOD JA, UNPUB; MANIATIS T, 1989, MOL CLONIG LAB MANUA; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; ORR JW, 1994, J BIOL CHEM, V269, P27715; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; STABEL S, 1991, METHOD ENZYMOL, V200, P670; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; WHELAN DH, 1998, SCIENCE, V279, P710; ZIEGLER W, UNPUB	22	955	980	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1998	281	5385					2042	2045		10.1126/science.281.5385.2042	http://dx.doi.org/10.1126/science.281.5385.2042			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748166				2022-12-28	WOS:000076161800060
J	Parkinson, IJ; Hawkesworth, CJ; Cohen, AS				Parkinson, IJ; Hawkesworth, CJ; Cohen, AS			Ancient mantle in a modern arc: Osmium isotopes in Izu-Bonin-Mariana forearc peridotites	SCIENCE			English	Article							ARCHEAN LITHOSPHERIC MANTLE; RE-OS; ABYSSAL PERIDOTITES; DEPLETED MANTLE; SYSTEMATICS; XENOLITHS; EVOLUTION; CRATON; MORB; ND	Mantle peridotites drilled from the Izu-Bonin-Mariana forearc have unradiogenic Os-187/Os-188 ratios (0.1193 to 0.1273), which give Proterozoic model ages of 820 to 1230 million years ago. If these peridotites are residues from magmatism during the initiation of subduction 40 to 48 million years ago, then the mantle that melted was much more depleted in incompatible elements than the source of mid-ocean ridge basalts (MORB). This result indicates that osmium isotopes record information about ancient melting events in the convecting upper mantle not recorded by incompatible Lithophile isotope tracers. Subduction zones may be a graveyard for ancient depleted mantle material. and portions of the convecting upper mantle may be less radiogenic in osmium isotopes than previously recognized.	Open Univ, Dept Earth Sci, Milton Keynes MK7 6AA, Bucks, England	Open University - UK	Parkinson, IJ (corresponding author), Open Univ, Dept Earth Sci, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.	I.J.Parkinson@open.ac.uk	Parkinson, Ian/C-7398-2009					Brandon AD, 1996, SCIENCE, V272, P861, DOI 10.1126/science.272.5263.861; Burnham OM, 1998, GEOCHIM COSMOCHIM AC, V62, P2293, DOI 10.1016/S0016-7037(98)00092-1; Cohen AS, 1996, ANAL CHIM ACTA, V332, P269, DOI 10.1016/0003-2670(96)00226-7; FRYER P, 1985, GEOLOGY, V13, P774, DOI 10.1130/0091-7613(1985)13<774:OAEOMF>2.0.CO;2; GRIFFIN WL, AGU SPEC MONOGR; Handler MR, 1997, EARTH PLANET SC LETT, V151, P61, DOI 10.1016/S0012-821X(97)00118-0; Hassler DR, 1998, SCIENCE, V280, P418, DOI 10.1126/science.280.5362.418; MCCULLOCH MT, 1994, GEOCHIM COSMOCHIM AC, V58, P4717, DOI 10.1016/0016-7037(94)90203-8; Meisel T, 1996, NATURE, V383, P517, DOI 10.1038/383517a0; MICHAEL PJ, 1985, INITIAL REP DEEP SEA, V82, P523; Mottl M.J., 1992, P ODP SCI RESULTS, V125, P373; Parkinson IJ, 1998, J PETROL, V39, P1577; PARKINSON IJ, 1992, P OCEAN DRILLING PRO, V0125; PEARCE JA, 1992, P OCEAN DRILLING PRO, V0125; PEARSON DG, 1995, EARTH PLANET SC LETT, V134, P341, DOI 10.1016/0012-821X(95)00125-V; PEARSON DG, 1995, GEOCHIM COSMOCHIM AC, V59, P959, DOI 10.1016/00167-0379(50)00143-; REISBERG L, 1995, NATURE, V376, P159, DOI 10.1038/376159a0; REISBERG L, 1991, EARTH PLANET SC LETT, V107, P406; ROYBARMAN M, 1994, GEOCHIM COSMOCHIM AC, V58, P5043, DOI 10.1016/0016-7037(94)90230-5; Smoliar MI, 1996, SCIENCE, V271, P1099, DOI 10.1126/science.271.5252.1099; SNOW JE, 1995, GEOCHIM COSMOCHIM AC, V59, P4219, DOI 10.1016/0016-7037(95)00239-V; SNOW JE, 1995, EARTH PLANET SC LETT, V133, P411, DOI 10.1016/0012-821X(95)00099-X; Taylor B., 1992, P ODP SCI RESULTS, V126, P627, DOI [10.2973/odp.proc.sr.126.163.1992, DOI 10.2973/ODP.PROC.SR.126.163.1992]; WALKER RJ, 1989, GEOCHIM COSMOCHIM AC, V53, P1583, DOI 10.1016/0016-7037(89)90240-8; WHITE WM, 1993, EARTH PLANET SC LETT, V115, P211, DOI 10.1016/0012-821X(93)90223-V; ZINDLER A, 1986, ANNU REV EARTH PL SC, V14, P493, DOI 10.1146/annurev.ea.14.050186.002425	26	157	167	3	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1998	281	5385					2011	2013		10.1126/science.281.5385.2011	http://dx.doi.org/10.1126/science.281.5385.2011			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748156				2022-12-28	WOS:000076161800050
J	Ushikubi, F; Segi, E; Sugimoto, Y; Murata, T; Matsuoka, T; Kobayashi, T; Hizaki, H; Tuboi, K; Katsuyama, M; Ichikawa, A; Tanaka, T; Yoshida, N; Narumiya, S				Ushikubi, F; Segi, E; Sugimoto, Y; Murata, T; Matsuoka, T; Kobayashi, T; Hizaki, H; Tuboi, K; Katsuyama, M; Ichikawa, A; Tanaka, T; Yoshida, N; Narumiya, S			Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3	NATURE			English	Article							PROSTANOID RECEPTORS; NEURAL MEDIATOR; NERVOUS-SYSTEM; FEVER; MECHANISM; EICOSANOIDS	Fever, a hallmark of disease, is elicited by exogenous pyrogens, that is, cellular components, such as lipopolysaccharide (LPS), of infectious organisms, as well as by non-infectious inflammatory insults. Both stimulate the production of cytokines, such as interleukin (IL)-1 beta, that act on the brain as endogenous pyrogens'. Fever can be suppressed by aspirin-like anti-inflammatory drugs. As these drugs share the ability to inhibit prostaglandin biosynthesis(2), it is thought that a prostaglandin is important in fever generation. Prostaglandin E-2 (PGE(2)) may be a neural mediator of fever(3), but this has been much debated(1,4-7). PGE, acts by interacting with four subtypes of PGE receptor, the EP1, EP2, EP3 and EP4 receptors(8). Here we generate mice lacking each of these receptors by homologous recombination. Only mice lacking the EP3 receptor fail to show a febrile response to PGE(2) and to either IL-1 beta or LPS. Our results establish that PGE(2) mediates fever generation in response to both exogenous and endogenous pyrogens by acting at the EP3 receptor.	Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan; Kyoto Univ, Dept Pharmaceut Sci, Dept Physiol Chem, Kyoto 6068315, Japan; Osaka Med Ctr Maternal & Child Hlth, Res Inst, Div Mol & Cellular Immunol, Osaka 5941101, Japan	Kyoto University; Kyoto University	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan.	snaru@mfour.med.kyoto-u.ac.jp	Tanaka, Takashi/O-8254-2015; Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X; Segi-Nishida, Eri/0000-0002-0803-6513; Murata, Takahiko/0000-0003-0132-5424				ALEXANDER SJ, 1989, PFLUG ARCH EUR J PHY, V413, P451, DOI 10.1007/BF00594172; BISHAI I, 1987, CAN J PHYSIOL PHARM, V65, P2225, DOI 10.1139/y87-352; CRANSTON WI, 1976, J PHYSIOL-LONDON, V259, P239, DOI 10.1113/jphysiol.1976.sp011464; DAVATELIS G, 1989, SCIENCE, V243, P1066, DOI 10.1126/science.2646711; DIPAULI R, 1972, J IMMUNOL, V109, P394; KATSUURA G, 1990, AM J PHYSIOL, V258, pE163, DOI 10.1152/ajpendo.1990.258.1.E163; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; KLUGER MJ, 1991, PHYSIOL REV, V71, P93, DOI 10.1152/physrev.1991.71.1.93; KOZAK W, 1995, AM J PHYSIOL-REG I, V269, pR969, DOI 10.1152/ajpregu.1995.269.5.R969; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; MILTON AS, 1970, J PHYSIOL-LONDON, V207, pP76; MILTON AS, 1989, ANN NY ACAD SCI, V559, P392; MITCHELL D, 1986, YALE J BIOL MED, V59, P159; MORLEY RM, 1990, AM J PHYSIOL, V258, pR1064, DOI 10.1152/ajpregu.1990.258.4.R1064; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Nguyen MT, 1997, NATURE, V390, P78, DOI 10.1038/36342; SAPER CB, 1994, NEW ENGL J MED, V330, P1880; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; STITT JT, 1986, YALE J BIOL MED, V59, P137; SUGIMOTO Y, 1994, NEUROSCIENCE, V62, P919, DOI 10.1016/0306-4522(94)90483-9; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; TOH H, 1995, FEBS LETT, V361, P17, DOI 10.1016/0014-5793(95)00129-W; USHIKUBI F, 1995, J LIPID MEDIAT CELL, V12, P343, DOI 10.1016/0929-7855(95)00022-I; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; ZAMPRONIO AR, 1994, AM J PHYSIOL, V266, pR1670, DOI 10.1152/ajpregu.1994.266.5.R1670; ZHENG H, 1995, IMMUNITY, V3, P9, DOI 10.1016/1074-7613(95)90154-X	27	536	564	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	1998	395	6699					281	284		10.1038/26233	http://dx.doi.org/10.1038/26233			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751056				2022-12-28	WOS:000075974600052
J	Albertsen, PC; Hanley, JA; Gleason, DF; Barry, MJ				Albertsen, PC; Hanley, JA; Gleason, DF; Barry, MJ			Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM SURVIVAL; RADICAL PROSTATECTOMY; MORTALITY; ANTIGEN	Context.-The appropriate therapy for men with localized prostate cancer is uncertain. Until results of clinical trials are available, men and their physicians need guidance. Objective.-To estimate survival based on a competing risk analysis stratified by age at diagnosis and histologic findings for men diagnosed as having clinically localized prostate cancer and who were managed conservatively. Design.-Retrospective cohort study, Setting.-Connecticut Tumor Registry. Patients.-A total of 767 men with localized prostate cancer diagnosed between 1971 and 1984, aged 55 to 74 years at diagnosis, either not treated or treated with immediate pr delayed hormonal therapy, and followed up for 10 to 20 years after diagnosis. Main Outcome Measures.-Estimates of the probability of dying from prostate cancer or other competing hazards, Results.-Men with tumors that have Gleason scores of 2 to 4, 5, 6, 7, and 8 to 10 face a 4% to 7%, 6% to 11%, 18% to 30%, 42% to 70%, and 60% to 87% chance, respectively, of dying from prostate cancer within 15 years of diagnosis depending on their age at diagnosis, Conclusions.-Men whose prostate biopsy specimens show Gleason score 2 to 4 disease face a minimal risk of death from prostate cancer within 15 years of diagnosis, Conversely, men whose biopsy specimens show Gleason score 7 to 10 disease face a high risk of death from prostate cancer when treated conservatively, even when cancer is diagnosed as late as age 74 years, Men with Gleason score 5 or 6 tumors face a modest risk of death from prostate cancer that increases slowly over at least 15 years of follow-up.	Univ Connecticut, Ctr Hlth, Div Urol, Farmington, CT 06030 USA; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; Massachusetts Gen Hosp, Gen Med Unit, Boston, MA 02114 USA	University of Connecticut; McGill University; Harvard University; Massachusetts General Hospital	Albertsen, PC (corresponding author), Univ Connecticut, Ctr Hlth, Div Urol, 263 Farmington Ave, Farmington, CT 06030 USA.				AHRQ HHS [HS 08397] Funding Source: Medline; NCRR NIH HHS [M01 RR06192] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008397] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006192] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; AUS G, 1995, J UROLOGY, V154, P460, DOI 10.1016/S0022-5347(01)67074-5; BAGSHAW MA, 1994, J UROLOGY, V152, P1781, DOI 10.1016/S0022-5347(17)32385-6; Blasko JC, 1996, UROL CLIN N AM, V23, P633, DOI 10.1016/S0094-0143(05)70342-6; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; Cowen ME, 1996, JAMA-J AM MED ASSOC, V275, P31; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Gerber GS, 1996, JAMA-J AM MED ASSOC, V276, P615; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; Holland, 1975, DISCRETE MULTIVARIAT, P123; HUGOSSON J, 1995, J UROLOGY, V154, P2115, DOI 10.1016/S0022-5347(01)66710-7; Johansson JE, 1997, JAMA-J AM MED ASSOC, V277, P467, DOI 10.1001/jama.277.6.467; Kalbfleisch J, 1980, STAT ANAL FAILURE TI, P168; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; MURPHY GP, 1982, J UROLOGY, V127, P928, DOI 10.1016/S0022-5347(17)54135-X; STENBACK M, 1995, ACTA ONCOL S4, V34, P62; Swanson G, 1996, JAMA-J AM MED ASSOC, V275, P31, DOI 10.1001/jama.1996.03530250035012; Walsh PC, 1997, JAMA-J AM MED ASSOC, V277, P497, DOI 10.1001/jama.277.6.497	22	516	533	1	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1998	280	11					975	980		10.1001/jama.280.11.975	http://dx.doi.org/10.1001/jama.280.11.975			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JC	9749479	Bronze			2022-12-28	WOS:000075891400030
J	Behringer, W; Kittler, H; Sterz, F; Domanovits, H; Schoerkhuber, W; Holzer, M; Mullner, M; Laggner, AN				Behringer, W; Kittler, H; Sterz, F; Domanovits, H; Schoerkhuber, W; Holzer, M; Mullner, M; Laggner, AN			Cumulative epinephrine dose during cardiopulmonary resuscitation and neurologic outcome	ANNALS OF INTERNAL MEDICINE			English	Article						epinephrine; neurologic manifestations; cardiopulmonary resuscitation; dose-response relationship, drug; outcome and process assessment (health care)	HOSPITAL CARDIAC-ARREST; VENTRICULAR-FIBRILLATION; BLOOD-FLOW; PERFUSION-PRESSURE; STANDARD; CPR; MODEL; NOREPINEPHRINE; IMPROVES; SEVERITY	Background: Epinephrine is the drug of choice in advanced cardiac life support, but it can have deleterious side effects after restoration of spontaneous circulation. Objective: To investigate the association between the cumulative epinephrine dose used in advanced cardiac life support and neurologic outcome after cardiac arrest. Design: Retrospective cohort study. Setting: University hospital. Patients: Adults admitted to the emergency department with witnessed, nontraumatic, normothermic ventricular fibrillation cardiac arrest and unsuccessful initial defibrillation. Measurements: Functional neurologic outcome was regularly assessed by cerebral performance category (CPC) within 6 months after cardiac arrest. A CPC of 1 or 2 was defined as favorable recovery. Results: Among 178 enrolled patients, the median cumulative epinephrine dose administered was 4 mg (range, 0 to 50 mg). In 151 patients (84%), spontaneous circulation was restored; 63 of these 151 patients (42%) had favorable neurologic recovery. Patients with an unfavorable CPC received a significantly higher cumulative dose of epinephrine than did patients with a favorable CPC (4 mg compared with 1 mg; P < 0.001). This finding persisted after stratification by duration of resuscitation. After possible cofounders were controlled for, the cumulative epinephrine dose remained an independent predictor of unfavorable neurologic outcome. Conclusions: The results indicate that an increasing cumulative dose of epinephrine administered during resuscitation is independently associated with unfavorable neurologic outcome after ventricular fibrillation cardiac arrest.	Univ Vienna, Sch Med, Vienna, Austria	University of Vienna	Sterz, F (corresponding author), Vienna Gen Hosp, Univ Clin, Dept Emergency Med, Waehringerguertel 18-20-6-D, A-1090 Vienna, Austria.		Kittler, Harald/K-7574-2013; Kittler, Harald/AAK-1502-2020	KITTLER, HARALD/0000-0002-0051-8016				Altman D.G., 1991, PRACTICAL STAT MED R; *AM HEART ASS, 1992, JAMA-J AM MED ASSOC, V268, P2205; [Anonymous], 1986, Am J Emerg Med, V4, P72; BARTON C, 1991, ANN EMERG MED, V20, P722, DOI 10.1016/S0196-0644(05)80830-3; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BEER RJ, 1994, RESUSCITATION, V27, P189, DOI 10.1016/0300-9572(94)90032-9; BROWN CG, 1987, CIRCULATION, V75, P491, DOI 10.1161/01.CIR.75.2.491; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; BROWN CG, 1986, ANN EMERG MED, V15, P1138, DOI 10.1016/S0196-0644(86)80853-8; BROWN CG, 1990, RESUSCITATION, V19, P1, DOI 10.1016/0300-9572(90)90094-U; BRUNETTE DD, 1990, ANN EMERG MED, V19, P8, DOI 10.1016/S0196-0644(05)82130-4; CALLAHAM M, 1991, JAMA-J AM MED ASSOC, V265, P1117, DOI 10.1001/jama.265.9.1117; CALLAHAM M, 1992, JAMA-J AM MED ASSOC, V268, P2667, DOI 10.1001/jama.268.19.2667; CHOUX C, 1995, RESUSCITATION, V29, P3, DOI 10.1016/0300-9572(94)00810-3; Crile G, 1906, J EXP MED, V8, P713, DOI 10.1084/jem.8.6.713; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; DITCHEY RV, 1988, CIRCULATION, V78, P382, DOI 10.1161/01.CIR.78.2.382; EISENBERG MS, 1990, ANN EMERG MED, V19, P1249, DOI 10.1016/S0196-0644(05)82283-8; GOETTING MG, 1991, ANN EMERG MED, V20, P22, DOI 10.1016/S0196-0644(05)81112-6; Hallstrom AP, 1996, CIRCULATION, V93, P2019, DOI 10.1161/01.CIR.93.11.2019; JENNETT B, 1975, LANCET, V1, P480; LINDNER KH, 1989, CRIT CARE MED, V17, P437, DOI 10.1097/00003246-198905000-00012; LINDNER KH, 1992, RESUSCITATION, V24, P147, DOI 10.1016/0300-9572(92)90021-4; LINDNER KH, 1991, AM J EMERG MED, V9, P27, DOI 10.1016/0735-6757(91)90008-8; LITTLE RA, 1985, Q J MED, V54, P133; LIVESAY JJ, 1978, J THORAC CARDIOV SUR, V76, P244; LONGSTRETH WT, 1983, NEW ENGL J MED, V308, P1378, DOI 10.1056/NEJM198306093082302; MARTENS PR, 1993, RESUSCITATION, V25, P227, DOI 10.1016/0300-9572(93)90119-B; MARWICK TH, 1988, LANCET, V2, P66; MULLER CP, 1989, EXP HEMATOL, V17, P1; NG AY, 1990, AM J EMERG MED, V8, P87, DOI 10.1016/0735-6757(90)90190-B; OLSON DW, 1989, ANN EMERG MED, V18, P250, DOI 10.1016/S0196-0644(89)80408-1; ONEIL BJ, 1994, CRIT CARE MED, V22, P194, DOI 10.1097/00003246-199402000-00006; PARADIS NA, 1991, JAMA-J AM MED ASSOC, V265, P1139, DOI 10.1001/jama.265.9.1139; PEPE PE, 1993, CRIT CARE MED, V21, P1838, DOI 10.1097/00003246-199312000-00009; REDDING JS, 1963, ANESTHESIOLOGY, V24, P203, DOI 10.1097/00000542-196303000-00008; REDDING JS, 1962, JAMA-J AM MED ASSOC, V182, P283; REDDING JS, 1968, JAMA-J AM MED ASSOC, V203, P93; RITTER G, 1985, AM HEART J, V110, P932, DOI 10.1016/0002-8703(85)90187-5; RIVERS EP, 1994, CHEST, V106, P1499, DOI 10.1378/chest.106.5.1499; ROGOVE HJ, 1995, CRIT CARE MED, V23, P18, DOI 10.1097/00003246-199501000-00007; RUBERTSSON S, 1995, CRIT CARE MED, V23, P1984, DOI 10.1097/00003246-199512000-00007; Schindler MB, 1996, NEW ENGL J MED, V335, P1473, DOI 10.1056/NEJM199611143352001; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; STUEVEN HA, 1989, RESUSCITATION, V17, pS71, DOI 10.1016/0300-9572(89)90092-0; SUGA H, 1983, CIRC RES, V53, P306, DOI 10.1161/01.RES.53.3.306; TANG W, 1991, CIRCULATION, V84, P2101, DOI 10.1161/01.CIR.84.5.2101; TANG WC, 1995, CIRCULATION, V92, P3089, DOI 10.1161/01.CIR.92.10.3089; WORTSMAN J, 1993, CRIT CARE MED, V21, P692, DOI 10.1097/00003246-199305000-00012	49	102	108	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1998	129	6					450	456		10.7326/0003-4819-129-6-199809150-00004	http://dx.doi.org/10.7326/0003-4819-129-6-199809150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JJ	9735082				2022-12-28	WOS:000075892100003
J	Greenough, A				Greenough, A			Gains and losses from dexamethasone for neonatal chronic lung disease	LANCET			English	Editorial Material							RESPIRATORY-DISTRESS SYNDROME; BRONCHOPULMONARY DYSPLASIA; CONTROLLED TRIAL; PRETERM INFANTS; FOLLOW-UP; POSTNATAL DEXAMETHASONE; THERAPY		Guys Kings & St Thomass Sch Med, Dept Child Hlth, London SE5 9RS, England	University of London; King's College London	Greenough, A (corresponding author), Guys Kings & St Thomass Sch Med, Dept Child Hlth, London SE5 9RS, England.							Bancalari E, 1998, EUR J PEDIATR, V157, pS31, DOI 10.1007/PL00014290; Bhuta T, 1998, ARCH DIS CHILD-FETAL, V79, pF26, DOI 10.1136/fn.79.1.F26; BROZANSKI BS, 1995, J PEDIATR-US, V126, P769, DOI 10.1016/S0022-3476(95)70410-8; CUMMINGS JJ, 1989, NEW ENGL J MED, V320, P1505, DOI 10.1056/NEJM198906083202301; DAgostino RB, 1995, CLIN PHARMACOL THER, V58, P605, DOI 10.1016/0009-9236(95)90016-0; Dimitriou G, 1997, EUR J PEDIATR, V156, P51; GREENOUGH A, 1992, EUR J PEDIATR, V151, P134, DOI 10.1007/BF01958959; JONES R, 1991, PEDIATRICS, V88, P421; JONES R, 1995, PEDIATRICS, V96, P897; Kovacs L, 1998, ACTA PAEDIATR, V87, P792, DOI 10.1080/080352598750013905; MAMMEL MC, 1987, DEV PHARMACOL THERAP, V10, P1; MASSARO D, 1986, AM J PHYSIOL, V251, pR218, DOI 10.1152/ajpregu.1986.251.2.R218; OSHEA TM, 1993, AM J DIS CHILD, V147, P658, DOI 10.1001/archpedi.1993.02160300064024; Rastogi A, 1996, PEDIATRICS, V98, P204; SAHEBJAMI H, 1989, EXP LUNG RES, V15, P961, DOI 10.3109/01902148909069638; SANDERS RJ, 1994, PEDIATR RES, V36, P122, DOI 10.1203/00006450-199407001-00022; Shinwell ES, 1996, ARCH DIS CHILD-FETAL, V74, pF33, DOI 10.1136/fn.74.1.F33; TSCHANZ SA, 1995, BIOL NEONATE, V68, P229; Yeh TF, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.5.e7; Yeh TF, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.4.e3	20	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					835	836		10.1016/S0140-6736(05)60002-5	http://dx.doi.org/10.1016/S0140-6736(05)60002-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742974				2022-12-28	WOS:000075857300004
J	Jones, AH				Jones, AH			Is the system really broken?	LANCET			English	Article							AUTHORSHIP		Univ Texas, Med Branch, Inst Med Humanities, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Jones, AH (corresponding author), Univ Texas, Med Branch, Inst Med Humanities, 2-210 Ashbel Smith Bldg,301 Univ Blvd, Galveston, TX 77555 USA.							Bhopal R, 1997, BRIT MED J, V314, P1009, DOI 10.1136/bmj.314.7086.1009; BIAGIOLI M, 1998, LIFE SCI FORUM, V12, P3; Davidson F, 1997, JAMA-J AM MED ASSOC, V277, P927; HORTON R, 1995, LANCET, V346, P1504, DOI 10.1016/S0140-6736(95)92043-9; Horton R, 1997, LANCET, V350, P5, DOI 10.1016/S0140-6736(05)66236-8; HORTON R, 1997, COLL RES SEM ETH ISS; JONES AH, 1997, 3 INT C PEER REV BIO; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; RENNIE D, 1991, JAMA-J AM MED ASSOC, V266, P3333, DOI 10.1001/jama.266.23.3333; SMITH R, 1997, BRIT MED J, V315, P744	10	3	3	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					894	895		10.1016/S0140-6736(05)60033-5	http://dx.doi.org/10.1016/S0140-6736(05)60033-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742998				2022-12-28	WOS:000075857300044
J	Kuo, D; Gifford, DR; Stein, MD				Kuo, D; Gifford, DR; Stein, MD			Curbside consultation practices and attitudes among primary care physicians and medical subspecialists	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Informal (curbside) consultations are an integral part of medical culture and may be of great value to patients and primary care physicians. However, little is known about physicians' behavior or attitudes toward curbside consultation. Objective.-To describe and compare curbside consultation practices and attitudes among primary care physicians and medical subspecialists. Design.-Survey mailed in June 1997. Participants.-Of 286 primary care physicians and 252 subspecialists practicing in Rhode Island, 213 primary care physicians and 200 subspecialists responded (response rate, 76.8%). Outcome Measures.-Self-reported practices of, reasons for, and attitudes about curbside consultation. Results.-Of primary care physicians, 70.4% (150/213) and 87.5%(175/200) of subspecialists reported participating in at least I curbside consultation during the previous week. In the previous week, primary care physicians obtained 3.2 curbside consultations, whereas subspecialists received 3.6 requests for curbside consultations. Subspecialties most frequently involved in curbside consultations were cardiology, gastroenterology, and infectious diseases; subspecialties that were requested to provide curbside consultations more often than they were formally consulted were endocrinology, infectious diseases, and rheumatology. Curbside consultations were most often used to select appropriate diagnostic tests and treatment plans and to determine the need for formal consultation. Subspecialists perceived more often than primary care physicians that information communicated in curbside consultations was insufficient (80.2% vs 49.8%; P < .001) and that important clinical detail was not described (77.6% vs 43.5%; P < .001). More subspecialists than primary care physicians felt that curbside consultations were essential for maintaining good relationships with other physicians (77.2% vs 38.6%, P < .001). Conclusions.-Curbside consultation serves important functions in the practice of medici ne. Despite the widespread use of curbside consultation, disagreement exists between primary care physicians and subspecialists as to the role of curbside consultation and the quality of the information exchanged.	Brown Univ, Dept Med, Providence, RI 02912 USA; Brown Univ, Dept Community Hlth, Providence, RI 02912 USA	Brown University; Brown University	Kuo, D (corresponding author), Morristown Mem Hosp, Dept Med, 100 Madison Ave, Morristown, NJ 07962 USA.				BHP HRSA HHS [2D28PE51016-07] Funding Source: Medline	BHP HRSA HHS		CARTLAND JDC, 1992, PEDIATRICS, V89, P183; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; Findling JW, 1996, ENDOCRINOLOGIST, V6, P328, DOI 10.1097/00019616-199607000-00009; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1151, DOI 10.1056/NEJM199410273311709; MAGNUSSEN CR, 1994, INFECT DIS CLIN PRAC, V1, P391; Manian FA, 1996, JAMA-J AM MED ASSOC, V275, P145; Manian FA, 1996, CLIN INFECT DIS, V22, P303, DOI 10.1093/clinids/22.2.303; MYERS JP, 1984, J INFECT DIS, V150, P797, DOI 10.1093/infdis/150.6.797; Pearson SD, 1998, J GEN INTERN MED, V13, P435, DOI 10.1046/j.1525-1497.1998.00131.x; WEINBERG AD, 1981, J MED EDUC, V56, P174	10	113	115	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1998	280	10					905	909		10.1001/jama.280.10.905	http://dx.doi.org/10.1001/jama.280.10.905			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115LN	9739975	Bronze			2022-12-28	WOS:000075666600037
J	Burley, SK; Roeder, RG				Burley, SK; Roeder, RG			TATA box mimicry by TFIID: Autoinhibition of pol II transcription	CELL			English	Review							URACIL-DNA GLYCOSYLASE; RNA-POLYMERASE-II; BINDING-PROTEIN; CRYSTAL-STRUCTURE; IN-VIVO; INITIATION; MUTATIONS; COMPLEX; INHIBITOR; DOMAIN		Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Burley, SK (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.			Burley, Stephen K./0000-0002-2487-9713				Auble DT, 1997, MOL CELL BIOL, V17, P4842, DOI 10.1128/MCB.17.8.4842; Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; LEE M, 1995, MOL CELL BIOL, V15, P5461; LEE TI, 1998, GENE DEV, V10, P1033; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Nyborg J, 1996, TRENDS BIOCHEM SCI, V21, P81, DOI 10.1016/0968-0004(96)30008-X; PATIKOGLOU G, 1997, ANNU REV BIOPH BIOM, V26, P287; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9	19	32	32	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 4	1998	94	5					551	553		10.1016/S0092-8674(00)81596-2	http://dx.doi.org/10.1016/S0092-8674(00)81596-2			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741619	Bronze			2022-12-28	WOS:000075851900002
J	Glickman, MH; Rubin, DM; Coux, O; Wefes, I; Pfeifer, G; Cjeka, Z; Baumeister, W; Fried, VA; Finley, D				Glickman, MH; Rubin, DM; Coux, O; Wefes, I; Pfeifer, G; Cjeka, Z; Baumeister, W; Fried, VA; Finley, D			A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3	CELL			English	Article							INITIATION-FACTOR EIF3; 20S PROTEASOME; MULTICATALYTIC PROTEASE; DEPENDENT PROTEASES; 20-S PROTEASOME; 11-S REGULATOR; SUBUNITS; COMPLEX; YEAST; PURIFICATION	The proteasome consists of a 20S proteolytic core particle (CP) and a 19S regulatory particle (RP), which selects ubiquitinated substrates for translocation into the CP. An eight-subunit subcomplex of the RP, the lid, can be dissociated from proteasomes prepared from a deletion mutant for Rpn10, an RP subunit. A second subcomplex, the base, contains all six proteasomal ATPases and links the RP to the CP. The base is sufficient to activate the CP for degradation of peptides or a nonubiquitinated protein, whereas the lid is required for ubiquitin-dependent degradation. By electron microscopy, the base and the lid correspond to the proximal and distal masses of the RP, respectively. The lid subunits share sequence motifs with components of the COPS/signalosome complex and eIF3, suggesting that these functionally diverse particles have a common evolutionary ancestry.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; New York Med Coll, Dept Cell Biol, Valhalla, NY 10595 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Harvard University; Harvard Medical School; New York Medical College; Max Planck Society	Finley, D (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Coux, Olivier/B-3406-2010; Coux, Olivier/P-6847-2019	Coux, Olivier/0000-0001-8455-3849; Coux, Olivier/0000-0001-8455-3849; Glickman, Michael/0000-0002-1222-8104	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043601, R37GM043601] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43601] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Beyer A, 1997, PROTEIN SCI, V6, P2043; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Celikel R, 1998, NAT STRUCT BIOL, V5, P189, DOI 10.1038/nsb0398-189; Chamovitz DA, 1998, NATO ADV SCI I H-CEL, V104, P83; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Fenton WA, 1997, PROTEIN SCI, V6, P743; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Finley D, 1998, TRENDS BIOCHEM SCI, V23, P244, DOI 10.1016/S0968-0004(98)01222-5; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Fujimuro M, 1998, FEBS LETT, V423, P149, DOI 10.1016/S0014-5793(98)00084-2; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Haracska L, 1997, FEBS LETT, V412, P331, DOI 10.1016/S0014-5793(97)00808-9; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; Hershey J, 1996, BIOCHIMIE, V78, P903, DOI 10.1016/S0300-9084(97)86711-9; HERSHKO A, 1998, IN PRESS ANN REV BIO; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P195, DOI 10.1016/S0968-0004(97)01058-X; MA CP, 1994, J BIOL CHEM, V269, P3539; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; MA CP, 1992, J BIOL CHEM, V267, P10515; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Realini C, 1997, J BIOL CHEM, V272, P25483, DOI 10.1074/jbc.272.41.25483; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; Wolf S, 1998, J MOL BIOL, V277, P13, DOI 10.1006/jmbi.1997.1589; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	47	711	728	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 4	1998	94	5					615	623		10.1016/S0092-8674(00)81603-7	http://dx.doi.org/10.1016/S0092-8674(00)81603-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741626	Bronze			2022-12-28	WOS:000075851900009
J	Munte, TF; Schiltz, K; Kutas, M				Munte, TF; Schiltz, K; Kutas, M			When temporal terms belie conceptual order	NATURE			English	Article							EVENT-RELATED POTENTIALS; WORKING-MEMORY; FRONTAL-CORTEX; COMPREHENSION; SENTENCE; CLAUSES	We conceive of time as a sequential order of real-world events, one event following another from past to present to future, This conception colours the way we speak of time ("we look forward to the time") and, as we show here, the way we process written statements referring to the temporal order of events, in real time. Terms such as 'before' and 'after' give us the linguistic freedom to express a series of events (real or imaginary) in any order. However, sentences that present events out of chronological order require additional discourse-level computation. Here we examine how and when these computations are carried out by contrasting brain potentials across two sentence types that differ only in their initial word ('After' X, Y versus 'Before' X,Y). At sites on the left frontal scalp, the responses to 'before' and 'after' sentences diverge within 300 ms; the size of this difference increases over the course of the sentences and is correlated with individual working-memory spans. Thus, we show that there are immediate and lasting consequences for neural processing of the discourse implications of a single word on sentence comprehension.	Univ Calif San Diego, Dept Cognit Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Med Hsch Hannover, Dept Neurol, D-30623 Hannover, Germany	University of California System; University of California San Diego; University of California System; University of California San Diego; Hannover Medical School	Munte, TF (corresponding author), Univ Calif San Diego, Dept Cognit Sci, La Jolla, CA 92093 USA.		Münte, Thomas/C-2077-2014	Schiltz, Kolja/0000-0003-3788-3241				Baayen R. H., 1993, CELEX LEXICAL DATABA; CARPENTER PA, 1995, ANNU REV PSYCHOL, V46, P91, DOI 10.1146/annurev.ps.46.020195.000515; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; GoldmanRakic PS, 1996, PHILOS T ROY SOC B, V351, P1445, DOI 10.1098/rstb.1996.0129; Graesser AC, 1997, ANNU REV PSYCHOL, V48, P163, DOI 10.1146/annurev.psych.48.1.163; Just MA, 1996, SCIENCE, V274, P114, DOI 10.1126/science.274.5284.114; KING JW, 1995, J COGNITIVE NEUROSCI, V7, P376, DOI 10.1162/jocn.1995.7.3.376; Langacker R.W., 1987, FDN COGNITIVE GRAMMA; MACARUSO P, 1989, LANG SPEECH, V32, P45, DOI 10.1177/002383098903200103; MCCARTHY G, 1985, ELECTROEN CLIN NEURO, V62, P203, DOI 10.1016/0168-5597(85)90015-2; McKoon G, 1998, ANNU REV PSYCHOL, V49, P25, DOI 10.1146/annurev.psych.49.1.25; MECKLINGER A, 1995, MEM COGNITION, V23, P477, DOI 10.3758/BF03197249; Muller HM, 1997, COGNITIVE BRAIN RES, V5, P193, DOI 10.1016/S0926-6410(96)00070-5; NATSOPOULOS D, 1986, J PSYCHOLINGUIST RES, V15, P243; NATSOPOULOS D, 1991, BRAIN LANG, V40, P444, DOI 10.1016/0093-934X(91)90142-N; Owen AM, 1997, EUR J NEUROSCI, V9, P1329, DOI 10.1111/j.1460-9568.1997.tb01487.x; PERRIN F, 1987, ELECTROEN CLIN NEURO, V66, P75, DOI 10.1016/0013-4694(87)90141-6; Petrides M, 1996, PHILOS T ROY SOC B, V351, P1455, DOI 10.1098/rstb.1996.0130; Stromswold K, 1996, BRAIN LANG, V52, P452, DOI 10.1006/brln.1996.0024; TROSBORG A, 1982, J CHILD LANG, V9, P381, DOI 10.1017/S0305000900004773; Turner Mark, 1991, READING MINDS STUDY	21	154	155	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1998	395	6697					71	73		10.1038/25731	http://dx.doi.org/10.1038/25731			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	116JY	9738499				2022-12-28	WOS:000075722200048
J	Rougier, P; Sahmoud, T; Nitti, D; Curran, D; Doci, R; De Waele, B; Nakajima, T; Rauschecker, H; Labianca, R; Pector, JC; Marsoni, S; Apolone, G; Lasser, P; Couvreur, ML; Wils, J				Rougier, P; Sahmoud, T; Nitti, D; Curran, D; Doci, R; De Waele, B; Nakajima, T; Rauschecker, H; Labianca, R; Pector, JC; Marsoni, S; Apolone, G; Lasser, P; Couvreur, ML; Wils, J		European Org Res Treatment Canc Gastrointestin; Grp Interdisciplinare Valutazione Intervent On; Japanese Fdn Canc Res	Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial	LANCET			English	Article							CLINICAL-TRIAL; ADENOCARCINOMA; CARCINOMA; THERAPY; COLON; CHEMOTHERAPY; PERFUSION	Background. There is conflicting evidence on the efficacy of regional adjuvant chemotherapy, via portal-vein infusion (PVI), after resection of colorectal cancer. We undertook a randomised controlled multicentre trial to investigate the efficacy of PVI (500 mg/m(2) fluorouracil plus 5000 IU heparin daily for 7 days). Methods. 1235 of about 1500 potentially eligible patients were randomly assigned surgery plus PVI or surgery alone (control). The patients were followed up for a median of 63 months, with yearly screening for recurrent disease. The primary endpoint was survival; analyses were by intention to treat. Findings. 619 patients in the control group and 616 in the PVI group met eligibility criteria. 164 (26%) control-group patients and 173 (28%) PVI-group patients died. 5-year survival did not differ significantly between the groups (73 vs 72%; 95% CI for difference -6 to 4). The control and PVI groups were also similar in terms of disease-free survival at 5 years (67 vs 65%) and the number of patients with liver metastases (79 vs 77%). Interpretation. PVI of fluorouracil, at a dose of 500 mg/m(2) for 7 days, cannot be recommended as the sole adjuvant treatment for high-risk colorectal cancer after complete surgical excision. However, these results cannot eliminate a small benefit when PVI is used at a higher dosage or in combination with mitomycin.	Hop Ambroise Pare, Dept Med, Serv Hepatogastroenterol, F-92104 Boulogne, France; Eortc Data Ctr, Brussels, Belgium; Univ Padua, Clin Chirurg 2, Padova, Italy; Ist Nazl Studio & Cura Tumori, I-20133 Milano, Italy; VUB, Acad Ziekenhuis, Brussels, Belgium; Canc Inst Hosp, Japanese Fdn Canc Res, Tokyo, Japan; Univ Gottingen, Klin & Poliklin, D-3400 Gottingen, Germany; Osped S Carlo Borromeo, Milano, Italy; Inst Jules Bordet, B-1000 Brussels, Belgium; Ist Ric Farmacol Mario Negri, Milano, Italy; Inst Gustave Roussy, Villejuif, France; Inst Gustave Roussy, Villejuif, France; St Laurentius Ziekenhuis, Roermond, Netherlands	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; European Organisation for Research & Treatment of Cancer; University of Padua; Fondazione IRCCS Istituto Nazionale Tumori Milan; Vrije Universiteit Brussel; Japanese Foundation for Cancer Research; University of Gottingen; Institut Jules Bordet; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Rougier, P (corresponding author), Hop Ambroise Pare, Dept Med, Serv Hepatogastroenterol, 9 Ave Charles De Gaulle, F-92104 Boulogne, France.	philippe.rougier@apr.ap-hop-paris.fr	Labianca, Roberto/N-1847-2016; Apolone, Giovanni/R-9799-2016	Labianca, Roberto/0000-0001-7149-822X; Apolone, Giovanni/0000-0001-5179-104X; Marsoni, Silvia/0000-0002-5361-7122; Curran, Desmond/0000-0002-7423-0111	NATIONAL CANCER INSTITUTE [U10CA011488] Funding Source: NIH RePORTER; NCI NIH HHS [5U1O-CA11488-20, 5U1O-CA11488-19, 5U1O-CA11488-18] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEART RW, 1990, ARCH SURG-CHICAGO, V125, P897; BUYSE M, 1988, JAMA-J AM MED ASSOC, V259, P357; COX DR, 1972, J R STAT SOC B, V34, P187; FIELDING LP, 1992, LANCET, V340, P502, DOI 10.1016/0140-6736(92)91708-G; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; GOSLIN R, 1982, DIS COLON RECTUM, V25, P749, DOI 10.1007/BF02553304; GRAY BN, 1987, ADJUVANT THERAPY CAN, V5, P537; Gray R, 1997, JNCI-J NATL CANCER I, V89, P497; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAFFER UT, 1995, LANCET, V345, P349; MANTEL N, 1959, J NATL CANCER I, V22, P719; METZGER U, 1987, WORLD J SURG, V11, P452, DOI 10.1007/BF01655809; METZGER U, 1989, P AN M AM SOC CLIN, V8, P105; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; Nitti D, 1997, EUR J CANCER, V33, P1209, DOI 10.1016/S0959-8049(97)00052-X; OLDHAM U, 1985, ACTA CHIR SCAND, V151, P675; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; TAYLOR I, 1985, BRIT J SURG, V72, P359, DOI 10.1002/bjs.1800720509; WERELDSMA JCJ, 1990, CANCER, V65, P425, DOI 10.1002/1097-0142(19900201)65:3<425::AID-CNCR2820650309>3.0.CO;2-M; WOLMARK N, 1990, J CLIN ONCOL, V8, P1466, DOI 10.1200/JCO.1990.8.9.1466	22	59	60	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 6	1998	351	9117					1677	1681		10.1016/S0140-6736(97)08169-5	http://dx.doi.org/10.1016/S0140-6736(97)08169-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734883				2022-12-28	WOS:000074088900007
J	Poll, DJ				Poll, DJ			David James Mearns Anderson - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					952	952						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756833				2022-12-28	WOS:000076409000067
J	Alter, DA; Basinski, ASH; Naylor, CD				Alter, DA; Basinski, ASH; Naylor, CD			A survey of provider experiences and perceptions of preferential access to cardiovascular care in Ontario, Canada	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; ARTERY BYPASS-SURGERY; UNITED-STATES; CORONARY ANGIOGRAPHY; SOCIOECONOMIC-STATUS; CARDIAC PROCEDURES; HEALTH; SERVICES	Background: The public health insurance system in Canada is predicated on equal access to care for persons in need. Objective: To determine the views and experiences of Ontario physicians and hospital administrators in providing patients with preferential access to specialized cardiovascular care on the basis of nonclinical factors. Design: Survey with self-administered questionnaire. Setting: Ontario, Canada. Participants: All Ontario cardiologists (n = 268), cardiac surgeons (n = 68), and hospital chief executives (n = 218) and random samples of internists (n = 300) and family physicians (n = 300). Measurements: Elicited responses (yes or no) to questions on whether and why preferential access occurred and whether the respondents had been personally involved in such a situation. Results: After undeliverable surveys and respondents no longer involved with acute care were excluded, the eligible response rate was 71.3% (788 of 1105 respondents). More than 80% of physicians and 53% of hospital chief executives had been personally involved in managing a patient who had received preferential access on the basis of factors other than medical need. Patients deemed most likely to receive such treatment were those with personal ties to the treating physicians (93% [95% CI, 91% to 95%]), high-profile public figures (85% [CI, 82% to 87%]), and politicians (83% [CI, 80% to 86%]), Physicians were significantly more likely than chief executives to indicate that hospital board members (81% and 68%; P < 0.001) and donors to hospital foundations (63% and 42%; P < 0.001) would receive preferential access. Most respondents indicated that preferential access was more likely to be provided if patients or families were well informed, aggressive, or potentially litigious. The survey did not permit estimation of the frequency of episodes of preferential access. Conclusions: Although equality of access is a cornerstone principle of Canada's universal health care system, some access to specialized cardiovascular services occurs preferentially on the basis of factors other than clinical need. The actual magnitude and consequences of this phenomenon remain unknown.	Univ Toronto, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Naylor, CD (corresponding author), Sunnybrook Hlth Sci Ctr, G-106,2075 Bayview Ave, N York, ON M4N 3M5, Canada.							ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; BADGLEY RF, 1992, CANADIAN HLTH CARE S, P193; BLUSTEIN J, 1993, JAMA-J AM MED ASSOC, V270, P344, DOI 10.1001/jama.270.3.344; COS JL, 1994, J GEN INTERN MED, V9, P674, DOI 10.1007/BF02599007; ENTERLINE PE, 1973, NEW ENGL J MED, V289, P1174, DOI 10.1056/NEJM197311292892206; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; GATSONIS CA, 1995, MED CARE, V33, P625, DOI 10.1097/00005650-199506000-00005; Gerdtham UG, 1997, HEALTH ECON, V6, P303, DOI 10.1002/(SICI)1099-1050(199705)6:3<303::AID-HEC270>3.0.CO;2-P; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; KATZ SJ, 1994, JAMA-J AM MED ASSOC, V272, P530, DOI 10.1001/jama.272.7.530; KATZ SJ, 1991, JAMA-J AM MED ASSOC, V266, P1108, DOI 10.1001/jama.266.8.1108; MCISAAC W, 1997, J HEALTH SERV RES PO, V2, P4; NAVARRORUBIO MD, 1995, AM J PREV MED, V11, P256, DOI 10.1016/S0749-3797(18)30455-0; Naylor C D, 1992, Health Econ, V1, P19, DOI 10.1002/hec.4730010106; NAYLOR CD, 1995, CAN J CARDIOL, V11, P670; NAYLOR CD, 1995, LANCET, V346, P1605, DOI 10.1016/S0140-6736(95)91934-1; NAYLOR CD, 1991, HEALTH AFFAIR, V10, P110, DOI 10.1377/hlthaff.10.3.110; Payne N, 1997, BRIT MED J, V314, P257, DOI 10.1136/bmj.314.7076.257; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; Roos NP, 1997, MILBANK Q, V75, P89, DOI 10.1111/1468-0009.00045; SHIN AY, 1998, THESIS U TORONTO TOR; SULLIVAN P, 1990, CAN MED ASSOC J, V142, P50; UGNAT AM, 1994, CAN MED ASSOC J, V151, P575	23	27	27	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1998	129	7					567	572		10.7326/0003-4819-129-7-199810010-00011	http://dx.doi.org/10.7326/0003-4819-129-7-199810010-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	123KN	9758578				2022-12-28	WOS:000076124500009
J	Ganzini, L; Johnston, WS; McFarland, BH; Tolle, SW; Lee, MA				Ganzini, L; Johnston, WS; McFarland, BH; Tolle, SW; Lee, MA			Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOPELESSNESS; LIFE; ILL; OUTPATIENTS; EUTHANASIA; DEPRESSION; FAMILIES; QUALITY; HISTORY; IMPACT	Background and Methods Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease that causes gradual paralysis, respiratory failure, and death, usually within three to five years after it has been diagnosed. Between 1995 and 1997, we surveyed patients with this disease in Oregon and Washington, as well as their family care givers, in order to determine their attitudes toward assisted suicide. Patients were considered to be willing to contemplate assisted suicide if they agreed with the statement, "Under some circumstances I would consider taking a prescription for a medicine whose sole purpose was to end my life," and disagreed with the statement, "I would never request or take a prescription for a medication whose sole purpose was to end my life." The Oregon Death with Dignity Act, which legalized physician-assisted suicide, was approved by Oregon voters in 1994 but did not go into effect until October 1997, after data collection for this study had been completed. Results Of 140 eligible persons with ALS, 100 (71 percent) agreed to participate in the study, as did 91 family care givers. The mean age of the patients with ALS was 54 years; the mean duration of illness since the diagnosis was 2.8 years. Fifty-six patients (56 percent) said they would consider assisted suicide, and 44 of the 56 agreed with the statement, "If physician-assisted suicide were legal, I would request a lethal prescription from a physician." One patient would have taken the medication immediately, and 36 would have kept it for future use. As compared with the patients who were opposed to assisted suicide, those who would consider it were mure likely to be men, had a higher level of education, were less likely to be religious, had higher scores for hopelessness, and rated their quality of life as lower. In 66 of 91 instances (73 percent), care givers and patients had the same attitude toward assisted suicide. Conclusions In Oregon and Washington, a majority of persons with ALS whom we surveyed would consider assisted suicide. Many would request a prescription for a lethal dose of medication well before they intended to use it. (N Engl J Med 1998;339: 967-73.) (C)1998, Massachusetts Medical Society.	Vet Affairs Med Ctr, Mental Hlth Div P 7 1DMH, Portland, OR 97207 USA; Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Ctr Eth Hlth Care, Portland, OR 97201 USA; Providence ElderPlace, Portland, OR USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Ganzini, L (corresponding author), Vet Affairs Med Ctr, Mental Hlth Div P 7 1DMH, Portland, OR 97207 USA.		Johnston, Wendy S/E-2491-2013	Johnston, Wendy S/0000-0002-4330-5563; McFarland, Bentson/0000-0001-9149-5616				ARMITAGE P, 1987, STAT METHOS MED RES; BATTIN MP, 1995, ACAD MED, V70, P583; BECK AT, 1990, AM J PSYCHIAT, V147, P190; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BROADHEAD WE, 1988, MED CARE, V26, P709, DOI 10.1097/00005650-198807000-00006; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; CASSEL C, 1980, DIAGNOSIS TREATMENT, P325; Cherny N I, 1994, J Palliat Care, V10, P71; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Covinsky KE, 1996, ARCH INTERN MED, V156, P1737, DOI 10.1001/archinte.156.15.1737; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Fleiss J. L., 1981, STAT METHODS RATES P, V2; HENDIN H, 1997, SEDUCED DEATH DOCTOR; LEE BC, 1997, OREGON HLTH LAW MANU, V2; Lord F. M., 1968, STAT THEORIES MENTAL; MASSIE MJ, 1994, J PAIN SYMPTOM MANAG, V9, P325, DOI 10.1016/0885-3924(94)90192-9; MILTON N, 1995, ISSUES LAW MED, V11, P123; MINKOFF K, 1973, AM J PSYCHIAT, V130, P455; Moberg D. O., 1965, OLDER PEOPLE THEIR S, P125; PEARLMAN RA, 1991, J GERONTOL, V46, pM31, DOI 10.1093/geronj/46.2.M31; RINGEL SP, 1993, NEUROLOGY, V43, P1316, DOI 10.1212/WNL.43.7.1316; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	29	231	232	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1998	339	14					967	973		10.1056/NEJM199810013391406	http://dx.doi.org/10.1056/NEJM199810013391406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	124MW	9753713	Bronze			2022-12-28	WOS:000076186900006
J	Hlatky, MA; Boothroyd, D; Horine, S; Winston, C; Brooks, MM; Rogers, W; Pitt, B; Reeder, G; Ryan, T; Smith, H; Whitlow, P; Wiens, R; Mark, DB				Hlatky, MA; Boothroyd, D; Horine, S; Winston, C; Brooks, MM; Rogers, W; Pitt, B; Reeder, G; Ryan, T; Smith, H; Whitlow, P; Wiens, R; Mark, DB			Employment after coronary angioplasty or coronary bypass surgery in patients employed at the time of revascularization	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-LIFE; MEDICAL THERAPY; ARTERY-DISEASE; RANDOMIZED TRIAL; GRAFT-SURGERY; SURVIVAL	Background: Patients who undergo coronary angioplasty have a shorter convalescence than those who undergo coronary bypass surgery. This may improve subsequent employment. Objective: To compare employment patterns after coronary angioplasty or surgery. Design: Multicenter, randomized clinical trial. Setting: Seven tertiary care hospitals. Patients: 409 employed patients with multivessel coronary artery disease. Intervention: Coronary bypass surgery or balloon angioplasty. Measurements: Time to return to work and time spent working during 4 years of follow-up. Results: Patients who underwent angioplasty returned to work 6 weeks sooner than patients who underwent coronary bypass surgery (P < 0.001), but long-term employment did not differ significantly (P > 0.2). Long-term employment was significantly lower among patients who were 60 to 64 years of age (P < 0.001), those who worked less than full-time at study entry (P < 0.001), and those who had less formal education (P = 0.005). Patients with only one source of health insurance were more likely to continue working (P = 0.005). Conclusions: Faster recovery after angioplasty speeds return to work but does not improve long-term employment, which is primarily associated with nonmedical factors.	Stanford Univ, Sch Med, Stanford, CA 94305 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA; Univ Alabama Birmingham, Birmingham, AL 35294 USA; Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Boston Univ, Sch Med, Div Cardiol, Boston, MA 02118 USA; Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA; St Louis Univ, Sch Med, St Louis, MO USA; Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA	Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Alabama System; University of Alabama Birmingham; University of Michigan System; University of Michigan; Mayo Clinic; Boston University; Cleveland Clinic Foundation; Saint Louis University; Duke University	Hlatky, MA (corresponding author), Stanford Univ, Sch Med, HRP Redwood Bldg,Room 150, Stanford, CA 94305 USA.	hlatky@stanford.edu		Boothroyd, Derek Brian/0000-0001-5387-6995; Brooks, Maria/0000-0002-2030-7873; Hlatky, Mark/0000-0003-4686-9441; Mark, Daniel/0000-0001-6340-8087	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL038610] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38610] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alderman EL, 1997, JAMA-J AM MED ASSOC, V277, P715; Alderman EL, 1996, NEW ENGL J MED, V335, P217; BARI INV, 1991, CIRCULATION S5, V84, P27; Chamberlain DA, 1997, LANCET, V350, P461; DAVIDSON DM, 1983, J CARDIAC REHABIL, V3, P60; HAMPTON JR, 1993, LANCET, V341, P573; HLATKY MA, 1986, AM J CARDIOL, V58, P911, DOI 10.1016/S0002-9149(86)80009-1; Hlatky MA, 1997, NEW ENGL J MED, V336, P92, DOI 10.1056/NEJM199701093360203; HLATKY MA, 1995, AM J CARDIOL, V75, pC34; HUEB WA, 1995, J AM COLL CARDIOL, V26, P1600, DOI 10.1016/0735-1097(95)00384-3; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; MARK DB, 1994, ANN INTERN MED, V120, P111, DOI 10.7326/0003-4819-120-2-199401150-00003; MARK DB, 1992, CIRCULATION, V86, P1485, DOI 10.1161/01.CIR.86.5.1485; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; ROGERS WJ, 1990, CIRCULATION, V82, P1647, DOI 10.1161/01.CIR.82.5.1647; VARNAUSKAS E, 1985, CIRCULATION, V72, P90; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; 1989, J AM COLL CARDIOL, V14, P1003	18	32	32	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1998	129	7					543	547		10.7326/0003-4819-129-7-199810010-00006	http://dx.doi.org/10.7326/0003-4819-129-7-199810010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123KN	9758574				2022-12-28	WOS:000076124500005
J	McKenzie, R; O'Fallon, A; Dale, J; Demitrack, M; Sharma, G; Deloria, M; Garcia-Borreguero, D; Blackwelder, W; Straus, SE				McKenzie, R; O'Fallon, A; Dale, J; Demitrack, M; Sharma, G; Deloria, M; Garcia-Borreguero, D; Blackwelder, W; Straus, SE			Low-dose hydrocortisone for treatment of chronic fatigue syndrome - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORTICOTROPIN-RELEASING HORMONE; PITUITARY-ADRENAL AXIS; DEFINITION; EPIDEMIOLOGY; RESPONSES	Context.-Chronic fatigue syndrome (CFS) is associated with a dysregulated hypothalamic-pituitary adrenal axis and hypocortisolemia. Objective.-To evaluate the efficacy and safety of low-dose oral hydrocortisone as a treatment for CFS. Design.-A randomized, placebo-controlled, double-blind therapeutic trial, conducted between 1992 and 1996. Setting.-A single-center study in a tertiary care research institution. Patients.-A total of 56 women and 14 men aged 18 to 55 years who met the 1988 Centers for Disease Control and Prevention case criteria for CFS and who withheld concomitant treatment with other medications. Intervention.-Oral hydrocortisone, 13 mg/m(2) of body surface area every morning and 3 mg/m(2) every afternoon, or placebo, for approximately 12 weeks. Main Outcome Measures.-A global Wellness scale and other self-rating instruments were completed repeatedly before and during treatment. Resting and cosyntropin-stimulated cortisol levels were obtained before and at the end of treatment. Patients recorded adverse effects on a checklist. Results.-The number of patients showing improvement on the Wellness scale was 19 (54.3%) of 35 placebo recipients vs 20 (66.7%) of 30 hydrocortisone recipients (P=.31). Hydrocortisone recipients had a greater improvement in mean Wellness score (6.3 vs 1.7 points; P=.06), a greater percentage (53% vs 29%; P=.04) recording an improvement of 5 or more points in Wellness score, and a higher average improvement in Wellness score on more days than did placebo recipients (P<.001). Statistical evidence of improvement was not seen with other self-rating scales. Although adverse symptoms reported by patients taking hydrocortisone were mild, suppression of adrenal glucocorticoid responsiveness was documented in 12 patients who received it vs none in the placebo group (P<.001). Conclusions.-Although hydrocortisone treatment was associated with some improvement in symptoms of CFS, the degree of adrenal suppression precludes its practical use for CFS.	NIAID, Clin Invest Lab, NIH, Bethesda, MD 20892 USA; NIAID, Div Microbiol & Infect Dis, NIH, Bethesda, MD 20892 USA; NIMH, Clin Psychobiol Branch, NIH, Bethesda, MD 20892 USA; Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Michigan System; University of Michigan	Straus, SE (corresponding author), NIAID, Clin Invest Lab, NIH, 10 Ctr Dr,Room 11N228, Bethesda, MD 20892 USA.	Sstraus@atlas.niaid.nih.gov	Demitrack, Mark A/I-7697-2013	Deloria Knoll, Maria/0000-0001-9041-2671				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; [Anonymous], 1972, CLIN PHARMACOL THER, V13, P694; Baram TZ, 1996, MOL PSYCHIATR, V1, P320; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BERGNER M, 1976, INT J HEALTH SERV, V6, P393, DOI 10.2190/RHE0-GGH4-410W-LA17; BUCHWALD D, 1995, ANN INTERN MED, V123, P81, DOI 10.7326/0003-4819-123-2-199507150-00001; CARROLL BJ, 1976, ARCH GEN PSYCHIAT, V33, P1309; CROFFORD LJ, 1994, ARTHRITIS RHEUM-US, V37, P1583, DOI 10.1002/art.1780371105; DEMITRACK MA, 1991, J CLIN ENDOCR METAB, V73, P1224, DOI 10.1210/jcem-73-6-1224; Derogatis LR., 1977, SCL 90 ADM SCORING P; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; GUNN WJ, 1993, CIBA F SYMP, V173, P83; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; JEFFERIES WM, 1967, ARCH INTERN MED, V119, P265, DOI 10.1001/archinte.119.3.265; JOSEPHVANDERPOOL JR, 1991, J CLIN ENDOCR METAB, V72, P1382, DOI 10.1210/jcem-72-6-1382; KRUESI MJP, 1989, J CLIN PSYCHIAT, V50, P53; Leese G, 1996, J CLIN ENDOCR METAB, V81, P1867, DOI 10.1210/jc.81.5.1867; Mawle AC, 1995, CLIN INFECT DIS, V21, P1386, DOI 10.1093/clinids/21.6.1386; Mawle AC, 1997, J INFECT DIS, V175, P136, DOI 10.1093/infdis/175.1.136; McNair DM, 1981, PROFILE MOOD STATES; PETERSON PK, 1990, AM J MED, V89, P554, DOI 10.1016/0002-9343(90)90172-A; SCHLUEDERBERG A, 1992, ANN INTERN MED, V117, P325, DOI 10.7326/0003-4819-117-4-325; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; STRAUS SE, 1988, NEW ENGL J MED, V319, P1692, DOI 10.1056/NEJM198812293192602; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; STRAUS SE, 1994, CHRONIC FATIGUE SYND; STROBER W, 1994, CHRONIC FATIGUE SYND, P207; TAERK GS, 1987, INT J PSYCHIAT MED, V17, P49; TAYLOR AL, 1988, NEW ENGL J MED, V319, P213, DOI 10.1056/NEJM198807283190405; TIRELLI U, 1994, SCAND J IMMUNOL, V40, P601, DOI 10.1111/j.1365-3083.1994.tb03511.x; Vercoulen JHMM, 1996, LANCET, V347, P858, DOI 10.1016/S0140-6736(96)91345-8; Wessely S, 1996, J ROY COLL PHYS LOND, V30, P497; WESSELY S, 1995, EPIDEMIOL REV, V17, P139, DOI 10.1093/oxfordjournals.epirev.a036170	34	141	143	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 30	1998	280	12					1061	1066		10.1001/jama.280.12.1061	http://dx.doi.org/10.1001/jama.280.12.1061			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FJ	9757853	Bronze			2022-12-28	WOS:000076002400034
J	Levy, JA				Levy, JA			Caution: should we be treating HIV infection early?	LANCET			English	Editorial Material							VIRUS TYPE-1 INFECTION; RESPONSES; CELLS; AIDS		Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Levy, JA (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.							ALLET B, 1998, LANCET, V351, P1958; Angel JB, 1998, J INFECT DIS, V177, P898, DOI 10.1086/515244; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Blackbourn DJ, 1996, P NATL ACAD SCI USA, V93, P13125, DOI 10.1073/pnas.93.23.13125; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; LEVY JA, 1995, LANCET, V345, P1619, DOI 10.1016/S0140-6736(95)90121-3; Levy JA, 1996, SCIENCE, V271, P670, DOI 10.1126/science.271.5249.670; Levy JA, 1996, JAMA-J AM MED ASSOC, V276, P161, DOI 10.1001/jama.276.2.161; LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001; LEVY JA, 1998, HIV PATHOENESIS AIDS; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; Montaner JSG, 1998, AIDS, V12, P1398, DOI 10.1097/00002030-199811000-00028; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; ROWLANDJONES SL, 1995, CURR OPIN IMMUNOL, V7, P448, DOI 10.1016/0952-7915(95)80087-5; Shearer GM, 1996, IMMUNOL TODAY, V17, P21, DOI 10.1016/0167-5699(96)80564-0; STRANFORD S, UNPUB HIV EXPOSED UN; Tenner-Racz K, 1998, J EXP MED, V187, P949, DOI 10.1084/jem.187.6.949	23	51	51	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 19	1998	352	9132					982	983		10.1016/S0140-6736(98)05391-4	http://dx.doi.org/10.1016/S0140-6736(98)05391-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752836				2022-12-28	WOS:000076002200041
J	Maclure, M; Dormuth, C; Naumann, T; McCormack, J; Rangno, R; Whiteside, C; Wright, JM				Maclure, M; Dormuth, C; Naumann, T; McCormack, J; Rangno, R; Whiteside, C; Wright, JM			Influences of educational interventions and adverse news about calcium-channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia	LANCET			English	Article							ESSENTIAL-HYPERTENSION; RISK; MANAGEMENT; SOCIETY; TRIALS	Background The way in which dissemination of evidence changes medical practice needs td be better understood. Controversy about calcium-channel blockers (CCB) in the past 3 years has provided a natural experiment, enabling assessment of the impact of media stories, a national warning letter, a teleconference, small group workshops, and newsletters on first-line prescribing of antihypertensive drugs. Methods We included all physicians (4403) in British Columbia who prescribed a thiazide diuretic, beta-blocker, inhibitor of angiotensin-converting enzyme (ACE), or CCB as the first antihypertensive agent for 36 507 residents aged 66 years and over, with no previous or concurrent sign of underlying cardiovascular disease. We used a database covering all prescriptions to elderly people to measure the change in proportion of newly treated patients who received each class of drug as first-line therapy. We used a matched cohort design for assessment of the teleconference and workshops, a randomised community design for the newsletters, and time-series analysis for the media impacts. Findings The proportion of patients who received a CCB as first-line therapy declined gradually from 22% in early 1994 to 15% in late 1996. This proportion was not affected by two waves of adverse news about CCBs in 1995, but fell by 5% for 5 months and by 3% for 1 month after two waves in 1996. The proportion of patients who received either a CCB or an ACE inhibitor as first-fine therapy, contrary to guidelines, was still 42% overall in 1996. The workshops and newsletters were followed by shifts from first-line CCB to first-line thiazide prescribing. Interpretation Changes in prescribing practices occur gradually with the accumulation of small impacts from educational interventions and lay media attention.	British Columbia Minist Hlth, Victoria, BC V8W 3C8, Canada; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Univ Victoria, Dept Econ, Victoria, BC V8W 2Y2, Canada; Lions Gate Hosp, N Vancouver, BC, Canada; Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; Univ British Columbia, Dept Pharmacol & Therapeut, Vancouver, BC V6T 1W5, Canada; Univ British Columbia, Dept Med, Vancouver, BC, Canada; Univ British Columbia, Dept Family Practice, Vancouver, BC, Canada	Harvard University; Harvard T.H. Chan School of Public Health; University of Victoria; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Maclure, M (corresponding author), British Columbia Minist Hlth, 1515 Blanshard St, Victoria, BC V8W 3C8, Canada.	mmaclure@bcsc02.gov.bc.ca		Dormuth, Colin/0000-0001-8577-8783; McCormack, James/0000-0002-7801-5515				Barnett AA, 1996, LANCET, V347, P313; Borhani NO, 1996, JAMA-J AM MED ASSOC, V276, P785, DOI 10.1001/jama.276.10.785; Dean M, 1996, LANCET, V348, P951, DOI 10.1016/S0140-6736(05)65348-2; FREEMANTLE N, 1998, COCHRANE LIB; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; *HLTH PROT BRANCH, 1996, DEAR DOCTOR, V44, P1; INSUA JT, 1994, ANN INTERN MED, V121, P355, DOI 10.7326/0003-4819-121-5-199409010-00008; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; Kaplan NM, 1996, JAMA-J AM MED ASSOC, V275, P1577, DOI 10.1001/jama.275.20.1577; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; MARWICK C, 1996, JAMA-J AM MED ASSOC, V275, P638; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; Myers MG, 1996, CAN MED ASSOC J, V155, P772; OGILVIE RI, 1993, CAN MED ASSOC J, V149, P575; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; PAHOR M, 1996, AM J HYPERTENS, V9, P1429; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; PSATY BZ, 1995, CIRCULATION, V91, P925; REUTER, 1995, VANCOUVER SUN   0311, pA15; ROTHMAN K, 1986, MODERN EPIDEMIOLOGY, P173; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SOUMERAI SB, 1992, MILBANK Q, V70, P155, DOI 10.2307/3350088; *THER IN, 1995, THERAPEUTICS LETT, V8; *THER IN, 1995, THERAPEUTICS LETT, V7; THOMSON MA, 1998, COCHRANE LIB; *WHO, 1993, J HYPERTENS, V11, P906	30	58	58	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 19	1998	352	9132					943	948		10.1016/S0140-6736(97)11390-3	http://dx.doi.org/10.1016/S0140-6736(97)11390-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752816				2022-12-28	WOS:000076002200009
J	Nedivi, E; Wu, GY; Cline, HT				Nedivi, E; Wu, GY; Cline, HT			Promotion of dendritic growth by CPG15, an activity-induced signaling molecule	SCIENCE			English	Article							RECEPTOR TYROSINE KINASES; GANGLION-CELL DENDRITES; STRIATE CORTEX; OPTIC TECTUM; NEURONS; EXPRESSION; CLONING; LIGANDS; CAMKII; FROGS	Activity-independent and activity-dependent mechanisms work in concert to regulate neuronal growth, ensuring the formation of accurate synaptic connections. CPG15, a protein regulated by synaptic activity, functions as a cell-surface growth-promoting molecule in vivo. In Xenopus laevis, CPG15 enhanced dendritic arbor growth in projection neurons, with no effect on interneurons. CPG15 controlled growth of neighboring neuron's through an intercellular signaling mechanism that requires, its glycosylphosphatidylinositol link. CPG15 may represent a new class of activity-regulated, membrane-bound, growth-promoting proteins that permit exquisite spatial and temporal control of neuronal structure.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Nedivi, E (corresponding author), MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA.		Nedivi, Elly/ABC-9923-2021	/0000-0002-1710-0767	NATIONAL EYE INSTITUTE [R29EY011894] Funding Source: NIH RePORTER; NEI NIH HHS [R29 EY011894, R29 EY011894-04] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTAL M, 1986, J COMP NEUROL, V246, P238, DOI 10.1002/cne.902460208; BODNARENKO SR, 1993, NATURE, V364, P144, DOI 10.1038/364144a0; Brummendorf T, 1996, CURR OPIN NEUROBIOL, V6, P584, DOI 10.1016/S0959-4388(96)80089-4; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Friedman GC, 1996, CURR OPIN NEUROBIOL, V6, P127, DOI 10.1016/S0959-4388(96)80018-3; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; KATZ LC, 1988, J NEUROSCI, V8, P3160; KOSSEL A, 1995, J NEUROSCI, V15, P3913; LUND JS, 1991, J COMP NEUROL, V309, P129, DOI 10.1002/cne.903090109; MACKETT M, 1985, DNA CLONING PRACTICA; MATSUMOTO N, 1986, J COMP PHYSIOL A, V159, P721, DOI 10.1007/BF00603726; Naeve GS, 1997, P NATL ACAD SCI USA, V94, P2648, DOI 10.1073/pnas.94.6.2648; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; Nedivi E, 1996, P NATL ACAD SCI USA, V93, P2048, DOI 10.1073/pnas.93.5.2048; NEDIVI E, UNPUB; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; SAMBROOK J, 1989, MOL CLONIGN LAB MANU; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHOLL DA, 1953, J ANAT, V87, P387; TIEMAN SB, 1982, J COMP NEUROL, V211, P353, DOI 10.1002/cne.902110403; WONG ROL, 1991, J NEUROBIOL, V22, P685, DOI 10.1002/neu.480220704; WU GY, 1995, NEURON, V14, P681, DOI 10.1016/0896-6273(95)90211-2; Wu GY, 1998, SCIENCE, V279, P222, DOI 10.1126/science.279.5348.222; Zou DJ, 1996, NEURON, V16, P529, DOI 10.1016/S0896-6273(00)80072-0	28	166	175	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1863	1866		10.1126/science.281.5384.1863	http://dx.doi.org/10.1126/science.281.5384.1863			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743502	Green Accepted			2022-12-28	WOS:000076007100057
J	Plath, K; Mothes, W; Wilkinson, BM; Stirling, CJ; Rapoport, TA				Plath, K; Mothes, W; Wilkinson, BM; Stirling, CJ; Rapoport, TA			Signal sequence recognition in posttranslational protein transport across the yeast ER membrane	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; ESCHERICHIA-COLI; SEC PROTEINS; TRANSLOCATION; COMPLEX; POLYPEPTIDES; COMPONENT; DOMAINS; KAR2P; BIP	We have analyzed how the signal sequence of prepor-alpha-factor is recognized during the first step of posttranslational protein transport into the yeast endoplasmic reticulum. Cross-linking studies indicate that the signal sequence interacts in a Kar2p- and ATP-independent reaction with Sec61p, the multispanning membrane component of the protein-conducting channel, by intercalation into transmembrane domains 2 and 7. While bound to Sec61p, the signal sequence forms a helix that is contacted on one side by Sec62p and Sec71p. The binding site is located at the interface of the protein channel and the lipid bilayer. Signal sequence recognition in cotranslational translocation in mammals appears to occur similarly. These results suggest a general mechanism by which the signal sequence could open the channel for polypeptide transport.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; University of Manchester	Rapoport, TA (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.			Plath, Kathrin/0000-0001-7796-3372	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054238] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54238] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; FLOWER AM, 1995, EMBO J, V14, P884, DOI 10.1002/j.1460-2075.1995.tb07070.x; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; ITO K, 1995, ADV CELL MOL BIOL M, V4, P35; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Matlack KES, 1997, SCIENCE, V277, P938, DOI 10.1126/science.277.5328.938; Mothes W, 1998, J CELL BIOL, V142, P355, DOI 10.1083/jcb.142.2.355; MURPHY CK, 1994, P NATL ACAD SCI USA, V91, P2557, DOI 10.1073/pnas.91.7.2557; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; OSBORNE RS, 1993, EMBO J, V12, P3391, DOI 10.1002/j.1460-2075.1993.tb06013.x; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SAKO T, 1991, J BACTERIOL, V173, P2289, DOI 10.1128/JB.173.7.2289-2296.1991; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; Wilkinson BM, 1997, EMBO J, V16, P4549, DOI 10.1093/emboj/16.15.4549	21	273	278	3	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					795	807		10.1016/S0092-8674(00)81738-9	http://dx.doi.org/10.1016/S0092-8674(00)81738-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753326	Bronze			2022-12-28	WOS:000076021200012
J	Rongo, C; Whitfield, CW; Rodal, A; Kim, SK; Kaplan, JM				Rongo, C; Whitfield, CW; Rodal, A; Kim, SK; Kaplan, JM			LIN-10 is a shared component of the polarized protein localization pathways in neurons and epithelia	CELL			English	Article							GLR-1 GLUTAMATE-RECEPTOR; ELEGANS VULVAR INDUCTION; PDZ-DOMAIN PROTEIN; C-ELEGANS; CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; FASCICLIN-II; GENE; CHANNEL; RECOGNITION	We tested the model that neurons and epithelial cells use a shared mechanism for polarized protein sorting by comparing the pathways for localizing basolateral and postsynaptic proteins in C. elegans. GLR-1 glutamate receptors are localized to postsynaptic elements of central synapses and, when ectopically expressed, to basolateral membranes of epithelial cells. Proper localization of GLR-1 in both neurons and epithelia requires the PDZ protein LIN-10, defining LIN-10 as a shared component of the basolateral and postsynaptic localization pathways. Changing the GLR-1 carboxyterminal sequence from a group I PDZ-binding consensus (-TAV) to a group II consensus (-FYV) restores GLR-1 synaptic localization in lin-10 mutants. Thus, these interneurons utilize at least two separate postsynaptic localization pathways.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA	University of California System; University of California Berkeley; Stanford University	Kaplan, JM (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032196] Funding Source: NIH RePORTER; NINDS NIH HHS [NS32196] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Borg JP, 1996, MOL CELL BIOL, V16, P6229; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHALFIE M, 1985, J NEUROSCI, V5, P956; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HART AC, 1995, NATURE, V378, P82, DOI 10.1038/378082a0; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hoskins R, 1996, DEVELOPMENT, V122, P97; Isaacson JS, 1998, NEURON, V20, P749, DOI 10.1016/S0896-6273(00)81013-2; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Keller P, 1997, J CELL SCI, V110, P3001; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; MARICQ AV, 1995, NATURE, V378, P78, DOI 10.1038/378078a0; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Sheng M, 1997, BIOESSAYS, V19, P847, DOI 10.1002/bies.950191004; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Thomas U, 1997, NEURON, V19, P787, DOI 10.1016/S0896-6273(00)80961-7; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	32	212	226	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1998	94	6					751	759		10.1016/S0092-8674(00)81734-1	http://dx.doi.org/10.1016/S0092-8674(00)81734-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753322	Bronze			2022-12-28	WOS:000076021200008
J	Sandweiss, DH; McInnis, H; Burger, RL; Cano, A; Ojeda, B; Paredes, R; Sandweiss, MD; Glascock, MD				Sandweiss, DH; McInnis, H; Burger, RL; Cano, A; Ojeda, B; Paredes, R; Sandweiss, MD; Glascock, MD			Quebrada Jaguay: Early South American maritime adaptations	SCIENCE			English	Article							CAVE	Excavations at Quebrada Jaguay 280 (QJ-280) (16 degrees 30'S) in south coastal Peru demonstrated that Paleoindian-age people of the Terminal Pleistocene (about 11,100 to 10,000 carbon-14 years before the present or about 13,000 to 11,000 calibrated years before the present) in South America relied on marine resources while resident on the coast, which extends the South American record of maritime exploitation by a millennium. This site supports recent evidence that Paleoindian-age people had diverse subsistence systems. The presence of obsidian at QJ-280 shows that the inhabitants had contact with the adjacent Andean highlands during the Terminal Pleistocene.	Univ Maine, Dept Anthropol, Orono, ME 04469 USA; Univ Maine, Inst Quaternary Studies, Orono, ME 04469 USA; Yale Univ, Peabody Museum Nat Hist, New Haven, CT 06520 USA; Univ Nacl Mayor San Marcos, Museo Hist Nat, Lima 14, Peru; Univ Maine, Dept Modern Languages, Orono, ME 04469 USA; Univ Missouri, Res Reactor Ctr, Columbia, MO 65211 USA	University of Maine System; University of Maine Orono; University of Maine System; University of Maine Orono; Yale University; Universidad Nacional Mayor de San Marcos; University of Maine System; University of Maine Orono; University of Missouri System; University of Missouri Columbia	Sandweiss, DH (corresponding author), Univ Maine, Dept Anthropol, S Stevens Hall, Orono, ME 04469 USA.		Sandweiss, Daniel/K-5808-2019; Glascock, Michael D./O-8951-2014	Cano, Asuncion/0000-0002-5759-4650; Glascock, Michael D./0000-0003-0686-7556				Bryan A. L., 1978, OCCASIONAL PAPERS U, P274; BURGER RL, IN PRESS ANDEAN PAST; Engel F., 1981, PREHISTORIC ANDEAN E, V2; Erlandson JM, 1996, RADIOCARBON, V38, P355, DOI 10.1017/S0033822200017689; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; FLADMARK KR, 1979, AM ANTIQUITY, V44, P55, DOI 10.2307/279189; Gruhn R., 1994, METHOD THEORY INVEST, P249; Keefer DK, 1998, SCIENCE, V281, P1833, DOI 10.1126/science.281.5384.1833; LYNCH TF, 1971, AM ANTIQUITY, V36, P139, DOI 10.2307/278667; Lynch Thomas F., 1991, CLOVIS ORIGINS ADAPT, P255; Richardson J.B., 1981, ANN CARNEGIE MUS, V50, P139; Roosevelt AC, 1996, SCIENCE, V272, P373, DOI 10.1126/science.272.5260.373; Sandweiss D. H., 1989, ECOLOGY SETTLEMENT H, P35; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; TAYLOR RE, 1967, SCIENCE, V158, P1180, DOI 10.1126/science.158.3805.1180-a; YESNER D., 1996, HUMANS END ICE AGE, P243; ZIOLKOWSKI MS, 1994, ANDES RADIOCARBON DA, P312	17	226	231	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1830	1832		10.1126/science.281.5384.1830	http://dx.doi.org/10.1126/science.281.5384.1830			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743490				2022-12-28	WOS:000076007100045
J	West, SC				West, SC			RuvA gets X-rayed on Holliday	CELL			English	Review							DNA BRANCH MIGRATION; JUNCTION; RECOMBINATION; COMPLEX		Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England		West, SC (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.			West, Stephen/0000-0001-8848-9418				ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hargreaves D, 1998, NAT STRUCT BIOL, V5, P441, DOI 10.1038/nsb0698-441; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; PANYUTIN IG, 1995, EMBO J, V14, P1819, DOI 10.1002/j.1460-2075.1995.tb07170.x; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; ROE SM, 1998, IN PRESS MOL CELL; van Gool AJ, 1998, EMBO J, V17, P1838, DOI 10.1093/emboj/17.6.1838; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; Whitby MC, 1996, J MOL BIOL, V264, P878, DOI 10.1006/jmbi.1996.0684; Zerbib D, 1998, J MOL BIOL, V281, P621, DOI 10.1006/jmbi.1998.1959	14	12	12	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					699	701		10.1016/S0092-8674(00)81729-8	http://dx.doi.org/10.1016/S0092-8674(00)81729-8			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753317	Bronze			2022-12-28	WOS:000076021200003
J	Rajamani, K; Fisher, M				Rajamani, K; Fisher, M			Bullet embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ So Calif, Sch Med, Los Angeles, CA 90033 USA	University of Southern California	Rajamani, K (corresponding author), Univ So Calif, Sch Med, Los Angeles, CA 90033 USA.								0	5	6	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1998	339	12					812	812		10.1056/NEJM199809173391205	http://dx.doi.org/10.1056/NEJM199809173391205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119QT	9738089				2022-12-28	WOS:000075909200005
J	Biagi, F; Poggioli, G; Mazzoni, G; Corazza, GR				Biagi, F; Poggioli, G; Mazzoni, G; Corazza, GR			Intestinal strictures	LANCET			English	Article							CELIAC-DISEASE; ULCERATION		Univ Bologna, Dept Med, I-40126 Bologna, Italy; Univ Bologna, Dept Surg, I-40126 Bologna, Italy; Univ Bologna, Dept Radiol, I-40126 Bologna, Italy	University of Bologna; University of Bologna; University of Bologna	Corazza, GR (corresponding author), Dept Internal Med, Via San Sisto 22E, I-67100 Laquila, Italy.		Biagi, Federico/G-2812-2011; poggioli, gilberto/AAC-7599-2022; Corazza, Gino Roberto/K-8500-2016	Biagi, Federico/0000-0002-2227-4622; Corazza, Gino Roberto/0000-0001-9532-0573				BAER AN, 1980, GASTROENTEROLOGY, V79, P754; Eltumi M, 1996, GUT, V39, P613, DOI 10.1136/gut.39.4.613; ROBERTSON DAF, 1983, GUT, V24, P565, DOI 10.1136/gut.24.6.565; TJANDRA JJ, 1994, BRIT J SURG, V81, P561, DOI 10.1002/bjs.1800810426; WRIGHT DH, 1995, BAILLIERE CLIN GASTR, V9, P351, DOI 10.1016/0950-3528(95)90035-7	5	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					876	876		10.1016/S0140-6736(98)06170-4	http://dx.doi.org/10.1016/S0140-6736(98)06170-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742981				2022-12-28	WOS:000075857300011
J	Sherwood, T; Peters, K				Sherwood, T; Peters, K			The value of discrimination	LANCET			English	Article							CONTRIBUTORS; AUTHORSHIP		Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Cambridge CB2 2SP, England	Addenbrooke's Hospital; University of Cambridge	Peters, K (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Hills Rd, Cambridge CB2 2SP, England.							Crossan L, 1998, BRIT MED J, V316, P1406, DOI 10.1136/bmj.316.7142.1406; Horton R, 1998, LANCET, V351, P688, DOI 10.1016/S0140-6736(98)22010-1; Horton R, 1997, LANCET, V350, P5, DOI 10.1016/S0140-6736(05)66236-8; LACHMANN PJ, 1997, R SOC SCI PUBLIC WIN, P8; Orwell George., 1961, COLLECTED ESSAYS; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; Smith R, 1997, BRIT MED J, V315, P696, DOI 10.1136/bmj.315.7110.696	7	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					896	897		10.1016/S0140-6736(05)60035-9	http://dx.doi.org/10.1016/S0140-6736(05)60035-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9743000				2022-12-28	WOS:000075857300046
J	Wang, XQ; Lin, XL; Loy, JA; Tang, J; Zhang, XJC				Wang, XQ; Lin, XL; Loy, JA; Tang, J; Zhang, XJC			Crystal structure of the catalytic domain of human plasmin complexed with streptokinase	SCIENCE			English	Article							ALPHA-CHYMOTRYPSIN; ACTIVATION; GENE; STAPHYLOKINASE; IDENTIFICATION; STABILITY; PROTEASES; PROENZYME; SEQUENCE; ZYMOGEN	Streptokinase is a plasminogen activator widely used in treating blood-clotting disorders. Complexes of streptokinase with human plasminogen can hydrolytically activate other plasminogen molecules to plasmin, which then dissolves blood clots. A similar binding activation mechanism also occurs in some key steps of blood coagulation. The crystal structure of streptokinase complexed with the catalytic unit of human plasmin was solved at 2.9 angstroms. The amino-terminal domain of streptokinase in the complex is hypothesized to enhance the substrate recognition. The carboxyl-terminal domain of streptokinase, which binds near the activation Loop of plasminogen, is Likely responsible for the contact activation of plasminogen in the complex.	Oklahoma Med Res Fdn, Crystallog Program, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Prot Studies Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	Zhang, XJC (corresponding author), Oklahoma Med Res Fdn, Crystallog Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.				NHLBI NIH HHS [HL 60626] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060626] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bachmann F., 1994, HEMOSTASIS THROMBOSI, V3rd, P1592; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CASTELLINO FJ, 1979, TRENDS BIOCHEM SCI, V4, P1, DOI 10.1016/0968-0004(79)90235-4; ConejeroLara F, 1996, PROTEIN SCI, V5, P2583, DOI 10.1002/pro.5560051221; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; DAWSON KM, 1994, BIOCHEMISTRY-US, V33, P12042, DOI 10.1021/bi00206a005; de la Cadena RA, 1994, HEMOSTASIS THROMBOSI, P219; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; GANU VS, 1982, INT J PEPT PROT RES, V20, P421; Grella DK, 1997, BLOOD, V89, P1585, DOI 10.1182/blood.V89.5.1585.1585_1585_1589; HAREL M, 1991, BIOCHEMISTRY-US, V30, P5217, DOI 10.1021/bi00235a015; ICHINOSE A, 1991, P NATL ACAD SCI USA, V88, P115, DOI 10.1073/pnas.88.1.115; JACKSON KW, 1982, BIOCHEMISTRY-US, V21, P6620, DOI 10.1021/bi00269a001; JACKSON KW, 1986, BIOCHEMISTRY-US, V25, P108, DOI 10.1021/bi00349a016; Jespers L, 1998, BIOCHEMISTRY-US, V37, P6380, DOI 10.1021/bi972807i; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; Lee SH, 1997, BIOCHEM MOL BIOL INT, V41, P199; LIN XL, 1994, METHOD ENZYMOL, V241, P195; LIN XL, ADV EXP MED BIOL, V306, P255; MALKE H, 1985, GENE, V34, P357, DOI 10.1016/0378-1119(85)90145-3; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; Medved LV, 1996, EUR J BIOCHEM, V239, P333, DOI 10.1111/j.1432-1033.1996.0333u.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; Nihalani D, 1998, PROTEIN SCI, V7, P637, DOI 10.1002/pro.5560070313; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PETERSEN TE, 1990, J BIOL CHEM, V265, P6104; Rabijns A, 1997, NAT STRUCT BIOL, V4, P357, DOI 10.1038/nsb0597-357; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REED GL, 1995, BIOCHEMISTRY-US, V34, P10266, DOI 10.1021/bi00032a021; Renatus M, 1997, BIOCHEMISTRY-US, V36, P13483, DOI 10.1021/bi971129x; Renatus M, 1997, EMBO J, V16, P4797, DOI 10.1093/emboj/16.16.4797; ROBBINS KC, 1981, METHOD ENZYMOL, V80, P379; RODRIGUEZ P, 1995, EUR J BIOCHEM, V229, P83, DOI 10.1111/j.1432-1033.1995.0083l.x; SCHIMMEL P, 1989, ACCOUNTS CHEM RES, V22, P232, DOI 10.1021/ar00163a001; SCHLOTT B, 1994, BBA-PROTEIN STRUCT M, V1204, P235, DOI 10.1016/0167-4838(94)90013-2; SHI GY, 1990, THROMB RES, V58, P317, DOI 10.1016/0049-3848(90)90101-H; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; Tachias K, 1997, J BIOL CHEM, V272, P28; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; VILLIERS CL, 1985, P NATL ACAD SCI USA, V82, P4477, DOI 10.1073/pnas.82.13.4477; Young KC, 1998, J BIOL CHEM, V273, P3110, DOI 10.1074/jbc.273.5.3110; YOUNG KC, 1995, J BIOL CHEM, V270, P29601, DOI 10.1074/jbc.270.49.29601; ZHANG XJ, 1995, J APPL CRYSTALLOGR, V28, P624, DOI 10.1107/S0021889895001063	48	194	212	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1662	1665		10.1126/science.281.5383.1662	http://dx.doi.org/10.1126/science.281.5383.1662			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733510				2022-12-28	WOS:000075856500043
J	Rossetti, Y; Rode, G; Pisella, L; Farne, A; Li, L; Boisson, D; Perenin, MT				Rossetti, Y; Rode, G; Pisella, L; Farne, A; Li, L; Boisson, D; Perenin, MT			Prism adaptation to a rightward optical deviation rehabilitates left hemispatial neglect	NATURE			English	Article							UNILATERAL VISUAL NEGLECT; VESTIBULAR STIMULATION; MOTOR CONTROL; HEMINEGLECT; CORTEX	A large proportion of right-hemisphere stroke patients show hemispatial neglect-a neurological deficit of perception, attention, representation, and/or performing actions within their left-sided space(1), inducing many functional debilitating effects on everyday life, and responsible for poor functional recovery and ability to benefit from treatment(2). The frequent parietal locus of the lesion producing neglect reflects the impairment of coordinate transformation used by the nervous system to represent extrapersonal space. Given that adaptation to a visual distortion can provide an efficient way to stimulate neural structures responsible for the transformation of sensorimotor coordinates, the aim of our study was to investigate the effect of prism adaptation on various neglect symptoms, including the pathological shift of the subjective midline to the right. All patients exposed to the optical shift of the visual field to the right were improved on their manual body-midline demonstration and on classical neuropsychological tests. Unlike other physiological manipulations used to improve neglect, this improvement lasted for at least two hours after prism removal and thus could be useful in rehabilitation programmes. The positive effect found for both sensorimotor and more cognitive spatial functions suggests that they share or depend on a common level of space representation linked to multisensory integration.	Hospices Civils Lyon, Hop Henry Gabrielle, Serv Reeduc Neurol, F-69565 St Genis Laval, France; Univ Claude Bernard, F-69565 St Genis Laval, France; Espace & Act, INSERM, U94, F-69676 Bron, France; Hop Neurol, Serv Reeduc, F-69003 Lyon, France	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon	Rossetti, Y (corresponding author), Hospices Civils Lyon, Hop Henry Gabrielle, Serv Reeduc Neurol, BP 57, F-69565 St Genis Laval, France.	rossetti@lyon151.inserm.fr	Rossetti, Yves/H-3693-2017; FARNE, ALESSANDRO/G-1238-2015; Pisella, Laure/H-6072-2017; Rode, Gilles/J-8933-2017	Rossetti, Yves/0000-0001-8867-4496; FARNE, ALESSANDRO/0000-0001-5769-3491; Pisella, Laure/0000-0001-6550-3774; 				ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; Chokron S, 1997, NEUROPSYCHOLOGIA, V35, P1503, DOI 10.1016/S0028-3932(97)00079-1; Clower DM, 1996, NATURE, V383, P618, DOI 10.1038/383618a0; Coello Y, 1996, NEUROPSYCHOLOGIA, V34, P879, DOI 10.1016/0028-3932(96)00003-6; Farne A, 1998, NEUROPSYCHOLOGIA, V36, P611, DOI 10.1016/S0028-3932(97)00164-4; GAINOTTI G, 1972, J NEUROL NEUROSUR PS, V35, P545, DOI 10.1136/jnnp.35.4.545; HALLIGAN PW, 1989, LANCET, V2, P908; HALLIGAN PW, 1993, CRIT REV PHYS REHABI, V5, P57; Heilman K.M., 1985, INT J CLIN NEUROPSYC, V2nd, P243; JEANNEROD M, 1993, VISUAL PERCEPTUAL DE, P439; KARNATH HO, 1994, BRAIN, V117, P1001, DOI 10.1093/brain/117.5.1001; Mattingley JB, 1998, NATURE, V392, P179, DOI 10.1038/32413; PERENIN MT, 1997, PARIETAL LOBE CONTRI, P298; PIZZAMIGLIO L, 1990, CORTEX, V26, P535, DOI 10.1016/S0010-9452(13)80303-6; Redding GM, 1996, J EXP PSYCHOL HUMAN, V22, P379, DOI 10.1037/0096-1523.22.2.379; RODE G, 1994, NEUROREPORT, V5, P869, DOI 10.1097/00001756-199404000-00004; ROSSETTI Y, 1993, PERCEPT PSYCHOPHYS, V54, P355, DOI 10.3758/BF03205270; ROSSI PW, 1990, NEUROLOGY, V40, P1597, DOI 10.1212/WNL.40.10.1597; RUBENS AB, 1985, NEUROLOGY, V35, P1019, DOI 10.1212/WNL.35.7.1019; Sakata Hideo, 1994, Current Opinion in Neurobiology, V4, P847, DOI 10.1016/0959-4388(94)90133-3; SCHENKENBERG T, 1980, NEUROLOGY, V30, P509, DOI 10.1212/WNL.30.5.509; Sugita Y, 1996, NATURE, V380, P523, DOI 10.1038/380523a0; Vallar G., 1997, PARIETAL LOBE CONTRI, P555; Walker R, 1996, NEUROPSYCHOL REHABIL, V6, P219, DOI 10.1080/713755508	24	611	617	0	94	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1998	395	6698					166	169		10.1038/25988	http://dx.doi.org/10.1038/25988			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744273				2022-12-28	WOS:000075829900040
J	Sampath, K; Rubinstein, AL; Cheng, AHS; Liang, JO; Fekany, K; Solnica-Krezel, L; Korzh, V; Halpern, ME; Wright, CVE				Sampath, K; Rubinstein, AL; Cheng, AHS; Liang, JO; Fekany, K; Solnica-Krezel, L; Korzh, V; Halpern, ME; Wright, CVE			Induction of the zebrafish ventral brain and floorplate requires cyclops/nodal signalling	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; DEVELOPING SPINAL-CORD; ACTIVIN-A; EXPRESSION; MIDLINE; PLATE; FOREBRAIN; DIFFERENTIATION; ASYMMETRY; PATTERN	Zebrafish cyclops (cyc) mutations cause deficiencies in the dorsal mesendoderm(1,2) and ventral neural tube(3,4), leading to neural defects and cyclopia(5,6). Here we report that cyc encodes a transforming growth factor-beta (TGF-beta)-related intercellular signalling molecule that is similar to mouse nodal(7). cyc is expressed in dorsal mesendoderm at gastrulation and in the prechordal plate until early somitogenesis. Expression reappears transiently in the left lateral-plate mesoderm, and in an unprecedented asymmetric pattern in the left forebrain. Injection of cyc RNA non-autonomously restores sonic hedgehog-expressing cells of the ventral brain and floorplate that are absent in cyc mutants, whereas inducing activities are abolished by cyc(m294), a mutation of a conserved cysteine in the mature ligand. Our results indicate that cyc provides an essential non-cell-autonomous signal at gastrulation, leading to induction of the floorplate and ventral brain.	Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37232 USA; Natl Univ Singapore, Inst Mol Agrobiol, Singapore 117604, Singapore; Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA	Vanderbilt University; Vanderbilt University; National University of Singapore; Carnegie Institution for Science	Wright, CVE (corresponding author), Vanderbilt Univ, Sch Med, Dept Cell Biol, 221 Kirkland Hall, Nashville, TN 37232 USA.		Korzh, Vladimir P/H-1596-2011	Korzh, Vladimir P/0000-0002-6580-7986; Sampath, Karuna/0000-0002-0729-1977				ARTINGER KB, 1993, NEURON, V11, P1147, DOI 10.1016/0896-6273(93)90227-I; Brand M, 1996, DEVELOPMENT, V123, P129; Butler A. B., 1996, HODOS H COMP VERTEBR; Chen JN, 1997, DEVELOPMENT, V124, P4373; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Dale JK, 1997, CELL, V90, P257, DOI 10.1016/S0092-8674(00)80334-7; FELDMAN B, IN PRESS NATURE; Halpern ME, 1997, DEV BIOL, V187, P154, DOI 10.1006/dbio.1997.8605; HATTA K, 1994, P NATL ACAD SCI USA, V91, P2061, DOI 10.1073/pnas.91.6.2061; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; Heisenberg CP, 1997, DEV BIOL, V184, P85, DOI 10.1006/dbio.1997.8511; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Knapik EW, 1998, NAT GENET, V18, P338, DOI 10.1038/ng0498-338; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; MACDONALD R, 1994, NEURON, V13, P1039, DOI 10.1016/0896-6273(94)90044-2; MASON AJ, 1994, MOL ENDOCRINOL, V8, P325, DOI 10.1210/me.8.3.325; Pera EM, 1997, DEVELOPMENT, V124, P4153; PITUELLO F, 1995, P NATL ACAD SCI USA, V92, P6952, DOI 10.1073/pnas.92.15.6952; POSTLETHWAIT JH, 1994, SCIENCE, V264, P699, DOI 10.1126/science.8171321; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Rebagliati MR, 1998, DEV BIOL, V199, P261, DOI 10.1006/dbio.1998.8935; Schier AF, 1996, DEVELOPMENT, V123, P165; Strahle U, 1997, Genes Funct, V1, P131; Talbot WS, 1998, GENETICS, V148, P373; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; THISSE C, 1994, DEV BIOL, V164, P420, DOI 10.1006/dbio.1994.1212; TOYAMA R, 1995, DEVELOPMENT, V121, P383; Varlet I, 1997, CURR OPIN GENET DEV, V7, P519, DOI 10.1016/S0959-437X(97)80080-9; VARLET J, 1997, COLD SPRING HAR S QU, V62, P105; WARGA RM, 1996, THESIS U TUBINGEN; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6	32	399	408	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1998	395	6698					185	189		10.1038/26020	http://dx.doi.org/10.1038/26020			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744278				2022-12-28	WOS:000075829900045
J	Monks, CRF; Freiberg, BA; Kupfer, H; Sciaky, N; Kupfer, A				Monks, CRF; Freiberg, BA; Kupfer, H; Sciaky, N; Kupfer, A			Three-dimensional segregation of supramolecular activation clusters in T cells	NATURE			English	Article							SIGNAL-TRANSDUCTION; B-CELLS; MEMBRANE; ADHESION; PROTEINS	Activation of T cells by antigen-presenting Cells (APCs) depends on the complex integration of signals that are delivered by multiple antigen receptors. Most receptor-proximal activation events in T cells(1,2) were identified using multivalent anti-receptor antibodies, eliminating the need to use the more complex APCs. As the physiological membrane-associated ligands ori the APC and the activating antibodies probably trigger the same biochemical pathways, it is unknown why the antibodies, even at saturating concentrations, fail to trigger some of the physiological T-cell responses(3). Here we study, at the level of the single cell, the responses of T cells to native ligands. We used a digital imaging system and analysed the three-dimensional distribution of receptors and intracellular proteins that cluster at the contacts between T cells and APCs during antigen-specific interactions(3,4). Surprisingly, instead of showing uniform oligomerization, these proteins clustered into segregated three-dimensional domains within the cell contacts. The antigen-specific formation of these new, spatially segregated supramolecular activation clusters may generate appropriate physiological responses and may explain the high sensitivity of the T cells to antigen.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Cellular & Struct Biol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kupfer, A (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.							ANDERSON MS, 1993, J EXP MED, V178, P1959, DOI 10.1084/jem.178.6.1959; Dittel BN, 1997, J IMMUNOL, V158, P4065; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HIRAOKA Y, 1990, BIOPHYS J, V57, P325, DOI 10.1016/S0006-3495(90)82534-0; KUPFER A, 1990, J MOL CELL IMMUNOL, V4, P317; KUPFER A, 1989, J EXP MED, V170, P1697, DOI 10.1084/jem.170.5.1697; KUPFER H, 1994, J EXP MED, V179, P1507, DOI 10.1084/jem.179.5.1507; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MCCLOSKEY MA, 1986, J CELL BIOL, V102, P2185, DOI 10.1083/jcb.102.6.2185; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PODACK ER, 1991, ANNU REV CELL BIOL, V7, P479, DOI 10.1146/annurev.cellbio.7.1.479; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	16	1890	1938	0	95	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1998	395	6697					82	86		10.1038/25764	http://dx.doi.org/10.1038/25764			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116JY	9738502				2022-12-28	WOS:000075722200051
J	Lewis, G; Bebbington, P; Brugha, T; Farrell, M; Gill, B; Jenkins, R; Meltzer, H				Lewis, G; Bebbington, P; Brugha, T; Farrell, M; Gill, B; Jenkins, R; Meltzer, H			Socioeconomic status, standard of living, and neurotic disorder	LANCET			English	Article							PSYCHIATRIC-MORBIDITY; PRIMARY-CARE; SOCIAL-CLASS; HEALTH; PREVALENCE; DEPRESSION; COMMUNITY	Background Evidence on the association between socioeconomic status and the prevalence of neurotic disorder is contradictory. We studied the association between three elements of socioeconomic status and the prevalence of neurotic psychiatric disorder in a representative sample of adults aged 16-64 living in private households in the UK. Methods A cross-sectional survey of 10 108 adults aged 16-65 resident in private households in the UK was selected by a multi-stage, clustered, random-sampling design. Neurotic disorders were defined using a standardised interview, the revised clinical interview schedule (CIS-R). Data for 9570 people were available for this study. Findings We used housing tenure and access to cars as measures of standard of living; both were associated with the prevalence of neurotic disorder even after adjustment for other socioeconomic and demographic variables. including Registrar General's Social Class and educational attainment. Those people with no access to a car had an odds ratio for neurotic disorder of 1.4 (95% CI 1.1-1.7), compared with those who had access to two or more cars. People who rented their homes were also at increased risk (1.3 [1.1-1.5]). We estimated that about 10% of the neurotic disorder in the UK could be attributed to the increased prevalence of those without cars who rented their homes. There was a complex interaction between Registrar General's Social Class and sex, and there was no independent association with educational attainment. Interpretation There is an independent association between low standard of living and the prevalence of neurotic psychiatric disorder. The UK has experienced one of the largest Increases In income inequality within western market economies over the past 20 years, and this inequality may have had adverse consequences for the mental health of the population.	Cardiff Univ, Cardiff CF4 4XN, S Glam, Wales; UCL, Sch Med, Div Psychiat, Whittington Hosp, London W1N 8AA, England; Univ Leicester, Leicester Gen Hosp, Dept Psychiat, Brandon Mental Hlth Unit, Leicester LE1 7RH, Leics, England; Inst Psychiat, London, England; Off Natl Stat, Social Survey Div, London, England	Cardiff University; University of London; University College London; UCL Medical School; University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Leicester; University of London; King's College London	Lewis, G (corresponding author), Cardiff Univ, Heath Pk, Cardiff CF4 4XN, S Glam, Wales.	wpcghl@cardiff.ac.uk	Jenkins, Rachel/E-4287-2010; Farrell, Michael P/A-4769-2012; Bebbington, Paul Ernest/C-1939-2008; Jenkins, Rachel/H-2953-2019; Lewis, Glyn/E-9944-2012; Brugha, Traolach/T-9326-2019	Jenkins, Rachel/0000-0002-2958-0331; Farrell, Michael P/0000-0001-7008-8130; Bebbington, Paul Ernest/0000-0002-6030-7456; Jenkins, Rachel/0000-0002-2958-0331; Lewis, Glyn/0000-0001-5205-8245; Brugha, Traolach/0000-0002-9786-9591				ABRAMSON LY, 1978, J ABNORM PSYCHOL, V87, P49, DOI 10.1037/0021-843X.87.1.49; ARAYA R, 1992, SOC PSYCH PSYCH EPID, V27, P168, DOI 10.1007/BF00789001; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; Brown G., 1978, SOCIAL ORIGINS DEPRE; BRUCE ML, 1991, ARCH GEN PSYCHIAT, V48, P470; DAHL E, 1994, SOCIOL HEALTH ILL, V16, P644, DOI 10.1111/1467-9566.ep11348752; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; Gore, 1987, HLTH LIFESTYLE SURVE; JENKINS R, 1985, BRIT J IND MED, V42, P147; Jenkins R, 1997, PSYCHOL MED, V27, P775, DOI 10.1017/S0033291797005308; Kish L, 1965, SURVEY SAMPLING; Last J., 1988, DICT EPIDEMIOLOGY; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; LEWIS G, 1993, J EPIDEMIOL COMMUN H, V47, P358, DOI 10.1136/jech.47.5.358; Mari JJ, 1986, BRIT J PSYCHIAT, V158, P368; Meltzer H, 1995, OPCS SURVEYS PSYCHIA; *OPCS, 1982, OPCS LONG STUD SER L, V1; POWER C, 1992, SOC PSYCH PSYCH EPID, V27, P284; RODGERS B, 1991, SOC PSYCH PSYCH EPID, V26, P104, DOI 10.1007/BF00782949; Smith GD, 1998, J EPIDEMIOL COMMUN H, V52, P153; STANSFELD SA, 1992, PSYCHOL MED, V22, P739, DOI 10.1017/S0033291700038186; Weich S, 1997, PSYCHOL MED, V27, P73, DOI 10.1017/S0033291796004023; Weich S, 1998, J EPIDEMIOL COMMUN H, V52, P8, DOI 10.1136/jech.52.1.8; Weich S, 1998, BMJ-BRIT MED J, V317, P115, DOI 10.1136/bmj.317.7151.115; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WILKINSON R, 1996, UNHEALTHY SOC AFFICT; [No title captured]	28	137	139	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 22	1998	352	9128					605	609		10.1016/S0140-6736(98)04494-8	http://dx.doi.org/10.1016/S0140-6736(98)04494-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	113TE	9746021				2022-12-28	WOS:000075567400009
J	Amu, O; Rajendran, S; Bolaji, II				Amu, O; Rajendran, S; Bolaji, II			Maternal choice alone should not determine method of delivery	BRITISH MEDICAL JOURNAL			English	Article							CESAREAN-SECTION; VAGINAL DELIVERY; PELVIC FLOOR		Leicester Gen Hosp, Dept Obstet & Gynaecol, Leicester LE5 4PW, Leics, England	University Hospitals of Leicester NHS Trust; Leicester General Hospital	Bolaji, II (corresponding author), Grimsby Hosp, Dept Obstet & Gynaecol, Grimsby DN33 2BA, England.		Bolaji, Ibrahim/X-3007-2018	Bolaji, Ibrahim/0000-0001-7512-4188				AlMufti R, 1996, LANCET, V347, P544, DOI 10.1016/S0140-6736(96)91176-9; BOLAJI II, 1993, EUR J OBSTET GYN R B, V51, P181, DOI 10.1016/0028-2243(93)90033-9; Department of Health, 1993, CHANGING CHILDBIRTH; Dolan B, 1997, BRIT MED J, V314, P1183, DOI 10.1136/bmj.314.7088.1183; Hemminki E, 1996, AM J OBSTET GYNECOL, V174, P1569, DOI 10.1016/S0002-9378(96)70608-7; MEEHAN FP, 1993, PROGR OBSTET GYNAECO, V10, P213; *NHS EX, 1997, CONS TREATM SUMM LEG; Pinkerton JV, 1996, AM J OBSTET GYNECOL, V175, P289, DOI 10.1016/S0002-9378(96)70137-0; SAVAGE W, 1993, BRIT J OBSTET GYNAEC, V100, P493, DOI 10.1111/j.1471-0528.1993.tb15280.x; SNOOKS SJ, 1990, BRIT J SURG, V77, P1358, DOI 10.1002/bjs.1800771213; Sultan AH, 1996, BRIT J OBSTET GYNAEC, V103, P731, DOI 10.1111/j.1471-0528.1996.tb09864.x; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; SULTAN AH, 1994, BRIT MED J, V308, P887, DOI 10.1136/bmj.308.6933.887; The Lancet, 1997, LANCET, V349, P815; Weinstein D, 1996, AM J OBSTET GYNECOL, V174, P192, DOI 10.1016/S0002-9378(96)70393-9	15	65	67	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1998	317	7156					463	465						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	112JF	9758469				2022-12-28	WOS:000075490200027
J	Breimer, LH				Breimer, LH			Another Titanic myth - Harvard's swimming test	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					938	938						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756818				2022-12-28	WOS:000076409000032
J	Elkington, A				Elkington, A			A memorable patient - An effective reproof	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					930	930						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756814				2022-12-28	WOS:000076409000028
J	Shortell, SM; Waters, TM; Clarke, KWB; Budetti, PP				Shortell, SM; Waters, TM; Clarke, KWB; Budetti, PP			Physicians as double agents - Maintaining trust in an era of multiple accountabilities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BENIGN PROSTATIC HYPERPLASIA; MANAGED CARE PLANS; CLINICAL-PRACTICE; ORGANIZATION; ARRANGEMENTS; SERVICES; PROGRAM		Univ Calif Berkeley, Sch Publ Hlth, Div Hlth Policy & Management, Berkeley, CA 94720 USA; Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Evanston, IL USA; Henry Ford Hlth Syst, Hlth Alliance, Detroit, MI USA	University of California System; University of California Berkeley; Northwestern University; Henry Ford Health System; Henry Ford Hospital	Shortell, SM (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Div Hlth Policy & Management, 407 Warren Hall, Berkeley, CA 94720 USA.			Waters, Teresa/0000-0002-3823-5177				Alexander JA, 1996, HOSP HEALTH SERV ADM, V41, P311; BARRY MJ, 1988, JAMA-J AM MED ASSOC, V259, P3010, DOI 10.1001/jama.259.20.3010; BARRY MJ, 1995, MED CARE, V33, P771, DOI 10.1097/00005650-199508000-00003; Bazzoli GJ, 1997, MILBANK Q, V75, P533, DOI 10.1111/1468-0009.00068; Berenson RA, 1997, HEALTH AFFAIR, V16, P171, DOI 10.1377/hlthaff.16.2.171; BERGQUIST W, 1995, BUILDING STRAIEGIC R; Burns L R, 1993, Health Care Manage Rev, V18, P7; Burns LR, 1997, HEALTH CARE MANAGE R, V22, P32, DOI 10.1097/00004010-199710000-00007; Chiu MT, 1997, AM J PUBLIC HEALTH, V87, P462; Conrad D, 1996, HEALTH SERV RES, V31, P235; CRAWSHAW R, 1995, JAMA-J AM MED ASSOC, V273, P1553, DOI 10.1001/jama.273.19.1553; Emanuel EJ, 1996, ANN INTERN MED, V124, P229, DOI 10.7326/0003-4819-124-2-199601150-00007; EPSTEIN AM, 1996, STRATEGIC CHOICES CH, P207; FLECK LM, 1995, FAM PRACT MANAGE, V2, P48; Frankford DM, 1998, ACAD MED, V73, P138, DOI 10.1097/00001888-199802000-00011; Frankford DM, 1997, J HEALTH POLIT POLIC, V22, P185, DOI 10.1215/03616878-22-1-185; Gold M, 1995, Health Care Financ Rev, V16, P155; GOLD M, 1995, MED CARE RES REV, V52, P307, DOI 10.1177/107755879505200301; Gray BH, 1997, HEALTH AFFAIR, V16, P34, DOI 10.1377/hlthaff.16.1.34; Halverson PK, 1997, MILBANK Q, V75, P113, DOI 10.1111/1468-0009.00046; *HOECHST MAR ROUS, 1995, MED GROUP PRACT DIG; KALUZNY AD, 1995, PARTNERS DANCE; KANTER RM, 1989, ACADEMY MANAGEMENT E, V3, P183; Kassirer JP, 1998, NEW ENGL J MED, V339, P397, DOI 10.1056/NEJM199808063390608; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; Kindig DA, 1998, HEALTH SERV RES, V33, P223; KLEIMAN MA, 1995, HLTH CARE FINANC JUN, P22; *L HARR ASS INC, 1996, PHYS EXP MAN CAR SUR; Loda FA, 1997, J ADOLESCENT HEALTH, V21, P157, DOI 10.1016/S1054-139X(97)00048-7; LUNDBERG GD, 1995, JAMA-J AM MED ASSOC, V273, P1539, DOI 10.1001/jama.273.19.1539; LUNDBERG GD, 1997, JAMA-J AM MED ASSOC, V278, P1703; Mechanic D, 1996, MILBANK Q, V74, P171, DOI 10.2307/3350245; Morrisey MA, 1996, HEALTH AFFAIR, V15, P62, DOI 10.1377/hlthaff.15.4.62; Pauly M.V., 1992, IMPROVING HLTH POLIC, P151; PEARSON SD, 1995, ANN INTERN MED, V123, P941, DOI 10.7326/0003-4819-123-12-199512150-00008; Pellegrino ED, 1995, J CLIN ETHIC, V6, P312; President's Advisory Commission on Consumer Protection and Quality in the Health Care Industry, 1998, QUAL 1 BETT HLTH CAR; Robinson JC, 1998, JAMA-J AM MED ASSOC, V279, P144, DOI 10.1001/jama.279.2.144; SHORTELL SM, IN PRESS MILLBANK Q; SHORTELL SM, 1996, REMAKING HLTH CARE A; Showstack J, 1996, JAMA-J AM MED ASSOC, V276, P1071, DOI 10.1001/jama.276.13.1071; THOMPSON RS, 1995, JAMA-J AM MED ASSOC, V273, P1130, DOI 10.1001/jama.273.14.1130; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; Unland J J, 1995, J Health Care Finance, V22, P42; WAGNER EH, 1995, MED CARE, V33, P765, DOI 10.1097/00005650-199508000-00002; ZAJAC EJ, 1994, HLTH CARE MANAGEMENT; 1997, REQUIREMENT PHYSICIA	47	110	112	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 30	1998	280	12					1102	1108		10.1001/jama.280.12.1102	http://dx.doi.org/10.1001/jama.280.12.1102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	121FJ	9757863				2022-12-28	WOS:000076002400044
J	Slifman, NR; Obermeyer, WR; Aloi, BK; Musser, SM; Correll, WA; Cichowicz, SM; Betz, JM; Love, LA				Slifman, NR; Obermeyer, WR; Aloi, BK; Musser, SM; Correll, WA; Cichowicz, SM; Betz, JM; Love, LA			Contamination of botanical dietary supplements by Digitalis lanata	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAB ANTIBODY FRAGMENTS; CARDIAC-GLYCOSIDES; DIGOXIN; AFFINITY; TEA		US FDA, Clin Res & Rev Staff, Off Special Nutr, Ctr Food Safety & Appl Nutr, Washington, DC 20204 USA; US FDA, Div Nat Prod, Off Plant & Dairy Foods & Beverages, Ctr Food Safety & Appl Nutr, Washington, DC 20204 USA; US FDA, Div Enforcement & Programs, Off Field Programs, Ctr Food Safety & Appl Nutr, Washington, DC 20204 USA; US FDA, Instrumentat & Biophys Branch, Off Sci Anal & Supp, Ctr Food Safety & Appl Nutr, Washington, DC 20204 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Love, LA (corresponding author), US FDA, Clin Res & Rev Staff, Off Special Nutr, Ctr Food Safety & Appl Nutr, HFS-452,200 C St SW, Washington, DC 20204 USA.							Allen G, 1996, BIOLOGICALS, V24, P19, DOI 10.1006/biol.1996.0002; ANSFORD AJ, 1981, MED J AUSTRALIA, V1, P360, DOI 10.5694/j.1326-5377.1981.tb135633.x; BAIN RJI, 1985, BRIT MED J, V290, P1624, DOI 10.1136/bmj.290.6482.1624; BREWSTER D, 1986, ANN TROP PAEDIATR, V6, P289, DOI 10.1080/02724936.1986.11748459; BRODY J, 1998, NY TIMES         042, pC7; BRUNETON J, 1995, PHARMACOGNOSY PHYTOC, P572; CHEUNG K, 1989, CLIN CHEM, V35, P295; DICKSTEIN ES, 1980, AM J MED, V69, P167, DOI 10.1016/0002-9343(80)90518-5; DRIGGERS DA, 1990, WESTERN J MED, V153, P331; DRIGGERS DA, 1989, WESTERN J MED, V151, P660; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Ernst E, 1998, AM J MED, V104, P170, DOI 10.1016/S0002-9343(97)00397-5; Evans W. C., 1996, TREASE EVANS PHARMAC, P309; HAYNES BE, 1985, ANN EMERG MED, V14, P350, DOI 10.1016/S0196-0644(85)80103-7; HOWLAND MA, 1994, GOLDFRANKS TOXICOLOG, P693; Ikeda Y, 1996, J CHROMATOGR A, V746, P255, DOI 10.1016/0021-9673(96)00340-8; Katzung B., 1998, BASIC CLIN PHARM, P197; KELLY RA, 1996, GOODMAN GILMANS PHAR, P809; Litovitz TL, 1997, AM J EMERG MED, V15, P447, DOI 10.1016/S0735-6757(97)90193-5; MEHANNA AS, 1995, PRINCIPLES MED CHEM, P366; MOE GK, 1975, PHARMACOL BASIS, P653; OSTERLOH J, 1982, JAMA-J AM MED ASSOC, V247, P1596, DOI 10.1001/jama.247.11.1596; POTTERTON D, 1983, CULPEPERS COLOR HERB, P145; RADFORD DJ, 1986, MED J AUSTRALIA, V144, P540, DOI 10.5694/j.1326-5377.1986.tb112283.x; *RES TRIANGL PARK, 1994, DIG DIG IMM FAB OV; RICH SA, 1993, ANN EMERG MED, V22, P1904, DOI 10.1016/S0196-0644(05)80420-2; SAFADI R, 1995, ARCH INTERN MED, V155, P2121, DOI 10.1001/archinte.155.19.2121; Shaw D, 1997, DRUG SAFETY, V17, P342, DOI 10.2165/00002018-199717050-00006; SHIH RD, 1984, GOLDFRANKS TOXICOLOG, P981; SHUMAIK GM, 1988, ANN EMERG MED, V17, P732, DOI 10.1016/S0196-0644(88)80625-5; SMITH TW, 1970, BIOCHEMISTRY-US, V9, P331, DOI 10.1021/bi00804a020; STAHL E, 1973, DRUG ANAL CHROMATOGR, P97; THOMAS RE, 1996, BURGERS MED CHEM DRU, V2, P153; TUNCOK Y, 1995, J TOXICOL-CLIN TOXIC, V33, P83, DOI 10.3109/15563659509020221; TYLER VE, 1988, PHARMACOGNOSY, P162; WAGNER H, 1984, PLANT DRUG ANAL THIN, P195; WAGNER H, 1996, CARDIAC GLYCOSIDES D, P99; WOOD L, 1997, HERBALGRAM, V40, P50	38	171	173	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1998	339	12					806	811		10.1056/NEJM199809173391204	http://dx.doi.org/10.1056/NEJM199809173391204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119QT	9738088				2022-12-28	WOS:000075909200004
J	Thomas, JH				Thomas, JH			Social life and the single nucleotide: Foraging behavior in C-elegans	CELL			English	Review							DEPENDENT PROTEIN-KINASE; CAENORHABDITIS-ELEGANS; DROSOPHILA		Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Thomas, JH (corresponding author), Univ Washington, Dept Genet, Seattle, WA 98195 USA.							de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; Hodgkin J, 1997, GENETICS, V146, P149; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Lemos VS, 1997, EUR J NEUROSCI, V9, P1144, DOI 10.1111/j.1460-9568.1997.tb01468.x; Marsh DJ, 1998, NAT MED, V4, P718, DOI 10.1038/nm0698-718; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; Pedrazzini T, 1998, NAT MED, V4, P722, DOI 10.1038/nm0698-722; Sokolowski MB, 1997, P NATL ACAD SCI USA, V94, P7373, DOI 10.1073/pnas.94.14.7373; SOKOLOWSKI MB, 1980, BEHAV GENET, V10, P291, DOI 10.1007/BF01067774; THOMAS JH, 1993, GENETICS, V134, P1105; Wilson E.O., 1975, P1	11	8	9	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 4	1998	94	5					549	550		10.1016/S0092-8674(00)81595-0	http://dx.doi.org/10.1016/S0092-8674(00)81595-0			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741618	Bronze			2022-12-28	WOS:000075851900001
J	Leroy, V; Newell, ML; Dabis, F; Peckham, C; Van de Perre, P; Bulterys, M; Kind, C; Simonds, RJ; Wiktor, S; Msellati, P				Leroy, V; Newell, ML; Dabis, F; Peckham, C; Van de Perre, P; Bulterys, M; Kind, C; Simonds, RJ; Wiktor, S; Msellati, P		Ghent Int Work Grp Mother Child Transmis HIV	International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 TRANSMISSION; INFANT; COUNTRIES; BORN; RISK	Background An understanding of the risk and timing of mother-to-child transmission of HIV-1 in the postnatal period is important for the development of public-health strategies. We aimed to estimate the rate and timing of late postnatal transmission of HIV-1. Methods We did an international multicentre pooled analysis of individual data from prospective cohort studies of children followed-up from birth born to HIV-1-infected mothers. We enrolled all uninfected children confirmed by HIV-1-DNA PCR, HIV-1 serology, or both. Late postnatal transmission was taken to have occurred if a child later became infected. We calculated duration of follow-up for non-infected children from the time of negative diagnosis to the date of the last laboratory follow-up, or for infected children to the mid-point between the date of last negative and first positive results. We stratified the analysis for breastfeeding. Findings Less than 5% of the 2807 children in four studies from industrialised countries (USA, Switzerland, France, and Europe) were breastfed and no HIV-1 infection was diagnosed. By contrast, late postnatal transmission occurred in 49 (5%) of 902 children in four cohorts from developing countries, in which breastfeeding was the norm (Rwanda [Butare and Kigali], Ivory Coast, Kenya), with an overall estimated risk of 3.2 per 100 child-years of breastfeeding follow-up (95% CI 3.1-3.8), with similar estimates in individual studies (p=0.10). Exact information on timing of infection and duration of breastfeeding was available for 20 of the 49 children with late postnatal transmission. We took transmission to have occurred midway between last negative and first positive HIV-1 tests. If breastfeeding had stopped at age 4 months transmission would have occurred in no infants, and in three if it had stopped at 6 months. Interpretation Risk of late postnatal transmission is consistently shown to be substantial for breastfed children born to HIV-1-positive mothers. This risk should be balanced against the effect of early weaning on infant mortality and morbidity and maternal fertility.	Univ Bordeaux 2, INSERM, U330, F-33076 Bordeaux, France; Inst Child Hlth, London, England; Ctr Muraz, Bobo Dioulasso, Burkina Faso; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Kantonsspital, Swiss Perinatal Cohort, CH-9007 St Gallen, Switzerland; Projet RETRO CL, Abidjan, Cote Ivoire; ORSTOM, Programme SIDA, Abidjan, Cote Ivoire	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; University of London; University College London; Centre Muraz; Centers for Disease Control & Prevention - USA; Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen; Institut de Recherche pour le Developpement (IRD)	Leroy, V (corresponding author), Univ Bordeaux 2, INSERM, U330, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	valeriane.leroy@dim.u-bordeaux2.fr	DABIS, FRANCOIS/S-9298-2019; Leroy, Valeriane/AAO-5175-2020; Leroy, Valeriane/GQB-1102-2022; Kind, Christian/AAJ-1103-2020; Van de Perre, Philippe/B-9692-2008; Leroy, Valeriane/F-8129-2013; SHCS, MoCHIV/G-4081-2011; Newell, Marie-Louise/AAE-8222-2019	DABIS, FRANCOIS/0000-0002-1614-8857; Leroy, Valeriane/0000-0003-3542-8616; Leroy, Valeriane/0000-0003-3542-8616; Van de Perre, Philippe/0000-0002-3912-0427; Leroy, Valeriane/0000-0003-3542-8616; Newell, Marie-Louise/0000-0002-1074-7699				Armitage P., 2001, STAT METHODS MED RES; Bertolli J, 1996, J INFECT DIS, V174, P722, DOI 10.1093/infdis/174.4.722; BULTERYS M, 1995, AIDS, V9, P93; Dabis F, 1995, AIDS, V9 Suppl A, pS67; DABIS F, 1992, AIDS, V7, P1139; DATTA P, 1992, PEDIATR INFECT DIS J, V11, P974, DOI 10.1097/00006454-199211110-00016; DATTA P, 1994, J INFECT DIS, V170, P1134, DOI 10.1093/infdis/170.5.1134; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; DUNN DT, 1995, AIDS, V9, P7; EPKINI ER, 1997, LANCET, V349, P1054; FINNEY DJ, 1995, J CLIN EPIDEMIOL, V48, P87, DOI 10.1016/0895-4356(94)00096-9; GRAY G, 1996, 11 INT C AIDS VANC C, P7; *JOINT UN PROGR HI, 1996, WKLY EPIDEMIOL REC, V71, P289; Karlsson K, 1997, PEDIATR INFECT DIS J, V16, P963, DOI 10.1097/00006454-199710000-00012; KIND C, 1995, EUR J PEDIATR, V154, P542, DOI 10.1007/s004310050339; Kuhn L, 1997, AM J PUBLIC HEALTH, V87, P926, DOI 10.2105/AJPH.87.6.926; LALLEMANT M, 1994, AIDS, V8, P1496; LEPAGE P, 1992, PEDIATR INFECT DIS J, V11, P892; MAYAUX MJ, 1995, J ACQ IMMUN DEF SYND, V8, P188; NAGELKERKE NJD, 1995, J ACQ IMMUN DEF SYND, V8, P176; NDUATI RW, 1995, J INFECT DIS, V172, P1461, DOI 10.1093/infdis/172.6.1461; NEWELL ML, 1992, LANCET, V339, P1007; Newell ML, 1997, AIDS, V11, pS165; NICOLL A, 1995, AIDS, V9, P107, DOI 10.1097/00002030-199509020-00001; Simonds RJ, 1998, AIDS, V12, P301, DOI 10.1097/00002030-199803000-00008; SIMONON A, 1994, J ACQ IMMUN DEF SYND, V7, P952; *STUD GROUP PREV M, 1995, SOC AFR SIDA, V7, P2; VandePerre P, 1997, AIDS PATIENT CARE ST, V11, P4, DOI 10.1089/apc.1997.11.4; VandePerre P, 1997, LANCET, V350, P221, DOI 10.1016/S0140-6736(05)62390-2; *WHO, 1997, WEEKLY EPIDEMIOLOGIC, V72, P17; *WHO, 1992, WKLY EPIDEMIOL REC, V24, P177; WOODROOFE M, 1985, ANN STAT, V13, P163, DOI 10.1214/aos/1176346584; ZIEGLER JB, 1985, LANCET, V1, P896	33	184	186	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 22	1998	352	9128					597	600		10.1016/S0140-6736(98)01419-6	http://dx.doi.org/10.1016/S0140-6736(98)01419-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746019				2022-12-28	WOS:000075567400007
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			A Frankenstein experiment	SCIENCE			English	Article									Medsite Commun, Boston, MA 01945 USA		Sikorski, R (corresponding author), Medsite Commun, Boston, MA 01945 USA.							Wakayama T, 1998, NAT BIOTECHNOL, V16, P639, DOI 10.1038/nbt0798-639	1	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1163	1164						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9735033				2022-12-28	WOS:000075531200041
J	Gonzalez-Ruiz, A; Wright, SG				Gonzalez-Ruiz, A; Wright, SG			Disparate amoebae	LANCET			English	Editorial Material							NONPATHOGENIC ENTAMOEBA-HISTOLYTICA; DIAGNOSIS; ZYMODEMES; DYSENTERY		Whittington Hosp, Dept Microbiol, London N19 5NF, England; Hosp Trop Dis, London, England	University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine	Gonzalez-Ruiz, A (corresponding author), Whittington Hosp, Dept Microbiol, London N19 5NF, England.							AGUIRRE A, 1995, T ROY SOC TROP MED H, V89, P187, DOI 10.1016/0035-9203(95)90488-3; BLANC DS, 1992, J PROTOZOOL, V39, P471, DOI 10.1111/j.1550-7408.1992.tb04834.x; BRUMPT E, 1925, B ACAD MED PARIS, V94, P942; CLARK CG, 1991, MOL BIOCHEM PARASIT, V49, P297, DOI 10.1016/0166-6851(91)90073-F; DIAMOND LS, 1993, J EUKARYOT MICROBIOL, V40, P340, DOI 10.1111/j.1550-7408.1993.tb04926.x; GATHIRAM V, 1987, S AFR MED J, V72, P669; GONZALEZRUIZ A, 1994, J CLIN MICROBIOL, V32, P964, DOI 10.1128/JCM.32.4.964-970.1994; GONZALEZRUIZ A, 1994, J CLIN PATHOL, V47, P236, DOI 10.1136/jcp.47.3.236; HAQUE R, 1993, J INFECT DIS, V167, P247, DOI 10.1093/infdis/167.1.247; MARTINEZ.A, 1973, NATURE-NEW BIOL, V245, P186, DOI 10.1038/newbio245186a0; RUIZPALACIOS GM, 1992, ARCHIVES OF MEDICAL RESEARCH, VOL 23, NO 2, P289; SARGEAUNT PG, 1978, T ROY SOC TROP MED H, V72, P519, DOI 10.1016/0035-9203(78)90174-8; TEIG MK, 1997, T ROY SOC TROP MED H, V91, P506; WHO, 1997, WKLY EPIDEMIOL REC R, V72, P97	14	19	19	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 6	1998	351	9117					1672	1673		10.1016/S0140-6736(05)77735-7	http://dx.doi.org/10.1016/S0140-6736(05)77735-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734879				2022-12-28	WOS:000074088900003
J	Hartman, D				Hartman, D			A book that changed my practice - School can be hell	BRITISH MEDICAL JOURNAL			English	Article																		Llewellyn Grace, 1997, TEENAGE LIBERATION H	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					956	956						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756837				2022-12-28	WOS:000076409000084
J	Finkelstein, JS; Klibanski, A; Arnold, AL; Toth, TL; Hornstein, MD; Neer, RM				Finkelstein, JS; Klibanski, A; Arnold, AL; Toth, TL; Hornstein, MD; Neer, RM			Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34) - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							X-RAY ABSORPTIOMETRY; GROWTH FACTOR-I; POSTMENOPAUSAL WOMEN; OVARIECTOMIZED RATS; MINERAL DENSITY; CORTICAL BONE; UNITED-STATES; OSTEOPOROSIS; THERAPY; MASS	Context.-Short-term intermittent administration of parathyroid hormone (PTH) prevents bone loss from the spine in women treated with a gonadotropin-releasing hormone (GnRH) analog. However, the effects of a longer period of PTH administration on bone mass in estrogen-deficient women, particularly on the hip and on cortical bone of the total body, are unknown. Objective.-To determine whether more prolonged PTH administration can prevent estrogen deficiency bone loss from the hip, spine, and total body in young women with endometriosis receiving GnRH analog (nafarelin acetate) therapy. Design.-Randomized controlled trial. Setting.-General Clinical Research Center of a tertiary care, university-affiliated hospital. Patients.-Forty-three women between the ages of 21 and 45 years with symptomatic endometriosis. Intervention.-Nafarelin alone (200 mu g intranasally twice daily) or nafarelin plus human parathyroid hormone-(1-34) (hPTH-[1-34]) (40 mu g subcutaneously daily). Main Outcome Measures.-The primary end points were bone mineral density (BMD) of the anterior-posterior and lateral spine, femoral neck, trochanter, radial shaft, and total body at 12 months of treatment. Results.-In the women who received nafarelin alone, the mean (SEM) BMDs of the anterior-posterior spine, lateral spine, femoral neck, trochanter, and total body were 4.9% (0.6%) (P<.001), 4.9% (0.8%) (P<.001), 4.7% (1.1%) (P<.001), 4.3% (0.9%) (P<.001), and 2.0% (0.6%) (P=.003) lower than at baseline after 12 months of therapy. In contrast, coadministration of hPTH-(1-34) increased BMD of the anterior-posterior spine by 2.1% (1.1%) (P=.09) and lateral spine by 7.5% (1.9%) (P=.002) and prevented bone loss from the femoral neck, trochanter, and total body, despite severe estrogen deficiency. Radial shaft BMD did not change significantly in either group. Serum bone-specific alkaline phosphatase and osteocalcin concentrations and urinary excretion of hydroxyproline and deoxypyridinoline increased 2-fold to 3-fold during the first 6 to 9 months of therapy in the women who received nafarelin plus hPTH-(1-34) and then declined. Changes in urinary deoxypyridinolone excretion were strongly predictive (r=0.85) of changes in spinal BMD in the women who received nafarelin plus hPTH-(1-34). Conclusions.-Parathyroid hormone prevents bone loss from the proximal femur and total body and increases lumbar spinal BMD in young women with GnRH analog-induced estrogen deficiency.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Vincent Obstet & Gynecol, Boston, MA 02114 USA; Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	Finkelstein, JS (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Bulfinch 327,55 Fruit St, Boston, MA 02114 USA.		Finkelstein, Joel/M-6463-2019		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043341] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-1066] Funding Source: Medline; NIDDK NIH HHS [R29 DK43341] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bauer W, 1929, J EXP MED, V49, P145, DOI 10.1084/jem.49.1.145; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CEDARS MI, 1990, OBSTET GYNECOL, V75, P641; CHILIBECK P, 1994, CAN ASSOC RADIOL J, V45, P297; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; EDMONDS DK, 1994, BRIT J OBSTET GYNAEC, V101, P24, DOI 10.1111/j.1471-0528.1994.tb13681.x; EJERSTED C, 1993, J BONE MINER RES, V8, P1097; FILICORI M, 1984, J CLIN INVEST, V73, P1638, DOI 10.1172/JCI111370; Finkelstein J. S., 1996, CECIL TXB MED, P1379; Finkelstein Joel S., 1996, P993; FINKELSTEIN JS, 1994, J CLIN ENDOCR METAB, V78, P724, DOI 10.1210/jc.78.3.724; FINKELSTEIN JS, 1992, NEW ENGL J MED, V326, P600, DOI 10.1056/NEJM199202273260904; FINKELSTEIN JS, 1994, NEW ENGL J MED, V331, P1618, DOI 10.1056/NEJM199412153312404; HERRMANNERLEE MPM, 1976, ENDOCR RES COMMUN, V3, P21, DOI 10.3109/07435807609057738; HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110; HOCK JM, 1988, ENDOCRINOLOGY, V122, P2899, DOI 10.1210/endo-122-6-2899; Hodsman AB, 1997, J CLIN ENDOCR METAB, V82, P620, DOI 10.1210/jc.82.2.620; HODSMAN AB, 1991, BONE MINER, V14, P67, DOI 10.1016/0169-6009(91)90103-7; HODSMAN AB, 1993, J CLIN INVEST, V91, P1138, DOI 10.1172/JCI116273; Hornstein MD, 1998, OBSTET GYNECOL, V91, P16, DOI 10.1016/S0029-7844(97)00620-0; JOHANSEN JS, 1988, J CLIN ENDOCR METAB, V67, P701, DOI 10.1210/jcem-67-4-701; KREAM BE, 1990, BONE, V11, P411, DOI 10.1016/8756-3282(90)90136-M; LARCOS G, 1991, J NUCL MED, V32, P2101; LEATHER AT, 1993, OBSTET GYNECOL, V81, P104; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; LIU CC, 1990, J BONE MINER RES, V5, P973; LIU CC, 1991, J BONE MINER RES, V6, P1071; Mitlak BH, 1996, J BONE MINER RES, V11, P430; NEER R, 1990, OSTEOPOROSIS 1990, P1314; NEER RM, 1993, OSTEOPOROSIS INT, V1, P204; PARSONS JA, 1973, ENDOCRINOLOGY, V92, P454, DOI 10.1210/endo-92-2-454; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; Reeve J, 1991, Osteoporos Int, V1, P162, DOI 10.1007/BF01625448; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; RIIS BJ, 1990, J CLIN ENDOCR METAB, V70, P920, DOI 10.1210/jcem-70-4-920; ROULEAU MF, 1986, ENDOCRINOLOGY, V118, P919, DOI 10.1210/endo-118-3-919; SCHARLA SH, 1990, J CLIN ENDOCR METAB, V70, P1055, DOI 10.1210/jcem-70-4-1055; Selye H, 1932, ENDOCRINOLOGY, V16, P547, DOI 10.1210/endo-16-5-547; SURREY ES, 1992, J CLIN ENDOCR METAB, V75, P558, DOI 10.1210/jc.75.2.558; SURREY ES, 1993, OBSTET GYNECOL, V81, P581; TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo-110-2-506; Taylor A, 1997, J BONE MINER RES, V12, P652, DOI 10.1359/jbmr.1997.12.4.652; WRONSKI TJ, 1994, BONE, V15, P51, DOI 10.1016/8756-3282(94)90891-5; WRONSKI TJ, 1993, ENDOCRINOLOGY, V132, P823, DOI 10.1210/en.132.2.823; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F	50	127	132	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 30	1998	280	12					1067	1073		10.1001/jama.280.12.1067	http://dx.doi.org/10.1001/jama.280.12.1067			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FJ	9757854				2022-12-28	WOS:000076002400035
J	Bruchez, M; Moronne, M; Gin, P; Weiss, S; Alivisatos, AP				Bruchez, M; Moronne, M; Gin, P; Weiss, S; Alivisatos, AP			Semiconductor nanocrystals as fluorescent biological labels	SCIENCE			English	Article							QUANTUM DOTS; MICROSCOPY; DNA; NANOPARTICLES	Semiconductor nanocrystals were prepared for use as fluorescent probes in biological staining and diagnostics. Compared with conventional fluorophores, the nanocrystals have a narrow, tunable. symmetric emission spectrum and are photochemically stable. The advantages of the broad, continuous excitation spectrum were demonstrated in a dual-emission, single-excitation labeling experiment on mouse fibroblasts. These nanocrystal probes are thus complementary and in some cases may be superior to existing fluorophores.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Weiss, S (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, 1 Cyclotron Rd, Berkeley, CA 94720 USA.		weiss, shimon/B-4164-2009; 周, 伊静/I-4058-2018; Alivisatos, Paul/N-8863-2015; Bruchez, Marcel P/C-2271-2009	weiss, shimon/0000-0002-0720-5426; Alivisatos, Paul/0000-0001-6895-9048; Bruchez, Marcel P/0000-0002-7370-4848				Alivisatos AP, 1996, J PHYS CHEM-US, V100, P13226, DOI 10.1021/jp9535506; Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; BEVERLOO HB, 1990, CYTOMETRY, V11, P784, DOI 10.1002/cyto.990110704; Correa-Duarte MA, 1998, CHEM PHYS LETT, V286, P497, DOI 10.1016/S0009-2614(98)00012-8; Dabbousi BO, 1997, J PHYS CHEM B, V101, P9463, DOI 10.1021/jp971091y; Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078; EYCHMULLER A, 1993, CHEM PHYS LETT, V208, P59, DOI 10.1016/0009-2614(93)80076-2; Guzelian AA, 1996, J PHYS CHEM-US, V100, P7212, DOI 10.1021/jp953719f; Hermann R, 1996, HISTOCHEM CELL BIOL, V106, P31; Hines MA, 1996, J PHYS CHEM-US, V100, P468, DOI 10.1021/jp9530562; JU JY, 1995, P NATL ACAD SCI USA, V92, P4347, DOI 10.1073/pnas.92.10.4347; Lackie PM, 1996, HISTOCHEM CELL BIOL, V106, P9; Liz-Marzan LM, 1996, LANGMUIR, V12, P4329, DOI 10.1021/la9601871; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; Nirmal M, 1996, NATURE, V383, P802, DOI 10.1038/383802a0; NIRMAL M, 1995, PHYS REV LETT, V75, P3728, DOI 10.1103/PhysRevLett.75.3728; Peng XG, 1998, J AM CHEM SOC, V120, P5343, DOI 10.1021/ja9805425; Peng XG, 1997, J AM CHEM SOC, V119, P7019, DOI 10.1021/ja970754m; Roederer M, 1996, CYTOMETRY, V24, P191, DOI 10.1002/(SICI)1097-0320(19960701)24:3<191::AID-CYTO1>3.0.CO;2-L; Roederer M, 1997, CYTOMETRY, V29, P328, DOI 10.1002/(SICI)1097-0320(19971201)29:4<328::AID-CYTO10>3.0.CO;2-W; SEVEUS L, 1992, CYTOMETRY, V13, P329, DOI 10.1002/cyto.990130402; WAGGONER A, 1995, METHOD ENZYMOL, V246, P362; WILCHEK M, 1989, TRENDS BIOCHEM SCI, V14, P408, DOI 10.1016/0968-0004(89)90289-2	25	7808	8397	56	2699	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					2013	2016		10.1126/science.281.5385.2013	http://dx.doi.org/10.1126/science.281.5385.2013			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748157				2022-12-28	WOS:000076161800051
J	Bertka, CM; Fei, YW				Bertka, CM; Fei, YW			Implications of Mars Pathfinder data for the accretion history of the terrestrial planets	SCIENCE			English	Article							HIGH-PRESSURE; INTERIOR STRUCTURE; CORE FORMATION; EARTH	Accretion models of the terrestrial planets often assume planetary bulk compositions with nonvolatile element abundance ratios equivalent to those of C1 carbonaceous chondrites. The moment of inertia factor of Mars reported by the Pathfinder team is inconsistent with a bulk planet C1 Fe/Si ratio or Fe content, which suggests that C1 chondrite accretion models are insufficient to explain the formation of Mars and the other terrestrial planets. Future planetary accretion models will have to account for variations in bulk Fe/Si ratios among the terrestrial planets.	Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA; Carnegie Inst Washington, Ctr High Pressure Res, Washington, DC 20015 USA	Carnegie Institution for Science; Carnegie Institution for Science	Bertka, CM (corresponding author), Carnegie Inst Washington, Geophys Lab, 5251 Broad Branch Rd NW, Washington, DC 20015 USA.		Fei, Yingwei/F-3709-2011	Fei, Yingwei/0000-0001-9955-5353				BADDING JV, 1992, HIGH PRESSURE RES AP; Bertka CM, 1998, EARTH PLANET SC LETT, V157, P79, DOI 10.1016/S0012-821X(98)00030-2; Bills BG, 1995, J GEOPHYS RES-PLANET, V100, P26305, DOI 10.1029/95JE02776; Clayton RN, 1996, GEOCHIM COSMOCHIM AC, V60, P1999, DOI 10.1016/0016-7037(96)00074-9; DREIBUS G, 1985, METEORITICS, V20, P367; DREIBUS G, 1997, RUSSIAN GEOL GEOPHYS, V38, P287; FEI Y, COMMUNICATION; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; GANAPATHY R, 1979, ORIGIN EARTH MOON; GANAPATHY R, 1974, P LUNAR PLANET SCI C, V2, P1181; GANAPATHY R, 1977, GEOCHEM J, V11, P111; Hillgren VJ, 1996, GEOCHIM COSMOCHIM AC, V60, P2257, DOI 10.1016/0016-7037(96)00079-8; KAULA WM, 1979, GEOPHYS RES LETT, V6, P194, DOI 10.1029/GL006i003p00194; KURAMOTO K, 1994, LUM PLAN SCI C, V25, P759; Li J, 1996, NATURE, V381, P686, DOI 10.1038/381686a0; OHTANI E, 1992, GEOPHYS RES LETT, V19, P2239, DOI 10.1029/92GL02369; Righter K, 1996, ICARUS, V124, P513, DOI 10.1006/icar.1996.0227; RINGWOOD AE, 1971, NATURE, V234, P89, DOI 10.1038/234089a0; RINGWOOD AE, 1959, GEOCHIM COSMOCHIM AC, V15, P257, DOI 10.1016/0016-7037(59)90062-6; Sohl F, 1997, J GEOPHYS RES-PLANET, V102, P1613, DOI 10.1029/96JE03419; THIBAULT Y, 1995, GEOCHIM COSMOCHIM AC, V59, P9911; TREIMAN AH, 1986, GEOCHIM COSMOCHIM AC, V50, P1071, DOI 10.1016/0016-7037(86)90389-3; UREY HC, 1952, PLANETS; WANKE H, 1988, PHILOS T R SOC A, V325, P545, DOI 10.1098/rsta.1988.0067; WASSON JT, 1988, PHILOS T R SOC A, V325, P535, DOI 10.1098/rsta.1988.0066; WETHERILL GW, 1994, GEOCHIM COSMOCHIM AC, V58, P4513, DOI 10.1016/0016-7037(94)90352-2; WOOD BJ, 1993, EARTH PLANET SC LETT, V117, P593, DOI 10.1016/0012-821X(93)90105-I; Zharkov V. N., 1996, Solar System Research, V30, P456	28	60	63	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1838	1840		10.1126/science.281.5384.1838	http://dx.doi.org/10.1126/science.281.5384.1838			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743493				2022-12-28	WOS:000076007100048
J	Marx, S; Spiegel, AM; Skarulis, MC; Doppman, JL; Collins, FS; Liotta, LA				Marx, S; Spiegel, AM; Skarulis, MC; Doppman, JL; Collins, FS; Liotta, LA			Multiple endocrine neoplasia type 1: Clinical and genetic topics	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	National-Institutes-of-Health Clinical Staff Conference	JUN 04, 1997	NIH, BETHESDA, MD		NIH		ZOLLINGER-ELLISON SYNDROME; MEN1 GENE; PARATHYROID TUMORS; PRIMARY HYPERPARATHYROIDISM; POSITIONAL CLONING; CUSHINGS-SYNDROME; CARCINOID-TUMORS; LONG-TERM; 11Q13; LOCALIZATION	Multiple endocrine neoplasia type 1 (MEN1) consists of benign, and sometimes malignant, tumors (often multiple in a tissue) of the parathyroids, enteropancreatic neuroendocrine system, anterior pituitary, and other tissues. Skin angiofibromas and skin collagenomas are common. Typically, MEN1 tumors begin two decades earlier than sporadic tumors. Because of tumor multiplicity and the tendency for postoperative tumor recurrence, specialized methods have been developed for preoperative and intraoperative localization of many MEN1-associated tumors. The MEN1 gene was recently isolated by positional cloning. This strategy progressively narrows the size of the candidate MEN1 gene interval on the chromosome and then finds and tests many or, if needed, all genes within that interval. The MEN1 gene was finally identified because it was the one gene that contained mutations in most DNAs from a test panel of MEN1 cases. It has been suggested that MEN1, like many hereditary cancer syndromes, is caused by mutation in a tumor suppressor gene that contributes to neoplasia when both gene copies in a tumor precursor cell have been sequentially inactivated ("two-hit" oncogenesis mechanism). Germline MEN1 mutations were found in most families with MEN1 and in most cases of sporadic MEN1. In addition, the MEN1 gene was the gene most likely to show acquired mutation in several sporadic or nonhereditary tumors-parathyroid adenomas, gastrinomas, insulinomas, and bronchial carcinoids. Most germline or acquired MEN1 mutations predicted truncation (and thus likely inactivation) of the encoded protein, supporting expectations for the "first hit" to a tumor suppressor gene. Testing for MEN1 germline mutation is possible in a research setting. Candidates for MEN1 mutation testing include patients with MEN1 or its phenocopies and first-degree relatives of persons with MEN1.	NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Marx, S (corresponding author), NIH, Bldg 10,Room 9C-101, Bethesda, MD 20892 USA.							Agarwal SK, 1997, HUM MOL GENET, V6, P1169, DOI 10.1093/hmg/6.7.1169; Akerstrom G, 1996, WORLD J SURG, V20, P173; Bassett JHD, 1998, AM J HUM GENET, V62, P232, DOI 10.1086/301729; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; Courseaux A, 1996, GENOMICS, V37, P354, DOI 10.1006/geno.1996.0570; Darling TN, 1997, ARCH DERMATOL, V133, P853, DOI 10.1001/archderm.133.7.853; Debelenko LV, 1997, CANCER RES, V57, P1039; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; Dong QH, 1997, J CLIN ENDOCR METAB, V82, P1416, DOI 10.1210/jc.82.5.1416; DOPPMAN J L, 1991, Journal of Bone and Mineral Research, V6, pS153; DOPPMAN JL, 1995, ANN INTERN MED, V123, P269, DOI 10.7326/0003-4819-123-4-199508150-00004; EmmertBuck MR, 1997, CANCER RES, V57, P1855; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Eng C, 1996, NEW ENGL J MED, V335, P943, DOI 10.1056/NEJM199609263351307; Erdheim J, 1903, BEITR PATHOL ANAT AL, V33, P158; FARID NR, 1980, AM J MED, V69, P874, DOI 10.1016/S0002-9343(80)80013-1; Fraker Douglas L., 1997, P1678; FRIEDMAN E, 1989, NEW ENGL J MED, V321, P213, DOI 10.1056/NEJM198907273210402; Gibril F, 1996, ANN INTERN MED, V125, P26, DOI 10.7326/0003-4819-125-1-199607010-00005; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Guru SC, 1997, GENOME RES, V7, P725, DOI 10.1101/gr.7.7.725; Guru SC, 1997, GENOMICS, V42, P436, DOI 10.1006/geno.1997.4783; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; HINDLE E, 1995, J CLIN ENDOCR METAB, V83, P302; Johnston LB, 1996, J CLIN ENDOCR METAB, V81, P346, DOI 10.1210/jc.81.1.346; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KYTOLA S, 1995, HUM GENET, V96, P449; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LEE VS, 1995, RADIOLOGY, V197, P627, DOI 10.1148/radiology.197.3.7480730; Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177; Lubensky IA, 1996, CANCER RES, V56, P5272; MALLETTE LE, 1974, MEDICINE, V53, P127, DOI 10.1097/00005792-197403000-00002; Manickam P, 1997, HUM GENET, V101, P102, DOI 10.1007/s004390050595; Marx S, 1998, GENETIC BASIS HUMAN, P489; MATON PN, 1986, NEW ENGL J MED, V315, P1, DOI 10.1056/NEJM198607033150101; Mayr B, 1997, EUR J ENDOCRINOL, V137, P684, DOI 10.1530/eje.0.1370684; Metz David C., 1994, P591; NORTON JA, 1992, ANN SURG, V215, P8, DOI 10.1097/00000658-199201000-00012; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; Olufemi SE, 1998, HUM MUTAT, V11, P264, DOI 10.1002/(SICI)1098-1004(1998)11:4<264::AID-HUMU2>3.3.CO;2-M; Ott J., 1991, ANAL HUMAN GENETIC L; Pack S, 1998, J INVEST DERMATOL, V110, P438, DOI 10.1046/j.1523-1747.1998.00140.x; PETTY EM, 1994, AM J HUM GENET, V54, P1060; RAM Z, 1995, J NEUROSURG, V83, P225, DOI 10.3171/jns.1995.83.2.0225; RIZZOLI R, 1985, AM J MED, V78, P467, DOI 10.1016/0002-9343(85)90340-7; ROSSIER PH, 1939, SCHWEIZ MED WOCHENSC, V69, P985; SCHEITHAUER BW, 1987, SEMIN DIAGN PATHOL, V4, P205; SCHMID JR, 1961, AM J MED, V31, P343, DOI 10.1016/0002-9343(61)90123-1; SERVICE FJ, 1991, MAYO CLIN PROC, V66, P711, DOI 10.1016/S0025-6196(12)62083-7; SKOSGEID B, 1992, J CLIN ENDOCR METAB, V75, P76; SMITH CM, 1995, HUM GENET, V96, P377; Tanaka C, 1998, J CLIN ENDOCR METAB, V83, P960, DOI 10.1210/jc.83.3.960; THAKKER RV, 1989, NEW ENGL J MED, V321, P218, DOI 10.1056/NEJM198907273210403; WEBER HC, 1995, GASTROENTEROLOGY, V108, P1637, DOI 10.1016/0016-5085(95)90124-8; WERMER P, 1954, AM J MED, V16, P363, DOI 10.1016/0002-9343(54)90353-8; WILFOND BS, 1995, AM J HUM GENET, V57, P1233; Zhuang ZP, 1997, CANCER RES, V57, P4682; Zhuang ZP, 1997, CANCER RES, V57, P5446	60	269	272	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1998	129	6					484	494		10.7326/0003-4819-129-6-199809150-00011	http://dx.doi.org/10.7326/0003-4819-129-6-199809150-00011			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	119JJ	9735087				2022-12-28	WOS:000075892100008
J	Herbein, G; Mahlknecht, U; Batliwalla, F; Gregersen, P; Pappas, T; Butler, J; O'Brien, WA; Verdin, E				Herbein, G; Mahlknecht, U; Batliwalla, F; Gregersen, P; Pappas, T; Butler, J; O'Brien, WA; Verdin, E			Apoptosis of CD8(+) T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; INFECTION; PROGRESSION; PHENOTYPE; ENTRY; AIDS; DISEASE; DEATH; CCR5	CD8-positive T cells are thought to play an important role in the control of infection by human immunodeficiency virus (HIV) as a result of their cytotoxic activity and by releasing soluble factors(1,2) in AIDS patients, the absolute number bf CD8(+) T lymphocytes is decreased in peripheral blood(3,4) and their turnover rate Is increased, suggesting that there is more cell renewal and cell death occurring(5). Anti-retroviral therapy raises CD8(+) T-cell counts in HIV-infected patients(6-8). Here we report that the death rate of CD8(+) T cells by apoptosis increased markedly during HIV infection of peripheral blood mononuclear cells in vitro. Apoptosis is induced in a dose-dependent manner by recombinant envelope glycoprotein gp120 from HIV strain X4, or by stromal-derived factor-1 (SDF-1), the physiological ligand of the chemokine receptor CXCR4. Apoptosis is mediated by the interaction between tumour-necrosis factor-alpha bound to the membrane of macrophages (mbTNF) and a receptor on CD8(+) T cells (TNF-receptor II, or TNFRII). The expression of both of these cell surface proteins is upregulated by HIV infection or by treatment with recombinant gp120 or SDF-1. Apoptosis of CD8(+) T cells isolated from HIV-infected patients is also mediated by macrophages through the interaction between mbTNF and TNFRII. These results indicate that the increased turnover of CD8(+) T cells in HIV-infected subjects is mediated by the HIV envelope protein through the CXCR4 chemokine receptor.	Picower Inst Med Res, Manhasset, NY 11010 USA; Univ Texas, Med Branch, Dept Med, Div Infect Dis, Galveston, TX 77555 USA; N Shore Univ Hosp, Cornell Univ Med Coll, Dept Med, Div Biol & Human Genet, Manhasset, NY 11030 USA; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA	Northwell Health; University of Texas System; University of Texas Medical Branch Galveston; Cornell University; Northwell Health; North Shore University Hospital; University of California System; University of California San Francisco; The J David Gladstone Institutes	Verdin, E (corresponding author), Picower Inst Med Res, Manhasset, NY 11010 USA.		Verdin, Eric/AAB-7999-2019	Verdin, Eric/0000-0003-3703-3183				Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLLIN M, 1994, J GEN VIROL, V75, P1597, DOI 10.1099/0022-1317-75-7-1597; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; DAAR ES, 1995, AIDS RES HUM RETROV, V11, P3, DOI 10.1089/aid.1995.11.3; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Effros RB, 1997, IMMUNOL TODAY, V18, P450, DOI 10.1016/S0167-5699(97)01079-7; Feinberg MB, 1997, CURR BIOL, V7, pR136, DOI 10.1016/S0960-9822(97)70072-1; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HELLER RA, 1992, CELL, V70, P47; Herbein G, 1998, J VIROL, V72, P660, DOI 10.1128/JVI.72.1.660-670.1998; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; MACKEWICZ CE, 1994, CLIN IMMUNOL IMMUNOP, V73, P80, DOI 10.1006/clin.1994.1172; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; SARIN A, 1994, J IMMUNOL, V153, P862; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543; WU MX, 1995, P NATL ACAD SCI USA, V92, P1525, DOI 10.1073/pnas.92.5.1525; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	26	350	362	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1998	395	6698					189	194		10.1038/26026	http://dx.doi.org/10.1038/26026			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744279				2022-12-28	WOS:000075829900046
J	Jura, M; Turner, J				Jura, M; Turner, J			A mysterious dust clump in a disk around an evolved binary star system	NATURE			English	Article							RED-RECTANGLE NEBULA; CIRCUMSTELLAR ENVELOPES; CARBON STARS; EVOLUTION; GRAINS	The discovery of planets in orbit around the pulsar PSR1257+12 (ref. 1) shows that planets may form around post-main-sequence stars(2). Other evolved stars, such as HD44179 (an evolved star which is part of the binary system that has expelled the gas and dust that make the Red Rectangle nebula), possess gravitationally bound orbiting dust disks(3,4). It is possible that planets might form from gravitational collapse in such disks(5). Here we report high-angular-resolution observations at millimetre and submillimetre wavelengths of the dusk disk associated with the Red Rectangle. We find a dust clump with an estimated mass near that of Jupiter in the outer region of the disk. The clump is larger than our Solar System, and far beyond where planet formation would normally be expected, so its nature is at present unclear.	Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Jura, M (corresponding author), Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA.							BANIT M, 1993, ASTROPHYS J, V415, P779, DOI 10.1086/173201; COHEN M, 1975, ASTROPHYS J, V196, P179, DOI 10.1086/153403; Cruzalebes P, 1996, ASTRON ASTROPHYS SUP, V116, P597, DOI 10.1051/aas:1996137; Greaves JS, 1997, ASTRON ASTROPHYS, V327, P342; Hora JL, 1996, ASTRON J, V112, P2064, DOI 10.1086/118163; Jura M, 1997, ASTROPHYS J, V474, P741, DOI 10.1086/303476; JURA M, 1995, ASTROPHYS J, V453, P721, DOI 10.1086/176433; Jura M, 1997, ASTROPHYS J, V485, P341, DOI 10.1086/304421; KOLYKHALOV PI, 1981, SOV ASTRON LETT, V6, P357; Lopez B, 1997, ASTRON ASTROPHYS, V322, P868; MATHIS JS, 1992, ASTRON ASTROPHYS, V259, pL39; OLOFSSON H, 1993, ASTROPHYS J SUPPL S, V87, P267, DOI 10.1086/191804; POLLACK JB, 1994, ASTROPHYS J, V421, P615, DOI 10.1086/173677; RODDIER F, 1995, ASTROPHYS J, V443, P249, DOI 10.1086/175520; SITKO ML, 1981, ASTROPHYS J, V247, P1024, DOI 10.1086/159112; Smail I, 1997, ASTROPHYS J, V490, pL5, DOI 10.1086/311017; VANDERVEEN WECJ, 1994, ASTRON ASTROPHYS, V285, P551; WAELKENS C, 1992, ASTRON ASTROPHYS, V256, pL15; WALKENS C, 1996, ASTRON ASTROPHYS, V314, pL17; WALMSLEY CM, 1991, ASTRON ASTROPHYS, V248, P555; Waters LBFM, 1998, NATURE, V391, P868, DOI 10.1038/36052; WATERS LBFM, 1992, ASTRON ASTROPHYS, V262, pL37; WATERS LBFM, 1993, ASTRON ASTROPHYS, V269, P242; WOLSZCZAN A, 1992, NATURE, V355, P145, DOI 10.1038/355145a0	25	25	25	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1998	395	6698					144	145		10.1038/25938	http://dx.doi.org/10.1038/25938			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744271				2022-12-28	WOS:000075829900032
J	Vargas, M; Kashefi, K; Blunt-Harris, EL; Lovley, DR				Vargas, M; Kashefi, K; Blunt-Harris, EL; Lovley, DR			Microbiological evidence for Fe(III) reduction on early Earth	NATURE			English	Article							SP-NOV; FE(III)-REDUCING BACTERIA; GEN-NOV; IRON; LIFE; SUBSURFACE; ORIGIN; DEEP; ENVIRONMENTS; BIOSPHERE	It is generally considered(1) that sulphur reduction was one of the earliest forms of microbial respiration, because the known microorganisms that are most closely related to the last common ancestor of modern life are primarily anaerobic, sulphur-reducing hyperthermophiles(2-4). However, geochemical evidence indicates that Fe(III) is more likely than sulphur to have been the first external electron acceptor of global significance in microbial metabolism(5-7) Here we show that Archaea and Bacteria that are most closely related to the last common ancestor can reduce Fe(III) to Fe(II) and conserve energy to support growth from this respiration. Surprisingly, even Thermotoga maritima, previously considered to have only a fermentative metabolism, could grow as a respiratory organism when Fe(III) was provided as an electron acceptor. These results provide microbiological evidence that Fe(III) reduction could have been an important process on early Earth and suggest that microorganisms might contribute to Fe(III) reduction in modern hot biospheres. Furthermore, our discovery that hyperthermophiles that had previously been thought to require sulphur for cultivation can instead be grown without the production of toxic and corrosive sulphide, should aid biochemical investigations of these poorly understood organisms.	Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Lovley, DR (corresponding author), Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA.	dlovley@microbio.u.mass.edu						ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; Barns SM, 1997, REV MINERAL, V35, P35; BOONE DR, 1995, INT J SYST BACTERIOL, V45, P441, DOI 10.1099/00207713-45-3-441; CAIRNSSMITH AG, 1992, ORIGINS LIFE EVOL B, V22, P161, DOI 10.1007/BF01808023; CHILDERS SE, 1992, APPL ENVIRON MICROB, V58, P3949, DOI 10.1128/AEM.58.12.3949-3953.1992; DEDUVE C, 1995, VITAL DUST, P1; DERONDE CEJ, 1994, GEOL SOC AM BULL, V106, P86, DOI 10.1130/0016-7606(1994)106<0086:EAGFOR>2.3.CO;2; GOLD T, 1992, P NATL ACAD SCI USA, V89, P6045, DOI 10.1073/pnas.89.13.6045; Greene AC, 1997, INT J SYST BACTERIOL, V47, P505, DOI 10.1099/00207713-47-2-505; HOBBIE JE, 1977, APPL ENVIRON MICROB, V33, P1225, DOI 10.1128/AEM.33.5.1225-1228.1977; HOLM NG, 1992, ORIGINS LIFE EVOL B, V22, P5, DOI 10.1007/BF01808015; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; Liu SV, 1997, SCIENCE, V277, P1106, DOI 10.1126/science.277.5329.1106; Lonergan DJ, 1996, J BACTERIOL, V178, P2402, DOI 10.1128/jb.178.8.2402-2408.1996; Lovley D.R., 1997, IRON RELATED TRANSIT, P187; Lovley D. R, 1990, IRON BIOMINERALS, P151; LOVLEY DR, 1987, NATURE, V330, P252, DOI 10.1038/330252a0; LOVLEY DR, 1986, APPL ENVIRON MICROB, V51, P683, DOI 10.1128/AEM.51.4.683-689.1986; Madigan MT., 1997, BROCK BIOL MICROORGA; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; PACE NR, 1991, CELL, V65, P531, DOI 10.1016/0092-8674(91)90082-A; RAVOT G, 1995, APPL ENVIRON MICROB, V61, P2053, DOI 10.1128/AEM.61.5.2053-2055.1995; Slobodkin A, 1997, INT J SYST BACTERIOL, V47, P541, DOI 10.1099/00207713-47-2-541; Stetter KO, 1996, FEMS MICROBIOL REV, V18, P149, DOI 10.1111/j.1574-6976.1996.tb00233.x; WALKER JCG, 1985, PRECAMBRIAN RES, V28, P205, DOI 10.1016/0301-9268(85)90031-2; WALKER JCG, 1987, NATURE, V329, P710, DOI 10.1038/329710a0	27	373	418	13	171	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1998	395	6697					65	67		10.1038/25720	http://dx.doi.org/10.1038/25720			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116JY	9738498				2022-12-28	WOS:000075722200046
J	Kaptchuk, TJ				Kaptchuk, TJ			Powerful placebo: the dark side of the randomised controlled trial	LANCET			English	Article									Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Kaptchuk, TJ (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Alternat Med Res, Boston, MA 02215 USA.				NIAMS NIH HHS [U24 AR3441] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1986, HIST THEORY INFORM C; BATTERMAN RC, 1955, JAMA-J AM MED ASSOC, V159, P1619, DOI 10.1001/jama.1955.02960340039009; BEECHER HK, 1953, J PHARMACOL EXP THER, V109, P393; BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; Cabot R.C., 1903, AM MED, V5, P344; DIEHL HS, 1993, JAMA-J AM MED ASSOC, V101, P2042; DINNERSTEIN AJ, 1966, PERSPECT BIOL MED, V10, P103; ERNST E, 1995, BMJ-BRIT MED J, V311, P551, DOI 10.1136/bmj.311.7004.551; Evans FJ, 1974, ADV NEUROL, V4, P289; GAY LN, 1949, B JOHNS HOPKINS HOSP, V84, P470; Gold H, 1937, J AMER MED ASSOC, V108, P2173, DOI 10.1001/jama.1937.02780260001001; GOTZSCHE PC, 1994, LANCET, V344, P925; HILL AB, 1952, NEW ENGL J MED, V247, P113, DOI 10.1056/NEJM195207242470401; HILL AB, 1990, CONTROL CLIN TRIALS, V11, P77; Jefferson T., 1898, WRITINGS T JEFFERSON, V9; JOYCE CRB, 1982, BRIT J CLIN PHARMACO, V13, P313, DOI 10.1111/j.1365-2125.1982.tb01380.x; KAPTCHUK TJ, 1998, IN PRESS B HIST MED; KAPTCHUK TJ, 1997, ADVANCES, V13, P48; KEMPTHORNE O, 1977, J STAT PLAN INFER, V1, P1, DOI 10.1016/0378-3758(77)90002-7; Kienle G S, 1996, Altern Ther Health Med, V2, P39; KIENLE GS, 1995, SOGENANNTE PLACEBOEF; KLEIJNEN J, 1994, LANCET, V344, P1347, DOI 10.1016/S0140-6736(94)90699-8; LIBERMAN RP, 1967, NEUROPSYCHOPHARMACOL, V5, P557; LILIENFELD AM, 1982, B HIST MED, V56, P1; Marks H., 1997, PROGR EXPT SCI THERA; McDonald C J, 1983, Stat Med, V2, P417; MCQUAY H, 1995, PAIN, V65, P331; Moerman D. E., 1983, MED ANTHROPOL Q, V14, P3, DOI [DOI 10.1525/MAQ.1983.14.4.02A00020, 10.1525/maq.1983.14.4.02a00020]; Pepper O., 1945, AM J PHARM, V117, P409; PORTER DR, 1993, BRIT J RHEUMATOL, V32, P463; ROBERTS AH, 1993, CLIN PSYCHOL REV, V13, P375, DOI 10.1016/0272-7358(93)90010-J; Rosenberg C, 1967, Bull Hist Med, V41, P223; SHAPIRO AK, 1968, PSYCHIAT QUART, V42, P653, DOI 10.1007/BF01564309; SHIDEMAN DE, 1958, WISC MED J, V57, P456; Spilker B., 1991, GUIDE CLIN TRIALS; SULLIVAN MD, 1993, J MED PHILOS, V18, P213, DOI 10.1093/jmp/18.2.213; Tuke Daniel Hack, 1884, ILLUSTRATIONS INFLUE; TYLER DB, 1946, AM J PHYSIOL, V146, P458, DOI 10.1152/ajplegacy.1946.146.3.458; WOLF S, 1950, J CLIN INVEST, V29, P100, DOI 10.1172/JCI102225; 1946, NY J MED, V17, P722; 1954, LANCET, V2, P321; 1885, MED RECORD, V27, P576	42	241	247	1	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 6	1998	351	9117					1722	1725		10.1016/S0140-6736(97)10111-8	http://dx.doi.org/10.1016/S0140-6736(97)10111-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734904				2022-12-28	WOS:000074088900039
J	Poenisch, C				Poenisch, C			Occasional notes - Merian Frederick's story	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Poenisch, C (corresponding author), 16463 Sutters Lane Ct, Northville, MI 48167 USA.							Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406	1	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1998	339	14					996	998		10.1056/NEJM199810013391411	http://dx.doi.org/10.1056/NEJM199810013391411			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124MW	9753718				2022-12-28	WOS:000076186900011
J	Annas, GJ				Annas, GJ			The shadowlands - Secrets, lies, and assisted reproduction	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INSEMINATION; DISCLOSURE; DONOR		Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				Advisory Committee on Human Radiation Experiments, 1995, FIN REP; ALTMAN LK, 1998, NY TIMES        0624, pA1; Andrews L, 1998, SCIENCE, V281, P651; Annas GJ, 1996, NEW ENGL J MED, V334, P1329, DOI 10.1056/NEJM199605163342012; ANNAS GJ, 1980, FAM LAW QUART, V14, P1; ANNAS GJ, 1993, STANDARD CARE LAW AM, P61; ANNAS GJ, 1997, BOSTON GLOBE    1130, pD1; Baran Annette, 1989, LETHAL SECRETS SHOCK; *COMM CONS SOC ETH, 1984, REP DISP EMBR PROD I; Department of Health and Social Security, 1984, REP COMM INQ HUM FER; ELIAS S, 1986, JAMA-J AM MED ASSOC, V255, P62, DOI 10.1001/jama.255.1.62; Ethics Committee of the American Fertility Society, 1994, FERTIL STERIL S1, V62, p1S; LEIBLUM SR, 1992, J PSYCHOSOM OBST GYN, V13, P267, DOI 10.3109/01674829209009199; LEWIS CS, 1994, LAST BATTLE; LEWIS CS, 1966, OTHER WORLDS ESSAYS, P22; MOSKOWITZ EM, 1998, NATL L J        0608, pA25; Nachtigall RD, 1997, FERTIL STERIL, V68, P83, DOI 10.1016/S0015-0282(97)81480-X; Nicholson William, 1991, SHADOWLANDS; *NY STAT TASK FORC, 1998, ASS REPR TECHN AN RE; *ONT LAW REF COMM, 1985, REP HUM ART REPR REL; Radin Margaret J., 1996, CONTESTED COMMODITIE; Robertson J., 1994, CHILDREN CHOICE; *ROYAL COMM NEW RE, 1993, PROC CAUT; Seelye Katharine Q., 1997, N Y TIMES, pA20	24	26	27	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1998	339	13					935	939		10.1056/NEJM199809243391325	http://dx.doi.org/10.1056/NEJM199809243391325			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121VY	9744980	Green Published			2022-12-28	WOS:000076037400032
J	Kaech, SM; Whitfield, CW; Kim, SK				Kaech, SM; Whitfield, CW; Kim, SK			The LIN-2/LIN-7/LIN-10 complex mediates basolateral membrane localization of the C-elegans EGF receptor LET-23 in vulval epithelial cells	CELL			English	Article							CAENORHABDITIS-ELEGANS; PDZ DOMAIN; MDCK CELLS; PROTEINS; BINDING; GENE; INDUCTION; POLARITY; ENCODES; PURIFICATION	In C. elegans, the LET-23 receptor tyrosine kinase is localized to the basolateral membranes of polarized vulval epithelial cells. lin-2, lin-7, and lin-10 are required for basolateral localization of LET-23, since LET-23 is mislocalized to the apical membrane in lin-2 lin-7, and lin-10 mutants. Yeast two-hybrid, in vitro binding, and in vivo coimmunoprecipitation experiments show that LIN-2, LIN-7, and LIN-10 form a protein complex. Furthermore, compensatory mutations in lin-7 and let-23 exhibit allele-specific suppression of apical mislocalization and signaling-defective phenotypes. These results present a mechanism for basolateral localization of LET-23 receptor tyrosine kinase by direct binding to the LIN-2/LIN-7/LIN-10 complex. Each of the binding interactions within this complex is conserved, suggesting that this complex may also mediate basolateral localization in mammals.	Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA	Stanford University	Kim, SK (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.				NIGMS NIH HHS [R01 GM043977] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043977] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; FERGUSON EL, 1985, GENETICS, V110, P17; Hata Y, 1996, J NEUROSCI, V16, P2488; HOBERT M, 1995, J CELL PHYSIOL, V162, P434, DOI 10.1002/jcp.1041620316; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; Mellian I, 1995, COLD SPRING HARB SYM, V60, P745, DOI 10.1101/SQB.1995.060.01.080; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; SIMSKE JS, 1996, CELL, V85, P2195; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Wood WB, 1988, NEMATODE CAENORHABDI; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	42	296	307	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					761	771		10.1016/S0092-8674(00)81735-3	http://dx.doi.org/10.1016/S0092-8674(00)81735-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753323	Green Accepted, Bronze			2022-12-28	WOS:000076021200009
J	Nelson, LS; Rosoff, ML; Li, C				Nelson, LS; Rosoff, ML; Li, C			Disruption of a neuropeptide gene, flp-1, causes multiple behavioral defects in Caenorhabditis elegans	SCIENCE			English	Article							C-ELEGANS; PRESYNAPTIC INHIBITION; FMRFAMIDE; PEPTIDES; PHE-MET-ARG-PHE-NH2; NEURONS; APLYSIA; SYSTEM; IDENTIFICATION; NOCICEPTION	Neuropeptides serve as important signaling molecules in the nervous system. The FMRFamide (Phe-Met-Arg-Phe-amide)-related neuropeptide gene family in the nematode Caenorhabditis elegans is composed of at Least 18 genes that may encode 53 distinct FMRFamide-related peptides. Disruption of one of these genes, flp-1, causes numerous behavioral defects, including uncoordination, hyperactivity, and insensitivity to high osmolarity. Conversely, overexpression of flp-1 results in the reciprocal phenotypes. On the basis of epistasis analysis, flp-1 gene products appear to signal upstream of a G protein-coupled second messenger system. These results demonstrate that varying the levels of FLP-1 neuropeptides can profoundly affect behavior and that members of this large neuropeptide gene family are not functionally redundant in C. elegans.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Li, C (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	li@bu.edu			NIA NIH HHS [AG00708] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BRENNER S, 1974, GENETICS, V77, P71; Brownlee DJA, 1996, PARASITOL TODAY, V12, P343, DOI 10.1016/0169-4758(96)10052-1; Brundage L, 1996, NEURON, V16, P999, DOI 10.1016/S0896-6273(00)80123-3; BRUNDAGE L, UNPUBAGE; BRUNDAGE L, COMMUNICATION; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; CHIBA O, 1992, NEUROSCI RES, V15, P255, DOI 10.1016/0168-0102(92)90046-F; CHIN GJ, 1994, BIOL BULL, V187, P185, DOI 10.2307/1542241; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; CULOTTI JG, 1978, GENETICS, V90, P243; DUSENBER.DB, 1974, J EXP ZOOL, V188, P41, DOI 10.1002/jez.1401880105; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; HORVITZ HR, 1982, SCIENCE, V216, P1012, DOI 10.1126/science.6805073; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; KAVALIERS M, 1990, NEUROSCI LETT, V115, P307, DOI 10.1016/0304-3940(90)90473-M; KAVALIERS M, 1993, NEUROSCI LETT, V157, P75, DOI 10.1016/0304-3940(93)90646-3; KUHLMAN JR, 1985, J NEUROSCI, V5, P2310; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; MACKEY SL, 1987, P NATL ACAD SCI USA, V84, P8730, DOI 10.1073/pnas.84.23.8730; Maule AG, 1996, PARASITOL TODAY, V12, P351, DOI 10.1016/0169-4758(96)10051-X; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; NAMBU JR, 1988, NEURON, V1, P55, DOI 10.1016/0896-6273(88)90209-7; Nelson LS, 1998, MOL BRAIN RES, V58, P103, DOI 10.1016/S0169-328X(98)00106-5; NELSON LS, UNPUB; NICHOLS R, 1988, J BIOL CHEM, V263, P12167; NICHOLS R, 1992, J MOL NEUROSCI, V3, P213, DOI 10.1007/BF03380141; PAYZA K, 1993, J NEUROCHEM, V60, P1894, DOI 10.1111/j.1471-4159.1993.tb13417.x; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; RAFFA RB, 1988, PEPTIDES, V9, P915, DOI 10.1016/0196-9781(88)90141-6; ROSOFF ML, 1992, J NEUROSCI, V12, P2356; RUSHFORTH AM, 1993, MOL CELL BIOL, V13, P902, DOI 10.1128/MCB.13.2.902; SCHINKMANN K, 1992, J COMP NEUROL, V315, P1; SCHNEIDER LE, 1988, P NATL ACAD SCI USA, V85, P1993, DOI 10.1073/pnas.85.6.1993; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; SMALL SA, 1989, SCIENCE, V243, P1603, DOI 10.1126/science.2538924; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TANG J, 1984, P NATL ACAD SCI-BIOL, V81, P5002, DOI 10.1073/pnas.81.15.5002; WARD S, 1973, P NATL ACAD SCI USA, V70, P817, DOI 10.1073/pnas.70.3.817; WAY JC, 1991, GENE DEV, V5, P2199, DOI 10.1101/gad.5.12a.2199; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILLIAMS BD, 1992, GENETICS, V131, P609; WONG TM, 1985, COMP BIOCHEM PHYS C, V81, P175, DOI 10.1016/0742-8413(85)90111-2; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	47	133	139	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	1998	281	5383					1686	1690		10.1126/science.281.5383.1686	http://dx.doi.org/10.1126/science.281.5383.1686			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733518				2022-12-28	WOS:000075856500051
J	Deutsch, A; Greshake, A; Pesonan, LJ; Pihlaja, P				Deutsch, A; Greshake, A; Pesonan, LJ; Pihlaja, P			RETRACTED: Unaltered cosmic spherules in a 1.4-Gyr-old sandstone from Finland (Retracted Article. See vol 429, pg 322, 2004)	NATURE			English	Article; Retracted Publication							MICROMETEORITES; GREENLAND; COLLECTION; SEDIMENTS; DUST; ICE	Micrometeorites-submillimetre-sized particles derived from asteroids and comets(1-5)-occur in significant quantities in deep sea sediments(1,2,4), and the ice sheets of Greenland(6,7) and Antarctica(8,9). The most abundant micrometeorites are cosmic spherules(3), which contain nickel-rich spinels(10) that were crystallized and oxidized during atmospheric entry, therefore recording the oxygen content in the uppermost atmosphere(10-12). But the use of micrometeorites for detecting past changes in the flux of incoming extraterrestrial matter, and as probes of the evolution of the atmosphere, has been hampered by the fact that most objects with depositional ages higher than 0.5 Mpr show severe chemical alteration(2). Here we report the discovery of unaltered cosmic spherules in a 1.4-Gyr-old(13-15) sandstone(16,17) (red bed) from Finland. From this we infer that red beds, a common lithology in the Earth's history, map contain substantial unbiased populations of fossil micrometeorites, The study of such populations would allow systematic research on variations in the micrometeorite flux from the early Proterozoic era to recent times(9) (a time span of about 2.5 Gyr), and could help to better constrain the time when the atmospheric oxygen content was raised to its present level(18-20)	Univ Munster, Inst Planetol, D-48149 Munster, Germany; Geol Survey Finland, FIN-02151 Espoo, Finland	University of Munster; Geological Survey of Finland (GTK)	Deutsch, A (corresponding author), Univ Munster, Inst Planetol, Wilhelm Klemm Str 10, D-48149 Munster, Germany.	deutsca@uni-muenster.de						AMATOV A, 1996, B GEOL SOC FINLAND, V21, P99; BECKERLING W, 1995, PLANET SPACE SCI, V43, P435, DOI 10.1016/0032-0633(94)00175-Q; BENCE AE, 1968, J GEOL, V76, P382, DOI 10.1086/627339; BLANCHARD MB, 1980, EARTH PLANET SC LETT, V46, P178, DOI 10.1016/0012-821X(80)90004-7; BROWNLEE DE, 1985, ANNU REV EARTH PL SC, V13, P147, DOI 10.1146/annurev.ea.13.050185.001051; BROWNLEE DE, 1984, NATURE, V309, P693, DOI 10.1038/309693a0; Brownlee DE, 1997, METEORIT PLANET SCI, V32, P157, DOI 10.1111/j.1945-5100.1997.tb01257.x; Brownlee DE, 1981, SEA, P733; BROWNLEE DE, 1983, CHONDRULES THEIR ORI, P122; Gayraud J., 1996, GEOL SOC AM SPEC PAP, V307, P425; GOODWIN AM, 1991, PRECAMBRIAN GEOLOGY; JEBANNO C, 1988, P LUNAR PLANET SCI C, V18, P623; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; Kerridge JF., 1988, METEORITES EARLY SOL; KOHONEN J, 1993, GEOL SURV FIN B, V369; LOVE SG, 1991, ICARUS, V89, P26, DOI 10.1016/0019-1035(91)90085-8; MARAIS DJD, 1992, NATURE, V359, P605, DOI 10.1038/359605a0; MARTTILA E, 1969, THESIS U TURKU; Marttila E., 1968, GEOLOGI, V20, P135; MAURETTE M, 1991, NATURE, V351, P44, DOI 10.1038/351044a0; MAURETTE M, 1987, NATURE, V328, P699, DOI 10.1038/328699a0; OHMOTO H, 1997, GEOCHEM NEWS, V93, P12; ROBIN E, 1992, EARTH PLANET SC LETT, V108, P181, DOI 10.1016/0012-821X(92)90021-M; ROBIN E, 1990, EARTH PLANET SC LETT, V97, P162, DOI 10.1016/0012-821X(90)90106-8; SOUMINEN V, 1991, GOEL SURV FIN B, V304; STEELE IM, 1992, GEOCHIM COSMOCHIM AC, V56, P2923, DOI 10.1016/0016-7037(92)90368-S; Taylor S, 1998, NATURE, V392, P899, DOI 10.1038/31894; TAYLOR S, 1991, METEORITICS, V26, P203, DOI 10.1111/j.1945-5100.1991.tb01040.x; THORSLUND P, 1981, NATURE, V289, P285, DOI 10.1038/289285a0	29	17	17	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 10	1998	395	6698					146	148		10.1038/25943	http://dx.doi.org/10.1038/25943			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744272				2022-12-28	WOS:000075829900033
J	Dominguez, R; Freyzon, Y; Trybus, KM; Cohen, C				Dominguez, R; Freyzon, Y; Trybus, KM; Cohen, C			Crystal structure of a vertebrate smooth muscle myosin motor domain and its complex with the essential light chain: Visualization of the pre-power stroke state	CELL			English	Article							X-RAY STRUCTURES; NUCLEOTIDE-BINDING; REGULATORY DOMAIN; MOLECULAR MOTORS; ATPASE ACTIVITY; SCALLOP MYOSIN; HEAVY-CHAIN; RESOLUTION; PROTEINS; SUBFRAGMENT-1	The crystal structures of an expressed vertebrate smooth muscle myosin motor domain (MD) and a motor domain-essential light chain (ELC) complex (MDE), both with a transition state analog (MgADP . AlF4-) in the active site, have been determined to 2.9 Angstrom and 3.5 Angstrom resolution, respectively. The MDE structure with an ATP analog (MgADP . BeFx) was also determined to 3.6 Angstrom resolution. In all three structures, a domain of the C-terminal region, the "converter," is rotated similar to 70 degrees from that in nucleotide-free skeletal subfragment 1 (S1). We have found that the MDE-BeFx and MDE-AlFx structures are almost identical, consistent with the fact that they both bind weakly to actin. A comparison of the lever arm positions in MDE-AlF4- and in nucleotide-free skeletal S1 shows that a potential displacement of similar to 10 nm can be achieved during the power stroke.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA	Brandeis University	Cohen, C (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA.				NHLBI NIH HHS [HL 38113] Funding Source: Medline; NIAMS NIH HHS [AR 17346, AR 41808] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038113, R01HL038113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR017346, R01AR017346, R01AR041808] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anson M, 1996, EMBO J, V15, P6069, DOI 10.1002/j.1460-2075.1996.tb00995.x; Brunger AT, 1992, XPLOR VERSION 3 1 MA; Burghardt TP, 1998, BIOCHEMISTRY-US, V37, P8035, DOI 10.1021/bi980015y; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FISHER AJ, 1995, BIOPHYS J, V68, pS19; Guilford WH, 1998, BIOPHYS J, V74, pA225; Gulick AM, 1997, BIOESSAYS, V19, P561, DOI 10.1002/bies.950190707; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; HIRATSUKA T, 1992, J BIOL CHEM, V267, P14949; Ho GY, 1997, J BIOL CHEM, V272, P4522, DOI 10.1074/jbc.272.7.4522; Holmes KC, 1996, CURR OPIN STRUC BIOL, V6, P781, DOI 10.1016/S0959-440X(96)80008-X; Holmes KC, 1998, CIBA F SYMP, V213, P76; HOLMES KC, 1997, CURR BIOL, V7, P112; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; HUSTON EE, 1988, BIOCHEMISTRY-US, V27, P8945, DOI 10.1021/bi00425a011; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; JOHNSON KA, 1978, BIOCHEMISTRY-US, V17, P3432, DOI 10.1021/bi00610a002; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jontes JD, 1997, J CELL BIOL, V139, P683, DOI 10.1083/jcb.139.3.683; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P59; Patterson B, 1997, J BIOL CHEM, V272, P27612, DOI 10.1074/jbc.272.44.27612; PerreaultMicale CL, 1996, J MUSCLE RES CELL M, V17, P543, DOI 10.1007/BF00124354; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1995, P NATL ACAD SCI USA, V92, P3864, DOI 10.1073/pnas.92.9.3864; Rayment I, 1996, J BIOL CHEM, V271, P15850, DOI 10.1074/jbc.271.27.15850; Rovner AS, 1997, J MUSCLE RES CELL M, V18, P103, DOI 10.1023/A:1018689102122; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; VANBUREN P, 1994, P NATL ACAD SCI USA, V91, P12403, DOI 10.1073/pnas.91.26.12403; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; YOUNT RG, 1995, BIOPHYS J, V68, pS44	43	572	588	0	12	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 4	1998	94	5					559	571		10.1016/S0092-8674(00)81598-6	http://dx.doi.org/10.1016/S0092-8674(00)81598-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741621	Bronze			2022-12-28	WOS:000075851900004
J	Zhang, LI; Tao, HW; Holt, CE; Harris, WA; Poo, MM				Zhang, LI; Tao, HW; Holt, CE; Harris, WA; Poo, MM			A critical window for cooperation and competition among developing retinotectal synapses	NATURE			English	Article							LONG-TERM POTENTIATION; OCULAR DOMINANCE COLUMNS; VISUAL-CORTEX; NMDA RECEPTORS; MAP FORMATION; SEGREGATION; PROJECTION; CELLS; CONNECTIVITY; TRANSMISSION	In the developing frog visual system, topographic refinement of the retinotectal projection depends on electrical activity. In vivo whole-cell recording from developing Xenopus tectal neurons shows that convergent retinotectal synapses undergo activity-dependent cooperation and competition following correlated pre- and postsynaptic spiking within a narrow time window. Synaptic inputs activated repetitively within 20 ms before spiking of the tectal neuron become potentiated, whereas subthreshold inputs activated within 20 ms after spiking become depressed. Thus both the initial synaptic strength and the temporal order of activation are critical for heterosynaptic interactions among convergent synaptic inputs during activity-dependent refinement of developing neural networks.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Poo, MM (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	mpooe@ucsd.edu	Tao, Huizhong W/HDM-9767-2022	Holt, Christine Elizabeth/0000-0003-2829-121X				[Anonymous], [No title captured]; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BEAR MF, 1992, J NEUROPHYSIOL, V67, P1; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brickley SG, 1998, J NEUROSCI, V18, P1491; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; Colman H, 1997, SCIENCE, V275, P356, DOI 10.1126/science.275.5298.356; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; Debanne D, 1998, J PHYSIOL-LONDON, V507, P237, DOI 10.1111/j.1469-7793.1998.237bu.x; FREGNAC Y, 1994, J NEUROPHYSIOL, V71, P1403, DOI 10.1152/jn.1994.71.4.1403; Gerstner W, 1997, J COMPUT NEUROSCI, V4, P79, DOI 10.1023/A:1008820728122; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRIS WA, 1980, J COMP NEUROL, V194, P303, DOI 10.1002/cne.901940203; Hebb Donald O., 1949, ORG BEHAV; HICKMOTT PW, 1993, J NEUROSCI, V13, P4339; HOLT CE, 1993, J NEUROBIOL, V24, P1400, DOI 10.1002/neu.480241011; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KOMATSU Y, 1988, J NEUROPHYSIOL, V59, P124, DOI 10.1152/jn.1988.59.1.124; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Mehta MR, 1997, P NATL ACAD SCI USA, V94, P8918, DOI 10.1073/pnas.94.16.8918; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MOONEY R, 1993, NEURON, V10, P815, DOI 10.1016/0896-6273(93)90198-Z; NAVEU D, 1996, NEURON, V16, P619; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; OROURKE NA, 1990, NEURON, V5, P159, DOI 10.1016/0896-6273(90)90306-Z; Penn AA, 1998, SCIENCE, V279, P2108, DOI 10.1126/science.279.5359.2108; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; REH TA, 1985, J NEUROSCI, V5, P1132; SAKAGUCHI DS, 1985, J NEUROSCI, V5, P3228; SCHMIDT JT, 1993, J NEUROBIOL, V24, P384, DOI 10.1002/neu.480240310; SCHMIDT JT, 1990, J NEUROSCI, V10, P233; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; STRYKER MP, 1986, J NEUROSCI, V6, P2117; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; Weliky M, 1997, NATURE, V386, P680, DOI 10.1038/386680a0; WILLSHAW DJ, 1976, PROC R SOC SER B-BIO, V194, P431, DOI 10.1098/rspb.1976.0087; WONG ROL, 1995, NATURE, V374, P716, DOI 10.1038/374716a0; Wu GY, 1996, SCIENCE, V274, P972, DOI 10.1126/science.274.5289.972	50	618	632	1	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1998	395	6697					37	44		10.1038/25665	http://dx.doi.org/10.1038/25665			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116JY	9738497				2022-12-28	WOS:000075722200038
J	Price, RW				Price, RW			Neuropathy complicating diffuse infiltrative lymphocytosis	LANCET			English	Editorial Material							PATHOGENESIS; INFECTION; CELLS		Univ Calif San Francisco, San Francisco Gen Hosp, Serv Neurol, San Francisco, CA 94110 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Price, RW (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Serv Neurol, San Francisco, CA 94110 USA.							DWYER E, 1993, J CLIN INVEST, V92, P495, DOI 10.1172/JCI116593; Gherardi RK, 1998, NEUROLOGY, V50, P1041, DOI 10.1212/WNL.50.4.1041; GUILLON JM, 1987, AM J MED, V82, P655, DOI 10.1016/0002-9343(87)90118-5; ITESCU S, 1993, J CLIN INVEST, V91, P2216, DOI 10.1172/JCI116448; Moulignier A, 1997, ANN NEUROL, V41, P438, DOI 10.1002/ana.410410406; Simpson David M., 1997, P189; TYOR WR, 1995, J ACQ IMMUN DEF SYND, V9, P379; Yang OO, 1997, ADV IMMUNOL, V66, P273, DOI 10.1016/S0065-2776(08)60600-8	8	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 22	1998	352	9128					592	594		10.1016/S0140-6736(05)79571-4	http://dx.doi.org/10.1016/S0140-6736(05)79571-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746016				2022-12-28	WOS:000075567400004
J	Ueda, S; Petrie, JR; Cleland, SJ; Elliott, HL; Connell, JMC				Ueda, S; Petrie, JR; Cleland, SJ; Elliott, HL; Connell, JMC			Insulin vasodilatation and the "arginine paradox"	LANCET			English	Article							NITRIC-OXIDE		Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Petrie, JR (corresponding author), Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland.							Chowienczyk P, 1997, LANCET, V350, P901, DOI 10.1016/S0140-6736(05)63263-1; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; MACALLISTER RJ, 1995, CLIN SCI, V89, P183, DOI 10.1042/cs0890183; Sobrevia L, 1996, J PHYSIOL-LONDON, V490, P775, DOI 10.1113/jphysiol.1996.sp021185; STEINBERG HO, 1994, J CLIN INVEST, V94, P1172, DOI 10.1172/JCI117433	5	11	11	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 28	1998	351	9107					959	960						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734951				2022-12-28	WOS:000072770900022
J	Cane, DE; Walsh, CT; Khosla, C				Cane, DE; Walsh, CT; Khosla, C			Biochemistry - Harnessing the biosynthetic code: Combinations, permutations, and mutations	SCIENCE			English	Review							MODULAR POLYKETIDE SYNTHASE; ENGINEERED BIOSYNTHESIS; SACCHAROPOLYSPORA-ERYTHRAEA; PEPTIDE SYNTHETASE; GENE-CLUSTER; PENICILLIUM-CHRYSOGENUM; MACROLIDE BIOSYNTHESIS; FUNCTION MUTAGENESIS; ERYTHROMYCIN; DOMAIN	Polyketides and non-ribosomal peptides are two large families of complex natural II products that are built from simple carboxylic acid or amino acid monomers, respectively, and that have important medicinal or agrochemical properties. Despite the substantial differences between these two classes of natural products, each is synthesized biologically under the control of exceptionally large, multifunctional proteins II termed polyketide synthases (PKSs) and non-ribosomal peptide synthetases (NRPSs) that contain repeated, coordinated groups of active sites called modules, in which each module is responsible for catalysis of one complete cycle of polyketide or polypeptide chain elongation and associated functional group modifications. It has recently become possible to use molecular genetic methodology to alter the number, content, and order of such modules and, in so doing, to alter rationally the structure of the resultant products. This review considers the promise and challenges inherent in the combinatorial manipulation of PKS and NRPS structure in order to generate entirely "unnatural" products.	Brown Univ, Dept Chem, Providence, RI 02912 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA	Brown University; Harvard University; Harvard Medical School; Stanford University; Stanford University; Stanford University	Cane, DE (corresponding author), Brown Univ, Dept Chem, Box H, Providence, RI 02912 USA.			Khosla, Chaitan/0000-0001-6529-495X	NATIONAL CANCER INSTITUTE [R01CA066736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020011, R01GM022172, R37GM020011] Funding Source: NIH RePORTER; NCI NIH HHS [CA66736] Funding Source: Medline; NIGMS NIH HHS [GM22172, GM20011] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGOURIDAS C, 1995, 35 INT C ANT AG CHEM; Aparicio JF, 1996, GENE, V169, P9, DOI 10.1016/0378-1119(95)00800-4; Bedford D, 1996, CHEM BIOL, V3, P827, DOI 10.1016/S1074-5521(96)90068-X; BEDFORD DJ, 1995, J BACTERIOL, V177, P4544, DOI 10.1128/jb.177.15.4544-4548.1995; Bohm I, 1998, CHEM BIOL, V5, P407, DOI 10.1016/S1074-5521(98)90157-0; CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; CANE DE, 1987, J AM CHEM SOC, V109, P1255, DOI 10.1021/ja00238a051; COQUE JJR, 1991, MOL MICROBIOL, V5, P1125, DOI 10.1111/j.1365-2958.1991.tb01885.x; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; CORTES J, 1995, SCIENCE, V268, P1487, DOI 10.1126/science.7770773; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Gehring AM, 1997, BIOCHEMISTRY-US, V36, P8495, DOI 10.1021/bi970453p; Gehring AM, 1998, BIOCHEMISTRY-US, V37, P2648, DOI 10.1021/bi9726584; Gehring AM, 1998, BIOCHEMISTRY-US, V37, P11637, DOI 10.1021/bi9812571; GOKHALE RS, UNPUB; Gold BG, 1997, MOL NEUROBIOL, V15, P285, DOI 10.1007/BF02740664; Griesgraber G, 1996, J ANTIBIOT, V49, P465, DOI 10.7164/antibiotics.49.465; GUTIERREZ S, 1991, J BACTERIOL, V173, P2354; Jacobsen JR, 1997, SCIENCE, V277, P367, DOI 10.1126/science.277.5324.367; Jacobsen JR, 1998, J AM CHEM SOC, V120, P9096, DOI 10.1021/ja9819514; Jacobsen JR, 1998, BIOORGAN MED CHEM, V6, P1171, DOI 10.1016/S0968-0896(98)00081-9; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; Kao CM, 1998, J AM CHEM SOC, V120, P2478, DOI 10.1021/ja973913a; KAO CM, 1995, J AM CHEM SOC, V117, P9105, DOI 10.1021/ja00140a043; Kao CM, 1996, J AM CHEM SOC, V118, P9184, DOI 10.1021/ja9617552; Kao CM, 1997, J AM CHEM SOC, V119, P11339, DOI 10.1021/ja972609e; Kealey JT, 1998, P NATL ACAD SCI USA, V95, P505, DOI 10.1073/pnas.95.2.505; KHOSLA C, IN PRESS ANN REV BIO; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; LARTEY PA, 1995, J MED CHEM, V38, P1793, DOI 10.1021/jm00010a024; LAU JF, UNPUB; Liu L, 1997, J AM CHEM SOC, V119, P10553, DOI 10.1021/ja972451y; MACCABE AP, 1991, J BIOL CHEM, V266, P12646; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; Marsden AFA, 1998, SCIENCE, V279, P199, DOI 10.1126/science.279.5348.199; MCDANIEL R, 1993, J AM CHEM SOC, V115, P11671, DOI 10.1021/ja00078a002; McDaniel R, 1997, J AM CHEM SOC, V119, P4309, DOI 10.1021/ja9702531; Nicolaou KC, 1997, ANGEW CHEM INT EDIT, V36, P2097, DOI 10.1002/anie.199720971; Oliynyk M, 1996, CHEM BIOL, V3, P833, DOI 10.1016/S1074-5521(96)90069-1; OMURA S, 1987, J MED CHEM, V30, P1941, DOI 10.1021/jm00394a001; Patten PA, 1997, CURR OPIN BIOTECH, V8, P724, DOI 10.1016/S0958-1669(97)80127-9; PIEPER R, 1995, NATURE, V378, P263, DOI 10.1038/378263a0; POHL NL, IN PRESS J AM CHEM S; Ruan X, 1997, J BACTERIOL, V179, P6416, DOI 10.1128/jb.179.20.6416-6425.1997; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; SMITH DJ, 1990, EMBO J, V9, P2743, DOI 10.1002/j.1460-2075.1990.tb07461.x; Summers RG, 1997, MICROBIOL-UK, V143, P3251, DOI 10.1099/00221287-143-10-3251; TSOI CJ, 1995, CHEM BIOL, V2, P355; van Wageningen AMA, 1998, CHEM BIOL, V5, P155, DOI 10.1016/S1074-5521(98)90060-6; vonDohren H, 1997, CHEM REV, V97, P2675, DOI 10.1021/cr9600262; WEBER G, 1994, CURR GENET, V26, P120, DOI 10.1007/BF00313798; Weissman KJ, 1997, BIOCHEMISTRY-US, V36, P13849, DOI 10.1021/bi971566b; Weissman KJ, 1998, ANGEW CHEM INT EDIT, V37, P1437, DOI 10.1002/(SICI)1521-3773(19980605)37:10<1437::AID-ANIE1437>3.0.CO;2-7; YUE S, 1987, J AM CHEM SOC, V109, P1253, DOI 10.1021/ja00238a050; 1997, CHEM REV, V97	57	534	637	2	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1998	282	5386					63	68		10.1126/science.282.5386.63	http://dx.doi.org/10.1126/science.282.5386.63			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756477				2022-12-28	WOS:000076294900037
J	Neuhauser, R; Comeron, F				Neuhauser, R; Comeron, F			ROSAT x-ray detection of a young brown dwarf in the Chamaeleon I dark cloud	SCIENCE			English	Article							LOW-MASS STARS; MAIN-SEQUENCE STARS; SPECTRAL SEQUENCE; PLEIADES; CANDIDATES; MEMBERS; CLUSTER; SEARCH	Photometry and spectroscopy of the object Cha H alpha 1, located in the Chamaeleon I star-forming cloud, show that it is a similar to 10(6)-year-old brown dwarf with spectral type M7.5 to M8 and 0.04 +/- 0.01 solar masses. Quiescent x-ray emission was detected in a 36-kilosecond observation with 31.4 +/- 7.7 x-ray photons, obtained with the Rontgen Satellite (ROSAT), with 9 sigma detection significance. This corresponds to an x-ray luminosity of 2.57 X 10(28) ergs per second and an x-ray to bolometric Luminosity ratio of 10(-3.44). These are typical values for late M-type stars. Because the interior of brown dwarfs may be similar to that of convective late-type stars, which are well-known x-ray sources, x-ray emission from brown dwarfs may indicate magnetic activity.	Max Planck Inst Extraterr Phys, D-85740 Garching, Germany; European So Observ, D-85748 Garching, Germany	Max Planck Society; European Southern Observatory	Neuhauser, R (corresponding author), Max Planck Inst Extraterr Phys, D-85740 Garching, Germany.	me@mpe.mpg.de; fcomeron@eso.org						Allard F, 1997, ANNU REV ASTRON ASTR, V35, P137, DOI 10.1146/annurev.astro.35.1.137; Basri G, 1996, ASTROPHYS J, V458, P600, DOI 10.1086/176842; BRAUN M, 1992, THESIS F SCHILLER U; BURROWS A, 1993, REV MOD PHYS, V65, P301, DOI 10.1103/RevModPhys.65.301; Burrows A, 1997, ASTROPHYS J, V491, P856, DOI 10.1086/305002; BURROWS A, 1995, NATURE, V375, P299, DOI 10.1038/375299a0; BURROWS A, UNPUB; CASANOVA S, 1995, ASTROPHYS J, V439, P752, DOI 10.1086/175214; Comeron F, 1998, ASTRON ASTROPHYS, V335, P522; COMERON F, UNPUB; DANTONA F, 1985, ASTROPHYS J, V296, P502, DOI 10.1086/163470; DANTONA F, UNPUB; DANTONA F, 1997, P M COOL STARS CLUST, P807; DORMAN B, 1989, ASTROPHYS J, V342, P1003, DOI 10.1086/167658; FEIGELSON ED, 1993, ASTROPHYS J, V416, P623, DOI 10.1086/173264; FEIGELSON ED, 1989, ASTROPHYS J, V338, P262, DOI 10.1086/167196; FLEMING T, UNPUB; Giampapa MS, 1996, ASTROPHYS J, V463, P707, DOI 10.1086/177284; KIRKPATRICK JD, 1991, ASTROPHYS J SUPPL S, V77, P417, DOI 10.1086/191611; KIRKPATRICK JD, 1995, ASTRON J, V109, P797, DOI 10.1086/117323; Kulkami SR, 1997, SCIENCE, V276, P1350, DOI 10.1126/science.276.5317.1350; Lawson WA, 1996, MON NOT R ASTRON SOC, V280, P1071; Leggett SK, 1996, ASTROPHYS J SUPPL S, V104, P117, DOI 10.1086/192295; LIEBERT J, 1992, ASTR SOC P, V26, P282; Luhman KL, 1998, ASTROPHYS J, V497, P354, DOI 10.1086/305447; Luhman KL, 1998, ASTROPHYS J, V493, P909, DOI 10.1086/305171; Luhman KL, 1997, ASTROPHYS J, V489, pL165, DOI 10.1086/316784; Martin EL, 1996, ASTROPHYS J, V469, P706, DOI 10.1086/177817; NEUHAUSER R, UNPUB; PFEFFERMANN E, 1988, P SOC PHOTO-OPT INS, V733, P519; PROSSER CF, 1991, ASTRON J, V101, P1361, DOI 10.1086/115772; REBOLO R, 1995, NATURE, V377, P129, DOI 10.1038/377129a0; STAUFFER JR, 1994, ASTRON J, V108, P155, DOI 10.1086/117053; STROM KM, 1994, ASTROPHYS J, V424, P237, DOI 10.1086/173886; Trumper J., 1982, Advances in Space Research, V2, P241, DOI 10.1016/0273-1177(82)90070-9; ZAPTEROOSORIO MR, 1997, ASTRON ASTROPHYS, V317, P164	36	82	83	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1998	282	5386					83	85		10.1126/science.282.5386.83	http://dx.doi.org/10.1126/science.282.5386.83			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756481				2022-12-28	WOS:000076294900041
J	Stenger, S; Hanson, DA; Teitelbaum, R; Dewan, P; Niazi, KR; Froelich, CJ; Ganz, T; Thoma-Uszynski, S; Melian, A; Bogdan, C; Porcelli, SA; Bloom, BR; Krensky, AM; Modlin, RL				Stenger, S; Hanson, DA; Teitelbaum, R; Dewan, P; Niazi, KR; Froelich, CJ; Ganz, T; Thoma-Uszynski, S; Melian, A; Bogdan, C; Porcelli, SA; Bloom, BR; Krensky, AM; Modlin, RL			An antimicrobial activity of cytolytic T cells mediated by granulysin	SCIENCE			English	Article							NITRIC-OXIDE SYNTHASE; NATURAL-KILLER; MYCOBACTERIUM-TUBERCULOSIS; LISTERIA-MONOCYTOGENES; MURINE MACROPHAGES; LYMPHOCYTES-T; TARGET-CELLS; NK-LYSIN; PERFORIN; INFECTION	Cytolytic T Lymphocytes (CTLs) kill intracellular pathogens by a granule-dependent mechanism. Granulysin, a protein found in granules of CTLs, reduced the viability of a broad spectrum of pathogenic bacteria, fungi, and parasites in vitro. Granulysin directly killed extracellular Mycobacterium tuberculosis, altering the membrane integrity of the bacillus, and, in combination with perforin, decreased the viability of intracellular M. tuberculosis. The ability of CTLs to kill intracellular M, tuberculosis was dependent on the presence of granulysin in cytotoxic granules, defining a mechanism by which T cells directly contribute to immunity against intracellular pathogens.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Pulm Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Stanford Univ, Dept Pediat, Div Immunol & Transplantat Biol, Stanford, CA 94305 USA; Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA; Evanston NW Healthcare Res Inst, Evanston, IL 60201 USA; Evanston Hosp Corp, Dept Med, Evanston, IL 60201 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Univ Erlangen Nurnberg, Inst Klin Mikrobiol Immunol & Hyg, D-91054 Erlangen, Germany	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Stanford University; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; NorthShore University Health System; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Erlangen Nuremberg	Modlin, RL (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA.	rmodlin@medicine.medsch.ucla.edu	Ganz, Tomas/AAN-3308-2020; Modlin, Robert L/M-7941-2014; Krensky, Alan/F-7956-2011; Ganz, Tomas/D-4567-2009	Modlin, Robert L/0000-0003-4720-031X; Bogdan, Christian/0000-0002-2300-0631; Ganz, Tomas/0000-0002-2830-5469				ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; Bonecini-Almeida MG, 1998, J IMMUNOL, V160, P4490; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; Cooper AM, 1997, INFECT IMMUN, V65, P1317, DOI 10.1128/IAI.65.4.1317-1320.1997; DELIBERO G, 1988, EUR J IMMUNOL, V18, P59, DOI 10.1002/eji.1830180110; DENIS M, 1991, CELL IMMUNOL, V132, P150, DOI 10.1016/0008-8749(91)90014-3; DESOUZA A, COMMUNICATION; DUKE RC, 1989, J EXP MED, V170, P1451, DOI 10.1084/jem.170.4.1451; FOREMAN JC, 1977, J PHYSIOL-LONDON, V271, P215, DOI 10.1113/jphysiol.1977.sp011997; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V229, P44, DOI 10.1006/bbrc.1996.1755; Froelich CJ, 1998, IMMUNOL TODAY, V19, P30, DOI 10.1016/S0167-5699(97)01184-5; HARTY JT, 1992, P NATL ACAD SCI USA, V89, P11612, DOI 10.1073/pnas.89.23.11612; Jackman RM, 1998, IMMUNITY, V8, P341, DOI 10.1016/S1074-7613(00)80539-7; JONGSTRA J, 1987, J EXP MED, V165, P601, DOI 10.1084/jem.165.3.601; KAPLAN G, COMMUNICATION; KAUFMANN SHE, 1986, J EXP MED, V164, P363, DOI 10.1084/jem.164.1.363; KAUFMANN SHE, 1988, IMMUNOL TODAY, V9, P168, DOI 10.1016/0167-5699(88)91292-3; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; Laochumroonvorapong P, 1997, INFECT IMMUN, V65, P127, DOI 10.1128/IAI.65.1.127-132.1997; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEIPPE M, 1994, MOL MICROBIOL, V14, P895, DOI 10.1111/j.1365-2958.1994.tb01325.x; LEIPPE M, 1995, CELL, V83, P17, DOI 10.1016/0092-8674(95)90229-5; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; MASSON D, 1985, J BIOL CHEM, V260, P9069; NEIGHBOUR PA, 1982, J IMMUNOL, V128, P1236; NEIGHBOUR PA, 1982, EUR J IMMUNOL, V12, P588, DOI 10.1002/eji.1830120711; Nicholson S, 1996, J EXP MED, V183, P2293, DOI 10.1084/jem.183.5.2293; ORME I, COMMUNICATION; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; Pena SV, 1997, J IMMUNOL, V158, P2680; QUAN PC, 1982, J IMMUNOL, V128, P1786; ROGERS RA, 1993, J CELL SCI, V106, P485; Stenger S, 1997, SCIENCE, V276, P1684, DOI 10.1126/science.276.5319.1684; Sugita M, 1996, SCIENCE, V273, P349, DOI 10.1126/science.273.5273.349; YABE T, 1990, J EXP MED, V172, P1159, DOI 10.1084/jem.172.4.1159; YODOI J, 1985, J IMMUNOL, V134, P1623	37	805	875	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1998	282	5386					121	125		10.1126/science.282.5386.121	http://dx.doi.org/10.1126/science.282.5386.121			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756476				2022-12-28	WOS:000076294900053
J	Krag, D; Weaver, D; Ashikaga, T; Moffat, F; Klimberg, VS; Shriver, C; Feldman, S; Kusminsky, R; Gadd, M; Kuhn, J; Harlow, S; Beitsch, P				Krag, D; Weaver, D; Ashikaga, T; Moffat, F; Klimberg, VS; Shriver, C; Feldman, S; Kusminsky, R; Gadd, M; Kuhn, J; Harlow, S; Beitsch, P			The sentinel node in breast cancer - A multicenter validation study	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GAMMA-PROBE; LYMPH-NODE; AXILLARY DISSECTION; MALIGNANT-MELANOMA; SURGERY; ARM; LYMPHADENECTOMY; LOCALIZATION; CARCINOMA; BIOPSY	Background Pilot studies indicate that probe-guided resection of radioactive sentinel nodes (the first nodes that receive drainage from tumors) can identify regional metastases in patients with breast cancer. To confirm this finding, we conducted a multicenter study of the method as used by 11 surgeons in a variety of practice settings. Methods We enrolled 443 patients with breast cancer. The technique involved the injection of 4 mi of technetium-99m sulfur colloid (1 mCi [37 MBq]) into the breast around the tumor or biopsy cavity. "Hot spots" representing underlying sentinel nodes were identified with a gamma probe. Sentinel nodes subjacent to hot spots were removed. All patients underwent a complete axillary lymphadenectomy. Results The overall rate of identification of hot spots was 93 percent (in 413 of 443 patients). The pathological status of the sentinel nodes was compared with that of the remaining axillary nodes. The accuracy of the sentinel nodes with respect to the positive or negative status of the axillary nodes was 97 percent (392 of 405); the specificity of the method was 100 percent, the positive predictive value was 100 percent, the negative predictive value was 96 percent (291 of 304), and the sensitivity was 89 percent (101 of 114). The sentinel nodes were outside the axilla in 8 percent of cases and outside of level 1 nodes in 11 percent of cases. Three percent of positive sentinel nodes were in nonaxillary locations. Conclusions Biopsy of sentinel nodes can predict the presence or absence of axillary-node metastases in patients with breast cancer. However, the procedure can be technically challenging, and the success rate varies according to the surgeon and the characteristics of the patient. (N Engl J Med 1998; 339:941-6.) (C)1998, Massachusetts Medical Society.	Univ Vermont, Ctr Canc, Burlington, VT 05405 USA; Univ Vermont, Dept Surg, Burlington, VT 05405 USA; Univ Vermont, Dept Pathol, Burlington, VT 05405 USA; Univ Vermont, Dept Biometry, Burlington, VT 05405 USA; Sylvester Canc Ctr, Miami, FL USA; Arkansas Canc Res Ctr, Little Rock, AR USA; Walter Reed Army Med Ctr, Washington, DC 20307 USA; Benedictine Hosp, Kingston, NY USA; Charleston Area Med Ctr, Charleston, WV USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Baylor Univ, Med Ctr, Dallas, TX USA; St Paul Hosp, Dallas, TX USA	University of Vermont; University of Vermont; University of Vermont; University of Vermont; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Harvard University; Massachusetts General Hospital; Baylor University; Baylor University Medical Center	Krag, D (corresponding author), Univ Vermont, Ctr Canc, Given Bldg E309, Burlington, VT 05405 USA.				NCI NIH HHS [P30CA22435, U01 CA65121-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA022435, U01CA065121] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEX JC, 1993, SURG ONCOL, V2, P137, DOI 10.1016/0960-7404(93)90001-F; ALEX JC, 1993, SURG ONCOL, V2, P303, DOI 10.1016/S0960-7404(06)80006-X; ASSA J, 1974, J SURG ONCOL, V6, P123, DOI 10.1002/jso.2930060206; Borgstein PJ, 1997, LANCET, V349, P1668, DOI 10.1016/S0140-6736(05)62634-7; Braithwaite LR, 1923, BRIT J SURG, V11, P7, DOI 10.1002/bjs.1800114103; BUSCH FM, 1963, J UROLOGY, V89, P106, DOI 10.1016/S0022-5347(17)64508-7; CABANAS RM, 1977, CANCER, V39, P456, DOI 10.1002/1097-0142(197702)39:2<456::AID-CNCR2820390214>3.0.CO;2-I; CHIAPPA S, 1963, J Radiol Electrol Med Nucl, V44, P613; CHIAPPA S, 1966, SURG GYNECOL OBSTETR, V123, P10; *CYTEL SOFTW, 1995, STATX WIND; DIXON WJ, 1992, BMDP STAT SOFTWARE M, V2; Fleming ID, 1997, AJCC CANC STAGING MA, P171; Giuliano AE, 1997, J CLIN ONCOL, V15, P2345, DOI 10.1200/JCO.1997.15.6.2345; GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015; GRAY HJ, 1939, BRIT J SURG, V26, P462; HLADIUK M, 1992, J SURG ONCOL, V50, P47, DOI 10.1002/jso.2930500114; HULTBORN KA, 1955, ACTA RADIOL, V43, P52, DOI 10.3109/00016925509172744; KRAG DN, 1995, ARCH SURG-CHICAGO, V130, P654; KRAG DN, 1993, SURG ONCOL, V2, P335, DOI 10.1016/0960-7404(93)90064-6; KRAG DN, 1998, BREAST J, V4, P67; LARSON D, 1986, INT J RADIAT ONCOL, V12, P1575, DOI 10.1016/0360-3016(86)90280-4; MAUNSELL E, 1993, CAN J SURG, V36, P315; MORROW M, 1981, ARCH SURG-CHICAGO, V116, P748; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; Pijpers R, 1997, J NUCL MED, V38, P366; PORTER EH, 1965, BRIT MED J, V5429, P251; *SAS I, 1989, SAS STAT US GUID VER; SAYEGH E, 1966, J UROLOGY, V95, P102, DOI 10.1016/S0022-5347(17)63419-0; STOLL BA, 1953, BMJ-BRIT MED J, V2, P796, DOI 10.1136/bmj.2.4840.796; THOMAS JM, 1979, BRIT J CANCER, V40, P540, DOI 10.1038/bjc.1979.219; VENDRELLTORNE E, 1972, J NUCL MED, V13, P801; Veronesi U, 1997, LANCET, V349, P1864, DOI 10.1016/S0140-6736(97)01004-0; WEINBERG J, 1950, SURG GYNECOL OBSTET, V90, P561; WEINBERG JA, 1951, J THORAC SURG, V22, P517	34	1545	1605	2	50	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1998	339	14					941	946		10.1056/NEJM199810013391401	http://dx.doi.org/10.1056/NEJM199810013391401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124MW	9753708	Bronze			2022-12-28	WOS:000076186900001
J	Chan, WCW; Nie, SM				Chan, WCW; Nie, SM			Quantum dot bioconjugates for ultrasensitive nonisotopic detection	SCIENCE			English	Article							CADMIUM SELENIDE NANOCRYSTALS; RECEPTOR-MEDIATED ENDOCYTOSIS; CDSE NANOCRYSTALS; MOLECULES; POLYMER; ORGANIZATION; CLUSTERS; METAL; DNA	Highly luminescent semiconductor quantum dots (zinc sulfide-capped cadmium selenide) have been covalently coupled to biomolecules for use in ultrasensitive biological detection. In comparison with organic dyes such as rhodamine, this class of luminescent labels is 20 times as bright, 100 times as stable against photobleaching, and one-third as wide in spectral linewidth. These nanometer-sized conjugates are water-soluble and biocompatible, Quantum dots that were labeled with the protein transferrin underwent receptor-mediated endocytosis in cultured HeLa cells, and those dots that were labeled with immunomolecules recognized specific antibodies or antigens.	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Nie, SM (corresponding author), Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.		周, 伊静/I-4058-2018; Nie, Shuming/E-4843-2011					Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; Andres RP, 1996, SCIENCE, V273, P1690, DOI 10.1126/science.273.5282.1690; Bangs LB, 1996, PURE APPL CHEM, V68, P1873, DOI 10.1351/pac199668101873; Blanton SA, 1996, APPL PHYS LETT, V69, P3905, DOI 10.1063/1.117565; BOWENKATARI JE, 1994, J PHYS CHEM-US, V98, P4109, DOI DOI 10.1021/J100066A034); BRUS L, 1991, APPL PHYS A-MATER, V53, P465, DOI 10.1007/BF00331535; CHAN WL, UNPUB; COLVIN VL, 1994, NATURE, V370, P354, DOI 10.1038/370354a0; DABBOUSI BO, 1995, APPL PHYS LETT, V66, P1316, DOI 10.1063/1.113227; Dabbousi BO, 1997, J PHYS CHEM B, V101, P9463, DOI 10.1021/jp971091y; DIAMANDIS EP, IMMUNOASSAY, P96; Dickson RM, 1997, NATURE, V388, P355, DOI 10.1038/41048; Edwards DA, 1996, P NATL ACAD SCI USA, V93, P1786, DOI 10.1073/pnas.93.5.1786; HAUGLAND RP, 1995, HDB FLUORESCENT PROB; Heath JR, 1996, J PHYS CHEM-US, V100, P3144, DOI 10.1021/jp951903v; HENGLEIN A, 1989, CHEM REV, V89, P1861, DOI 10.1021/cr00098a010; Hermanson G. T., 1996, BIOCONJUGATE TECHNIQ; Hines MA, 1996, J PHYS CHEM-US, V100, P468, DOI 10.1021/jp9530562; ISSAC PG, 1994, PROTOCOLS NUCL ACID; Kricka L, 1995, NONISOTOPIC PROBING; Lu HP, 1997, NATURE, V385, P143, DOI 10.1038/385143a0; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335; Nirmal M, 1996, NATURE, V383, P802, DOI 10.1038/383802a0; PECK K, 1989, P NATL ACAD SCI USA, V86, P4087, DOI 10.1073/pnas.86.11.4087; Peng XG, 1998, J AM CHEM SOC, V120, P5343, DOI 10.1021/ja9805425; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; VandenBout DA, 1997, SCIENCE, V277, P1074, DOI 10.1126/science.277.5329.1074; WILSON WL, 1993, SCIENCE, V262, P1242, DOI 10.1126/science.262.5137.1242	32	6651	7263	39	2294	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					2016	2018		10.1126/science.281.5385.2016	http://dx.doi.org/10.1126/science.281.5385.2016			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748158				2022-12-28	WOS:000076161800052
J	Arioglu, E; Doppman, J; Gomes, M; Kleiner, D; Mauro, D; Barlow, C; Papanicolaou, DA				Arioglu, E; Doppman, J; Gomes, M; Kleiner, D; Mauro, D; Barlow, C; Papanicolaou, DA			Cushing's syndrome caused by corticotropin secretion by pulmonary tumorlets	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									NICHHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NIDDKD, Diabet Branch, Bethesda, MD 20892 USA; NIH, Ctr Clin, Dept Radiol, Bethesda, MD USA; Georgetown Univ Hosp, Dept Thorac & Cardiovasc Surg, Washington, DC 20007 USA; NCI, Dept Pathol, Bethesda, MD USA; Natl Human Genome Res Inst, Lab Genet Dis Res, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Papanicolaou, DA (corresponding author), NICHHD, Dev Endocrinol Branch, NIH, Bldg 10,Rm 10N262,10 Ctr Dr,MSC 1862, Bethesda, MD 20892 USA.		Kleiner, David E/N-2770-2013	Kleiner, David E/0000-0003-3442-4453; Oral, Elif/0000-0002-9171-1144				BONIKOS DS, 1976, HUM PATHOL, V7, P461, DOI 10.1016/S0046-8177(76)80060-3; DOPPMAN JL, 1992, RADIOLOGY, V184, P71, DOI 10.1148/radiology.184.1.1319078; GOULD VE, 1983, LAB INVEST, V49, P519; PAGEL W, 1927, VIRCHOWS ARCH PATHOL, V263, P583; PASS HI, 1990, ANN THORAC SURG, V50, P52, DOI 10.1016/0003-4975(90)90085-K; RANCHOD M, 1977, CANCER, V39, P1135, DOI 10.1002/1097-0142(197703)39:3<1135::AID-CNCR2820390319>3.0.CO;2-B; RODGERSSULLIVAN RF, 1978, AM REV RESPIR DIS, V117, P799; TATEISHI R, 1973, ARCH PATHOL, V96, P198; WATANABE H, 1985, ACTA PATHOL JAPON, V35, P1221; WHITWELL F, 1955, J PATHOL BACTERIOL, V70, P529, DOI 10.1002/path.1700700231	10	35	37	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1998	339	13					883	886		10.1056/NEJM199809243391304	http://dx.doi.org/10.1056/NEJM199809243391304			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121VY	9744972	Bronze			2022-12-28	WOS:000076037400004
J	Cohen, L; Henzel, WJ; Baeuerle, PA				Cohen, L; Henzel, WJ; Baeuerle, PA			IKAP is a scaffold protein of the I kappa B kinase complex	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; ALPHA PROTEOLYSIS; ACTIVATION; PHOSPHORYLATION; SIGNAL; FAMILY; CASCADE; STE5; BETA	The transcription factor NF-kappa B coordinates the activation of numerous genes in response to pathogens and pro-inflammatory cytokines, and is, therefore, vital in the development of acute and chronic inflammatory diseases(1-6). NF-kappa B is activated by phsophorylation of its inhibitory subunit, I kappa B-alpha (ref. 7), on serine residues 32 and 36 by cytokine-activated I kappa B kinases (IKKs); this phosphorylation precedes rapid degradation of I kappa B8-11. IKK-alpha and IKK-beta isozymes are found in large complexes of relative molecular mass 700,000-900,000 (M-r 70K-90K), but little is known about other components that organize and regulate these complexes(12-17). IKK-alpha was independently discovered as a NF-kappa B-inducing kinase(18) (NIK)-associated protein in a yeast two-hybrid screen(19), and IKK-beta was also identified by homology screening(20). It is, however, unknown whether NIK is part of the IKK complex. Here we isolate large, interleukin-1-inducible IKK complexes that contain NIK, IKK-alpha, IKK-beta, I kappa B-alpha, NF-kappa B/RelA and a protein of M-r 150K. This latter component is a new protein, termed IKK-complex-associated protein (IKAP), which can bind NIK and IKKs and assemble them into an active kinase complex. We show that IKAP is a scaffold protein and a regulator for three different kinases involved in pro-inflammatory cytokine signalling.	Tularik Inc, San Francisco, CA 94080 USA; Genentech Inc, San Francisco, CA 94080 USA	Roche Holding; Genentech	Baeuerle, PA (corresponding author), Tularik Inc, 2 Corp Dr, San Francisco, CA 94080 USA.	baeuerle@tularik.com		Henzel, William/0000-0003-2940-3797				Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHOI KY, 1994, CELL, V78, P499; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; HENZEL WJ, 1995, CURR PROT PROTEIN SC, V1; LEI L, 1998, P NATL ACAD SCI USA, V95, P3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARCUS S, 1996, P NATL ACAD SCI USA, V271, P1128; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PRINTEN JA, 1994, GENETICS, V138, P609; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SIEBENLIST U, 1995, INDUCIBLE GENE EXPRE, V1, P93; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yajima H, 1997, BIOSCI BIOTECH BIOCH, V61, P704, DOI 10.1271/bbb.61.704; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	31	252	268	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	1998	395	6699					292	296		10.1038/26254	http://dx.doi.org/10.1038/26254			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751059				2022-12-28	WOS:000075974600055
J	Barchas, JD; Marzuk, PM				Barchas, JD; Marzuk, PM			General psychiatry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MAJOR DEPRESSION; MOOD DISORDERS; OLANZAPINE; PLACEBO; CORTEX; TRIAL		Cornell Univ, Med Ctr, New York Hosp, Dept Psychiat, New York, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital	Barchas, JD (corresponding author), Cornell Univ, Med Ctr, New York Hosp, Dept Psychiat, 525 E 68 St,Box 171, New York, NY 10021 USA.							Andreasen NC, 1997, SCIENCE, V275, P1586, DOI 10.1126/science.275.5306.1586; Benowitz NL, 1997, NEW ENGL J MED, V337, P1230, DOI 10.1056/NEJM199710233371710; Bremner JD, 1997, BIOL PSYCHIAT, V41, P23, DOI 10.1016/S0006-3223(96)00162-X; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; Duman RS, 1997, ARCH GEN PSYCHIAT, V54, P597; Emslie GJ, 1997, ARCH GEN PSYCHIAT, V54, P1031; Hurt RD, 1997, NEW ENGL J MED, V337, P1195, DOI 10.1056/NEJM199710233371703; Judd LL, 1997, ARCH GEN PSYCHIAT, V54, P989; McEwen BS, 1997, MOL PSYCHIATR, V2, P255, DOI 10.1038/sj.mp.4000254; Nelson CA, 1997, CHILD DEV, V68, P970, DOI 10.1111/j.1467-8624.1997.tb01974.x; Post RM, 1997, ARCH GEN PSYCHIAT, V54, P607; Rauch SL, 1997, BIOL PSYCHIAT, V42, P446, DOI 10.1016/S0006-3223(97)00145-5; Rees G, 1997, SCIENCE, V275, P835, DOI 10.1126/science.275.5301.835; Reus VI, 1997, LANCET, V349, P1264, DOI 10.1016/S0140-6736(97)22018-0; Soares JC, 1997, BIOL PSYCHIAT, V41, P86, DOI 10.1016/S0006-3223(96)00006-6; Solomon DA, 1997, ARCH GEN PSYCHIAT, V54, P1001; Thase ME, 1997, ARCH GEN PSYCHIAT, V54, P1009; Tollefson GD, 1997, AM J PSYCHIAT, V154, P457; Travis MJ, 1997, CURR OPIN PSYCHIATR, V10, P16, DOI 10.1097/00001504-199701000-00005; Volpicelli JR, 1997, ARCH GEN PSYCHIAT, V54, P737	20	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1998	280	11					961	962		10.1001/jama.280.11.961	http://dx.doi.org/10.1001/jama.280.11.961			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	119JC	9749469				2022-12-28	WOS:000075891400012
J	Chassin, MR; Galvin, RW				Chassin, MR; Galvin, RW		Natl Roundtable Hlth Care Quality	The urgent need to improve health care quality - Institute of medicine National Roundtable on Health Care Quality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG EVENTS; FEE-FOR-SERVICE; HOSPITALIZED-PATIENTS; AMBULATORY CARE; OUTCOMES; INSURANCE; MORTALITY; APPROPRIATENESS; TERMINATION; PREVENTION	Objective.-To identify issues related to the quality of health care in the United States, including its measurement, assessment, and improvement, requiring action by health care professionals or other constituencies in the public or private sectors. Participants.-The National Roundtable on Health Care Quality, convened by the Institute of Medicine, a component of the National Academy of Sciences, comprised 20 representatives of the private and public sectors, practicing medicine and nursing, representing academia, business, consumer advocacy, and the health media, and including the heads of federal health programs. The roundtable met 6 times between February 1996 and January 1998. It explored ongoing, rapid changes in health care and the implications of these changes for the quality of health and health care in the United States. Evidence.-Roundtable members held discussions with a wide variety of experts, convened conferences, commissioned papers, and drew on their individual professional experience. Consensus Process.-At the end of its deliberations, roundtable members reached consensus on the conclusions described in this article by a series of discussions at committee meetings and reviews of successive draft documents, the first of which was created by the listed authors and the Institute of Medicine project director. The drafts were revised following these discussions, and the final document was approved according to the formal report review procedures of the National Research Council of the National Academy of Sciences. Conclusions.-The quality of health care can be precisely defined and measured with a degree of scientific accuracy comparable with that of most measures used in clinical medicine. Serious and widespread quality problems exist throughout American medicine. These problems, which may be classified as underuse, overuse, or misuse, occur in small and large communities alike, in all parts of the country, and with approximately equal frequency in managed care and fee-for-service systems of care. Very large numbers of Americans are harmed as a direct result. Quality of care is the problem, not managed care. Current efforts to improve will not succeed unless we undertake a major, systematic effort to overhaul how we deliver health care services, educate and train clinicians, and assess and improve quality.	Mt Sinai Sch Med, Dept Hlth Policy, New York, NY USA; Motorola Inc, Schaumburg, IL 60196 USA	Icahn School of Medicine at Mount Sinai	Chassin, MR (corresponding author), Natl Acad Sci, Inst Med, 2101 Constitut Ave NW, Washington, DC 20418 USA.							[Anonymous], 1998, QUAL 1 BETT HLTH CAR; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P2398, DOI 10.1001/jama.269.18.2398; BLUMENTHAL D, IN PRESS MILBANK Q; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Brook RH, 1997, JAMA-J AM MED ASSOC, V278, P1612, DOI 10.1001/jama.278.19.1612; Chassin MR, 1997, HEALTH AFFAIR, V16, P151, DOI 10.1377/hlthaff.16.3.151; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; Council of the Institute of Medicine, 1994, AM HLTH TRANS PROT I; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; FLOOD AB, 1984, MED CARE, V22, P115, DOI 10.1097/00005650-198402000-00003; FLOOD AB, 1984, MED CARE, V22, P98, DOI 10.1097/00005650-198402000-00002; FRANKS P, 1993, AM J PUBLIC HEALTH, V83, P1295, DOI 10.2105/AJPH.83.9.1295; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P737, DOI 10.1001/jama.270.6.737; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; GREENSPAN AM, 1988, NEW ENGL J MED, V318, P158, DOI 10.1056/NEJM198801213180306; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; KLEINMAN LC, 1994, JAMA-J AM MED ASSOC, V271, P1250, DOI 10.1001/jama.271.16.1250; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; Lohr KN, 1990, MEDICARE STRATEGY QU; Longo DR, 1997, JAMA-J AM MED ASSOC, V278, P1579, DOI 10.1001/jama.278.19.1579; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; *NAT COMM QUAL ASS, 1997, ROAD MAP INF SYST EV; Nyquist AC, 1998, JAMA-J AM MED ASSOC, V279, P875, DOI 10.1001/jama.279.11.875; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; *PA HLTH CAR COST, 1996, FOC HEART ATT 1993 S; *PA HLTH CAR COST, 1995, CONS GUID COR ART BY; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; RUSSELL LB, 1993, NEW ENGL J MED, V329, P352, DOI 10.1056/NEJM199307293290511; Schuster M. A., 1997, WHY QUALITY US HLTH; SHORTELL SM, IN PRESS MILBANK Q; SISK JE, IN PRESS MILBANK Q; SORLIE PD, 1994, ARCH INTERN MED, V154, P2409, DOI 10.1001/archinte.154.21.2409; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; UDVARHELYI IS, 1991, ANN INTERN MED, V115, P394, DOI 10.7326/0003-4819-115-5-394; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P3298, DOI 10.1001/jama.262.23.3298	40	933	940	0	48	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1998	280	11					1000	1005		10.1001/jama.280.11.1000	http://dx.doi.org/10.1001/jama.280.11.1000			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JC	9749483				2022-12-28	WOS:000075891400034
J	Nolte, RT; Wisely, GB; Westin, S; Cobb, JE; Lambert, MH; Kurokawa, R; Rosenfeld, MG; Willson, TM; Glass, CK; Milburn, MV				Nolte, RT; Wisely, GB; Westin, S; Cobb, JE; Lambert, MH; Kurokawa, R; Rosenfeld, MG; Willson, TM; Glass, CK; Milburn, MV			Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma	NATURE			English	Article							THYROID-HORMONE RECEPTOR; NUCLEAR-RECEPTOR; TRANSACTIVATION DOMAIN; TRANSCRIPTIONAL COACTIVATOR; ESTROGEN-RECEPTOR; CRYSTAL-STRUCTURE; RETINOIC ACID; AF-2 ACTIVITY; FATTY-ACIDS; RXR-ALPHA	The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a ligand-dependent transcription factor that is Important in adipocyte differentiation and glucose homeostasis and which depends on Interactions with co-activators, including steroid receptor co-activating factor-1 (SRC-1), Here we present the X-ray crystal structure of the human apo-PPAR-gamma ligand-binding domain (LBD), at 2.2 Angstrom resolution; this structure reveals a large binding pocket, which may explain the diversity of ligands for PPAR-gamma, We also describe the ternary complex containing the PPAR-gamma LED, the antidiabetic ligand rosiglitazone (BRL49653), and 88 amino acids of human SRC-1 at 2.3 Angstrom resolution. Glutamate and lysine residues that are highly conserved in LBDs of nuclear receptors form a 'charge clamp' that contacts backbone atoms of the LXXLL helices of SRC-1. These results, together with the observation that two consecutive LXXLL motifs of SRC-1 make identical contacts with both subunits of a PPAR-gamma homodimer, suggest a general mechanism for the assembly of nuclear receptors with co-activators.	Glaxo Wellcome Inc, Res & Dev, Div Chem, Dept Struct Chem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Div Chem, Dept Med Chem, Res Triangle Pk, NC 27709 USA; Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA	GlaxoSmithKline; GlaxoSmithKline; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Milburn, MV (corresponding author), Glaxo Wellcome Inc, Res & Dev, Div Chem, Dept Struct Chem, Res Triangle Pk, NC 27709 USA.		Glass, Christopher/AAI-3933-2021; feinstein, doug/M-9414-2019	Glass, Christopher/0000-0003-4344-3592; 				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; BRUNGER A, 1992, XPLOR VERSION 3 0 SY; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Buckle DR, 1996, BIOORG MED CHEM LETT, V6, P2127, DOI 10.1016/0960-894X(96)00382-4; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Collaborative Computational Project, 1994, ACTA CRYST D, V50, P760; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Feng X, 1997, GENE DEV, V11, P59, DOI 10.1101/gad.11.1.59; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hulin B, 1996, CURR PHARM DESIGN, V2, P85; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KEEN H, 1994, NEW ENGL J MED, V331, P1226, DOI 10.1056/NEJM199411033311812; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; TONE Y, 1994, J BIOL CHEM, V269, P31157; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; Zhu YJ, 1996, GENE EXPRESSION, V6, P185	47	1606	1661	3	94	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1998	395	6698					137	143		10.1038/25931	http://dx.doi.org/10.1038/25931			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744270				2022-12-28	WOS:000075829900031
J	Tsai, TF; Popovici, F; Cernescu, C; Campbell, GL; Nedelcu, NI; Laurentia, V; Spantulescu, L; Chitu, V; Ruta, S; Tardei, G; Craciun, D; Nicolaiciuc, D; Pitigoi, D; Ceianu, C; Nicolescu, G; Ungureanu, A; Vladimirescu, LA; Deubel, V; LeGuenno, B; Han, L; Savage, H; Tengelsen, L; Tengelsen, EA; Knauert, F; Mangiafico, JA; Rossi, C				Tsai, TF; Popovici, F; Cernescu, C; Campbell, GL; Nedelcu, NI; Laurentia, V; Spantulescu, L; Chitu, V; Ruta, S; Tardei, G; Craciun, D; Nicolaiciuc, D; Pitigoi, D; Ceianu, C; Nicolescu, G; Ungureanu, A; Vladimirescu, LA; Deubel, V; LeGuenno, B; Han, L; Savage, H; Tengelsen, L; Tengelsen, EA; Knauert, F; Mangiafico, JA; Rossi, C		Investigative Team	West Nile encephalitis epidemic in southeastern Romania	LANCET			English	Article							VIRUSES	Background West Nile fever (WNF) is a mosquito-borne flavivirus infection endemic in Africa and Asia. In 1996, the first major WNF epidemic in Europe occurred in Romania, with a high rate of neurological infections. We investigated the epidemic to characterise transmission patterns in this novel setting and to determine its origin. Methods Hospital-based surveillance identified patients admitted with acute aseptic meningitis and encephalitis in 40 Romanian districts, including Bucharest. Infection was confirmed with IgM capture and indirect IgG ELISAs. In October, 1996, we surveyed outpatients in Bucharest and seven other districts to estimate seroprevalence and to detect infected patients not admitted to hospital. We also measured the rates of infection and seropositivity in mosquitoes and birds, respectively. Results Between July 15 and Oct 12, we identified 393 patients with serologically confirmed or probable WNF infection, of whom 352 had acute central-nervous-system infections. 17 patients older than 50 years died. Fatality/case ratio and disease incidence increased with age. The outbreak was confined to 14 districts In the lower Danube valley and Bucharest (attack rate 12.4/100 000 people) with a seroprevalence of 4.1%. The number of mild cases could not be estimated. WN virus was recovered from Culex pipiens mosquitoes, the most likely vector, and antibodies to WN virus were found in 41% of domestic fowl. Interpretation The epidemic in Bucharest reflected increased regional WNF transmission in 1996. Epidemics of Cx pipiens-borne WNF could occur in other European cities with conditions conducive to transmission.	Ctr Dis Control, Div Vector Borne Infect Dis, Ft Collins, CO 80522 USA; Bucharest Prevent Med Ctr, Bucharest, Romania; Inst Virol, Bucharest, Romania; Minist Hlth, Bucharest, Romania; Cantacuzino Inst, Bucharest, Romania; Ctr Natl Reference Fievres Hemorrag & Arbovirus, Paris, France; Ctr Dis Control & Prevent, Ft Collins, CO USA; US Army Med Res Inst Infect Dis, Fort Detrick, MD USA	Romanian Academy of Sciences; Stefan S. Nicolau Institute of Virology; Cantacuzino Institute Bucharest; Centers for Disease Control & Prevention - USA; United States Army Medical Research Institute of Infectious Diseases; United States Department of Defense; United States Army	Tsai, TF (corresponding author), Ctr Dis Control, Div Vector Borne Infect Dis, Ft Collins, CO 80522 USA.		Ruta, Simona/A-9569-2010; Ceianu, Cornelia-Svetlana/A-7423-2018; Institute of Virology, Stefan S Nicolau/HGE-9069-2022	Ruta, Simona/0000-0002-2492-6073; 				Berthet FX, 1997, J GEN VIROL, V78, P2293, DOI 10.1099/0022-1317-78-9-2293; Curry-Lindahl K., 1981, BIRD MIGRATION AFRIC, V1; DARWISH MA, 1987, T ROY SOC TROP MED H, V81, P1001, DOI 10.1016/0035-9203(87)90378-6; DRAGANESCU N, 1991, Revue Roumaine de Virologie, V42, P47; Draganescu N., 1993, Revue Roumaine de Virologie, V44, P207; DRAGANESCU N, 1989, REV ROUM MED VIROL, V40, P257; DUCA E, 1963, REV MED CHIR SOC MED, V67, P399; El-Harrak M., 1997, VIROLOGIE, V1, P248; ESPMARK A, 1984, AM J TROP MED HYG, V33, P1203, DOI 10.4269/ajtmh.1984.33.1203; FLATAU E, 1981, ISRAEL J MED SCI, V17, P1057; GADOTH N, 1979, ARCH NEUROL-CHICAGO, V36, P172, DOI 10.1001/archneur.1979.00500390090012; GEORGE S, 1987, INDIAN J MED RES, V86, P131; GEORGES AJ, 1987, ANN INST PASTEUR VIR, V138, P237, DOI 10.1016/S0769-2617(87)80007-2; KLINGBERG MA, 1959, P 6 INT C TROP MED, V5, P132; LeGuenno B, 1996, LANCET, V348, P1315, DOI 10.1016/S0140-6736(05)65799-6; Lundstrom J. O., 1994, Bulletin of the Society for Vector Ecology, V19, P23; MARBERG K, 1956, AM J HYG, V64, P259, DOI 10.1093/oxfordjournals.aje.a119838; MCINTOSH BM, 1976, S AFR J SCI, V72, P295; MISKOLCZY D, 1958, NEUROLOGIA PSIHIATRI, V2, P139; MITCHELL CJ, 1995, J VECTOR ECOL, V20, P44; MONATH TP, 1997, CLIN VIROLOGY, P1133; PANTHIER R, 1968, ANN I PASTEUR PARIS, V115, P435; PEIRIS JSM, 1994, HDB ZOONOSES B, P139; PERELMAN A, 1974, AM J TROP MED HYG, V23, P1150, DOI 10.4269/ajtmh.1974.23.1150; PURI B, 1994, ARCH VIROL, V134, P29, DOI 10.1007/BF01379104; TAYLOR RM, 1956, AM J TROP MED HYG, V5, P579, DOI 10.4269/ajtmh.1956.5.579; TOPCIU V, 1968, ARCH ROUM PATHOL EXP, V27, P531; Tsai Theodore F., 1995, P980; VARSANO N, 1982, ISRAEL J MED SCI, V18, P11; YUKIO S, 1991, VIROLOGY, V182, P753; 1995, LOUISIANA MORBIDITY, V5, P3	31	543	581	0	37	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 5	1998	352	9130					767	771		10.1016/S0140-6736(98)03538-7	http://dx.doi.org/10.1016/S0140-6736(98)03538-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737281				2022-12-28	WOS:000075762700010
J	Shi, YG; Wang, YF; Jayaraman, L; Yang, HJ; Massague, J; Pavletich, NP				Shi, YG; Wang, YF; Jayaraman, L; Yang, HJ; Massague, J; Pavletich, NP			Crystal structure of a Smad MH1 domain bound to DNA: Insights on DNA binding in TGF-beta signaling	CELL			English	Article							GROWTH-FACTOR-BETA; MAD-RELATED PROTEIN; TUMOR-SUPPRESSOR; RECOGNITION; DPC4; TRANSDUCTION; PATHWAYS; NUCLEUS; COMPLEX; KINASE	The Smad family of proteins, which are frequently targeted by tumorigenic mutations in cancer, mediate TGF-beta signaling from cell membrane to nucleus. The crystal structure of a Smad3 MH1 domain bound to an optimal DNA sequence determined at 2.8 Angstrom resolution reveals a novel DNA-binding motif. In the crystals, base-specific DNA recognition is provided exclusively by a conserved Ii-residue beta hairpin that is embedded in the major groove of DNA. A surface loop region, to which tumorigenic mutations map, has been identified as a functional surface important for Smad activity. This structure establishes a framework for understanding how Smad proteins may act in concert with other transcription factors in the regulation of TGF-beta-responsive genes.	Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Princeton University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Shi, YG (corresponding author), Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA.			Massague, Joan/0000-0001-9324-8408; Shi, Yigong/0000-0003-2030-168X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KLAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Massague J, 1996, CANCER SURV, V27, P41; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Saenger W., 1984, PRINCIPLES NUCL ACID; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Ye XM, 1995, CHEM BIOL, V2, P827, DOI 10.1016/1074-5521(95)90089-6; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	41	584	614	1	73	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 4	1998	94	5					585	594		10.1016/S0092-8674(00)81600-1	http://dx.doi.org/10.1016/S0092-8674(00)81600-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741623	Bronze			2022-12-28	WOS:000075851900006
J	Weinert, T				Weinert, T			DNA damage and checkpoint pathways: Molecular anatomy and interactions with repair	CELL			English	Review							CYCLE; ARREST		Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA	University of Arizona	Weinert, T (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA.							Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; DESANY BA, 1998, IN PRESS GENES DEV; ELKIND MM, 1963, J NATL CANCER I, V30, P705; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GRIFFITHS DJG, 1995, EMBO J, V14, P101; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; Paciotti V, 1998, EMBO J, V17, P4199, DOI 10.1093/emboj/17.14.4199; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PAULOVICH AG, 1998, IN PRESS GENETICS; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; ZHAO X, 1998, IN PRESS MOL CELL	24	230	238	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 4	1998	94	5					555	558		10.1016/S0092-8674(00)81597-4	http://dx.doi.org/10.1016/S0092-8674(00)81597-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741620	Bronze			2022-12-28	WOS:000075851900003
J	Spiro, HM				Spiro, HM			Peptic ulcer: Moynihan's or Marshall's disease?	LANCET			English	Article									Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Yale University	Spiro, HM (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St, New Haven, CT 06520 USA.							Alexander F, 1950, PSYCHOSOMATIC MED IT; Cabot R., 1915, SOCIAL SERVICE ART H; Chan FKL, 1997, LANCET, V350, P975, DOI 10.1016/S0140-6736(97)04523-6; LEVANT JA, 1973, NEW ENGL J MED, V289, P555, DOI 10.1056/NEJM197309132891104; MARSHALL BJ, 1984, LANCET, V1, P1311; Ryle J.A., 1948, CHANGING DISCIPLINES; Selye H, 1956, J BONE JOINT SURG; SPIRO HM, 1974, NEW ENGL J MED, V291, P567, DOI 10.1056/NEJM197409122911107	8	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 22	1998	352	9128					645	646		10.1016/S0140-6736(97)12058-X	http://dx.doi.org/10.1016/S0140-6736(97)12058-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746042	hybrid			2022-12-28	WOS:000075567400044
J	Sorum, PC				Sorum, PC			Two tiers of physicians in France - General pediatrics declines, general practice rises	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH-CARE SYSTEM; UNITED-STATES; MEDICINE; REFORM; DIFFERENCE; LESSONS		Albany Med Coll, Dept Med, Albany, NY 12208 USA; Albany Med Coll, Dept Pediat, Albany, NY 12208 USA	Albany Medical College; Albany Medical College	Sorum, PC (corresponding author), Albany Med Primary Care Network, 724 Watervliet Shaker Rd, Latham, NY 12110 USA.							BEAUFILS F, 1995, SOC FRANCAISE PEDIAT, P179; BRODIN M, 1995, SOC FRANCAISE PEDIAT, P3; Colin C, 1997, LANCET, V349, P791, DOI 10.1016/S0140-6736(97)01388-3; *CTR RECH, 1997, EC SANT 97; Davidson C, 1997, LANCET, V350, P1645, DOI 10.1016/S0140-6736(05)64270-5; del Torso S, 1997, Pediatrics, V99, pE8, DOI 10.1542/peds.99.1.e8; DUBOIS O, 1995, SOC FRANCAISE PEDIAT, P151; DUMAS R, 1995, SOC FRANCAISE PEDIAT, P41; DUPUIS C, 1997, QUOTIDIEN MED   0604, P1; FIELDING JE, 1993, JAMA-J AM MED ASSOC, V270, P748, DOI 10.1001/jama.270.6.748; GIGONNET JM, 1995, ENSEIGNEMENT AVENIER, P35; Halpern Sydney, 1988, AM PEDIAT SOCIAL DYN; HASSENTEUFEL P, 1997, MED FACE ETAT COMP E; Jackson JL, 1997, ARCH INTERN MED, V157, P155, DOI 10.1001/archinte.157.2.155; KURTZEMANN G, 1995, SOC FRANCAISE PEDIAT, P27; Lassey M. L., 1997, HLTH CARE SYSTEMS WO; LEFAOU AL, 1997, EC SANTE QUESTIONS; LEFAOU AL, 1992, MED APHP CARRIERES S; MATHIEU H, 1995, SOC FRANCAISE PEDIAT, P111; PIETTE JC, 1993, POSTGRAD MED J, V69, pS31; RANDOLPH L, 1997, PHYSICIAN CHARACTERI; Schatz IJ, 1996, ACAD MED, V71, P35, DOI 10.1097/00001888-199601000-00015; *SERV TECHN CNANTS, 1997, 1997 CONV NAT MED GE; Simon CJ, 1997, HEALTH AFFAIR, V16, P89, DOI 10.1377/hlthaff.16.6.89; Sorum PC, 1998, JAMA-J AM MED ASSOC, V280, P659, DOI 10.1001/jama.280.7.659; Stevens Rosemary, 1971, AM MED PUBLIC INTERE; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; WILLARD D, 1995, SOC FRANCAISE PEDIAT, P133; WILSFORD D, 1987, J HEALTH POLIT POLIC, V12, P481, DOI 10.1215/03616878-12-3-481; WOLSTENHOLME RJ, 1988, POSTGRAD MED J, V64, P407, DOI 10.1136/pgmj.64.751.407; 1995, SOC FRANCAISE PEDIAT, P195; 1994, INTERN MED S1, V9, pS31	32	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 30	1998	280	12					1099	1101		10.1001/jama.280.12.1099	http://dx.doi.org/10.1001/jama.280.12.1099			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FJ	9757862				2022-12-28	WOS:000076002400043
J	Sinclair, R				Sinclair, R			Fortnightly review - Male pattern androgenetic alopecia	BRITISH MEDICAL JOURNAL			English	Review							DERMAL PAPILLA CELLS; TOPICAL MINOXIDIL; HAIR-GROWTH; BALDNESS; SCALP; MEN		Univ Melbourne, St Vincents Hosp, Dept Dermatol, Melbourne, Vic 3065, Australia	St Vincent's Hospital Melbourne; University of Melbourne	Sinclair, R (corresponding author), Univ Melbourne, St Vincents Hosp, Dept Dermatol, Victoria Parade, Melbourne, Vic 3065, Australia.	sinclair@svhm.org.au	Sinclair, Rodney/AAI-8355-2020	Sinclair, Rodney/0000-0001-6751-1428				[Anonymous], METABOLIC BASIS INHE; BURTON JL, 1979, BRIT J DERMATOL, V100, P567, DOI 10.1111/j.1365-2133.1979.tb05582.x; CASH TF, 1992, J AM ACAD DERMATOL, V26, P926, DOI 10.1016/0190-9622(92)70134-2; CASH TF, 1988, MED ASPECTS HUM SEX, V22, P67; Chen W, 1996, DERMATOLOGY, V193, P177, DOI 10.1159/000246242; CURTOIS M, 1994, SKIN PHARMACOL, V7, P84; Ellis JA, 1998, J INVEST DERMATOL, V110, P849, DOI 10.1046/j.1523-1747.1998.00224.x; HAMILTON JB, 1951, ANN NY ACAD SCI, V53, P708, DOI 10.1111/j.1749-6632.1951.tb31971.x; Hamilton JB, 1942, AM J ANAT, V71, P451, DOI 10.1002/aja.1000710306; HAMILTON JB, 1960, J CLIN ENDOCR METAB, V20, P1309, DOI 10.1210/jcem-20-10-1309; HECHT A, 1985, FDA CONSUMER    0419, P1; Hutchinson PE, 1997, BRIT J DERMATOL, V136, P159; IMPERATO.J, 1974, SCIENCE, V186, P1213, DOI 10.1126/science.186.4170.1213; ITAMI S, 1990, J INVEST DERMATOL, V94, P150, DOI 10.1111/1523-1747.ep12874003; Kaufman KD, 1996, DERMATOL CLIN, V14, P697, DOI 10.1016/S0733-8635(05)70396-X; KLIGMAN AM, 1988, CLIN DERMATOL, V6, P108, DOI 10.1016/0738-081X(88)90074-0; KUHLWEIN A, 1985, Z HAUTKRANKHEITEN, V60, P576; KUSTER W, 1984, J AM ACAD DERMATOL, V11, P921, DOI 10.1016/S0190-9622(84)80498-3; Lepaw M I, 1979, J Dermatol Surg Oncol, V5, P201; LI LN, 1995, NAT MED, V1, P705, DOI 10.1038/nm0795-705; NORSTROM RE, 1979, ACTA DERM-VENEREOL, V59, P266; Obana N, 1996, INT CONGR SER, V1111, P307; Oliver RF., 1989, BIOL WOOL HAIR, P51; OLSEN E, 1997, AUST J DERMATOL, V38, pA316; OLSEN EA, 1987, J AM ACAD DERMATOL, V17, P97, DOI 10.1016/S0190-9622(87)70179-0; ORENTREICH D, 1995, HAIR TRANSPLANTATION, P1; ORENTREICH N, 1959, ANN NY ACAD SCI, V83, P462; RANDALL VA, 1994, CLIN ENDOCRINOL, V40, P439, DOI 10.1111/j.1365-2265.1994.tb02483.x; RANDALL VA, 1992, J ENDOCRINOL, V133, P141, DOI 10.1677/joe.0.1330141; RUSHTON DH, 1991, CLIN EXP DERMATOL, V16, P188, DOI 10.1111/j.1365-2230.1991.tb00343.x; Rushton DH, 1996, INT CONGR SER, V1111, P359; SAVIN RC, 1987, J AM ACAD DERMATOL, V16, P696, DOI 10.1016/S0190-9622(87)70090-5; SETTY LR, 1970, AM J PHYS ANTHROPOL, V33, P49, DOI 10.1002/ajpa.1330330108; SIMPSON NB, 1997, DIS HAIR SCALP; Unger WP, 1994, DISORDERS HAIR GROWT, P353; WHITING DA, 1993, J AM ACAD DERMATOL, V28, P755, DOI 10.1016/0190-9622(93)70106-4	36	126	131	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 26	1998	317	7162					865	869		10.1136/bmj.317.7162.865	http://dx.doi.org/10.1136/bmj.317.7162.865			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748188	Green Published			2022-12-28	WOS:000076222300024
J	Teh, LS				Teh, LS			Life long frustration - Tea for two and two for tea	BRITISH MEDICAL JOURNAL			English	Article													Teh, Lee-Suan/I-3241-2019						0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1998	317	7162					874	874		10.1136/bmj.317.7162.874	http://dx.doi.org/10.1136/bmj.317.7162.874			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748191	Green Published			2022-12-28	WOS:000076222300027
J	Hoyt, DB				Hoyt, DB			Is it time for a new injury score?	LANCET			English	Editorial Material							SEVERITY; CARE		Univ Calif San Diego, Med Ctr, Dept Surg, San Diego, CA 92103 USA	University of California System; University of California San Diego	Hoyt, DB (corresponding author), Univ Calif San Diego, Med Ctr, Dept Surg, San Diego, CA 92103 USA.							BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brenneman FD, 1998, J TRAUMA, V44, P580, DOI 10.1097/00005373-199804000-00003; CHAMPION HR, 1990, J TRAUMA, V30, P539, DOI 10.1097/00005373-199005000-00003; Committee on Medical Aspects of Automotive Safety, 1971, JAMA-J AM MED ASSOC, V215, P277, DOI [DOI 10.1001/JAMA.1971.03180150059012, 10.1001/jama.1971.03180150059012]; COPES WS, 1990, J TRAUMA, V30, P1200, DOI 10.1097/00005373-199010000-00003; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Rutledge R, 1998, J TRAUMA, V44, P41, DOI 10.1097/00005373-199801000-00003	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 19	1998	352	9132					920	921		10.1016/S0140-6736(98)00014-2	http://dx.doi.org/10.1016/S0140-6736(98)00014-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752809				2022-12-28	WOS:000076002200002
J	Gaymard, F; Pilot, G; Lacombe, B; Bouchez, D; Bruneau, D; Boucherez, J; Michaux-Ferriere, N; Thibaud, JB; Sentenac, H				Gaymard, F; Pilot, G; Lacombe, B; Bouchez, D; Bruneau, D; Boucherez, J; Michaux-Ferriere, N; Thibaud, JB; Sentenac, H			Identification and disruption of a plant shaker-like outward channel involved in K+ release into the xylem sap	CELL			English	Article							RECTIFYING POTASSIUM CHANNEL; ARABIDOPSIS-THALIANA; ION CHANNELS; GUARD-CELLS; SACCHAROMYCES-CEREVISIAE; XENOPUS OOCYTES; EXPRESSION; GENE; ROOTS; PROTOPLASTS	SKOR, a K+ channel identified in Arabidopsis, displays the typical hydrophobic core of the Shaker channel superfamily, a cyclic nucleotide-binding domain, and an ankyrin domain. Expression in Xenopus oocytes identified SKOR as the first member of the Shaker family in plants to be endowed with outwardly rectifying properties. SKOR expression is localized in root stelar tissues. A knockout mutant shows both lower shoot K+ content and lower xylem sap K+ concentration, indicating that SKOR is involved in K+ release into the xylem sap toward the shoots. SKOR expression is strongly inhibited by the stress phytohormone abscisic acid, supporting the hypothesis that control of KC translocation toward the shoots is part of the plant response to water stress.	INRA, CNRS URA 2133, F-34060 Montpellier 1, France; INRA, F-78026 Versailles, France; BIOTROP, CIRAD, F-34032 Montpellier, France	INRAE; INRAE; UDICE-French Research Universities; Universite Paris Saclay; CIRAD	Gaymard, F (corresponding author), INRA, CNRS URA 2133, F-34060 Montpellier 1, France.		Bouchez, David/B-7463-2019; Lacombe, Benoit/B-1202-2013	Bouchez, David/0000-0003-3545-4339; Pilot, Guillaume/0000-0001-7520-1059; Sentenac, Herve/0000-0003-3641-4822; Lacombe, Benoit/0000-0001-9924-3093; THIBAUD, Jean-Baptiste/0000-0002-0824-6465				ALLEN GJ, 1995, PLANT CELL, V7, P1473; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Blatt MR, 1997, J MEMBRANE BIOL, V158, P241, DOI 10.1007/s002329900261; BOUCHEZ D, 1993, CR ACAD SCI III-VIE, V316, P1188; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; Butt AD, 1997, J PLANT PHYSIOL, V150, P652, DOI 10.1016/S0176-1617(97)80279-9; Camilleri C, 1998, PLANT J, V14, P633, DOI 10.1046/j.1365-313X.1998.00159.x; CAO YW, 1995, PLANT PHYSIOL, V109, P1093, DOI 10.1104/pp.109.3.1093; Cherel I, 1996, BIOCHEM SOC T, V24, P964, DOI 10.1042/bst0240964; CLARKSON DT, 1993, PHILOS T R SOC B, V341, P5, DOI 10.1098/rstb.1993.0086; Daram P, 1997, EMBO J, V16, P3455, DOI 10.1093/emboj/16.12.3455; deBoer AH, 1997, J EXP BOT, V48, P441, DOI 10.1093/jxb/48.Special_Issue.441; DECOURSEY TE, 1995, J GEN PHYSIOL, V106, P745, DOI 10.1085/jgp.106.4.745; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; Dreyer I, 1997, BIOPHYS J, V72, P2143, DOI 10.1016/S0006-3495(97)78857-X; Eisenman G., 1961, S MEMBRANE TRANSPORT, P163; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; Gaymard F, 1996, J BIOL CHEM, V271, P22863, DOI 10.1074/jbc.271.37.22863; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; Hirsch RE, 1998, SCIENCE, V280, P918, DOI 10.1126/science.280.5365.918; HOFGEN R, 1988, NUCLEIC ACIDS RES, V16, P9877, DOI 10.1093/nar/16.20.9877; Ichida AM, 1997, PLANT CELL, V9, P1843, DOI 10.1105/tpc.9.10.1843; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Kochian LV, 1988, ADV BOT RES, V15, P136; Krysan PJ, 1996, P NATL ACAD SCI USA, V93, P8145, DOI 10.1073/pnas.93.15.8145; Lagarde D, 1996, PLANT J, V9, P195, DOI 10.1046/j.1365-313X.1996.09020195.x; LOBREAUX S, 1992, PLANT MOL BIOL, V19, P563, DOI 10.1007/BF00026783; Maathuis FJM, 1997, PLANT PHYSIOL, V114, P1141, DOI 10.1104/pp.114.4.1141; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MacRobbie EAC, 1997, J EXP BOT, V48, P515, DOI 10.1093/jxb/48.Special_Issue.515; MCKINNEY EC, 1995, PLANT J, V8, P613, DOI 10.1046/j.1365-313X.1995.8040613.x; MINET M, 1992, PLANT J, V2, P417; NAIRN CJ, 1988, GENE, V65, P247, DOI 10.1016/0378-1119(88)90461-1; NAKAMURA RL, 1995, PLANT PHYSIOL, V109, P371, DOI 10.1104/pp.109.2.371; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; PRITCHARD J, 1991, J EXP BOT, V42, P1043, DOI 10.1093/jxb/42.8.1043; Roberts SK, 1997, J EXP BOT, V48, P839, DOI 10.1093/jxb/48.4.839; Roberts SK, 1998, PLANT PHYSIOL, V116, P145, DOI 10.1104/pp.116.1.145; Roberts SK, 1995, PLANT J, V8, P811, DOI 10.1046/j.1365-313X.1995.8060811.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SHARP RE, 1990, PLANT PHYSIOL, V93, P1337, DOI 10.1104/pp.93.4.1337; Thiel G, 1997, TRENDS PLANT SCI, V2, P339, DOI 10.1016/S1360-1385(97)84621-3; THOMINE S, 1994, FEBS LETT, V340, P45, DOI 10.1016/0014-5793(94)80170-3; UOZUMI N, 1995, J BIOL CHEM, V270, P24276, DOI 10.1074/jbc.270.41.24276; VERY AA, 1995, PLANT J, V7, P321, DOI 10.1046/j.1365-313X.1995.7020321.x; VOYTAS DF, 1990, GENETICS, V126, P713; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WEGNER LH, 1994, PLANT PHYSIOL, V105, P799, DOI 10.1104/pp.105.3.799; Wegner LH, 1997, PLANT PHYSIOL, V115, P1707, DOI 10.1104/pp.115.4.1707; Zhang JH, 1996, PLANT CELL PHYSIOL, V37, P598, DOI 10.1093/oxfordjournals.pcp.a028987	57	531	584	5	81	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 4	1998	94	5					647	655		10.1016/S0092-8674(00)81606-2	http://dx.doi.org/10.1016/S0092-8674(00)81606-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741629	Bronze			2022-12-28	WOS:000075851900012
J	Savage, B; Almus-Jacobs, F; Ruggeri, ZM				Savage, B; Almus-Jacobs, F; Ruggeri, ZM			Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow	CELL			English	Article							VONWILLEBRAND-FACTOR-BINDING; VON-WILLEBRAND-FACTOR; GLYCOPROTEIN-IIB-IIIA; ENDOTHELIAL-CELLS; ALPHA(2)BETA(1) INTEGRIN; MONOCLONAL-ANTIBODIES; IIB/IIIA COMPLEX; SHEAR-STRESS; VI COLLAGEN; ALPHA-CHAIN	We have used confocal videomicroscopy in real time to delineate the adhesive interactions supporting platelet thrombus formation on biologically relevant surfaces. Type I collagen fibrils exposed to flowing blood adsorb von Willebrand factor (VWF), to which platelets become initially tethered with continuous surface translocation mediated by the membrane glycoprotein Ib alpha. This step is essential at high wall shear rates to allow subsequent irreversible adhesion and thrombus growth mediated by the integrins alpha(2)beta(1) and alpha(IIb)beta(3). On subendothelial matrix, endogenous vWF and adsorbed plasma vWF synergistically initiate platelet recruitment, and alpha(2)beta(1) remains key along with alpha(IIb)beta(3) for normal thrombus development at all but low shear rates. Thus, hemodynamic forces and substrate characteristics define the platelet adhesion pathways leading to thrombogenesis.	Scripps Res Inst, Roon Res Ctr Arteriosclerosis & Thrombosis, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, La Jolla, CA 92037 USA; Scripps Res Inst, Roon Res Ctr Arteriosclerosis & Thrombosis, Dept Vasc Biol, Div Expt Hemostasis & Thrombosis, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Savage, B (corresponding author), Scripps Res Inst, Roon Res Ctr Arteriosclerosis & Thrombosis, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NHLBI NIH HHS [HL-42846, HL-48728, HL-31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R37HL042846, R01HL042846, P01HL048728] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALEVRIADOU BR, 1993, BLOOD, V81, P1263; BACK LD, 1977, J BIOMECH, V10, P339, DOI 10.1016/0021-9290(77)90006-9; BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P17; Celikel R, 1998, NAT STRUCT BIOL, V5, P189, DOI 10.1038/nsb0398-189; CELIKEL R, 1997, BLOOD CELL MOL DIS, V23, P124; Chiang TM, 1997, J CLIN INVEST, V100, P514, DOI 10.1172/JCI119560; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DIAZRICART M, 1993, BLOOD, V82, P491; DISE CA, 1982, J BIOL CHEM, V257, P4701; DU XP, 1994, J BIOL CHEM, V269, P18287; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FeldingHabermann B, 1996, J BIOL CHEM, V271, P5892, DOI 10.1074/jbc.271.10.5892; FOLIE BJ, 1988, BLOOD, V72, P1393; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; FUJIMURA Y, 1991, BLOOD, V77, P113; GINSBERG MH, 1993, THROMB HAEMOSTASIS, V70, P87; GOSPODAROWICZ D, 1981, J CELL PHYSIOL, V107, P171, DOI 10.1002/jcp.1041070203; HANDA M, 1986, J BIOL CHEM, V261, P2579; Ichinohe T, 1997, J BIOL CHEM, V272, P63; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; MOHRI H, 1989, J BIOL CHEM, V264, P17361; Moroi M, 1996, BLOOD, V88, P2081, DOI 10.1182/blood.V88.6.2081.bloodjournal8862081; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NIIYA K, 1987, BLOOD, V70, P475; PARETI FI, 1987, J BIOL CHEM, V262, P13835; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PISCHEL KD, 1988, J CLIN INVEST, V81, P505, DOI 10.1172/JCI113348; PLOW EF, 1985, BLOOD, V66, P724; PLOW EF, 1984, J BIOL CHEM, V259, P5385; POLANOWSKAGRABOWSKA R, 1993, BIOCHEM J, V296, P543, DOI 10.1042/bj2960543; RAND JH, 1991, J CLIN INVEST, V88, P253, DOI 10.1172/JCI115285; ROSS JM, 1995, BLOOD, V85, P1826, DOI 10.1182/blood.V85.7.1826.bloodjournal8571826; ROTH GJ, 1986, BIOCHEMISTRY-US, V25, P8357, DOI 10.1021/bi00374a004; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Schneppenheim R, 1996, P NATL ACAD SCI USA, V93, P3581, DOI 10.1073/pnas.93.8.3581; SPORN LA, 1989, J CELL BIOL, V108, P1283, DOI 10.1083/jcb.108.4.1283; TANGELDER GJ, 1988, AM J PHYSIOL, V254, pH1059, DOI 10.1152/ajpheart.1988.254.6.H1059; THIAGARAJAN P, 1988, J BIOL CHEM, V263, P3035; USAMI S, 1993, ANN BIOMED ENG, V21, P77, DOI 10.1007/BF02368167; VICENTE V, 1988, J BIOL CHEM, V263, P18473; VICENTE V, 1990, J BIOL CHEM, V265, P274; WAGNER DD, 1984, P NATL ACAD SCI-BIOL, V81, P471, DOI 10.1073/pnas.81.2.471; WARE J, 1993, J CLIN INVEST, V92, P1213, DOI 10.1172/JCI116692; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; YAMADA KM, 1990, CANCER RES, V50, P4485	51	638	658	1	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 4	1998	94	5					657	666		10.1016/S0092-8674(00)81607-4	http://dx.doi.org/10.1016/S0092-8674(00)81607-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741630	Bronze			2022-12-28	WOS:000075851900013
J	Rugg, MD				Rugg, MD			Neuroscience - Memories are made of this	SCIENCE			English	Editorial Material									Univ St Andrews, Sch Psychol, Wellcome Brain Res Grp, St Andrews KY16 9JU, Fife, Scotland	University of St Andrews	Rugg, MD (corresponding author), Univ St Andrews, Sch Psychol, Wellcome Brain Res Grp, St Andrews KY16 9JU, Fife, Scotland.	mdr@st-andrews.ac.uk						Baddeley AD., 1990, HUMAN MEMORY THEORY; Brewer JB, 1998, SCIENCE, V281, P1185, DOI 10.1126/science.281.5380.1185; Gabrieli JDE, 1997, SCIENCE, V276, P264, DOI 10.1126/science.276.5310.264; Rugg M.D., 1995, OX PSYCH S, P133; Squire LR, 1997, PHILOS T R SOC B, V352, P1663, DOI 10.1098/rstb.1997.0148; Stern CE, 1996, P NATL ACAD SCI USA, V93, P8660, DOI 10.1073/pnas.93.16.8660; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; Wagner AD, 1998, SCIENCE, V281, P1188, DOI 10.1126/science.281.5380.1188	8	19	20	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 21	1998	281	5380					1151	1152		10.1126/science.281.5380.1151	http://dx.doi.org/10.1126/science.281.5380.1151			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9735030				2022-12-28	WOS:000075531200035
J	McCaughey, ES; Mulligan, J; Voss, LD; Betts, PR				McCaughey, ES; Mulligan, J; Voss, LD; Betts, PR			Randomised trial of growth hormone in short normal girls	LANCET			English	Article							SHORT NORMAL-CHILDREN; IDIOPATHIC SHORT STATURE; PUBERTAL MATURATION; FINAL HEIGHT; THERAPY; DEFICIENCY; BOYS	Background There are few data on the long-term outcome of growth-hormone treatment in short normal children. We assessed the impact of growth-hormone treatment on pubertal development and near-final height in girls. Methods In a randomised controlled trial, we studied ten girls, with a mean age of 8.07 years and height 2 SDs or more below the mean for their age, and eight short untreated controls matched for age, and 20 short untreated girls who did not give consent for randomisation. The girls received either 30 IU/m(2) somatropin per week as daily subcutaneous injections or no treatment. We assessed pubertal staging and height gain every 6 months. Findings Eight treated girls completed a mean of 6.2 years' therapy. By a mean age of 16.4 years, their mean height SD score had changed significantly from -2.42 to -1.14 (p=0.008) and they were, on average, 7.5 cm taller than the girls in the control group (height SD scores did not change significantly from -2.55) and 6.0 cm taller than the non-consent group. The timing of each pubertal stage, and the age and amplitude of peak height Velocity were similar for all groups. Interpretation Growth-hormone therapy effectively increased height SD score among short normal girls started on treatment in early to mid childhood, with no untoward effect on pubertal progression.	Southampton Univ Hosp, Southampton SO16 6YD, Hants, England	University of Southampton	McCaughey, ES (corresponding author), Southampton Univ Hosp, Southampton SO16 6YD, Hants, England.							ALBERTSSONWIKLAND K, 1988, ACTA PAEDIATR SCAND, P77; BENJAMIN M, 1984, HASTINGS CENT REP, V14, P5, DOI 10.2307/3561875; DARENDELILER F, 1990, ACTA ENDOCRINOL-COP, V122, P414, DOI 10.1530/acta.0.1220414; DIEKEMA DS, 1990, PERSPECT BIOL MED, V34, P109; Downie AB, 1996, ARCH DIS CHILD, V75, P32, DOI 10.1136/adc.75.1.32; FURLANETTO RW, 1995, J PEDIATR-US, V127, P857; GUYDA H, 1993, PEDIAT RES S, V33, P43; GUYDA HJ, 1994, TRENDS ENDOCRIN MET, V5, P334, DOI 10.1016/1043-2760(94)90163-5; Hindmarsh PC, 1996, LANCET, V348, P13, DOI 10.1016/S0140-6736(96)01038-0; HOPWOOD NJ, 1993, J PEDIATR-US, V123, P215, DOI 10.1016/S0022-3476(05)81691-9; KAPLOWITZ PB, 1995, J PEDIATR-US, V126, P478, DOI 10.1016/S0022-3476(95)70475-2; LANTOS J, 1989, JAMA-J AM MED ASSOC, V261, P1020, DOI 10.1001/jama.261.7.1020; LIPPE B, 1989, J PEDIATR-US, V115, P585, DOI 10.1016/S0022-3476(89)80286-0; LOCHE S, 1994, J PEDIATR-US, V125, P196, DOI 10.1016/S0022-3476(94)70192-X; MCCAUGHEY ES, 1994, ARCH DIS CHILD, V71, P201, DOI 10.1136/adc.71.3.201; NEELY EK, 1994, ANNU REV MED, V45, P407; Price DA, 1996, HORM RES, V45, P59, DOI 10.1159/000184850; RABEN MS, 1962, NEW ENGL J MED, V266, P82, DOI 10.1056/NEJM196201112660207; RekersMombarg LTM, 1996, ARCH DIS CHILD, V75, P175, DOI 10.1136/adc.75.3.175; STANHOPE R, 1992, HORM RES, V38, P9, DOI 10.1159/000182563; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; TANNER JM, 1989, FOETUS MAN; Tanner JM., 1983, ASSESSMENT SKELETAL; UNDERWOOD LE, 1989, ACTA PAEDIATR SCAND, P18; VOSS L, 1989, ACTA PAEDIATR SCAND, P65; VOSS LD, 1992, BMJ-BRIT MED J, V305, P1400, DOI 10.1136/bmj.305.6866.1400; WALKER JM, 1990, LANCET, V336, P1331, DOI 10.1016/0140-6736(90)92891-K; WIT JM, 1995, CLIN ENDOCRINOL, V42, P365, DOI 10.1111/j.1365-2265.1995.tb02644.x; ZADIK Z, 1994, J PEDIATR-US, V125, P189, DOI 10.1016/S0022-3476(18)31671-8	29	68	72	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 28	1998	351	9107					940	944						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734940				2022-12-28	WOS:000072770900011
J	Beecroft, N; Cochrane, GM; Milburn, HJ				Beecroft, N; Cochrane, GM; Milburn, HJ			Effect of sex of fetus on asthma during pregnancy: blind prospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Guys Hosp, Dept Resp Med & Allergy, London SE1 9RT, England; United Med & Dent Sch Guys & St Thomas Hosp, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Milburn, HJ (corresponding author), Guys Hosp, Chest Clin, London SE1 9RT, England.							BEYNON HLC, 1988, LANCET, V2, P370; JUNIPER EF, 1989, AM REV RESPIR DIS, V140, P924, DOI 10.1164/ajrccm/140.4.924; SCHATZ M, 1988, Journal of Allergy and Clinical Immunology, V81, P509, DOI 10.1016/0091-6749(88)90187-X; Skobeloff EM, 1996, ARCH INTERN MED, V156, P1837, DOI 10.1001/archinte.156.16.1837; WHITE RJ, 1989, RESP MED, V83, P103, DOI 10.1016/S0954-6111(89)80222-7	5	59	59	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	1998	317	7162					856	857		10.1136/bmj.317.7162.856	http://dx.doi.org/10.1136/bmj.317.7162.856			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748178	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000076222300019
J	Lin, DNC; Laughlin, G; Bodenheimer, P; Rozyczka, M				Lin, DNC; Laughlin, G; Bodenheimer, P; Rozyczka, M			The formation of substellar objects induced by the collision of protostellar disks	SCIENCE			English	Article							DWARF GALAXIES; GIANT PLANETS; CLOUDS; EVOLUTION; ENVIRONMENT; TAILS; MODEL; STAR; MASS	Simulations of a close encounter between two protostars, each surrounded by a relatively massive disk, resulted in the ejection of some of the disk material into a tidal tail. A portion of the tail condensed into an object with a mass in the range of 5 to 10 jovian masses. This mechanism may explain the existence of the single objects of substellar mass that have recently been discovered.	Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Univ Calif Santa Cruz, Lick Observ, Board Studies Astron & Astrophys, Santa Cruz, CA 95064 USA; Nicholas Copernicus Astron Ctr, PL-00716 Warsaw, Poland	University of California System; University of California Berkeley; University of California System; University of California Santa Cruz	Laughlin, G (corresponding author), Univ Calif Berkeley, Dept Astron, 601 Campbell Hall, Berkeley, CA 94720 USA.	gpl@astro.berkeley.edu						BARNES JE, 1992, NATURE, V360, P715, DOI 10.1038/360715a0; BODENHEIMER P, 1986, ICARUS, V67, P391, DOI 10.1016/0019-1035(86)90122-3; BODENHEIMER P, 1980, ICARUS, V41, P293, DOI 10.1016/0019-1035(80)90012-3; BONNELL I, 1992, ASTROPHYS J, V400, P579, DOI 10.1086/172020; Burrows A, 1997, ASTROPHYS J, V491, P856, DOI 10.1086/305002; Chamberlin TC, 1901, ASTROPHYS J, V14, P17, DOI 10.1086/140831; CLARKE CJ, 1991, MON NOT R ASTRON SOC, V249, P584, DOI 10.1093/mnras/249.4.584; DANTONA F, 1994, ASTROPHYS J SUPPL S, V90, P467, DOI 10.1086/191867; DEBUFFON GLL, 1745, FORMATION PLANETES; ELMEGREEN BG, 1993, ASTROPHYS J, V412, P90, DOI 10.1086/172903; GLENN AD, 1997, B AM ASTRON SOC, V29, P1379; HERNQUIST L, 1989, ASTROPHYS J SUPPL S, V70, P419, DOI 10.1086/191344; HIBBARD JE, 1995, ASTRON J, V110, P140, DOI 10.1086/117502; Hogerheijde MR, 1998, ASTROPHYS J, V502, P315, DOI 10.1086/305885; Hunsberger SD, 1996, ASTROPHYS J, V462, P50, DOI 10.1086/177126; JEANS J, 1917, MEM R ASTRON SOC LON, V62, P1; LARSON RB, 1990, ASTROPHYS SPACE SC L, V162, P389; LIN DNC, 1982, MON NOT R ASTRON SOC, V198, P707, DOI 10.1093/mnras/198.3.707; Osorio MRZ, 1998, ASTR SOC P, V134, P51; SCHWEIZER F, 1978, STRUCTURE PROPERTIES, P279; Spitzer L, 1939, ASTROPHYS J, V90, P675, DOI 10.1086/144138; TEREBEY S, 1990, ASTROPHYS J, V362, pL63, DOI 10.1086/185848; TEREBEY S, 1998, B AM ASTRON SOC, V30, P933; TOOMRE A, 1972, ASTROPHYS J, V178, P623, DOI 10.1086/151823; WATKINS SJ, IN PRESS MON NOT R A; Whitworth AP, 1997, MON NOT R ASTRON SOC, V291, P578, DOI 10.1093/mnras/291.3.578; WOOLFSON MM, 1989, ORIGIN SOLAR SYSTEM, P15; ZWICKY F, 1956, ERG EXAKT NATURWISS, V29, P344, DOI 10.1007/BFb0118841	29	29	29	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1998	281	5385					2025	2027		10.1126/science.281.5385.2025	http://dx.doi.org/10.1126/science.281.5385.2025			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748161				2022-12-28	WOS:000076161800055
J	Vacquier, VD				Vacquier, VD			Evolution of gamete recognition proteins	SCIENCE			English	Review							SPERM-ACTIVATING PEPTIDES; EGG VITELLINE ENVELOPE; FERTILIZATION PROTEIN; RAPID EVOLUTION; POTENTIAL ROLE; SEA-URCHINS; RECEPTOR; CHLAMYDOMONAS; BIOSYNTHESIS; GLYCOPROTEIN	Although fertilization has been studied for more than a century, the cell surface proteins mediating the process are only now becoming known. Gamete interaction in animals appears to be molecularly complex. Although it is difficult to generalize at present, diversity of structure may be a recurring theme in the evolution of fertilization proteins. Examples of rapid evolution of fertilization proteins by positive selection are known, and concerted evolution call influence the differentiation of gamete recognition proteins between closely related species.	Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Vacquier, VD (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA.				NICHD NIH HHS [HD 12986] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012986, R01HD012986] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Alves AP, 1997, J BIOL CHEM, V272, P6965, DOI 10.1074/jbc.272.11.6965; BOLAND W, 1995, P NATL ACAD SCI USA, V92, P37, DOI 10.1073/pnas.92.1.37; BOOKBINDER LH, 1995, SCIENCE, V269, P86, DOI 10.1126/science.7604284; Chen J, 1998, P NATL ACAD SCI USA, V95, P6193, DOI 10.1073/pnas.95.11.6193; Darszon A, 1996, CURR TOP DEV BIOL, V34, P117, DOI 10.1016/S0070-2153(08)60710-3; Edwards SV, 1998, TRENDS ECOL EVOL, V13, P305, DOI 10.1016/S0169-5347(98)01416-5; Eisenbach M., 1995, CURR OPIN ENDOCRINOL, V2, P468; Evans JP, 1997, DEV BIOL, V187, P79, DOI 10.1006/dbio.1997.8611; Ferris PJ, 1997, P NATL ACAD SCI USA, V94, P8634, DOI 10.1073/pnas.94.16.8634; Ferris PJ, 1996, MOL BIOL CELL, V7, P1235, DOI 10.1091/mbc.7.8.1235; Foltz KR, 1995, INT REV CYTOL, V163, P249, DOI 10.1016/S0074-7696(08)62212-3; Gao Z, 1998, J BIOL CHEM, V273, P3415, DOI 10.1074/jbc.273.6.3415; Hardy Daniel M., 1994, Seminars in Developmental Biology, V5, P217, DOI 10.1006/sedb.1994.1029; Hoshi Motonori, 1994, Seminars in Developmental Biology, V5, P201, DOI 10.1006/sedb.1994.1027; Kohno N, 1998, BIOCHEM BIOPH RES CO, V245, P658, DOI 10.1006/bbrc.1998.8501; KOPF GS, 1998, ENCY REPROD, V1, P17; Kubo H, 1997, DEV GROWTH DIFFER, V39, P405; LI WH, 1991, FUNDAMENTALS MOL EVO; Lum L, 1997, DEV BIOL, V191, P131, DOI 10.1006/dbio.1997.8609; LUPORINI P, 1995, J EUKARYOT MICROBIOL, V42, P208, DOI 10.1111/j.1550-7408.1995.tb01567.x; McLeskey SB, 1998, INT REV CYTOL, V177, P57; Meizel S, 1997, BIOL REPROD, V56, P569, DOI 10.1095/biolreprod56.3.569; METZ EC, IN PRESS P NATL ACAD; Miller RL, 1996, J EXP BIOL, V199, P311; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Nishigaki T, 1996, ZYGOTE, V4, P237, DOI 10.1017/S0967199400003154; PALUMBI SR, 1991, MOL BIOL EVOL, V8, P227; ROSENBERG HF, 1995, NAT GENET, V10, P219, DOI 10.1038/ng0695-219; SHAW A, 1993, SCIENCE, V262, P1864, DOI 10.1126/science.8266073; Shilling FM, 1997, DEV BIOL, V186, P155, DOI 10.1006/dbio.1997.8586; Singson A, 1998, CELL, V93, P71, DOI 10.1016/S0092-8674(00)81147-2; SUZUKI N, 1995, ZOOL SCI, V12, P13, DOI 10.2108/zsj.12.13; Swanson WJ, 1998, SCIENCE, V281, P710, DOI 10.1126/science.281.5377.710; SWANSON WJ, 1995, BIOCHEMISTRY-US, V34, P14202, DOI 10.1021/bi00043a026; Swanson WJ, 1997, P NATL ACAD SCI USA, V94, P6724, DOI 10.1073/pnas.94.13.6724; Ulrich AS, 1998, J BIOL CHEM, V273, P16748, DOI 10.1074/jbc.273.27.16748; Vacquier VD, 1997, J MOL EVOL, V44, pS15, DOI 10.1007/PL00000049; VACQUIER VD, 1995, DEV GROWTH DIFFER, V37, P1; VACQUIER VD, IN PRESS ADV DEV BIO; van Huijsduijnen RH, 1998, GENE, V206, P273, DOI 10.1016/S0378-1119(97)00597-0; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; Yamagata K, 1998, J BIOL CHEM, V273, P10470, DOI 10.1074/jbc.273.17.10470; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105	44	268	276	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					1995	1998		10.1126/science.281.5385.1995	http://dx.doi.org/10.1126/science.281.5385.1995			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748153	Green Submitted			2022-12-28	WOS:000076161800047
J	Zhu, YA; Richardson, JA; Parada, LF; Graff, JM				Zhu, YA; Richardson, JA; Parada, LF; Graff, JM			Smad3 mutant mice develop metastatic colorectal cancer	CELL			English	Article							TGF-BETA-RECEPTOR; NEURAL CREST MIGRATION; COLON-CANCER; TARGETED DISRUPTION; KNOCKOUT MICE; MAD PROTEINS; GENE; MUTATION; CELLS; IDENTIFICATION	TGF beta-related growth factors have been implicated in a variety of developmental and physiological processes in organisms ranging from nematodes to mammals. TGF beta transduces its signal to the interior of the cell via Smad2, Smad3, and Smad4. We report the cloning and targeted disruption of the mouse Smad3 gene. Smad3 mutant mice are viable and fertile. Between 4 and 6 months of age, the Smad3 mutant mice become moribund with colorectal adenocarcinomas. The neoplasms penetrate through the intestinal wall and metastasize to lymph nodes. These results directly implicate TGF beta signaling in the pathogenesis of colorectal cancer and provide a compelling animal model for the study of human colorectal cancer.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Parada, LF (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Zhu, Yuan/ABF-8405-2020; Parada, luis F/B-9400-2014					Arai T, 1998, CANCER LETT, V122, P157, DOI 10.1016/S0304-3835(97)00384-4; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BRESALIER RS, 1998, SLEISENGER FORDTRANS, P1906; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Candia AF, 1997, DEVELOPMENT, V124, P4467; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COHEN AM, 1997, CANC PRINCIPLES PRAC, V5, P1144; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fenoglio-Preiser CM, 1989, GASTROINTESTINAL PAT; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan B, 1994, MANIPULATING MOUSE E; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JIRCINY J, 1994, TRENDS GENET, V10, P164; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lu SL, 1998, NAT GENET, V19, P17, DOI 10.1038/ng0598-17; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Oshima H, 1997, CANCER RES, V57, P1644; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; Riggins GJ, 1997, CANCER RES, V57, P2578; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Schutte M, 1996, CANCER RES, V56, P2527; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; SU L, 1992, SCIENCE, V256, P658; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Tomlinson I, 1997, CANCER METAST REV, V16, P67, DOI 10.1023/A:1005744323215; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; White RL, 1998, CELL, V92, P591, DOI 10.1016/S0092-8674(00)81124-1; Wick W, 1996, ONCOGENE, V12, P973; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	63	547	580	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					703	714		10.1016/S0092-8674(00)81730-4	http://dx.doi.org/10.1016/S0092-8674(00)81730-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753318	Bronze			2022-12-28	WOS:000076021200004
J	Canman, CE; Lim, DS; Cimprich, KA; Taya, Y; Tamai, K; Sakaguchi, K; Appella, E; Kastan, MB; Siliciano, JD				Canman, CE; Lim, DS; Cimprich, KA; Taya, Y; Tamai, K; Sakaguchi, K; Appella, E; Kastan, MB; Siliciano, JD			Activation of the ATM kinase by ionizing radiation and phosphorylation of p53	SCIENCE			English	Article							CELL-CYCLE CHECKPOINT; ATAXIA-TELANGIECTASIA CELLS; PROTEIN-KINASE; DNA-DAMAGE; PATHWAYS; RECOMBINATION; INDUCTION; PRODUCT; DEFECT; MDM2	The p53 tumor suppressor protein is activated and phosphorylated on serine-15 in response to various DNA damaging agents. The gene product mutated in ataxia telangiectasia, ATM, acts upstream of p53 in a signal transduction pathway initiated by ionizing radiation. Immunoprecipitated ATM had intrinsic protein kinase activity and phosphorylated p53 on serine-15 in a manganese-dependent manner. Ionizing radiation, but not ultraviolet radiation, rapidly enhanced this p53-directed kinase activity of endogenous ATM. These observations, along with the fact that phosphorylation of p53 on serine-15 in response to ionizing radiation is reduced in ataxia telangiectasia cells, suggest that ATM is a protein kinase that phosphorylates p53 in vivo.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan; MBL Co Ltd, Ina Labs, Nagano 396, Japan; NIH, Cell Biol Lab, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; Stanford University; National Cancer Center - Japan; National Institutes of Health (NIH) - USA	Kastan, MB (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St,D-1034, Memphis, TN 38105 USA.		Lim, Dae-Sik/C-1599-2011; Tamai, Katsuyuki/F-4743-2013	Lim, Dae-Sik/0000-0003-2356-7555; Tamai, Katsuyuki/0000-0003-4094-3911; Sakaguchi, Kazuyasu/0000-0002-8434-4171; , Christine/0000-0001-8892-7430	NCI NIH HHS [CA71387] Funding Source: Medline; NIEHS NIH HHS [ES05777] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES005777, R01ES005777] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; CANMAN CE, 1994, CANCER RES, V54, P5054; CANMAN CE, UNPUB; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KHANNA KK, 1993, ONCOGENE, V8, P3307; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Rathmell WK, 1997, CANCER RES, V57, P68; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHAFMAN TD, 1995, CANCER RES, V55, P3242; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	25	1663	1702	0	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1677	1679		10.1126/science.281.5383.1677	http://dx.doi.org/10.1126/science.281.5383.1677			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733515				2022-12-28	WOS:000075856500048
J	Westin, S; Kurokawa, R; Nolte, RT; Wisely, GB; McInerney, EM; Rose, DW; Milburn, MV; Rosenfeld, MG; Glass, CK				Westin, S; Kurokawa, R; Nolte, RT; Wisely, GB; McInerney, EM; Rose, DW; Milburn, MV; Rosenfeld, MG; Glass, CK			Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators	NATURE			English	Article							THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; 9-CIS RETINOIC ACID; TRANSCRIPTIONAL ACTIVATION; CRYSTAL-STRUCTURE; COACTIVATOR; SUPERFAMILY; PATHWAYS; COMPLEX; P300	Retinoic-acid receptor-alpha (RAR-alpha) and peroxisome proliferator-activated receptor-gamma (PPAR-gamma) are members of the nuclear-receptor superfamily that bind to DNA as heterodimers with retinoid-X receptors (RXRs)(1,2). PPAR-RXR heterodimers can be activated by PPAR or RXR ligands(3), whereas RAR-RXR heterodimers are selectively activated by RAR ligands only, because of allosteric inhibition of the binding of ligands to RXR by RAR(4,5). However, RXR ligands can potentiate the transcriptional effects of RAR ligands in cells(6), Transcriptional activation by nuclear receptors requires a carboxy-terminal helical region, termed activation function-2 (AF-2) (refs 7-9), that forms part of the ligand-binding pocket and undergoes a conformational change required for the recruitment of co-activator proteins, including NCoA-1/SRC-1 (refs 10-17), Here we show that allosteric inhibition of RXR results from a rotation of the RXR AF-2 helix that places it in contact with the RAR coactivator-binding site. Recruitment of an LXXLL motif of SRC-1 to RAR in response to ligand displaces the RXR AF-2 domain, allowing RXR ligands to bind and promote the binding of a second LXXLL motif from the same SRC-1 molecule, These results may partly explain the different responses of nuclear-receptor heterodimers to RXR-specific ligands.	Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Glaxo Wellcome Inc, Dept Struct Chem, Res Triangle Pk, NC 27709 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; GlaxoSmithKline	Glass, CK (corresponding author), Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592				BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JY, 1996, NATURE, V382, P829; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GLASS C. K., 1994, ENDOCR REV, V15, P1503; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; NOLTE RT, IN PRESS NATURE; ONATE SA, 1995, SCIENCE, V270, P1354; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	28	295	309	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1998	395	6698					199	202		10.1038/26040	http://dx.doi.org/10.1038/26040			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744281				2022-12-28	WOS:000075829900048
J	Wernerman, J				Wernerman, J			Documentation of clinical benefit of specific aminoacid nutrients	LANCET			English	Editorial Material							SUPPLEMENTED PARENTERAL-NUTRITION; BONE-MARROW TRANSPLANTATION; IMMUNE-ENHANCING DIET; DOUBLE-BLIND; GLUTAMINE; TRIAL		Huddinge Univ Hosp, Dept Anaesthesiol & Intens Care, S-14186 Huddinge, Sweden	Karolinska Institutet	Wernerman, J (corresponding author), Huddinge Univ Hosp, Dept Anaesthesiol & Intens Care, S-14186 Huddinge, Sweden.							BOWER RH, 1995, CRIT CARE MED, V23, P436, DOI 10.1097/00003246-199503000-00006; CALDER PC, 1994, CLIN NUTR, V13, P2, DOI 10.1016/0261-5614(94)90003-5; DESMET SS, 1994, INTENS CARE MED, V20, P298; DUNHAM M, 1997, SHOCK S1, V7, P147; Griffiths RD, 1997, NUTRITION, V13, P295; Kudsk KA, 1996, ANN SURG, V224, P531, DOI 10.1097/00000658-199610000-00011; LARSSON J, 1990, BRIT J SURG, V77, P413, DOI 10.1002/bjs.1800770418; MOORE FA, 1994, J TRAUMA, V37, P607, DOI 10.1097/00005373-199410000-00014; Roth E, 1982, Clin Nutr, V1, P25, DOI 10.1016/0261-5614(82)90004-8; SCHLOERB PR, 1993, JPEN-PARENTER ENTER, V17, P407, DOI 10.1177/0148607193017005407; SOUBA WW, 1985, JPEN-PARENTER ENTER, V9, P608, DOI 10.1177/0148607185009005608; STREAT SJ, 1987, J TRAUMA, V27, P262, DOI 10.1097/00005373-198703000-00006; Tucker HN, 1996, NUTR REV, V54, P111; ZIEGLER TR, 1992, ANN INTERN MED, V116, P821, DOI 10.7326/0003-4819-116-10-821	14	1	2	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					756	757		10.1016/S0140-6736(05)60675-7	http://dx.doi.org/10.1016/S0140-6736(05)60675-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737276				2022-12-28	WOS:000075762700005
J	Nussberger, J; Cugno, M; Amstutz, C; Cicardi, M; Pellacani, A; Agostoni, A				Nussberger, J; Cugno, M; Amstutz, C; Cicardi, M; Pellacani, A; Agostoni, A			Plasma bradykinin in angio-oedema	LANCET			English	Article							HEREDITARY ANGIONEUROTIC-EDEMA; CONVERTING-ENZYME-INHIBITION; KININS	Background Bradykinin is believed to be the main mediator of symptoms in hereditary (HA) and acquired (AA) angio-oedema due to C1 esterase inhibitor deficiency, as well as in angio-oedema that complicates treatment with inhibitors of angiotensin-converting enzyme (ACE). Difficulties in the measurement of kinin concentrations, however, have so far precluded the demonstration of an incontrovertible change in plasma bradykinin concentrations in these disorders. By developing a reliable assay we have been able tc follow bradykinin concentrations during attacks and during remission in HA and in AA, and also in a patient treated with an ACE-inhibitor. Methods Liquid-phase extraction, high-performance liquid chromatography, and RIA were used for specific measurement of plasma bradykinin concentrations in 22 patients with HA and in 22 healthy volunteers of similar age and sex distribution. Four patients with AA and one hypertensive patient treated with the ACE inhibitor captopril were also studied. Findings Among the healthy volunteers plasma bradykinin concentration was inversely proportional to age. The geometric mean plasma bradykinin concentration in the healthy volunteers was 2.2 fmol/mL (SD 2.2). compared with 3.9 fmol/mL (3.7) among patients with HA during remission (p=0.095). Bradykinin was also high in the patients with AA (10.4 fmol/mL [1.6]). During acute attacks of oedema, in both HA and AA, plasma bradykinin rose to two to 12 times the upper limit of normal. Infusion of C1-esterase inhibitor (the deficient factor in both HA and AA) immediately lowered bradykinin concentrations. In the patient receiving the ACE-inhibitor captopril, bradykinin concentration was very high at 47 fmol/mL during an acute attack of angio-oedema, but normal at 3.2 fmol/mL in remission after withdrawal of the drug. Interpretation A sensitive method for measurement of plasma bradykinin provided the means to show that concentrations of this peptide decrease with age in healthy people. Although the differences between patients in remission and healthy controls did not reach statistical significance, there were substantial rises in bradykinin during acute attacks of hereditary, acquired, or captopril-induced angio-oedema.	Univ Lausanne Hosp, Div Hypertens, Lausanne, Switzerland; Univ Milan, Maggiore Hosp, IRCCS, Inst Internal Med, Milan, Italy	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Nussberger, J (corresponding author), CHU Vaudois, CH-1011 Lausanne, Switzerland.		Cugno, Massimo/K-8106-2016; cicardi, marco/K-9219-2016	Cugno, Massimo/0000-0002-9918-0763; cicardi, marco/0000-0003-1251-225X				AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39; Cicardi M, 1996, CLIN EXP IMMUNOL, V106, P475, DOI 10.1046/j.1365-2249.1996.d01-866.x; Cugno M, 1997, BLOOD, V89, P3213, DOI 10.1182/blood.V89.9.3213; CURD JG, 1980, J EXP MED, V152, P742, DOI 10.1084/jem.152.3.742; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; de la Cadena RA, 1994, HEMOSTASIS THROMBOSI, P219; Donaldson V H, 1977, Trans Assoc Am Physicians, V90, P174; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DONALDSON VH, 1983, NEW ENGL J MED, V308, P1094, DOI 10.1056/NEJM198305053081810; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; JACKSON J, 1986, NATURE, V323, P722, DOI 10.1038/323722a0; Lung CC, 1997, J ALLERGY CLIN IMMUN, V99, P134, DOI 10.1016/S0091-6749(97)81054-8; PELLACANI A, 1994, CLIN SCI, V87, P567, DOI 10.1042/cs0870567; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; SHAPIRA M, 1983, NEW ENGL J MED, V308, P1050; SHOEMAKER LR, 1994, CLIN EXP IMMUNOL, V95, P22; SLATER EE, 1988, JAMA-J AM MED ASSOC, V260, P967, DOI 10.1001/jama.260.7.967; TALAMO RC, 1969, J LAB CLIN MED, V74, P816; Zahedi R, 1997, J IMMUNOL, V159, P983	23	575	588	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 6	1998	351	9117					1693	1697		10.1016/S0140-6736(97)09137-X	http://dx.doi.org/10.1016/S0140-6736(97)09137-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734886				2022-12-28	WOS:000074088900010
J	Berenguer, M; Wright, TL				Berenguer, M; Wright, TL			Are HCV-infected individuals candidates for hepatitis A vaccine?	LANCET			English	Editorial Material							FAILURE		Vet Adm, Gastrointestinal Sect, San Francisco, CA 94121 USA		Berenguer, M (corresponding author), Vet Adm, Gastrointestinal Sect, San Francisco, CA 94121 USA.		Berenguer, Marina/ABG-8602-2020	Berenguer, Marina/0000-0001-9246-4264				AKRIVADES EA, 1990, ANN INTERN MED, V110, P838; HOOFNAGLE JH, 1995, HEPATOLOGY, V21, P240, DOI 10.1002/hep.1840210137; KEEFE EB, 1995, AM J GASTROENTEROL, V90, P210; Keeffe EB, 1998, HEPATOLOGY, V27, P881, DOI 10.1002/hep.510270336; OZSOYLU S, 1989, LANCET, V1, P901; Vento S, 1998, NEW ENGL J MED, V338, P286, DOI 10.1056/NEJM199801293380503; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702	7	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 28	1998	351	9107					924	925						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734933				2022-12-28	WOS:000072770900004
J	Mutton, D; Ide, RG; Alberman, E				Mutton, D; Ide, RG; Alberman, E			Trends in prenatal screening for and diagnosis of Down's syndrome: England and Wales, 1989-97	BRITISH MEDICAL JOURNAL			English	Article									St Bartholomews Med Coll, Dept Environm & Prevent Med, Wolfson Inst Prevent Med, Natl Down Syndrome Cytogenet Register, London EC1M 6BQ, England; Royal London Med Coll, London EC1M 6BQ, England	University of London; Queen Mary University London; University of London; Queen Mary University London	Mutton, D (corresponding author), St Bartholomews Med Coll, Dept Environm & Prevent Med, Wolfson Inst Prevent Med, Natl Down Syndrome Cytogenet Register, London EC1M 6BQ, England.							ALBERMAN E, 1995, BRIT J OBSTET GYNAEC, V102, P445, DOI 10.1111/j.1471-0528.1995.tb11315.x; Haddow JE, 1998, LANCET, V352, P336, DOI 10.1016/S0140-6736(98)22031-9; Morris J K, 1994, J Med Screen, V1, P233; *OFF NAT STAT, 1997, J MED SCREEN, V4, P95	4	31	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					922	923						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756810				2022-12-28	WOS:000076409000024
J	Turrell, AR; Castleden, CM; Freestone, B				Turrell, AR; Castleden, CM; Freestone, B			Long stay care and the NHS: discontinuities between policy and practice	BRITISH MEDICAL JOURNAL			English	Article							PRIVATE NURSING-HOME; ELDERLY PEOPLE; RESIDENTIAL CARE; HOSPITALS		Univ Sheffield, Trent Inst Hlth Serv Res, Sheffield S1 4DA, S Yorkshire, England; Leicester Gen Hosp, Med Elderly Dept, Leicester LE5 4PW, Leics, England; Leicestershire Hlth Author, Leicester LE5 4QF, Leics, England	University of Sheffield; University Hospitals of Leicester NHS Trust; Leicester General Hospital	Turrell, AR (corresponding author), Univ Sheffield, Trent Inst Hlth Serv Res, Sheffield S1 4DA, S Yorkshire, England.							ANDREW RA, 1988, J ROY COLL GEN PRACT, V38, P546; Benbow SJ, 1997, BRIT MED J, V314, P1868, DOI 10.1136/bmj.314.7098.1868; BLACK D, 1975, BRIT MED J, V815, P441; *BRIT GER SOC, 1997, MED CAR NURS HOM PAT; CARTWRIGHT A, 1991, AGE AGEING, V20, P271, DOI 10.1093/ageing/20.4.271; *CHART SOC PHYS PR, 1993, PHYSIOTHERAPY, V79, P404; Ferguson B, 1996, EFFECTIVE HLTH CARE, V2, P1; Greaves D, 1997, J MED ETHICS, V23, P77, DOI 10.1136/jme.23.2.77; HARRISON R, 1990, AGE AGEING, V19, P97, DOI 10.1093/ageing/19.2.97; HEPPLE J, 1989, AGE AGEING, V18, P61, DOI 10.1093/ageing/18.1.61; *HLTH COMM, 1996, 591 HC, V1; HUMPHREYS HI, 1986, J ROY COLL GEN PRACT, V36, P500; LIANG W, 1996, LAINGS REV PRIVATE H; Mattimore TJ, 1997, J AM GERIATR SOC, V45, P818, DOI 10.1111/j.1532-5415.1997.tb01508.x; PEET SM, 1995, BRIT MED J, V311, P1063, DOI 10.1136/bmj.311.7012.1063; SNAPE J, 1997, AGE AGEING, V26, P317; STERN MC, 1993, BRIT MED J, V306, P827, DOI 10.1136/bmj.306.6881.827; TAYLOR IC, 1994, ULSTER MED J, V63, P170; TURNER G, 1991, HLTH TRENDS, V22, P158; Victor C R, 1994, Qual Health Care, V3, P210, DOI 10.1136/qshc.3.4.210; WILLIAMS EI, 1992, BRIT J GEN PRACT, V42, P477	21	23	24	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					942	944						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756820				2022-12-28	WOS:000076409000040
J	Kastner, S; De Weerd, P; Desimone, R; Ungerleider, LC				Kastner, S; De Weerd, P; Desimone, R; Ungerleider, LC			Mechanisms of directed attention in the human extrastriate cortex as revealed by functional MRI	SCIENCE			English	Article							VISUAL SELECTIVE ATTENTION; NEURAL MECHANISMS; AREAS; MACAQUE; V4; PERCEPTION; STIMULUS; V3; V2; MT	A typical scene contains many different objects, but the capacity of the visual system to process multiple stimuli at a given time is limited, Thus, attentional mechanisms are required to select relevant objects from among the many objects competing for visual processing. Evidence from functional magnetic resonance imaging (MRI) in humans showed that when multiple stimuli are present simultaneously in the visual field, their cortical representations within the object recognition pathway interact in a competitive, suppressive fashion. Directing attention to one of the stimuli counteracts the suppressive influence of nearby stimuli. This mechanism may serve to filter out irrelevant information in cluttered visual scenes.	NIMH, Lab Brain & Cognit, NIH, Bethesda, MD 20892 USA; NIMH, Neuropsychol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Kastner, S (corresponding author), NIMH, Lab Brain & Cognit, NIH, Bldg 49,Room 1B80, Bethesda, MD 20892 USA.	sabine@ln.nimh.nih.gov	Desimone, Robert/G-1121-2018	Kastner, Sabine/0000-0002-9742-965X				BOUSSAOUD D, 1991, J COMP NEUROL, V306, P554, DOI 10.1002/cne.903060403; Conner CE, 1997, J NEUROSCI, V17, P3201; De Simone R., UNPUB; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DeYoe EA, 1996, P NATL ACAD SCI USA, V93, P2382, DOI 10.1073/pnas.93.6.2382; DRIVER J, 1989, J EXP PSYCHOL HUMAN, V15, P448, DOI 10.1037/0096-1523.15.3.448; DUNCAN J, 1989, PSYCHOL REV, V96, P433, DOI 10.1037/0033-295X.96.3.433; DUNCAN J, 1980, PSYCHOL REV, V87, P272, DOI 10.1037/0033-295X.87.3.272; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; GATTASS R, 1988, J NEUROSCI, V8, P1831; GATTASS R, 1981, J COMP NEUROL, V201, P519, DOI 10.1002/cne.902010405; HADJIKHANI, 1998, NATURE NEUROSCI, V1, P235; HEINZE HJ, 1994, NATURE, V372, P543, DOI 10.1038/372543a0; Luck SJ, 1997, J NEUROPHYSIOL, V77, P24, DOI 10.1152/jn.1997.77.1.24; MANGUN GR, 1995, PSYCHOPHYSIOLOGY, V32, P4, DOI 10.1111/j.1469-8986.1995.tb03400.x; McKeefry DJ, 1997, BRAIN, V120, P2229, DOI 10.1093/brain/120.12.2229; MILLER EK, 1993, BRAIN RES, V616, P25, DOI 10.1016/0006-8993(93)90187-R; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; Rees G, 1997, SCIENCE, V275, P835, DOI 10.1126/science.275.5301.835; Rees G, 1997, SCIENCE, V278, P1616, DOI 10.1126/science.278.5343.1616; Reynolds J., 1995, Society for Neuroscience Abstracts, V21, P1759; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; SHIPP S, 1995, NEUROIMAGE, V2, P125, DOI 10.1006/nimg.1995.1015; Talairach I., 1988, COPLANAR STEREOTACTI; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; TREISMAN A, 1985, COMPUT VISION GRAPH, V31, P156, DOI 10.1016/S0734-189X(85)80004-9; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; Vandenberghe R, 1997, J NEUROSCI, V17, P3739	30	675	689	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1998	282	5386					108	111		10.1126/science.282.5386.108	http://dx.doi.org/10.1126/science.282.5386.108			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756472				2022-12-28	WOS:000076294900049
J	Kielkopf, CL; White, S; Szewczyk, JW; Turner, JM; Baird, EE; Dervan, PB; Rees, DC				Kielkopf, CL; White, S; Szewczyk, JW; Turner, JM; Baird, EE; Dervan, PB; Rees, DC			A structural basis for recognition of A center dot T and T center dot A base pairs in the minor groove of B-DNA	SCIENCE			English	Article							SEQUENCE-SPECIFIC RECOGNITION; CRYSTAL-STRUCTURE; NUCLEIC-ACIDS; IMIDAZOLE; COMPLEX; BINDING; POLYAMIDES; RESOLUTION; MOLECULES; PROTEINS	Polyamide dimers containing three types of aromatic rings-pyrrole, imidazole, and hydroxypyrrole-afford a small-molecule recognition code that discriminates among all four Watson-Crick base pairs in the minor groove. The crystal structure of a specific polyamide dimer-DNA complex establishes the structural basis for distinguishing T.A from A.T base pairs. Specificity for the T.A base pair is achieved by means of distinct hydrogen bonds between pairs of substituted pyrroles on the Ligand and the O2 of thymine and N3 of adenine, In addition, shape-selective recognition of an asymmetric cleft between the thymine-O2 and the adenine-C2 was observed. Although hitherto similarities among the base pairs in the minor groove have been emphasized, the structure illustrates differences that allow specific minor groove recognition,	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Dervan, PB (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.							ADES SE, 1995, BIOCHEMISTRY-US, V34, P14601, DOI 10.1021/bi00044a040; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Baird EE, 1996, J AM CHEM SOC, V118, P6141, DOI 10.1021/ja960720z; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Brameld K, 1997, J PHYS CHEM B, V101, P4851, DOI 10.1021/jp970199a; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P83; BRUNGER TA, 1992, XPLOR VERSION 3 1 SY; CHEN X, 1994, NAT STRUCT BIOL, V1, P169, DOI 10.1038/nsb0394-169; Choo Y, 1997, CURR OPIN STRUC BIOL, V7, P117, DOI 10.1016/S0959-440X(97)80015-2; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; GEIERSTANGER BH, 1994, SCIENCE, V266, P646, DOI 10.1126/science.7939719; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; Kielkopf CL, 1998, NAT STRUCT BIOL, V5, P104, DOI 10.1038/nsb0298-104; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; Kopka ML, 1997, STRUCTURE, V5, P1033, DOI 10.1016/S0969-2126(97)00255-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MRKSICH M, 1992, P NATL ACAD SCI USA, V89, P7586, DOI 10.1073/pnas.89.16.7586; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS KA, 1993, BIOPHYS J, V64, pA166; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PARKINSON G, 1991, ACTA CRYSTALLOGR A, V47, P110; PELTON JG, 1989, P NATL ACAD SCI USA, V86, P7586; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STEITZ TA, 1990, Q REV BIOPHYS, V23, P203; Trauger JW, 1996, NATURE, V382, P559, DOI 10.1038/382559a0; TRAVERS AA, 1995, NAT STRUCT BIOL, V2, P615, DOI 10.1038/nsb0895-615; TuckerKellogg L, 1997, STRUCTURE, V5, P1047, DOI 10.1016/S0969-2126(97)00256-6; WADE WS, 1992, J AM CHEM SOC, V114, P8783, DOI 10.1021/ja00049a006; WAHL MC, 1997, TRENDS BIOCHEM SCI, V22, P98; White S, 1998, NATURE, V391, P468, DOI 10.1038/35106; White S, 1997, CHEM BIOL, V4, P569, DOI 10.1016/S1074-5521(97)90243-X; WHITE S, 1996, BIOCHEMISTRY-US, V35, P6147; WHITE S, 1997, J AM CHEM SOC, V119, P6953; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WONG JM, 1994, NUCLEIC ACIDS RES, V22, P1890, DOI 10.1093/nar/22.10.1890	39	277	289	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 2	1998	282	5386					111	115		10.1126/science.282.5386.111	http://dx.doi.org/10.1126/science.282.5386.111			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756473				2022-12-28	WOS:000076294900050
J	Seilacher, A; Bose, PK; Pfluger, F				Seilacher, A; Bose, PK; Pfluger, F			Triploblastic animals more than 1 billion years ago: Trace fossil evidence from India	SCIENCE			English	Article								Some intriguing bedding plane features that were observed in the Meso-proterozoic Chorhat Sandstone are biological and can be interpreted as the burrows of wormlike undermat miners (that is, infaunal animals that excavated tunnels underneath microbial mats), These burrows suggest that triploblastic animals existed more than a billion years ago. They also suggest that the diversification of animal designs proceeded very slowly before the appearance of organisms with hard skeletons, which was probably the key event in the Cambrian evolutionary explosion, and before the ecological changes that accompanied that event.	Univ Tubingen, Inst Geol Palaontol, D-72076 Tubingen, Germany; Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA; Jadavpur Univ, Dept Geol Sci, Calcutta 700032, W Bengal, India	Eberhard Karls University of Tubingen; Yale University; Jadavpur University	Seilacher, A (corresponding author), Univ Tubingen, Inst Geol Palaontol, D-72076 Tubingen, Germany.							Ayala FJ, 1998, P NATL ACAD SCI USA, V95, P606, DOI 10.1073/pnas.95.2.606; Bengtson S, 1998, NATURE, V391, P529, DOI 10.1038/35245; Crimes T. Peter, 1994, P105; DAVIDSON EH, 1995, SCIENCE, V270, P1319, DOI 10.1126/science.270.5240.1319; Fedonkin MA, 1997, NATURE, V388, P868, DOI 10.1038/42242; FORTEY RA, 1996, BIOL J LINN SOC, V57, P113; GEHLING JG, 1991, MEMOIRS GEOLOGICAL S, V20, P181; HOFMANN HJ, 1971, B GEOL SURV CANADA, V189, P146; Li CW, 1998, SCIENCE, V279, P879, DOI 10.1126/science.279.5352.879; PFLUGER F, 1995, NEUES JB GEOLOGIE PA, V195, P75; RAJAGOPALAN G, 1993, GROUP DISCUSSION VIN, P35; SARKAR S, 1996, NEUES JB GEOL PAL, V7, P432; SEILACHER A, 1997, GEOL SOC AM ABSTR, V32, P193; SEILACHER A, 1992, J GEOL SOC LONDON, V149, P609; Seilacher A., 1997, FOSSIL ART; Seilacher A., 1994, BIOSTABILIZATION SED, P97; SRIVASTAVA AP, 1988, J GEOL SOC INDIA, V32, P527; SRIVASTAVA AP, 1986, NUCL TRACTS, P41; SRIVASTAVA AP, 1985, INDIAN J EARTH SCI, V12, P89; Tugarinov A.I., 1965, GEOKHIMIYA, V6, P652; VINOGRADOV AP, 1966, ABSOLYUTNOYE DATIROV; VINOGRADOV AP, 1964, P INT GEOL C, V10, P652; Wray GA, 1996, SCIENCE, V274, P568, DOI 10.1126/science.274.5287.568; Xiao SH, 1998, NATURE, V391, P553, DOI 10.1038/35318	24	182	200	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 2	1998	282	5386					80	83		10.1126/science.282.5386.80	http://dx.doi.org/10.1126/science.282.5386.80			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756480				2022-12-28	WOS:000076294900040
J	Evans, SA				Evans, SA			Selling cheese - a beginner's guide	BRITISH MEDICAL JOURNAL			English	Article																		BUZAN T, 1994, MIND MAPPING BOOK; *I SCI INF, 1996, J CIT REP CD ROM SCI; TURNER B, 1998, WRITERS HDB	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1998	317	7162					893	893		10.1136/bmj.317.7162.893	http://dx.doi.org/10.1136/bmj.317.7162.893			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748202	Green Published			2022-12-28	WOS:000076222300066
J	Barton, NH; Charlesworth, B				Barton, NH; Charlesworth, B			Why sex and recombination?	SCIENCE			English	Review							DELETERIOUS MUTATIONS; EVOLUTIONARY ADVANTAGE; SELECTION; POPULATIONS; REPRODUCTION; MEIOSIS; ACCUMULATION; AMPHIMIXIS; PARASITE	Most higher organisms reproduce sexually, despite the automatic reproductive advantage experienced by asexual variants. This implies the operation of selective forces that confer an advantage to sexuality and genetic recombination, at either the population or individual level. The effect of sex and recombination in breaking down negative correlations between favorable variants at different genetic loci, which increases the efficiency of natural selection, is likely to be a major factor favoring their evolution and maintenance. Various processes that can cause such an effect have been studied theoretically. It has, however, so far proved hard to discriminate among them empirically.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Barton, NH (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	n.barton@ed.ac.uk; brian.charlesworth@ed.ac.uk	Rabelink, Ton J./A-5316-2008	Rabelink, Ton J./0000-0001-6780-5186				ANTONOVICS J, 1984, EVOLUTION, V38, P103, DOI 10.1111/j.1558-5646.1984.tb00263.x; BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; BARTON NH, 1995, GENET RES, V65, P123, DOI 10.1017/S0016672300033140; BARTON NH, 1986, J THEOR BIOL, V120, P381, DOI 10.1016/S0022-5193(86)80033-9; BARTON NH, 1994, GENET RES, V64, P199, DOI 10.1017/S0016672300032857; BELL G, 1988, J EVOLUTION BIOL, V1, P67, DOI 10.1046/j.1420-9101.1988.1010067.x; BELL G, 1982, MASTERPIECE NATURE E; Bernstein H, 1988, EVOLUTION SEX EXAMIN, P139; Birdsell J, 1996, P NATL ACAD SCI USA, V93, P908, DOI 10.1073/pnas.93.2.908; Birky CW, 1996, GENETICS, V144, P427; Brooks LD., 1988, EVOLUTION SEX, P87; Charlesworth B, 1996, GENET RES, V67, P27, DOI 10.1017/S0016672300033450; CHARLESWORTH B, 1993, GENET RES, V61, P205, DOI 10.1017/S0016672300031372; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; CHARLESWORTH B, 1990, GENET RES, V55, P199, DOI 10.1017/S0016672300025532; CHARLESWORTH D, 1979, GENETICS, V93, P237; CHARLESWORTH D, 1993, GENET RES, V61, P39, DOI 10.1017/S0016672300031086; CHARLESWORTH D, 1977, GENETICS, V86, P213; CROW J. F., 1970, Biomathematics. Volume 1. Mathematical topics in population genetics., P128; DYBDAHL MF, 1995, P ROY SOC B-BIOL SCI, V260, P99, DOI 10.1098/rspb.1995.0065; Dybdahl MF, 1998, EVOLUTION, V52, P1057, DOI [10.1111/j.1558-5646.1998.tb01833.x, 10.2307/2411236]; ELLSTRAND NC, 1985, EVOLUTION, V39, P657, DOI 10.1111/j.1558-5646.1985.tb00402.x; ESHEL I, 1970, Theoretical Population Biology, V1, P88, DOI 10.1016/0040-5809(70)90043-2; FELDMAN MW, 1980, P NATL ACAD SCI-BIOL, V77, P4838, DOI 10.1073/pnas.77.8.4838; Feldman MW, 1996, ANNU REV GENET, V30, P261, DOI 10.1146/annurev.genet.30.1.261; FELSENSTEIN J, 1965, GENETICS, V52, P349; FELSENSTEIN J, 1974, GENETICS, V78, P737; Fisher R.A., 1930, GENETICAL THEORY NAT; HAMILTON WD, 1980, OIKOS, V35, P282, DOI 10.2307/3544435; HILL WG, 1966, GENET RES, V8, P269, DOI 10.1017/S0016672300010156; Judson Olivia P., 1996, Trends in Ecology and Evolution, V11, P41, DOI 10.1016/0169-5347(96)81040-8; Keightley PD, 1998, CURR BIOL, V8, pR235, DOI 10.1016/S0960-9822(98)70148-4; KELLEY SE, 1994, PHILOS T R SOC B, V346, P295, DOI 10.1098/rstb.1994.0146; KELLEY SE, 1988, NATURE, V331, P714, DOI 10.1038/331714a0; Kirkpatrick M, 1997, AM NAT, V150, P1, DOI 10.1086/286054; Kirzhner VM, 1996, P NATL ACAD SCI USA, V93, P6532, DOI 10.1073/pnas.93.13.6532; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1993, J HERED, V84, P372, DOI 10.1093/oxfordjournals.jhered.a111358; Kondrashov AS, 1996, GENET RES, V68, P165, DOI 10.1017/S0016672300034054; Lloyd D.G., 1980, Evolutionary Biology (New York), V13, P69; MANNING JT, 1984, ACTA BIOTHEOR, V33, P219, DOI 10.1007/BF00048429; Mather K, 1943, BIOL REV CAMB PHILOS, V18, P32, DOI 10.1111/j.1469-185X.1943.tb00287.x; MAYNARD SMITH J., 1978, EVOLUTION SEX; Maynard Smith J., 1971, GROUP SELECTION, P163; MAYNARDSMITH J, 1988, GENET RES, V51, P59; Michod R. E., 1988, THE EVOLUTION OF SEX; Morgan T.H., 1913, HEREDITY SEX; Muller HJ, 1932, AM NAT, V66, P118, DOI 10.1086/280418; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; NEE S, 1989, J THEOR BIOL, V140, P499, DOI 10.1016/S0022-5193(89)80111-0; Otto SP, 1997, THEOR POPUL BIOL, V51, P134, DOI 10.1006/tpbi.1997.1301; Otto SP, 1997, GENETICS, V147, P879; Otto SP, 1998, TRENDS ECOL EVOL, V13, P145, DOI 10.1016/S0169-5347(97)01260-3; Otto SP, 1997, NATURE, V390, P343, DOI 10.1038/36996; PAMILO P, 1987, GENET RES, V49, P135, DOI 10.1017/S0016672300026938; PECK JR, 1994, GENETICS, V137, P597; Peck JR, 1998, NATURE, V391, P889, DOI 10.1038/36099; Powell J. R., 1997, PROGR PROSPECTS EVOL; REIK W, 1997, FRONTIERS MOL BIOL G; Schon I, 1998, P ROY SOC B-BIOL SCI, V265, P235, DOI 10.1098/rspb.1998.0287; Sekelsky JJ, 1998, GENETICS, V148, P1587; SMITH JM, 1990, ANNU REV ECOL SYST, V21, P1; SMITH JM, 1988, EVOLUTION SEX, P106; THORNSON G, 1974, THEOR POPUL BIOL, V5, P155; True JR, 1996, GENETICS, V142, P507; Van Valen L., 1973, EVOL THEORY REV, V1, P1, DOI DOI 10.1038/344864A0; VANVALEN L, 1975, EVOLUTION, V29, P87, DOI 10.1111/j.1558-5646.1975.tb00816.x; WEST SA, IN PRESS J EVOL BIOL; Williams G.C., 1975, Journal Cell Biol, VNo. 8, pi; WILSON DS, 1983, EVOLUTION, V37, P428; Zeyl C, 1997, NATURE, V388, P465, DOI 10.1038/41312	72	554	569	5	203	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1998	281	5385					1986	1990		10.1126/science.281.5385.1986	http://dx.doi.org/10.1126/science.281.5385.1986			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748151				2022-12-28	WOS:000076161800045
J	Lewis, A				Lewis, A			Susan Elizabeth Jean ("Sue") Munby - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					821	821		10.1136/bmj.317.7161.821	http://dx.doi.org/10.1136/bmj.317.7161.821			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740585	Green Published			2022-12-28	WOS:000076084200078
J	Parish, LC; Witkowski, JA				Parish, LC; Witkowski, JA			Melanoma and the radiograph: sanctity of human life	LANCET			English	Editorial Material									Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Jefferson Ctr Int Dermatol, Philadelphia, PA 19107 USA; Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA	Jefferson University; Jefferson University; University of Pennsylvania	Parish, LC (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA.							American Joint Committee on Cancer, 1992, MAN STAG CANC, P143; BALCH CM, 1993, CANC PRINCIPLES PRAC, P163; BALCH CM, 1992, CUTANEOUS MELANOMA, P188; SACRE R, 1982, ANTICANCER RES, V2, P47; SALK D, 1988, SEMIN ONCOL, V15, P608; TAFRA L, 1995, J THORAC CARDIOV SUR, V110, P119, DOI 10.1016/S0022-5223(05)80017-0; Terhune MH, 1998, ARCH DERMATOL, V134, P569, DOI 10.1001/archderm.134.5.569	7	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 19	1998	352	9132					922	923		10.1016/S0140-6736(05)61508-5	http://dx.doi.org/10.1016/S0140-6736(05)61508-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752811				2022-12-28	WOS:000076002200004
J	Dean, M				Dean, M			London - UK government responds to variant-CJD news and waiting lists	LANCET			English	News Item																			0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					795	795		10.1016/S0140-6736(05)60695-2	http://dx.doi.org/10.1016/S0140-6736(05)60695-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737298				2022-12-28	WOS:000075762700032
J	Hughes, IA				Hughes, IA			Congenital adrenal hyperplasia - a continuum of disorders	LANCET			English	Editorial Material							21-HYDROXYLASE DEFICIENCY; EXPERIENCE; DIAGNOSIS; GENETICS		Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Hughes, IA (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England.							BATCH JA, 1993, ARCH DIS CHILD, V68, P453, DOI 10.1136/adc.68.4.453; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Chin DS, 1998, J CLIN ENDOCR METAB, V83, P1940, DOI 10.1210/jc.83.6.1940; HUGHES IA, 1979, ARCH DIS CHILD, V59, P743; Jaaskelainen J, 1997, PEDIATR RES, V41, P30; MERCADO AB, 1995, J CLIN ENDOCR METAB, V80, P2014, DOI 10.1210/jc.80.7.2014; MILLER WL, 1989, ANNU REV GENET, V23, P371, DOI 10.1146/annurev.ge.23.120189.002103; MULAIKAL RM, 1987, NEW ENGL J MED, V316, P178, DOI 10.1056/NEJM198701223160402; PANG S, 1988, PEDIATRICS, V81, P866; Pang SY, 1997, ENDOCRIN METAB CLIN, V26, P853, DOI 10.1016/S0889-8529(05)70285-1; Premawardhana LDKE, 1997, CLIN ENDOCRINOL, V46, P327, DOI 10.1046/j.1365-2265.1997.1360962.x; Rumsby G, 1998, CLIN ENDOCRINOL, V48, P707, DOI 10.1046/j.1365-2265.1998.00402.x; Scherz R, 1994, SCREENING, V3, P77; Therrell BL, 1998, PEDIATRICS, V101, P583, DOI 10.1542/peds.101.4.583; WEDELL A, 1994, J CLIN ENDOCR METAB, V78, P1145, DOI 10.1210/jc.78.5.1145; YOUNG MC, 1998, CLIN ENDOCRINOL, P450	16	46	47	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					752	754		10.1016/S0140-6736(98)22037-X	http://dx.doi.org/10.1016/S0140-6736(98)22037-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737273				2022-12-28	WOS:000075762700002
J	Swash, M				Swash, M			Dropped-head and bent-spine syndromes; axial myopathies?	LANCET			English	Editorial Material									Royal London Hosp, St Bartholomews & Royal London Sch Med & Dent, Dept Neurol, London E1 1BB, England	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	Swash, M (corresponding author), Royal London Hosp, St Bartholomews & Royal London Sch Med & Dent, Dept Neurol, London E1 1BB, England.			Swash, Michael/0000-0002-8717-8914				BORG K, 1989, J NEUROL SCI, V91, P53, DOI 10.1016/0022-510X(89)90075-0; Katz JS, 1996, NEUROLOGY, V46, P917, DOI 10.1212/WNL.46.4.917; Oerlemans WGH, 1998, J NEUROL NEUROSUR PS, V65, P258, DOI 10.1136/jnnp.65.2.258; SCHWARTZ MS, 1988, MUSCLE NERVE, V11, P1240, DOI 10.1002/mus.880111208; Serratrice G, 1996, J NEUROL NEUROSUR PS, V60, P51, DOI 10.1136/jnnp.60.1.51; SUAREZ GA, 1992, NEUROLOGY, V42, P1625, DOI 10.1212/WNL.42.8.1625; SWASH M, 1997, NEUROMUSCULAR DIS, P541	7	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					758	758		10.1016/S0140-6736(05)60677-0	http://dx.doi.org/10.1016/S0140-6736(05)60677-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737278				2022-12-28	WOS:000075762700007
J	Tielsch, JM				Tielsch, JM			Appropriate technology for cataract surgery	LANCET			English	Editorial Material									Johns Hopkins Univ, Dept Int Hlth, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Tielsch, JM (corresponding author), Johns Hopkins Univ, Dept Int Hlth, Baltimore, MD 21205 USA.			Tielsch, James/0000-0002-1151-060X				Fletcher A, 1998, AM J OPHTHALMOL, V125, P26, DOI 10.1016/S0002-9394(99)80231-1; Natchiar GN, 1998, AM J OPHTHALMOL, V125, P1, DOI 10.1016/S0002-9394(99)80229-3; Prajna  NV, 1998, AM J OPHTHALMOL, V125, P14, DOI 10.1016/S0002-9394(99)80230-X; STARK WJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1441, DOI 10.1001/archopht.1989.01070020515030; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115	5	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					754	755		10.1016/S0140-6736(05)60673-3	http://dx.doi.org/10.1016/S0140-6736(05)60673-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737274	hybrid			2022-12-28	WOS:000075762700003
J	Daily, G; Dasgupta, P; Bolin, B; Crosson, P; du Guerny, J; Ehrlich, P; Folke, C; Jansson, AM; Jansson, BO; Kautsky, N; Kinzig, A; Levin, S; Maler, KG; Pinstrup-Andersen, P; Siniscalco, D; Walker, B				Daily, G; Dasgupta, P; Bolin, B; Crosson, P; du Guerny, J; Ehrlich, P; Folke, C; Jansson, AM; Jansson, BO; Kautsky, N; Kinzig, A; Levin, S; Maler, KG; Pinstrup-Andersen, P; Siniscalco, D; Walker, B			Policy forum: Global food supply - Food production, population growth, and the environment	SCIENCE			English	Editorial Material							HUMAN APPROPRIATION; COSTS		Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Univ Cambridge, Fac Econ & Polit, Cambridge CB3 9DD, England; Resources Future Inc, Washington, DC 20036 USA; Univ Stockholm, Dept Meteorol, S-10691 Stockholm, Sweden; FAO, I-00100 Rome, Italy; Univ Stockholm, Dept Syst Ecol, S-10691 Stockholm, Sweden; Beijer Int Inst Ecol Econ, Stockholm, Sweden; Princeton Univ, Princeton Environm Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Stockholm Sch Econ, S-11383 Stockholm, Sweden; Int Food Policy Res Inst, Washington, DC 20036 USA; Fdn Eni Enrico Mattei, Milan, Italy; CSIRO, Lyneham, ACT, Australia	Stanford University; University of Cambridge; Resources for the Future; Stockholm University; Food & Agriculture Organization of the United Nations (FAO); Stockholm University; Royal Swedish Academy of Sciences; Beijer Institute of Ecological Economics; Princeton University; Princeton University; Stockholm School of Economics; CGIAR; International Food Policy Research Institute (IFPRI); Fondazione Mattei; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Daily, G (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	Partha.Dasgupta@econ.cam.ac.uk	Walker, Brian H/F-2386-2011; Levin, Simon A/J-1218-2014; Folke, Carl/Z-1545-2019	Levin, Simon A/0000-0002-8216-5639; Folke, Carl/0000-0002-4050-3281				[Anonymous], 1996, ULTIMATE RESOURCE; Arrow K, 1996, CLIMATE CHANGE EC SO, P125; Cleaver K.M., 1994, REVERSING SPIRAL POP; CROSSON P, 1995, SCIENCE, V269, P461, DOI 10.1126/science.269.5223.461; CROSSON P, 1994, FOOD POLICY, V19, P105, DOI 10.1016/0306-9192(94)90064-7; CROSSON P, 1996, 4 FAO WORLD FOOD SUM; Daily GC, 1997, NATURES SERVICES SOC, DOI DOI 10.12987/9780300188479-039; Dasgupta P., 1993, INQUIRY WELL BEING D; DASGUPTA P, 1991, P WORLD BANK ANN C D, P101; Folke C, 1998, ECOL APPL, V8, pS63, DOI 10.1890/1051-0761(1998)8[S63:TEFCFS]2.0.CO;2; HOLDREN JP, 1974, AM SCI, V62, P282; Matson PA, 1998, SCIENCE, V280, P112, DOI 10.1126/science.280.5360.112; PIMENTEL D, 1995, SCIENCE, V267, P1117, DOI 10.1126/science.267.5201.1117; Pinstrup-Andersen P, 1994, WORLD FOOD TRENDS FU; Postel SL, 1996, SCIENCE, V271, P785, DOI 10.1126/science.271.5250.785; SAFINA C, 1995, SCI AM, V273, P46, DOI 10.1038/scientificamerican1195-46; SIMON J, 1997, ECONOMIST, V345, P21; Vitousek PM, 1997, ECOL APPL, V7, P737, DOI 10.2307/2269431; VITOUSEK PM, 1986, BIOSCIENCE, V36, P368, DOI 10.2307/1310258; WATERLOW JC, IN PRESS FEEDING WOR; Witte W, 1998, SCIENCE, V279, P996, DOI 10.1126/science.279.5353.996	21	76	85	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 28	1998	281	5381					1291	1292		10.1126/science.281.5381.1291	http://dx.doi.org/10.1126/science.281.5381.1291			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9735046				2022-12-28	WOS:000075666800027
J	Williams, J; Tallis, G; Dalton, C; Ng, S; Beaton, S; Catton, M; Elliott, J; Carnie, J				Williams, J; Tallis, G; Dalton, C; Ng, S; Beaton, S; Catton, M; Elliott, J; Carnie, J			Community outbreak of psittacosis in a rural Australian town	LANCET			English	Article							ORNITHOSIS	Background Health authorities in Victoria, Australia were notified of three men from a rural town with atypical pneumonia, admitted to hospital over 8 days. Initial serological testing suggested Chlamydia psittaci as the cause. We did a case-control study to find risk factors for psittacosis. Methods We searched for cases of pneumonia or severe flu-like illness through family physicians and the regional hospital. We selected three controls per case from the region's electoral roll. We collected blood for serological tests and administered questionnaires to all cases and controls. Findings We found 16 cases of psittacosis and one died. Most cases were clustered within a small geographical area, with a median age of 58 years (range 23-76), 15 (94%) of whom were male. Keeping, handling, or feeding domestic or wild birds was not associated with illness. Cases spent a median of 17.5 h per week in their garden, compared with a median of 5.2 h for controls (p=0.04) and were more likely to have mowed lawns during the 3 weeks before onset of illness than controls (odds ratio 4.81 [95% CI 1.08-33.37]). Interpretation We showed that psittacosis outbreaks are not limited to direct contact with birds and pose new challenges for disease control. Modifications may be needed to work outdoors to decrease the risk psittacosis.	Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia; Dept Human Serv, Infect Dis Unit, Fairfield, Vic, Australia; Royal Melbourne Hosp, Melbourne, Vic, Australia	Australian National University; Royal Melbourne Hospital	Williams, J (corresponding author), ACHS Care Evaluat Program, Aikkenhead Ctr, Level 9,41 Victoria Parade, Fitzroy, Vic 3065, Australia.			Williams, Joanne/0000-0002-5633-1592				ANDREWS BE, 1981, LANCET, V1, P632; [Anonymous], 1995, CONTROL COMMUNICABLE; KHATIB R, 1995, SCAND J INFECT DIS, V27, P519, DOI 10.3109/00365549509047058; Meyer KF, 1942, MEDICINE, V21, P175, DOI 10.1097/00005792-194205010-00003; NAGINGTON J, 1984, J HYG-CAMBRIDGE, V92, P9, DOI 10.1017/S0022172400063981; PALMER SR, 1981, LANCET, V2, P798; PETHER JVS, 1989, EPIDEMIOL INFECT, V103, P395, DOI 10.1017/S0950268800030752; ROBERTS JP, 1978, AVIAN DIS, V22, P698, DOI 10.2307/1589647; SCHAFFNER W, 1990, PRINCIPLES PRACTICE, P1440; SCHLOSSBERG D, 1993, ARCH INTERN MED, V153, P2594, DOI 10.1001/archinte.153.22.2594; VERBRUGGE LM, 1989, J HEALTH SOC BEHAV, V30, P282, DOI 10.2307/2136961; WATSON MW, 1991, J CLIN MICROBIOL, V29, P1188, DOI 10.1128/JCM.29.6.1188-1193.1991; 1992, MMWR MORB MORTAL WKL, V41, P794	13	51	51	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 6	1998	351	9117					1697	1699		10.1016/S0140-6736(97)10444-5	http://dx.doi.org/10.1016/S0140-6736(97)10444-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734887				2022-12-28	WOS:000074088900011
J	Ball, R				Ball, R			A memorable patient - Sending the right message	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					944	944						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756822				2022-12-28	WOS:000076409000041
J	Rosamond, WD; Chambless, LE; Folsom, AR; Cooper, LS; Conwill, DE; Clegg, L; Wang, CH; Heiss, G				Rosamond, WD; Chambless, LE; Folsom, AR; Cooper, LS; Conwill, DE; Clegg, L; Wang, CH; Heiss, G			Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMMUNITY SURVEILLANCE; ALAMEDA COUNTY; RISK-FACTORS; SURVEY MHS; MINNESOTA; DECLINE; EXPERIENCE; MORBIDITY; PROJECT; DEATH	Background and Methods To clarify the determinants of contemporary trends in mortality from coronary heart disease (CHD), we conducted surveillance of hospital admissions for myocardial infarction and of in-hospital and out-of-hospital deaths due to CHD among 35-to-74-year-old residents of four communities of varying size in the United States (a total of 352,481 persons in 1994). Between 1987 and 1994, we estimate that there were 11,869 hospitalizations for myocardial infarction (on the basis of 8572 hospitalizations sampled) and 3407 fatal coronary events (3023 sampled). Results The largest average annual decrease in mortality due to CHD occurred among white men (change in mortality, -4.7 percent; 95 percent confidence interval, -2.2 to -7.1 percent), followed by white women (-4.5 percent; 95 percent confidence interval, -0.7 to -8.2 percent), black women (-4.1 percent; 95 percent confidence interval, -10.3 to +2.5 percent), and black men (-2.5 percent; 95 percent confidence interval, -6.9 to +2.2 percent). Overall, in-hospital mortality from CHD fell by 5.1 percent per year, whereas out-of-hospital mortality declined by 3.6 percent per year. There was no evidence of a decline in the incidence of hospitalization for a first myocardial infarction among either men or women; in fact, such hospital admissions increased by 7.4 percent per year (95 percent confidence interval, 0.5 to 14.8 percent) among black women and 2.9 percent per year (95 percent confidence interval, -3.6 to +9.9 percent) among black men. Rates of recurrent myocardial infarction decreased, and survival after myocardial infarction improved. Conclusions From 1987 to 1994, we observed a stable or slightly increasing incidence of hospitalization for myocardial infarction. Nevertheless, there were significant annual decreases in mortality from CHD. The decline in mortality in the four communities we studied may be due largely to improvements in the treatment and secondary prevention of myocardial infarction. (N Engl J Med 1998;339:861-7) (C)1998, Massachusetts Medical Society.	Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA; NHLBI, Bethesda, MD 20892 USA; Univ Mississippi, Med Ctr, Dept Prevent Med, Div Epidemiol, Jackson, MS 39216 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Mississippi; University of Mississippi Medical Center	Rosamond, WD (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, CB 7400,McGavran-Greenberg Hall, Chapel Hill, NC 27599 USA.				DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055018, N01HC055015, N01HC055016] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-55018, N01-HC-55016, N01-HC-55015] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASSAF AR, 1993, NEW ENGL J MED, V329, P931, DOI 10.1056/NEJM199309233291307; BURKE GL, 1989, J CLIN EPIDEMIOL, V42, P17, DOI 10.1016/0895-4356(89)90021-8; COHN BA, 1988, AM J EPIDEMIOL, V127, P1143, DOI 10.1093/oxfordjournals.aje.a114908; EDLAVITCH SA, 1990, J CLIN EPIDEMIOL, V43, P93, DOI 10.1016/0895-4356(90)90061-S; ELVEBACK LR, 1986, MAYO CLIN PROC, V61, P896, DOI 10.1016/S0025-6196(12)62612-3; FORTMANN SP, 1986, AM J EPIDEMIOL, V123, P656, DOI 10.1093/oxfordjournals.aje.a114285; GILLUM RF, 1994, J AM COLL CARDIOL, V23, P1273, DOI 10.1016/0735-1097(94)90367-0; Goff DC, 1997, CIRCULATION, V95, P1433; GOLDBERG RJ, 1993, CIRCULATION, V87, P1947, DOI 10.1161/01.CIR.87.6.1947; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; HIGGINS MW, 1988, TRENDS CORONARY HEAR, P301; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; KAPLAN GA, 1988, AM J EPIDEMIOL, V127, P1131, DOI 10.1093/oxfordjournals.aje.a114907; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; Nichaman M Z, 1993, Ann Epidemiol, V3, P42; PANKOW JS, 1994, J CLIN EPIDEMIOL, V47, P1051, DOI 10.1016/0895-4356(94)90121-X; PEDERSEN TR, 1994, LANCET, V344, P1383; Sidney S, 1996, CIRCULATION, V93, P11; Sytkowski PA, 1996, AM J EPIDEMIOL, V143, P338, DOI 10.1093/oxfordjournals.aje.a008748; White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; World Health Organization, 1980, INT CLASSIFICATION D; 1997, MMWR MORB MORTAL WKL, V46, P146	24	625	651	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1998	339	13					861	867		10.1056/NEJM199809243391301	http://dx.doi.org/10.1056/NEJM199809243391301			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121VY	9744969				2022-12-28	WOS:000076037400001
J	Veatch, A; Dikman, SH				Veatch, A; Dikman, SH			Human immunodeficiency virus nephropathy and intraglomerular Cryptococcus neoformans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Mt Sinai Hosp, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Veatch, A (corresponding author), Mt Sinai Hosp, New York, NY 10029 USA.								0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1998	339	13					887	887		10.1056/NEJM199809243391305	http://dx.doi.org/10.1056/NEJM199809243391305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121VY	9744973				2022-12-28	WOS:000076037400005
J	Abbas, D				Abbas, D			Never again	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					783	783		10.1136/bmj.317.7161.783	http://dx.doi.org/10.1136/bmj.317.7161.783			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740564	Green Published			2022-12-28	WOS:000076084200024
J	Popoola, J; Muller, AF; Pollock, L; O'Donnell, P; Carmichael, P; Stevens, P				Popoola, J; Muller, AF; Pollock, L; O'Donnell, P; Carmichael, P; Stevens, P			Late onset interstitial nephritis associated with mesalazine treatment	BRITISH MEDICAL JOURNAL			English	Article							5-AMINOSALICYLIC ACID; DISEASE		Kent & Canterbury Hosp NHS Trust, Dept Renal Med, Canterbury CT1 3NG, Kent, England; Kent & Canterbury Hosp NHS Trust, Dept Gastroenterol, Canterbury CT1 3NG, Kent, England; Univ London Kings Coll Hosp, Dept Histopathol, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Stevens, P (corresponding author), Kent & Canterbury Hosp NHS Trust, Dept Renal Med, Canterbury CT1 3NG, Kent, England.		Popoola, Joyce/AAP-8481-2020	Popoola, Joyce/0000-0002-3114-3501				DeBroe ME, 1997, NEPHROL DIAL TRANSPL, V12, P1839; Hamling J, 1997, DIGESTION, V58, P304, DOI 10.1159/000201459; Manenti L, 1997, NEPHROL DIAL TRANSPL, V12, P2031, DOI 10.1093/oxfordjournals.ndt.a027787; MEHTA RP, 1990, CAN MED ASSOC J, V143, P1031; Smilde T J, 1994, Ned Tijdschr Geneeskd, V138, P2557; THULUVATH PJ, 1994, GUT, V35, P1493, DOI 10.1136/gut.35.10.1493; WITTE T, 1994, NEPHRON, V67, P481, DOI 10.1159/000188024; World MJ, 1996, NEPHROL DIAL TRANSPL, V11, P614, DOI 10.1093/oxfordjournals.ndt.a027349; 1992, DRUG THER B, V30, P50	9	37	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					795	797		10.1136/bmj.317.7161.795	http://dx.doi.org/10.1136/bmj.317.7161.795			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740571	Green Published			2022-12-28	WOS:000076084200035
J	Spring, MW; Hartley, B; Scoble, JE; Viberti, GC				Spring, MW; Hartley, B; Scoble, JE; Viberti, GC			A man with diabetes and unexplained renal failure	LANCET			English	Article							DISEASE		United Med & Dent Sch Guys & St Thomas Hosp, Dept Metab Med, London SE1 9RT, England; United Med & Dent Sch Guys & St Thomas Hosp, Dept Histopathol, London SE1 9RT, England; United Med & Dent Sch Guys & St Thomas Hosp, Dept Nephrol, London SE1 9RT, England	University of London; King's College London; University of London; King's College London; University of London; King's College London	Spring, MW (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, Dept Metab Med, London SE1 9RT, England.							MOGENSEN CE, 1983, DIABETES, V32, P64, DOI 10.2337/diab.32.2.S64; Rhodes JM, 1996, LANCET, V347, P1641, DOI 10.1016/S0140-6736(96)91482-8; Scoble JE, 1996, NEPHROL DIAL TRANSPL, V11, P1516; VIDT DG, 1988, CLEV CLIN J MED, V56, P407; Woolfson RG, 1998, LANCET, V351, P1331, DOI 10.1016/S0140-6736(05)79058-9	5	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 19	1998	352	9132					956	956		10.1016/S0140-6736(98)07198-0	http://dx.doi.org/10.1016/S0140-6736(98)07198-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752819				2022-12-28	WOS:000076002200012
J	Smith, R				Smith, R			Open your eyes	LANCET			English	Article									British Med Journal, London WC1H 9TD, England		Smith, R (corresponding author), British Med Journal, BMA House,Tavistock Sq, London WC1H 9TD, England.								0	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					898	899		10.1016/S0140-6736(05)60038-4	http://dx.doi.org/10.1016/S0140-6736(05)60038-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9743003				2022-12-28	WOS:000075857300049
J	Sierra-Honigmann, MR; Nath, AK; Murakami, C; Garcia-Cardena, G; Papapetropoulos, A; Sessa, WC; Madge, LA; Schechner, JS; Schwabb, MB; Polverini, PJ; Flores-Riveros, JR				Sierra-Honigmann, MR; Nath, AK; Murakami, C; Garcia-Cardena, G; Papapetropoulos, A; Sessa, WC; Madge, LA; Schechner, JS; Schwabb, MB; Polverini, PJ; Flores-Riveros, JR			Biological action of leptin as an angiogenic factor	SCIENCE			English	Article							MESSENGER-RNA; OB PROTEIN; OBESE GENE; CELLS; RECEPTOR; MICE; EXPRESSION; ACTIVATION; ADIPOSITY; TISSUES	Leptin is a hormone that regulates food intake, and its receptor (OB-Rb) is expressed primarily in the hypothalamus. Here, it is shown that OB-Rb is also expressed in human vasculature and in primary cultures of human endothelial coils, In vitro and in vivo assays revealed that Leptin has angiogenic activity. In vivo, Leptin induced neovascularization in corneas from normal rats but not in corneas from fa/fa Zucker rats, which Lack functional Leptin receptors. These observations indicate that the vascular endothelium is a target for Leptin and suggest a physiological mechanism whereby Leptin-induced angiogenesis may facilitate increased energy expenditure.	Yale Univ, Sch Med, Boyer Ctr Mol Med, New Haven, CT 06536 USA; Univ Michigan, Sch Dent, Dept Oral Med Pathol Surg, Ann Arbor, MI 48109 USA; Bayer Corp, Inst Metab Disorders, West Haven, CT 06516 USA	Yale University; University of Michigan System; University of Michigan; Bayer AG	Sierra-Honigmann, MR (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, 333 Cedar St, New Haven, CT 06536 USA.	rocio_sierra-honigmann@qm.yale.edu	Andreas, Papapetropoulos/AAJ-3089-2020; Garcia-Cardena, Guillermo/Q-6649-2019; Sessa, William C/B-6844-2011; Polverini, Peter/AAJ-8392-2020	Sessa, William C/0000-0001-5759-1938; Papapetropoulos, Andreas/0000-0002-4253-5930				AUERBACH R, 1991, PHARMACOL THERAPEUT, V51, P1, DOI 10.1016/0163-7258(91)90038-N; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Castle VP, 1997, LAB INVEST, V77, P51; Crandall DL, 1997, MICROCIRCULATION-LON, V4, P211, DOI 10.3109/10739689709146786; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Flier JS, 1997, P NATL ACAD SCI USA, V94, P4242, DOI 10.1073/pnas.94.9.4242; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; Kieffer TJ, 1997, DIABETES, V46, P1087, DOI 10.2337/diabetes.46.6.1087; Koyama K, 1997, DIABETES, V46, P1276, DOI 10.2337/diabetes.46.8.1276; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Sarmiento U, 1997, LAB INVEST, V77, P243; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; SIERRAHONIGMANN MR, UNPUB; SierraHonigmann R, 1996, LAB INVEST, V74, P684; Tuominen JA, 1997, ACTA PHYSIOL SCAND, V160, P83, DOI 10.1046/j.1365-201X.1997.00102.x; WHITE DW, 1996, CTOKINE GROWTH FACTO, V7, P3003; Zachow RJ, 1997, ENDOCRINOLOGY, V138, P847, DOI 10.1210/en.138.2.847; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	25	1144	1210	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	1998	281	5383					1683	1686		10.1126/science.281.5383.1683	http://dx.doi.org/10.1126/science.281.5383.1683			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733517				2022-12-28	WOS:000075856500050
J	Brown, MA; Buddle, ML; Farrell, T; Davis, G; Jones, M				Brown, MA; Buddle, ML; Farrell, T; Davis, G; Jones, M			Randomised trial of management of hypertensive pregnancies by Korotkoff phase IV or phase V	LANCET			English	Article							DIASTOLIC BLOOD-PRESSURE; PREECLAMPSIA; SOUNDS	Background There is debate about whether diastolic blood pressure should be recorded as the fourth (muffling, K4) or fifth (disappearance, K5) Korotkoff sound in pregnancy. We compared maternal and fetal outcomes and the likelihood that episodes of severe hypertension would be recorded when hypertensive pregnancies were managed according to either K4 or K5. Methods 220 pregnant women with diastolic hypertension (K4 greater than or equal to 90 mm Hg) after the 20th week of gestation were enrolled in a prospective randomised study at two obstetric units in Australia; they were randomly assigned management with K4 (n=103) or K5 (n=117) for the remainder of the pregnancy. Clinical management was according to a uniform department protocol. Analysis was by intention to treat. All the women completed the trial. Findings An episode of severe hypertension (systolic greater than or equal to 170 mm Hg, diastolic greater than or equal to 110 mm Hg, or both) was more likely to be recorded with use of K4 than with use of K5 (39 [38%] vs 30 [26%] women, p=0.051), mainly because of a greater likelihood that severe diastolic hypertension would be recorded (34 [33%] vs 20 [17%], p=0.006). The frequency of severe systolic hypertension and simultaneous severe systolic and diastolic hypertension did not differ between groups. Pregnancy was prolonged by an average of 2 weeks in both groups, and there were no significant differences between the groups in laboratory data, requirements for antihypertensive treatment, birthweight, fetal growth retardation, or perinatal mortality. There was no eclampsia or significant maternal morbidity in either group. Interpretation A change from use of K4 to K5 would mean that one fewer case of severe diastolic hypertension would be recorded for every six hypertensive pregnancies, but all other episodes of severe hypertension would be recorded with similar frequency. Since the K4/K5 difference is smaller in hypertensive than in normotensive pregnant women and since K5 is closer to the actual intra-arterial pressure and more reliably detected, universal adoption of K5 to record diastolic blood pressure in hypertensive pregnancy should be considered.	St George Hosp, Dept Renal Med, Kogarah, NSW 2217, Australia; St George Hosp, Dept Med, Kogarah, NSW 2217, Australia; St George Hosp, Dept Obstet, Kogarah, NSW 2217, Australia; Univ New S Wales, Hurstville Community Hosp, Kogarah, NSW, Australia; Instat Australia, Mt Kuring Gai, NSW, Australia	St George Hospital; St George Hospital; St George Hospital; University of New South Wales Sydney	Brown, MA (corresponding author), St George Hosp, Dept Renal Med, Kogarah, NSW 2217, Australia.	mark.brown@bigpond.com	Jones, Michael/A-9013-2013	Jones, Michael/0000-0003-0565-4938				BLANK SG, 1994, HYPERTENSION, V24, P234, DOI 10.1161/01.HYP.24.2.234; Brown MA, 1996, MED J AUSTRALIA, V165, P360, DOI 10.5694/j.1326-5377.1996.tb125017.x; BROWN MA, 1995, CLIN EXP PHARMACOL P, V22, P781, DOI 10.1111/j.1440-1681.1995.tb01937.x; BROWN MA, 1994, AM J OBSTET GYNECOL, V171, P661, DOI 10.1016/0002-9378(94)90079-5; BROWN MA, 1991, BRIT MED J, V303, P120, DOI 10.1136/bmj.303.6794.120-d; BROWN MA, 1993, MED J AUSTRALIA, V158, P700; DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; deSwiet M, 1996, BRIT J OBSTET GYNAEC, V103, P862; GALLERY EDM, 1994, HYPERTENS PREGNANCY, V13, P285, DOI 10.3109/10641959409072230; HANSONN L, 1992, BLOOD PRESSURE, V1, P13; JOHENNING AR, 1995, HYPERTENS PREGNANCY, V14, P301, DOI 10.3109/10641959509015676; JOHENNING AR, 1992, AM J OBSTET GYNECOL, V167, P577, DOI 10.1016/S0002-9378(11)91552-X; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; LOPEZ MC, 1994, AM J OBSTET GYNECOL, V170, P574, DOI 10.1016/S0002-9378(94)70230-6; MACGILLIVRAY I, 1969, CLIN SCI, V37, P395; Machin D., 1987, STAT TABLES DESIGN C; PERRY IJ, 1990, BRIT MED J, V301, P1198, DOI 10.1136/bmj.301.6762.1198; Pirie AM, 1996, LANCET, V347, P618, DOI 10.1016/S0140-6736(96)91314-8; QUINN M, 1993, AM J OBSTET GYNECOL, V168, P1893, DOI 10.1016/0002-9378(93)90713-S; RAFTERY EB, 1968, CARDIOVASC RES, V2, P210, DOI 10.1093/cvr/2.2.210; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; Rubin P, 1996, BRIT MED J, V313, P4, DOI 10.1136/bmj.313.7048.4; Saudan PJ, 1997, BRIT J OBSTET GYNAEC, V104, P1159, DOI 10.1111/j.1471-0528.1997.tb10940.x; SELIGMAN S, 1987, BRIT J OBSTET GYNAEC, V94, P497, DOI 10.1111/j.1471-0528.1987.tb03139.x; Shennan A, 1996, LANCET, V347, P139, DOI 10.1016/S0140-6736(96)90338-4; 1990, AM J OBSTET GYNECOL, V163, P1689	26	39	39	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 5	1998	352	9130					777	781		10.1016/S0140-6736(98)03270-X	http://dx.doi.org/10.1016/S0140-6736(98)03270-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737283				2022-12-28	WOS:000075762700012
J	Steinbauer, JR; Cantor, SB; Holzer, CE; Volk, RJ				Steinbauer, JR; Cantor, SB; Holzer, CE; Volk, RJ			Ethnic and sex bias in primary care screening tests for alcohol use disorders	ANNALS OF INTERNAL MEDICINE			English	Article							IDENTIFICATION TEST AUDIT; UNITED-STATES; DRUG MODULES; AUDADIS-ADR; DRINKING; CAGE; QUESTIONNAIRE; RELIABILITY; PREVALENCE; HISPANICS	Background: The use of self-report screening tests for alcohol use disorders in the primary care setting has been advocated. Objective: To test for ethnic and sex bias in three self-report screening tests for alcohol use disorders in a primary care population. Design: Cross-sectional study with patients randomly selected from appointment lists. Setting: University-based family practice clinic. Patients: Probability sample of 1333 adult family practice patients stratified by sex and ethnicity. Measurements: Patients completed 1) a diagnostic interview to determine the presence of a current alcohol use disorder and 2) three screening tests: the CAGE questionnaire, the Self-Administered Alcoholism Screening Test (SAAST), and the Alcohol Use Disorders Identification Test (AUDIT). Results: The areas under the receiver-operating characteristic (ROC) curves for the CAGE questionnaire and the SAAST ranged from 0.61 to 0.88 and were particularly poor for African-American men and Mexican-American women. For the AUDIT, the area under the ROC curves was greater than 0.90 for each patient subgroup. The sensitivity of the CAGE questionnaire and the SAAST at standard cut-points was lowest for Mexican-American women (0.21 and 0.13, respectively). Positive likelihood ratios for the AUDIT were similar to or higher than those for' the other screening tests, whereas negative likelihood ratios were lowest for the AUDIT (<0.33), indicating the superiority of this test in ruling out a disorder. Conclusions: A marked inconsistency in the accuracy of common self-report screening tests for alcohol use disorders was found when these tests were used in a single clinical site with male and female family practice patients of different ethnic backgrounds. The AUDIT does not seem to be affected by ethnic and sex bias.	Univ Texas, MD Anderson Cancer Ctr, Dept Med Specialties, Gen Internal Med Sect, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Psychiat & Behav Sci, Galveston, TX 77555 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Medical Branch Galveston	Volk, RJ (corresponding author), Baylor Coll Med, Dept Family Med & Community Med, 5510 Greenbriar, Houston, TX 77005 USA.			Cantor, Scott/0000-0002-7072-6048; Volk, Robert/0000-0001-8811-5854	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [D32PE016033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R03AA009496] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09496] Funding Source: Medline; BHP HRSA HHS [D32-PE16033] Funding Source: Medline	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); BHP HRSA HHS		Allen JP, 1997, ALCOHOL CLIN EXP RES, V21, P613, DOI 10.1097/00000374-199706000-00008; ALLEN JP, 1995, ARCH INTERN MED, V155, P1726, DOI 10.1001/archinte.155.16.1726; *AM AC FAM PHYS, 1994, AG CHARTS PER HLTH E; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Babor T., 1989, ALCOHOL HEALTH RES W, V13, P371; Babor TF., 1989, ALCOHOL USE DISORDER, V1, P45; BERESFORD TP, 1988, PREV MED, V17, P653, DOI 10.1016/0091-7435(88)90058-8; BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; CAETANO R, 1988, J STUD ALCOHOL, V49, P462, DOI 10.15288/jsa.1988.49.462; Caetano R, 1997, J STUD ALCOHOL, V58, P565, DOI 10.15288/jsa.1997.58.565; CAETANO R, 1983, DRUG ALCOHOL DEPEN, V12, P37, DOI 10.1016/0376-8716(83)90053-4; *CAN TASK FORC PER, 1989, CAN MED ASSOC J, V141, P4; CENTOR RM, 1992, TWOBYTWO ANAL VERSIO; CENTOR RM, 1995, ROC ANAL WINDOWS VER; Chatterji S, 1997, DRUG ALCOHOL DEPEN, V47, P171, DOI 10.1016/S0376-8716(97)00088-4; CHERPITEL CJ, 1995, ANN EMERG MED, V26, P158, DOI 10.1016/S0196-0644(95)70146-X; CHERPITEL CJ, 1995, J STUD ALCOHOL, V56, P695, DOI 10.15288/jsa.1995.56.695; CHEUNG YW, 1991, INT J ADDICT, V25, P581, DOI 10.3109/10826089109077262; Clark WB, 1991, ALCOHOL AM DRINKING; COLLIGAN RC, 1990, SELF ADM ALCOHOLISM; CONIGRAVE KM, 1995, ADDICTION, V90, P1349, DOI 10.1046/j.1360-0443.1995.901013496.x; Cottler LB, 1997, DRUG ALCOHOL DEPEN, V47, P195, DOI 10.1016/S0376-8716(97)00090-2; DAVIS LJ, 1989, ALCOHOL CLIN EXP RES, V13, P224, DOI 10.1111/j.1530-0277.1989.tb00316.x; DAVIS LJ, 1987, J CLIN PSYCHOL, V43, P423; DAVIS LJ, 1987, ALCOHOL CLIN EXP RES, V11, P269, DOI 10.1111/j.1530-0277.1987.tb01306.x; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; EWING JA, 1970, P 29 INT C ALC DRUG; GILBERT MJ, 1991, ALCOHOL HLTH RES WOR, V0015, P00234; Grant B., 1992, PSYCTESTS, DOI [10.1037/t04807-000, DOI 10.1037/T04807-000]; GRANT BF, 1995, DRUG ALCOHOL DEPEN, V39, P37, DOI 10.1016/0376-8716(95)01134-K; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HELZER JE, 1991, PSYCHIAT DISORDERS A, P81; Herd D, 1996, ADDICTION, V91, P845, DOI 10.1111/j.1360-0443.1996.tb03579.x; HURT RD, 1980, MAYO CLIN PROC, V55, P365; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; MAGRUDERHABIB K, 1991, J FAM PRACTICE, V32, P406; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MORSE RM, 1975, J STUD ALCOHOL, V36, P400, DOI 10.15288/jsa.1975.36.400; MURRAYLYON IM, 1991, LANCET, V338, P1089, DOI 10.1016/0140-6736(91)91955-T; *NAT I ALC AB ALC, 1993, 8 SPEC REP US C ALC; NIERENBERG AA, 1988, JAMA-J AM MED ASSOC, V259, P1699, DOI 10.1001/jama.259.11.1699; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; Sox HC, 1988, MED DECISION MAKING; STEINWEG DL, 1993, AM J MED, V94, P520, DOI 10.1016/0002-9343(93)90088-7; SWENSON W, 1973, MAYO CLIN P, V50, P204; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Ustun B, 1997, DRUG ALCOHOL DEPEN, V47, P161, DOI 10.1016/S0376-8716(97)00087-2; Volk RJ, 1997, ADDICTION, V92, P197, DOI 10.1046/j.1360-0443.1997.9221978.x; Volk RJ, 1997, J GEN INTERN MED, V12, P763, DOI 10.1046/j.1525-1497.1997.07162.x; WENRICH MD, 1995, J GEN INTERN MED, V10, P631, DOI 10.1007/BF02602748	55	106	106	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1998	129	5					353	362		10.7326/0003-4819-129-5-199809010-00002	http://dx.doi.org/10.7326/0003-4819-129-5-199809010-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	114RL	9735062				2022-12-28	WOS:000075622600002
J	McCormack, G; Fenelon, LE; Sheehan, K; McCormick, PA				McCormack, G; Fenelon, LE; Sheehan, K; McCormick, PA			Postpartum coma	LANCET			English	Article							DISEASE		St Vincents Hosp, Liver Unit, Dublin 4, Ireland; St Vincents Hosp, Dept Microbiol, Dublin 4, Ireland; St Vincents Hosp, Dept Pathol, Dublin 4, Ireland	University College Dublin; University College Dublin; University College Dublin	McCormick, PA (corresponding author), St Vincents Hosp, Liver Unit, Dublin 4, Ireland.							Anderson BE, 1997, CLIN MICROBIOL REV, V10, P203, DOI 10.1128/CMR.10.2.203; Drancourt M, 1996, LANCET, V347, P441, DOI 10.1016/S0140-6736(96)90012-4; REGENERY RL, 1992, LANCET, V339, P1443; Stites D.P., 1994, BASIC CLIN IMMUNOLOG; Wolf JL, 1996, MED CLIN N AM, V80, P1167, DOI 10.1016/S0025-7125(05)70484-3	5	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 6	1998	351	9117					1700	1700		10.1016/S0140-6736(98)03075-X	http://dx.doi.org/10.1016/S0140-6736(98)03075-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734888				2022-12-28	WOS:000074088900012
J	Pender, MP				Pender, MP			Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis	LANCET			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; RECOVERY; LYMPHOCYTES; LINES	I postulate that multiple sclerosis is an autoimmune disease that involves genetically determined failure of activation-induced apoptosis of autoreactive T cells in the central nervous system. Activation of central-nervous-system-reactive T cells in peripheral lymphoid organs by exposure to crossreacting antigens or superantigens derived from common infectious agents may trigger attacks of multiple sclerosis. In normal individuals these activated T cells are deleted by activation-induced apoptosis, but in individuals predisposed to multiple sclerosis they survive, proliferate, and damage the central nervous system. The clinical course of multiple sclerosis may vary according to the antigens in the central nervous system being targeted: targeting of myelin antigens leads to a relapsing-remitting course of clinical recovery due to remyelination or other mechanisms; targeting of axonal antigens leads to a progressive course from onset because axonal regeneration is limited in the central nervous system. This hypothesis can account for many characteristics of multiple sclerosis and has predictions that can be tested.	Univ Queensland, Royal Brisbane Hosp, Dept Med, Herston, Qld 4029, Australia	Royal Brisbane & Women's Hospital; University of Queensland	Pender, MP (corresponding author), Univ Queensland, Royal Brisbane Hosp, Dept Med, Clin Sci Bldg, Herston, Qld 4029, Australia.		Pender, Michael P/F-4110-2010	Pender, Michael/0000-0003-3792-3768				Acarin N, 1996, ACTA NEUROL SCAND, V93, P99; Bell JI, 1996, NAT GENET, V13, P377, DOI 10.1038/ng0896-377; CHALK JB, 1994, BRAIN, V117, P975, DOI 10.1093/brain/117.5.975; Dowling P, 1997, J NEUROL SCI, V149, P1, DOI 10.1016/S0022-510X(97)05213-1; Greer JM, 1997, BRAIN, V120, P1447, DOI 10.1093/brain/120.8.1447; MARTIN R, 1990, J IMMUNOL, V145, P540; OZAWA K, 1994, BRAIN, V117, P1311, DOI 10.1093/brain/117.6.1311; PENDER MP, 1991, J NEUROL SCI, V104, P81, DOI 10.1016/0022-510X(91)90219-W; PENDER MP, 1992, J AUTOIMMUN, V5, P401, DOI 10.1016/0896-8411(92)90001-7; PENDER MP, 1984, BRAIN, V107, P699, DOI 10.1093/brain/107.3.699; PENDER MP, 1995, AUTOIMMUNE NEUROLOGI, P89; SCHLUESENER HJ, 1985, J IMMUNOL, V135, P3128; SCHMIED M, 1993, AM J PATHOL, V143, P446; TABI Z, 1995, INT IMMUNOL, V7, P967, DOI 10.1093/intimm/7.6.967; TABI Z, 1994, EUR J IMMUNOL, V24, P2609, DOI 10.1002/eji.1830241107; Thompson AJ, 1997, BRAIN, V120, P1085, DOI 10.1093/brain/120.6.1085; TUOHY VK, 1996, ANN NEURAL, V40, P519; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; White CA, 1998, J NEUROIMMUNOL, V82, P47, DOI 10.1016/S0165-5728(97)00187-2; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8	20	99	106	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 28	1998	351	9107					978	981						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734959				2022-12-28	WOS:000072770900047
J	Kennedy, BP; Kawachi, I; Glass, R; Prothrow-Stith, D				Kennedy, BP; Kawachi, I; Glass, R; Prothrow-Stith, D			Income distribution, socioeconomic status, and self rated health in the United States: multilevel analysis	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; INEQUALITY	Objective: To determine the effect of inequalities in income within a state on self rated health status while controlling for individual characteristics such as socioeconomic status. Design: Cross sectional multilevel study. Data were collected on income distribution in each of the 50 states in the United States. The Gini coefficient was used to measure statewide inequalities in income. Random probability samples of individuals in each state were collected by the 1993 and 1994 behavioural risk factor surveillance system, a random digit telephone survey. The survey collects information on an individual's income, education, self rated health and other health risk factors. Setting: All 50 states. Subjects: Civilian, non-institutionalised (that is, non-incarcerated and non-hospitalised) US residents aged 18 years or older. Main outcome measure: Self rated health status. Results: When personal characteristics and household income were controlled for, individuals living in states with the greatest inequalities in income were 30% more likely to report their health as fair or poor than individuals living in states with the smallest inequalities in income. Conclusions: Inequality in the distribution of income was associated with an adverse impact on health independent of the effect of household income.	Harvard Univ, Sch Publ Hlth, Div Publ Hlth Practice, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Kennedy, BP (corresponding author), Harvard Univ, Sch Publ Hlth, Div Publ Hlth Practice, 718 Huntington Ave, Boston, MA 02115 USA.							ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037/0003-066X.49.1.15; Atkinson AB, 1995, INCOME DISTRIBUTION; BenShlomo Y, 1996, BRIT MED J, V312, P1013; BLALOCK HM, 1984, ANNU REV SOCIOL, V10, P353; Ferraro KF, 1997, J HEALTH SOC BEHAV, V38, P38, DOI 10.2307/2955360; Fiscella K, 1997, BRIT MED J, V314, P1724, DOI 10.1136/bmj.314.7096.1724; Gravelle H, 1998, BMJ-BRIT MED J, V316, P382, DOI 10.1136/bmj.316.7128.382; HAGAN HC, 1994, PUBLIC HLTH REP, V109, P665; HAUSER RM, 1970, AM J SOCIOL, V75, P645, DOI 10.1086/224894; IDLER EL, 1995, J GERONTOL B-PSYCHOL, V50, pS344, DOI 10.1093/geronb/50B.6.S344; Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359; Kaplan GA, 1996, BRIT MED J, V312, P999; Kawachi I, 1997, AM J PUBLIC HEALTH, V87, P1491, DOI 10.2105/AJPH.87.9.1491; KAWACHI I, 1994, 942 JOINT PROGR SOC; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; MOR V, 1989, J CLIN EPIDEMIOL, V42, P895, DOI 10.1016/0895-4356(89)90103-0; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; Smith GD, 1996, BRIT MED J, V312, P987; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; Townsend P., 1988, BLACK REPORT INEQUAL; Wilcox VL, 1996, J GERONTOL B-PSYCHOL, V51, pS96, DOI 10.1093/geronb/51B.2.S96; WILKINSON R, 1996, UNHEALTHY SOC AFFICT; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; Wilkinson RG, 1997, BRIT MED J, V314, P591, DOI 10.1136/bmj.314.7080.591; WILKINSON RG, 1997, BRIT MED J, V314, P1728; [No title captured]	26	484	494	2	61	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					917	921						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	128LV	9756809				2022-12-28	WOS:000076409000023
J	Lundgren, E; Szabo, E; Ljunghall, S; Bergstrom, R; Holmberg, L; Rastad, J				Lundgren, E; Szabo, E; Ljunghall, S; Bergstrom, R; Holmberg, L; Rastad, J			Population based case-control study of sick leave in postmenopausal women before diagnosis of hyperparathyroidism	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SERUM-CALCIUM; FOLLOW-UP; BONE LOSS; HYPERCALCEMIA; MAMMOGRAPHY; PREVALENCE; SURGERY; DISEASE; VALUES	Objective: To analyse sick leave in women at risk of primary hyperparathyroidism before its diagnosis. Design: Case-control study nested within a screened cohort of postmenopausal women. Cases were women with hyperparathyroidism without prior knowledge of their disease and no traditional symptoms or complications. Controls were women from the screened population without hyperparathyroidism. Setting Population based screening within a Swedish community. Subject: 48 case-control pairs of women aged 55-70 years. Main outcome measure: Sick leave during the 5 years before diagnosis. Results: Total duration of sickness benefits was longer in the cases than controls, and this discrepancy included sick leave on full time or half time and for periods of longer than a week Cases had an increased risk of sick leave more than half of the investigated time compared with controls (odds ratio 12). Doctors' certificates showed that the overrepresented sick leave in the cases related mainly to cardiovascular diseases. Conclusion: Asymptomatic mild primary hyperparathyroidism in postmenopausal women is accompanied by a previously unrecognised morbidity, which has consequences for clinical management of the disorder and its impact on the health economy.	Uppsala Univ, Dept Surg, S-75185 Uppsala, Sweden; Uppsala Univ, Dept Internal Med, S-75185 Uppsala, Sweden; Uppsala Univ, Dept Stat, S-75185 Uppsala, Sweden	Uppsala University; Uppsala University; Uppsala University	Lundgren, E (corresponding author), Uppsala Univ, Dept Surg, S-75185 Uppsala, Sweden.	ewa.lundgren@kirurgi.uu.se						HEDBACK G, 1991, WORLD J SURG, V15, P399, DOI 10.1007/BF01658740; HORNQUIST JO, 1990, SCAND J SOC MED, V18, P91, DOI 10.1177/140349489001800202; KLEEREKOPER M, 1994, AM J MED, V96, P99, DOI 10.1016/0002-9343(94)90127-9; LJUNGDAHL LO, 1991, SCAND J SOC MED, V19, P148, DOI 10.1177/140349489101900302; LJUNGHALL S, 1991, J BONE MINER RES S2, V6, P111; LJUNGHALL S, 1989, CLIN DISORDERS BONE; Lundgren E, 1997, SURGERY, V121, P287, DOI 10.1016/S0039-6060(97)90357-3; MARTIN P, 1990, ARCH INTERN MED, V150, P1495, DOI 10.1001/archinte.150.7.1495; MEEMA HE, 1991, J BONE MINER RES, V6, P9; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; PALMER M, 1988, EUR J CLIN INVEST, V18, P39, DOI 10.1111/j.1365-2362.1988.tb01163.x; PALMER M, 1987, LANCET, V1, P59; PARFITT AM, 1991, J BONE MINER RES, V6, P95; RAO DS, 1988, J CLIN ENDOCR METAB, V67, P1294, DOI 10.1210/jcem-67-6-1294; Soreide JA, 1997, SURGERY, V122, P1117, DOI 10.1016/S0039-6060(97)90216-6; *SWED INS BOARD, 1996, SICK LEAV SWED 1990; THURFJELL EL, 1994, RADIOLOGY, V193, P351, DOI 10.1148/radiology.193.2.7972742; Wermers RA, 1998, AM J MED, V104, P115, DOI 10.1016/S0002-9343(97)00270-2	18	31	31	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	1998	317	7162					848	851		10.1136/bmj.317.7162.848	http://dx.doi.org/10.1136/bmj.317.7162.848			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748176	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000076222300017
J	Zaidi, A; Clough, P; Scheepers, B; Fitzpatrick, A				Zaidi, A; Clough, P; Scheepers, B; Fitzpatrick, A			Lesson of the week - Treatment resistant epilepsy or convulsive syncope	BRITISH MEDICAL JOURNAL			English	Review							MANAGEMENT		Manchester Royal Infirm, Manchester Heart Ctr, Manchester M13 9WL, Lancs, England; David Lewis Ctr Epilepsy, Alderley Edge SK9 7UD, Cheshire, England	University of Manchester	Zaidi, A (corresponding author), Manchester Royal Infirm, Manchester Heart Ctr, Oxford Rd, Manchester M13 9WL, Lancs, England.							BEERMAN B, 1977, BRIT HEART J, V1, P754; BOESEN F, 1983, ACTA NEUROL SCAND, V68, P49; DAY SC, 1982, AM J MED, V73, P15, DOI 10.1016/0002-9343(82)90913-5; DIMARCO JP, 1990, ANN INTERN MED, V113, P53, DOI 10.7326/0003-4819-113-1-53; DUVOISIN RC, 1962, ARCH NEUROL-CHICAGO, V7, P219, DOI 10.1001/archneur.1962.04210030057008; FITZPATRICK A, 1989, LANCET, V1, P658, DOI 10.1016/S0140-6736(89)92155-7; GASTAUT H, 1957, LANCET, V2, P1018; GIBSON TC, 1984, AM J CARDIOL, V53, P1013, DOI 10.1016/0002-9149(84)90628-3; GRUBB BP, 1991, ANN INTERN MED, V115, P871, DOI 10.7326/0003-4819-115-11-871; KAPOOR WN, 1992, JAMA-J AM MED ASSOC, V268, P2553, DOI 10.1001/jama.268.18.2553; KAPOOR WN, 1990, MEDICINE, V69, P160, DOI 10.1097/00005792-199005000-00004; KAPOOR WN, 1983, NEW ENGL J MED, V309, P197, DOI 10.1056/NEJM198307283090401; KLEIN LJ, 1964, AM J MED, V37, P263, DOI 10.1016/0002-9343(64)90010-5; LIN JTY, 1982, ANN NEUROL, V11, P525, DOI 10.1002/ana.410110513; MANOLIS AS, 1990, ANN INTERN MED, V112, P850, DOI 10.7326/0003-4819-112-11-850; SHORVON S, 1987, EPILEPSY YOUNG PEOPL, P3; SILVERSTEIN MD, 1982, JAMA-J AM MED ASSOC, V248, P1185, DOI 10.1001/jama.248.10.1185; SUTTON R, 1995, J CARDIOVASC ELECTR, V6, P569, DOI 10.1111/j.1540-8167.1995.tb00429.x	18	16	16	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1998	317	7162					869	870		10.1136/bmj.317.7162.869	http://dx.doi.org/10.1136/bmj.317.7162.869			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748189	Green Published			2022-12-28	WOS:000076222300025
J	Abe, O; Abe, R; Enomoto, K; Kikuchi, K; Koyama, H; Nomura, Y; Sakai, K; Sugimachi, K; Tominaga, T; Uchino, J; Yoshida, M; Benraadt, J; van de Velde, AO; van Dongen, JA; Vermorken, JB; Giokas, G; Lissaios, B; Harvey, VJ; Holdaway, TM; Kay, RG; Mason, BH; Coates, A; Forbes, JF; Focan, C; Lobelle, JP; Gates, GD; Powell, J; Durand, M; Mauriac, L; Bartholomeus, S; Piccart, MJ; Gelman, RS; Henderson, IC; Shapiro, CL; Hancock, AK; Masood, MB; Parker, D; Price, JJ; Jackson, S; Ragaz, J; Delozier, T; Mace-Lesec'h, J; Haybittle, JL; Berry, D; Broadwater, G; Cirrincione, C; Muss, H; Norton, L; Baum, M; Houghton, J; Riley, D; Dent, DM; Gudgeon, CA; Hacking, A; Gordon, NH; Davis, HL; Romestaing, P; Lehingue, Y; Owen, JR; Meier, P; Howell, A; Ribeiro, GC; Swindell, R; Albano, J; de Oliveira, CF; Gervasio, H; Gordilho, J; Carstensen, B; Palshof, T; Johansen, H; Korzeniowski, S; Skolyszewski, J; Portnoj, SM; Andersen, KW; Axelsson, CK; Blichert-Toft, M; Mouridsen, HT; Overgaard, M; Rose, C; Corcoran, N; Trampisch, HJ; Comis, RL; Davidson, NE; Gray, R; Robert, N; Tormey, DC; Wood, W; Chetty, U; Forrest, P; Jack, W; Rossbach, J; Sylvester, RJ; van de Velde, CJH; Cunningham, MP; Bonneterre, J; Fumoleau, P; Namer, M; Bastert, G; Rauschecker, H; Sauer, R; Sauerbrei, W; Schauer, A; Schumacher, M; de Schryver, A; Belfiglio, M; Mari, E; Nicolucci, A; Scorpiglione, N; Yosef, HMA; McArdle, CS; Smith, DC; Lara, PC; Boccardo, F; Rubagotti, A; Erazo, A; Medina, JY; Izuo, M; Morishita, Y; Bentley, A; Doran, Z; Fentiman, IS; Hayward, JL; Rubens, RD; Kaufmann, M; Jonat, W; Scheurlen, H; von Fournier, D; Fountzilas, G; Klafstrom, P; Blomqvist, C; Cuzick, J; Margreiter, R; Castiglione, M; Cavilli, F; Collins, J; Forbes, J; Gelber, RD; Goldhirsch, A; Lindtner, J; Price, KN; Rudenstam, CM; Senn, HJ; Bliss, JM; Chilvers, CED; Coombes, RC; Marty, M; Borovik, R; Brufman, G; Hayat, H; Robinson, E; Wigler, N; Pannuti, F; Takashima, S; Yasutomi, T; Sonoo, H; Yamashita, J; Ogawa, M; Welvaart, K; Hupperets, PSGJ; Bonte, J; Tengrup, I; Tennvall-Nittby, L; Martin, P; Romain, S; Ingle, JN; Suman, VJ; Buzdar, AU; Smith, T; Hakes, T; Wittes, R; de la Huerta, R; Sainz, MG; Bonadonna, G; del Vecchio, M; Valagussa, P; Veronesi, U; Dubois, JB; Bianco, AR; Lippman, ME; Pierce, LJ; Simon, R; Steinberg, SM; Myles, JD; Pater, JL; Pritchard, KI; Anderson, S; Brown, A; Bryant, J; Costantino, J; Dignam, J; Fisher, B; Redmond, C; Wieand, S; Wolmark, N; Jackson, IM; Palmer, MK; Bengtsson, NO; Larsson, LG; Lythgoe, JP; Kissin, M; Hannisdal, E; Varhaug, JE; Nissen-Meyer, R; Blamey, RW; Mitchell, AK; Robertson, JFR; Ueo, H; Mathe, G; Misset, JL; Abu-Zahra, HT; Clarke, EA; McLaughlin, JR; Clark, RM; Levine, M; Morimoto, K; Sawa, K; Takatsuka, Y; Gundersen, S; Hauer-Jensen, M; Host, H; Crossley, E; Harris, A; Beighton, A; Clarke, M; Collins, R; Davies, C; Evans, V; Godwin, J; Greaves, E; Harwood, C; Jackson, D; James, S; Lau, E; Mead, G; Naughten, A; Peto, R; Tooth, A; Rambert, P; Asselain, B; Salmon, RJ; Vilcoq, JR; Arriagada, R; Hill, C; Laplanche, A; Le, MG; Spielmann, M; Cocconi, G; di Blasio, B; Catalano, R; Creech, RH; Brockschmidt, J; Cooper, MR; Andrysek, O; Barkmanova, J; Falkson, CI; Abraham, M; Klijn, JGM; Treurniet-Donker, AD; van Putten, WLJ; Easton, D; Powles, TJ; Gazet, JC; Semiglazov, V; Deshpande, N; di Martino, L; Douglas, P; Lindtner, A; Notter, G; Bryant, AJS; Ewing, GH; Krushen-Kosloski, JL; George, WD; Gould, A; Stewart, HJ; Stroner, P; Moller, TR; Ryden, S; Carstensen, J; Hatschek, T; Soderberg, M; Carpenter, JT; Albain, K; Crowley, J; Green, S; Martino, S; Osborne, CK; Ravdin, PM; Rutqvist, LE; Wallgren, A; Holm, LE; Thurlimann, B; Brenner, H; Hercbergs, A; Yoshimoto, M; DeBoer, G; Paterson, AHG; Meakin, JW; Panzarella, T; Naja, A; Bahi, J; Reid, M; Spittle, M; Senanayake, F; Bergh, J; Holmberg, L; Sevelda, P; Zielinsky, CC; Gnant, M; Jakesz, R; Buchanan, RB; Cross, M; Dunn, JA; Gillespie, WM; Kelly, K; Morrison, JM; Litton, A; Chlebowski, RT; Bezwoda, WR; Caffier, H				Abe, O; Abe, R; Enomoto, K; Kikuchi, K; Koyama, H; Nomura, Y; Sakai, K; Sugimachi, K; Tominaga, T; Uchino, J; Yoshida, M; Benraadt, J; van de Velde, AO; van Dongen, JA; Vermorken, JB; Giokas, G; Lissaios, B; Harvey, VJ; Holdaway, TM; Kay, RG; Mason, BH; Coates, A; Forbes, JF; Focan, C; Lobelle, JP; Gates, GD; Powell, J; Durand, M; Mauriac, L; Bartholomeus, S; Piccart, MJ; Gelman, RS; Henderson, IC; Shapiro, CL; Hancock, AK; Masood, MB; Parker, D; Price, JJ; Jackson, S; Ragaz, J; Delozier, T; Mace-Lesec'h, J; Haybittle, JL; Berry, D; Broadwater, G; Cirrincione, C; Muss, H; Norton, L; Baum, M; Houghton, J; Riley, D; Dent, DM; Gudgeon, CA; Hacking, A; Gordon, NH; Davis, HL; Romestaing, P; Lehingue, Y; Owen, JR; Meier, P; Howell, A; Ribeiro, GC; Swindell, R; Albano, J; de Oliveira, CF; Gervasio, H; Gordilho, J; Carstensen, B; Palshof, T; Johansen, H; Korzeniowski, S; Skolyszewski, J; Portnoj, SM; Andersen, KW; Axelsson, CK; Blichert-Toft, M; Mouridsen, HT; Overgaard, M; Rose, C; Corcoran, N; Trampisch, HJ; Comis, RL; Davidson, NE; Gray, R; Robert, N; Tormey, DC; Wood, W; Chetty, U; Forrest, P; Jack, W; Rossbach, J; Sylvester, RJ; van de Velde, CJH; Cunningham, MP; Bonneterre, J; Fumoleau, P; Namer, M; Bastert, G; Rauschecker, H; Sauer, R; Sauerbrei, W; Schauer, A; Schumacher, M; de Schryver, A; Belfiglio, M; Mari, E; Nicolucci, A; Scorpiglione, N; Yosef, HMA; McArdle, CS; Smith, DC; Lara, PC; Boccardo, F; Rubagotti, A; Erazo, A; Medina, JY; Izuo, M; Morishita, Y; Bentley, A; Doran, Z; Fentiman, IS; Hayward, JL; Rubens, RD; Kaufmann, M; Jonat, W; Scheurlen, H; von Fournier, D; Fountzilas, G; Klafstrom, P; Blomqvist, C; Cuzick, J; Margreiter, R; Castiglione, M; Cavilli, F; Collins, J; Forbes, J; Gelber, RD; Goldhirsch, A; Lindtner, J; Price, KN; Rudenstam, CM; Senn, HJ; Bliss, JM; Chilvers, CED; Coombes, RC; Marty, M; Borovik, R; Brufman, G; Hayat, H; Robinson, E; Wigler, N; Pannuti, F; Takashima, S; Yasutomi, T; Sonoo, H; Yamashita, J; Ogawa, M; Welvaart, K; Hupperets, PSGJ; Bonte, J; Tengrup, I; Tennvall-Nittby, L; Martin, P; Romain, S; Ingle, JN; Suman, VJ; Buzdar, AU; Smith, T; Hakes, T; Wittes, R; de la Huerta, R; Sainz, MG; Bonadonna, G; del Vecchio, M; Valagussa, P; Veronesi, U; Dubois, JB; Bianco, AR; Lippman, ME; Pierce, LJ; Simon, R; Steinberg, SM; Myles, JD; Pater, JL; Pritchard, KI; Anderson, S; Brown, A; Bryant, J; Costantino, J; Dignam, J; Fisher, B; Redmond, C; Wieand, S; Wolmark, N; Jackson, IM; Palmer, MK; Bengtsson, NO; Larsson, LG; Lythgoe, JP; Kissin, M; Hannisdal, E; Varhaug, JE; Nissen-Meyer, R; Blamey, RW; Mitchell, AK; Robertson, JFR; Ueo, H; Mathe, G; Misset, JL; Abu-Zahra, HT; Clarke, EA; McLaughlin, JR; Clark, RM; Levine, M; Morimoto, K; Sawa, K; Takatsuka, Y; Gundersen, S; Hauer-Jensen, M; Host, H; Crossley, E; Harris, A; Beighton, A; Clarke, M; Collins, R; Davies, C; Evans, V; Godwin, J; Greaves, E; Harwood, C; Jackson, D; James, S; Lau, E; Mead, G; Naughten, A; Peto, R; Tooth, A; Rambert, P; Asselain, B; Salmon, RJ; Vilcoq, JR; Arriagada, R; Hill, C; Laplanche, A; Le, MG; Spielmann, M; Cocconi, G; di Blasio, B; Catalano, R; Creech, RH; Brockschmidt, J; Cooper, MR; Andrysek, O; Barkmanova, J; Falkson, CI; Abraham, M; Klijn, JGM; Treurniet-Donker, AD; van Putten, WLJ; Easton, D; Powles, TJ; Gazet, JC; Semiglazov, V; Deshpande, N; di Martino, L; Douglas, P; Lindtner, A; Notter, G; Bryant, AJS; Ewing, GH; Krushen-Kosloski, JL; George, WD; Gould, A; Stewart, HJ; Stroner, P; Moller, TR; Ryden, S; Carstensen, J; Hatschek, T; Soderberg, M; Carpenter, JT; Albain, K; Crowley, J; Green, S; Martino, S; Osborne, CK; Ravdin, PM; Rutqvist, LE; Wallgren, A; Holm, LE; Thurlimann, B; Brenner, H; Hercbergs, A; Yoshimoto, M; DeBoer, G; Paterson, AHG; Meakin, JW; Panzarella, T; Naja, A; Bahi, J; Reid, M; Spittle, M; Senanayake, F; Bergh, J; Holmberg, L; Sevelda, P; Zielinsky, CC; Gnant, M; Jakesz, R; Buchanan, RB; Cross, M; Dunn, JA; Gillespie, WM; Kelly, K; Morrison, JM; Litton, A; Chlebowski, RT; Bezwoda, WR; Caffier, H		Early Breast Canc Trialists Collaborative Gr	Polychemotherapy for early breast cancer: an overview of the randomised trials	LANCET			English	Article							REQUIRING PROLONGED OBSERVATION; ESTROGEN RECEPTORS; CHEMOTHERAPY; TAMOXIFEN; PATIENT; TUMORS; DESIGN; WOMEN	Background There have been many randomised trials of adjuvant prolonged polychemotherapy among women with early breast cancer, and an updated overview of their results is presented. Methods In 1995, information was sought on each woman in any randomised trial that began before 1990 and involved treatment groups that differed only with respect to the chemotherapy regimens that were being compared. Analyses involved about 18 000 women in 47 trials of prolonged polychemotherapy versus no chemotherapy, about 6000 in 11 trials of longer versus shorter polychemotherapy, and about 6000 in 11 trials of anthracycline-containing regimens versus CMF (cyclophosphamide, methotrexate, and fluorouracil). Findings For recurrence, polychemotherapy produced substantial and highly significant proportional reductions both among women aged under 50 at randomisation (35% [SD 4] reduction; 2p<0.00001) and among those aged 50-69 (20% [SD 3] reduction; 2p<0.00001); few women aged 70 or over had been studied. For mortality, the reductions were also significant both among women aged under 50 (27% [SD 5] reduction; 2p<0.00001) and among those aged 50-69 (11% [SD 3] reduction; 2p=0.0001). The recurrence reductions emerged chiefly during the first 5 years of follow-up, whereas the difference in survival grew throughout the first 10 years. After standardisation for age and time since randomisation, the proportional reductions in risk were similar for women with node-negative and node-positive disease. Applying the proportional mortality reduction observed in all women aged under 50 at randomisation would typically change a 10-year survival of 71% for those with node-negative disease to 78% (an absolute benefit of 7%), and of 42% for those with node-positive disease to 53% (an absolute benefit of 11%). The smaller proportional mortality reduction observed in all women aged 50-69 at randomisation would translate into smaller absolute benefits, changing a 10-year survival of 67% for those with node-negative disease to 69% (an absolute gain of 2%) and of 46% for those with node-positive disease to 49% (an absolute gain of 3%). The age-specific benefits of polychemotherapy appeared to be largely irrespective of menopausal status at presentation, oestrogen receptor status of the primary tumour, and of whether adjuvant tamoxifen had been given. In terms of other outcomes, there was a reduction of about one-fifth (2p=0.05) in contralateral breast cancer, which has already been included in the analyses of recurrence, and no apparent adverse effect on deaths from causes other than breast cancer (death rate ratio 0.89 [SD 0.09]). The directly randomised comparisons of longer versus shorter durations of polychemotherapy did not indicate any survival advantage with the use of more than about 3-6 months of polychemotherapy. By contrast, directly randomised comparisons did suggest that, compared with CMF alone, the anthracycline-containing regimens studied produced somewhat greater effects on recurrence (2p=0.006) and mortality (69% vs 72% 5-year survival; log-rank 2p=0.02). But this comparison is one of many that could have been selected for emphasis, the 99% CI reaches zero, and the results of several of the relevant trials are not yet available. Interpretation Some months of adjuvant polychemotherapy (eg, with CMF or an anthracycline-containing regimen) typically produces an absolute improvement of about 7-11% in 10-year survival for women aged under 50 at presentation with early breast cancer, and of about 2-3% for those aged 50-69 (unless their prognosis is likely to be extremely good even without such treatment). Treatment decisions involve consideration not only of improvements in cancer recurrence and survival but also of adverse side-effects of treatment, and this report makes no recommendations as to who should or should not be treated.	Radcliffe Infirm, Imperial Canc Res Fund, Nuffield Dept Clin Med, MRC,Clin Trial Serv Unit,EBCTCG Secretariat, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Abe, O (corresponding author), Radcliffe Infirm, Imperial Canc Res Fund, Nuffield Dept Clin Med, MRC,Clin Trial Serv Unit,EBCTCG Secretariat, Oxford OX2 6HE, England.		Pritchard, Kathleen I/I-2184-2014; Nicolucci, Antonio/ABI-6234-2020; Gkiokas, Georgios/AAE-6312-2020; Fentiman, Ian/AAB-9886-2020; Gnant, Michael/AAN-7054-2020; Fentiman, Ian S/I-7644-2019; McLaughlin, John R/E-4577-2013; Brenner, Hermann/B-4627-2017; Brenner, Hermann/ABE-6383-2020; Fountzilas, George/ABF-2139-2020; Jonat, Walter/E-3024-2010; Barkmanova, Jaroslava/A-1411-2017; Boccardo, Francesco Mario/AAF-2654-2019	Pritchard, Kathleen I/0000-0003-0758-9666; Gnant, Michael/0000-0003-1002-2118; Brenner, Hermann/0000-0002-6129-1572; Brenner, Hermann/0000-0002-6129-1572; Barkmanova, Jaroslava/0000-0003-1406-7292; Boccardo, Francesco Mario/0000-0002-5392-4077; Arriagada, Rodrigo/0000-0002-3134-1735; Coombes, Raoul Charles/0000-0002-4811-1100; Gray, Richard/0000-0003-4440-574X; Bergh, Jonas/0000-0001-5526-1847; Bliss, Judith/0000-0001-7957-7424				ABE O, 1992, LANCET, V339, P71; ABE O, 1995, NEW ENGL J MED, V333, P1444; ALBAIN K, 1997, P ASCO, V16, P450; [Anonymous], 1996, Lancet, V348, P1189; [Anonymous], 1988, NEW ENGL J MED, V319, P1681; [Anonymous], 1992, Lancet, V339, P1; Clahsen PC, 1997, J CLIN ONCOL, V15, P2526, DOI 10.1200/JCO.1997.15.7.2526; Clarke M, 1998, LANCET, V351, P1451; COLLINS R, 1996, OXFORD TXB MED, V1, P21; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1; ELWOOD JM, 1980, BRIT J CANCER, V42, P635, DOI 10.1038/bjc.1980.296; FISHER B, 1990, J CLIN ONCOL, V8, P1005, DOI 10.1200/JCO.1990.8.6.1005; Fisher B, 1997, JNCI-J NATL CANCER I, V89, P1673, DOI 10.1093/jnci/89.22.1673; GOLDHIRSCH A, 1985, J CLIN ONCOL, V3, P1059; LIPPMAN ME, 1978, NEW ENGL J MED, V298, P1223, DOI 10.1056/NEJM197806012982203; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Pritchard KI, 1997, J CLIN ONCOL, V15, P2302, DOI 10.1200/JCO.1997.15.6.2302; RAGAZ J, 1988, P AN M AM SOC CLIN, V7, P12	19	1668	1692	3	72	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 19	1998	352	9132					930	942						13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752815				2022-12-28	WOS:000076002200008
J	Bateman, NT; Leach, RM				Bateman, NT; Leach, RM			ABC of oxygen - Acute oxygen therapy	BRITISH MEDICAL JOURNAL			English	Article									St Thomass Hosp, Dept Resp Med, London, England; Guys & St Thomass Hosp Trust, London, England		Bateman, NT (corresponding author), St Thomass Hosp, Dept Resp Med, London, England.								0	119	125	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					798	801		10.1136/bmj.317.7161.798	http://dx.doi.org/10.1136/bmj.317.7161.798			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740573	Green Published			2022-12-28	WOS:000076084200037
J	Koepp, MJ; Richardson, MP; Brooks, DJ; Duncan, JS				Koepp, MJ; Richardson, MP; Brooks, DJ; Duncan, JS			Focal cortical release of endogenous opioids during reading-induced seizures	LANCET			English	Article							POSITRON EMISSION TOMOGRAPHY; C-11 DIPRENORPHINE; OPIATE RECEPTOR; EPILEPSY; PET; ACTIVATION; WORDS; BRAIN; TASK	Background Studies in animals implicate endogenous release of opioid peptides as a mechanism for terminating partial and generalised seizures. To localise dynamic changes in opioid neurotransmission associated with partial seizures and higher cognitive function, we investigated the release of endogenous opioids in patients with reading-induced seizures compared with healthy controls. Methods Five patients who had reading epilepsy and six controls had C-11-diprenorphine (DPN) positron-emission-tomography (PET) scans while reading a string of symbols (baseline) or a scientific paper (activation). Statistical parametric mapping was used to find areas with differences in opioid-receptor binding. Findings On activation scans mean C-11-DPN binding to opioid receptors was significantly lower (p<0.05 corrected for multiple non-independent comparisons) in the left parieto-temporo-occipital cortex (Brodmann area 37) in reading-epilepsy patients compared with controls. Interpretation These findings suggest that opioid-like substances are involved in the termination of reading-induced seizures.	Hammersmith Hosp, MRC, Cyclotron Unit, London W12 0HS, England; Inst Neurol, London WC1N 3BG, England; Natl Soc Epilepsy, London WC1N 3BG, England	Imperial College London; University of London; University College London; University of London; University College London	Duncan, JS (corresponding author), Hammersmith Hosp, MRC, Cyclotron Unit, London W12 0HS, England.	j.duncan@ion.ucl.ac.uk	Richardson, Mark P/E-5385-2010	Richardson, Mark P/0000-0001-8925-3140; Brooks, David/0000-0003-2602-2518; Duncan, John S/0000-0002-1373-0681	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALAJOUANINE T, 1959, Rev Neurol (Paris), V101, P463; ANDERSEN RA, 1989, ANNU REV NEUROSCI, V12, P377, DOI 10.1146/annurev.neuro.12.1.377; BAILEY DL, 1992, ANN NUCL MED, V6, P121; Bajorek J G, 1986, Adv Neurol, V44, P489; BARTENSTEIN PA, 1993, J NEUROL NEUROSUR PS, V56, P1295, DOI 10.1136/jnnp.56.12.1295; BICKFORD REGINALD G., 1956, TRANS AMER NEUROL ASSOC, V81, P100; BOTTINI G, 1994, BRAIN, V117, P1241, DOI 10.1093/brain/117.6.1241; BROOKS JE, 1971, ARCH NEUROL-CHICAGO, V25, P97, DOI 10.1001/archneur.1971.00490020015001; CHENG JG, 1990, EPILEPSY RES, V6, P141; CUNNINGHAM VJ, 1993, J CEREBR BLOOD F MET, V13, P15, DOI 10.1038/jcbfm.1993.5; DEWEY SL, 1993, P NATL ACAD SCI USA, V90, P11816, DOI 10.1073/pnas.90.24.11816; DEWEY SL, 1995, J NEUROSCI, V15, P821; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; FRISTON KJ, 1995, HUMAN BRAIN MAPPING, V2, P165; FROST JJ, 1993, J RECEPTOR RES, V13, P39, DOI 10.3109/10799899309073644; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; JONES AKP, 1994, J NEUROSCI METH, V51, P123, DOI 10.1016/0165-0270(94)90002-7; KARTSOUNIS LD, 1988, J NEUROL NEUROSUR PS, V51, P128, DOI 10.1136/jnnp.51.1.128; Madar I, 1997, ANN NEUROL, V41, P358, DOI 10.1002/ana.410410311; MORRIS BJ, 1995, TRENDS NEUROSCI, V18, P350, DOI 10.1016/0166-2236(95)93927-P; Morris ED, 1995, HUM BRAIN MAPP, V3, P35, DOI 10.1002/hbm.460030105; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; PREVETT MC, 1994, EPILEPSY RES, V19, P71, DOI 10.1016/0920-1211(94)90090-6; Price CJ, 1996, CEREB CORTEX, V6, P62, DOI 10.1093/cercor/6.1.62; PRICE CJ, 1994, BRAIN, V117, P1255, DOI 10.1093/brain/117.6.1255; RADHAKRISHNAN K, 1995, BRAIN, V118, P75, DOI 10.1093/brain/118.1.75; RANABADRAN K, 1990, INT J CLIN PHARM TH, V28, P47; SEEGER TF, 1984, BRAIN RES, V305, P303, DOI 10.1016/0006-8993(84)90436-0; Theodore WH, 1996, EPILEPSIA, V37, P796, DOI 10.1111/j.1528-1157.1996.tb00654.x; TORTELLA FC, 1988, TRENDS PHARMACOL SCI, V9, P36; TORTELLA FC, 1988, NEUROBIOLOGY AMINO A, P163; Weeks RA, 1997, J CEREBR BLOOD F MET, V17, P943, DOI 10.1097/00004647-199709000-00003; Wolf Peter, 1992, P281	33	74	74	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 19	1998	352	9132					952	955		10.1016/S0140-6736(97)09077-6	http://dx.doi.org/10.1016/S0140-6736(97)09077-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752818				2022-12-28	WOS:000076002200011
J	Mirzaei, S; Knoll, P; Lipp, RW; Wenzel, T; Koriska, K; Kohn, H				Mirzaei, S; Knoll, P; Lipp, RW; Wenzel, T; Koriska, K; Kohn, H			Bone scintigraphy in screening of torture survivors	LANCET			English	Article							STRESS-FRACTURES; DIAGNOSIS	Background In most developed countries, survivors of physical torture inflicted for political, religious, or ethnic reasons face ever more stringent review when seeking asylum. In Austria, asylum seekers are required by immigration authorities to undergo medical examination as part of the review. Bone scintigraphy can detect bone lesions that are not detectable clinically or radiologically. We assessed the value of bone scintigraphy as corroboration of alleged injuries. Methods Human-rights organisations referred 25 asylum seekers to us from countries where torture is practised. We included patients who claimed to have been beaten by the security forces in their home country because of political or religious conviction or ethnic origin. Injuries had been inflicted 4 months to 2 years (in one case 5 years) earlier. The patients (three women, 22 men) from 12 countries were categorised retrospectively into two groups: group A (n=12), tortured with blows from hard objects, and group B (n=13), tortured with blows from fists and kicks. We also used a control group of 25 individuals with the same age and sex distribution from the same countries who had no history of torture. Findings In group A, bone scans showed abnormalities in the area of alleged injury in all patients, whereas radiography was positive in only five patients. In group B, bone scans in the alleged areas of damage were positive in seven patients, but radiography yielded no positive outcomes. Among the controls there was one abnormal scan due to a known coxarthrosis. Interpretation Our preliminary results suggest that bone scintigraphy is a sensitive, non-invasive tool to document trauma some years after the actual injury.	Wilhelminenspital Stadt Wien, Dept Nucl Med, A-1171 Vienna, Austria; Wilhelminenspital Stadt Wien, Ludwig Boltzmann Inst Nucl Med, A-1171 Vienna, Austria; Karl Franzens Univ Graz, Dept Internal Med, Div Nucl Med & Endocrinol, A-8010 Graz, Austria; Univ Vienna, Dept Psychiat, A-1010 Vienna, Austria; Elisabeth Hosp, Dept Nucl Med, Vienna, Austria	Wilhelminenspital; Ludwig Boltzmann Institute; Wilhelminenspital; University of Graz; University of Vienna	Mirzaei, S (corresponding author), Wilhelminenspital Stadt Wien, Dept Nucl Med, A-1171 Vienna, Austria.		Mirzaei, Siroos/AAK-1715-2021	Wenzel, Thomas/0000-0003-3990-1773				CONWAY JJ, 1993, SEMIN NUCL MED, V23, P321, DOI 10.1016/S0001-2998(05)80111-4; GESLIEN GE, 1976, RADIOLOGY, V121, P683, DOI 10.1148/121.3.683; HAASE GM, 1980, J TRAUMA, V20, P873, DOI 10.1097/00005373-198010000-00009; HOREV G, 1990, PEDIATR RADIOL, V20, P469, DOI 10.1007/BF02075211; LOK V, 1991, LANCET, V337, P846, DOI 10.1016/0140-6736(91)92548-G; MARTIN P, 1983, SEMIN NUCL MED, V13, P104; MATIN P, 1979, J NUCL MED, V20, P1227; MONTGOMERY E, 1994, DAN MED BULL, V41, P588; Reeder MT, 1996, SPORTS MED, V22, P198, DOI 10.2165/00007256-199622030-00006; RICHARD P, 1979, J NUCL MED, V20, P1271; ROUB LW, 1979, RADIOLOGY, V132, P431, DOI 10.1148/132.2.431; SCHMIDT C, 1985, RADIOLOGE, V25, P104; SMITH FW, 1980, PEDIATR RADIOL, V10, P103, DOI 10.1007/BF01001749; SZASZ I, 1981, Clinical Nuclear Medicine, V6, P97, DOI 10.1097/00003072-198103000-00001; TAWN DJ, 1989, BRIT J RADIOL, V62, P790, DOI 10.1259/0007-1285-62-741-790	15	11	11	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 19	1998	352	9132					949	951		10.1016/S0140-6736(98)05049-1	http://dx.doi.org/10.1016/S0140-6736(98)05049-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752817				2022-12-28	WOS:000076002200010
J	Rigau-Perez, JG; Clark, GG; Gubler, DJ; Reiter, P; Sanders, RJ; Vorndam, AV				Rigau-Perez, JG; Clark, GG; Gubler, DJ; Reiter, P; Sanders, RJ; Vorndam, AV			Dengue and dengue haemorrhagic fever	LANCET			English	Article							LINKED IMMUNOSORBENT-ASSAY; POLYMERASE CHAIN-REACTION; BORNE DISEASE-CONTROL; AEDES-AEGYPTI; HEMORRHAGIC-FEVER; SHOCK SYNDROME; JAPANESE ENCEPHALITIS; COMMUNITY PARTICIPATION; VECTOR CONTROL; RISK-FACTORS	The incidence and geographical distribution of dengue have greatly increased in recent years. Dengue is an acute mosquito-transmitted viral disease characterised ny fever, headache, muscle and joint pains, rash, nausea, and vomiting. Some infections result in dengue haemorrhagic fever (DHF), a syndrome that in its most severe form can threaten the patient's life, primarily through increased vascular permeability and shock. The case fatality rate in patients with dengue shock syndrome can be as high as 44%. For decades, two distinct hypotheses to explain the mechanism of DHF have been debated-secondary infection or viral virulence. However, a combination of both now seems to be the plausible explanation. The geographical expansion of DHF presents the need for well-documented clinical, epidemiological, and virological descriptions of the syndrome; in the Americas. Biological and social research are essential to develop effective mosquito control, medications to reduce capillary leakage, and a safe tetravalent vaccine.	CDC, Dengue Branch, San Juan, PR 00921 USA; CDC, Div Vector Borne Infect Dis, San Juan, PR USA; CDC, Div Vector Borne Infect Dis, Ft Collins, CO USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Rigau-Perez, JG (corresponding author), CDC, Dengue Branch, 2 Calle Casia, San Juan, PR 00921 USA.	Jor1@cdc.gov						Bhamarapravati Natth, 1997, P367; BRAVO JR, 1987, T ROY SOC TROP MED H, V81, P816, DOI 10.1016/0035-9203(87)90041-1; BrisenoGarcia B, 1996, EMERG INFECT DIS, V2, P133, DOI 10.3201/eid0202.960210; Brown JL, 1996, T ROY SOC TROP MED H, V90, P140, DOI 10.1016/S0035-9203(96)90115-7; BURKE DS, 1982, J CLIN MICROBIOL, V16, P1034, DOI 10.1128/JCM.16.6.1034-1042.1982; BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172; Centers for Disease Control and Prevention (CDC), 1995, MMWR, V44, P21; Chambers TJ, 1997, VACCINE, V15, P1494, DOI 10.1016/S0264-410X(97)00195-3; Chaturvedi Umesh C., 1997, P291; Christophers S.R., 1960, AEDES AEGYPT L YELLO; CHUNGUE E, 1989, T ROY SOC TROP MED H, V83, P708, DOI 10.1016/0035-9203(89)90404-5; Chye JK, 1997, CLIN INFECT DIS, V25, P1374, DOI 10.1086/516126; CLARKE DH, 1958, AM J TROP MED HYG, V7, P561, DOI 10.4269/ajtmh.1958.7.561; COBRA C, 1995, AM J EPIDEMIOL, V142, P1204, DOI 10.1093/oxfordjournals.aje.a117579; de Wazieres B, 1998, LANCET, V351, P498, DOI 10.1016/S0140-6736(05)78686-4; Dietz V, 1996, P R Health Sci J, V15, P201; FOCKS DA, 1995, AM J TROP MED HYG, V53, P489, DOI 10.4269/ajtmh.1995.53.489; Gordon A J, 1989, Int Q Community Health Educ, V10, P193, DOI 10.2190/MJXC-5FCF-6UQD-NPCY; GORDON AJ, 1998, HLTH ED RES, V3, P399; Gubler D. J., 1988, The arboviruses: epidemiology and ecology. Volume II., P223; GUBLER DJ, 1981, AM J TROP MED HYG, V30, P1094, DOI 10.4269/ajtmh.1981.30.1094; GUBLER DJ, 1994, AM J TROP MED HYG, V50, P50, DOI 10.4269/ajtmh.1994.50.50; GUBLER DJ, 1978, AM J TROP MED HYG, V27, P581, DOI 10.4269/ajtmh.1978.27.581; Gubler DJ, 1996, ACTA TROP, V61, P169, DOI 10.1016/0001-706X(95)00103-L; GUBLER DJ, 1989, AM J TROP MED HYG, V40, P571, DOI 10.4269/ajtmh.1989.40.571; GUBLER DJ, 1981, B WORLD HEALTH ORGAN, V59, P623; GUBLER DJ, 1984, AM J TROP MED HYG, V33, P158, DOI 10.4269/ajtmh.1984.33.158; GUBLER DJ, 1976, AM J TROP MED HYG, V25, P146, DOI 10.4269/ajtmh.1976.25.146; GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55; Gubler DJ, 1997, DENGUE DENGUE HEMORR; Gubler DJ, 2014, DENGUE AND DENGUE HEMORRHAGIC FEVER, 2ND EDITION, P1, DOI 10.1079/9781845939649.0001; Guzman M. G., 1997, Revista Panamericana de Salud Publica, V1, P193; Halstead S., 1992, DENGUE WORLDWIDE PRO, DOI DOI 10.3201/eid1408.080287; HALSTEAD SB, 1969, AM J TROP MED HYG, V18, P984, DOI 10.4269/ajtmh.1969.18.984; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HALSTEAD SB, 1989, REV INFECT DIS, V11, pS830; HALSTEAD SB, 1965, YALE J BIOL MED, V37, P434; HALSTEAD SB, 1993, DIS CONTROL PRIORITI, P303; Halstead Scott B., 1997, P23; HOBER D, 1993, AM J TROP MED HYG, V48, P324, DOI 10.4269/ajtmh.1993.48.324; INNIS BL, 1989, AM J TROP MED HYG, V40, P418, DOI 10.4269/ajtmh.1989.40.418; Kalayanarooj S, 1997, J INFECT DIS, V176, P313, DOI 10.1086/514047; Karp B E, 1997, Md Med J, V46, P299; Kinney RM, 1997, VIROLOGY, V230, P300, DOI 10.1006/viro.1997.8500; KLIKS SC, 1988, AM J TROP MED HYG, V38, P411, DOI 10.4269/ajtmh.1988.38.411; KOOPMAN JS, 1991, AM J EPIDEMIOL, V133, P1168, DOI 10.1093/oxfordjournals.aje.a115829; KUBERSKI T, 1977, AM J TROP MED HYG, V26, P775, DOI 10.4269/ajtmh.1977.26.775; Kuno G, 1995, EPIDEMIOL REV, V17, P321, DOI 10.1093/oxfordjournals.epirev.a036196; KURANE I, 1994, ARCH VIROL, P59; Laferl H, 1997, LANCET, V350, P1072, DOI 10.1016/S0140-6736(97)08170-1; LAM SK, 1996, NEUROL J SE ASIA, V20, P3; LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992; LEONTSINI E, 1993, T ROY SOC TROP MED H, V87, P267, DOI 10.1016/0035-9203(93)90120-F; LLOYD LS, 1994, AM J TROP MED HYG, V50, P401, DOI 10.4269/ajtmh.1994.50.401; Lum LCS, 1996, AM J TROP MED HYG, V54, P256, DOI 10.4269/ajtmh.1996.54.256; Meltzer MI, 1998, AM J TROP MED HYG, V59, P265, DOI 10.4269/ajtmh.1998.59.265; MONATH TP, 1996, FIELDS VIROLOGY, P961; MORENS DM, 1994, CLIN INFECT DIS, V19, P500, DOI 10.1093/clinids/19.3.500; MORIER L, 1987, LANCET, V1, P1028, DOI 10.1016/S0140-6736(87)92289-6; NEWTON EAC, 1992, AM J TROP MED HYG, V47, P709, DOI 10.4269/ajtmh.1992.47.709; NIMMANNITYA S, 1969, AM J TROP MED HYG, V18, P954, DOI 10.4269/ajtmh.1969.18.954; NIMMANNITYA S, 1987, Southeast Asian Journal of Tropical Medicine and Public Health, V18, P398; Nimmannitya Suchitra, 1994, Tropical Medicine, V36, P249; Pan American Health Organization, 1994, PHAO SCI PUBL, V548, P3; Pan American Health Organization, 1994, PAHO SCI PUBL, V548; Pinheiro Fransisco P., 1997, World Health Statistics Quarterly, V50, P161; PUTNAM JL, 1995, J PARASITOL, V81, P170, DOI 10.2307/3283915; RAMIREZRONDA CH, 1994, INFECT DIS CLIN N AM, V8, P107; Reiter Paul, 1997, P425; RicoHesse R, 1997, VIROLOGY, V230, P244, DOI 10.1006/viro.1997.8504; Rigau-Perez J G, 1997, Rev Panam Salud Publica, V1, P381; Rigau-Perez Jose G., 1997, P405; ROSENBAUM J, 1995, AM J TROP MED HYG, V53, P111, DOI 10.4269/ajtmh.1995.53.111; RUSSELL PK, 1967, J IMMUNOL, V99, P291; SANGKAWIBHA N, 1984, AM J EPIDEMIOL, V120, P653, DOI 10.1093/oxfordjournals.aje.a113932; SCHOFIELD CJ, 1993, B ENTOMOL RES, V83, P1, DOI 10.1017/S0007485300041717; SCOTT RM, 1976, AM J TROP MED HYG, V25, P866, DOI 10.4269/ajtmh.1976.25.866; SHARP TW, 1995, AM J TROP MED HYG, V53, P89, DOI 10.4269/ajtmh.1995.53.89; SILER J. F., 1926, PHILIPPINE JOUR SCI, V29, P1; SUMARMO, 1983, B WORLD HEALTH ORGAN, V61, P693; TASSNIYOM S, 1993, PEDIATRICS, V92, P111; Tassniyom S, 1997, J PEDIATR-US, V131, P525, DOI 10.1016/S0022-3476(97)70055-6; THISYAKORN U, 1993, CLIN INFECT DIS, V16, P295, DOI 10.1093/clind/16.2.295; Thisyakorn Usa, 1994, Journal of the Medical Association of Thailand, V77, P410; TORRES EM, 1995, SALUD PUBLICA MEX S, V37, P29; Trent Dennis W., 1997, P379; Trofa AF, 1997, JAMA-J AM MED ASSOC, V277, P1546, DOI 10.1001/jama.277.19.1546; Vaughn DW, 1997, J INFECT DIS, V176, P322, DOI 10.1086/514048; Vorndam Vance, 1997, P313; Whiteford LM, 1997, MED ANTHROPOL Q, V11, P202, DOI 10.1525/maq.1997.11.2.202; WHO, 1986, DENG HAEM FEV DIAGN, P7; WHO, 1986, DENG HAEM FEV DIAGN; WINCH P, 1991, J TROP MED HYG, V94, P377; WINCH P, 1992, HEALTH POLICY PLANN, V7, P342, DOI 10.1093/heapol/7.4.342; WINCH PJ, 1994, ACTA TROP, V56, P327, DOI 10.1016/0001-706X(94)90104-X	95	610	655	1	78	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 19	1998	352	9132					971	977		10.1016/S0140-6736(97)12483-7	http://dx.doi.org/10.1016/S0140-6736(97)12483-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752834				2022-12-28	WOS:000076002200039
J	Bredt, DS				Bredt, DS			Sorting out genes that regulate epithelial and neuronal polarity	CELL			English	Review							NITRIC-OXIDE SYNTHASE; K+ CHANNELS; PROTEIN; CELLS		Univ Calif San Francisco, Sch Med, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Bredt, DS (corresponding author), Univ Calif San Francisco, Sch Med, Dept Physiol, 513 Parnassus Ave, San Francisco, CA 94143 USA.							Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; Hata Y, 1996, J NEUROSCI, V16, P2488; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Keller P, 1997, J CELL SCI, V110, P3001; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KOMAU HC, 1995, SCIENCE, V269, P1737; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MOSTOV KE, 1995, BIOESSAYS, V17, P129, DOI 10.1002/bies.950170208; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545	22	54	61	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					691	694		10.1016/S0092-8674(00)81727-4	http://dx.doi.org/10.1016/S0092-8674(00)81727-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753315	Bronze			2022-12-28	WOS:000076021200001
J	Keefer, DK; deFrance, SD; Moseley, ME; Richardson, JB; Satterlee, DR; Day-Lewis, A				Keefer, DK; deFrance, SD; Moseley, ME; Richardson, JB; Satterlee, DR; Day-Lewis, A			Early maritime economy and EL Nino events at Quebrada Tacahuay, Peru	SCIENCE			English	Article							NORTHERN COASTAL PERU; EARLY HISTORY; AMERICA; CORMORANTS; RECORD	The archaeological site of Quebrada Tacahuay, Peru, dates to 12,700 to 12,500 calibrated years before the present (10,770 to 10,530 carbon-14 years, before the present). it contains some of the oldest evidence of maritime-based economic activity in the New World. Recovered materials include a hearth, Lithic cutting tools and flakes, and abundant processed marine fauna, primarily seabirds and fish. Sediments below and above the occupation Layer were probably generated by El Nino events, indicating that El Nino was active during the Pleistocene as well as during the early and middle Holocene.	US Geol Survey, Menlo Park, CA 94025 USA; Corpus Christi Museum Sci & Hist, Corpus Christi, TX 78401 USA; Univ Florida, Dept Anthropol, Gainesville, FL 32611 USA; Carnegie Museum Nat Hist, Div Anthropol, Pittsburgh, PA 15206 USA; Univ Pittsburgh, Dept Anthropol, Pittsburgh, PA 15206 USA; NE Louisiana Univ, Dept Geosci, Monroe, LA 71209 USA; Stanford Univ, Dept Geophys, Stanford, CA 94305 USA	United States Department of the Interior; United States Geological Survey; State University System of Florida; University of Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Louisiana System; University of Louisiana Monroe; Stanford University	Keefer, DK (corresponding author), US Geol Survey, 345 Middlefield Rd,MS 977, Menlo Park, CA 94025 USA.							AINLEY DG, 1981, CONDOR, V83, P120, DOI 10.2307/1367418; ALDENDERFER M, IN PRESS QUAT INC; Bard E, 1996, NATURE, V382, P241, DOI 10.1038/382241a0; CAVIEDES CN, 1984, GEOGR REV, V74, P267, DOI 10.2307/214939; CHAUCHAT C, 1992, CAHIERS QUATEMAIRE, V18; Chauchat Claude, 1988, PERUVIAN PREHISTORY, P41; DeVries TJ, 1997, SCIENCE, V276, P965, DOI 10.1126/science.276.5314.965; Diaz Amanda, 1993, Bulletin de l'Institut Francais d'Etudes Andines, V22, P159; DUFFY DC, 1983, CONDOR, V85, P305, DOI 10.2307/1367066; Moseley M.E., 1975, MARITIME FDN ANDEAN; Moseley Michael, 1992, ANDEAN PAST, V3, P5; Ortlieb L, 1996, QUATERNARY SCI REV, V15, P857, DOI 10.1016/S0277-3791(96)00062-5; ORTLIEB L, 1993, GLOBAL PLANET CHANGE, V7, P181, DOI 10.1016/0921-8181(93)90049-T; Ortlieb Luc, 1990, Boletin de la Sociedad Geologica del Peru, V81, P127; Ossa P., 1978, EARLY MAN AM CIRCUMP, P290; Richardson III J. B., 1978, EARLY MAN AM CIRCUMP, V1, P274; RICHARDSON JB, 1992, REV ARQUEOLOGIA AM, V6, P71; Roosevelt AC, 1996, SCIENCE, V272, P373, DOI 10.1126/science.272.5260.373; Sandweiss DH, 1996, SCIENCE, V273, P1531, DOI 10.1126/science.273.5281.1531; Sandweiss DH, 1998, SCIENCE, V281, P1830, DOI 10.1126/science.281.5384.1830; Sandweiss DH, 1997, SCIENCE, V276, P966; SANDWEISS DH, 1989, BR ARCHAEOL REP INT, V5451, P35; *SOC AM ARCH, 1998, SOC AM ARCH 63 ANN M; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; Wells L. E., 1988, THESIS STANFORD U ST; WELLS LE, 1990, GEOLOGY, V18, P1134, DOI 10.1130/0091-7613(1990)018<1134:HHOTEN>2.3.CO;2; Wells LE, 1997, SCIENCE, V276, P966; WELLS LE, 1987, J GEOPHYS RES-OCEANS, V92, P14463, DOI 10.1029/JC092iC13p14463	28	168	172	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1833	1835		10.1126/science.281.5384.1833	http://dx.doi.org/10.1126/science.281.5384.1833			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743491				2022-12-28	WOS:000076007100046
J	Donchin, O; Gribova, A; Steinberg, O; Bergman, H; Vaadia, E				Donchin, O; Gribova, A; Steinberg, O; Bergman, H; Vaadia, E			Primary motor cortex is involved in bimanual coordination	NATURE			English	Article							NEURONAL-ACTIVITY; CORTICAL AREAS; RHESUS-MONKEY; MOVEMENTS; HAND; TASK; ARM; SYNCHRONIZATION; CONNECTIONS; DIRECTION	Many voluntary movements involve coordination between the limbs(1,2). However, there have been very few attempts to study the neuronal mechanisms that mediate this coordination. Here we have studied the activity of cortical neurons while monkeys performed tasks that required coordination between the two arms. We found that most neurons in the primary motor cortex (MI) show activity specific to bimanual movements (bimanual-related activity), which is strikingly different from the activity of the same neurons during unimanual movements. Moreover, units in the supplementary motor area (SMA; the area of cortex most often associated with bimanual coordination(3)) showed no more bimanual-related activity than units in MI. Our results challenge the classic view that MI controls the contralateral (opposite) side of the body and that SMA. is responsible for the coordination of the arms. Rather, our data suggest that both cortical areas share the control of bilateral coordination.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Physiol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Ctr Neural Computat, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Vaadia, E (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Physiol, IL-91120 Jerusalem, Israel.	eilon@hbf.huji.ac.il	Vaadia, Eilon/E-9347-2011; Donchin, Opher/A-4389-2008	Donchin, Opher/0000-0003-0963-4467				BRINKMAN C, 1979, J NEUROPHYSIOL, V42, P681, DOI 10.1152/jn.1979.42.3.681; BRINKMAN C, 1984, J NEUROSCI, V4, P918; BRINKMAN J, 1973, BRAIN, V96, P653, DOI 10.1093/brain/96.4.653; CRAMMOND D J, 1991, Society for Neuroscience Abstracts, V17, P308; Donchin O., 1996, Society for Neuroscience Abstracts, V22, P2022; EVARTS EV, 1968, J NEUROPHYSIOL, V31, P14, DOI 10.1152/jn.1968.31.1.14; FRANZ EA, 1991, ACTA PSYCHOL, V77, P137, DOI 10.1016/0001-6918(91)90028-X; GEORGOPOULOS AP, 1992, SCIENCE, V256, P1692, DOI 10.1126/science.256.5064.1692; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; JENNY AB, 1979, J COMP NEUROL, V188, P137, DOI 10.1002/cne.901880111; JONES EG, 1986, CEREB CORTEX, V5, P113; KAROL EA, 1971, BRAIN, V94, P471, DOI 10.1093/brain/94.3.471; KELSO JAS, 1979, J EXP PSYCHOL HUMAN, V5, P229, DOI 10.1037/0096-1523.5.2.229; KIM SG, 1993, SCIENCE, V261, P615, DOI 10.1126/science.8342027; LECAS JC, 1986, J NEUROPHYSIOL, V56, P1680, DOI 10.1152/jn.1986.56.6.1680; LUPPINO G, 1993, J COMP NEUROL, V338, P114, DOI 10.1002/cne.903380109; MATSUZAKA Y, 1992, J NEUROPHYSIOL, V68, P653, DOI 10.1152/jn.1992.68.3.653; MUAKKASSA KF, 1979, BRAIN RES, V177, P176, DOI 10.1016/0006-8993(79)90928-4; Murthy VN, 1996, J NEUROPHYSIOL, V76, P3968, DOI 10.1152/jn.1996.76.6.3968; Perepelkin P. D., 1996, Society for Neuroscience Abstracts, V22, P2022; Roelfsema PR, 1997, NATURE, V385, P157, DOI 10.1038/385157a0; ROUILLER EM, 1994, EXP BRAIN RES, V102, P227; SCHWARTZ AB, 1994, SCIENCE, V265, P540, DOI 10.1126/science.8036499; Scott SH, 1997, J NEUROPHYSIOL, V77, P1016, DOI 10.1152/jn.1997.77.2.1016; Taira M, 1996, EXP BRAIN RES, V109, P367; TANJI J, 1988, J NEUROPHYSIOL, V60, P325, DOI 10.1152/jn.1988.60.1.325; TANJI J, 1987, NATURE, V327, P618, DOI 10.1038/327618a0; TOKUNO H, 1993, J COMP NEUROL, V333, P199, DOI 10.1002/cne.903330206; Wiesendanger M, 1996, ADV NEUROL, V70, P85; WIESENDANGER M, 1993, INT CONGR SER, V1024, P253	30	223	226	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	1998	395	6699					274	278		10.1038/26220	http://dx.doi.org/10.1038/26220			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751054				2022-12-28	WOS:000075974600050
J	Lessard, N; Pare, M; Lepore, F; Lassonde, W				Lessard, N; Pare, M; Lepore, F; Lassonde, W			Early-blind human subjects localize sound sources better than sighted subjects	NATURE			English	Article							CATS SUPERIOR COLLICULUS; AUDITORY SPACE; CEREBRAL-CORTEX; PLASTICITY; NEURONS; MAP; COMPENSATION; MIDBRAIN; MOTION; BRAIN	Do blind persons develop capacities of their remaining senses that exceed those of sighted individuals? Besides anecdotal suggestions, two views based on experimental studies have been advanced(1). The first proposes that blind individuals should be severely impaired, given that vision is essential to develop spatial concepts(2), The second suggests that compensation occurs through the remaining senses, allowing them to develop an accurate concept of space(3). Here we investigate how an ecologically critical function, namely three-dimensional spatial mapping, is carried out by early-blind individuals with or without residual vision. Subjects were tested under monaural and binaural listening conditions. We find that early-blind subjects can map the auditory environment with equal or better accuracy than sighted subjects. Furthermore, unlike sighted subjects, they can correctly localize sounds monaurally, Surprisingly, blind individuals with residual peripheral vision localized sounds less precisely than sighted or totally blind subjects, confirming that compensation varies according to the aetiology and extent of blindness(4). Our results resolve a long-standing controversy in that they provide behavioural evidence that totally blind individuals have better auditory ability than sighted subjects, enabling them to compensate for their loss of vision.	Univ Montreal, Dept Psychol, Grp Rech Neuropsychol Expt, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Ctr Rech Sci Neurol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Lepore, F (corresponding author), Univ Montreal, Dept Psychol, Grp Rech Neuropsychol Expt, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	leporef@ere.umontreal.ca						Axelrod S., 1959, EFFECTS EARLY BLINDN; BUTLER RA, 1987, PERCEPT PSYCHOPHYS, V41, P1, DOI 10.3758/BF03208206; CHALUPA LM, 1977, J PHYSIOL-LONDON, V270, P595, DOI 10.1113/jphysiol.1977.sp011971; Feldman DE, 1997, J NEUROSCI, V17, P6820; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; KING AJ, 1993, EXP PHYSIOL, V78, P559, DOI 10.1113/expphysiol.1993.sp003708; KUJALA T, 1992, ELECTROEN CLIN NEURO, V84, P469, DOI 10.1016/0168-5597(92)90034-9; Kujala T, 1997, PSYCHOPHYSIOLOGY, V34, P213, DOI 10.1111/j.1469-8986.1997.tb02134.x; KUJALA T, 1995, EXP BRAIN RES, V104, P519; MIDDLEBROOKS JC, 1984, J NEUROSCI, V4, P2621; POIRIER P, 1993, BRAIN, V116, P53, DOI 10.1093/brain/116.1.53; RAUSCHECKER JP, 1994, EUR J NEUROSCI, V6, P149, DOI 10.1111/j.1460-9568.1994.tb00256.x; RAUSCHECKER JP, 1983, EXP BRAIN RES, V50, P69; RAUSCHECKER JP, 1993, J NEUROSCI, V13, P4538; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; RICE C, 1970, AM F BLIND RES B, V22, P1, DOI DOI 10.3758/S13414-011-0160-4; SLATTERY WH, 1994, HEARING RES, V75, P38, DOI 10.1016/0378-5955(94)90053-1; SPITZER MW, 1991, SCIENCE, V254, P721, DOI 10.1126/science.1948053; STUMPF E, 1992, EXP BRAIN RES, V88, P158, DOI 10.1007/BF02259137; TORONCHUK JM, 1992, EXP BRAIN RES, V88, P169, DOI 10.1007/BF02259138	20	413	423	1	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1998	395	6699					278	280		10.1038/26228	http://dx.doi.org/10.1038/26228			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751055				2022-12-28	WOS:000075974600051
J	D'Amico, AV; Whittington, R; Malkowicz, SB; Schultz, D; Blank, K; Broderick, GA; Tomaszewski, JE; Renshaw, AA; Kaplan, I; Beard, CJ; Wein, A				D'Amico, AV; Whittington, R; Malkowicz, SB; Schultz, D; Blank, K; Broderick, GA; Tomaszewski, JE; Renshaw, AA; Kaplan, I; Beard, CJ; Wein, A			Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADJUVANT THERAPY; ANTIGEN; CARCINOMA; ADENOCARCINOMA; IMPLANTATION; MANAGEMENT; FAILURE; RISK	Context.-Interstitial radiation (implant) therapy is used to treat clinically localized adenocarcinoma of the prostate, but how it compares with other treatments is not known. Objective.-To estimate control of prostate-specific antigen (PSA) after radical prostatectomy (RP), external beam radiation (RT), or implant with or without neoadjuvant androgen deprivation therapy in patients with clinically localized prostate cancer. Design.-Retrospective cohort study of outcome data compared using Cox regression multivariable analyses. Setting and Patients.-A total of 1872 men treated between January 1989 and October 1997 with an RP (n = 888) or implant with or without neoadjuvant androgen deprivation therapy (n = 218) at the Hospital of the University of Pennsylvania, Philadelphia, or RT (n = 766) at the Joint Center for Radiation Therapy, Boston, Mass, were enrolled. Main Outcome Measure.-Actuarial freedom from PSA failure (defined as PSA outcome), Results.-The relative risk (RR) of PSA failure in low-risk patients (stage Tie, T2a and PSA level less than or equal to 10 ng/mL and Gleason score less than or equal to 6) treated using RT, implant plus androgen deprivation therapy, or implant therapy was 1.1 (95% confidence interval [CI], 0.5-2.7), 0.5 (95% CI, 0.1-1.9), and 1.1 (95% CI, 0.3-3.6), respectively, compared with those patients treated with RP. The RRs of PSA failure in the intermediate-risk patients (stage T2b or Gleason score of 7 or PSA level >10 and less than or equal to 20 ng/mL) and high-risk patients (stage T2c or PSA level >20 ng/mL or Gleason score greater than or equal to 8) treated with implant compared with RP were 3.1 (95% CI, 1.5-6.1) and 3.0 (95% CI, 1.8-5.0), respectively, The addition of androgen deprivation to implant therapy did not improve PSA outcome in high-risk patients but resulted in a PSA outcome that was not statistically different compared with the results obtained using RP or RT in intermediate-risk patients. These results were unchanged when patients were stratified using the traditional rankings of biopsy Gleason scores of 2 through 4 vs 5 through 6 vs 7 vs 8 through 10, Conclusions.-Low-risk patients had estimates of 5-year PSA outcome after treatment with RP, RT, or implant with or without neoadjuvant androgen deprivation that were not statistically different, whereas intermediate- and high-risk patients treated with RP or RT did better then those treated by implant, Prospective randomized trials are needed to verify these findings.	Harvard Univ, Sch Med, Joint Ctr Radiat Therapy, Boston, MA 02215 USA; Hosp Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Urol, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; Millersville Univ, Dept Math, Millersville, PA 17551 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Pennsylvania State System of Higher Education (PASSHE); Millersville University of Pennsylvania; Harvard University; Brigham & Women's Hospital	D'Amico, AV (corresponding author), Harvard Univ, Sch Med, Joint Ctr Radiat Therapy, 330 Brookline Ave,5th Floor, Boston, MA 02215 USA.		Broderick, Gregory/R-1356-2019	Broderick, Gregory/0000-0003-2949-5425				Adolfsson J, 1997, UROLOGY, V50, P722, DOI 10.1016/S0090-4295(97)00320-8; Beahrs O. H., 1992, AM JOINT COMMITTEE C; BLASKO JC, 1995, J UROLOGY, V154, P1096, DOI 10.1016/S0022-5347(01)66985-4; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; COX DR, 1972, J R STAT SOC B, V34, P187; Cox JD, 1997, INT J RADIAT ONCOL, V37, P1035; DAmico AV, 1997, J CLIN ONCOL, V15, P1465, DOI 10.1200/JCO.1997.15.4.1465; DAmico AV, 1997, INT J RADIAT ONCOL, V37, P1053, DOI 10.1016/S0360-3016(96)00633-5; DAmico AV, 1997, J UROLOGY, V158, P1422, DOI 10.1016/S0022-5347(01)64230-7; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; HANKS GE, 1995, J UROLOGY, V154, P456, DOI 10.1016/S0022-5347(01)67073-3; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kupelian PA, 1997, INT J RADIAT ONCOL, V37, P1043, DOI 10.1016/S0360-3016(96)00590-1; LEE WR, 1995, J CLIN ONCOL, V13, P464, DOI 10.1200/JCO.1995.13.2.464; Lerner SE, 1996, J UROLOGY, V156, P137, DOI 10.1016/S0022-5347(01)65967-6; Neter J, 1983, APPL LINEAR REGRESSI, P150; OESTERLING JE, 1995, J UROLOGY, V154, P1090, DOI 10.1016/S0022-5347(01)66984-2; PARTIN AW, 1995, UROLOGY, V45, P831, DOI 10.1016/S0090-4295(99)80091-0; PISANSKY TM, 1993, J CLIN ONCOL, V11, P2158, DOI 10.1200/JCO.1993.11.11.2158; Pisansky TM, 1997, CANCER-AM CANCER SOC, V79, P337, DOI 10.1002/(SICI)1097-0142(19970115)79:2<337::AID-CNCR17>3.0.CO;2-1; Ragde H, 1997, CANCER, V80, P442, DOI 10.1002/(SICI)1097-0142(19970801)80:3<442::AID-CNCR12>3.0.CO;2-X; Wallner K, 1996, J CLIN ONCOL, V14, P449, DOI 10.1200/JCO.1996.14.2.449; ZAGARS GK, 1995, INT J RADIAT ONCOL, V32, P293, DOI 10.1016/0360-3016(95)00077-C; ZIETMAN AL, 1994, J UROLOGY, V151, P640, DOI 10.1016/S0022-5347(17)35036-X; ZIETMAN AL, 1994, UROLOGY, V43, P828, DOI 10.1016/0090-4295(94)90144-9	25	3377	3450	3	111	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1998	280	11					969	974		10.1001/jama.280.11.969	http://dx.doi.org/10.1001/jama.280.11.969			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JC	9749478	Bronze			2022-12-28	WOS:000075891400029
J	Benedek, TG				Benedek, TG			Treatment of systemic lupus erythematosus: from cod-liver oil to cyclosporin	LANCET			English	Article									Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15217 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Benedek, TG (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, 1130 Wightman St, Pittsburgh, PA 15217 USA.							CRISSEY JT, 1956, ARCH DERMATOL, V74, P69, DOI 10.1001/archderm.1956.01550070071013; Davidson AM, 1938, ARCH DERMATOL SYPH, V37, P247, DOI 10.1001/archderm.1938.01480080080009; DUBOIS EL, 1954, ARCH INTERN MED, V93, P667, DOI 10.1001/archinte.1954.00240290025003; DUHRING IA, 1881, PRACTICAL TREATISE D, P440; Friedberg CK, 1936, ARCH INTERN MED, V58, P662, DOI 10.1001/archinte.1936.00170140087006; GOLDMAN L, 1953, JAMA-J AM MED ASSOC, V152, P1428, DOI 10.1001/jama.1953.63690150002009a; HASERICK JR, 1953, AMA ARCH DERM SYPH, V68, P714, DOI 10.1001/archderm.1953.01540120098014; HENKIND P, 1963, NEW ENGL J MED, V269, P433, DOI 10.1056/NEJM196308292690901; Hutchinson J, 1880, Br Med J, V1, P650; Keil H, 1937, ARCH DERMATOL SYPH, V36, P729, DOI 10.1001/archderm.1937.01480040046004; LANSBURY J, 1953, COMROES ARTHRITIS AL, P665; MacLeod JMH, 1908, LANCET, V2, P1271; MONTGOMERY H, 1949, ARCH DERMATOL SYPH, V60, P356, DOI 10.1001/archderm.1949.01530030052006; MULLINS JF, 1956, JAMA-J AM MED ASSOC, V161, P879, DOI 10.1001/jama.1956.62970090020017k; OLEARY PA, 1953, AMA ARCH DERM SYPH, V67, P633, DOI 10.1001/archderm.1953.01540060095017; PAGE F, 1951, LANCET, V261, P755; Payne JF, 1894, CLIN J, V4, P223; PISTINER M, 1991, SEMIN ARTHRITIS RHEU, V21, P55, DOI 10.1016/0049-0172(91)90057-7; Schamberg JF, 1927, ARCH DERMATOL SYPH, V15, P119, DOI 10.1001/archderm.1927.02370260003001; STEINBER.AD, 1971, ANN INTERN MED, V75, P165, DOI 10.7326/0003-4819-75-2-165; TOKUDA M, 1994, ARTHRITIS RHEUM, V37, P551, DOI 10.1002/art.1780370416; Tolman MM, 1938, NEW ENGL J MED, V219, P688, DOI 10.1056/NEJM193811032191802; ZIFF M, 1958, ARTHRITIS RHEUM-US, V1, P332, DOI 10.1002/art.1780010405	23	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	1998	352	9131					901	902		10.1016/S0140-6736(98)11008-5	http://dx.doi.org/10.1016/S0140-6736(98)11008-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9743005				2022-12-28	WOS:000075857300051
J	Ciccone, A; Motto, C; Aritzu, E; Piana, A; Candelise, L				Ciccone, A; Motto, C; Aritzu, E; Piana, A; Candelise, L		MAST-I Collaborative Grp	Risk of aspirin use plus thrombolysis after acute ischaemic stroke: a further MAST-I analysis	LANCET			English	Article							ACUTE ISCHEMIC STROKE; THERAPY		Univ Milano, Ist Clin Neurol, IRCCS, Osped Maggiore Policlin, I-20162 Milano, Italy; Osped Niguarda Ca Granda, Div Neurol, I-20162 Milano, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Ospedale Niguarda Ca' Granda	Ciccone, A (corresponding author), Univ Milano, Ist Clin Neurol, IRCCS, Osped Maggiore Policlin, I-20162 Milano, Italy.	Alfonso.ciccone@pmp.it	Ciccone, Alfonso/AAB-6942-2022	Ciccone, Alfonso/0000-0002-4590-3575				Adams HP, 1996, CIRCULATION, V94, P1167, DOI 10.1161/01.CIR.94.5.1167; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; CANDELISE L, 1995, LANCET, V346, P1509; Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5	4	10	10	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					880	880		10.1016/S0140-6736(05)60007-4	http://dx.doi.org/10.1016/S0140-6736(05)60007-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742986				2022-12-28	WOS:000075857300016
J	Houdijk, APJ; Rijnsburger, ER; Jansen, J; Wesdorp, RIC; Weiss, JK; McCamish, MA; Teerlink, T; Meuwissen, SGM; Haarman, HJTM; Thijs, LG; van Leeuwen, PAM				Houdijk, APJ; Rijnsburger, ER; Jansen, J; Wesdorp, RIC; Weiss, JK; McCamish, MA; Teerlink, T; Meuwissen, SGM; Haarman, HJTM; Thijs, LG; van Leeuwen, PAM			Randomised trial of glutamine-enriched enteral nutrition on infectious morbidity in patients with multiple trauma	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; PARENTERAL-NUTRITION; SOLUBLE RECEPTORS; SEPTIC MORBIDITY; ABDOMINAL-TRAUMA; INJURY; GUT; SEVERITY; RELEASE; SEPSIS	Background Infections are an important cause of morbidity and mortality in patients with multiple trauma. Studies in both animals and human beings have suggested that glutamine-enriched nutrition decreases the number of infections. Methods Patients with multiple trauma with an expected survival of more than 48 h, and who had an Injury Severity Score of 20 or more, were randomly allocated glutamine-supplemented enteral nutrition or a balanced, isonitrogenous, isocaloric enteral-feeding regimen along with usual care. Each patient was assessed every 8 h for infection, the primary endpoint. Data were analysed both per protocol, which included enteral feeding for at least 5 days, and by intention to treat. Findings 72 patients were enrolled and 60 received enteral feeding (29 glutamine-supplemented) for at least 5 days. Five (17%) of 29 patients in the glutamine-supplemented group had pneumonia compared with 14 (45%) of 31 patients in the control group (p<0.02). Bacteraemia occurred in two (7%) patients in glutamine group and 13 (42%) in the control group (p<0.005). One patient in the glutamine group had sepsis compared with eight (26%) patients in the control group (p<0.02). Interpretation There was a low frequency of pneumonia, sepsis, and bacteraemia in patients with multiple trauma who received glutamine-supplemented enteral nutrition. Larger studies are needed to investigate whether glutamine-supplemented enteral nutrition reduces mortality.	Free Univ Amsterdam Hosp, Dept Surg, NL-1081 HV Amsterdam, Netherlands; Free Univ Amsterdam Hosp, Dept Clin Chem, NL-1081 HV Amsterdam, Netherlands; Free Univ Amsterdam Hosp, Dept Gastroenterol, NL-1081 HV Amsterdam, Netherlands; Free Univ Amsterdam Hosp, Dept Acute Internal Med, NL-1081 HV Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands; Abbott Labs, Ross Prod Div, Columbus, OH USA; Ohio State Univ, Dept Med, Columbus, OH 43210 USA	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam; Abbott Laboratories; University System of Ohio; Ohio State University	van Leeuwen, PAM (corresponding author), Free Univ Amsterdam Hosp, Dept Surg, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.		Xia, Xianfeng/F-9169-2011					BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BEMELMAN FJ, 1994, NEPHROL DIAL TRANSPL, V9, P1786; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BORDER JR, 1987, ANN SURG, V206, P427, DOI 10.1097/00000658-198710000-00004; CINAT ME, 1994, J AM COLL SURGEONS, V179, P529; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; ERTEL W, 1995, J TRAUMA, V39, P879, DOI 10.1097/00005373-199511000-00011; GODFRIED MH, 1993, AIDS, V7, P33, DOI 10.1097/00002030-199301000-00005; HARRIS JA, 1919, CARNEGIE I WASHINGTO, V279; HOCH RC, 1993, CRIT CARE MED, V21, P839, DOI 10.1097/00003246-199306000-00010; HOUDIJK APJ, 1994, JPEN-PARENTER ENTER, V18, P422, DOI 10.1177/0148607194018005422; HUDIJK APJ, 1994, AM J PHYSIOL, V297, pG1035; KIRK SJ, 1990, J PARENTER ENTER NUT, V14, P226; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; Long CL, 1996, J TRAUMA, V40, P97, DOI 10.1097/00005373-199601000-00018; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; NEWSHOLME EA, 1985, BIOSCIENCE REP, V5, P393, DOI 10.1007/BF01116556; ODWYER ST, 1989, JPEN-PARENTER ENTER, V13, P579, DOI 10.1177/0148607189013006579; OMAHONY JB, 1984, J TRAUMA, V24, P869, DOI 10.1097/00005373-198410000-00001; RABINOVICI R, 1993, J TRAUMA, V35, P698, DOI 10.1097/00005373-199311000-00008; SOUBA WW, 1990, J SURG RES, V48, P1, DOI 10.1016/0022-4804(90)90136-P; SOUBA WW, 1990, J SURG RES, V48, P383, DOI 10.1016/0022-4804(90)90080-L; TAN LR, 1993, J TRAUMA, V34, P634, DOI 10.1097/00005373-199305000-00004; TEERLINK T, 1994, CLIN CHEM, V40, P245; TRAN DD, 1993, SURGERY, V114, P21; VANDERHULST RRWJ, 1993, LANCET, V341, P1363, DOI 10.1016/0140-6736(93)90939-E; WINDMUELLER HG, 1980, J BIOL CHEM, V255, P107; ZIEGLER TR, 1992, ANN INTERN MED, V116, P821, DOI 10.7326/0003-4819-116-10-821	29	448	473	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					772	776		10.1016/S0140-6736(98)02007-8	http://dx.doi.org/10.1016/S0140-6736(98)02007-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737282				2022-12-28	WOS:000075762700011
J	Laurance, J				Laurance, J			This is what the game is about	LANCET			English	Editorial Material									The Independent, London E14 5DL, England		Laurance, J (corresponding author), The Independent, 1 Canada Sq,Canary Wharf, London E14 5DL, England.							Deary IJ, 1998, LANCET, V351, P1726, DOI 10.1016/S0140-6736(97)10317-8	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 6	1998	351	9117					1727	1728		10.1016/S0140-6736(98)02390-3	http://dx.doi.org/10.1016/S0140-6736(98)02390-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734906				2022-12-28	WOS:000074088900041
J	Soulen, RJ; Byers, JM; Osofsky, MS; Nadgorny, B; Ambrose, T; Cheng, SF; Broussard, PR; Tanaka, CT; Nowak, J; Moodera, JS; Barry, A; Coey, JMD				Soulen, RJ; Byers, JM; Osofsky, MS; Nadgorny, B; Ambrose, T; Cheng, SF; Broussard, PR; Tanaka, CT; Nowak, J; Moodera, JS; Barry, A; Coey, JMD			Measuring the spin polarization of a metal with a superconducting point contact	SCIENCE			English	Article							FERROMAGNET; FILMS; CRO2; TRANSITION; FE	A superconducting point contact is used to determine the spin polarization at the Fermi energy of several metals. Because the process of supercurrent conversion at a superconductor-metal interface (Andreev reflection) is limited by the minority spin population near the Fermi surface, the differential conductance of the point contact can reveal the spin polarization of the metal. This technique has been applied to a variety of metals where the spin polarization ranges from 35 to 90 percent: Ni0.8Fe0.2, Ni, Co, Fe, NiMnSb, La0.7Sr0.3MnO3, and CrO2.	George Washington Univ, Dept Phys, Washington, DC 20052 USA; USN, Res Lab, Washington, DC 20375 USA; MIT, Francis Bitter Natl Magnet Lab, Cambridge, MA 02139 USA; Univ Dublin Trinity Coll, Dept Phys, Dublin 2, Ireland	George Washington University; United States Department of Defense; United States Navy; Naval Research Laboratory; Massachusetts Institute of Technology (MIT); Trinity College Dublin	Byers, JM (corresponding author), George Washington Univ, Dept Phys, Washington, DC 20052 USA.	byers@foucault.nrl.navy.mil	Nadgorny, Boris/AAD-3118-2019; Osofsky, Michael S/A-1050-2010	Coey, John Michael David/0000-0003-0053-8452				ANDREEV AF, 1964, SOV PHYS JETP-USSR, V19, P1228; BLONDER GE, 1983, PHYS REV B, V27, P112, DOI 10.1103/PhysRevB.27.112; BLONDER GE, 1982, PHYS REV B, V25, P4515, DOI 10.1103/PhysRevB.25.4515; Broussard PR, 1997, APPL SURF SCI, V115, P80, DOI 10.1016/S0169-4332(96)00848-3; DEGROOT RA, 1983, PHYS REV LETT, V50, P2024, DOI 10.1103/PhysRevLett.50.2024; DEJONG MJM, 1995, PHYS REV LETT, V74, P1657, DOI 10.1103/PhysRevLett.74.1657; Feder R., 1985, POLARIZED ELECT SURF; HARRIS VG, UNPUB; KAMPER KP, 1987, PHYS REV LETT, V59, P2788, DOI 10.1103/PhysRevLett.59.2788; MacLaren JM, 1997, PHYS REV B, V56, P11827, DOI 10.1103/PhysRevB.56.11827; MESERVEY R, 1994, PHYS REP, V238, P173, DOI 10.1016/0370-1573(94)90105-8; Moodera JS, 1998, PHYS REV LETT, V80, P2941, DOI 10.1103/PhysRevLett.80.2941; PRINZ GA, 1995, PHYS TODAY, V48, P58, DOI 10.1063/1.881459; PRINZ GA, 1981, APPL PHYS LETT, V39, P397, DOI 10.1063/1.92750; Ranno L, 1997, J APPL PHYS, V81, P5774, DOI 10.1063/1.364682; SCHWARZ K, 1986, J PHYS F MET PHYS, V16, pL211, DOI 10.1088/0305-4608/16/9/002; Sharvin Yu. V., 1965, ZH EKSP TEOR FIZ+, V48, P984; STEARNS MB, 1977, J MAGN MAGN MATER, V5, P167, DOI 10.1016/0304-8853(77)90185-8; UPADHYAY SK, IN PRESS PHYS REV LE	19	1504	1526	7	238	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 2	1998	282	5386					85	88		10.1126/science.282.5386.85	http://dx.doi.org/10.1126/science.282.5386.85			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756482				2022-12-28	WOS:000076294900042
J	Inwald, AC				Inwald, AC			Best of motives, worst of consequences	BRITISH MEDICAL JOURNAL			English	Editorial Material											Inwald, AC (corresponding author), 96 St Johns Way, London N19 3RN, England.		Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283					0	2	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					809	809		10.1136/bmj.317.7161.809	http://dx.doi.org/10.1136/bmj.317.7161.809			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740575	Green Published			2022-12-28	WOS:000076084200040
J	Lowe, M; Rabouille, C; Nakamura, N; Watson, R; Jackman, M; Jamsa, E; Rahman, D; Pappin, DJC; Warren, G				Lowe, M; Rabouille, C; Nakamura, N; Watson, R; Jackman, M; Jamsa, E; Rahman, D; Pappin, DJC; Warren, G			Cdc2 kinase directly phosphorylates the cis-Golgi matrix protein GM130 and is required for Golgi fragmentation in mitosis	CELL			English	Article							CELL-FREE SYSTEM; VESICLE DOCKING; MITOTIC FRAGMENTATION; HELA-CELLS; IN-VIVO; TRANSPORT; INHIBITOR; APPARATUS; P115; MEMBRANES	Mitotic fragmentation of the Golgi apparatus can be largely explained by disruption of the interaction between GM130 and the vesicle-docking protein p115. Here we identify a single serine (Ser-25) in GM130 as the key phosphorylated target and Cdc2 as the responsible kinase. MEK1, a component of the MAP kinase signaling pathway recently implicated in mitotic Golgi fragmentation, was not required for GM130 phosphorylation or mitotic fragmentation either in vitro or in vivo. We propose that Cdc2 is directly involved in mitotic Golgi fragmentation and that signaling via MEK1 is not required for this process.	Imperial Canc Res Fund, Cell Biol Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Prot Sequencing Lab, London WC2A 3PX, England; Wellcome CRC Inst, Cambridge CB2 1QR, England	Cancer Research UK; Cancer Research UK	Warren, G (corresponding author), Imperial Canc Res Fund, Cell Biol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Nakamura, Nobuhiro/F-7811-2011; Jokitalo, Eija/C-8375-2009	Nakamura, Nobuhiro/0000-0002-8836-6714; Jokitalo, Eija/0000-0002-4159-6934; Pappin, Darryl/0000-0002-8981-8401	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Levine TP, 1996, J BIOL CHEM, V271, P17304, DOI 10.1074/jbc.271.29.17304; MACKAY D, 1993, FEBS LETT, V336, P549, DOI 10.1016/0014-5793(93)80874-T; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MISTELI T, 1995, J CELL BIOL, V130, P1027, DOI 10.1083/jcb.130.5.1027; MISTELI T, 1995, J CELL SCI, V108, P2715; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Sohda M, 1998, J BIOL CHEM, V273, P5385, DOI 10.1074/jbc.273.9.5385; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; STUART RA, 1993, J BIOL CHEM, V268, P4050; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	35	255	260	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1998	94	6					783	793		10.1016/S0092-8674(00)81737-7	http://dx.doi.org/10.1016/S0092-8674(00)81737-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753325	Bronze			2022-12-28	WOS:000076021200011
J	Peter, BJ; Ullsperger, C; Hiasa, H; Marians, KJ; Cozzarelli, NR				Peter, BJ; Ullsperger, C; Hiasa, H; Marians, KJ; Cozzarelli, NR			The structure of supercoiled intermediates in DNA replication	CELL			English	Article							ESCHERICHIA-COLI; TOPOISOMERASE-IV; ELECTRON-MICROSCOPY; STRAND; DECATENATION; MOLECULES; PROTEIN; GYRASE; YEAST	We studied the structure of replication intermediates accumulated by Tus-induced arrest of plasmid DNA replication at termination sites. For intermediates generated both in vitro with purified components and in vivo, superhelical stress is distributed throughout the entire partially replicated molecule; daughter DNA segments are wound around each other, and the unreplicated region is supercoiled. Thus, unlinking of parental DNA strands by topoisomerases can be carried out both behind and in front of the replication fork. We explain why previous studies with prokaryotic and eukaryotic replication intermediates discerned only supercoiling in the unreplicated portion.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	University of California System; University of California Berkeley; Memorial Sloan Kettering Cancer Center	Cozzarelli, NR (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B., 1980, MECH STUDIES DNA REP, P809, DOI DOI 10.1016/B978-0-12-048850-6.50072-7; Ausubel FM, 1988, MOL REPROD DEV; BASTIA D, 1981, P NATL ACAD SCI-BIOL, V78, P2095, DOI 10.1073/pnas.78.4.2095; BATES AD, 1993, DNA TOPOLOGY; Benjamin KR, 1996, J MOL BIOL, V256, P50, DOI 10.1006/jmbi.1996.0067; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; BOURGAUX P, 1972, J MOL BIOL, V70, P399, DOI 10.1016/0022-2836(72)90548-7; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; Eckstein F., 1995, NUCLEIC ACIDS MOL BI, P115; FUKE M, 1972, P NATL ACAD SCI USA, V69, P89, DOI 10.1073/pnas.69.1.89; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P26959; HIASA H, 1994, J BIOL CHEM, V269, P32655; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; ISHIMI Y, 1992, J BIOL CHEM, V267, P462; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; KHODURSKY AB, 1997, THESIS U CALIFORNIA; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Kleinschmidt A.K.=, 1968, METHODS ENZYMOL, V12, P361; Kornberg A., 1992, DNA REPLICATION; LANG D, 1970, BIOPOLYMERS, V9, P373, DOI 10.1002/bip.1970.360090310; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LOHMAN TM, 1996, ANNU REV BIOCHEM, V65, P168; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; Roca J, 1996, GENES CELLS, V1, P17, DOI 10.1046/j.1365-2443.1996.01001.x; Sambrook J., 2002, MOL CLONING LAB MANU; SEBRING ED, 1971, J VIROL, V8, P478, DOI 10.1128/JVI.8.4.478-490.1971; SEBRING ED, 1974, J MOL BIOL, V90, P371, DOI 10.1016/0022-2836(74)90380-5; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; Wang J. C., 1990, DNA TOPOLOGY ITS BIO, P321; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P2311, DOI 10.1073/pnas.74.6.2311; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	38	120	124	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					819	827		10.1016/S0092-8674(00)81740-7	http://dx.doi.org/10.1016/S0092-8674(00)81740-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753328	Bronze			2022-12-28	WOS:000076021200014
J	Hood, VL; Tannen, RL				Hood, VL; Tannen, RL			Protection of acid-base balance by pH regulation of acid production	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HYPOXIC LACTIC-ACIDOSIS; DIABETIC-KETOACIDOSIS; SODIUM-BICARBONATE; METABOLIC CONSEQUENCES; RESPIRATORY-ACIDOSIS; MUSCLE METABOLISM; EXERCISE; ALKALOSIS; EXCRETION; THERAPY		Univ Vermont, Coll Med, Burlington, VT 05401 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Vermont; University of Pennsylvania	Hood, VL (corresponding author), Univ Vermont, Coll Med, 317 Burgess Bldg,Fletcher Allen Hlth Care, Burlington, VT 05401 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK025248] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-07378] Funding Source: Medline; NIDDK NIH HHS [DK25248, DK32939] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adlersberg D, 1923, BIOCHEM Z, V143, P527; ARIEFF AI, 1978, KIDNEY INT, V14, P645; ARIEFF AI, 1976, METABOLISM, V25, P307, DOI 10.1016/0026-0495(76)90088-3; ARIEFF AI, 1980, AM J PHYSIOL, V239, pF135, DOI 10.1152/ajprenal.1980.239.2.F135; BERRY MN, 1967, METABOLISM, V16, P537, DOI 10.1016/0026-0495(67)90084-4; BLECHNER JN, 1968, AM J OBSTET GYNECOL, V100, P1; BROWN JC, 1989, AM J PHYSIOL, V257, pF170, DOI 10.1152/ajprenal.1989.257.2.F170; CAIN SM, 1964, AM J PHYSIOL, V206, P1437, DOI 10.1152/ajplegacy.1964.206.6.1437; COOPER DJ, 1990, ANN INTERN MED, V112, P492, DOI 10.7326/0003-4819-112-7-492; Cusi K, 1994, DIABETES REV, V2, P195; Davies HW, 1920, J PHYSIOL-LONDON, V54, P32; EHRSAM RE, 1982, J APPL PHYSIOL, V53, P63, DOI 10.1152/jappl.1982.53.1.63; EICHENHOLZ A, 1962, J APPL PHYSIOL, V17, P283, DOI 10.1152/jappl.1962.17.2.283; EICHENHOLZ A, 1963, METABOLISM, V12, P164; ELKINTON JR, 1960, AM J MED, V29, P554, DOI 10.1016/0002-9343(60)90090-5; ELLISON RG, 1965, CLIN RES, V13, P74; FARFOURNOUX P, 1987, AM J PHYSIOL, V252, pG200; FIELDS ALA, 1981, CANCER-AM CANCER SOC, V47, P2026, DOI 10.1002/1097-0142(19810415)47:8<2026::AID-CNCR2820470821>3.0.CO;2-G; FRALEY DS, 1980, NEW ENGL J MED, V303, P1100, DOI 10.1056/NEJM198011063031907; FULOP M, 1975, DIABETES, V24, P785, DOI 10.2337/diabetes.24.9.785; GABOW PA, 1978, ARCH INTERN MED, V138, P1481, DOI 10.1001/archinte.138.10.1481; GAMBLE W, 1961, J APPL PHYSIOL, V16, P593, DOI 10.1152/jappl.1961.16.4.593; Gennari FJ, 1996, SEMIN DIALYSIS, V9, P404, DOI 10.1111/j.1525-139X.1996.tb00876.x; GEVERS W, 1963, CLIN SCI, V25, P343; GIEBISCH G, 1955, J CLIN INVEST, V34, P231, DOI 10.1172/JCI103076; GOLDSTEIN PJ, 1972, J PHYSIOL-LONDON, V223, P261, DOI 10.1113/jphysiol.1972.sp009846; GOUGEONREYBURN R, 1989, METABOLISM, V38, P1222, DOI 10.1016/0026-0495(89)90163-7; GRAF H, 1985, AM J PHYSIOL, V249, pF630, DOI 10.1152/ajprenal.1985.249.5.F630; GRAF H, 1985, SCIENCE, V227, P754, DOI 10.1126/science.3969564; Haldane JBS, 1924, LANCET, V1, P537; HALE PJ, 1984, BMJ-BRIT MED J, V289, P1035, DOI 10.1136/bmj.289.6451.1035; HAMM LL, 1990, KIDNEY INT, V38, P728, DOI 10.1038/ki.1990.265; HANNAFORD MC, 1982, AM J PHYSIOL, V243, pE251, DOI 10.1152/ajpendo.1982.243.3.E251; HIRCHE H, 1975, PFLUG ARCH EUR J PHY, V356, P209, DOI 10.1007/BF00583833; Hood V., 1994, DIABETES REV ALEX, V2, P177; HOOD VL, 1990, AM J PHYSIOL, V259, pE327, DOI 10.1152/ajpendo.1990.259.3.E327; HOOD VL, 1988, METABOLISM, V37, P573, DOI 10.1016/0026-0495(88)90174-6; HOOD VL, 1988, AM J PHYSIOL, V255, pF479, DOI 10.1152/ajprenal.1988.255.3.F479; HOOD VL, 1982, AM J PHYSIOL, V242, pF238, DOI 10.1152/ajprenal.1982.242.3.F238; HOOD VL, 1985, AM J PHYSIOL, V249, pF220, DOI 10.1152/ajprenal.1985.249.2.F220; HOOD VL, 1991, ACID BASE ELECTROLYT, V1, P1; HUCKABEE WE, 1958, J CLIN INVEST, V37, P244, DOI 10.1172/JCI103603; JONES NL, 1977, J APPL PHYSIOL, V43, P959, DOI 10.1152/jappl.1977.43.6.959; Kamel K, 1996, J AM SOC NEPHROL, V7, pA0527; KAMEL KS, 1990, KIDNEY INT, V38, P507, DOI 10.1038/ki.1990.232; KAUFMAN AM, 1985, AM J PHYSIOL, V248, pF796, DOI 10.1152/ajprenal.1985.248.6.F796; KOWALCHUK JM, 1984, J APPL PHYSIOL, V57, P1558, DOI 10.1152/jappl.1984.57.5.1558; LAGRANGE BM, 1989, AM J PHYSIOL, V256, pF437, DOI 10.1152/ajprenal.1989.256.3.F437; LEACH WJ, 1981, CLIN RES, V29, pA411; LEALPINT.E, 1973, AM J PHYSIOL, V224, P1463, DOI 10.1152/ajplegacy.1973.224.6.1463; LEMANN J, 1966, J CLIN INVEST, V45, P1608, DOI 10.1172/JCI105467; LEMANN J, 1965, J CLIN INVEST, V44, P507, DOI 10.1172/JCI105164; LIPSKY SR, 1954, J CLIN INVEST, V33, P1269, DOI 10.1172/JCI103002; MacKay EM, 1941, J BIOL CHEM, V138, P63; MINUK HL, 1980, AM J PHYSIOL, V238, pE322, DOI 10.1152/ajpendo.1980.238.4.E322; MORRIS LR, 1986, ANN INTERN MED, V105, P836, DOI 10.7326/0003-4819-105-6-836; NAHAS GG, 1967, AM J PHYSIOL, V212, P765, DOI 10.1152/ajplegacy.1967.212.4.765; NEARY RH, 1987, BRIT MED J, V294, P1462, DOI 10.1136/bmj.294.6585.1462; Okuda Y, 1996, J CLIN ENDOCR METAB, V81, P314, DOI 10.1210/jc.81.1.314; RELMAN AS, 1972, KIDNEY INT, V1, P347, DOI 10.1038/ki.1972.46; ROMEH S A, 1986, American Journal of Physiology, V250, pF702; SAPIR DG, 1976, METABOLISM, V25, P211, DOI 10.1016/0026-0495(76)90051-2; SIMPSON DP, 1983, AM J PHYSIOL, V244, pF223, DOI 10.1152/ajprenal.1983.244.3.F223; SPRIET LL, 1985, AM J PHYSIOL, V248, pC337, DOI 10.1152/ajpcell.1985.248.3.C337; SPRIET LL, 1986, AM J PHYSIOL, V251, pR833, DOI 10.1152/ajpregu.1986.251.5.R833; STACPOOLE PW, 1993, ENDOCRIN METAB CLIN, V22, P221, DOI 10.1016/S0889-8529(18)30163-4; STAUBLI C, 1908, DTSCH ARCH KLIN MED, V93, P107; STEPHENS TW, 1983, BIOCHEM J, V212, P521, DOI 10.1042/bj2120521; STINEBAUGH BJ, 1975, METABOLISM, V24, P915, DOI 10.1016/0026-0495(75)90082-7; SUTTON JR, 1981, CLIN SCI, V61, P331, DOI 10.1042/cs0610331; TOBIN RB, 1971, AM J PHYSIOL, V221, P1151, DOI 10.1152/ajplegacy.1971.221.4.1151; TRIVEDI B, 1986, AM J PHYSIOL, V250, P1039; URIBARRI J, 1995, KIDNEY INT, V47, P624, DOI 10.1038/ki.1995.79; VEGA FV, 1974, AM J PHYSIOL, V227, P168, DOI 10.1152/ajplegacy.1974.227.1.168; YAJIMA M, 1975, AM J PHYSIOL, V228, P1053; ZBOROWSK.DT, 1967, J APPL PHYSIOL, V22, P746, DOI 10.1152/jappl.1967.22.4.746	76	96	102	3	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1998	339	12					819	826		10.1056/NEJM199809173391207	http://dx.doi.org/10.1056/NEJM199809173391207			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119QT	9738091				2022-12-28	WOS:000075909200007
J	Nelkin, D				Nelkin, D			The performance of science	LANCET			English	Article									NYU, Dept Sociol, New York, NY 10003 USA	New York University	Nelkin, D (corresponding author), NYU, Dept Sociol, 269 Mercer St, New York, NY 10003 USA.								0	9	9	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					893	893		10.1016/S0140-6736(05)60031-1	http://dx.doi.org/10.1016/S0140-6736(05)60031-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742996	hybrid			2022-12-28	WOS:000075857300042
J	Turner, RC; Holman, RR; Cull, CA; Stratton, IM; Matthews, DR; Frighi, V; Manley, SE; Neil, A; McElroy, K; Wright, D; Kohner, E; Fox, C; Hadden, D; Mehta, Z; Smith, A; Nugent, Z; Peto, R; Adlel, AI; Mann, JI; Bassett, PA; Oakes, SF; Dornan, TL; Aldington, S; Lipinski, H; Collum, R; Harrison, K; MacIntyre, C; Skinner, S; Mortemore, A; Nelson, D; Cockley, S; Levien, S; Bodsworth, L; Willox, R; Biggs, T; Dove, S; Beattie, E; Gradwell, M; Staples, S; Lam, R; Taylor, F; Leung, L; Carter, RD; Brownlee, SM; Fisher, KE; Islam, K; Jelfs, R; Williams, PA; Williams, FA; Sutton, PJ; Ayres, A; Logie, LJ; Lovatt, C; Evans, MA; Stowell, LA; Ross, I; Kennedy, IA; Croft, D; Keen, AH; Rose, C; Raikou, M; Fletcher, AE; Bulpitt, C; Battersby, C; Yudkin, JS; Stevens, R; Stearn, MR; Palmer, SL; Hammersley, MS; Franklin, SL; Spivey, RS; Levy, JC; Tidy, CR; Bell, NJ; Steemson, J; Barrow, BA; Coster, R; Waring, K; Nolan, L; Truscott, E; Walravens, N; Cook, L; Lampard, H; Merle, C; Parker, P; McVittie, J; Draisey, I; Murchison, LE; Brunt, AHE; Williams, MJ; Pearson, DW; Petrie, XMP; Lean, MEJ; Walmsley, D; Lyall, F; Christie, E; Church, J; Thomson, E; Farrow, A; Stowers, JM; Stowers, M; McHardy, K; Patterson, N; Wright, AD; Levi, NA; Shearer, ACI; Thompson, RJW; Taylor, G; Rayton, S; Bradbury, M; Glover, A; Smyth-Osbourne, A; Parkes, C; Graham, J; England, P; Gyde, S; Eagle, C; Chakrabarti, B; Smith, J; Sherwell, J; Oakley, NW; Whitehead, MA; Hollier, GP; Pilkington, T; Simpson, J; Anderson, M; Martin, S; Kean, J; Rice, B; Rolland, A; Nisbet, J; Kohner, EM; Dornhorst, A; Doddridge, MC; Dumskyij, M; Walji, S; Sharp, P; Sleightholm, M; Vanterpool, G; Frost, G; Roseblade, M; Elliott, S; Forrester, S; Foster, M; Myers, K; Chapman, R; Hayes, JR; Henry, RW; Featherston, MS; Archbold, GPR; Copeland, M; Harper, R; Richardson, I; Davison, HA; Alexander, L; Scarpello, JHB; Shiers, DE; Tucker, RJ; Worthington, JRH; Angris, S; Bates, A; Walton, J; Teasdale, M; Browne, J; Stanley, S; Davis, BA; Strange, RC; Hadden, DR; Kennedy, L; Atkinson, AB; Bell, PM; McCance, DR; Rutherford, J; Culbert, AM; Hegan, C; Tennet, H; Webb, N; Robinson, I; Holmes, J; Nesbitt, S; Spathis, AS; Hyer, S; Nanson, ME; James, LM; Tyrell, JM; Davis, C; Strugnell, P; Booth, M; Petrie, H; Clark, D; Hulland, S; Barron, JL; Gould, BC; Singer, J; Badenoch, A; McGregor, M; Isenberg, L; Eckert, M; Alibhai, K; Marriot, E; Cox, C; Price, R; Fernandez, M; Ryle, A; Clarke, S; Wallace, G; Mehmed, E; Lankester, JA; Howard, E; Waite, A; MacFarlane, S; Greenwood, RH; Wilson, J; Denholm, MJ; Temple, RC; Whitfield, K; Johnson, F; Munroe, C; Gorick, S; Duckworth, E; Fatman, M; Rainbow, S; Borthwick, L; Wheatcroft, DJ; Seaman, RJ; Christie, RA; Wheatcroft, W; Musk, P; White, J; McDougal, S; Bond, M; Raniga, P; Day, JL; Doshi, MJ; Wilson, JG; Howard-Williams, JR; Humphreys, H; Graham, A; Hicks, K; Hexman, S; Bayliss, P; Pledger, D; Newton, RW; Jung, RT; Roxburgh, C; Kilgallon, B; Dick, L; Waugh, N; Kilby, S; Ellingford, A; Burns, J; Fox, CV; Holloway, MC; Coghill, HM; Hein, N; Fox, A; Cowan, W; Richard, M; Quested, K; Evans, SJ; Paisey, RB; Brown, NPR; Tucker, AJ; Paisey, R; Garrett, F; Hogg, J; Park, P; Williams, K; Harvey, P; Wilcocks, R; Mason, S; Frost, J; Warren, C; Rocket, P; Bower, L; Roland, JM; Brown, DJ; Youens, J; Stanton-King, K; Mungall, H; Ball, V; Maddison, W; Donnelly, D; King, S; Griffin, P; Smith, S; Church, S; Dunn, G; Wilson, A; Palmer, K; Brown, PM; Humphriss, D; Davidson, AJM; Rose, R; Armistead, L; Townsend, S; Poon, P; Peacock, IDA; Culverwell, NJC; Charlton, MH; Connolly, BPS; Peacock, J; Barrett, J; Wain, J; Beeston, W; King, G; Hill, PG; Boulton, AJM; Robertson, AM; Katoulis, V; Olukoga, A; McDonald, H; Kumar, S; Abouaesha, F; Abuaisha, B; Knowles, EA; Higgins, S; Booker, J; Sunter, J; Breislin, K; Parker, R; Raval, P; Curwell, J; Davenport, H; Shawcross, G; Prest, A; Grey, J; Cole, H; Sereviratne, C; Young, RJ; Clyne, JR; Gibson, M; O'Connell, I; Wong, LM; Wilson, SJ; Wright, KL; Wallace, C; McDowell, D; Burden, AC; Sellen, EM; Gregory, R; Roshan, M; Vaghela, N; Burden, M; Sherriff, C; Mansingh, S; Clarke, J; Grenfell, J; Tooke, JE; MacLeod, K; Seamark, C; Rammell, M; Pym, C; Stockman, J; Yeo, C; Piper, J; Leighton, L; Green, E; Hoyle, M; Jones, K; Hudson, A; James, AJ; Shore, A; Higham, A; Martin, B; Neil, HAW; Butterfield, WJH; Doll, WRS; Eastman, R; Ferris, FR; Kurinij, N; McPherson, K; Mahler, RF; Meade, TW; Shafer, G; Watkins, PJ; Keen, H; Siegel, D; Wright, AD; Betteridge, DJ; Cohen, RD; Currie, D; Darbyshire, J; Forrester, JV; Guppy, T; Johnston, DG; McGuire, A; Murphy, M; el-Nahas, AM; Pentecost, B; Spiegelhalter, D; Alberti, KGMM; Denton, R; Home, PD; Howell, S; Jarrett, JR; Marks, V; Marmot, M; Ward, JD				Turner, RC; Holman, RR; Cull, CA; Stratton, IM; Matthews, DR; Frighi, V; Manley, SE; Neil, A; McElroy, K; Wright, D; Kohner, E; Fox, C; Hadden, D; Mehta, Z; Smith, A; Nugent, Z; Peto, R; Adlel, AI; Mann, JI; Bassett, PA; Oakes, SF; Dornan, TL; Aldington, S; Lipinski, H; Collum, R; Harrison, K; MacIntyre, C; Skinner, S; Mortemore, A; Nelson, D; Cockley, S; Levien, S; Bodsworth, L; Willox, R; Biggs, T; Dove, S; Beattie, E; Gradwell, M; Staples, S; Lam, R; Taylor, F; Leung, L; Carter, RD; Brownlee, SM; Fisher, KE; Islam, K; Jelfs, R; Williams, PA; Williams, FA; Sutton, PJ; Ayres, A; Logie, LJ; Lovatt, C; Evans, MA; Stowell, LA; Ross, I; Kennedy, IA; Croft, D; Keen, AH; Rose, C; Raikou, M; Fletcher, AE; Bulpitt, C; Battersby, C; Yudkin, JS; Stevens, R; Stearn, MR; Palmer, SL; Hammersley, MS; Franklin, SL; Spivey, RS; Levy, JC; Tidy, CR; Bell, NJ; Steemson, J; Barrow, BA; Coster, R; Waring, K; Nolan, L; Truscott, E; Walravens, N; Cook, L; Lampard, H; Merle, C; Parker, P; McVittie, J; Draisey, I; Murchison, LE; Brunt, AHE; Williams, MJ; Pearson, DW; Petrie, XMP; Lean, MEJ; Walmsley, D; Lyall, F; Christie, E; Church, J; Thomson, E; Farrow, A; Stowers, JM; Stowers, M; McHardy, K; Patterson, N; Wright, AD; Levi, NA; Shearer, ACI; Thompson, RJW; Taylor, G; Rayton, S; Bradbury, M; Glover, A; Smyth-Osbourne, A; Parkes, C; Graham, J; England, P; Gyde, S; Eagle, C; Chakrabarti, B; Smith, J; Sherwell, J; Oakley, NW; Whitehead, MA; Hollier, GP; Pilkington, T; Simpson, J; Anderson, M; Martin, S; Kean, J; Rice, B; Rolland, A; Nisbet, J; Kohner, EM; Dornhorst, A; Doddridge, MC; Dumskyij, M; Walji, S; Sharp, P; Sleightholm, M; Vanterpool, G; Frost, G; Roseblade, M; Elliott, S; Forrester, S; Foster, M; Myers, K; Chapman, R; Hayes, JR; Henry, RW; Featherston, MS; Archbold, GPR; Copeland, M; Harper, R; Richardson, I; Davison, HA; Alexander, L; Scarpello, JHB; Shiers, DE; Tucker, RJ; Worthington, JRH; Angris, S; Bates, A; Walton, J; Teasdale, M; Browne, J; Stanley, S; Davis, BA; Strange, RC; Hadden, DR; Kennedy, L; Atkinson, AB; Bell, PM; McCance, DR; Rutherford, J; Culbert, AM; Hegan, C; Tennet, H; Webb, N; Robinson, I; Holmes, J; Nesbitt, S; Spathis, AS; Hyer, S; Nanson, ME; James, LM; Tyrell, JM; Davis, C; Strugnell, P; Booth, M; Petrie, H; Clark, D; Hulland, S; Barron, JL; Gould, BC; Singer, J; Badenoch, A; McGregor, M; Isenberg, L; Eckert, M; Alibhai, K; Marriot, E; Cox, C; Price, R; Fernandez, M; Ryle, A; Clarke, S; Wallace, G; Mehmed, E; Lankester, JA; Howard, E; Waite, A; MacFarlane, S; Greenwood, RH; Wilson, J; Denholm, MJ; Temple, RC; Whitfield, K; Johnson, F; Munroe, C; Gorick, S; Duckworth, E; Fatman, M; Rainbow, S; Borthwick, L; Wheatcroft, DJ; Seaman, RJ; Christie, RA; Wheatcroft, W; Musk, P; White, J; McDougal, S; Bond, M; Raniga, P; Day, JL; Doshi, MJ; Wilson, JG; Howard-Williams, JR; Humphreys, H; Graham, A; Hicks, K; Hexman, S; Bayliss, P; Pledger, D; Newton, RW; Jung, RT; Roxburgh, C; Kilgallon, B; Dick, L; Waugh, N; Kilby, S; Ellingford, A; Burns, J; Fox, CV; Holloway, MC; Coghill, HM; Hein, N; Fox, A; Cowan, W; Richard, M; Quested, K; Evans, SJ; Paisey, RB; Brown, NPR; Tucker, AJ; Paisey, R; Garrett, F; Hogg, J; Park, P; Williams, K; Harvey, P; Wilcocks, R; Mason, S; Frost, J; Warren, C; Rocket, P; Bower, L; Roland, JM; Brown, DJ; Youens, J; Stanton-King, K; Mungall, H; Ball, V; Maddison, W; Donnelly, D; King, S; Griffin, P; Smith, S; Church, S; Dunn, G; Wilson, A; Palmer, K; Brown, PM; Humphriss, D; Davidson, AJM; Rose, R; Armistead, L; Townsend, S; Poon, P; Peacock, IDA; Culverwell, NJC; Charlton, MH; Connolly, BPS; Peacock, J; Barrett, J; Wain, J; Beeston, W; King, G; Hill, PG; Boulton, AJM; Robertson, AM; Katoulis, V; Olukoga, A; McDonald, H; Kumar, S; Abouaesha, F; Abuaisha, B; Knowles, EA; Higgins, S; Booker, J; Sunter, J; Breislin, K; Parker, R; Raval, P; Curwell, J; Davenport, H; Shawcross, G; Prest, A; Grey, J; Cole, H; Sereviratne, C; Young, RJ; Clyne, JR; Gibson, M; O'Connell, I; Wong, LM; Wilson, SJ; Wright, KL; Wallace, C; McDowell, D; Burden, AC; Sellen, EM; Gregory, R; Roshan, M; Vaghela, N; Burden, M; Sherriff, C; Mansingh, S; Clarke, J; Grenfell, J; Tooke, JE; MacLeod, K; Seamark, C; Rammell, M; Pym, C; Stockman, J; Yeo, C; Piper, J; Leighton, L; Green, E; Hoyle, M; Jones, K; Hudson, A; James, AJ; Shore, A; Higham, A; Martin, B; Neil, HAW; Butterfield, WJH; Doll, WRS; Eastman, R; Ferris, FR; Kurinij, N; McPherson, K; Mahler, RF; Meade, TW; Shafer, G; Watkins, PJ; Keen, H; Siegel, D; Wright, AD; Betteridge, DJ; Cohen, RD; Currie, D; Darbyshire, J; Forrester, JV; Guppy, T; Johnston, DG; McGuire, A; Murphy, M; el-Nahas, AM; Pentecost, B; Spiegelhalter, D; Alberti, KGMM; Denton, R; Home, PD; Howell, S; Jarrett, JR; Marks, V; Marmot, M; Ward, JD		UK Prospective Diabet Study Grp	Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)	LANCET			English	Article							MICROVASCULAR COMPLICATIONS; NIDDM PATIENTS; HEART-DISEASE; MELLITUS; THERAPY; SECONDARY; TRIAL	Background Improved blood-glucose control decreases the progression of diabetic microvascular disease, but the effect on macrovascular complications is unknown. There is concern that sulphonylureas may increase cardiovascular mortality in patients with type 2 diabetes and that high insulin concentrations may enhance atheroma formation. We compared the effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial. Methods 3867 newly diagnosed patients with type 2 diabetes, median age 54 years (IQR 48-60 years), who after 3 months' diet treatment had a mean of two fasting plasma glucose (FPG) concentrations of 6.1-15.0 mmol/L were randomly assigned intensive policy with a sulphonylurea (chlorpropamide, glibenclamide, or. glipizide) or with insulin, or conventional policy with diet. The aim in the intensive group was FPG less than 6 mmol/L. in the conventional group, the aim was the best achievable FPG with diet atone; drugs were added only if there were hyperglycaemic symptoms or FPG greater than 15 mmol/L. Three aggregate endpoints were used to assess differences between conventional and intensive treatment: any diabetes-related endpoint (sudden death, death from hyperglycaemia or hypoglycaemia, fatal or non-fatal myocardial infarction, angina, heart failure, stroke, renal failure, amputation [of at least one digit], vitreous haemorrhage, retinopathy requiring photocoagulation, blindness in one eye,or cataract extraction); diabetes-related death (death from myocardial infarction, stroke, peripheral vascular disease, renal disease, hyperglycaemia or hypoglycaemia, and sudden death); all-cause mortality. Single clinical endpoints and surrogate subclinical endpoints were also assessed. All analyses were by intention to treat and frequency of hypoglycaemia was also analysed by actual therapy. Findings Over 10 years, haemoglobin A(1c) (HbA(1c)) was 7.0% (6.2-8.2) in the intensive group compared with 7.9% (6.9-8.8) in the conventional group-an 11% reduction. There was no difference in HbA(1c) among agents in the intensive group. Compared with the conventional group, the risk in the intensive group was 12% lower (95% CI 1-21, p=0.029) for any diabetes-related endpoint; 10% lower (-11 to 27, p=0.34) for any diabetes-related death; and 6% lower (-10 to 20, p=0.44) for all-cause mortality. Most of the risk reduction in the any diabetes-related aggregate endpoint was due to a 25% risk reduction (7-40, p=0.0099) in microvascular endpoints, including the need for retinal photocoagulation. There was no difference for any of the three aggregate endpoints the three intensive agents (chlorpropamide, glibenclamide, or insulin). Patients in the intensive group had more hypoglycaemic episodes than those in the conventional group on both types of analysis (both p<0.0001). The rates of major hypoglycaemic episodes per year were 0.7% with conventional treatment, 1.0% with chlorpropamide, 1.4% with glibenclamide, and 1.8% with insulin. Weight gain was significantly higher in the intensive group (mean 2.9 kg) than in the conventional group (p<0.001), and patients assigned insulin had a greater gain in weight (4.0 kg) than those assigned chlorpropamide (2.6 kg) or glibenclamide (1.7 kg). Interpretation Intensive blood-glucose control by either sulphonylureas or insulin substantially decreases the risk of microvascular complications, but not macrovascular disease, in patients with type 2 diabetes. None of the individual drugs had an adverse effect on cardiovascular outcomes. All intensive treatment increased the risk of hypoglycaemia.	Radcliffe Infirm, Diabet Res Labs, UKPDS Grp, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Turner, RC (corresponding author), Radcliffe Infirm, Diabet Res Labs, UKPDS Grp, Woodstock Rd, Oxford OX2 6HE, England.		Mirabel, Irene/AAU-6655-2020; Denton, Richard/ABC-9914-2020; Burden, Felix/AAE-9711-2020; Marmot, M G/Y-3920-2019; Aldington, Steve J/G-7828-2012; Yudkin, John S/C-1988-2008; stratton, irene/AAZ-3627-2020; Frighi, Valeria/AAD-2648-2022; Smith, Jane/B-6254-2009	Marmot, M G/0000-0002-2431-6419; Aldington, Steve J/0000-0003-1808-3580; stratton, irene/0000-0003-1172-7865; Frighi, Valeria/0000-0001-8177-8778; Frost, Gary/0000-0003-0529-6325; Manley, Susan/0000-0002-8298-4511				ABRAIRA C, 1995, DIABETES CARE, V18, P1113, DOI 10.2337/diacare.18.8.1113; American Diabetes Association, 1998, DIABETES CARE, V21, pS23, DOI [10.2337/diacare.21.1.S23, DOI 10.2337/DIACARE.21.1.S23]; American Diabetes Association, 1998, DIABETES CARE S1, V12, pS20, DOI DOI 10.2337/DIACARE.21.1.S20; [Anonymous], 1995, Diabetes, V44, P1249; Balkau B, 1998, DIABETES CARE, V21, P360, DOI 10.2337/diacare.21.3.360; Birkeland KI, 1996, DIABETOLOGIA, V39, P1629, DOI 10.1007/s001250050626; British Multicentre Study Group, 1984, DIABETOLOGIA, V26, P109; CHIASSON JL, 1994, ANN INTERN MED, V121, P928, DOI 10.7326/0003-4819-121-12-199412150-00004; CHOW CC, 1995, DIABETES CARE, V18, P307, DOI 10.2337/diacare.18.3.307; DAVIES E G, 1989, Eye (London), V3, P764; DECOURTEN M, 1997, DIABETIC MED, V14, P5; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; Diabet Control Complications Trial Res Grp, 1995, DIABETES CARE, V18, P1415; Dunn NR, 1996, BRIT J GEN PRACT, V46, P401; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 1998, DIABETES CARE S1, V21, pS5; FULLER JH, 1979, J CHRON DIS, V32, P721, DOI 10.1016/0021-9681(79)90051-1; Genuth S, 1996, ANN INTERN MED, V124, P104, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00005; Hayward RA, 1997, JAMA-J AM MED ASSOC, V278, P1663, DOI 10.1001/jama.278.20.1663; HENRY RR, 1993, DIABETES CARE, V16, P21, DOI 10.2337/diacare.16.1.21; Holman R. R., 1996, Diabetologia, V39, pA44; KNATTERUD GL, 1978, JAMA-J AM MED ASSOC, V240, P37, DOI 10.1001/jama.240.1.37; Kumar S, 1996, DIABETOLOGIA, V39, P701; MANLEY SE, 1992, CLIN CHEM, V38, P2294; MANLEY SE, 1994, DIABETIC MED, V11, P534; Matthews DR, 1998, DIABETIC MED, V15, P297, DOI 10.1002/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.3.CO;2-N; MELANDER A, 1988, BAILLIERE CLIN ENDOC, V2, P443, DOI 10.1016/S0950-351X(88)80042-9; Metropolitan Life Foundation New weight standards for men and women, 1959, STAT B, V40, P1; MILLER M, 1976, DIABETES, V25, P1129; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; POGATSA G, 1995, DIABETES RES CLIN PR, V28, pS91, DOI 10.1016/0168-8227(95)01103-K; Pyorala K, 1979, Diabetes Care, V2, P131, DOI 10.2337/diacare.2.2.131; REICHARD P, 1991, J INTERN MED, V230, P101, DOI 10.1111/j.1365-2796.1991.tb00415.x; SCHMITT JK, 1993, AM J HYPERTENS, V6, P317; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SMITS P, 1995, DIABETOLOGIA, V38, P116, DOI 10.1007/BF02369361; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; STOUT RW, 1990, DIABETES CARE, V13, P631, DOI 10.2337/diacare.13.6.631; STOUT RW, 1992, DIABETES ATHEROSCLER, P165; Stratton I, 1996, DIABETOLOGIA, V39, P1554, DOI 10.1007/s001250050614; Turner R, 1996, ANN INTERN MED, V124, P136, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00011; TURNER RC, 1991, DIABETOLOGIA, V34, P877; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; *UKPDS GROUP, 1992, DIABETOLOGIA, V36, P835; World Health Organization, 1985, WHO TECHN REP SER, V727; World Health Organization, 1978, INT CLASS PROC MED; Wright AD, 1998, DIABETES CARE, V21, P87; YKIJARVINEN H, 1992, NEW ENGL J MED, V327, P1426, DOI 10.1056/NEJM199211123272005	47	14456	15032	46	1615	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	1998	352	9131					837	853		10.1016/s0140-6736(98)07019-6	http://dx.doi.org/10.1016/s0140-6736(98)07019-6			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742976				2022-12-28	WOS:000075857300006
J	Caplin, ME; Buscombe, JR; Hilson, AJ; Jones, AL; Watkinson, AF; Burroughs, AK				Caplin, ME; Buscombe, JR; Hilson, AJ; Jones, AL; Watkinson, AF; Burroughs, AK			Carcinoid tumour	LANCET			English	Article							ENDOCRINE GASTROENTEROPANCREATIC TUMORS; SOMATOSTATIN-RECEPTOR SCINTIGRAPHY; METASTATIC NEUROENDOCRINE TUMORS; LIVER-TRANSPLANTATION; GASTRIC CARCINOIDS; SURGICAL-TREATMENT; SMALL-BOWEL; THERAPY; OCTREOTIDE; MANAGEMENT	Carcinoid tumours are often indolent asymptomatic tumours. However, a small but significant proportion are malignant and difficult to manage. Multiple endocrine neoplasia type 1 (MEN-1) may be associated with carcinoid tumours and should therefore be considered in the investigation of these patients. This review puts into context the use of newer imaging modalities, including octreotide scintigraphy. The therapeutic treatment options are discussed, including the use of octreotide, the role of receptor-targeted therapy, hepatic-artery embolisation, and the arguments against chemotherapy. We review the need for careful patient selection when considering curative and palliative surgery, including liver transplantation. We conclude that there are now better diagnostic tools and therapeutic options available for those patients with malignant carcinoid tumours, and that these patients are best managed by a multidisciplinary approach. Earlier detection and treatment of these tumours should lead to improved quality of life and survival, which, ideally, should be assessed in formal trials.	Royal Free Hosp, Sch Med, Neuroendocrine Tumour Grp & Clin, London NW3 2PF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Caplin, ME (corresponding author), Royal Free Hosp, Sch Med, Neuroendocrine Tumour Grp & Clin, London NW3 2PF, England.	caplin@rfhsm.ac.uk	Burroughs, Andrew K/C-5645-2009	Burroughs, Andrew K/0000-0001-6527-457X				AHLMAN H, 1993, ENDOCRIN METAB CLIN, V22, P889, DOI 10.1016/S0889-8529(18)30140-3; ARNOLD R, 1994, DIGESTION, V55, P107, DOI 10.1159/000201211; Arnold R, 1996, GUT, V38, P430, DOI 10.1136/gut.38.3.430; ARNOLD R, 1995, FRONT GASTROINT RES, V23, P431; ASPESTRAND F, 1993, ACTA RADIOL, V34, P468; Bax NDS, 1996, ANTI-CANCER DRUG, V7, P17, DOI 10.1097/00001813-199601001-00004; BLACK WC, 1968, LAB INVEST, V19, P473; CAPLIN ME, 1998, IN PRESS AM J GASTRO; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Chughtai TS, 1997, SURGERY, V122, P801, DOI 10.1016/S0039-6060(97)90090-8; COHN G, 1986, WORLD J SURG, V10, P548, DOI 10.1007/BF01655522; Creutzfeldt W, 1996, WORLD J SURG, V20, P126, DOI 10.1007/s002689900020; Critchley M, 1997, POSTGRAD MED J, V73, P399, DOI 10.1136/pgmj.73.861.399; DAVIS Z, 1973, SURG GYNECOL OBSTET, V137, P637; DELELLIS RA, 1984, AM J SURG PATHOL, V8, P295; DiBartolomeo M, 1996, CANCER-AM CANCER SOC, V77, P402, DOI 10.1002/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4; Dong QH, 1997, J CLIN ENDOCR METAB, V82, P1416, DOI 10.1210/jc.82.5.1416; Dousset B, 1996, WORLD J SURG, V20, P908, DOI 10.1007/s002689900138; Dusmet ME, 1996, WORLD J SURG, V20, P189, DOI 10.1007/s002689900029; ERIKSSON B, 1990, ACTA ENDOCRINOL-COP, V122, P154; FELDMAN JM, 1986, AM J MED, V81, P41, DOI 10.1016/0002-9343(86)90583-8; GERSTLE JT, 1995, J AM COLL SURGEONS, V180, P427; GILLIGAN CJ, 1995, AM J GASTROENTEROL, V90, P338; GIOVANNINI M, 1993, GASTROEN CLIN BIOL, V17, P26; GODWIN JD, 1975, CANCER, V36, P560, DOI 10.1002/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4; GOODWIN JD, 1975, CANCER, V36, P560; GUSTAFSEN J, 1986, SCAND J GASTROENTERO, V21, P816, DOI 10.3109/00365528609011123; HAJARIZADEH H, 1992, AM J SURG, V163, P479, DOI 10.1016/0002-9610(92)90392-5; Hodgson HJ, 1992, GASTROENTEROL CLIN N, P643; HOEFNAGEL CA, 1987, EUR J NUCL MED, V13, P187, DOI 10.1007/BF00256489; Hughes MJ, 1996, ANN ONCOL, V7, P208; JANSON ET, 1994, EUR J ENDOCRINOL, V131, P577, DOI 10.1530/eje.0.1310577; Janson ET, 1997, ANN ONCOL, V8, P685, DOI 10.1023/A:1008215730767; KAPLAN LM, 1991, HARRISONS PRINCIPLES, P1386; Kisker O, 1997, J AM COLL SURGEONS, V184, P487; Koura AN, 1997, CANCER, V79, P1294, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1294::AID-CNCR4>3.0.CO;2-H; Krenning E. P., 1997, Journal of Nuclear Medicine, V38, p47P; Kwekkeboom DJ, 1996, WORLD J SURG, V20, P157, DOI 10.1007/s002689900024; LAMERS CB, 1978, AM J MED, V64, P607, DOI 10.1016/0002-9343(78)90580-6; Lang H, 1997, ANN SURG, V225, P347, DOI 10.1097/00000658-199704000-00002; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LEHY T, 1989, GASTROENTEROLOGY, V96, P1029, DOI 10.1016/0016-5085(89)91620-X; LeTreut YP, 1997, ANN SURG, V225, P355, DOI 10.1097/00000658-199704000-00003; Loftus J P, 1995, Adv Surg, V28, P317; MARLINK RG, 1990, CANCER, V65, P2227, DOI 10.1002/1097-0142(19900515)65:10<2227::AID-CNCR2820651011>3.0.CO;2-C; MELMON KL, 1965, GASTROENTEROLOGY, V48, P18; Mitchell ME, 1996, J CLIN GASTROENTEROL, V23, P284, DOI 10.1097/00004836-199612000-00009; MITTY HA, 1985, RADIOLOGY, V155, P623, DOI 10.1148/radiology.155.3.4001362; Modlin IM, 1997, AM J GASTROENTEROL, V92, P633; MOERTEL CG, 1994, ANN INTERN MED, V120, P302, DOI 10.7326/0003-4819-120-4-199402150-00008; MOERTEL CG, 1991, CANCER, V67, P33, DOI 10.1002/1097-0142(19910101)67:1<33::AID-CNCR2820670107>3.0.CO;2-E; MOERTEL CG, 1968, CANCER-AM CANCER SOC, V21, P270, DOI 10.1002/1097-0142(196802)21:2<270::AID-CNCR2820210217>3.0.CO;2-9; Moertel CG, 1992, TXB INTERNAL MED, P1166; MOERTEL CG, 1961, CANCER, V14, P1901; MULLER J, 1987, AM J SURG PATHOL, V11, P909; Nagaoka S, 1996, SURG TODAY, V26, P184, DOI 10.1007/BF00311504; *NCI, 1987, SURV EP END RES SEER; Nobels FRE, 1997, J CLIN ENDOCR METAB, V82, P2622, DOI 10.1210/jc.82.8.2622; NocaudieCalzada M, 1996, EUR J NUCL MED, V23, P1448, DOI 10.1007/BF01254466; NORHEIM I, 1986, J CLIN ENDOCR METAB, V63, P605, DOI 10.1210/jcem-63-3-605; NORTON JA, 1994, DIGESTION, V55, P98, DOI 10.1159/000201209; OBERG K, 1993, ENDOCRIN METAB CLIN, V22, P941, DOI 10.1016/S0889-8529(18)30142-7; OBERG K, 1994, DIGESTION, V3, P64; Oberndorfer S, 1907, FRANKFURT Z PATHOL, V1, P426; Otte A, 1998, LANCET, V351, P417, DOI 10.1016/S0140-6736(05)78355-0; PELLIKKA PA, 1993, CIRCULATION, V87, P1188, DOI 10.1161/01.CIR.87.4.1188; Perault C, 1997, J NUCL MED, V38, P1234; PLATT AJ, 1992, LANCET, V339, P1416, DOI 10.1016/0140-6736(92)91235-Z; Rindi G, 1996, WORLD J SURG, V20, P168, DOI 10.1007/s002689900026; RINDI G, 1993, GASTROENTEROLOGY, V105, P1264; ROTHMUND M, 1994, DIGESTION, V55, P86, DOI 10.1159/000201207; ROTHMUND M, 1994, DIGESTION, V104, P994; Ruszniewski P, 1996, GUT, V39, P279, DOI 10.1136/gut.39.2.279; Semelka RC, 1996, JMRI-J MAGN RESON IM, V6, P855, DOI 10.1002/jmri.1880060603; Severson RK, 1996, CANCER EPIDEM BIOMAR, V5, P81; SOGA J, 1971, CANCER-AM CANCER SOC, V28, P990, DOI 10.1002/1097-0142(1971)28:4<990::AID-CNCR2820280424>3.0.CO;2-K; SOLICIA C, 1981, PHYSL GASTROINTESTIN, P39; SUGIMOTO E, 1995, ACTA RADIOL, V36, P367; SUTEDJA TG, 1995, CHEST, V107, P556, DOI 10.1378/chest.107.2.556; Taal BG, 1996, J CLIN ONCOL, V14, P1829, DOI 10.1200/JCO.1996.14.6.1829; TEH BT, 1997, MEDICINE, V76, P31; Troncone L, 1997, ANTICANCER RES, V17, P1823; VINCENT JM, 1993, CLIN RADIOL, V48, P11, DOI 10.1016/S0009-9260(05)80100-X; WAHLUND KG, 1981, CLIN CHIM ACTA, V110, P71, DOI 10.1016/0009-8981(81)90302-8; Wallace S, 1996, WORLD J SURG, V20, P147, DOI 10.1007/s002689900023; Warburton R, 1997, ANN CLIN BIOCHEM, V34, P424, DOI 10.1177/000456329703400415; WILLIAMS ED, 1963, LANCET, V1, P238; Williams I M, 1997, HPB Surg, V10, P241, DOI 10.1155/1997/46751	88	274	284	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					799	805		10.1016/S0140-6736(98)02286-7	http://dx.doi.org/10.1016/S0140-6736(98)02286-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737302				2022-12-28	WOS:000075762700041
J	Chen, RZ; Pettersson, U; Beard, C; Jackson-Grusby, L; Jaenisch, R				Chen, RZ; Pettersson, U; Beard, C; Jackson-Grusby, L; Jaenisch, R			DNA hypomethylation leads to elevated mutation rates	NATURE			English	Article							HOMOLOGOUS RECOMBINATION; V(D)J RECOMBINATION; METHYLATION; CELLS; MOUSE; METHYLTRANSFERASE; EXPRESSION; GENE	Genome-wide demethylation has been suggested to be a step in carcinogenesis(1). Evidence for this notion comes from the frequently observed global DNA hypomethylation in tumour cells(2), and from a recent study suggesting that defects in DNA methylation might contribute to the genomic instability of some colorecal tumour cell lines(3). DNA hypomethylation has also been associated with abnormal chromosomal structures, as observed in cells from patients with ICF (Immunodeficiency, Centromeric instability and Facial abnormalities) syndrome(4,5) and in cells treated with the demethylating agent 5-azadeoxycytidine(6). Here we report that murine embryonic stem cells nullizygous for the major DNA methyltransferase (Dnmt1) gene exhibited significantly elevated mutation rates at both the endogenous hypoxanthine phosphoribosyltransferase (Hprt) gene and an integrated viral thymidine kinase (tk) transgene. Gene deletions were the predominant mutations at both loci. The major cause of the observed tk deletions was either mitotic recombination or chromosomal loss accompanied by duplication of the remaining chromosome. Our results imply an important role for mammalian DNA methylation in maintaining genome stability.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Jaenisch, R (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.							BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; ENGLER P, 1993, MOL CELL BIOL, V13, P571, DOI 10.1128/MCB.13.1.571; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Ji WZ, 1997, MUTAT RES-FUND MOL M, V379, P33, DOI 10.1016/S0027-5107(97)00088-2; KENDAL WS, 1988, CANCER RES, V48, P1060; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lei H, 1996, DEVELOPMENT, V122, P3195; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LOEB LA, 1991, CANCER RES, V51, P3075; Maloisel L, 1998, GENE DEV, V12, P1381, DOI 10.1101/gad.12.9.1381; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MONK M, 1987, DEVELOPMENT, V99, P371; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; PROFFITT JH, 1984, MOL CELL BIOL, V4, P985, DOI 10.1128/MCB.4.5.985; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SHIROISHI T, 1995, ADV BIOPHYS, V31, P119, DOI 10.1016/0065-227X(95)99387-5; SHULMAN MJ, 1995, EMBO J, V14, P4102, DOI 10.1002/j.1460-2075.1995.tb00082.x; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; WAHLS WP, 1990, CELL, V60, P95, DOI 10.1016/0092-8674(90)90719-U; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	27	715	757	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1998	395	6697					89	93		10.1038/25779	http://dx.doi.org/10.1038/25779			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116JY	9738504				2022-12-28	WOS:000075722200053
J	Rao, JK; Allen, NB; Pincus, T				Rao, JK; Allen, NB; Pincus, T			Limitations of the 1990 American college of Rheumatology classification criteria in the diagnosis of vasculitis	ANNALS OF INTERNAL MEDICINE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTIBODY C-ANCA; WEGENER GRANULOMATOSIS; ARTHRITIS; MORTALITY; OSTEOARTHRITIS; QUESTIONNAIRE; NOMENCLATURE	Background: The American College of Rheumatology (ACR) established criteria to discriminate among patients with seven types of vasculitis. Although designated as "classification criteria" for research, these criteria are often used for diagnosis. Objective: To examine the operating characteristics of the 1990 ACR classification criteria in the diagnosis of Wegener granulomatosis, giant-cell arteritis, polyarteritis nodosa, and hypersensitivity vasculitis. Design: Prospective cohort study. Setting: University medical center and Veterans Affairs medical center. Patients: 198 consecutive patients referred to rheumatologists for evaluation of possible vasculitis. Measurements: Blinded chart audits were done to classify patients according to the 1990 ACR classification criteria for Wegener granulomatosis, polyarteritis nodosa, giant-cell arteritis, and hypersensitivity vasculitis on the basis of the patients' initial presentation. Chart audits done 2 to 8 months after baseline provided the patients' final diagnoses, which were considered the gold standard, as in the development of the ACR criteria. Test operating characteristics of the ACR classification criteria were calculated according to 2 x 2 tables for the entire cohort and for only the patients with a final diagnosis of vasculitis. Results: Vasculitis was diagnosed in 51 (26%) patients. Thirty-eight (75%) of 51 patients with vasculitis and 31 (21%) of 147 patients without vasculitis met ACR criteria for one or more types of vasculitis. The positive predictive values for the four vasculitides according to ACR criteria were 17% to 29% for the entire cohort and 29% to 75% for only the patients with a final diagnosis of vasculitis. Conclusion: The 1990 ACR classification criteria function poorly in the diagnosis of specific vasculitides.	Richard L Roudebush Vet Affairs Med Ctr, Ctr Hlth Sci Res 11H, Indianapolis, IN 46202 USA; Duke Univ, Med Ctr, Div Rheumatol Allergy & Immunol, Durham, NC 27710 USA; Vanderbilt Univ, Sch Med, Div Rheumatol & Immunol, Nashville, TN 37232 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Duke University; Vanderbilt University	Rao, JK (corresponding author), Richard L Roudebush Vet Affairs Med Ctr, Ctr Hlth Sci Res 11H, 1481 W 10th St, Indianapolis, IN 46202 USA.							ALARCONSEGOVIA D, 1977, MED CLIN N AM, V61, P241, DOI 10.1016/S0025-7125(16)31330-X; ALTMAN R, 1991, ARTHRITIS RHEUM, V34, P505, DOI 10.1002/art.1780340502; ALTMAN R, 1990, ARTHRITIS RHEUM, V33, P1601, DOI 10.1002/art.1780331101; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BLOCH DA, 1990, ARTHRITIS RHEUM, V33, P1068; BLOCH DA, 1990, ARTHRITIS RHEUM, V33, P1137; CALABRESE LH, 1990, ARTHRITIS RHEUM, V33, P1108; FRIES JF, 1990, ARTHRITIS RHEUM, V33, P1135; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1065; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; Jennette JC, 1997, NEW ENGL J MED, V337, P1512, DOI 10.1056/NEJM199711203372106; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; LIE JT, 1987, PATHOL ANNU, V22, P125; LIE JT, 1994, ARTHRITIS RHEUM-US, V37, P181, DOI 10.1002/art.1780370205; LIGHTFOOT RW, 1990, ARTHRITIS RHEUM, V33, P1088; NIERENBERG AA, 1988, JAMA-J AM MED ASSOC, V259, P1699, DOI 10.1001/jama.259.11.1699; Panush RS, 1997, B RHEUM DIS, V46, P3; PINCUS T, 1987, J RHEUMATOL, V14, P240; PINCUS T, 1984, ARTHRITIS RHEUM-US, V27, P864, DOI 10.1002/art.1780270805; PINCUS T, 1994, ANN INTERN MED, V120, P26, DOI 10.7326/0003-4819-120-1-199401010-00005; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; RAO JK, 1995, ANN INTERN MED, V123, P925, DOI 10.7326/0003-4819-123-12-199512150-00005; RAO JK, 1995, LANCET, V346, P926, DOI 10.1016/S0140-6736(95)91555-9; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; WARD MM, 1995, ARTHRITIS RHEUM, V38, P1492, DOI 10.1002/art.1780381016; WARD MM, 1990, ARCH INTERN MED, V150, P849, DOI 10.1001/archinte.150.4.849	28	252	265	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1998	129	5					345	352		10.7326/0003-4819-129-5-199809010-00001	http://dx.doi.org/10.7326/0003-4819-129-5-199809010-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114RL	9735061				2022-12-28	WOS:000075622600001
J	Eisenberg, S; Aksentijevich, I; Deng, ZM; Kastner, DL; Matzner, Y				Eisenberg, S; Aksentijevich, I; Deng, ZM; Kastner, DL; Matzner, Y			Diagnosis of familial Mediterranean fever by a molecular genetics method	ANNALS OF INTERNAL MEDICINE			English	Article						periodic disease; mutation; molecular sequence data; polymerase chain reaction; diagnosis	COLCHICINE; FREQUENCY; ATTACKS; FLUIDS; TRIAL; ARMS	Background: Familial Mediterranean fever is a recessively inherited disorder characterized by episodes of fever with abdominal pain, pleurisy, or arthritis. The familial Mediterranean fever gene, designated MEFV, was recently cloned, and at least three missense mutations (M680I, M694V, and V726A) that account for a large percentage of patients with this disease were identified. Objective: To establish a diagnostic test for familial Mediterranean fever. Design: Cross-sectional study of a convenience sample of patients attending familial Mediterranean fever clinics. Setting: Tertiary referral hospitals. Patients: 107 patients with familiar Mediterranean fever, their family members, and controls. Measurements: Mutations in the 107 samples were assessed by amplifying genomic DNA with use of primers that selectively amplify the normal or altered DNA sequence of the 3 MEFV mutations (amplification refractory mutation system [ARMS]). Mutations were independently assessed by automated sequencing of genomic DNA amplified by polymerase chain reaction to evaluate the sensitivity and specificity of the ARMS assay. Results: The ARMS assay correctly identified M680I, M694V, and V726A mutations in 82 persons with mutations documented by DNA sequencing (21 homozygotes, 2 compound heterozygotes, and 59 simple heterozygotes). Of 7 persons known from family studies to be noncarriers and 18 unrelated persons who were negative for these mutations by sequencing, none had MEFV mutations according to ARMS. Conclusion: The ARMS assay is a rapid, cost-effective, and accurate method for detecting three common mutations in familial Mediterranean fever.	Hadassah Univ Hosp, Hematol Unit, IL-91240 Jerusalem, Israel; NIAMSD, Arthrit & Rheumatism Branch, Bethesda, MD 20892 USA	Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Matzner, Y (corresponding author), Hadassah Univ Hosp, Hematol Unit, Mt Scopus, IL-91240 Jerusalem, Israel.	matzner@cc.huji.ac.il	Aksentijevich, Ivona/AAF-1335-2019					Aksentijevich I, 1997, CELL, V90, P797; Bernot A, 1997, NAT GENET, V17, P25; Chen XG, 1998, HUM MUTAT, V11, P456, DOI 10.1002/(SICI)1098-1004(1998)11:6<456::AID-HUMU6>3.0.CO;2-G; DANIELS M, 1995, AM J MED GENET, V55, P311, DOI 10.1002/ajmg.1320550313; DINARELLO CA, 1974, NEW ENGL J MED, V291, P934, DOI 10.1056/NEJM197410312911804; DRACOPOLI NC, 1995, CURRENT PROTOCOLS HU; FERRIE RM, 1992, AM J HUM GENET, V51, P251; HELLER H, 1958, ARCH INTERN MED, V102, P50, DOI 10.1001/archinte.1958.00260190052007; Livneh A, 1997, ARTHRITIS RHEUM-US, V40, P1879, DOI 10.1002/art.1780401023; MATZNER Y, 1990, ARCH INTERN MED, V150, P1289, DOI 10.1001/archinte.150.6.1289; MATZNER Y, 1984, NEW ENGL J MED, V311, P287, DOI 10.1056/NEJM198408023110503; MATZNER Y, 1984, BLOOD, V63, P629; MATZNER Y, 1995, CRIT REV ONCOL HEMAT, V18, P197, DOI 10.1016/1040-8428(94)00130-L; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; REIMANN HA, 1948, JAMA-J AM MED ASSOC, V136, P239, DOI 10.1001/jama.1948.02890210023004; ROGERS DB, 1989, AM J MED GENET, V34, P168, DOI 10.1002/ajmg.1320340206; Samuels J, 1998, MEDICINE, V77, P268, DOI 10.1097/00005792-199807000-00005; SIEGAL S, 1945, ANN INTERN MED, V23, P1, DOI 10.7326/0003-4819-23-1-1; SOHAR E, 1967, AM J MED, V43, P227, DOI 10.1016/0002-9343(67)90167-2; ZEMER D, 1974, NEW ENGL J MED, V291, P932, DOI 10.1056/NEJM197410312911803; ZEMER D, 1986, NEW ENGL J MED, V314, P1001, DOI 10.1056/NEJM198604173141601	21	80	82	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1998	129	7					539	+		10.7326/0003-4819-129-7-199810010-00005	http://dx.doi.org/10.7326/0003-4819-129-7-199810010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123KN	9758573				2022-12-28	WOS:000076124500004
J	Modell, M; Wonke, B; Anionwu, E; Khan, M; Tai, SS; Lloyd, M; Modell, B				Modell, M; Wonke, B; Anionwu, E; Khan, M; Tai, SS; Lloyd, M; Modell, B			A multidisciplinary approach for improving services in primary care: randomised controlled trial of screening for haemoglobin disorders	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SICKLE-CELL DISORDERS; PRENATAL-DIAGNOSIS; THALASSEMIA; AUDIT	Objective: to investigate the feasibility of improving screening for carriers of haemoglobin disorders in general practice by using a nurse facilitator to work with primary care teams and the relevant haematology laboratories; to identify problems in communication between all those involved in delivering the service, and to implement solutions. Design: Two year, practice based randomised controlled trial. Setting North London area where 29% of residents and 43% of births are in ethnic groups at risk for haemoglobin disorders. Subjects: 26 of the 93 practices using the services of the area's haematology laboratory agreed to take part and were randomly divided into control and intervention practices. Main outcome measure: Change in number of requests for screening tests for haemoglobin disorders made by control and intervention practices in baseline and intervention years. Results: the number of screening tests requested varied from 0-150 in the 93 practices in the baseline year. Study practices tended to have made a moderate number of requests (10-50) during this period. During the intervention year intervention practices made 292 more requests (99% increase) and control practices made 74 fewer requests (23% decrease; P = 0.001 for difference in median change). Four practices, three of which were singlehanded, accounted for 75% of the increase. The number of requests from intervention practices, adjusted for baseline requests, was 3.2 times higher than control practices (P < 0.0001). Conclusion: general practitioners and practice nurses ware willing to undertake a new genetic screening service (or expand an existing one) if they are persuaded that it benefits the health of a significant proportion of their practice population. They need appropriate tools (for example, information materials for carriers and groups at risk), and the laboratory must be sensitive to their needs. Preconceptional carrier screening and counselling need to be coupled with antenatal screening.	Royal Free & Univ Coll Med Sch, Whittington Hosp, London N19 5NF, England; Whittington Hosp Trust, London N19 5NF, England; UCL, Inst Child Hlth, Mothercare Unit Clin Genet & Fetal Med, London WC1N 1EH, England	University of London; University College London; University of London; University College London	Modell, M (corresponding author), Royal Free & Univ Coll Med Sch, Whittington Hosp, London N19 5NF, England.	m.modell@ucl.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANGASTINIOTIS M, 1986, World Health Forum, V7, P291; Anionwu EN, 1997, CHILD CARE HLTH DEV, V23, P431, DOI 10.1111/j.1365-2214.1997.tb00912.x; Armitage P., 2001, STAT METHODS MED RES; Bland JM, 1997, BRIT MED J, V315, P600; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; DONNER A, 1994, J STAT PLAN INFER, V42, P37, DOI 10.1016/0378-3758(94)90188-0; FAIRWEATHER DVI, 1980, BRIT J OBSTET GYNAEC, V87, P87, DOI 10.1111/j.1471-0528.1980.tb04499.x; Haines A, 1996, BRIT J GEN PRACT, V46, P115; *HLTH ED AUTH, 1998, SICKL CELL THAL ACH; Modell B, 1997, BRIT MED J, V315, P779, DOI 10.1136/bmj.315.7111.779; MODELL B, 1980, BMJ-BRIT MED J, V281, P737; Neuenschwander H, 1997, BRIT MED J, V315, P784; OLD JM, 1990, LANCET, V336, P834, DOI 10.1016/0140-6736(90)92338-I; OSTROWSKY JT, 1985, AM J PUBLIC HEALTH, V75, P732, DOI 10.2105/AJPH.75.7.732; PETROU M, 1992, J MED GENET, V29, P820, DOI 10.1136/jmg.29.11.820; ROBERTS BE, 1988, CLIN LAB HAEMATOL, V10, P87; *WORK PART STAND M, 1993, SICKL CELL THAL OTH	18	46	47	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 19	1998	317	7161					788	791		10.1136/bmj.317.7161.788	http://dx.doi.org/10.1136/bmj.317.7161.788			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740569	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000076084200033
J	Tamblyn, R; Abrahamowicz, M; Brailovsky, C; Grand'Maison, P; Lescop, J; Norcini, J; Girard, N; Haggerty, J				Tamblyn, R; Abrahamowicz, M; Brailovsky, C; Grand'Maison, P; Lescop, J; Norcini, J; Girard, N; Haggerty, J			Association between licensing examination scores and resource use and quality of care in primary care practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTINUING MEDICAL-EDUCATION; INAPPROPRIATE MEDICATION; SCREENING MAMMOGRAPHY; GENERAL-PRACTICE; CHART AUDIT; PHYSICIAN CHARACTERISTICS; PREVENTIVE PRACTICES; SCHOOL PERFORMANCES; DRUG EXPENDITURES; ELDERLY PATIENTS	Context.-Clinical competence is a determinant of the quality of care delivered, and may be associated with use of health care resources by primary care physicians. Clinical competence is assumed to be assessed by licensing examinations, yet there is a paucity of information on whether scores achieved predict subsequent practice. Objective.-To determine if licensing examination scores were associated with selected aspects of quality of care and resource use in initial primary care practice. Design.-Prospective cohort study of recently licensed family physicians, followed up for the first 18 months of practice. Setting.-The Quebec health care system. Participants.-A total of 614 family physicians who passed the licensing examination between 1991 and 1993 and entered fee-for-service practice in Quebec. Main Outcome Measures.-All patients seen by physicians were identified by the universal health insurance board and all health services provided to these patients were retrieved for the 18 months prior to (baseline) and after (follow-up) the physicians' entry into practice. Medical service and prescription claims files were used to measure rates of resource use (specialty consultation, symptom-relief prescribing compared with disease-specific prescribing) and quality of care (inappropriate prescribing, mammography screening). Baseline data were used to adjust for differences in practice population. Results.-Study physicians saw a total of 1 116 389 patients, of whom 113 535 (10.2%) were elderly and 83 391 (7.5%) were women aged 50 to 69 years. Physicians with higher licensing examination scores referred more of their patients for consultation (3.8/1000 patients per SD increase in score; 95% confidence interval [CI], 1.2-7.0; P=.005), prescribed to elderly patients fewer inappropriate medications (-2.7/1000 patients per SD increase in score; 95% CI, -4.8 to -0.7; P=.009) and more disease-specific medications relative to symptom-relief medications (3.9/1000 patients per SD increase in score; 95% CI, 0.3 to 7.4; P=.03), and referred more women aged 50 to 69 years (6.6/1000 patients per SD increase in score; 95% CI, 1.2-11.9; P=.02) for mammography screening. If patients of physicians with the lowest scores had experienced the same rates of consultation, prescribing, and screening as patients of physicians with the highest scores, an additional 3027 patients would have been referred, 179 fewer elderly patients would have been prescribed symptom-relief medication, 912 more elderly patients would have been prescribed disease-specific medication, 189 fewer patients would have received inappropriate medication, and 121 more women would have received mammography screening. Conclusions.-Licensing examination scores are significant predictors of consultation, prescribing, and mammography screening rates in initial primary care practice.	McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Biostat & Epidemiol, Montreal, PQ, Canada; Univ Laval, Ctr Evaluat Sci Sante, Quebec City, PQ, Canada; Univ Sherbrooke, Dept Family Med, Sherbrooke, PQ J1K 2R1, Canada; Quebec Coll Phys, Montreal, PQ, Canada; Amer Board Internal Med, Philadelphia, PA USA	McGill University; McGill University; Laval University; University of Sherbrooke; American Board of Internal Medicine	Tamblyn, R (corresponding author), Div Clin Epidemiol, Ross Pavil 4-11,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	mi64@musica.mcgill.ca	Tamblyn, Robyn/L-6010-2016	Abrahamowicz, Michal/0000-0002-3172-3952; Norcini, John/0000-0002-8464-4115				ANDERSON GM, 1993, INQUIRY-J HEALTH CAR, V30, P199; ASHTON CM, 1995, ANN INTERN MED, V122, P415, DOI 10.7326/0003-4819-122-6-199503150-00003; Bashook PG, 1998, BRIT MED J, V316, P545, DOI 10.1136/bmj.316.7130.545; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATTISTA RN, 1986, MED CARE, V24, P216, DOI 10.1097/00005650-198603000-00004; BATTISTA RN, 1990, AM J PREV MED, V6, P6, DOI 10.1016/S0749-3797(18)31038-9; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; BEERS MH, 1990, ANN INTERN MED, V112, P61, DOI 10.7326/0003-4819-112-1-61; BEERS MH, 1992, ANN INTERN MED, V117, P684, DOI 10.7326/0003-4819-117-8-684; BELLAMY N, 1989, MED J AUSTRALIA, V151, P531, DOI 10.5694/j.1326-5377.1989.tb128510.x; Bindman AB, 1996, J GEN INTERN MED, V11, P269, DOI 10.1007/BF02598266; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; CALMAN NS, 1992, J FAM PRACTICE, V35, P31; *CAN MED ASS, 1994, STRENGTH FDN ROL PHY, P1; CASE SM, 1995, PRACTICALLY CRADLE G; Case W. G., 1996, ACAD MED S, V71, pS31; COCKBURN J, 1989, MED J AUSTRALIA, V151, P391, DOI 10.5694/j.1326-5377.1989.tb101221.x; COLL PP, 1989, J AM GERIATR SOC, V37, P957, DOI 10.1111/j.1532-5415.1989.tb07281.x; *COMM SAF MED, 1986, BMJ-BRIT MED J, V292, P614; DAVIDSON W, 1995, CAN MED ASSOC J, V152, P1227; DAVIDSON W, 1994, CAN MED ASSOC J, V150, P917; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DILLON EC, 1994, OPHTHALMOLOGY, V101, P1627; ELAM CL, 1994, ACAD MED, V69, P155, DOI 10.1097/00001888-199402000-00025; ELAM CL, 1994, ACAD MED, V69, P852, DOI 10.1097/00001888-199410000-00018; FERGUSON RI, 1990, NEW ZEAL MED J, V103, P558; FERRY ME, 1985, J AM GERIATR SOC, V33, P616, DOI 10.1111/j.1532-5415.1985.tb06318.x; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; Friday GA, 1997, ANN ALLERG ASTHMA IM, V78, P221, DOI 10.1016/S1081-1206(10)63391-1; GABE J, 1990, BRIT J ADDICT, V85, P41; GABEL RA, 1992, INT ANESTHESIOL CLIN, V30, P93, DOI 10.1097/00004311-199230020-00009; GANN P, 1993, ANN INTERN MED, V118, P893, DOI 10.7326/0003-4819-118-11-199306010-00011; GERVAS J, 1994, FAM PRACT, V11, P307, DOI 10.1093/fampra/11.3.307; GRANDMAISON P, 1992, CAN MED ASSOC J, V146, P1735; HANDFIELDJONES R, 1990, CAN FAM PHYSICIAN, V36, P2069; HAYNES RB, 1984, JAMA-J AM MED ASSOC, V251, P61, DOI 10.1001/jama.251.1.61; HOHMANN AA, 1989, MED CARE, V27, P478, DOI 10.1097/00005650-198905000-00004; HOLM M, 1988, DAN MED BULL, V35, P495; Holt W S Jr, 1992, Fam Med, V24, P524; Homer CJ, 1996, PEDIATRICS, V98, P18; ILIFFE S, 1994, J ROY SOC MED, V87, P11; JOHNSON JA, 1995, ARCH INTERN MED, V155, P1949, DOI 10.1001/archinte.155.18.1949; KNOTTNERUS JA, 1990, BRIT J GEN PRACT, V40, P178; KRUSE J, 1987, OBSTET GYNECOL, V70, P744; Lawler FH, 1997, J FAM PRACTICE, V44, P369; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEAF DA, 1995, J GEN INTERN MED, V10, P194, DOI 10.1007/BF02600254; Legorreta AP, 1998, ARCH INTERN MED, V158, P457, DOI 10.1001/archinte.158.5.457; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2328; LEXCHIN J, 1993, CAN FAM PHYSICIAN, V39, P2298; LINDLEY CM, 1992, AGE AGEING, V21, P294, DOI 10.1093/ageing/21.4.294; LIPTON HL, 1995, INT J TECHNOL ASSESS, V11, P485, DOI 10.1017/S0266462300008692; LIPTON HL, 1993, MED CARE, V31, P1069, DOI 10.1097/00005650-199312000-00001; LIVINGSTON SA, 1989, PASSING SCORES; LOWY FH, 1991, HLTH AFF MILLWOO SPR, P215; MADELEY RJ, 1991, J PUBLIC HEALTH MED, V12, P22; MAHEUX B, 1989, AM J PREV MED, V5, P201, DOI 10.1016/S0749-3797(18)31081-X; MCGAVOCK H, 1988, BRIT MED J, V296, P900, DOI 10.1136/bmj.296.6626.900; MOLSTAD S, 1990, EUR J CLIN PHARMACOL, V39, P9; MONTANO DE, 1995, AM J PUBLIC HEALTH, V85, P795, DOI 10.2105/AJPH.85.6.795; MUSTIN HD, 1994, JAMA-J AM MED ASSOC, V272, P115; *NAT PHARM STRAT O, 1993, NAT PHARM STRAT DISC; Nicolucci A, 1996, DIABETES CARE, V19, P927, DOI 10.2337/diacare.19.9.927; NOONE A, 1989, J ROY COLL GEN PRACT, V39, P404; NORCINI JJ, 1987, J GEN INTERN MED, V2, P336; OCONNOR AM, 1995, CAN J PUBLIC HEALTH, V86, P42; OSBORN EH, 1991, J FAM PRACTICE, V32, P465; Partridge MR, 1997, J ACCID EMERG MED, V14, P16; RAMSEY PG, 1989, ANN INTERN MED, V110, P719, DOI 10.7326/0003-4819-110-9-719; *REG ASS MAL QUEB, 1994, STAT ANN 1992, P1; REYNOLDS GA, 1991, BMJ-BRIT MED J, V302, P1250, DOI 10.1136/bmj.302.6787.1250; ROTH SH, 1988, ANN INTERN MED, V109, P353, DOI 10.7326/0003-4819-109-5-353; Salive ME, 1996, PREV MED, V25, P561, DOI 10.1006/pmed.1996.0090; SANTELL JP, 1994, AM J HOSP PHARM, V51, P177, DOI 10.1093/ajhp/51.2.177; Selinger H A, 1989, Fam Med, V21, P56; Sirontnik K. A., 1974, EVALUATION ED, P453; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; Swanson DB, 1996, ACAD MED, V71, pS28, DOI 10.1097/00001888-199601000-00034; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; TAMBLYN R, 1994, EVAL HEALTH PROF, V17, P198, DOI 10.1177/016327879401700205; Tamblyn R, 1997, ANN INTERN MED, V127, P429, DOI 10.7326/0003-4819-127-6-199709150-00003; TAMBLYN R, 1993, J CONTIN EDUC HEALTH, V13, P273, DOI DOI 10.1002/chp.4750130403; TAMBLYN RM, 1994, CAN MED ASSOC J, V150, P1801; TAMBLYN RM, 1996, FINAL REPORT VALID A; VANDERWAALS FW, 1993, BRIT MED J, V307, P363, DOI 10.1136/bmj.307.6900.363; VERHULST SJ, 1993, ACAD MED, V68, pS61, DOI 10.1097/00001888-199302000-00033; WAREHAM NJ, 1993, THORAX, V48, P1117, DOI 10.1136/thx.48.11.1117; WILCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292; WILKIN D, 1987, J R COLL GEN PRACT, V37, P351; WILLIAMS CL, 1994, ATHEROSCLEROSIS, V108, pS117, DOI 10.1016/0021-9150(94)90157-0; WILLKINS R, 1993, HLTH REP, V5, P157; WRIGHT RA, 1993, JAMA-J AM MED ASSOC, V269, P2544, DOI 10.1001/jama.269.19.2544; YAPHE J, 1992, CAN FAM PHYSICIAN, V38, P2314; [No title captured]	96	108	112	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1998	280	11					989	996		10.1001/jama.280.11.989	http://dx.doi.org/10.1001/jama.280.11.989			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	119JC	9749481	Bronze			2022-12-28	WOS:000075891400032
J	Mandl, KD; Kohane, IS; Brandt, AM				Mandl, KD; Kohane, IS; Brandt, AM			Electronic patient-physician communication: Problems and promise	ANNALS OF INTERNAL MEDICINE			English	Article							WORLD-WIDE-WEB; HEALTH-CARE; INTERNET; INFORMATION; TELEMEDICINE; SATISFACTION; TECHNOLOGY; ADVICE; TRIAL	A critical mass of Internet users will soon enable wide diffusion of electronic communication within medical practice. E-mail between physicians and patients offers important opportunities for better communication. Linking patients and physicians through e-mail may increase the involvement of patients in supervising and documenting their own health care, processes that may activate patients and contribute to improved health. These new linkages may have profound implications for the patient-physician relationship. Although the federal government proposes regulation of telemedicine technologies and medical software, communications technologies are evolving under less scrutiny. Unless these technologies are implemented with substantial forethought, they may disturb delicate balances in the patient-physician relationship, widen social disparities in health outcomes, and create barriers to access to health care. This paper seeks to identify the promise and pitfalls of electronic patient-physician communication before such technology becomes widely distributed. A research agenda is proposed that would provide data that are useful for careful shaping of the communications infrastructure. The paper addresses the need to 1) define appropriate use of the various modes of patient-physician communication, 2) ensure the security and confidentiality of patient information, 3) create user interfaces that guide patients in effective use of the technology, 4) proactively assess medicolegal liability, and 5) ensure access to the technology by a multicultural, multilingual population with varying degrees of literacy.	Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA; MIT, Cambridge, MA 02139 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Mandl, KD (corresponding author), Childrens Hosp, Div Emergency Med, MA-001,300 Longwood Ave, Boston, MA 02115 USA.		Kohane, Isaac Kohane/K-3716-2012	Kohane, Isaac Kohane/0000-0003-2192-5160				ACKERMAN M, 1998, NEXT GENERATION INTE; ALLELY EB, 1995, J MED SYST, V19, P207, DOI 10.1007/BF02257174; Aronson S H, 1977, Med Hist, V21, P69; BAER L, 1995, JAMA-J AM MED ASSOC, V273, P1943; Balas EA, 1997, JAMA-J AM MED ASSOC, V278, P152, DOI 10.1001/jama.278.2.152; BERTAKIS KD, 1977, J FAM PRACTICE, V5, P217; Bysinger B, 1997, Health Manag Technol, V18, P44; ChiLum BI, 1996, JAMA-J AM MED ASSOC, V275, P1361, DOI 10.1001/jama.275.17.1361; Dertouzos Michael, 1997, WHAT WILL BE NEW WOR; Diffie W., 1998, PRIVACY LINE POLITIC; Ferguson S., 2020, J ED ONLINE; FISCHER CS, 1992, AM CALLING SOCIAL HI, P176; Fraser HSF, 1997, BRIT MED J, V314, P1600, DOI 10.1136/bmj.314.7094.1600; FRIDSMA DB, 1994, P 18 ANN S COMP APPL; GLOWNIAK JV, 1995, ANN INTERN MED, V123, P123, DOI 10.7326/0003-4819-123-2-199507150-00008; GLOWNIAK JV, 1994, JAMA-J AM MED ASSOC, V271, P1934, DOI 10.1001/jama.271.24.1934; Gray J, 1997, J AM MED INFORM ASSN, P413; GREENE MG, 1994, SOC SCI MED, V38, P1279, DOI 10.1016/0277-9536(94)90191-0; Gross T P, 1996, Stud Health Technol Inform, V28, P17; Gurak LJ, 1997, PERSUASION PRIVACY C; GUSTAFSON DH, 1994, J AM MED INFORM ASSN, P604; Halamka JD, 1997, J AM MED INFORM ASSN, P349; Hamvas A, 1996, NEW ENGL J MED, V334, P1635, DOI 10.1056/NEJM199606203342504; Hof Robert D., 1997, BUS WEEK        0505, P64; Hoffman DL, 1998, SCIENCE, V280, P390, DOI 10.1126/science.280.5362.390; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P611, DOI 10.1001/jama.279.8.611; Jones MG, 1997, J AM MED INFORM ASSN, V4, P399, DOI 10.1136/jamia.1997.0040399; Kane B, 1998, J AM MED INFORM ASSN, V5, P104, DOI 10.1136/jamia.1998.0050104; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; KASSIRER JP, 1992, NEW ENGL J MED, V326, P195, DOI 10.1056/NEJM199201163260310; KATZ J, 1996, MOTIVATIONS BARRIERS; Keen J, 1998, BRIT MED J, V316, P1291, DOI 10.1136/bmj.316.7140.1291; Kobak KA, 1997, JAMA-J AM MED ASSOC, V278, P905, DOI 10.1001/jama.278.11.905; Kohane I S, 1996, Proc AMIA Annu Fall Symp, P608; KORSCH BM, 1984, PEDIATRICS, V74, P917; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; LINKINS RW, 1994, ARCH PEDIAT ADOL MED, V148, P908, DOI 10.1001/archpedi.1994.02170090022002; MANDL KD, 1998, IN PRESS P AMIA ANN; MEEKER M, 1996, INTERNET REPORT M ST; METCALFE B, 1995, INFOWORLD       1204, P61; Miller RA, 1997, ANN INTERN MED, V127, P842, DOI 10.7326/0003-4819-127-9-199711010-00014; *NAT RES COUNC COM, 1997, REC PROT EL HLTH INF; Neill R A, 1994, Arch Fam Med, V3, P268, DOI 10.1001/archfami.3.3.268; Peters R, 1997, JAMA-J AM MED ASSOC, V277, P505, DOI 10.1001/jama.277.6.505; POOLE SR, 1993, PEDIATRICS, V92, P670; Rind DM, 1997, ANN INTERN MED, V127, P138, DOI 10.7326/0003-4819-127-2-199707150-00008; RIVEST RL, 1978, COMMUN ACM, V21, P120, DOI [10.1145/359340.359342, 10.1145/357980.358017]; Rogers E., 2003, DIFFUSION INNOVATION, VFifth; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; SLACK WV, 1966, NEW ENGL J MED, V274, P194, DOI 10.1056/NEJM196601272740406; SZOLOVITS P, 1994, J AM MED INFORM ASSN, V1, P316, DOI 10.1136/jamia.1994.95236164; Szolovits P., 1994, TR604 MIT LAB COMP S; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; Weeda DF, 1998, TRANSFUSION, V38, P86, DOI 10.1046/j.1537-2995.1998.38198141504.x; Wenner H, 1997, Med Device Technol, V8, P22; Widman LE, 1997, ARCH INTERN MED, V157, P209, DOI 10.1001/archinte.157.2.209; Young KT, 1998, ARCH PEDIAT ADOL MED, V152, P255; 1997, CONSUMER REPORTS, V62, P27; 1997, HOSP CASE MANAG, V5, P81	59	141	147	1	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1998	129	6					495	500		10.7326/0003-4819-129-6-199809150-00012	http://dx.doi.org/10.7326/0003-4819-129-6-199809150-00012			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	119JJ	9735088	Green Published			2022-12-28	WOS:000075892100009
J	Banin, S; Moyal, L; Shieh, SY; Taya, Y; Anderson, CW; Chessa, L; Smorodinsky, NI; Prives, C; Reiss, Y; Shiloh, Y; Ziv, Y				Banin, S; Moyal, L; Shieh, SY; Taya, Y; Anderson, CW; Chessa, L; Smorodinsky, NI; Prives, C; Reiss, Y; Shiloh, Y; Ziv, Y			Enhanced phosphorylation of p53 by ATN in response to DNA damage	SCIENCE			English	Article							ATAXIA-TELANGIECTASIA GENE; PHOSPHOINOSITIDE 3-KINASE; CELL-CYCLE; MAMMALIAN TARGET; PROTEIN; PRODUCT; KINASE; WORTMANNIN; INHIBITION; RAPAMYCIN	The ATM protein, encoded by the gene responsible for the human genetic disorder ataxia telangiectasia (A-T), regulates several cellular responses to DNA breaks. ATM shares a phosphoinositide 3-kinase-related domain with several proteins, some of them protein kinases. A wortmannin-sensitive protein kinase activity was associated with endogenous or recombinant ATM and was abolished by structural ATM mutations. In vitro substrates included the translation repressor PHAS-I and the p53 protein. ATM phosphorylated p53 in vitro on a single residue, serine-15, which is phosphorylated in vivo in response to DNA damage. This activity was markedly enhanced within minutes after treatment of cells with a radiomimetic drug; the total amount of ATM remained unchanged. Various damage-induced responses may be activated by enhancement of the protein kinase activity of ATM.	Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Ramat Aviv, Israel; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 104, Japan; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Univ Rome La Sapienza, Dipartimento Med Sperimentale, I-00161 Rome, Italy; Tel Aviv Univ, George S Wise Fac Life Sci, Hybridoma Unit, IL-69978 Ramat Aviv, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Ramat Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Columbia University; National Cancer Center - Japan; United States Department of Energy (DOE); Brookhaven National Laboratory; Sapienza University Rome; Tel Aviv University; Tel Aviv University	Shiloh, Y (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Ramat Aviv, Israel.		Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31763] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANIN S, UNPUB; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; FISCELLA M, 1993, ONCOGENE, V8, P1519; Gilad S, 1998, AM J HUM GENET, V62, P551, DOI 10.1086/301755; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GOLDBERG IH, 1995, ENEDIYNE ANTIBIOTICS, P327; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HAUPT Y, 1997, NATURE, V387, P286; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1996, ONCOGENE, V13, P2707; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN TA, 1902, SCIENCE, V266, P94; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; MOYAL L, UNPUB; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; SHILOH Y, 1998, GENETIC BASIS HUMAN, P275; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; WILICIANO JD, 1997, GENE DEV, V11, P3471; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	32	1668	1716	0	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1674	1677		10.1126/science.281.5383.1674	http://dx.doi.org/10.1126/science.281.5383.1674			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733514				2022-12-28	WOS:000075856500047
J	Fleischmann, KE; Hunink, MGM; Kuntz, KM; Douglas, PS				Fleischmann, KE; Hunink, MGM; Kuntz, KM; Douglas, PS			Exercise echocardiography or exercise SPECT imaging? - A meta-analysis of diagnostic test performance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; EMISSION COMPUTED-TOMOGRAPHY; DOBUTAMINE STRESS ECHOCARDIOGRAPHY; MYOCARDIAL-ISCHEMIA; TC-99M SESTAMIBI; TECHNETIUM-99M-SESTAMIBI SPECT; PERFUSION SCINTIGRAPHY; QUANTITATIVE-ANALYSIS; METAANALYTIC METHOD; MULTICENTER TRIAL	Context.-Cardiac imaging has advanced rapidly, providing clinicians with several choices for evaluating patients with suspected coronary artery disease, but few studies compare modalities directly. .-To review the contemporary literature and to compare the diagnostic performance of exercise echocardiography (ECHO) and exercise single-photon emission computed tomography (SPECT) imaging in the diagnosis of coronary artery disease. Data Sources.-Studies published between January 1990 and October 1997 identified from MEDLINE search; bibliographies of reviews and original articles; and suggestions from experts in each area. Study Selection.-Articles were included if they discussed exercise ECHO and/or exercise SPECT imaging with thallous chloride TI 201 (thallium)or technetium Tc 99m sestamibi for detection and/or evaluation of coronary artery disease, if data on coronary angiography were presented as the reference test, and if the absolute numbers of true-positive, false-negative, true-negative, and false-positive observations were available or derivable from the data presented. Studies performed exclusively in patients after myocardia infarction, after percutaneous transluminal coronary angioplasty, after coronary artery bypass grafting, or with recent unstable coronary syndromes were excluded. Data Extraction.-ClinicaI variables, technical factors, and test performance were independently extracted by 2 reviewers on a standardized spreadsheet. Discrepancies were resolved by consensus. Results.-Forty-four articles met inclusion criteria. in pooled data weighted by the sample size of each study, exercise ECHO had a sensitivity of 85% (95% confidence interval [CI], 83%-87%) with a specificity of 77% (95% CI, 74%-80%). Exercise SPECT yielded a similar sensitivity of 87% (95% CI, 86%-88%) but a lower specificity of 64% (95% CI, 60%-68%), In a summary receiver operating characteristic model comparing exercise ECHO performance to exercise SPECT, exercise ECHO was associated with significantly better discriminatory power (parameter estimate, 1.18; 95% CI, 0.71-1.65), when adjusted for age, publication year, and a setting including known coronary artery disease for SP ECT studies. In models comparing the discriminatory abilities of exercise ECHO and exercise SPECT vs exercise testing without imaging, both ECHO and SPECT performed significantly better than exercise testing. The incremental improvement in performance was greater for ECHO (3.43; 95% CI, 2.74-4.11) than for SPECT (1.49; 95% CI, 0.91-2.08). Conclusions.-Exercise ECHO and exercise SPECT have similar sensitivities for the detection of coronary artery disease, but exercise ECHO has better specificity and, therefore, higher overall discriminatory capabilities as used in contemporary practice.	Univ Calif San Francisco, Med Ctr, Div Cardiovasc, Div Cardiol, San Francisco, CA 94143 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Clin Epidemiol Sect, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div Cardiovasc, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Erasmus Univ, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Dept Radiol, NL-3000 DR Rotterdam, Netherlands	University of California System; University of California San Francisco; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Erasmus University Rotterdam; Erasmus University Rotterdam	Fleischmann, KE (corresponding author), Univ Calif San Francisco, Med Ctr, Div Cardiovasc, Div Cardiol, 505 Parnassus Ave, San Francisco, CA 94143 USA.	Fleischm@cardio.ucsf.edu		Douglas, Pamela/0000-0001-9876-4049	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002964] Funding Source: NIH RePORTER; NHLBI NIH HHS [1K08HL02964-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALAM M, 1991, EUR HEART J, V12, P760; BEGG CB, 1983, BIOMETRICS, V39, P207, DOI 10.2307/2530820; BELESLIN BD, 1994, CIRCULATION, V90, P1168, DOI 10.1161/01.CIR.90.3.1168; BERMAN DS, 1993, J AM COLL CARDIOL, V22, P1455, DOI 10.1016/0735-1097(93)90557-H; BJORNSTAD K, 1995, CARDIOLOGY, V86, P514, DOI 10.1159/000176932; CHAE SC, 1993, J AM COLL CARDIOL, V21, P1305, DOI 10.1016/0735-1097(93)90301-G; CHRISTIAN TF, 1992, AM J CARDIOL, V70, P14, DOI 10.1016/0002-9149(92)91382-E; COHEN JL, 1993, AM J CARDIOL, V72, P1226, DOI 10.1016/0002-9149(93)90288-N; CROUSE LJ, 1991, AM J CARDIOL, V67, P1213, DOI 10.1016/0002-9149(91)90929-F; DAGIANTI A, 1995, J AM COLL CARDIOL, V26, P18, DOI 10.1016/0735-1097(95)00121-F; DEPUEY E, 1995, J NUCL MED, V36, P952; DETRANO R, 1988, AM J MED, V84, P699, DOI 10.1016/0002-9343(88)90107-6; DETRANO R, 1989, PROG CARDIOVASC DIS, V32, P173, DOI 10.1016/0033-0620(89)90025-X; deVries SO, 1996, ACAD RADIOL, V3, P361, DOI 10.1016/S1076-6332(96)80257-1; FARMER JA, 1992, HEART DISEASE, P1125; FLEMING RM, 1991, J AM COLL CARDIOL, V17, P1297, DOI 10.1016/S0735-1097(10)80139-1; GALANTI G, 1991, AM HEART J, V122, P1609, DOI 10.1016/0002-8703(91)90278-P; GUPTA NC, 1992, J AM COLL CARDIOL, V19, P248, DOI 10.1016/0735-1097(92)90474-2; Hambye AS, 1996, J NUCL CARDIOL, V3, P464, DOI 10.1016/S1071-3581(96)90056-2; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hecht H S, 1993, J Am Soc Echocardiogr, V6, P177; Heiba SI, 1997, J NUCL MED, V38, P1510; Ho YL, 1997, CARDIOLOGY, V88, P379, DOI 10.1159/000177363; HOFFMANN R, 1993, AM J CARDIOL, V72, P555, DOI 10.1016/0002-9149(93)90351-C; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; Jun T, 1996, CHIN MED J, V109, P381; KIAT H, 1990, AM HEART J, V120, P1255, DOI 10.1016/0002-8703(90)90234-O; KOTLER TS, 1990, ANN INTERN MED, V113, P684, DOI 10.7326/0003-4819-113-9-684; LITTENBERG B, 1993, MED DECIS MAKING, V13, P313, DOI 10.1177/0272989X9301300408; LUOHTOLATI M, 1996, ANN MED, V28, P73; MAHMARIAN JJ, 1990, J AM COLL CARDIOL, V15, P318, DOI 10.1016/S0735-1097(10)80055-5; MANNTING F, 1993, J NUCL MED, V34, P601; MARANGELLI V, 1994, J AM COLL CARDIOL, V24, P117, DOI 10.1016/0735-1097(94)90551-7; MARWICK TH, 1992, J AM COLL CARDIOL, V19, P74, DOI 10.1016/0735-1097(92)90054-Q; MARWICK TH, 1995, J AM COLL CARDIOL, V26, P335, DOI 10.1016/0735-1097(95)80004-Z; MARWICK TH, 1994, BRIT HEART J, V72, P31; MARWICK TH, 1995, J AM COLL CARDIOL, V26, P1180, DOI 10.1016/0735-1097(96)81472-0; MIDGETTE AS, 1993, MED DECIS MAKING, V13, P253, DOI 10.1177/0272989X9301300313; MINOVES M, 1993, CLIN CARDIOL, V16, P16, DOI 10.1002/clc.4960160104; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; NGUYEN T, 1990, J AM COLL CARDIOL, V16, P1375, DOI 10.1016/0735-1097(90)90379-4; Oguzhan A, 1997, JPN HEART J, V38, P333; OKEEFE JH, 1995, AM J CARDIOL, V75, pD25, DOI 10.1016/S0002-9149(99)80399-3; PALMAS W, 1995, J AM COLL CARDIOL, V25, P1024, DOI 10.1016/0735-1097(94)00523-S; POZZOLI MMA, 1991, AM J CARDIOL, V67, P350, DOI 10.1016/0002-9149(91)90040-R; QUINONES MA, 1992, CIRCULATION, V85, P1026, DOI 10.1161/01.CIR.85.3.1026; ROGER VL, 1994, J AM COLL CARDIOL, V24, P109, DOI 10.1016/0735-1097(94)90549-5; Roger VL, 1997, CIRCULATION, V95, P405; ROZANSKI A, 1983, NEW ENGL J MED, V309, P518, DOI 10.1056/NEJM198309013090902; Rubello D, 1995, Q J Nucl Med, V39, P111; Ryan T, 1993, J Am Soc Echocardiogr, V6, P186; SALUSTRI A, 1992, AM HEART J, V124, P75, DOI 10.1016/0002-8703(92)90922-I; SOLOT G, 1993, NUCL MED COMMUN, V14, P23, DOI 10.1097/00006231-199301000-00006; SYLVEN C, 1994, CLIN CARDIOL, V17, P132, DOI 10.1002/clc.4960170306; Taillefer R, 1997, J AM COLL CARDIOL, V29, P69, DOI 10.1016/S0735-1097(96)00435-4; Tawa C B, 1996, J Am Soc Echocardiogr, V9, P33, DOI 10.1016/S0894-7317(96)90102-9; VANTRAIN KF, 1990, J NUCL MED, V31, P1168; VANTRAIN KF, 1993, J NUCL MED, V34, P1494; VANTRAIN KF, 1994, J NUCL MED, V35, P609; WILLIAMS MJ, 1994, AM J CARDIOL, V74, P435	61	337	350	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1998	280	10					913	920		10.1001/jama.280.10.913	http://dx.doi.org/10.1001/jama.280.10.913			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115LN	9739977	Bronze			2022-12-28	WOS:000075666600039
J	Wary, KK; Mariotti, A; Zurzolo, C; Giancotti, FG				Wary, KK; Mariotti, A; Zurzolo, C; Giancotti, FG			A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth	CELL			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; MAP KINASE; ALPHA(6)BETA(4) INTEGRIN; CYCLE PROGRESSION; ADAPTER PROTEINS; C-SRC; ADHESION; ACTIVATION; RAS; VIP21-CAVEOLIN	Caveolin-l functions as a membrane adaptor to link the integrin cw subunit to the tyrosine kinase Fyn. Upon integrin ligation, Fyn is activated and binds, via its SH3 domain, to Shc. Shc is subsequently phosphorylated at tyrosine 317 and recruits Grb2. This sequence of events is necessary to couple integrins to the Ras-ERK pathway and promote cell cycle progression. These findings reveal an unexpected function of caveolin-l and Fyn in integrin signaling and anchorage-dependent cell growth.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Naples, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy	Memorial Sloan Kettering Cancer Center; University of Naples Federico II	Giancotti, FG (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.		Zurzolo, Chiara/AAH-5225-2019	Mariotti, Agnese/0000-0002-3704-7908; ZURZOLO, Chiara/0000-0001-6048-6602; Wary, Kishore/0000-0001-8851-8565	NATIONAL CANCER INSTITUTE [R01CA058976, P30CA008748, R37CA058976] Funding Source: NIH RePORTER; NCI NIH HHS [CA58976, P30 CA08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHEN WT, 1985, J CELL BIOL, V100, P1103, DOI 10.1083/jcb.100.4.1103; Clark EA, 1997, BBA-REV CANCER, V1333, pR9, DOI 10.1016/S0304-419X(97)00028-0; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lipardi C, 1998, J CELL BIOL, V140, P617, DOI 10.1083/jcb.140.3.617; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	37	589	599	0	30	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 4	1998	94	5					625	634		10.1016/S0092-8674(00)81604-9	http://dx.doi.org/10.1016/S0092-8674(00)81604-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741627	Bronze			2022-12-28	WOS:000075851900010
J	Robinson, SM; Mackenzie-Ross, S; Hewson, GLC; Egleston, C; Prevost, AT				Robinson, SM; Mackenzie-Ross, S; Hewson, GLC; Egleston, C; Prevost, AT			Psychological effect of witnessed resuscitation on bereaved relatives	LANCET			English	Article							PSYCHOMETRIC PROPERTIES; INVENTORY; ANXIETY; SCALE	Background Established practice is for the relatives of critically ill patients to be excluded from the clinical area during resuscitation. We aimed to discover whether relatives wanted to be present during the resuscitation of a family member and whether witnessing resuscitation had any adverse psychological effects on bereaved relatives. Methods In this pilot study, relatives of patients who required resuscitation were given the option to remain with the patient during resuscitation or were not given this choice and directed to the relatives' room (control group). The unit of randomisation was the patient who required resuscitation and not the relatives. One close relative was paired with each patient. All relatives were accompanied by a chaperone who gave emotional support and provided technical information on the resuscitation. Relatives were followed up 1 month after the resuscitation. We used a questionnaire to ask about the decision to be present, or absent during resuscitation, Bereaved relatives also completed five standardised psychological questionnaires to assess anxiety, depression, grief, intrusive imagery, and avoidance behaviour. Findings 25 patients underwent resuscitation (13 in witnessed resuscitation group, 12 in control group), Three patients in the witnessed group survived, all the control group patients died. Two relatives in each group were lost to follow-up. Thus, eight relatives who witnessed resuscitation and ten control-group relatives were followed up. There were no reported adverse psychological effects among the relatives who witnessed resuscitation, all of whom were satisfied with their decision to remain with the patient. The clinical team became convinced of the benefits to relatives of allowing them to witness resuscitation if they wished, so the trial was terminated. Interpretation In the context of the emergency department, routine exclusion of relatives from the resuscitation room may no longer be appropriate.	Addenbrookes NHS Trust, Emergency Dept, Cambridge CB2 2QQ, England; UCL, Subdept Clin Hlth Psychol, London, England; Univ Cambridge, Inst Publ Hlth, Dept Community Med, Ctr Appl Med Stat, Cambridge, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of London; University College London; University of Cambridge	Robinson, SM (corresponding author), Addenbrookes NHS Trust, Emergency Dept, Cambridge CB2 2QQ, England.			Robinson, Susan/0000-0002-1796-6739; Prevost, A. Toby/0000-0003-1723-0796				Back D, 1994, Nurs Times, V90, P34; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; DOYLE CJ, 1987, ANN EMERG MED, V16, P107; Gregory C M, 1995, Accid Emerg Nurs, V3, P136, DOI 10.1016/S0965-2302(95)80006-9; Hanson C, 1992, J Emerg Nurs, V18, P104; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; JUDKINS KC, 1994, BRIT MED J, V309, P406; OSUAGWN CC, 1991, J EMERG NURS, V17, P36; SCHILLING RJ, 1994, BRIT MED J, V309, P406, DOI 10.1136/bmj.309.6951.406; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; ZISOOK S, 1982, AM J PSYCHIAT, V139, P1590; ZOLTIE N, 1994, BRIT MED J, V309, P406	14	256	261	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 22	1998	352	9128					614	617		10.1016/S0140-6736(97)12179-1	http://dx.doi.org/10.1016/S0140-6736(97)12179-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	113TE	9746023				2022-12-28	WOS:000075567400011
J	White, NJ				White, NJ			Not much progress in treatment of cerebral malaria	LANCET			English	Editorial Material							FALCIPARUM-MALARIA; CONTROLLED TRIAL; IRON CHELATION; DOUBLE-BLIND; CHILDREN; ARTEMETHER; QUININE; DEXAMETHASONE; COMA		Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand	Mahidol University	White, NJ (corresponding author), Mahidol Univ, Fac Trop Med, 420-6 Rajvithi Rd, Bangkok 10400, Thailand.		White, Nick/AAC-6527-2019; White, Nicholas J/I-4629-2012	White, Nick/0000-0002-1897-1978; 				Cabantchik ZI, 1996, ACTA HAEMATOL-BASEL, V95, P70, DOI 10.1159/000203952; DIPERRI G, 1995, J INFECT DIS, V171, P1317, DOI 10.1093/infdis/171.5.1317; GORDEUK V, 1992, NEW ENGL J MED, V327, P1473, DOI 10.1056/NEJM199211193272101; GORDEUK VR, 1993, AM J TROP MED HYG, V48, P193, DOI 10.4269/ajtmh.1993.48.193; Hien TT, 1996, NEW ENGL J MED, V335, P76, DOI 10.1056/NEJM199607113350202; HOFFMAN SL, 1988, J INFECT DIS, V158, P325, DOI 10.1093/infdis/158.2.325; Karbwang J, 1995, T ROY SOC TROP MED H, V89, P668, DOI 10.1016/0035-9203(95)90437-9; Looareesuwan S, 1998, AM J TROP MED HYG, V58, P348, DOI 10.4269/ajtmh.1998.58.348; PUNYAGUPTA S, 1974, American Journal of Tropical Medicine and Hygiene, V23, P551; TAYLOR TE, 1993, LANCET, V341, P661, DOI 10.1016/0140-6736(93)90423-E; TAYLOR TE, 1992, CLIN EXP IMMUNOL, V90, P357, DOI 10.1111/j.1365-2249.1992.tb05851.x; Thuma PE, 1998, T ROY SOC TROP MED H, V92, P214, DOI 10.1016/S0035-9203(98)90753-2; van der Torn M, 1998, T ROY SOC TROP MED H, V92, P325, DOI 10.1016/S0035-9203(98)91032-X; vanHensbroek MB, 1996, J INFECT DIS, V174, P1091, DOI 10.1093/infdis/174.5.1091; vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201; WARRELL DA, 1982, NEW ENGL J MED, V306, P313, DOI 10.1056/NEJM198202113060601	16	32	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 22	1998	352	9128					594	595		10.1016/S0140-6736(05)79572-6	http://dx.doi.org/10.1016/S0140-6736(05)79572-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746017				2022-12-28	WOS:000075567400005
J	Neumann, AU; Lam, NP; Dahari, H; Gretch, DR; Wiley, TE; Layden, TJ; Perelson, AS				Neumann, AU; Lam, NP; Dahari, H; Gretch, DR; Wiley, TE; Layden, TJ; Perelson, AS			Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy	SCIENCE			English	Article							VIRUS-INFECTION; RAPID TURNOVER; IN-VIVO; ALFA; LYMPHOCYTES; CLEARANCE; VIRIONS	To better understand the dynamics of hepatitis C virus and the antiviral effect of interferon-alpha-2b (IFN), viral decline in 23 patients during therapy was analyzed with a mathematical model. The analysis indicates that the major initial effect of IFN is to block virion production or release, with blocking efficacies of 81, 95, and 96% for daily doses of 5, 10, and 15 million international units, respectively. The estimated virion half-life (t(1/2)) was, on average, 2.7 hours, with pretreatment production and clearance of 10(12) virions per day. The estimated infected cell death rate exhibited large interpatient variation (corresponding t(1/2) = 1.7 to 70 days), was inversely correlated with baseline viral load, and was positively correlated with alanine aminotransferase levels. Fast death rates were predictive of virus being undetectable by polymerase chain reaction at 3 months. These findings show that infection with hepatitis C virus is highly dynamic and that early monitoring of viral load can help guide therapy.	Univ Illinois, Dept Pharm Practice, Chicago, IL 60612 USA; Bar Ilan Univ, Dept Life Sci, IL-52900 Ramat Gan, Israel; Santa Fe Inst, Santa Fe, NM 87501 USA; Univ Washington, Hepatatis Lab, Seattle, WA 98144 USA; Univ Illinois, Dept Med, Sect Digest & Liver Dis, Chicago, IL 60612 USA; Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Bar Ilan University; The Santa Fe Institute; University of Washington; University of Washington Seattle; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; United States Department of Energy (DOE); Los Alamos National Laboratory	Neumann, AU (corresponding author), Univ Illinois, Dept Pharm Practice, Chicago, IL 60612 USA.	neumann@macs.biu.ac.il; NancyLam@uic.edu	Perelson, Alan S/Z-1959-2019; Cheng, Yushao/E-6256-2011	Perelson, Alan S/0000-0002-2455-0002; 	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006555] Funding Source: NIH RePORTER; NCRR NIH HHS [RR06555] Funding Source: Medline; NIDDK NIH HHS [A1/DK41320-2] Funding Source: Medline; PHS HHS [A139049-2] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bekkering FC, 1997, HEPATOLOGY, V26, P1691; DEFRANCESCO R, 1997, 2 INT C THER VIR HEP; Di Bisceglie AM, 1998, LANCET, V351, P351, DOI 10.1016/S0140-6736(97)07361-3; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; FAUSTO N, 1996, HEPATOLOGY TXB LIVER, P32; Fukumoto T, 1996, HEPATOLOGY, V24, P1351, DOI 10.1053/jhep.1996.v24.pm0008938160; Gretch DR, 1997, HEPATOLOGY, V26, pS43, DOI 10.1002/hep.510260708; Gretch DR, 1997, HEPATITIS C VIRUS: GENETIC HETEROGENEITY AND VIRAL LOAD, P57; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KHAKOO S, IN PRESS BR J CLIN P; L'Brown J, 1998, LANCET, V351, P78, DOI 10.1016/S0140-6736(05)78157-5; Lam NP, 1997, HEPATOLOGY, V26, P1692; Lam NP, 1997, HEPATOLOGY, V26, P226; LAM NP, UNPUB; MARTELL M, 1992, J VIROL, V66, P3225, DOI 10.1128/JVI.66.5.3225-3229.1992; MOLLA A, 1997, 2 INT C THER VIR HEP; Nelson DR, 1997, J IMMUNOL, V158, P1473; Nelson DR, 1998, HEPATOLOGY, V28, P225, DOI 10.1002/hep.510280129; Nguyen TT, 1996, J VIRAL HEPATITIS, V3, P75, DOI 10.1111/j.1365-2893.1996.tb00084.x; Nowak MA, 1996, P NATL ACAD SCI USA, V93, P4398, DOI 10.1073/pnas.93.9.4398; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; Pawlotsky JM, 1998, J VIROL, V72, P2795, DOI 10.1128/JVI.72.4.2795-2805.1998; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PETERS M, 1989, SEMIN LIVER DIS, V9, P235, DOI 10.1055/s-2008-1040516; Polyak SJ, 1997, J INFECT DIS, V175, P1101, DOI 10.1086/516448; Polyak SJ, 1998, J VIROL, V72, P4288, DOI 10.1128/JVI.72.5.4288-4296.1998; Rehermann B, 1996, J CLIN INVEST, V98, P1432, DOI 10.1172/JCI118931; Sherlock, 1997, DIS LIVER BILIARY SY, V30, P61; Tong MJ, 1997, HEPATOLOGY, V26, P1640, DOI 10.1002/hep.510260637; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Yasui K, 1998, J INFECT DIS, V177, P1475, DOI 10.1086/515309; Zeuzem S, 1996, HEPATOLOGY, V23, P366	33	1712	1818	1	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1998	282	5386					103	107		10.1126/science.282.5386.103	http://dx.doi.org/10.1126/science.282.5386.103			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756471				2022-12-28	WOS:000076294900048
J	Katlama, C; Valantin, MA; Matheron, S; Coutellier, A; Calvez, V; Descamps, D; Longuet, C; Bonmarchand, M; Tubiana, R; De Sa, M; Lancar, R; Agut, H; Brun-Vezinet, F; Costagliola, D				Katlama, C; Valantin, MA; Matheron, S; Coutellier, A; Calvez, V; Descamps, D; Longuet, C; Bonmarchand, M; Tubiana, R; De Sa, M; Lancar, R; Agut, H; Brun-Vezinet, F; Costagliola, D			Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection	ANNALS OF INTERNAL MEDICINE			English	Article						human immunodeficiency virus infections; stavudine; lamivudine; anti-HIV agents; antiviral agents	IMMUNODEFICIENCY-VIRUS INFECTION; ZIDOVUDINE COMBINATION THERAPY; CUBIC MILLIMETER; PHASE I/II; CD4 CELLS; MONOTHERAPY; SAFETY; ZALCITABINE; ADULTS; TRIAL	Background: A combination of two nucleoside analogues is currently the core of any antiretroviral regimen for HIV-1 infection. Stavudine plus lamivudine has shown an additive effect in vitro, as well as an absence of overlapping toxicity and cross-resistance. Objective: To evaluate the antiviral efficacy of stavudine plus lamivudine in treatment-naive patients and in patients previously treated with other nucleoside reverse transcriptase inhibitors. Design: Prospective, open-label pilot study. Setting: Three urban clinical centers in Paris. Patients: 83 patients with CD4(+) cell counts between 50 and 400 cells/mm(3) (42 treatment-naive and 41 treatment-experienced patients). Interventions: Stavudine, 40 mg twice daily (30 mg twice daily in patients with a body weight less than or equal to 60 kg), and lamivudine, 150 mg twice daily. Measurements: Primary end points for efficacy included changes in plasma viral load and CD4(+) cell count at 24 weeks compared with baseline. Results: Therapy with stavudine plus lamivudine resulted in a median decrease of 1.66 log(10) (10(1.66)) (range, -3.04 to -0.79 log(10)) in plasma HIV-1 RNA; the median increase in CD4(+) cell count was 108 cells/mm(3) (range, -58 to 406 cells/mm(3)) at week 24 in treatment-naive patients. In treatment-experienced patients, the median reduction in plasma HIV-1 RNA was 0.55 log(10) (range, -2.86 to 0.52 log(10)), and the median increase in CD4(+) cell count was 46 cells/mm(3) (range, -188 to 311 cells/mm(3)). The percentages of patients with less than 3000 HIV-1 RNA copies/mL and less than 400 copies/mL at 24 weeks were, respectively, 57% (95% CI, 41% to 72%) and 26% (CI, 12% to 40%) among treatment-naive patients and 22% (CI, 10% to 38%) and 5% (CI, 1% to 17%) among treatment-experienced patients. Of 82 patients, 14 (17%) experienced grade 3 or 4 toxicity and 2 discontinued therapy because of intolerance toward treatment. Conclusion: Stavudine plus lamivudine seems to have a potent antiviral effect in treatment-naive and treatment-experienced patients. No major drug-limiting toxicity was found. This two-nucleoside combination should be considered in multidrug therapy for HIV.	Hop La Pitie Salpetriere, Dept Infect Dis, F-75013 Paris, France; Hop La Pitie Salpetriere, Dept Med, F-75013 Paris, France; Hop La Pitie Salpetriere, Dept Virol, F-75013 Paris, France; Hop Bichat Claude Bernard, Dept Infect Dis, F-75018 Paris, France; Inst St Antoine Rech Sante, INSERM, SC4, F-75012 Paris, France; Hop Bichat Claude Bernard, Dept Virol, F-75018 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Sanofi-Aventis; Sanofi France; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Katlama, C (corresponding author), Hop La Pitie Salpetriere, Dept Infect Dis, 47 Blvd Hop, F-75013 Paris, France.		Matheron, Sophie/D-7420-2017; Costagliola, Dominique/H-5849-2011	Matheron, Sophie/0000-0001-7879-6553; Costagliola, Dominique/0000-0003-0765-0869				Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; Bartlett JA, 1996, ANN INTERN MED, V125, P161, DOI 10.7326/0003-4819-125-3-199608010-00001; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; GILLINGS D, 1991, DRUG INF J, V25, P411, DOI DOI 10.1177/009286159102500311; Griffith BP, 1996, J INFECT DIS, V173, P1252, DOI 10.1093/infdis/173.5.1252; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; KATIAMA C, 1996, 3 C RETR OPP INF WAS, P196; Katlama C, 1996, JAMA-J AM MED ASSOC, V276, P118, DOI 10.1001/jama.276.2.118; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; LIN PF, 1994, J INFECT DIS, V170, P1157, DOI 10.1093/infdis/170.5.1157; Merrill DP, 1996, J INFECT DIS, V173, P355, DOI 10.1093/infdis/173.2.355; MURRAY HW, 1995, J INFECT DIS, V171, pS123, DOI 10.1093/infdis/171.Supplement_2.S123; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PETERSEN EA, 1995, J INFECT DIS, V171, pS131, DOI 10.1093/infdis/171.Supplement_2.S131; PLUDA JM, 1995, J INFECT DIS, V171, P1438, DOI 10.1093/infdis/171.6.1438; POLLARD R, 1996, 3 C RETR OPP INF WAS; Saravolatz LD, 1996, NEW ENGL J MED, V335, P1099, DOI 10.1056/NEJM199610103351503; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; SOMMADOSSI JP, 1998, 5 C RETR OPP INF CHI, P362; Spruance SL, 1997, ANN INTERN MED, V126, P355, DOI 10.7326/0003-4819-126-5-199703010-00003; Staszewski S, 1996, JAMA-J AM MED ASSOC, V276, P111, DOI 10.1001/jama.276.2.111; VANLEEUWEN R, 1995, J INFECT DIS, V171, P1166, DOI 10.1093/infdis/171.5.1166; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282	26	43	43	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1998	129	7					525	+		10.7326/0003-4819-129-7-199810010-00003	http://dx.doi.org/10.7326/0003-4819-129-7-199810010-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123KN	9758571				2022-12-28	WOS:000076124500002
J	Marin, I; Baker, BS				Marin, I; Baker, BS			The evolutionary dynamics of sex determination	SCIENCE			English	Review							DETERMINATION FACTOR TRANSFORMER-2; MAMMALIAN Y-CHROMOSOME; FLY MEGASELIA-SCALARIS; DROSOPHILA-MELANOGASTER; MUSCA-DOMESTICA; GENE; SRY; LETHAL; DIVERGENCE; SEQUENCE	There is substantial cytogenetic data indicating that the process of sex determination can evolve relatively rapidly. However, recent molecular studies on the evolution of the regulatory genes that control sex determination in the insect Drosophila melanogaster, the nematode Caenorhabditis elegans, and mammals suggest that, although certain sex determination regulatory genes have evolved relatively rapidly, other sex determination regulatory genes are quite conserved. Thus, studies of the evolution of sex determination, a process that appears to have elements that, undergo substantial evolutionary change and others that may be conserved, could provide substantial insights into the kinds of forces that both drive and constrain the evolution of developmental hierarchies.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Marin, I (corresponding author), Univ Valencia, Dept Genet, Burjassot 46100, Spain.		Marin, Ignacio/A-9524-2009	Marin, Ignacio/0000-0002-1315-8961				Barton NH, 1998, SCIENCE, V281, P1986, DOI 10.1126/science.281.5385.1986; Blackman Roger L., 1995, P57; Bopp D, 1996, DEVELOPMENT, V122, P971; BULL J J, 1988, P96; Bull J.J., 1983, EVOLUTION SEX DETERM; BULL JJ, 1977, HEREDITY, V39, P1, DOI 10.1038/hdy.1977.38; BURTIS K, UNPUB; Chandler D, 1997, MOL CELL BIOL, V17, P2908, DOI 10.1128/MCB.17.5.2908; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; CHARNOV E L, 1982; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; Dauwalder B, 1996, P NATL ACAD SCI USA, V93, P9004, DOI 10.1073/pnas.93.17.9004; deBono M, 1996, GENETICS, V144, P587; Dubendorfer Andreas, 1992, Seminars in Developmental Biology, V3, P349; FRANCO MG, 1982, GENET RES, V40, P279, DOI 10.1017/S0016672300019157; Fredga Karl, 1994, P419; Gerhart J, 1997, CELLS EMBRYOS EVOLUT; GRAVES JAM, 1995, BIOESSAYS, V17, P311, DOI 10.1002/bies.950170407; Graves JAM, 1996, ANNU REV GENET, V30, P233, DOI 10.1146/annurev.genet.30.1.233; GRIFFITHS R, 1991, P ROY SOC B-BIOL SCI, V244, P123, DOI 10.1098/rspb.1991.0060; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; JUST W, 1995, NAT GENET, V11, P117, DOI 10.1038/ng1095-117; Karlin S., 1986, THEORETICAL STUDIES; Kent J, 1996, DEVELOPMENT, V122, P2813; Kuwabara PE, 1996, GENETICS, V144, P597; MATSUO N, 1995, J BIOL CHEM, V270, P28216, DOI 10.1074/jbc.270.47.28216; Meise M, 1998, DEVELOPMENT, V125, P1487; MULLERHOLTKAMP F, 1995, J MOL EVOL, V41, P467, DOI 10.1007/BF00160318; Nothiger R., 1987, Results and Problems in Cell Differentiation, V14, P271; ONEIL MT, 1992, GENETICS, V131, P113; ONeill RJW, 1997, MOL BIOL EVOL, V14, P350, DOI 10.1093/oxfordjournals.molbev.a025769; Pamilo P, 1997, MOL BIOL EVOL, V14, P49, DOI 10.1093/oxfordjournals.molbev.a025701; Penalva LOF, 1996, GENETICS, V144, P1653; Raff R. A., 1996, SHAPE LIFE GENES DEV; Ramkissoon Y, 1996, CURR OPIN GENET DEV, V6, P316, DOI 10.1016/S0959-437X(96)80008-6; Raymond CS, 1998, NATURE, V391, P691, DOI 10.1038/35618; Saccone G, 1998, DEVELOPMENT, V125, P1495; Schafer AJ, 1996, BIOESSAYS, V18, P955, DOI 10.1002/bies.950181205; Schmidt R, 1997, GENETICS, V147, P271; Shearman DCA, 1998, INSECT MOL BIOL, V7, P355, DOI 10.1046/j.1365-2583.1998.740355.x; Sievert V, 1997, GENOME, V40, P211, DOI 10.1139/g97-030; Swain A, 1998, NATURE, V391, P761, DOI 10.1038/35799; TRAUT W, 1990, CHROMOSOMA, V99, P407, DOI 10.1007/BF01726692; Tucker PK, 1995, PHILOS T R SOC B, V350, P221, DOI 10.1098/rstb.1995.0155; WALTHOUR CS, 1994, GENETICS, V136, P1367; Waxman D, 1998, SCIENCE, V279, P1210, DOI 10.1126/science.279.5354.1210; White M. J. D, 1973, ANIMAL CYTOLOGY EVOL; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WILKINS AS, 1995, BIOESSAYS, V17, P71, DOI 10.1002/bies.950170113	50	227	246	6	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1998	281	5385					1990	1994		10.1126/science.281.5385.1990	http://dx.doi.org/10.1126/science.281.5385.1990			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748152				2022-12-28	WOS:000076161800046
J	Marzo, I; Brenner, C; Zamzami, N; Jurgensmeier, JM; Susin, SA; Vieira, HLA; Prevost, MC; Xie, ZH; Matsuyama, S; Reed, JC; Kroemer, G				Marzo, I; Brenner, C; Zamzami, N; Jurgensmeier, JM; Susin, SA; Vieira, HLA; Prevost, MC; Xie, ZH; Matsuyama, S; Reed, JC; Kroemer, G			Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis	SCIENCE			English	Article							PERMEABILITY TRANSITION PORE; PROAPOPTOTIC PROTEIN BAX; CELL-DEATH; NUCLEAR APOPTOSIS; MAMMALIAN-CELLS; INNER MEMBRANE; CYTOCHROME-C; BCL-2; CHANNEL; YEAST	The proapoptotic Bax protein induces cell death by acting on mitochondria. Bax binds to the permeability transition pore complex (PTPC), a composite proteaceous channel that is involved in the regulation of mitochondrial membrane permeability. Immunodepletion of Bax from PTPC or purification of PTPC from Bax-deficient mice yielded a PTPC that could not permeabilize membranes in response to atractyloside, a proapoptotic Ligand of the adenine nucleotide translocator (ANT). Bax and ANT coimmunoprecipitated and interacted in the yeast two-hybrid system: Ectopic expression of Bax Induced cell death in wild-type but not in ANT-deficient yeast. Recombinant Bax and purified ANT, but neither of them alone, efficiently formed atractyloside-responsive channels in artificial membranes. Hence, the proapoptotic molecule Bax and the constitutive mitochondrial protein ANT cooperate within the PTPC to increase mitochondrial membrane permeability and to trigger cell death.	CNRS, UPR 420, F-94801 Villejuif, France; Univ Technol Compiegne, CNRS, UPRES A6022, F-60200 Compiegne, France; Burnham Inst, La Jolla, CA 92037 USA; Inst Pasteur, Unite Oncol Virale, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne; Sanford Burnham Prebys Medical Discovery Institute; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Kroemer, G (corresponding author), CNRS, UPR 420, 19 Rue Guy Moquet, F-94801 Villejuif, France.	kroemer@infobiogen.fr	Susin, Santos A/Q-6754-2017; Vieira, Helena/AAZ-9562-2021; Juergensmeier, Juliane/I-4117-2013; Marzo, Isabel/E-6918-2016; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	Susin, Santos A/0000-0002-3366-1628; Marzo, Isabel/0000-0002-2315-9079; KROEMER, Guido/0000-0002-9334-4405; Vieira, Helena/0000-0001-9415-3742				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Bisaccia F, 1996, BBA-PROTEIN STRUCT M, V1292, P281, DOI 10.1016/0167-4838(95)00215-4; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; GironCalle J, 1996, BIOCHEMISTRY-US, V35, P15440, DOI 10.1021/bi960840j; GonzalezBarroso MM, 1997, BIOCHEMISTRY-US, V36, P10930, DOI 10.1021/bi971104y; Greenawalt J W, 1974, Methods Enzymol, V31, P310; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Jurgensmeier JM, 1997, MOL BIOL CELL, V8, P325; KLINGENBERG M, 1980, J MEMBRANE BIOL, V56, P97, DOI 10.1007/BF01875961; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lohret TA, 1997, J CELL BIOL, V137, P377, DOI 10.1083/jcb.137.2.377; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MARZO I, UNPUB; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; REINHART PH, 1982, BIOCHEM J, V204, P731, DOI 10.1042/bj2040731; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Ruck A, 1998, FEBS LETT, V426, P97, DOI 10.1016/S0014-5793(98)00317-2; SALVAYRE AN, 1997, FASEB J, V11, P809; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; SUSIN SA, IN PRESS METHODS ENZ; TRGON T, 1991, FEBS LETT, V289, P159; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xie ZH, 1998, BIOCHEMISTRY-US, V37, P6410, DOI 10.1021/bi973052i; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zha HB, 1997, J BIOL CHEM, V272, P31482, DOI 10.1074/jbc.272.50.31482; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha HB, 1996, MOL CELL BIOL, V16, P6494; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	48	1038	1097	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					2027	2031		10.1126/science.281.5385.2027	http://dx.doi.org/10.1126/science.281.5385.2027			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748162				2022-12-28	WOS:000076161800056
J	Hricik, DE; Chung-Park, M; Sedor, JR				Hricik, DE; Chung-Park, M; Sedor, JR			Glomerulonephritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							IDIOPATHIC MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; SYSTEMIC LUPUS-ERYTHEMATOSUS; ACUTE POSTSTREPTOCOCCAL GLOMERULONEPHRITIS; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; POST-STREPTOCOCCAL GLOMERULONEPHRITIS; LONG-TERM PROGNOSIS; IGA NEPHROPATHY; CONTROLLED TRIAL; RENAL BIOPSY; CRESCENTIC GLOMERULONEPHRITIS		Univ Hosp Cleveland, Dept Med, Div Nephrol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; Metrohlth Med Ctr, Div Nephrol, Cleveland, OH USA	University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University; MetroHealth System	Hricik, DE (corresponding author), Univ Hosp Cleveland, Dept Med, Div Nephrol, 11100 Euclid Ave, Cleveland, OH 44106 USA.							[Anonymous], 1997, Am J Kidney Dis, V30, pS40; APPEL GB, 1987, AM J MED, V83, P877, DOI 10.1016/0002-9343(87)90645-0; AUSTIN HA, 1994, KIDNEY INT, V45, P544, DOI 10.1038/ki.1994.70; BALDWIN DS, 1977, AM J MED, V62, P12, DOI 10.1016/0002-9343(77)90345-X; BALLOU SP, 1982, ARTHRITIS RHEUM, V25, P55, DOI 10.1002/art.1780250109; BALOW JE, 1984, NEW ENGL J MED, V311, P491, DOI 10.1056/NEJM198408233110802; Balow JE, 1996, KIDNEY INT, V49, pS88; Bansal VK, 1997, AM J KIDNEY DIS, V29, P193, DOI 10.1016/S0272-6386(97)90029-9; BENE MC, 1993, CONTRIB NEPHROL, V104, P153; Berden JHM, 1997, KIDNEY INT, V52, P538, DOI 10.1038/ki.1997.365; BERGSTEIN JM, 1995, PEDIATR NEPHROL, V9, P268, DOI 10.1007/BF02254181; BHAN AK, 1979, J EXP MED, V150, P1410, DOI 10.1084/jem.150.6.1410; Bolton WK, 1996, SEMIN NEPHROL, V16, P517; BOLTON WK, 1984, J CLIN INVEST, V73, P1263, DOI 10.1172/JCI111328; BOUMPAS DT, 1992, LANCET, V340, P741, DOI 10.1016/0140-6736(92)92292-N; BOUMPAS DT, 1995, ANN INTERN MED, V122, P940, DOI 10.7326/0003-4819-122-12-199506150-00009; Brenner BM, 1996, KIDNEY INT, V49, P1774, DOI 10.1038/ki.1996.265; CAMERON JS, 1973, BRIT MED J, V3, P668, DOI 10.1136/bmj.3.5882.668; CATTRAN DC, 1995, KIDNEY INT, V47, P1130, DOI 10.1038/ki.1995.161; CATTRAN DC, 1994, AM J KIDNEY DIS, V23, P247, DOI 10.1016/S0272-6386(12)80980-2; CIBRIK DM, 1997, PRIMER KIDNEY DIS, P141; CLARKSON AR, 1993, CONTRIB NEPHROL, V104, P189; COUSER WG, 1993, KIDNEY INT, V44, pS19; CZERKINSKY C, 1986, J CLIN INVEST, V77, P1931, DOI 10.1172/JCI112522; DAMICO G, 1988, AM J KIDNEY DIS, V12, P353, DOI 10.1016/S0272-6386(88)80023-4; DEOLIVIERA J, 1995, AM J KIDNEY DIS, V25, P380, DOI 10.1016/0272-6386(95)90098-5; DONADIO JV, 1994, NEW ENGL J MED, V331, P1194, DOI 10.1056/NEJM199411033311804; Dooley MA, 1997, KIDNEY INT, V51, P1188, DOI 10.1038/ki.1997.162; EMANCIPATOR SN, 1994, AM J KIDNEY DIS, V23, P451, DOI 10.1016/S0272-6386(12)81011-0; ESDAILE JM, 1993, SEMIN ARTHRITIS RHEU, V23, P135, DOI 10.1016/S0049-0172(05)80019-8; ESDAILE JM, 1989, Q J MED, V72, P779; FALK RJ, 1988, NEW ENGL J MED, V318, P1651, DOI 10.1056/NEJM198806233182504; FELSON DT, 1984, NEW ENGL J MED, V311, P1528, DOI 10.1056/NEJM198412133112402; GALLA JH, 1995, KIDNEY INT, V47, P377, DOI 10.1038/ki.1995.50; GALLA JH, 1984, LANCET, V2, P522; GharaeeKermani M, 1996, AM J PATHOL, V148, P961; Gourley MF, 1996, ANN INTERN MED, V125, P549, DOI 10.7326/0003-4819-125-7-199610010-00003; *GRUPP IT STUD NEF, 1992, AM J KIDNEY DIS, V19, P473; Haas M, 1997, AM J KIDNEY DIS, V30, P621, DOI 10.1016/S0272-6386(97)90485-6; Habib R, 1973, Clin Nephrol, V1, P194; HABIB R, 1975, KIDNEY INT, V7, P204, DOI 10.1038/ki.1975.32; HALE GM, 1986, KIDNEY INT, V29, P718, DOI 10.1038/ki.1986.57; HEILMAN RL, 1987, AM J KIDNEY DIS, V9, P98, DOI 10.1016/S0272-6386(87)80086-0; HINGLAIS N, 1974, AM J MED, V56, P52, DOI 10.1016/0002-9343(74)90750-5; Hogan SL, 1996, J AM SOC NEPHROL, V7, P23; HOLM SE, 1988, APMIS, V96, P189, DOI 10.1111/j.1699-0463.1988.tb05289.x; HOOD SA, 1981, CLIN NEPHROL, V16, P55; Hricik D E, 1982, Dis Mon, V28, P1; IBELS LS, 1994, MEDICINE, V73, P79, DOI 10.1097/00005792-199403000-00002; JACKSON S, 1991, AM J KIDNEY DIS, V17, P55, DOI 10.1016/S0272-6386(12)80251-4; JACOB L, 1989, P NATL ACAD SCI USA, V86, P4669, DOI 10.1073/pnas.86.12.4669; Jennette JC, 1997, NEW ENGL J MED, V337, P1512, DOI 10.1056/NEJM199711203372106; JENNETTE JC, 1985, KIDNEY INT, V28, P944, DOI 10.1038/ki.1985.222; JOHNSON RJ, 1994, KIDNEY INT, V46, P1255, DOI 10.1038/ki.1994.393; JOHNSON RJ, 1994, KIDNEY INT, V45, P1769, DOI 10.1038/ki.1994.230; Johnson RJ, 1997, AM J PATHOL, V151, P1179; JULIAN BA, 1988, AM J MED, V84, P129, DOI 10.1016/0002-9343(88)90019-8; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; KASHGARIAN M, 1994, KIDNEY INT, V45, P928, DOI 10.1038/ki.1994.123; KERR PG, 1997, DIS KIDNEY, V2, P1619; KIM Y, 1980, ANNU REV MED, V31, P273, DOI 10.1146/annurev.me.31.020180.001421; Lal DPSS, 1996, J CLIN PATHOL, V49, P942, DOI 10.1136/jcp.49.11.942; LANGE K, 1983, CLIN NEPHROL, V19, P3; LEVEY AS, 1992, ANN INTERN MED, V116, P114, DOI 10.7326/0003-4819-116-2-114; Levy JB, 1997, J NEPHROL, V10, P7; LEWIS EJ, 1992, NEW ENGL J MED, V326, P1373, DOI 10.1056/NEJM199205213262101; LOMAXSMITH JD, 1983, AM J PATHOL, V113, P359; Main I W, 1995, Curr Opin Nephrol Hypertens, V4, P354, DOI 10.1097/00041552-199507000-00012; MCENERY PT, 1990, J PEDIATR-US, V116, pS109, DOI 10.1016/S0022-3476(05)82712-X; MESTECKY J, 1993, CONTRIB NEPHROL, V104, P172; MOKRZYCKI MH, 1994, AM J KIDNEY DIS, V23, P817, DOI 10.1016/S0272-6386(12)80135-1; Moroni G, 1998, AM J KIDNEY DIS, V31, P681, DOI 10.1053/ajkd.1998.v31.pm9531186; Moroni G, 1996, KIDNEY INT, V50, P2047, DOI 10.1038/ki.1996.528; Nachman PH, 1996, J AM SOC NEPHROL, V7, P33; Oliveira DBG, 1997, CLIN EXP IMMUNOL, V107, P8, DOI 10.1046/j.1365-2249.1997.d01-898.x; OOI YM, 1976, KIDNEY INT, V9, P46, DOI 10.1038/ki.1976.6; PEDERSEN RS, 1995, SCAND J UROL NEPHROL, V29, P265, DOI 10.3109/00365599509180574; PETER G, 1977, NEW ENGL J MED, V297, P311, DOI 10.1056/NEJM197708112970606; PETTERSSON EE, 1994, CLIN NEPHROL, V41, P183; POLLOCK C, 1989, KIDNEY INT, V36, P1045, DOI 10.1038/ki.1989.299; POONKING R, 1993, J EXP MED, V178, P759, DOI 10.1084/jem.178.2.759; POTTER EV, 1982, NEW ENGL J MED, V307, P725, DOI 10.1056/NEJM198209163071205; RENNKE HG, 1994, KIDNEY INT, V45, P1044, DOI 10.1038/ki.1994.141; ROCCATELLO D, 1993, LAB INVEST, V69, P714; RODRIGUEZITURBE B, 1979, PAEDIATRICIAN, V8, P307; RODRIGUEZITURBE B, 1987, PEDIAT NEPHROLOGY, P407; ROSTOKER G, 1994, ANN INTERN MED, V120, P476, DOI 10.7326/0003-4819-120-6-199403150-00005; Roy S 3rd, 1976, Adv Pediatr, V23, P35; SAGEL I, 1973, ANN INTERN MED, V79, P492, DOI 10.7326/0003-4819-79-4-492; Savill J, 1996, KIDNEY INT, V49, pS14; SCHACHT RG, 1976, NEW ENGL J MED, V295, P977, DOI 10.1056/NEJM197610282951803; SCHENA FP, 1990, NEPHROL DIAL TRANSPL, V5, P47; SCHENA FP, 1990, AM J MED, V89, P209; SCHMEKEL B, 1981, ACTA MED SCAND, V210, P363; SCHWARTZ MM, 1993, AM J KIDNEY DIS, V21, P374, DOI 10.1016/S0272-6386(12)80263-0; SCHWARTZ MM, 1989, AM J KIDNEY DIS, V13, P273, DOI 10.1016/S0272-6386(89)80033-2; SEDOR JR, 1993, KIDNEY INT, V43, pS65; Sloan RP, 1996, J AM SOC NEPHROL, V7, P299; TEJANI A, 1990, NEPHRON, V55, P1, DOI 10.1159/000185909; TORNROTH T, 1976, LAB INVEST, V35, P461; VALLOTA EH, 1974, J EXP MED, V139, P1249, DOI 10.1084/jem.139.5.1249; VARADE WS, 1990, AM J KIDNEY DIS, V16, P196, DOI 10.1016/S0272-6386(12)81018-3; VILLARREAL H, 1979, J EXP MED, V149, P459, DOI 10.1084/jem.149.2.459; WILSON CB, 1991, KIDNEY, P1062; WYATT RJ, 1988, AM J KIDNEY DIS, V12, P437, DOI 10.1016/S0272-6386(88)80042-8; YOSHIDA H, 1995, J CLIN INVEST, V96, P2162, DOI 10.1172/JCI118270	106	82	87	4	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1998	339	13					888	899		10.1056/NEJM199809243391306	http://dx.doi.org/10.1056/NEJM199809243391306			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121VY	9744974				2022-12-28	WOS:000076037400006
J	Xu, L; Lavinsky, RM; Dasen, JS; Flynn, SE; McInerney, EM; Mullen, TM; Heinzel, T; Szeto, D; Korzus, E; Kurokawa, R; Aggarwal, AK; Rose, DW; Glass, CK; Rosenfeld, MG				Xu, L; Lavinsky, RM; Dasen, JS; Flynn, SE; McInerney, EM; Mullen, TM; Heinzel, T; Szeto, D; Korzus, E; Kurokawa, R; Aggarwal, AK; Rose, DW; Glass, CK; Rosenfeld, MG			Signal-specific co-activator domain requirements for Pit-1 activation	NATURE			English	Article							MEDIATE TRANSCRIPTIONAL RESPONSES; PROLACTIN GENE; HISTONE DEACETYLASE; N-COR; REPRESSION; CBP; HORMONE; COACTIVATOR; RECEPTORS; DNA	POU-domain proteins, such as the pituitary-specific factor Pit-1, are members of the homeodomain family of proteins which are important in development and homeostasis, acting constitutively or in response to signal-transduction pathways to either repress or activate the expression of specific genes(1). Here we show that whereas homeodomain-containing repressors such as Rpx(2) seem to recruit only a co-repressor complex, the activity of Pit-1 (ref. 3) is determined by a regulated balance between a co-repressor complex that contains N-CoR/SMRT4,5, mSin3A/B6-8 and histone deacetylases(6-8), and a co-activator complex that includes the CREB-binding protein (CBP)(9) and p/CAF(10). Activation of Pit-1 by cyclic AMP or growth factors depends on distinct amino- and carboxy-terminal domains of CBP, respectively. Furthermore, the histone acetyltransferase functions of CBP11,12 or p/CAF(10) are required for Pit-1 function that is stimulated by cyclic AMP or growth factors, respectively. These data show that there is a switch in specific requirements for histone acetyltransferases and CBP domains in mediating the effects of different signal-transduction pathways on specific DNA-bound transcription factors.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, Grad Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Whittier Diabet Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept & Sch Med, La Jolla, CA 92093 USA; CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Rosenfeld, MG (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Heinzel, Thorsten/B-1013-2015; Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592; MULLEN, Tina-Marie/0000-0001-6150-8084				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ELSHOLTZ HP, 1991, J BIOL CHEM, V266, P22919; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hermesz E, 1996, DEVELOPMENT, V122, P41; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MURDOCH GH, 1985, J BIOL CHEM, V260, P1852; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OKIMURA Y, 1994, MOL ENDOCRINOL, V8, P1559, DOI 10.1210/me.8.11.1559; ONATE SA, 1995, SCIENCE, V270, P1354; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	28	241	242	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1998	395	6699					301	306		10.1038/26270	http://dx.doi.org/10.1038/26270			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751061				2022-12-28	WOS:000075974600057
J	Mochizuki, T; Saijoh, Y; Tsuchiya, K; Shirayoshi, Y; Takai, S; Taya, C; Yonekawa, H; Yamada, K; Nihei, H; Nakatsuji, N; Overbeek, PA; Hamada, H; Yokoyama, T				Mochizuki, T; Saijoh, Y; Tsuchiya, K; Shirayoshi, Y; Takai, S; Taya, C; Yonekawa, H; Yamada, K; Nihei, H; Nakatsuji, N; Overbeek, PA; Hamada, H; Yokoyama, T			Cloning of inv, a gene that controls left/right asymmetry and kidney development	NATURE			English	Article							NODAL EXPRESSION; YEAST; MOUSE; SIMILARITY; DROSOPHILA; PROTEINS; INVERSUS; MUTATION; EMBRYOS; NOTCH	Most vertebrate internal organs show a distinctive left/right asymmetry. The inv (inversion of embryonic turning) mutation in mice was created previously by random insertional mutagenesis(1); it produces both a constant reversal of left/right polarity (situs inversus) and cyst formation in the kidneys(2). Asymmetric expression patterns of the genes nodal and lefty are reversed in the inv mutant(3-6), indicating that inv may act early in left/right determination. Here we identify a new gene located at the inv locus. The encoded protein contains 15 consecutive repeats of an Ank/Swi6 motif(7,8) at its amino terminus. Expression of the gene is the highest in the kidneys and liver among adult tissues, and is seen in presomite-stage embryos. Analysis of the transgenic genome and the structure of the candidate gene indicate that the candidate gene is the only gene that is disrupted in inv mutants. Transgenic introduction of a minigene encoding the candidate protein restores normal left/right asymmetry and kidney development in the inv mutant, confirming the identity of the candidate gene.	Japan Sci & Technol Corp, Crest, Tokyo 1700013, Japan; Tokyo Womens Med Univ, Sch Med, Dept Med, Kidney Ctr,Shinjuku Ku, Tokyo 1628600, Japan; Tokyo Womens Med Univ, Sch Med, Dept Anat & Dev Biol, Shinjuku Ku, Tokyo 1628600, Japan; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 565, Japan; Natl Inst Genet, Mammalian Dev Lab, Mishima, Shizuoka 411, Japan; Inst Med Ctr Japan, Res Inst, Dept Genet, Shinjuku Ku, Tokyo 162, Japan; Tokyo Metropolitan Inst Med Sci, Dept Lab Anim Sci, Bunkyo Ku, Tokyo 113, Japan	Japan Science & Technology Agency (JST); Tokyo Women's Medical University; Tokyo Women's Medical University; Osaka University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Tokyo Metropolitan Institute of Medical Science	Yokoyama, T (corresponding author), Japan Sci & Technol Corp, Crest, Tokyo 1700013, Japan.	tyoko@research.twmc.ac.jp	Hamada, Hiroshi/N-6374-2015	Hamada, Hiroshi/0000-0002-7196-5948; Overbeek, Paul/0000-0001-9784-2084; Saijoh, Yukio/0000-0002-7548-4789				ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; HOGAN B, 1986, MANIPULATING MOUSE E, P153; Hummel K. P., 1959, Journal of Heredity, V50, P9; Hyatt BA, 1996, NATURE, V384, P62, DOI 10.1038/384062a0; Hyatt BA, 1998, CELL, V93, P37, DOI 10.1016/S0092-8674(00)81144-7; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; KLAR AJS, 1994, TRENDS GENET, V10, P392, DOI 10.1016/0168-9525(94)90055-8; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LAWRENCE JB, 1988, CELL, V52, P51; LAYTON WM, 1976, J HERED, V67, P336, DOI 10.1093/oxfordjournals.jhered.a108749; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0; YOCHEM J, 1989, CELL, V58, P887; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YOKOYAMA T, 1995, DEVELOPMENTAL MECHANISMS OF HEART DISEASE, P513; YOKOYAMA T, 1990, NUCLEIC ACIDS RES, V18, P7293, DOI 10.1093/nar/18.24.7293; YOST HJ, 1992, NATURE, V357, P158, DOI 10.1038/357158a0	29	208	213	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 10	1998	395	6698					177	181		10.1038/26006	http://dx.doi.org/10.1038/26006			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744276				2022-12-28	WOS:000075829900043
J	Dustin, ML; Olszowy, MW; Holdorf, AD; Li, J; Bromley, S; Desai, N; Widder, P; Rosenberger, F; van der Merwe, PA; Allen, PM; Shaw, AS				Dustin, ML; Olszowy, MW; Holdorf, AD; Li, J; Bromley, S; Desai, N; Widder, P; Rosenberger, F; van der Merwe, PA; Allen, PM; Shaw, AS			A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts	CELL			English	Article							ADHESION MOLECULE-1 ICAM-1; PRESENTING B-CELLS; ANTIGEN RECEPTOR; CYTOPLASMIC DOMAIN; BINDING-PROTEIN; CD2; RECOGNITION; ACTIVATION; COMPLEX; LFA-1	Recognition of antigen by T cells requires the formation of a specialized junction between the T cell and the antigen-presenting cell. This junction is generated by the recruitment and the exclusion of specific proteins from the contact area. The mechanisms that regulate these events are unknown. Here we demonstrate that ligand engagement of the adhesion molecule, CD2, initiates a process of protein segregation, CD2 clustering, and cytoskeletal polarization. Although protein segregation was not dependent on the cytoplasmic domain of CD2, CD2 clustering and cytoskeletal polarization required an interaction of the CD2 cytoplasmic domain with a novel SH3-containing protein. This novel protein, called CD2AP, is likely to facilitate receptor patterning in the contact area by linking specific adhesion receptors to the cytoskeleton.	Washington Univ, Inst Biomed Comp, Dept Pathol, Sch Med, St Louis, MO 63110 USA; Washington Univ, Inst Biomed Comp, Ctr Immunol, Sch Med, St Louis, MO 63110 USA; Univ Oxford, Sir William Dunn Sch Pathol, MRC, Cellular Immunol Unit, Oxford OX1 3RE, England	Washington University (WUSTL); Washington University (WUSTL); University of Oxford	Shaw, AS (corresponding author), Washington Univ, Inst Biomed Comp, Dept Pathol, Sch Med, St Louis, MO 63110 USA.		Dustin, Michael/AAM-4611-2020; van der Merwe, P. Anton/F-8539-2011	Dustin, Michael/0000-0003-4983-6389; Holdorf, Amy/0000-0001-5699-4081				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BOCKENSTEDT LK, 1988, J IMMUNOL, V141, P1904; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CLAYTON LK, 1987, EUR J IMMUNOL, V17, P1367, DOI 10.1002/eji.1830170922; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; Dustin ML, 1997, P NATL ACAD SCI USA, V94, P3909, DOI 10.1073/pnas.94.8.3909; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EVAN GI, 1985, MOL CELL BIOL, V4, P2843; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Garbe TR, 1996, MOL MED, V2, P134, DOI 10.1007/BF03402209; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; HAHN WC, 1992, P NATL ACAD SCI USA, V89, P7179, DOI 10.1073/pnas.89.15.7179; HE Q, 1988, CELL, V54, P979, DOI 10.1016/0092-8674(88)90112-2; JEFFERIES WA, 1985, J EXP MED, V162, P117, DOI 10.1084/jem.162.1.117; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; KILEEN N, 1992, EMBO J, V11, P4329; KUPFER A, 1986, P NATL ACAD SCI USA, V83, P6080, DOI 10.1073/pnas.83.16.6080; KUPFER A, 1989, J EXP MED, V170, P1697, DOI 10.1084/jem.170.5.1697; Lowin-Kropf B, 1998, J CELL BIOL, V140, P861, DOI 10.1083/jcb.140.4.861; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12861; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; MONKS CRF, 1998, IN PRESS NATURE, V395; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; OLIVE D, 1986, EUR J IMMUNOL, V16, P1063, DOI 10.1002/eji.1830160906; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; PREZA C, 1992, J OPT SOC AM A, V9, P219, DOI 10.1364/JOSAA.9.000219; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; Sambrook J., 1989, MOL CLONING; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; TAKEI F, 1985, J IMMUNOL, V134, P1403; TEMPONI M, 1988, SEMIN ONCOL, V15, P595; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; XU P, 1995, J BIOL CHEM, V270, P25316, DOI 10.1074/jbc.270.43.25316	48	571	592	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 4	1998	94	5					667	677		10.1016/S0092-8674(00)81608-6	http://dx.doi.org/10.1016/S0092-8674(00)81608-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741631	Green Published, Bronze			2022-12-28	WOS:000075851900014
J	Hallam, SJ; Jin, Y				Hallam, SJ; Jin, Y			lin-14 regulates the timing of synaptic remodelling in Caenorhabditis elegans	NATURE			English	Article							HETEROCHRONIC GENE LIN-14; NERVOUS-SYSTEM; C-ELEGANS; NEUROMUSCULAR-JUNCTIONS; NEMATODE; CONNECTIVITY; EXPRESSION; MUTANTS; PROTEIN; ENCODES	In the nematode Caenorhabditis elegans six GABAergic motor neurons, known as DDs(1,2), remodel their patterns of synaptic connectivity during larval development(3). DD remodelling involves a complete reversal of the direction of information now within nerve processes without marked changes in process morphology. We used a marker localized in vivo to DD presynaptic zones to analyse how the timing of DD remodelling is controlled. In wild-type animals, DDs remodel their synaptic outputs within a 3-5-hour period at the end of the first larval stage. We show that the heterochronic gene lin-14, which controls the timing of stage-specific cell lineages(4,5), regulates the timing of DD synaptic output remodelling. In lin-14 loss-of-function mutants, DDs remodel precociously. The degree of precocious remodelling is correlated with the level of lin-14 activity. Expression of lin-14(+) in the DDs of lin-14-null mutants rescues the precocious remodelling, indicating that lin-14 can act cell-autonomously. Consistent with this hypothesis, LIN-14 protein levels decrease in the DDs before remodelling. Our observations reveal a role of heterochronic genes in non-dividing cells, and provide an example of cell-autonomous respecification of neuronal connectivity.	Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Jin, Y (corresponding author), Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA.	jin@biology.ucsc.edu		Jin, Yishi/0000-0002-9371-9860				ALLEY KE, 1990, J NEUROBIOL, V21, P1092, DOI 10.1002/neu.480210713; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; AMBROS V, 1994, TRENDS GENET, V10, P123, DOI 10.1016/0168-9525(94)90213-5; AMBROS V, 1987, GENE DEV, V1, P398, DOI 10.1101/gad.1.4.398; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN LL, 1991, J NEUROSCI, V11, P2920; CLARK SG, 1994, GENETICS, V137, P987; DOTTI CG, 1987, NATURE, V330, P254, DOI 10.1038/330254a0; Euling S, 1996, CELL, V84, P667, DOI 10.1016/S0092-8674(00)81045-4; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HARRIS WA, 1990, J NEUROBIOL, V21, P953, DOI 10.1002/neu.480210702; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Levine Richard B., 1995, Current Opinion in Neurobiology, V5, P28, DOI 10.1016/0959-4388(95)80083-2; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; NAITO M, 1992, NUCLEIC ACIDS RES, V20, P2967, DOI 10.1093/nar/20.12.2967; Nonet ML, 1998, J NEUROSCI, V18, P70; PURVES D, 1985, NATURE, V315, P404, DOI 10.1038/315404a0; PURVES D, 1980, SCIENCE, V210, P153, DOI 10.1126/science.7414326; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TRUMAN JW, 1990, J NEUROBIOL, V21, P1072, DOI 10.1002/neu.480210711; WHITE JG, 1978, NATURE, V271, P764, DOI 10.1038/271764a0; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; WIGHTMAN B, 1991, GENE DEV, V5, P1813, DOI 10.1101/gad.5.10.1813; WIGSTON DJ, 1990, J NEUROSCI, V10, P1753	29	131	134	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 3	1998	395	6697					78	82		10.1038/25757	http://dx.doi.org/10.1038/25757			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116JY	9738501				2022-12-28	WOS:000075722200050
J	Schneider, BL; Patton, EE; Lanker, S; Mendenhall, MD; Wittenberg, C; Futcher, B; Tyers, M				Schneider, BL; Patton, EE; Lanker, S; Mendenhall, MD; Wittenberg, C; Futcher, B; Tyers, M			Yeast G1 cyclins are unstable in G1 phase	NATURE			English	Article							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; MATING PHEROMONE; PROTEASOME PATHWAY; RAPID DEGRADATION; G2 CYCLINS; PHOSPHORYLATION; PROTEIN; KINASE; TURNOVER	In most eukaryotes, commitment to cell division occurs in late G1 phase at an event called Start in the yeast Saccharomyces cerevisiae(1), and called the restriction point in mammalian cells(2). Start is triggered by the cyclin-dependent kinase Cdc28 and three rate-limiting activators, the G1 cyclins Cln1, Cln2 and Cln3 (ref. 3). Cyclin accumulation in G1 is driven in part by the cell-cycle-regulated transcription of CLN1 and CLN2, which peaks at Start(3). CLN transcription is modulated by physiological signals that regulate G1 progression(4,5), but it is unclear whether Cln protein stability is cell-cycle-regulated It has been suggested that once cells pass Start, Cln proteolysis is triggered by the mitotic cyclins Clb1, 2, 3 and 4 (ref. 6), But here we show that G1 cyclins are unstable in G1 phase, and that Clb-Cdc28 activity is not needed for G1 cyclin turnover. Cln instability thus provides a means to couple Cln-Cdc28 activity to transcriptional regulation and protein synthetic rate in pre-Start G1 cells.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Grad Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Kentucky, Dept Biochem, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	Cold Spring Harbor Laboratory; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Scripps Research Institute; University of Kentucky	Futcher, B (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	futcher@cshl.org; tyers@mshri.on.ca	Tyers, Michael/ABE-3194-2021					AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; Blondel M, 1996, NATURE, V384, P279, DOI 10.1038/384279a0; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; CROSS FR, 1995, CURR OPIN CELL BIOL, V7, P790, DOI 10.1016/0955-0674(95)80062-X; CROSS FR, 1993, MOL CELL BIOL, V13, P3266, DOI 10.1128/MCB.13.6.3266; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; KO HA, 1990, J BIOL CHEM, V265, P21652; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; VALDIVIESO MH, 1993, MOL CELL BIOL, V13, P1013, DOI 10.1128/MCB.13.2.1013; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; ZETTERBERG A, 1991, COLD SH Q B, V56, P137	30	58	59	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1998	395	6697					86	89		10.1038/25774	http://dx.doi.org/10.1038/25774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116JY	9738503				2022-12-28	WOS:000075722200052
J	Rolla, G; Brussino, L; Colagrande, P; Scappaticci, E; Morello, M; Bergerone, S; Ottobrelli, A; Cerutti, E; Polizzi, S; Bucca, C				Rolla, G; Brussino, L; Colagrande, P; Scappaticci, E; Morello, M; Bergerone, S; Ottobrelli, A; Cerutti, E; Polizzi, S; Bucca, C			Exhaled nitric oxide and impaired oxygenation in cirrhotic patients before and after liver transplantation	ANNALS OF INTERNAL MEDICINE			English	Article							HEPATOPULMONARY SYNDROME; DISEASE; ABNORMALITIES	Background: Nitric oxide may be involved in the impaired oxygenation of cirrhotic patients, a condition that improves in most patients after liver transplantation. Objective: To compare oxygenation and nitric oxide concentrations before and after liver transplantation. Design: Before-and-after observational study. Setting: Academic medical center. Patients: 18 patients with cirrhosis and no obvious cardiopulmonary disease who underwent successful orthotopic liver transplantation. Intervention: Orthotopic liver transplantation. Measurements: Blood gas analysis, measurement of exhaled nitric oxide, contrast-enhanced echocardiography, and pulmonary function tests. Results: Before transplantation, the mean (+/- SD) exhaled nitric oxide concentration was higher in patients than in normal controls (13 +/- 4.9 parts per billion [ppb] compared with 5.75 +/- 1.9 ppb; P < 0.001). After transplantation, the alveolar-arterial oxygen gradient significantly decreased (from 17.3 +/- 7.1 mm Hg to 9 +/- 5.2 mm Hg; P < 0.001), as did the exhaled nitric oxide concentration (from 13 +/- 4.9 ppb to 6.2 +/- 2.8 ppb; P < 0.001). The decrease in the exhaled nitric oxide concentration was significantly correlated with the decrease in the alveolar-arterial oxygen gradient (r = 0.56; P = 0.014). Five patients met the criteria for the diagnosis of the hepatopulmonary syndrome before transplantation; the syndrome was cured by transplantation. Conclusions: The correlation between the decrease in exhaled nitric oxide concentration after liver transplantation and the improvement in oxygenation reinforces the hypothesis that nitric oxide is an important mediator of impaired oxygenation in patients with cirrhosis.	Univ Turin, Dipartimento Sci Biomed & Oncol Umana, I-10126 Turin, Italy; Osped Molinette, Ctr Trapianto Epat, I-10126 Turin, Italy	University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette	Rolla, G (corresponding author), Univ Turin, Dipartimento Sci Biomed & Oncol Umana, Via Genova 3, I-10126 Turin, Italy.		Bucca, Caterina/C-9886-2009; Rolla, Giovanni/C-9901-2009; brussino, luisa/J-2486-2012	Bucca, Caterina/0000-0002-9941-9236; Rolla, Giovanni/0000-0001-5997-7172; brussino, luisa/0000-0001-7249-7616				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P2185; BARZILAI B, 1991, AM J CARDIOL, V68, P1507, DOI 10.1016/0002-9149(91)90287-U; Battaglia SE, 1997, HEPATOLOGY, V25, P1228, DOI 10.1002/hep.510250527; CREMONA G, 1995, EUR RESPIR J, V8, P1883, DOI 10.1183/09031936.95.08111883; Fallon MB, 1997, GASTROENTEROLOGY, V113, P606, DOI 10.1053/gast.1997.v113.pm9247483; HOURANI JM, 1991, AM J MED, V90, P693; ISAWA T, 1978, AM REV RESPIR DIS, V118, P55; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KROWKA MJ, 1985, MAYO CLIN PROC, V60, P407, DOI 10.1016/S0025-6196(12)60852-0; KROWKA MJ, 1994, CHEST, V105, P1528, DOI 10.1378/chest.105.5.1528; MATSUMOTO A, 1995, ANN INTERN MED, V123, P110, DOI 10.7326/0003-4819-123-2-199507150-00005; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RodriguezRoisin R, 1997, GASTROENTEROLOGY, V113, P682, DOI 10.1053/gast.1997.v113.agast971130682; RODRIGUEZROISIN R, 1994, EUR RESPIR J, V7, P839; Rolla G, 1997, HEPATOLOGY, V26, P842, DOI 10.1002/hep.510260406; SCHRADER PC, 1983, B EUR PHYSIOPATH RES, V19, P43; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260, DOI 10.1164/ajrccm.155.1.9001322; SOGNI P, 1995, J HEPATOL, V23, P218, DOI 10.1016/0168-8278(95)80339-4	18	132	140	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1998	129	5					375	378		10.7326/0003-4819-129-5-199809010-00005	http://dx.doi.org/10.7326/0003-4819-129-5-199809010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114RL	9735065				2022-12-28	WOS:000075622600005
J	Tatsis, E; Schnabel, A; Gross, WL				Tatsis, E; Schnabel, A; Gross, WL			Interferon-alpha treatment of four patients with the Churg-Strauss syndrome	ANNALS OF INTERNAL MEDICINE			English	Article							IDIOPATHIC HYPEREOSINOPHILIC-SYNDROME; CYCLOPHOSPHAMIDE THERAPY; ALLERGIC GRANULOMATOSIS; PULSE CYCLOPHOSPHAMIDE; CORONARY INVOLVEMENT; VASCULITIS; ANGIITIS	Background: Interferon-cr is reported to have a beneficial effect on patients with the idiopathic hypereosinophilic syndrome. Objective: To study the effect of interferon-cr on the Churg-Strauss syndrome. Design: Case series. Setting: University hospital. Patients: Four patients with biopsy-proven Churg-Strauss syndrome. Intervention: Interferon-cr at dosages of 7.5 to 63 million U per week. Measurements: Disease extent, disease activity, and blood eosinophil count in a treatment period ranging from 14 to 25 months. Results: Interferon-alpha therapy led to remission of disease and a substantial reduction of the prednisolone requirement in two patients who had attained incomplete remission with cyclophosphamide or methotrexate. The third patient's condition stabilized, and the fourth patient maintained remission. During interferon-alpha therapy, the blood eosinophil count in all patients decreased in a dose-dependent manner and paralleled the extent of clinical disease and disease activity. Conclusions: Interferon-alpha may be an effective treatment for the Churg-Strauss syndrome. It seems to exert its effect primarily by producing a dose-dependent decrease in the blood eosinophil count.	Med Univ Lubeck, Poliklin Rheumatol, D-23538 Lubeck, Germany; Rheumaklin Bad Bramstedt, D-24572 Bad Bramstedt, Germany	University of Lubeck	Tatsis, E (corresponding author), Med Univ Lubeck, Poliklin Rheumatol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.							Aldebert D, 1996, BLOOD, V87, P2354, DOI 10.1182/blood.V87.6.2354.bloodjournal8762354; BUTTERFIELD JH, 1994, ANN INTERN MED, V121, P648, DOI 10.7326/0003-4819-121-9-199411010-00003; CHUMBLEY LC, 1977, MAYO CLIN PROC, V52, P477; CHURG A, 1995, CHEST, V108, P320, DOI 10.1378/chest.108.2.320; CLUTTERBUCK EJ, 1990, NEPHROL DIAL TRANSPL, V5, P161, DOI 10.1093/ndt/5.3.161; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; FAUCI AS, 1979, NEW ENGL J MED, V301, P235, DOI 10.1056/NEJM197908023010503; GUILLEVIN L, 1995, ARTHRITIS RHEUM, V38, P1638, DOI 10.1002/art.1780381116; Hellemans S, 1997, HEART, V77, P576, DOI 10.1136/hrt.77.6.576; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; Jennette JC, 1997, NEW ENGL J MED, V337, P1512, DOI 10.1056/NEJM199711203372106; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; KOZAK M, 1995, CHEST, V107, P578, DOI 10.1378/chest.107.2.578; LANHAM JG, 1984, MEDICINE, V63, P65, DOI 10.1097/00005792-198403000-00001; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806; REINHOLDKELLER E, 1994, ARTHRITIS RHEUM, V37, P919, DOI 10.1002/art.1780370622; SEHGAL M, 1995, MAYO CLIN PROC, V70, P337, DOI 10.4065/70.4.337; ZIELINSKI RM, 1990, ANN INTERN MED, V113, P716, DOI 10.7326/0003-4819-113-9-716	18	138	144	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1998	129	5					370	374		10.7326/0003-4819-129-5-199809010-00004	http://dx.doi.org/10.7326/0003-4819-129-5-199809010-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114RL	9735064				2022-12-28	WOS:000075622600004
J	Saito, N; Ebara, S; Ohotsuka, K; Kumeta, H; Takaoka, K				Saito, N; Ebara, S; Ohotsuka, K; Kumeta, H; Takaoka, K			Natural history of scoliosis in spastic cerebral palsy	LANCET			English	Article							SEGMENTAL SPINAL INSTRUMENTATION; FUSION; DEFORMITY; ROD	Background Although the frequent occurrence of scoliosis in patients who have spastic cerebral palsy is well known and surgical treatment has often been recommended for these patients, little is known about the natural history of scoliosis in this population. We aimed to clarify the natural history of scoliosis from childhood through to adulthood and provide objective data on proper surgical indications for such patients. Methods The participants were 37 institutionalised patients with severe spastic cerebral palsy and scoliosis. All the participants had a series of radiographs taken, starting at a mean age of 7.8 years; they were followed up for an average of 17.3 years. We retrospectively reviewed radiographs and assessed the effect of five factors on progression of scoliosis: sex, degree of spasticity, initial physical capability, pattern of spinal curve, and location of curve. Findings Scoliosis usually started before the age of 10 years and progressed rapidly during the growth period. In many cases, even after growth had ended, continuous progression was seen. The mean magnitude of the curves at final examination was 55 degrees (Cobb angle). In 11 (85%) of 13 patients who had a spinal curve of more than 40 degrees before age 15 years, the scoliosis progressed to more than 60 degrees by the time of the final examination. Meanwhile, in only three (13%) of 24 patients who had a curve of less than 40 degrees at age 15 years, did the scoliosis progress to more than 60 degrees. Severe scoliosis (greater than or equal to 60 degrees) developed predominantly in those who had total body involvement (67%), were bedridden (100%), or had throacolumbar curves (57%). Interpretation The risk factors for progression of scoliosis in spastic cerebral palsy are: having a spinal curve of 40 degrees before age 15 years; having total body involvement; being bedridden; and having a thoracolumbar curve. Patients with these risk factors might benefit from early surgical intervention to prevent progression to severe scoliosis.	Shinshu Univ, Sch Med, Dept Orthopaed Surg, Matsumoto, Nagano, Japan; Nagano Rehabil Ctr, Dept Orthopaed Surg, Nagano, Japan; E Nagano Hosp, Dept Orthopaed Surg, Nagano, Japan	Shinshu University	Saito, N (corresponding author), Shinshu Univ, Sch Med, Dept Orthopaed Surg, Asahi 3-1-1, Matsumoto, Nagano, Japan.							Balmer G A, 1970, J Bone Joint Surg Br, V52, P134; BOACHIEADJEI O, 1989, J BONE JOINT SURG AM, V71A, P548, DOI 10.2106/00004623-198971040-00011; BONNETT C, 1976, J BONE JOINT SURG AM, V58, P328, DOI 10.2106/00004623-197658030-00006; BROWN JC, 1982, SPINE, V7, P570, DOI 10.1097/00007632-198211000-00010; Bulman WA, 1996, J PEDIATR ORTHOPED, V16, P314, DOI 10.1097/01241398-199605000-00005; CASSIDY C, 1994, J PEDIATR ORTHOPED, V14, P731, DOI 10.1097/01241398-199414060-00008; GERSOFF WK, 1988, J BONE JOINT SURG AM, V70A, P41, DOI 10.2106/00004623-198870010-00007; KALEN V, 1992, J PEDIATR ORTHOPED, V12, P337, DOI 10.1097/01241398-199205000-00010; LONSTEIN JE, 1983, J BONE JOINT SURG AM, V65, P43, DOI 10.2106/00004623-198365010-00007; LONSTEIN JE, 1994, TXB SCOLIOSIS OTHER, P45; MADIGAN RR, 1981, SPINE, V6, P583, DOI 10.1097/00007632-198111000-00009; Majd ME, 1997, SPINE, V22, P1461, DOI 10.1097/00007632-199707010-00007; Miller A, 1996, J PEDIATR ORTHOPED, V16, P332, DOI 10.1097/01241398-199605000-00007; NASH CL, 1969, J BONE JOINT SURG AM, VA 51, P223, DOI 10.2106/00004623-196951020-00002; RENSHAW TS, 1995, J BONE JOINT SURG AM, V77, P1590, DOI 10.2106/00004623-199510000-00016; RINSKY LA, 1990, CLIN ORTHOP RELAT R, V253, P100; ROBSON P, 1968, DEV MED CHILD NEUROL, V10, P447; ROSENTHAL RK, 1974, DEV MED CHILD NEUROL, V16, P664; SPONSELLER PD, 1986, J PEDIATR ORTHOPED, V6, P559, DOI 10.1097/01241398-198609000-00006; STANITSKI CL, 1982, SPINE, V7, P563, DOI 10.1097/00007632-198211000-00009; SUZUKI S, 1993, SPINE, V18, P2290, DOI 10.1097/00007632-199311000-00026; SWANK SM, 1989, SPINE, V14, P750, DOI 10.1097/00007632-198907000-00018; THOMETZ JG, 1988, J BONE JOINT SURG AM, V70A, P1290, DOI 10.2106/00004623-198870090-00002	23	158	167	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 6	1998	351	9117					1687	1692		10.1016/S0140-6736(98)01302-6	http://dx.doi.org/10.1016/S0140-6736(98)01302-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734885				2022-12-28	WOS:000074088900009
J	Schnuelle, P; van der Woude, FJ				Schnuelle, P; van der Woude, FJ			Should A(2) kidneys be transplanted into B or O recipients?	LANCET			English	Editorial Material							ACCELERATED ACUTE REJECTION; RENAL-TRANSPLANTATION; GRAFT-SURVIVAL; A2; EXPERIENCE; ALLOGRAFTS; DONORS		Univ Heidelberg, Univ Hosp Mannheim, Fac Med, Med Clin 5, D-68135 Mannheim, Germany	Ruprecht Karls University Heidelberg	Schnuelle, P (corresponding author), Univ Heidelberg, Univ Hosp Mannheim, Fac Med, Med Clin 5, D-68135 Mannheim, Germany.							ALEXANDRE GPJ, 1987, TRANSPLANT P, V19, P4538; BARIETY J, 1980, KIDNEY INT, V17, P820, DOI 10.1038/ki.1980.94; BRYNGER H, 1984, TRANSPLANT P, V16, P1175; COOK DJ, 1987, TRANSPLANT P, V19, P4549; HANTO DW, 1993, TRANSPLANTATION, V56, P743; JAKOBSEN A, 1987, TRANSPLANT P, V19, P4561; MENDEZ R, 1991, TRANSPLANT P, V23, P1738; Nelson PW, 1998, TRANSPLANTATION, V65, P256; NELSON PW, 1992, AM J SURG, V164, P541, DOI 10.1016/S0002-9610(05)81197-3; PORT FK, 1991, AM J KIDNEY DIS, V17, P519, DOI 10.1016/S0272-6386(12)80492-6; RYDBERG L, 1987, TRANSPLANT P, V19, P4528; SHAPIRA Z, 1987, TRANSPLANT P, V19, P4562; WELSH KI, 1987, TRANSPLANT P, V19, P4565	13	16	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 6	1998	351	9117					1675	1676		10.1016/S0140-6736(05)77737-0	http://dx.doi.org/10.1016/S0140-6736(05)77737-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734881				2022-12-28	WOS:000074088900005
J	Gemke, RJBJ; Tasker, RC				Gemke, RJBJ; Tasker, RC			Clinical assessment of acute coma in children	LANCET			English	Editorial Material							SCALE		Wilhelmina Childrens Hosp, Dept Paediat Cardiol, NL-3501 CA Utrecht, Netherlands; Great Ormond St Hosp Children, London WC1N 3JH, England	Wilhelmina Kinderziekenhuis; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Gemke, RJBJ (corresponding author), Wilhelmina Childrens Hosp, Dept Paediat Cardiol, NL-3501 CA Utrecht, Netherlands.		Tasker, Robert C/R-5837-2019	Tasker, Robert/0000-0003-3647-8113				GORDON NS, 1983, NEUROPEDIATRICS, V14, P3, DOI 10.1055/s-2008-1059545; Kirkpatrick PJ, 1997, J NEUROL NEUROSUR PS, V62, P109, DOI 10.1136/jnnp.62.2.109; LOVEJOY FH, 1974, AM J DIS CHILD, V128, P36, DOI 10.1001/archpedi.1974.02110260038007; MORRAY JP, 1984, CRIT CARE MED, V12, P1018, DOI 10.1097/00003246-198412000-00002; PLUM F, 1966, DIAGNOSIS COMA STUPO; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; SIMPSON DA, 1991, CHILD NERV SYST, V7, P183; Tatman A, 1997, ARCH DIS CHILD, V77, P519, DOI 10.1136/adc.77.6.519; TEASDALE G, 1974, LANCET, V2, P81; YAGER JY, 1990, AM J DIS CHILD, V144, P1088, DOI 10.1001/archpedi.1990.02150340032019	11	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 28	1998	351	9107					926	927						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734935				2022-12-28	WOS:000072770900006
J	Logie, DE				Logie, DE			Mozambique: investing in peace	LANCET			English	Editorial Material																		Harrison KA, 1997, LANCET, V349, P644, DOI 10.1016/S0140-6736(97)02192-2; *JUB 2000, 1997, JUL 2000 DEBT CUTT H; MARSHALL J, 1990, REV AFRICAN POLITICA, V47, P28; *OXF POL PAP, 1994, DEBT REL MOZ INV PEA	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 28	1998	351	9107					982	983						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734961				2022-12-28	WOS:000072770900049
J	Rosen, CJ				Rosen, CJ			Pre-emptive bone strikes in prevention of osteoporosis	LANCET			English	Editorial Material							WOMEN; FRACTURES		Univ Maine, St Joseph Hosp, Maine Ctr Osteoporosis Res & Educ, Bangor, ME 04401 USA	University of Maine System; University of Maine Orono	Rosen, CJ (corresponding author), Univ Maine, St Joseph Hosp, Maine Ctr Osteoporosis Res & Educ, Bangor, ME 04401 USA.							Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; McClung M, 1998, ANN INTERN MED, V128, P253, DOI 10.7326/0003-4819-128-4-199802150-00001	7	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 28	1998	351	9107					927	928						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734936				2022-12-28	WOS:000072770900007
J	Baker, J				Baker, J			An important lesson - The hazards of self management	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					910	910						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756804				2022-12-28	WOS:000076409000019
J	Jarvis, P; Chen, LJ; Li, HM; Pete, CA; Fankhauser, C; Chory, J				Jarvis, P; Chen, LJ; Li, HM; Pete, CA; Fankhauser, C; Chory, J			An Arabidopsis mutant defective in the plastid general protein import apparatus	SCIENCE			English	Article							DEVELOPMENTAL REGULATION; CHLOROPLAST ENVELOPE; CHLOROPHYLL-A; EXPRESSION; TRANSPORT; COMPONENTS; LEAF; DNA	Elaborate mechanisms have evolved for the translocation of nucleus-encoded proteins across the plastid envelope membrane. Although putative components of the import apparatus have been identified biochemically, their role in import remains to be proven in vivo. An Arabidopsis mutant lacking a new component of the import machinery [translocon at the outer envelope membrane of chloroplasts (Toc33), a 33-kilodalton protein] has been isolated. The functional similarity of Toc33 to another translocon component (Toc34) implies that multiple different translocon complexes are present in plastids. Processes that are mediated by Toc33 operate during the early stages of plastid and Leaf development. The data demonstrate the in vivo role of a translocon component in plastid protein import.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Salk Inst Biol Studies, Neuronal Struct & Funct Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA	Salk Institute; Academia Sinica - Taiwan; Salk Institute; Howard Hughes Medical Institute; Salk Institute	Chory, J (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	chory@salk.edu	Fankhauser, Christian/ABE-8757-2021; Li, Hsou-min/AAZ-8011-2021; Fankhauser, Christian/C-4291-2018	Fankhauser, Christian/0000-0003-4719-5901; Li, Hsou-min/0000-0002-0211-7339; Fankhauser, Christian/0000-0003-4719-5901				Akita M, 1997, J CELL BIOL, V136, P983, DOI 10.1083/jcb.136.5.983; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; DAHLIN C, 1991, PLANT CELL, V3, P1131, DOI 10.1105/tpc.3.10.1131; DEAN C, 1982, PLANT PHYSIOL, V69, P904, DOI 10.1104/pp.69.4.904; FANKHAUSER C, UNPUB; Fuks B, 1997, PLANT PHYSIOL, V114, P405, DOI 10.1104/pp.114.2.405; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; LAMPPA GK, 1985, MOL CELL BIOL, V5, P1370, DOI 10.1128/MCB.5.6.1370; Li HM, 1997, J BIOL CHEM, V272, P10968; LI HM, 1995, PLANT CELL, V7, P1599, DOI 10.1105/tpc.7.10.1599; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; LOPEZJUEZ E, IN PRESS PLANT PHYSL; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; PERRY SE, 1991, METHOD CELL BIOL, V34, P327; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; REINBOTHE C, 1995, MOL CELL BIOL, V15, P6206; Reinbothe S, 1996, PLANT CELL, V8, P763, DOI 10.1105/tpc.8.5.763; Schnell DJ, 1997, TRENDS CELL BIOL, V7, P303, DOI 10.1016/S0962-8924(97)01111-2; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SEEDORF M, 1995, FEBS LETT, V367, P19, DOI 10.1016/0014-5793(95)00529-I; VIRO M, 1980, PLANTA, V150, P41, DOI 10.1007/BF00385613; Wan JX, 1996, J BIOL CHEM, V271, P31227, DOI 10.1074/jbc.271.49.31227	24	273	313	2	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1998	282	5386					100	103		10.1126/science.282.5386.100	http://dx.doi.org/10.1126/science.282.5386.100			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756470				2022-12-28	WOS:000076294900047
J	Carr, PL; Ash, AS; Friedman, RH; Scaramucci, A; Barnett, RC; Szalacha, L; Palepu, A; Moskowitz, MA				Carr, PL; Ash, AS; Friedman, RH; Scaramucci, A; Barnett, RC; Szalacha, L; Palepu, A; Moskowitz, MA			Relation of family responsibilities and gender to the productivity and career satisfaction of medical faculty	ANNALS OF INTERNAL MEDICINE			English	Article						job satisfaction; faculty, medical; career mobility; sex factors; child rearing	ACADEMIC MEDICINE; INTERNAL-MEDICINE; WOMEN PHYSICIANS; SEX-DIFFERENCES; MEN FACULTY; DEPARTMENTS	Background: Studies have found that female faculty publish less, have slower career progress, and generally have a more difficult time in academic careers than male faculty. The relation of family (dependent) responsibilities to gender and academic productivity is unclear. Objective: To describe dependent responsibilities by gender and to identify their relation to the aspirations, goals, rate of progress, academic productivity, and career satisfaction of male and female medical school faculty. Design: 177-item survey questionnaire. Setting: 24 randomly selected medical schools in the contiguous United States. Participants: 1979 respondents from a probability sample of full-time academic medical school faculty. Measurements: The main end point for measuring academic productivity was the total number of publications in refereed journals. Perceived career progress and career satisfaction were assessed by using Likert scales. Results: For both male and female faculty, more than 90% of time devoted to family responsibilities was spent on child care. Among faculty with children, women had greater obstacles to academic careers and less institutional support, including research funding from their institutions (46% compared with 57%; P < 0.001) and secretarial sup port (0.68 full-time equivalents compared with 0.83 full-time equivalents; P = 0.003), than men. Compared with men with children, women with children had fewer publications (18.3 compared with 29.3; P < 0.001), slower self-perceived career progress (2.6 compared with 3.1; P < 0.001), and lower career satisfaction (5.9 compared with 6.6; P < 0.001). However, no significant differences between the sexes were seen for faculty without children. Conclusions: Compared with female faculty without children and compared with men, female faculty with children face major obstacles in academic careers. Some of these obstacles can be easily modified (for example, by eliminating after-hours meetings and creating part-time career tracks). Medical schools should address these obstacles and provide support for faculty with children.	Massachusetts Gen Hosp, Boston Med Ctr, Boston, MA 02114 USA; Radcliffe Coll, Murray Res Ctr, Cambridge, MA USA; Harvard Univ, Grad Sch Educ, Boston, MA 02115 USA	Boston Medical Center; Harvard University; Massachusetts General Hospital; Harvard University	Carr, PL (corresponding author), Massachusetts Gen Hosp, Womens Hlth Associates, Blake 10,55 Fruit St, Boston, MA 02114 USA.		Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253; Friedman, Robert/0000-0002-9440-2443; Palepu, Anita/0000-0002-7881-4800				Barnett RC, 1998, ACAD MED, V73, P180, DOI 10.1097/00001888-199802000-00017; BEATY HN, 1986, ANN INTERN MED, V104, P90, DOI 10.7326/0003-4819-104-1-90; BICKEL J, 1988, NEW ENGL J MED, V319, P1579, DOI 10.1056/NEJM198812153192405; CARR P, 1992, J GEN INTERN MED, V7, P418, DOI 10.1007/BF02599159; CARR PL, 1993, ANN INTERN MED, V119, P908, DOI 10.7326/0003-4819-119-9-199311010-00008; COLE JR, 1987, SCI AM, V256, P119, DOI 10.1038/scientificamerican0287-119; Cole JR, 1991, OUTER CIRCLE WOMEN S; Fried LP, 1996, JAMA-J AM MED ASSOC, V276, P898, DOI 10.1001/jama.276.11.898; GRANT L, 1988, J AM MED WOMEN ASSOC, V43, P115; GRAVES PL, 1985, JAMA-J AM MED ASSOC, V254, P781, DOI 10.1001/jama.254.6.781; Hitchcock MA, 1995, ACAD MED, V70, P1108, DOI 10.1097/00001888-199512000-00014; Kaplan SH, 1996, NEW ENGL J MED, V335, P1282, DOI 10.1056/NEJM199610243351706; KOMAROMY M, 1993, NEW ENGL J MED, V328, P322, DOI 10.1056/NEJM199302043280507; LEVEY BA, 1990, ACAD MED, V65, P102, DOI 10.1097/00001888-199002000-00011; LEVINSON W, 1993, ANN INTERN MED, V119, P220, DOI 10.7326/0003-4819-119-3-199308010-00008; LEVINSON W, 1989, NEW ENGL J MED, V321, P1511, DOI 10.1056/NEJM198911303212205; LONG JS, 1992, SOC FORCES, V71, P159, DOI 10.2307/2579971; MCGLYNN EA, 1989, PHYSICIAN JOB SATISF; RELMAN AS, 1980, NEW ENGL J MED, V302, P1252, DOI 10.1056/NEJM198005293022209; Sonnert G, 1996, AM SCI, V84, P63; TESCH BJ, 1995, JAMA-J AM MED ASSOC, V273, P1022, DOI 10.1001/jama.273.13.1022; WILKINSON CJ, 1986, ANESTHESIOLOGY, V64, P496, DOI 10.1097/00000542-198604000-00014	22	299	299	2	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1998	129	7					532	+		10.7326/0003-4819-129-7-199810010-00004	http://dx.doi.org/10.7326/0003-4819-129-7-199810010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123KN	9758572				2022-12-28	WOS:000076124500003
J	Norman, PE; Semmens, JB; Lawrence-Brown, MMD; Holman, CDJ				Norman, PE; Semmens, JB; Lawrence-Brown, MMD; Holman, CDJ			Long term relative survival after surgery for abdominal aortic aneurysm in Western Australia: population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective: To determine the long term relative survival of all patients who had surgery for abdominal aortic aneurysm in Western Australia during 1985-94. Design: Population based study. Setting: Western Australia Subjects: All patients who had had surgery for abdominal aortic aneurysm in Western, Australia during 1985-94. Main outcome measures: Morbidity and mortality data of patients admitted and surgically treated for abdominal aortic aneurysm in Western Australia during 1985-94. Elective, ruptured, and acute non-ruptured cases were analysed separately. Independent analyses for sex and patients aged 80 years or more were also undertaken. Postoperative (>30 days) relative survival was assessed against age and sex matched controls. Results: Overall, 1475 (1257 men, 218 women) cases were identified The crude five year survival after elective surgery, including deaths within 30 days of surgery was 79% for both men and women. When compared with a matched population the five year relative survival after elective surgery was 94.9% (95% confidence interval 89.9% to 99.9%) for men but only 88.0% (76.3% to 99.7%) for women. The five year relative survival of those aged 80 years and over was good: 116.6% (89.1% to 144.0%) compared with 92.4% (87.7% to 97.0%) for those under 80 years of age (men and women combined). Cardiovascular disease caused 57.8% of the 341 deaths after 30 days. Conclusion: In a condition such as abdominal aortic aneurysm, which occurs in elderly patients, relative survival is more clinically meaningful than crude survival. The five year relative survival in cases of elective and ruptured abdominal aortic aneurysm was better in men than in women This is probably because of greater comorbidity in women with abdominal aortic aneurysm and this deserves more attention in the future. The long term survival outcome in octogenarians supports surgery in selected cases.	Univ Western Australia, Fremantle Hosp, Dept Surg, Fremantle, WA 6959, Australia; Univ Western Australia, Dept Publ Hlth, Ctr Hlth Serv Res, Nedlands, WA 6009, Australia; Royal Perth Hosp, Dept Vasc Surg, Perth, WA 6000, Australia	University of Western Australia; University of Western Australia; Royal Perth Hospital; University of Western Australia	Norman, PE (corresponding author), Univ Western Australia, Fremantle Hosp, Dept Surg, POB 480, Fremantle, WA 6959, Australia.	pnorman@cyllene.uwa.edu.au	Holman, Cashel DJ/B-6173-2009; Norman, Paul E/C-5485-2013	Norman, Paul E/0000-0003-3406-0506				Campbell W B, 1991, Eur J Vasc Surg, V5, P111; EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101; ESTEVE J, 1990, STAT MED, V9, P529, DOI 10.1002/sim.4780090506; HAKULINEN T, 1982, BIOMETRICS, V38, P933, DOI 10.2307/2529873; JOHNSTON KW, 1994, J VASC SURG, V20, P163, DOI 10.1016/0741-5214(94)90002-7; MULUK SC, 1994, J VASC SURG, V20, P880, DOI 10.1016/0741-5214(94)90224-0; *OFF NAT COD CTR A, 1995, TAB LIST DIS; *OFF NCC AUSTR VER, 1995, TAB LIST ANN IND PRO; OLSEN PS, 1991, J CARDIOVASC SURG, V32, P636; Semmens JB, 1998, BRIT J SURG, V85, P648; Semmens JB, 1998, AUST NZ J SURG, V68, P397, DOI 10.1111/j.1445-2197.1998.tb04786.x; SOREIDE O, 1982, SURGERY, V91, P188; STONEBRIDGE PA, 1993, BRIT J SURG, V80, P585, DOI 10.1002/bjs.1800800511; THERNEAU T, 1994, 52 MAYO CLIN; THOMAS PRS, 1988, BRIT J SURG, V75, P733, DOI 10.1002/bjs.1800750804; World Health Organization, 1978, INT CLASS PROC MED; World Health Organization, 1977, INT CLASS DIS MAN IN	17	94	96	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	1998	317	7162					852	856		10.1136/bmj.317.7162.852	http://dx.doi.org/10.1136/bmj.317.7162.852			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748177	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000076222300018
J	Greenberg, DS				Greenberg, DS			Science's own superstition	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 19	1998	352	9132					998	998		10.1016/S0140-6736(05)61560-7	http://dx.doi.org/10.1016/S0140-6736(05)61560-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752852				2022-12-28	WOS:000076002200061
J	Laidlaw, DAH; Harrad, RA; Hopper, CD; Whitaker, A; Donovan, JL; Brookes, ST; Marsh, GW; Peters, TJ; Sparrow, JM; Frankel, SJ				Laidlaw, DAH; Harrad, RA; Hopper, CD; Whitaker, A; Donovan, JL; Brookes, ST; Marsh, GW; Peters, TJ; Sparrow, JM; Frankel, SJ			Randomised trial of effectiveness of second eye cataract surgery	LANCET			English	Article							QUALITY-OF-LIFE; VISUAL FUNCTION; UNILATERAL CATARACT; PREVALENCE; EXTRACTION; OUTCOMES; ACUITY; 2ND	Background The effectiveness of cataract surgery on one eye is well established; but concerns over healthcare expenditure have called into question the value of cataract surgery on the second eye. We examined the effects of second eye surgery in terms of patient perceptions as well as through visual acuity, contrast sensitivity, and stereoacuity tests. Methods 208 otherwise healthy patients awaiting second eye cataract surgery were recruited into our randomised trial. At randomisation participants were allocated expedited surgery (planned to take place within 6 weeks) or routine surgery (routine waiting time, 7-12 months). Assessments were made at randomisation and again at review after about 6 months. Eight primary trial outcomes consisted of four questionnaire items and four visual function tests, done with bath eyes open. Findings Traditional clinical tests of success in cataract surgery (visual acuity and contrast sensitivity) showed only slight differences in binocular vision in favour of the expedited-surgery group. There were major benefits for the expedited-surgery group in terms of reported visual symptoms and effects on quality of life. At review, differences in self-reported vision related difficulties between the two groups ranged from 11% (95% CI 4.4-17%, activities) to 30% (19-41%, reading). Stereoacuity was better in the expedited surgery group, the difference between the groups for the proportions with stereoacuity of 3000 s of are or worse was 58% (47-69%). Interpretation This trial has shown that there is a clear benefit from second eye cataract surgery.	Univ Bristol, Bristol Eye Hosp, Dept Ophthalmol, Bristol BS1 2LX, Avon, England; Univ Bristol, Bristol Eye Hosp, Dept Social Med, Bristol BS1 2LX, Avon, England	Bristol Eye Hospital; University of Bristol; Bristol Eye Hospital; University of Bristol	Sparrow, JM (corresponding author), Univ Bristol, Bristol Eye Hosp, Dept Ophthalmol, Bristol BS1 2LX, Avon, England.			Peters, Tim/0000-0003-2881-4180	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILEY IL, 1980, AM J OPTOM PHYS OPT, V57, P378; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; BRENNER MH, 1993, ARCH OPHTHALMOL-CHIC, V111, P680, DOI 10.1001/archopht.1993.01090050114040; COURTNEY P, 1992, EYE, V6, P487, DOI 10.1038/eye.1992.103; DESAI P, 1993, EYE, V7, P489, DOI 10.1038/eye.1993.107; Desai P, 1996, BRIT J OPHTHALMOL, V80, P868, DOI 10.1136/bjo.80.10.868; DONOVAN JL, 1993, J EPIDEMIOL COMMUN H, V47, P158, DOI 10.1136/jech.47.2.158; ELLIOTT DB, 1991, CLIN VISION SCI, V6, P471; Ferguson B, 1996, EFFECTIVE HLTH CARE, V2, P1; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0; GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196; Hall JC, 1996, SURGERY, V119, P466, DOI 10.1016/S0039-6060(96)80149-8; HARRAD RA, 1994, INVEST OPHTH VIS SCI, V35, P1964; Horton R, 1996, LANCET, V347, P984, DOI 10.1016/S0140-6736(96)90137-3; Howard IP, 1995, BINOCULAR VISION STE; JAVITT JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P686, DOI 10.1001/archopht.1993.01090050120041; JAVITT JC, 1995, OPHTHALMOLOGY, V102, P1583; KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428; KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546; Kwapiszeski BR, 1996, J CATARACT REFR SURG, V22, P441, DOI 10.1016/S0886-3350(96)80039-3; LAIDLAW A, 1993, EYE, V7, P680, DOI 10.1038/eye.1993.155; MANGIONE CM, 1994, ARCH OPHTHALMOL-CHIC, V112, P1419, DOI 10.1001/archopht.1994.01090230033017; NEWELL DJ, 1992, INT J EPIDEMIOL, V21, P837, DOI 10.1093/ije/21.5.837; Oppenheim A., 1992, QUESTIONNAIRE DEISGN; PARHAN S, 1991, VISION SCI, V6, P355; PELLI DG, 1988, CLIN VISION SCI, V2, P187; POWE NR, 1994, ARCH OPHTHALMOL-CHIC, V112, P239, DOI 10.1001/archopht.1994.01090140115033; SCHEIN OD, 1995, OPHTHALMOLOGY, V102, P817, DOI 10.1016/S0161-6420(95)30952-9; Scotcher SM, 1997, BRIT J OPHTHALMOL, V81, P1050, DOI 10.1136/bjo.81.12.1050; STEINBERG EP, 1993, ARCH OPHTHALMOL-CHIC, V111, P1041, DOI 10.1001/archopht.1993.01090080037016; Streiner DL., 1995, HLTH MEASUREMENT SCA, V2nd ed.; TIELSCH JM, 1995, ARCH OPHTHALMOL-CHIC, V113, P1312, DOI 10.1001/archopht.1995.01100100100038; *US DHHS, 1993, AHCPR PUBL, P97	33	114	115	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 19	1998	352	9132					925	929		10.1016/S0140-6736(97)12536-3	http://dx.doi.org/10.1016/S0140-6736(97)12536-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752814				2022-12-28	WOS:000076002200007
J	Cecconi, F; Alvarez-Bolado, G; Meyer, BI; Roth, KA; Gruss, P				Cecconi, F; Alvarez-Bolado, G; Meyer, BI; Roth, KA; Gruss, P			Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development	CELL			English	Article							EMBRYONIC STEM-CELLS; C-ELEGANS CED-4; CAENORHABDITIS-ELEGANS; INSITU HYBRIDIZATION; RETINITIS-PIGMENTOSA; NOONAN-SYNDROME; DEFICIENT MICE; BCL-2 FAMILY; CYTOCHROME-C; GENE	The cytosolic protein APAF1, human homolog of C. elegans CED-4 participates in the CASPASE 9 (CASP9)-dependent activation of CASP3 in the general apoptotic pathway. We have generated by gene trap a null allele of the murine Apaf1. Homozygous mutants die at embryonic day 16.5. Their phenotype includes severe craniofacial malformations, brain overgrowth, persistence of the interdigital webs, and dramatic alterations of the lens and retina. Homozygous embryonic fibroblasts exhibit reduced response to various apoptotic stimuli. In situ immunodetection shows that the absence of Apaf1 protein prevents the activation of Casp3 in vivo. In agreement with the reported function of CED-4 in C. elegans, this phenotype can be correlated with a defect of apoptosis. Our findings suggest that Apaf1 is essential for Casp3 activation in embryonic brain and is a key regulator of developmental programmed cell death in mammals.	Max Planck Inst Biophys Chem, Dept Mol Cell Biol, D-37077 Gottingen, Germany; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Max Planck Society; Washington University (WUSTL)	Gruss, P (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Cell Biol, D-37077 Gottingen, Germany.		Cecconi, Francesco/K-3969-2016	Cecconi, Francesco/0000-0002-5614-4359; Alvarez-Bolado, Gonzalo/0000-0002-3044-1603; Roth, Kevin/0000-0002-0643-995X	NINDS NIH HHS [NS35107, NS35484] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035484, R01NS035107] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BUNT SM, 1981, BRAIN RES, V211, P399, DOI 10.1016/0006-8993(81)90712-5; CAPECCHI MR, 1974, P NATL ACAD SCI USA, V71, P4732, DOI 10.1073/pnas.71.12.4732; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chowdhury K, 1997, NUCLEIC ACIDS RES, V25, P1531, DOI 10.1093/nar/25.8.1531; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COULOMBRE JL, 1963, SCIENCE, V142, P1489, DOI 10.1126/science.142.3598.1489; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; FERGUSON MWJ, 1988, DEVELOPMENT, V103, P41; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; Harris BS, 1997, TERATOLOGY, V55, P231, DOI 10.1002/(SICI)1096-9926(199704)55:4<231::AID-TERA3>3.3.CO;2-U; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hoeppner DJ, 1996, BBA-REV CANCER, V1242, P217, DOI 10.1016/0304-419X(95)00017-A; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; JACOBSON M, 1981, DEV NEUROBIOLOGY; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JAMIESON CR, 1994, NAT GENET, V8, P357, DOI 10.1038/ng1294-357; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lang RA, 1997, CELL DEATH DIFFER, V4, P12, DOI 10.1038/sj.cdd.4400211; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lorenzetti ME, 1996, AM J MED GENET, V65, P97, DOI 10.1002/(SICI)1096-8628(19961016)65:2<97::AID-AJMG1>3.0.CO;2-R; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rehen SK, 1996, DEVELOPMENT, V122, P1439; Richman J, 1996, CURR BIOL, V6, P364, DOI 10.1016/S0960-9822(02)00496-7; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; SILVER J, 1973, J MORPHOL, V140, P159, DOI 10.1002/jmor.1051400204; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; SRINIVASAN A, 1998, IN PRESS CELL DEATH; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WELL M, 1996, J CELL BIOL, V133, P1053; WONG P, 1994, BIOCHEM CELL BIOL, V72, P489, DOI 10.1139/o94-066; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	61	770	790	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					727	737		10.1016/S0092-8674(00)81732-8	http://dx.doi.org/10.1016/S0092-8674(00)81732-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753320	hybrid			2022-12-28	WOS:000076021200006
J	Nathan, DM				Nathan, DM			Some answers, more controversy, from UKPDS	LANCET			English	Editorial Material							DEPENDENT DIABETES-MELLITUS; COMPLICATIONS		Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Nathan, DM (corresponding author), Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA.							*DCCT RES GROUP, 1993, NEW ENGL J MED, V329, P978; Genuth S, 1996, ANN INTERN MED, V124, P104, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00005; NATHAN DM, 1995, DIABETES CARE, V18, P251, DOI 10.2337/diacare.18.2.251; NATHAN DM, 1997, LANCET S1, V350, P4; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Stearne MR, 1998, BRIT MED J, V317, P713; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; The University Group Diabetes Program, 1970, DIABETES S2, V19, P747; TURNER RC, 1991, DIABETOLOGIA, V34, P877; TURNER RC, 1995, DIABETES, V44, P1249	10	128	134	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					832	833		10.1016/S0140-6736(98)22937-0	http://dx.doi.org/10.1016/S0140-6736(98)22937-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742972				2022-12-28	WOS:000075857300002
J	Feldman, B; Gates, MA; Egan, ES; Dougan, ST; Rennebeck, G; Sirotkin, HI; Schier, AF; Talbot, WS				Feldman, B; Gates, MA; Egan, ES; Dougan, ST; Rennebeck, G; Sirotkin, HI; Schier, AF; Talbot, WS			Zebrafish organizer development and germ-layer formation require nodal-related signals	NATURE			English	Article							GOOSECOID EXPRESSION; SPEMANN ORGANIZER; MUTANT EMBRYOS; NO TAIL; GENE; MESODERM; MOUSE; SPECIFICATION; GASTRULATION; NUCLEI	The vertebrate body plan is established during gastrulation, when cells move inwards to form the mesodermal and endodermal germ layers. Signals from a region of dorsal mesoderm, which is termed the organizer, pattern the body axis by specifying the fates of neighbouring cells(1,2). The organizer is itself induced by earlier signals(1). Although members of the transforming growth factor-beta (TGF-beta) and Wnt families have been implicated in the formation of the organizer, no endogenous signalling molecule is known to be required for this process(1). Here we report that the zebrafish squint (sqt)(3) and cyclops (cyc)(4) genes have essential, although partly redundant, functions in organizer development and also in the formation of mesoderm and endoderm. We show that the sqt gene encodes a member of the TGF-beta superfamily that is related to mouse nodal. cyc encodes another nodal-related protein(5,6), which is consistent with our genetic evidence that sqt and cyc have overlapping functions. The sqt gene is expressed in a dorsal region of the blastula that includes the extraembryonic yolk syncytial layer (YSL). The YSL has been implicated as a source of signals that induce organizer development and mesendoderm formation(2,7). Misexpression of sqt RNA within the embryo or specifically in the YSL induces expanded or ectopic dorsal mesoderm, These results establish an essential role for nodal-related signals in organizer development and mesendoderm formation.	NYU Med Ctr, Skirball Inst Biomol Med, Dev Genet Program, New York, NY 10016 USA; NYU Med Ctr, Dept Cell Biol, New York, NY 10016 USA	New York University; New York University	Talbot, WS (corresponding author), NYU Med Ctr, Skirball Inst Biomol Med, Dev Genet Program, 540 1st Ave, New York, NY 10016 USA.		Dougan, Scott/B-8416-2008	Dougan, Scott/0000-0003-0214-4772; Schier, Alexander Franz/0000-0001-7645-5325; , William/0000-0002-2048-7472; Feldman, Benjamin/0000-0003-4838-8641				CONLON FL, 1994, DEVELOPMENT, V120, P1919; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; Heisenberg CP, 1997, DEV BIOL, V184, P85, DOI 10.1006/dbio.1997.8511; JONES CM, 1995, DEVELOPMENT, V121, P3651; Joseph EM, 1997, DEV BIOL, V184, P367, DOI 10.1006/dbio.1997.8510; Kanki JP, 1997, DEVELOPMENT, V124, P881; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Knapik EW, 1998, NAT GENET, V18, P338, DOI 10.1038/ng0498-338; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; Mizuno T, 1996, NATURE, V383, P131, DOI 10.1038/383131a0; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Rebagliati MR, 1998, DEV BIOL, V199, P261, DOI 10.1006/dbio.1998.8935; SAMPATH K, IN PRESS NATUR; Schier AF, 1996, DEVELOPMENT, V123, P165; Schier AF, 1997, DEVELOPMENT, V124, P327; Schier AF, 1998, CURR OPIN GENET DEV, V8, P464, DOI 10.1016/S0959-437X(98)80119-6; Schneider S, 1996, MECH DEVELOP, V57, P191, DOI 10.1016/0925-4773(96)00546-1; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; STRAHLE U, 1993, GENE DEV, V7, P1436, DOI 10.1101/gad.7.7b.1436; Talbot WS, 1998, GENETICS, V148, P373; THISSE C, 1994, DEV BIOL, V164, P420, DOI 10.1006/dbio.1994.1212; THISSE C, 1993, DEVELOPMENT, V119, P1203; TOYAMA R, 1995, DEVELOPMENT, V121, P383; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	29	553	578	2	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1998	395	6698					181	185		10.1038/26013	http://dx.doi.org/10.1038/26013			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744277				2022-12-28	WOS:000075829900044
J	Taylor, ND; Kassai, R				Taylor, ND; Kassai, R			The healer and the healed: Works and life of Kenzaburo Oe	LANCET			English	Article							MEDICINE; EDUCATION		Greenville Hosp Syst, Dept Res, Greenville, SC 29605 USA; Nikko Mem Hosp, Hokkaido Ctr Family Med, Muroran, Hokkaido 0518501, Japan	Greenville Health System	Taylor, ND (corresponding author), Greenville Hosp Syst, Dept Res, 712 Grove Rd, Greenville, SC 29605 USA.							Abse D, 1998, LANCET, V351, P362, DOI 10.1016/S0140-6736(97)10380-4; ABSE D, 1995, DOCTORING STORIES PO, P222; BASCOM GS, 1991, FAINT ECHOES, P68; Calman KC, 1997, LANCET, V350, P1622; CHARON R, 1995, ANN INTERN MED, V122, P599, DOI 10.7326/0003-4819-122-8-199504150-00008; CHEKHOV A, 1951, WORLDS BEST DOCTOR S, P255; DAVIS C, 1997, DETAILS FLESH, P62; HUNTER KM, 1995, ACAD MED, V70, P787, DOI 10.1097/00001888-199509000-00014; Jones AH, 1997, LANCET, V349, P275, DOI 10.1016/S0140-6736(96)12240-6; Jones AH, 1997, LANCET, V349, P1243, DOI 10.1016/S0140-6736(97)03395-3; McLellan MF, 1996, LANCET, V348, P109, DOI 10.1016/S0140-6736(96)03521-0; McLellan MF, 1996, LANCET, V348, P1014, DOI 10.1016/S0140-6736(96)07316-3; Napier S. J., 1991, ESCAPE WASTELAND ROM; NATHAN J, 1977, TEACH US OUTGROW OUR, pR23; OE K, 1996, HIROSHIMA NOTES, P23; Oe K, 1996, HEALING FAMILY; OE K, 1995, GEORGIA REV, V49, P342; OE K, 1981, FOOTBALL GAME 1 YEAR; OE K, 1996, HIROSHIMA NOTES, P124; Oe Kenzaburo, 1969, PERSONAL MATTER; REMNICK D, 1995, NEW YORKER      1120, P40; SELZER R, 1982, LETT YOUNG DOCTOR, P21; STONE J, 1990, COUNTRY HEARTS, P29; STONE J, 1990, COUNTRY HEARTS, P65; STONE J, 1980, ALL THIS RAIN, P4; Wilson Michiko., 1986, MARGINAL WORLD OE KE; WILSON MN, 1995, GEORGIA REV, V49, P344; YOM SS, 1998, JAMA-J AM MED ASSOC, V279, P77	28	0	0	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 22	1998	352	9128					642	644		10.1016/S0140-6736(98)06246-1	http://dx.doi.org/10.1016/S0140-6736(98)06246-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746041				2022-12-28	WOS:000075567400043
J	Deary, IJ; Whiteman, MC; Fowkes, FGR				Deary, IJ; Whiteman, MC; Fowkes, FGR			Medical research and the popular media	LANCET			English	Editorial Material									Univ Edinburgh, Dept Psychol, Edinburgh EH8 9JZ, Midlothian, Scotland; Univ Edinburgh, Dept Publ Hlth Sci, Wolfson Unit Prevent Peripheral Vasc Dis, Edinburgh EH8 9JZ, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Deary, IJ (corresponding author), Univ Edinburgh, Dept Psychol, 7 George Sq, Edinburgh EH8 9JZ, Midlothian, Scotland.		Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X				Whiteman MC, 1997, LANCET, V350, P541, DOI 10.1016/S0140-6736(96)03141-8	1	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 6	1998	351	9117					1726	1727		10.1016/S0140-6736(97)10317-8	http://dx.doi.org/10.1016/S0140-6736(97)10317-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734905				2022-12-28	WOS:000074088900040
J	Bloche, MG				Bloche, MG			Physicians as caretakers and collaborators	LANCET			English	Editorial Material									Georgetown Univ, Ctr Law, Washington, DC 20001 USA	Georgetown University	Bloche, MG (corresponding author), Georgetown Univ, Ctr Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.							BLOCHE MG, 1993, INT J LAW PSYCHIAT, V16, P301, DOI 10.1016/0160-2527(93)90002-V	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 28	1998	351	9107					982	982						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734960				2022-12-28	WOS:000072770900048
J	Anderson, JD; Schubert, G; Jacobson, RA; Lau, EL; Moore, WB; Sjogren, WL				Anderson, JD; Schubert, G; Jacobson, RA; Lau, EL; Moore, WB; Sjogren, WL			Europa's differentiated internal structure: Inferences from four Galileo encounters	SCIENCE			English	Article							SATELLITES; MOMENTS; MODELS	Radio Doppler data from four encounters of the Galileo spacecraft with the jovian moon Europa have been used to refine models of Europa's interior. Europa is most Likely differentiated into a metallic core surrounded by a rock mantle and a water ice-liquid outer shell, but the data cannot eliminate the possibility of a uniform mixture of dense silicate and metal beneath the water ice-liquid shell. The size of a metallic core is uncertain because of its unknown composition, but it could be as targe as about 50 percent of Europa's radius. The thickness of Europa's outer shell of water ice-liquid must lie in the range of about 80 to 170 kilometers.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of California System; University of California Los Angeles	Anderson, JD (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.							Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; Anderson JD, 1996, SCIENCE, V272, P709, DOI 10.1126/science.272.5262.709; ANDERSON JD, 1974, EXPT GRAVITATION, P163; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; COHEN ER, 1997, PHYS TODAY, V50, pBG7; Davies ME, 1992, CELEST MECH DYN ASTR, V53, P377, DOI 10.1007/BF00051818; DERMOTT SF, 1979, ICARUS, V37, P310, DOI 10.1016/0019-1035(79)90137-4; Geissler PE, 1998, NATURE, V391, P368, DOI 10.1038/34869; HUBBARD WB, 1978, ICARUS, V33, P336, DOI 10.1016/0019-1035(78)90153-7; Kaula W.M., 1966, THEORY SATELLITE GEO; KHURANA KK, IN PRESS NATURE; Kivelson MG, 1997, SCIENCE, V276, P1239, DOI 10.1126/science.276.5316.1239; Kliore AJ, 1997, SCIENCE, V277, P355, DOI 10.1126/science.277.5324.355; LIESKE JH, 1977, ASTRON ASTROPHYS, V56, P333; Moyer T., 1971, JPLTR321527 CALTECH; MUELLER S, 1988, ICARUS, V76, P437, DOI 10.1016/0019-1035(88)90014-0; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; Rappaport N, 1997, ICARUS, V126, P313, DOI 10.1006/icar.1996.5661; SCHUBERT G, 1977, PHILOS T R SOC A, V285, P523, DOI 10.1098/rsta.1977.0096; SCHUBERT G, 1994, ICARUS, V111, P433, DOI 10.1006/icar.1994.1154; SCHUBERT G, 1986, SATELLITES, P629; Seidelmann P. K., 1992, EXPLANATORY SUPPLEME; Sullivan R, 1998, NATURE, V391, P371, DOI 10.1038/34874; TAPLEY BD, 1973, RECENT ADV DYNAMICAL, P396; ULMER P, 1995, SCIENCE, V268, P858, DOI 10.1126/science.268.5212.858; WOO R, 1979, J GEOPHYS RES-SPACE, V84, P7288, DOI 10.1029/JA084iA12p07288; ZHARKOV VN, 1985, ICARUS, V61, P92, DOI 10.1016/0019-1035(85)90157-5	27	280	286	2	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					2019	2022		10.1126/science.281.5385.2019	http://dx.doi.org/10.1126/science.281.5385.2019			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748159				2022-12-28	WOS:000076161800053
J	Thapa, PB; Gideon, P; Cost, TW; Milam, AB; Ray, WA				Thapa, PB; Gideon, P; Cost, TW; Milam, AB; Ray, WA			Antidepressants and the risk of falls among nursing home residents	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRICYCLIC ANTI-DEPRESSANTS; HIP FRACTURE; ORTHOSTATIC HYPOTENSION; PSYCHOTROPIC-DRUGS; ELDERLY PATIENTS; INJURIES; NORTRIPTYLINE; IMIPRAMINE; PREVENTION; FLUOXETINE	Background In nursing home residents, the use of tricyclic and other heterocyclic antidepressants is associated with an increased risk of falls. The newer selective serotonin-reuptake-inhibitor antidepressants are largely free of the side effects of the tricyclic agents thought to cause falls and so have been hypothesized to be safer for those at high risk for falls. Methods We retrospectively identified an inception cohort of 2428 nursing home residents in Tennessee who were new users of tricyclic antidepressants (665 subjects), selective serotonin-reuptake inhibitors (612 subjects), or trazodone (304 subjects) or nonusers of antidepressants (847 subjects). We ascertained the number of falls during therapy and during a similar follow-up period for nonusers, then calculated the rate ratios for fails with adjustments for an extensive set of potential confounding factors. Results The new users of each type of antidepressant had higher rates of falls than the nonusers, with adjusted rate ratios of 2.0 (95 percent confidence interval, 1.8 to 2.2) for tricyclic antidepressants, 1.8 (1.6 to 2.0) for selective serotonin-reuptake inhibitors, and 1.2 (1.0 to 1.4) for trazodone. The rate ratios increased with the daily dose for tricyclic antidepressants, reaching 2.4 (95 percent confidence interval, 2.1 to 2.8) for doses of 50 mg or more of amitriptyline or its equivalent, and for the serotonin-reuptake inhibitors, reaching 1.9 (1.7 to 2.2) for 20 mg or more of fluoxetine or its equivalent. The elevated rates of falls persisted through the first 180 days of therapy and beyond. Conclusions in this large study of nursing home residents, there was little difference in rates of falls between those treated with tricyclic antidepressants and those treated with selective serotonin-reuptake inhibitors. Hence, the preferential use of the newer antidepressants is unlikely to reduce the higher rate of falls among nursing home residents taking antidepressants. (N Engl J Med 1998;339:875-82.) (C)1998, Massachusetts Medical Society.	Vanderbilt Univ, Sch Med, Dept Prevent Med, Div Pharmacoepidemiol, Nashville, TN 37212 USA; Cost Consulting, Nashville, TN USA; Pharmaceut Consulting Serv, Murfreesboro, TN USA	Vanderbilt University	Ray, WA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Prevent Med, Med Ctr N,A-1124, Nashville, TN 37232 USA.				PHS HHS [R49/CCR410144] Funding Source: Medline; FDA HHS [FD-U-000073-11] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); FDA HHS		*AM MED ASS, 1993, DRUG EV ANN 1993; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; Cumming RG, 1997, EPIDEMIOL REV, V19, P244, DOI 10.1093/oxfordjournals.epirev.a017956; FREDMAN L, 1989, J GERONTOL, V44, P149; FRIEDHOFF AJ, 1992, JAMA-J AM MED ASSOC, V268, P1018, DOI 10.1001/jama.1992.03490080092032; GLASSMAN AH, 1979, LANCET, V1, P468; GLASSMAN AH, 1981, ARCH GEN PSYCHIAT, V38, P815; GLASSMAN AH, 1982, J CLIN PSYCHIAT, V43, P35; HYER L, 1982, INT J BEHAVIORAL GER, V1, P33; KANTEN DN, 1993, J AM GERIATR SOC, V41, P662, DOI 10.1111/j.1532-5415.1993.tb06741.x; Katz I R, 1988, Clin Geriatr Med, V4, P203; KATZ IR, 1990, J CLIN PSYCHIAT, V51, P41; KATZ IR, 1998, CLIN GERIATRIC PSYCH, P153; LaghrissiThode F, 1995, PSYCHOPHARMACOL BULL, V31, P659; LAGHRISSITHODE F, 1995, AM J GERIAT PSYCHIAT, V3, P217, DOI 10.1097/00019442-199522330-00005; Li XS, 1996, PSYCHIAT RES, V63, P191, DOI 10.1016/0165-1781(96)02878-8; LIPSITZ LA, 1991, J GERONTOL, V46, P114; Liu B, 1998, LANCET, V351, P1303, DOI 10.1016/S0140-6736(97)09528-7; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; Monane M, 1996, CLIN GERIATR MED, V12, P847; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MOSSEY JM, 1989, AM J PUBLIC HEALTH, V79, P279, DOI 10.2105/AJPH.79.3.279; MURPHY E, 1988, BRIT J PSYCHIAT, V152, P347, DOI 10.1192/bjp.152.3.347; MYERS AH, 1991, AM J EPIDEMIOL, V133, P1179, DOI 10.1093/oxfordjournals.aje.a115830; Parmelee PA, 1989, J GERONTOL, V44, P22; PARMELEE PA, 1992, J GERONTOL, V47, P3; RAY WA, 1992, J CLIN PSYCHOPHARM, V12, P386; RAY WA, 1991, ARCH INTERN MED, V151, P754, DOI 10.1001/archinte.151.4.754; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; Ray WA, 1997, JAMA-J AM MED ASSOC, V278, P557, DOI 10.1001/jama.278.7.557; Regestein Q, 1998, CLIN GERIATRIC PSYCH, P395; ROOSE SP, 1987, ARCH GEN PSYCHIAT, V44, P273; ROOSE SP, 1987, J CLIN PSYCHOPHARM, V7, P247; ROVNER BW, 1991, JAMA-J AM MED ASSOC, V265, P2672; ROVNER BW, 1991, JAMA-J AM MED ASSOC, V265, P993, DOI 10.1001/jama.265.8.993; RUTHAZER R, 1993, AM J PUBLIC HEALTH, V83, P746, DOI 10.2105/AJPH.83.5.746; Sabbe B, 1996, J AFFECT DISORDERS, V40, P149, DOI 10.1016/0165-0327(96)00052-3; SEPPALA T, 1978, ANN CLIN RES, V10, P214; SMALL GW, 1998, CLIN GERIATRIC PSYCH, P245; Thapa PB, 1996, J AM GERIATR SOC, V44, P273, DOI 10.1111/j.1532-5415.1996.tb00913.x; THAPA PB, 1995, AM J EPIDEMIOL, V142, P202, DOI 10.1093/oxfordjournals.aje.a117619; Thapa PB, 1996, J GERONTOL A-BIOL, V51, pM239, DOI 10.1093/gerona/51A.5.M239; Tideiksaar R., 1989, FALLING OLD AGE ITS; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; TINETTI ME, 1992, ANN INTERN MED, V116, P369, DOI 10.7326/0003-4819-116-5-369; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WORTHINGTON J, 1995, PSYCHOPHARMACOL BULL, V31, P223	48	296	303	0	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1998	339	13					875	882		10.1056/NEJM199809243391303	http://dx.doi.org/10.1056/NEJM199809243391303			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	121VY	9744971				2022-12-28	WOS:000076037400003
J	Hirabayashi, H; Hirosawa, H; Kobayashi, H; Murata, Y; Edwards, PG; Fomalont, EB; Fujisawa, K; Ichikawa, T; Kii, T; Lovell, JEJ; Moellenbrock, GA; Okayasu, R; Inoue, M; Kawaguchi, N; Kameno, S; Shibata, KM; Asaki, Y; Bushimata, T; Enome, S; Horiuchi, S; Miyaji, T; Umemoto, T; Migenes, V; Wajima, K; Nakajima, J; Morimoto, M; Ellis, J; Meier, DL; Murphy, DW; Preston, RA; Smith, JG; Tingay, SJ; Traub, DL; Wietfeldt, RD; Benson, JM; Claussen, MJ; Flatters, C; Romney, JD; Ulvestad, JS; D'Addario, LR; Langston, GI; Minter, AH; Carlson, BR; Dewdney, PE; Jauncey, DL; Reynolds, JE; Taylor, AR; McCulloch, PM; Cannon, WH; Gurvits, LI; Mioduszewski, AJ; Schilizzi, RT; Booth, RS				Hirabayashi, H; Hirosawa, H; Kobayashi, H; Murata, Y; Edwards, PG; Fomalont, EB; Fujisawa, K; Ichikawa, T; Kii, T; Lovell, JEJ; Moellenbrock, GA; Okayasu, R; Inoue, M; Kawaguchi, N; Kameno, S; Shibata, KM; Asaki, Y; Bushimata, T; Enome, S; Horiuchi, S; Miyaji, T; Umemoto, T; Migenes, V; Wajima, K; Nakajima, J; Morimoto, M; Ellis, J; Meier, DL; Murphy, DW; Preston, RA; Smith, JG; Tingay, SJ; Traub, DL; Wietfeldt, RD; Benson, JM; Claussen, MJ; Flatters, C; Romney, JD; Ulvestad, JS; D'Addario, LR; Langston, GI; Minter, AH; Carlson, BR; Dewdney, PE; Jauncey, DL; Reynolds, JE; Taylor, AR; McCulloch, PM; Cannon, WH; Gurvits, LI; Mioduszewski, AJ; Schilizzi, RT; Booth, RS			Overview and initial results of the very long baseline interferometry space observatory programme	SCIENCE			English	Article							EXTRAGALACTIC RADIO-SOURCES; VLBI SURVEY; GHZ; SATELLITE; EVOLUTION; REDSHIFTS; EMISSION; MOTION; SCALE; JETS	High angular resolution images of extragalactic radio sources are being made with the Highly Advanced Laboratory for Communications and Astronomy (HALCA) satellite and ground-based radio telescopes as part of the Very Long Baseline Interferometry (VLBI) Space Observatory Programme (VSOP). VSOP observations at 1.6 and 5 gigahertz of the milli-arc-second-scale structure of radio quasars enable the quasar core size and the corresponding brightness temperature to be determined, and they enable the motions of jet components that are close to the core to be studied. Here, VSOP images of the gamma-ray source 1156 + 295, the quasar 1548 + 056, the ultraluminous quasar 0014 + 813, and the superluminal quasar 0212 + 735 are presented and discussed.	Inst Space & Astronaut Sci, Kanagawa 2298510, Japan; Natl Astron Observ, Tokyo 1818588, Japan; Univ Guanajuato, Guanajuato, Mexico; Commun Res Labs, Mito, Ibaraki 3108512, Japan; Kagoshima Univ, Kagoshima 8900064, Japan; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Natl Radio Astron Observ, Socorro, NM 87801 USA; Natl Radio Astron Observ, Green Bank, WV 24944 USA; Natl Res Council Canada, Herzberg Inst Astrophys, Dominion Radio Astrophys Observ, Penticton, BC V2A 6K3, Canada; Australia Telescope Natl Facil, Epping, NSW 2122, Australia; Univ Calgary, Calgary, AB T2N 1N4, Canada; Univ Tasmania, Hobart, Tas 7000, Australia; York Univ, Ctr Res Earth & Space Technol, Downsview, ON M3J 3K1, Canada; Joint Inst VLBI Europe, NL-7991 PD Dwingeloo, Netherlands; PN Lebedev Phys Inst, Ctr Astro Space, Moscow 117810, Russia; Chalmers, Onsala Space Observ, S-43662 Onsala, Sweden	Japan Aerospace Exploration Agency (JAXA); Institute of Space & Astronautical Science (ISAS); National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); Universidad de Guanajuato; National Institute of Information & Communications Technology (NICT) - Japan; Kagoshima University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); National Radio Astronomy Observatory (NRAO); National Radio Astronomy Observatory (NRAO); National Research Council Canada; Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Calgary; University of Tasmania; York University - Canada; Russian Academy of Sciences; Russian Academy of Science Lebedev Physical Institute; Chalmers University of Technology	Hirabayashi, H (corresponding author), Inst Space & Astronaut Sci, Kanagawa 2298510, Japan.	hirax@vsop.isas.ac.jp	Horiuchi, Shinji/AAV-3497-2021; McCulloch, Peter/ABG-1643-2020; Wajima, Kiyoaki/ABA-6807-2020; Nakajima, Jun/Q-3693-2016; Tingay, Steven J/B-5271-2013	Horiuchi, Shinji/0000-0002-8395-3557; Wajima, Kiyoaki/0000-0003-3823-7954; Nakajima, Jun/0000-0002-9584-2627; Tingay, Steven J/0000-0002-8195-7562; Lovell, James/0000-0001-5273-9817; Gurvits, Leonid/0000-0002-0694-2459				BAARS JWM, 1977, ASTRON ASTROPHYS, V61, P99; Cappi M, 1997, ASTROPHYS J, V478, P492, DOI 10.1086/303817; CHARLOT P, 1990, ASTRON ASTROPHYS, V229, P51; DADDARIO LR, 1991, IEEE T INSTRUM MEAS, V40, P584, DOI 10.1109/19.87023; Fey AL, 1996, ASTROPHYS J SUPPL S, V105, P299, DOI 10.1086/192315; FOMALONT EB, UNPUB; GURVITS L, UNPUB; HIRABAYASHI H, UNPUB; Hirosawa H, 1996, SPACE TECHNOL, V16, P161; HUGHES PA, 1989, ASTROPHYS J, V341, P54, DOI 10.1086/167471; Kawaguchi N., 1994, VLBI TECHNOLOGY PROG, P26; KELLERMANN II, 1969, ASTROPHYS J, V155, pL71; Kellermann KI, 1998, ASTRON J, V115, P1295, DOI 10.1086/300308; KUHR H, 1983, ASTROPHYS J, V75, pL33; LANZETTA KM, 1995, ASTROPHYS J, V440, P435, DOI 10.1086/175286; LAWRENCE CR, 1986, ASTRON J, V91, P494, DOI 10.1086/114027; LINFIELD RP, 1990, ASTROPHYS J, V358, P350, DOI 10.1086/168992; MARSCHER AP, 1991, ASTROPHYS J, V371, P491, DOI 10.1086/169912; Moellenbrock GA, 1996, ASTRON J, V111, P2174, DOI 10.1086/117953; Mukherjee R, 1997, ASTROPHYS J, V490, P116, DOI 10.1086/304851; PEARSON TJ, 1988, ASTROPHYS J, V328, P114, DOI 10.1086/166274; Piner BG, 1997, ASTROPHYS J, V485, pL61, DOI 10.1086/310820; READHEAD ACS, 1994, ASTROPHYS J, V426, P51, DOI 10.1086/174038; ROMNEY JD, 1995, P NATL ACAD SCI USA, V92, P11360, DOI 10.1073/pnas.92.25.11360; SCHMIDT M, 1974, ASTROPHYS J, V195, P253; Swenson, 1986, INTERFEROMETRY SYNTH; TAYLOR GB, 1994, ASTROPHYS J SUPPL S, V95, P345, DOI 10.1086/192101; WHITE GL, 1988, ASTROPHYS J, V327, P561, DOI 10.1086/166216; WITZEL A, 1988, ASTRON ASTROPHYS, V206, P245; YOU TH, 1998, AAS GSFC INT S SPAC; Zensus JA, 1997, ANNU REV ASTRON ASTR, V35, P607, DOI 10.1146/annurev.astro.35.1.607	31	176	183	4	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 18	1998	281	5384					1825	1829		10.1126/science.281.5384.1825	http://dx.doi.org/10.1126/science.281.5384.1825			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743489	Green Submitted			2022-12-28	WOS:000076007100044
J	Diaz-Mitoma, F; Sibbald, RG; Shafran, SD; Boon, R; Saltzman, RL				Diaz-Mitoma, F; Sibbald, RG; Shafran, SD; Boon, R; Saltzman, RL		Collaborative Famciclovir Genital Her	Oral famciclovir for the suppression of recurrent genital herpes - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	36th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 15-18, 1996	NEW ORLEANS, LOUISIANA	Amer Soc Microbiol			SIMPLEX VIRUS-INFECTION; DOUBLE-BLIND TRIAL; PLACEBO-CONTROLLED TRIAL; LONG-TERM SUPPRESSION; ACYCLOVIR THERAPY; MULTICENTER; PHARMACOKINETICS	Context.-Recurrent genital herpes simplex virus (HSV) may be treated episodically, but this may not be sufficient for patients with frequent recurrences. Objective.-To determine the efficacy and safety of famciclovir in the suppression of recurrent genital HSV infection Design.-A randomized, double-blind, placebo-controlled, parallel-group study. Setting.-Thirty university, hospital, or private outpatient referral centers in Canada and Europe. Patients.-A total of 455 patients (223 men, 232 women) aged 18 years or older with a history of 6 or more episodes of genital herpes during 12 of the most recent 24 months, in the absence of suppressive therapy, received study medication. Intervention.-Oral famciclovir, 125 mg or 250 mg 3 times daily or 250 mg twice daily, or placebo for 52 weeks. Main Outcome Measures.-Time to the first recurrence of genital HSV infection; the proportion of patients remaining free of HSV recurrence at 6 months; frequency of adverse events. Results.-ln an intent-to-treat analysis, famciclovir significantly delayed the time to the first recurrence of genital herpes at all dose regimens (hazard ratios, 2.9-3.3; P < .001); median time to recurrence for famciclovir recipients was 222 to 336 days compared with 47 days for placebo recipients. The proportion of patients remaining free of HSV recurrence was approximately 3 times higher in famciclovir recipients (79%-86%) than in placebo recipients (27%) at 6 months (relative risks, 2.9-3.1; P < .001); efficacy was maintained at 12 months. Famciclovir was well tolerated with an adverse experience profile comparable to placebo. Conclusions.-Oral famciclovir (125 mg or 250 mg 3 times daily or 250 mg twice daily) is an effective, well-tolerated treatment for the suppression of genital HSV infection in patients with frequent recurrences.	Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada; Womens Coll Hosp, Toronto, ON M5S 1B2, Canada; Univ Alberta, Dept Med, Div Infect Dis, Edmonton, AB, Canada; SmithKline Beecham Pharmaceut, Harlow CM19 5AD, Essex, England; SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA	University of Ottawa; Children's Hospital of Eastern Ontario; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Alberta; GlaxoSmithKline; GlaxoSmithKline	Diaz-Mitoma, F (corresponding author), Childrens Hosp Eastern Ontario, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.		Diaz-Mitoma, Francisco/AAA-2522-2019	Diaz-Mitoma, Francisco/0000-0003-0292-4859				BAKER DA, 1994, J INT MED RES, V22, pA24; BAKER DA, 1989, OBSTET GYNECOL, V73, P84; BOYD MR, 1989, ANTIVIRAL CHEMOTHERA, V9, P83; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; DEMIRANDA P, 1983, J ANTIMICROB CHEMOTH, V12, P29, DOI 10.1093/jac/12.suppl_B.29; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; FIFE KH, 1994, J INFECT DIS, V169, P1338, DOI 10.1093/infdis/169.6.1338; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; JOHNSON RE, 1994, SEX TRANSM DIS S, V21, P2; KINGHORN GR, 1988, AM J MED, V85, P26; KROON S, 1990, GENITOURIN MED, V66, P101; MATTISON HR, 1988, AM J MED, V85, P20; MERTZ GJ, 1988, AM J MED, V85, P14; Mertz GJ, 1997, ARCH INTERN MED, V157, P343, DOI 10.1001/archinte.157.3.343; MERTZ GJ, 1988, JAMA-J AM MED ASSOC, V260, P201, DOI 10.1001/jama.260.2.201; MINDEL A, 1988, LANCET, V1, P926; Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19; PUE MA, 1994, J ANTIMICROB CHEMOTH, V33, P119, DOI 10.1093/jac/33.1.119; Sacks SL, 1996, JAMA-J AM MED ASSOC, V276, P44, DOI 10.1001/jama.276.1.44; SACKS SL, 1994, P 6 INT C INF DIS AP; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401; THIN RN, 1985, J ANTIMICROB CHEMOTH, V16, P219, DOI 10.1093/jac/16.2.219; TYRING S, 1997, 55 ANN M AM AC DERM	24	90	99	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1998	280	10					887	892		10.1001/jama.280.10.887	http://dx.doi.org/10.1001/jama.280.10.887			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115LN	9739972	Bronze			2022-12-28	WOS:000075666600034
J	Roberts, TE				Roberts, TE		Extracorporeal Membrane Oxygenation Ec Working; Extracorporeal Membrane Oxygenation Trial Steer	Economic evaluation and randomised controlled trial of extracorporeal membrane oxygenation: UK collaborative trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEONATAL CARE ALONGSIDE; ECMO TRIAL; COST	Objective: To compare the resource implications and short term outcomes of extracorporeal membrane oxygenation and conventional management for term babies with severe respiratory failure. Design: Cost effectiveness evaluation alongside a randomised controlled trial. Setting: 55 approved recruiting hospitals in the United Kingdom. These hospitals provided conventional management, but infants randomised to extracorporeal membrane oxygenation were transferred to one of five specialist centres. Subjects: 185 mature newborn infants (gestational age at birth >35 weeks, birth weight > 2 kg) with severe respiratory failure (oxygenation index > 40) recruited between 1993 and 1995. The commonest diagnoses were persistent pulmonary hypertension due to meconium aspiration, congenital diaphragmatic hernia, isolated persistent fetal circulation, sepsis, and idiopathic respiratory distress syndrome. Main outcome measure: Cost effectiveness based on survival at 1 year of age without severe disability. Results: 63 (68%) of the 93 infants randomised to extracorporeal membrane oxygenation survived to 1 year compared with 38 (41%) of the 92 infants who received conventional management Of those that survived, one infant in each arm was lost to follow up and the proportion with disability at 1 year was similar in the two arms of the trial. One child in each arm had severe disability. The estimated additional cost of extracorporeal membrane oxygenation per additional surviving infant without severe disability was pound 51 222 and the cost per surviving infant with no disability was pound 75 327. Conclusions: Extracorporeal membrane oxygenation for term neonates with severe respiratory failure would increase overall survival without disability. Although the policy will increase costs of neonatal health care, it is likely to be as cost effective as other life extending technologies.	Univ Birmingham, Hlth Econ Facil, Birmingham B15 2RT, W Midlands, England	University of Birmingham	Roberts, TE (corresponding author), Univ Birmingham, Hlth Econ Facil, Birmingham B15 2RT, W Midlands, England.	robertte@hsmc.bham.ac.uk	Roberts, Tracy/AAO-4610-2021	Roberts, Tracy/0000-0002-0624-0537				*ECSURF, IN PRESS ARCH DIS CH; Field D, 1996, LANCET, V348, P75; FORDHAM R, 1992, J PUBLIC HEALTH MED, V14, P127; Hallam L, 1996, HEALTH ECON, V5, P167, DOI 10.1002/(SICI)1099-1050(199603)5:2<167::AID-HEC192>3.0.CO;2-N; HOWARD S, 1995, HEALTH ECON, V4, P265, DOI 10.1002/hec.4730040403; Howard S, 1996, INT J TECHNOL ASSESS, V12, P80, DOI 10.1017/S0266462300009417; Johnson A, 1998, PEDIATRICS, V101; Mugford M, 1995, SOZ PRAVENTIV MED, V40, P361, DOI 10.1007/BF01325418; NETTEN A, 1995, UNIT COSTS COMMUNITY; PECKHAM M, 1991, LANCET, V338, P367, DOI 10.1016/0140-6736(91)90494-A; *REV BOD DOCT DENT, 1994, 23 REV BOD DOCT DENT; *REV BOD NURS STAF, 1994, 11 REV BOD NURS STAF; ROBERTS T, 1998, EC EVALUATION ALONGS; SOSNOWSKI AW, 1990, BRIT MED J, V301, P1163, DOI 10.1136/bmj.301.6761.1163-c; Stevens A, 1995, Health Trends, V27, P37; TARNOWMORDI W, 1997, CLIN EC EVALUATION S; TARNOWMORDI WO, 1992, MRC NEWS, V57, P16; *WORK GROUP SPEC M, 1993, HOSP DOCT TRAIN FUT	18	56	57	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 3	1998	317	7163					911	915						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756807				2022-12-28	WOS:000076409000020
J	Weiss, RA				Weiss, RA			Science, medicine, and the future - Xenotransplantation	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TRANSPLANTATION; RETROVIRUS; PIGS		Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Weiss, RA (corresponding author), Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England.							Akiyoshi DE, 1998, J VIROL, V72, P4503, DOI 10.1128/JVI.72.5.4503-4507.1998; Bach FH, 1998, NAT MED, V4, P141, DOI 10.1038/nm0298-141; Bach FH, 1996, IMMUNOL TODAY, V17, P379, DOI 10.1016/0167-5699(96)10024-4; Butler D, 1998, NATURE, V391, P320; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; *DEP HLTH ADV GROU, 1997, AN TISS HUM; Dorling A, 1997, LANCET, V349, P867, DOI 10.1016/S0140-6736(96)09404-4; Gage FH, 1998, NATURE, V392, P18; GROTH CG, 1994, LANCET, V344, P1402, DOI 10.1016/S0140-6736(94)90570-3; Heneine W, 1998, LANCET, V352, P695, DOI 10.1016/S0140-6736(98)07145-1; LeTissier P, 1997, NATURE, V389, P681, DOI 10.1038/39489; Martin U, 1998, LANCET, V352, P692, DOI 10.1016/S0140-6736(98)07144-X; Meng XJ, 1997, P NATL ACAD SCI USA, V94, P9860, DOI 10.1073/pnas.94.18.9860; OSullivan JD, 1997, LANCET, V349, P93, DOI 10.1016/S0140-6736(96)06162-4; Patience C, 1998, LANCET, V352, P699, DOI 10.1016/S0140-6736(98)04369-4; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; Philbey AW, 1998, EMERG INFECT DIS, V4, P269, DOI 10.3201/eid0402.980214; Platt JL, 1996, CURR OPIN IMMUNOL, V8, P721, DOI 10.1016/S0952-7915(96)80091-4; Warden J, 1998, BRIT MED J, V317, P365; Weiss RA, 1998, NATURE, V391, P327, DOI 10.1038/34772; Wilson CA, 1998, J VIROL, V72, P3082, DOI 10.1128/JVI.72.4.3082-3087.1998	22	30	31	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 3	1998	317	7163					931	934						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756815				2022-12-28	WOS:000076409000029
J	Charney, P; Walsh, JME; Nattinger, AB				Charney, P; Walsh, JME; Nattinger, AB			Update in women's health	ANNALS OF INTERNAL MEDICINE			English	Article							POSTMENOPAUSAL WOMEN; MYOCARDIAL-INFARCTION; REPLACEMENT THERAPY; HEART-DISEASE; ESTROGEN; HYPERCHOLESTEROLEMIA; SIMVASTATIN; MORTALITY; SURVIVAL		Albert Einstein Med Ctr, Bronx, NY USA; Univ Calif San Francisco, Mt Zion Med Ctr, Outpatient Dept, San Francisco, CA 94143 USA; Med Coll Wisconsin, Milwaukee, WI USA	Yeshiva University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; Medical College of Wisconsin	Charney, P (corresponding author), Jacobi Med Ctr, Dept Med, 1400 Pelham Pkwy S, Bronx, NY 10461 USA.	charney@aecom.yu.edu		Nattinger, Ann/0000-0002-8189-3300				Behar S, 1997, AM HEART J, V133, P290, DOI 10.1016/S0002-8703(97)70222-9; Cauley JA, 1997, ARCH INTERN MED, V157, P2181, DOI 10.1001/archinte.157.19.2181; Darling GM, 1997, NEW ENGL J MED, V337, P595, DOI 10.1056/NEJM199708283370903; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KERLIKOWSKE K, 1997, MONOGR NATL CANC I, V22, P79; Langer RD, 1997, NEW ENGL J MED, V337, P1792, DOI 10.1056/NEJM199712183372502; Pearson TA, 1997, JAMA-J AM MED ASSOC, V277, P1320, DOI 10.1001/jama.277.16.1320; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Schrott HG, 1997, JAMA-J AM MED ASSOC, V277, P1281, DOI 10.1001/jama.277.16.1281; Sellers TA, 1997, ANN INTERN MED, V127, P973, DOI 10.7326/0003-4819-127-11-199712010-00004; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001	11	9	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1998	129	7					551	558		10.7326/0003-4819-129-7-199810010-00009	http://dx.doi.org/10.7326/0003-4819-129-7-199810010-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123KN	9758576				2022-12-28	WOS:000076124500007
J	Biederman, J				Biederman, J			A 55-year-old man with attention-deficit/hyperactivity disorder	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DEFICIT-HYPERACTIVITY DISORDER; PSYCHIATRIC STATUS; CHILDHOOD-ONSET; RISK-FACTORS; QUANTITATIVE MORPHOLOGY; CAUDATE-NUCLEUS; CORPUS-CALLOSUM; DOUBLE-BLIND; CHILDREN; ADULTS		Harvard Univ, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Biederman, J (corresponding author), Care of Hartman EE, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							*AM ACAD PED, 1996, CLASS CHILD AD MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BARKLEY RA, 1994, CLIN NEUROPSYCHOL, V8, P121, DOI 10.1080/13854049408401552; BARRICKMAN L, 1991, J AM ACAD CHILD PSY, V30, P762, DOI 10.1097/00004583-199109000-00010; BIEDERMAN J, 1993, AM J PSYCHIAT, V150, P1792; BIEDERMAN J, 1992, ARCH GEN PSYCHIAT, V49, P728; BIEDERMAN J, 1995, ARCH GEN PSYCHIAT, V52, P464; BIEDERMAN J, 1995, J AM ACAD CHILD PSY, V34, P1495, DOI 10.1097/00004583-199511000-00017; BIEDERMAN J, 1991, AM J PSYCHIAT, V148, P564; BIEDERMAN J, 1991, ARCH GEN PSYCHIAT, V48, P633; BIEDERMAN J, 1995, AM J PSYCHIAT, V152, P431; BIEDERMAN J, 1990, J AM ACAD CHILD PSY, V29, P526, DOI 10.1097/00004583-199007000-00004; BROWN RT, 1984, J CLIN PSYCHIAT, V45, P473; CASAT CD, 1989, PSYCHOPHARMACOL BULL, V25, P198; CASTELLANOS FX, 1994, AM J PSYCHIAT, V151, P1791; DEUTSCH CK, 1990, J AM ACAD CHILD PSY, V29, P189, DOI 10.1097/00004583-199003000-00006; FARAONE S, 1994, CHILD ADOLESC PSYCHI, V3, P285; FARAONE SV, 1994, HARVARD REV PSYCHIAT, V1, P271, DOI 10.3109/10673229409017090; FARAONE SV, 1992, PSYCHIATR GENET, V2, P257, DOI 10.1097/00041444-199210000-00004; Filipek PA, 1997, NEUROLOGY, V48, P589, DOI 10.1212/WNL.48.3.589; Gaub M, 1997, J AM ACAD CHILD PSY, V36, P1036, DOI 10.1097/00004583-199708000-00011; GIEDD JN, 1994, AM J PSYCHIAT, V151, P665; GITTELMAN R, 1985, ARCH GEN PSYCHIAT, V42, P937; Goldman LS, 1998, JAMA-J AM MED ASSOC, V279, P1100, DOI 10.1001/jama.279.14.1100; GOODMAN R, 1989, BRIT MED J, V298, P1407, DOI 10.1136/bmj.298.6685.1407; GOODMAN R, 1989, J CHILD PSYCHOL PSYC, V30, P691, DOI 10.1111/j.1469-7610.1989.tb00782.x; GOODMAN R, 1989, J CHILD PSYCHOL PSYC, V30, P671, DOI 10.1111/j.1469-7610.1989.tb00781.x; HECHTMAN L, 1992, PSYCHIATR CLIN N AM, V1, P553, DOI DOI 10.1016/S1056-4993(18)30603-5; HYND GW, 1990, ARCH NEUROL-CHICAGO, V47, P919, DOI 10.1001/archneur.1990.00530080107018; HYND GW, 1993, J CHILD NEUROL, V8, P339, DOI 10.1177/088307389300800409; MANNUZZA S, 1993, ARCH GEN PSYCHIAT, V50, P565; MANNUZZA S, 1991, ARCH GEN PSYCHIAT, V48, P77; MANSHADI M, 1983, J CLIN PSYCHIAT, V44, P379; Milberger S, 1997, BIOL PSYCHIAT, V41, P65, DOI 10.1016/0006-3223(95)00653-2; RAPOPORT JL, 1978, SCIENCE, V199, P560, DOI 10.1126/science.341313; SAFER DJ, 1988, JAMA-J AM MED ASSOC, V260, P2256, DOI 10.1001/jama.260.15.2256; Schachar R, 1993, J Child Adolesc Psychopharmacol, V3, P81, DOI 10.1089/cap.1993.3.81; Seidman LJ, 1997, J CONSULT CLIN PSYCH, V65, P150, DOI 10.1037/0022-006X.65.1.150; Seidman LJ, 1997, J AM ACAD CHILD PSY, V36, P366, DOI 10.1097/00004583-199703000-00015; SEMRUDCLIKEMAN M, 1994, J AM ACAD CHILD PSY, V33, P875, DOI 10.1097/00004583-199407000-00014; Spencer T, 1996, J AM ACAD CHILD PSY, V35, P409, DOI 10.1097/00004583-199604000-00008; Spencer T, 1998, AM J PSYCHIAT, V155, P693, DOI 10.1176/ajp.155.5.693; Spencer T, 1998, J CLIN PSYCHIAT, V59, P59; SPENCER T, 1995, ARCH GEN PSYCHIAT, V52, P434; Swanson JM, 1998, MOL PSYCHIATR, V3, P38, DOI 10.1038/sj.mp.4000354; WEISS G, 1985, J AM ACAD CHILD PSY, V24, P211, DOI 10.1016/S0002-7138(09)60450-7; WENDER PH, 1990, AM J PSYCHIAT, V147, P1018; Wilens TE, 1996, AM J PSYCHIAT, V153, P1147; WILENS TE, 1992, PSYCHIAT CLIN N AM, P191; ZAMETKIN AJ, 1990, NEW ENGL J MED, V323, P1361, DOI 10.1056/NEJM199011153232001; Zametkin AJ, 1987, PSYCHOPHARMACOLOGY 3, P837	52	11	11	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 30	1998	280	12					1086	1092		10.1001/jama.280.12.1086	http://dx.doi.org/10.1001/jama.280.12.1086			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	121FJ	9757857				2022-12-28	WOS:000076002400038
J	Grubb, RL; Derdeyn, CP; Fritsch, SM; Carpenter, DA; Yundt, KD; Videen, TO; Spitznagel, EL; Powers, WJ				Grubb, RL; Derdeyn, CP; Fritsch, SM; Carpenter, DA; Yundt, KD; Videen, TO; Spitznagel, EL; Powers, WJ			Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITRON EMISSION TOMOGRAPHY; INTRACRANIAL ARTERIAL BYPASS; CEREBRAL BLOOD-FLOW; CEREBROVASCULAR-DISEASE; O-15 RADIOTRACERS; MISERY-PERFUSION; PERFORMANCE; ISCHEMIA; SURGERY; HUMANS	Context.-The relative importance of hemodynamic factors in the pathogenesis and treatment of stroke in patients with carotid artery occlusion remains controversial. Objective.-To test the hypothesis that stage II cerebral hemodynamic failure (increased oxygen extraction measured by positron emission tomography [PET]) distal to symptomatic carotid artery occlusion is an independent risk factor for subsequent stroke in medically treated patients. Design and Setting.-Prospective, blinded, longitudinal cohort study of patients referred from a group of regional hospitals between 1992 and 1996, Patients.-From 419 subjects referred, 81 with previous stroke or transient ischemic attack in the territory of an occluded carotid artery were enrolled. All were followed up to completion of the study, with average follow-up of 31.5 months. Main Outcome Measures.-Telephone contact every 6 months recorded the subsequent occurrence of all stroke, ipsilateral ischemic stroke, and death. Results.-Stroke occurred in 12 of 39 patients with stage II hemodynamic failure and in 3 of 42 patients without (P=.005); stroke was ipsilateral in 11 of 39 patients with stage II hemodynamic failure and in 2 of 42 patients without (P=.004). Six deaths occurred in each group (P=.94). The age-adjusted relative risk conferred by stage II hemodynamic failure was 6.0 (95% confidence interval [CI], 1.7-21.6) for all stroke and 7.3 (95% CI, 1.6-33.4) for ipsilateral stroke. Conclusions.-Stage II hemodynamic failure defines a subgroup of patients with symptomatic carotid occlusion who are at high risk for subsequent stroke when treated medically, A randomized trial evaluating surgical revascularization in this high-risk subgroup is warranted.	Washington Univ, Med Ctr, E Bldg Imaging Ctr, Dept Neurol & Neurol Surg, St Louis, MO 63110 USA; Washington Univ, Edward Mallinckrodt Inst Radiol, St Louis, MO 63110 USA; Washington Univ, Dept Math, St Louis, MO 63110 USA; Jewish Hosp St Louis, Lillian Strauss Inst Neurosci, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital	Powers, WJ (corresponding author), Washington Univ, Med Ctr, E Bldg Imaging Ctr, Dept Neurol & Neurol Surg, 4525 Scott Ave,Box 8225, St Louis, MO 63110 USA.	wjp@npg.wustl.edu			NIA NIH HHS [AG05681, AG03991] Funding Source: Medline; NINDS NIH HHS [NS28947] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG003991, P50AG005681] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BALOW J, 1966, NEUROLOGY, V16, P559, DOI 10.1212/WNL.16.6.559; BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904; Barnett HJM, 1997, STROKE, V28, P1857; BARON JC, 1981, STROKE, V12, P454, DOI 10.1161/01.STR.12.4.454; BOZZAO L, 1989, STROKE, V20, P735, DOI 10.1161/01.STR.20.6.735; Derdeyn CP, 1998, STROKE, V29, P754, DOI 10.1161/01.STR.29.4.754; GIBBS JM, 1984, LANCET, V1, P310; GIBBS JM, 1987, J NEUROL NEUROSUR PS, V50, P140, DOI 10.1136/jnnp.50.2.140; HANKEY GJ, 1991, CEREBROVASC DIS, V1, P245, DOI 10.1159/000108851; Klijn CJM, 1997, STROKE, V28, P2084, DOI 10.1161/01.STR.28.10.2084; MINTUN MA, 1984, J NUCL MED, V25, P177; PESSIN MS, 1977, NEW ENGL J MED, V296, P358, DOI 10.1056/NEJM197702172960703; POWERS WJ, 1989, ANN NEUROL, V25, P325, DOI 10.1002/ana.410250403; POWERS WJ, 1984, NEUROLOGY, V34, P1168, DOI 10.1212/WNL.34.9.1168; POWERS WJ, 1991, ANN NEUROL, V29, P231, DOI 10.1002/ana.410290302; POWERS WJ, 1987, ANN INTERN MED, V106, P27, DOI 10.7326/0003-4819-106-1-27; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; SAMSON Y, 1985, STROKE, V16, P609, DOI 10.1161/01.STR.16.4.609; SPINKS TJ, 1992, PHYS MED BIOL, V37, P1637, DOI 10.1088/0031-9155/37/8/002; STREIFLER JY, 1995, ARCH NEUROL-CHICAGO, V52, P246, DOI 10.1001/archneur.1995.00540270034016; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; THIELE BL, 1980, NEUROLOGY, V30, P1041, DOI 10.1212/WNL.30.10.1041; VIDEEN TO, 1987, J CEREBR BLOOD F MET, V7, P513, DOI 10.1038/jcbfm.1987.97; WIENHARD K, 1994, J COMPUT ASSIST TOMO, V18, P110, DOI 10.1097/00004728-199401000-00023; Yamauchi H, 1996, J NEUROL NEUROSUR PS, V61, P18, DOI 10.1136/jnnp.61.1.18; Yokota C, 1998, STROKE, V29, P640, DOI 10.1161/01.STR.29.3.640	26	556	584	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 30	1998	280	12					1055	1060		10.1001/jama.280.12.1055	http://dx.doi.org/10.1001/jama.280.12.1055			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FJ	9757852	Bronze			2022-12-28	WOS:000076002400033
J	Drife, JO				Drife, JO			Soundings - Letter from America	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1998	317	7162					892	892		10.1136/bmj.317.7162.892	http://dx.doi.org/10.1136/bmj.317.7162.892			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748200	Green Published			2022-12-28	WOS:000076222300064
J	McCreadie, R; Macdonald, E; Blacklock, C; Tilak-Singh, D; Wiles, D; Halliday, J; Paterson, J				McCreadie, R; Macdonald, E; Blacklock, C; Tilak-Singh, D; Wiles, D; Halliday, J; Paterson, J			Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study	BRITISH MEDICAL JOURNAL			English	Article									Crichton Royal Hosp, Dept Clin Res, Dumfries DG1 4TG, Scotland; Dumfries & Galloway Royal Infirm, Dept Biochem, Dumfries DG1 4AP, Scotland; Greencroft Med Ctr N, Annan DG12 6BG, Scotland		McCreadie, R (corresponding author), Crichton Royal Hosp, Dept Clin Res, Dumfries DG1 4TG, Scotland.							CATIGNANI GL, 1983, CLIN CHEM, V29, P708; *DEP HLTH, 1991, DICT REF VAL FOND EN; HEIMENDINGER J, 1995, AM J CLIN NUTR, V61, p1397S, DOI 10.1093/ajcn/61.6.1397S; *SCOTT OFF HOM HLT, 1993, SCHOTT DIET; YARNELL JWG, 1983, HUM NUTR-APPL NUTR, V37, P103	5	130	131	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					784	785		10.1136/bmj.317.7161.784	http://dx.doi.org/10.1136/bmj.317.7161.784			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740565	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000076084200025
J	Bracy, JL; Sachs, DH; Iacomini, J				Bracy, JL; Sachs, DH; Iacomini, J			Inhibition of xenoreactive natural antibody production by retroviral gene therapy	SCIENCE			English	Article							XENOTRANSPLANTATION; PIG; REJECTION; BARRIERS; SAFE; LINE	The major barrier to transplantation across discordant species, such as from pig to human, is rejection mediated by xenoreactive natural antibodies (XNA) that bind the carbohydrate epitope Gal alpha 1-3Gal beta 1-4GlcNAc-R (alpha Gal) on donor tissues. This epitope is synthesized by the enzyme glucosyltransferase uridine 5'-diphosphate galactose:beta-D-galactosyl-1.4-N-acetyl-D-glucosaminide alpha(1-3)galactosyltransferase (E.C. 2.4.1.151), pr simply alpha GT. When a functional alpha GT gene was introduced by retroviral gene transfer into bone marrow cells, alpha GaL XNA production in a murine model ceased. Thus, genetic engineering of bone marrow may overcome humoral rejection of discordant xenografts and may be useful for inducing B cell tolerance.	Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; Allegheny Univ Hlth Sci, Mol & Cellular Biol Program, Philadelphia, PA 19129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Drexel University	Iacomini, J (corresponding author), Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Bldg 149-5210,13th St, Boston, MA 02129 USA.							ARMENTANO D, 1987, J VIROL, V61, P1647, DOI 10.1128/JVI.61.5.1647-1650.1987; Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; BACH FH, 1995, NAT MED, V1, P869, DOI 10.1038/nm0995-869; Bagley J, 1998, TRANSPLANTATION, V65, P1233, DOI 10.1097/00007890-199805150-00015; BRACY JL, UNPUB; Cooper DKC, 1997, WORLD J SURG, V21, P901, DOI 10.1007/s002689900324; GALILI U, 1988, INFECT IMMUN, V56, P1730, DOI 10.1128/IAI.56.7.1730-1737.1988; GOOD AH, 1992, TRANSPL P, V24, P559; HANTZOPOULOS PA, 1989, P NATL ACAD SCI USA, V86, P3519, DOI 10.1073/pnas.86.10.3519; KOREN E, 1994, TRANSPLANT P, V26, P1166; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; ORIOL R, 1993, TRANSPLANTATION, V56, P1433, DOI 10.1097/00007890-199312000-00031; Platt JL, 1996, CRIT REV IMMUNOL, V16, P331; Platt JL, 1998, NATURE, V392, P11; Platt JL, 1997, XENOTRANSPLANTATION, P8; Sachs David H., 1995, Xenotransplantation, V2, P234, DOI 10.1111/j.1399-3089.1995.tb00101.x; SACHS DH, 1994, PATHOL BIOL, V42, P217; STRAHAN KM, 1995, IMMUNOGENETICS, V41, P101, DOI 10.1007/BF00182319; THALL A, 1996, TRANSPLANT P, V28, P561; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; Tumbleson M. E., 1986, SWINE BIOMEDICAL RES; WOOD C, 1979, ARCH BIOCHEM BIOPHYS, V198, P1, DOI 10.1016/0003-9861(79)90389-8; Yang YG, 1998, J EXP MED, V187, P1335, DOI 10.1084/jem.187.8.1335	25	107	115	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1845	1847		10.1126/science.281.5384.1845	http://dx.doi.org/10.1126/science.281.5384.1845			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743496				2022-12-28	WOS:000076007100051
J	Brotherton, DH; Dhanaraj, V; Wick, S; Brizuela, L; Domaille, PJ; Volyanik, E; Xu, X; Parisini, E; Smith, BO; Archer, SJ; Serrano, M; Brenner, SL; Blundell, TL; Laue, ED				Brotherton, DH; Dhanaraj, V; Wick, S; Brizuela, L; Domaille, PJ; Volyanik, E; Xu, X; Parisini, E; Smith, BO; Archer, SJ; Serrano, M; Brenner, SL; Blundell, TL; Laue, ED			Crystal structure of the complex of the cyclin D dependent kinase Cdk6 bound to the cell-cycle inhibitor p19(INK4d)	NATURE			English	Article							TGF-BETA; PROTEIN; IDENTIFICATION; PHOSPHORYLATION; P15(INK4B); ACTIVATION; P16(INK4); P27(KIP1); MELANOMA; ANKYRIN	The crystal structure of the cyclin D-dependent kinase Cdk6 bound to the p19(INK4d) protein has been determined at 1.9 Angstrom resolution. The results provide the first structural Information for a cyclin D-dependent protein kinase and show how the INK4 family of CDK inhibitors bind. The structure indicates that the conformational changes Induced by p19(INK4d) Inhibit both productive binding of ATP and the cyclin-induced rearrangement of the kinase from an Inactive to an active conformation. The structure also shows how binding of an INK4 inhibitor would prevent binding of p27(Kip1), resulting In Its redistribution to other CDKs. identification of the critical residues involved in the Interaction explains how mutations in Cdk4 and p16(INK4a) result in loss of kinase inhibition and cancer.	Univ Cambridge, Dept Biochem, Cambridge Ctr Mol Recognit, Cambridge CB2 1GA, England; Mitotix Inc, Cambridge, MA 02139 USA; Dupont Merck Pharmaceut Co, Wilmington, DE 19880 USA; Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	University of Cambridge; DuPont; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Laue, ED (corresponding author), Univ Cambridge, Dept Biochem, Cambridge Ctr Mol Recognit, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	e.d.laue@bioc.cam.ac.uk	Serrano, Manuel/H-2634-2015; Smith, Brian O/J-1899-2015	Serrano, Manuel/0000-0001-7177-9312; Smith, Brian O/0000-0003-3363-4168; Laue, Ernest/0000-0002-7476-4148; Wick, Scott/0000-0002-6906-4980; PARISINI, Emilio/0000-0002-5529-0039	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BRUNGER AT, 1992, XPLOR VERSION 3 U SY; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Coleman KG, 1997, J BIOL CHEM, V272, P18869, DOI 10.1074/jbc.272.30.18869; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DellaRagione F, 1996, J BIOL CHEM, V271, P15942, DOI 10.1074/jbc.271.27.15942; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harper JW, 1997, CANCER SURV, V29, P91; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hubbard SJ, 1993, NACCESS COMPUTER PRO; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; Tsao H, 1998, CANCER RES, V58, P109; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; YANG R, 1995, CANCER RES, V55, P2503; Zhang B, 1996, J BIOL CHEM, V271, P28734, DOI 10.1074/jbc.271.46.28734; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	49	173	174	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	1998	395	6699					244	250		10.1038/26164	http://dx.doi.org/10.1038/26164			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751051				2022-12-28	WOS:000075974600041
J	Kemp, M				Kemp, M			Mammary models	NATURE			English	Editorial Material									Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.								0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1998	395	6699					227	227		10.1038/26126	http://dx.doi.org/10.1038/26126			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751045	Bronze			2022-12-28	WOS:000075974600029
J	Rothwarf, DM; Zandi, E; Natoli, G; Karin, M				Rothwarf, DM; Zandi, E; Natoli, G; Karin, M			IKK-gamma is an essential regulatory subunit of the I kappa B kinase complex	NATURE			English	Article							TRANSCRIPTION FACTOR; ACTIVATION; ALPHA; PHOSPHORYLATION; DISSOCIATION; BETA	Pro-inflammatory cytokines activate the transcription factor NF-kappa B by stimulating the activity of a protein kinase that phosphorylates I kappa B, an inhibitor of NF-kappa B1-5, af sites that trigger its ubiquitination and degradation. This results in the nuclear translocation of freed NF-kappa B dimers and the activation of transcription of target genes(6,7). Many of these target genes code for immunoregulatory proteins(8,9). A large, cytokine-responsive I kappa B kinase (IKK) complex has been purified and the genes encoding two of its subunits have been cloned(1,2,5). These subunits, IKK-alpha and IKK-beta, are protein kinases whose function is needed for NF-kappa B activation by pro-inflammatory stimuli. Here, by using a monoclonal antibody against IKK-alpha, we purify the IKK complex to homogeneity from human cell lines. We find that IKK is composed of similar amounts of IKK-alpha, IKK-beta and two other polypeptides, for which we obtained partial sequences. These polypeptides are differentially processed forms of a third subunit, IKK-gamma. Molecular cloning and sequencing indicate that IKK-gamma is composed of several potential coiled-coil moths. IKK-gamma interacts preferentially with IKK-beta and is required for the activation of the IKK complex. An IKK-gamma carboxy-terminal truncation mutant that still binds IKK-beta blocks the activation of IKK and NF-kappa B.	Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu	Natoli, gioacchino/ABB-8679-2020; Natoli, gioacchino/J-2100-2018	Natoli, Gioacchino/0000-0003-0711-2411				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Frishman D, 1996, PROTEIN ENG, V9, P133, DOI 10.1093/protein/9.2.133; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rost B, 1996, METHOD ENZYMOL, V266, P525; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	18	810	871	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	1998	395	6699					297	300		10.1038/26261	http://dx.doi.org/10.1038/26261			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751060				2022-12-28	WOS:000075974600056
J	Sechi, LA; Zingaro, L; De Carli, S; Sechi, G; Catena, C; Falleti, E; Dell'Anna, E; Bartoli, E				Sechi, LA; Zingaro, L; De Carli, S; Sechi, G; Catena, C; Falleti, E; Dell'Anna, E; Bartoli, E			Increased serum lipoprotein(a) levels in patients with early renal failure	ANNALS OF INTERNAL MEDICINE			English	Article							APOLIPOPROTEIN(A) PHENOTYPES; SIZE POLYMORPHISM; DISEASE; PLASMA; ABNORMALITIES; HEMODIALYSIS; DIALYSIS; RISK	Background: Elevated serum lipoprotein(a) levels have been found in patients with end-stage renal disease and in patients undergoing dialysis, suggesting that this lipoprotein contributes to the increased cardiovascular risk seen in these patients. It is not known whether lipoprotein(a) levels are elevated in the early phases of renal disease. Objective: To evaluate levels of lipoprotein(a) and other lipids and the prevalence of atherosclerotic disease in patients with early renal failure. Design: Cross-sectional study. Setting: Hypertension clinic of a university medical center. Patients: 257 patients with normal renal function and 160 patients with early impairment of renal function (creatinine clearance, 30 to 89 mL/min per 1.73 m(2) of body surface area). Measurements: Renal function was assessed by 24-hour creatinine clearance, proteinuria, and microalbuminuria. Cardiovascular disease status was also assessed. Serum lipoprotein(a), lipids, apolipoproteins, and apolipoprotein(a) isoforms were measured. Results: Age, blood pressure, and serum lipoprotein(a) levels were greater in patients with early renal failure than in those with normal renal function and were independently associated with the presence of decreased creatinine clearance. Serum lipoprotein(a) and creatinine clearance were inversely correlated. The prevalence of coronary artery, cerebrovascular, and peripheral vascular disease was greater in patients with early renal failure than in those with normal renal function. The frequency distribution of apolipoprotein(a) isoforms was similar in patients with normal and those with impaired renal function. Conclusions: Serum lipoprotein(a) levels are elevated in patients with early impairment of renal function and are associated with greater prevalence of cardiovascular disease. An inverse correlation between serum lipoprotein(a) level and creatinine clearance and a frequency distribution of apolipoprotein(a) isoforms similar to that of normal patients point to decreased renal catabolism as a probable mechanism of lipoprotein(a) elevation in patients with early renal failure.	Univ Udine, Sch Med, Osped Civile, Dept Internal Med,Hypertens Unit,Padigl Med, I-33100 Udine, Italy	University of Udine	Sechi, LA (corresponding author), Univ Udine, Sch Med, Osped Civile, Dept Internal Med,Hypertens Unit,Padigl Med, I-33100 Udine, Italy.	sechi@uniud.it	Sechi, Leonardo Antonio/Y-3109-2018; dell'anna, m. elisabetta/AAO-1673-2020	dell'anna, m. elisabetta/0000-0002-5376-670X; Catena, Cristiana/0000-0001-5039-435X				Arnadottir M, 1996, NEPHRON, V72, P712, DOI 10.1159/000188970; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; Bostom AG, 1997, ANN INTERN MED, V127, P1089, DOI 10.7326/0003-4819-127-12-199712150-00006; CHAN MK, 1981, KIDNEY INT, V19, P625, DOI 10.1038/ki.1981.62; DIEPLINGER H, 1993, J CLIN INVEST, V91, P397, DOI 10.1172/JCI116213; HAFFNER SM, 1992, J AM SOC NEPHROL, V3, P1156; HIRATA K, 1993, KIDNEY INT, V44, P1062, DOI 10.1038/ki.1993.349; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; JENSEN T, 1988, DIABETOLOGIA, V31, P142, DOI 10.1007/BF00276846; KIM KE, 1988, DISEASES KIDNEY, P3093; Kronenberg F, 1996, CRIT REV CL LAB SCI, V33, P495, DOI 10.3109/10408369609080056; Kronenberg F, 1996, AM J KIDNEY DIS, V27, P1, DOI 10.1016/S0272-6386(96)90026-8; KRONENBERG F, 1995, J AM SOC NEPHROL, V6, P110; RADER DJ, 1994, ANN INTERN MED, V120, P1012, DOI 10.7326/0003-4819-120-12-199406150-00008; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; SECHI LA, 1992, METABOLISM, V41, P1261, DOI 10.1016/0026-0495(92)90019-7; Sechi LA, 1997, JAMA-J AM MED ASSOC, V277, P1689, DOI 10.1001/jama.277.21.1689; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; ZANCHETTI A, 1993, HYPERTENSION, V22, P392	20	70	70	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1998	129	6					457	461		10.7326/0003-4819-129-6-199809150-00006	http://dx.doi.org/10.7326/0003-4819-129-6-199809150-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JJ	9735083				2022-12-28	WOS:000075892100004
J	Whitmarsh, AJ; Cavanagh, L; Tournier, C; Yasuda, L; Davis, RJ				Whitmarsh, AJ; Cavanagh, L; Tournier, C; Yasuda, L; Davis, RJ			Mammalian scaffold complex that selectively mediates MAP kinase activation	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; N-TERMINAL KINASE; PROTEIN-KINASE; JUN KINASE; PHOSPHORYLATES; SAPK/JNK; CLONING; CASCADE; MEMBER; FAMILY	The c-Jun NH2-terminal kinase (JNK) group of mitogen-activated protein (MAP) kinases is activated by the exposure of cells to multiple forms of stress. A putative scaffold protein was identified that interacts with multiple components of the JNK signaling pathway, including the mixed-lineage group of MAP kinase kinase kinases (MLK), the MAP kinase kinase MKK7, and the MAP kinase JNK. This scaffold protein selectively enhanced JNK activation by the MLK signaling pathway. These data establish that a mammalian scaffold protein can mediate activation of a MAP kinase signaling pathway.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Davis, RJ (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med, Worcester, MA 01605 USA.			Yasuda, Jun/0000-0002-3887-6871; Tournier, Cathy/0000-0002-4618-2570; Whitmarsh, Alan/0000-0003-1184-6610				BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; CHOI KY, 1994, CELL, V78, P499; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; EllingerZiegelbauer H, 1997, J BIOL CHEM, V272, P2668, DOI 10.1074/jbc.272.5.2668; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; HIRAI S, 1996, ONCOGENE, V12, P341; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; TOUMIER C, 1997, P NATL ACAD SCI USA, V94, P7337; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; WANG W, 1997, J BIOL CHEM, V272, P2271; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITMARSH AJ, UNPUB	29	580	605	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1671	1674		10.1126/science.281.5383.1671	http://dx.doi.org/10.1126/science.281.5383.1671			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733513				2022-12-28	WOS:000075856500046
J	Lamm, RD				Lamm, RD			Marginal medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MANAGED CARE; QUALITY; COST		Univ Denver, Ctr Publ Policy & Contemporary Issues, Denver, CO 80208 USA	University of Denver	Lamm, RD (corresponding author), Univ Denver, Ctr Publ Policy & Contemporary Issues, 2199 S Univ Blvd, Denver, CO 80208 USA.							*AM MED ASS, 1981, AM MED ASS ETH OP; ATTINGER EO, 1987, WORLD HEALTH FORUM, V8, P309; CALLAHAN D, 1997, FALSE HOPES; Charlesworth M., 1993, BIOETHICS LIBERAL SO; Eddy DM, 1997, HEALTH AFFAIR, V16, P162, DOI 10.1377/hlthaff.16.3.162; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P817, DOI 10.1001/jama.272.10.817; FUCHS V, 1992, CORN U MED COLL HLTH; HOLMES OW, 1976, ENCY BRITANNICA MICR, P94; Katz L A, 1997, HMO Pract, V11, P102; LEVIT KR, 1994, HEALTH CARE FINANC R, V16, P247; MORREIM EH, 1995, J LAW MED ETHICS, V23, P247, DOI 10.1111/j.1748-720X.1995.tb01361.x; *MULT COUNT MED SO, 1988, OREGON HLTH DECI NOV; WEISBROD BA, 1991, J ECON LIT, V29, P523	13	16	17	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1998	280	10					931	933		10.1001/jama.280.10.931	http://dx.doi.org/10.1001/jama.280.10.931			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	115LN	9739981				2022-12-28	WOS:000075666600043
J	Caroni, P				Caroni, P			Driving the growth cone	SCIENCE			English	Editorial Material							AXON GUIDANCE; RHO; GTPASES		Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Caroni, P (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.							Abel T, 1998, SCIENCE, V279, P338, DOI 10.1126/science.279.5349.338; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; COLOMARINO SA, 1995, CELL, V81, P621; Fitzsimonds RM, 1998, PHYSIOL REV, V78, P143, DOI 10.1152/physrev.1998.78.1.143; Gallo G, 1998, J NEUROSCI, V18, P5403, DOI 10.1523/JNEUROSCI.18-14-05403.1998; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; LOHOF AM, 1992, J NEUROSCI, V12, P1253; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; Shirasaki R, 1998, SCIENCE, V279, P105, DOI 10.1126/science.279.5347.105; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123	18	15	15	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1465	1466		10.1126/science.281.5382.1465	http://dx.doi.org/10.1126/science.281.5382.1465			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9750116				2022-12-28	WOS:000075738100027
J	Hengartner, M				Hengartner, M			Apoptosis - Death by crowd control	SCIENCE			English	Editorial Material									Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Hengartner, M (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	hengartn@cshl.org	Hengartner, Michael O/E-6235-2011; Hengartner, Michael O/A-7058-2008	Hengartner, Michael/0000-0002-7584-596X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chaudhary D, 1998, J BIOL CHEM, V273, P17708, DOI 10.1074/jbc.273.28.17708; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Peter ME, 1997, P NATL ACAD SCI USA, V94, P12736, DOI 10.1073/pnas.94.24.12736; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355	9	45	55	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 28	1998	281	5381					1298	1299		10.1126/science.281.5381.1298	http://dx.doi.org/10.1126/science.281.5381.1298			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9735047				2022-12-28	WOS:000075666800034
J	Arnold, J; Ouwehand, W; Smith, GA; Cohen, H				Arnold, J; Ouwehand, W; Smith, GA; Cohen, H			A young woman with petechiae	LANCET			English	Article							IDIOPATHIC THROMBOCYTOPENIC PURPURA		Univ London Imperial Coll Sci Technol & Med, Sch Med, St Marys NHS Trust, Dept Haematol, London W2 1NY, England; Univ Cambridge, Dept Haematol, Cambridge CB2 1TN, England; Natl Blood Serv, E Anglia, England	Imperial College London; University of Cambridge	Arnold, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, St Marys NHS Trust, Dept Haematol, Praed St,St Marys Campus, London W2 1NY, England.		Smith, Graham/Q-1319-2019	Smith, Graham/0000-0003-1003-8996				CAFFREY EA, 1981, LANCET, V2, P316; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; Karpatkin S, 1997, LANCET, V349, P1531, DOI 10.1016/S0140-6736(96)12118-8; KIEFEL V, 1987, BLOOD, V70, P1722; MCMILLAN R, 1987, BLOOD, V70, P1040	5	14	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 22	1998	352	9128					618	618		10.1016/S0140-6736(98)05194-0	http://dx.doi.org/10.1016/S0140-6736(98)05194-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746024				2022-12-28	WOS:000075567400012
J	Leclercq, R; Courvalin, P				Leclercq, R; Courvalin, P			Streptogramins: an answer to antibiotic resistance in gram-positive bacteria	LANCET			English	Editorial Material							RP-59500 QUINUPRISTIN-DALFOPRISTIN; IN-VITRO; STAPHYLOCOCCUS-AUREUS; QUINUPRISTIN/DALFOPRISTIN; ERYTHROMYCIN		Hop Cote de Nacre, Microbiol Serv, F-14033 Caen, France; Inst Pasteur, Unite Agents Antibacteriens, F-75015 Paris, France	CHU de Caen NORMANDIE; Universite de Caen Normandie; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Leclercq, R (corresponding author), Hop Cote de Nacre, Microbiol Serv, F-14033 Caen, France.							Allignet J, 1996, ANTIMICROB AGENTS CH, V40, P2523, DOI 10.1128/AAC.40.11.2523; Bouanchaud DH, 1997, J ANTIMICROB CHEMOTH, V39, P15, DOI 10.1093/jac/39.suppl_1.15; Cocito C, 1997, J ANTIMICROB CHEMOTH, V39, P7, DOI 10.1093/jac/39.suppl_1.7; DUVAL J, 1985, J ANTIMICROB CHEMOTH, V16, P137, DOI 10.1093/jac/16.suppl_A.137; Eliopoulos GM, 1998, ANTIMICROB AGENTS CH, V42, P1088, DOI 10.1128/AAC.42.5.1088; FANTIN B, 1995, ANTIMICROB AGENTS CH, V39, P400, DOI 10.1128/AAC.39.2.400; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093/jac/40.1.135; HoogkampKorstanje JAA, 1997, J ANTIMICROB CHEMOTH, V40, P427, DOI 10.1093/jac/40.3.427; Leclercq R, 1997, CLIN INFECT DIS, V24, P545, DOI 10.1093/clind/24.4.545; LECLERCQ R, 1991, ANTIMICROB AGENTS CH, V35, P1273, DOI 10.1128/AAC.35.7.1273; LONCLE V, 1993, ANTIMICROB AGENTS CH, V37, P2159, DOI 10.1128/AAC.37.10.2159; Low DE, 1995, MICROB DRUG RESIST, V1, P223, DOI 10.1089/mdr.1995.1.223; OBRIEN TF, 1982, REV INFECT DIS, V4, P351; Pankuch GA, 1996, ANTIMICROB AGENTS CH, V40, P2071, DOI 10.1128/AAC.40.9.2071; WEISBLUM B, 1995, ANTIMICROB AGENTS CH, V39, P577, DOI 10.1128/AAC.39.3.577; Welton LA, 1998, ANTIMICROB AGENTS CH, V42, P705, DOI 10.1128/AAC.42.3.705; Williams JD, 1997, J ANTIMICROB CHEMOTH, V39, P41, DOI 10.1093/jac/39.suppl_1.41	18	29	29	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 22	1998	352	9128					591	592		10.1016/S0140-6736(05)79570-2	http://dx.doi.org/10.1016/S0140-6736(05)79570-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746015				2022-12-28	WOS:000075567400003
J	Shuster, E				Shuster, E			The Nuremberg Code: Hippocratic ethics and human rights	LANCET			English	Article									Vet Affairs Med Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Shuster, E (corresponding author), Vet Affairs Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA.	Shuster.Evelyne@Forum.va.gov						*ADV COMM HUM RAD, 1995, FIN REP ADV COMM HUM, P130; ALEXANDER L, 1973, NEW ENGL J MED, V289, P324; ALEXANDER L, 1970, ANN NY ACAD SCI, V169, P344, DOI 10.1111/j.1749-6632.1970.tb54741.x; Alexander L., 1976, PSYCHIAT J U OTTAWA, V1, P40; Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; Annas G J, 1996, J Contemp Health Law Policy, V12, P297; Annas G J, 1992, Health Matrix Clevel, V2, P119; Annas George J., 1992, NAZI DOCTORS NUREMBE; Bernard C., 1957, INTRO LIT CORRES TON; Burkert Walter, 1996, CREATION SACRED TRAC; CANGUILHEIM G, 1998, IDEOLOGY RATIONALITY, P50; CANGUILHEM G, 1968, ETUDES HIST PHILOS S, P383; *COUNC INT ORG MED, 1993, INT ETH GUID BIOM RE; *COUNC PHARM CHEM, 1951, JAMA-J AM MED ASSOC, V147, P864; French Howard W, 1997, N Y Times Web, pA14; Grodin Michael, 1992, NAZI DOCTORS NUREMBE; JONES WHS, 1923, HIPPOCRATIC CORPUS O, V1; JONES WHS, 1923, HIPPOCRATIC CORPUS O, V2; Katz J, 1996, JAMA-J AM MED ASSOC, V276, P1662, DOI 10.1001/jama.276.20.1662; Katz J., 1984, SILENT WORLD DOCTOR; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; Shuster E, 1997, NEW ENGL J MED, V337, P1436, DOI 10.1056/NEJM199711133372006; SHUSTER E, 1972, MED SOIMEME; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Varmus H, 1997, NEW ENGL J MED, V337, P1003, DOI 10.1056/NEJM199710023371411; WIGODSKY H, 1995, ADVISORY COMMITTEE H, P130; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038; YOUNG WR, 1964, LIFE MAGAZINE   1009, V57	28	44	47	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 28	1998	351	9107					974	977						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734958				2022-12-28	WOS:000072770900046
J	Vincent, JL				Vincent, JL			Search for effective immunomodulating strategies against sepsis	LANCET			English	Editorial Material							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; SEPTIC SHOCK; ANTIBODY		Free Univ Brussels, Erasme Univ Hosp, Dept Intens Care, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Vincent, JL (corresponding author), Free Univ Brussels, Erasme Univ Hosp, Dept Intens Care, 808 Route Lennik, B-1070 Brussels, Belgium.			Vincent, Jean-Louis/0000-0001-6011-6951				BAGBY GJ, 1991, J INFECT DIS, V163, P83, DOI 10.1093/infdis/163.1.83; Fekade D, 1996, NEW ENGL J MED, V335, P311, DOI 10.1056/NEJM199608013350503; FIEDLER VB, 1992, J LAB CLIN MED, V120, P574; Friedman G, 1997, J CRIT CARE, V12, P183, DOI 10.1016/S0883-9441(97)90030-7; MARCHANT A, 1995, J CLIN IMMUNOL, V15, P266, DOI 10.1007/BF01540884; MUNOZ C, 1991, J CLIN INVEST, V88, P1747, DOI 10.1172/JCI115493; OPAL SM, 1990, J INFECT DIS, V161, P1148, DOI 10.1093/infdis/161.6.1148; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; SCHIRMER WJ, 1989, ARCH SURG-CHICAGO, V124, P445; Stuber F, 1996, CRIT CARE MED, V24, P381, DOI 10.1097/00003246-199603000-00004; vanderPoll T, 1997, AM J RESP CRIT CARE, V155, P603, DOI 10.1164/ajrccm.155.2.9032201; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302; Vincent JL, 1997, CRIT CARE MED, V25, P372, DOI 10.1097/00003246-199702000-00029	13	41	42	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 28	1998	351	9107					922	923						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734931				2022-12-28	WOS:000072770900002
J	Hortobagyi, GN				Hortobagyi, GN			Drug therapy - Treatment of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HIGH-DOSE CHEMOTHERAPY; PHASE-II TRIAL; METASTATIC BREAST; ADJUVANT RADIOTHERAPY; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; RANDOMIZED TRIALS; MEDICAL PROGRESS; FAMILY HISTORY; NURSES HEALTH		Univ Texas, MD Anderson Cancer Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hortobagyi, GN (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Breast Med Oncol, 1515 Holcombe Blvd,Box 56, Houston, TX 77030 USA.							ABE O, 1992, LANCET, V339, P71; ABE O, 1995, NEW ENGL J MED, V333, P1444; Abe O, 1996, NEW ENGL J MED, V334, P1003; AHERN RP, 1993, BRIT J CANCER, V67, P801, DOI 10.1038/bjc.1993.146; ANDERSON DE, 1992, CANCER-AM CANCER SOC, V70, P1740, DOI 10.1002/1097-0142(19920915)70:4+<1740::AID-CNCR2820701615>3.0.CO;2-1; [Anonymous], 1996, Lancet, V348, P1189; Antman KH, 1997, J CLIN ONCOL, V15, P1870, DOI 10.1200/JCO.1997.15.5.1870; Ballo MS, 1996, CANCER, V78, P773; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BERAL V, 1995, LANCET, V345, P1642, DOI 10.1016/S0140-6736(95)90151-5; BEZWODA WR, 1995, J CLIN ONCOL, V13, P2483, DOI 10.1200/JCO.1995.13.10.2483; BOOSER DJ, 1994, DRUGS, V47, P223, DOI 10.2165/00003495-199447020-00002; Brenner AJ, 1997, PROG CLIN BIOL RES, V396, P63; Buzdar AU, 1997, CANCER, V79, P730, DOI 10.1002/(SICI)1097-0142(19970215)79:4<730::AID-CNCR10>3.3.CO;2-Z; Cady Blake, 1996, P251; CARMICHAEL J, 1995, J CLIN ONCOL, V13, P2731, DOI 10.1200/JCO.1995.13.11.2731; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Chu KC, 1996, JNCI-J NATL CANCER I, V88, P1571, DOI 10.1093/jnci/88.21.1571; Ciatto S, 1993, BREAST, V2, P87, DOI DOI 10.1016/0960-9776(93)90163-A; Clarke M, 1998, LANCET, V351, P1451; COLDITZ GA, 1993, CANCER-AM CANCER SOC, V71, P1480, DOI 10.1002/cncr.2820710413; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P1548; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; CUMMINGS SR, 1998, P AM SOC CLIN ONCOL, V17; CUZICK J, 1987, CANCER TREAT REP, V71, P15; CUZICK J, 1994, J CLIN ONCOL, V12, P447, DOI 10.1200/JCO.1994.12.3.447; CUZICK J, 1987, CANCER TREAT REP, V71, P7; DAngelo PC, 1997, AM J SURG, V174, P297, DOI 10.1016/S0002-9610(97)00109-8; DELENA M, 1978, CANCER CHEMOTH PHARM, V1, P53, DOI 10.1007/BF00253147; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; DELTURCO MR, 1994, JAMA-J AM MED ASSOC, V271, P1593, DOI 10.1001/jama.1994.03510440053032; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DIERAS V, 1995, SEMIN ONCOL, V22, P33; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; *EAL BREAST CANC T, 1992, LANCET, V339, P1; EDDY DM, 1992, J CLIN ONCOL, V10, P1653; ENG C, 1994, LANCET, V343, P709, DOI 10.1016/S0140-6736(94)91585-7; ENG C, 1994, LANCET, V343, P926; Engels K, 1997, EXS, V79, P113; FARROW DC, 1992, NEW ENGL J MED, V326, P1097, DOI 10.1056/NEJM199204233261701; Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483; Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; FISHER B, 1977, CANCER, V40, P574, DOI 10.1002/1097-0142(197707)40:1+<574::AID-CNCR2820400724>3.0.CO;2-O; Garne JP, 1997, CANCER-AM CANCER SOC, V79, P69, DOI 10.1002/(SICI)1097-0142(19970101)79:1<69::AID-CNCR10>3.3.CO;2-2; GHEZZI P, 1994, JAMA-J AM MED ASSOC, V271, P1587, DOI 10.1001/jama.1994.03510440047031; Giuliano AE, 1997, J CLIN ONCOL, V15, P2345, DOI 10.1200/JCO.1997.15.6.2345; Gradishar WJ, 1997, J CLIN ONCOL, V15, P840, DOI 10.1200/JCO.1997.15.2.840; Greenberg PAC, 1996, J CLIN ONCOL, V14, P2197, DOI 10.1200/JCO.1996.14.8.2197; Hall F M, 1997, Surg Oncol Clin N Am, V6, P403; HALL WH, 1991, JAMA-J AM MED ASSOC, V265, P391; HAND R, 1991, JAMA-J AM MED ASSOC, V266, P3429, DOI 10.1001/jama.266.24.3429; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HARRIS JR, 1992, NEW ENGL J MED, V327, P390, DOI 10.1056/NEJM199208063270606; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HENDERSON IC, 1988, J CLIN ONCOL, V6, P1501, DOI 10.1200/JCO.1988.6.9.1501; HENDERSON IC, 1998, P AN M AM SOC CLIN, V17, pA101; HENDERSON IC, 1991, BREAST DIS, P604; Hortobagyi G N, 1997, Oncology (Williston Park), V11, P29; HORTOBAGYI GN, 1994, CANCER-AM CANCER SOC, V74, P416, DOI 10.1002/cncr.2820741329; HORTOBAGYI GN, 1995, CA-CANCER J CLIN, V45, P199, DOI 10.3322/canjclin.45.4.199; Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401; Hortobagyi GN, 1997, SEMIN ONCOL, V24, pS4; HORTOBAGYI GN, 1987, SEMIN HEMATOL, V24, P56; Hortobagyi GN, 1996, SEMIN ONCOL, V23, P1; HORTOBAGYI GN, 1996, DIS BREAST, P585; HORTOBAGYI GN, 1996, ONCOLOGY, V10, P30; HORTOBAGYI GN, 1995, PRINCIPLES PRACTICE, P1868; HORTOBAGYI GN, 1997, ONCOLOGY HUNTINGR, V11, P943; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; Howell A, 1996, EUR J CANCER, V32A, P576, DOI 10.1016/0959-8049(96)00032-9; IBRAHIM NK, 1995, AM J CLIN ONCOL-CANC, V18, P407, DOI 10.1097/00000421-199510000-00010; JAIYESIMI IA, 1992, J CLIN ONCOL, V10, P1014, DOI 10.1200/JCO.1992.10.6.1014; Johnson SA, 1996, CANCER TREAT REV, V22, P127, DOI 10.1016/S0305-7372(96)90032-8; JUDSON IR, 1992, SEMIN ONCOL, V19, P687; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KHALKHALI I, 1994, EUR J NUCL MED, V21, P357, DOI 10.1007/BF00947973; KING MC, 1993, JAMA-J AM MED ASSOC, V269, P1975, DOI 10.1001/jama.269.15.1975; Krag D, 1998, NEW ENGL J MED, V339, P941, DOI 10.1056/NEJM199810013391401; Leitch AM, 1997, CA-CANCER J CLIN, V47, P150, DOI 10.3322/canjclin.47.3.150; MADIGAN MP, 1995, J NATL CANCER I, V87, P1681, DOI 10.1093/jnci/87.22.1681; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; McKenzie K, 1996, Prog Clin Biol Res, V394, P183; Meyer JE, 1996, AM J ROENTGENOL, V167, P179, DOI 10.2214/ajr.167.1.8659367; Morris AD, 1997, CANCER J, V3, P6; NABHOLTZ J, 1997, P AN M AM SOC CLIN, V16, pA519; Nabholtz JM, 1996, J CLIN ONCOL, V14, P1858, DOI 10.1200/JCO.1996.14.6.1858; *OFF MED APPL RES, 1997, NIH CONS STAT, V15, P1; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; PAGE DL, 1990, SURG CLIN N AM, V70, P831; Parker SL, 1997, CA-CANCER J CLIN, V47, P68; Ragaz J, 1997, NEW ENGL J MED, V337, P956, DOI 10.1056/NEJM199710023371402; Rahman ZU, 1997, J CLIN ONCOL, V15, P3171, DOI 10.1200/JCO.1997.15.10.3171; Ranson MR, 1997, J CLIN ONCOL, V15, P3185, DOI 10.1200/JCO.1997.15.10.3185; Recht A, 1996, NEW ENGL J MED, V334, P1356, DOI 10.1056/NEJM199605233342102; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; SCHORNAGEL JH, 1992, ANN ONCOL, V3, P549, DOI 10.1093/oxfordjournals.annonc.a058258; SLAMON D, 1998, P AN M AM SOC CLIN, V17, pA98; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smith JM, 1996, CORONARY ARTERY DIS, V7, P1; Solin LJ, 1996, J CLIN ONCOL, V14, P754, DOI 10.1200/JCO.1996.14.3.754; Somerfield MR, 1997, J CLIN ONCOL, V15, P2149; Stuart NSA, 1996, EUR J CANCER, V32A, P1888, DOI 10.1016/0959-8049(96)00191-8; TABAR L, 1992, LANCET, V339, P412, DOI 10.1016/0140-6736(92)90090-P; TEICHER BA, 1995, CRIT REV ONCOL HEMAT, V20, P9, DOI 10.1016/1040-8428(94)00142-G; THERIAULT RL, 1996, DIS BREAST, P819; VAHDAT L, 1995, HIGH DOSE CANC THERA, P802; VALERO V, 1995, J CLIN ONCOL, V13, P2886, DOI 10.1200/JCO.1995.13.12.2886; VERWEIJ J, 1994, ANN ONCOL, V5, P495, DOI 10.1093/oxfordjournals.annonc.a058903; Walker RA, 1997, CANCER METAST REV, V16, P5, DOI 10.1023/A:1005740222307; WICKERHAM DL, 1998, 34 ANN M AM SOC CLIN; WILSON RE, 1984, SURG GYNECOL OBSTET, V159, P309	112	550	583	1	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1998	339	14					974	984		10.1056/NEJM199810013391407	http://dx.doi.org/10.1056/NEJM199810013391407			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124MW	9753714				2022-12-28	WOS:000076186900007
J	Kleinman, S; Busch, MP; Hall, L; Thomson, R; Glynn, S; Gallahan, D; Ownby, HE; Williams, AE				Kleinman, S; Busch, MP; Hall, L; Thomson, R; Glynn, S; Gallahan, D; Ownby, HE; Williams, AE		Retrovirus Epidemiology Donor Study	False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-LABORATORY-DIRECTORS; CONSENSUS CONFERENCE; WESTERN-BLOT; IDENTIFICATION; TRANSFUSION; INFECTION; DONORS; PLASMA; RNA; PCR	Context.-Persons at risk of human immunodeficiency virus 1 (HIV-1) infection have been classified incorrectly as HIV infected because of Western blot results, but the frequency of false-positive Western blot results is unknown. Objectives.-To determine the frequency of false-positive HIV-1 Western blot results in US blood donors and to make projections to other screened populations. Secondarily, to validate an algorithm for evaluating possible false-positive cases. Design.-A retrospective cohort study of HIV-1 enzyme immunoassay (EIA) and Western blot results from large blood donor screening programs in which donors with suspected false-positive Western blot results underwent HIV-1 RNA polymerase chain reaction (PCR) testing and follow-up HIV-1 serology. Setting.-Five US blood centers participating in the Retrovirus Epidemiology Donor Study. Participants.-More than 5 million allogeneic and autologous blood donors who successfully donated blood at 1 of the 5 participating centers from 1991 through 1995. Main Outcome Measures.-Rate of false positivity by Western blot and true HIV-1 infection status as determined by HIV-I RNA PCR and by serologic followup of blood donors more than 5 weeks after donation. Results.-Of 421 donors who were positive for HIV-1 by Western blot, 39 (9.3%) met the criteria of possible false positivity because they lacked reactivity to p31. Of these, 20 (51.3%) were proven by PCR not to be infected with HIV-1. The false-positive prevalence was 4.8% of Western blot-positive donors and 0.0004% (1 in 251 000) of all donors (95% confidence interval, 1 in 173 000 to 1 in 379 000 donors). Conclusions.-A false diagnosis of HIV-1 infection can result from the combination of EIA and Western blot testing in blood donor and other HIV-1 screening programs. Individuals with a positive Western blot result lacking the p31 band should be counseled that, although they may be HIV infected, there is uncertainty about this conclusion. These individuals should be further evaluated by RNA PCR testing (if feasible) and HIV serologic analysis on a follow-up sample.	Westat Inc, Rockville, MD USA; SRA Technol, Rockville, MD USA; Irwin Mem Blood Ctr, San Francisco, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Amer Red Cross, SE Michigan Reg, Detroit, MI USA; Amer Red Cross, Greater Chesapeake & Potomac Reg, Baltimore, MD USA	Westat; University of California System; University of California San Francisco; American Red Cross; American Red Cross	Kleinman, S (corresponding author), 1281 Rockcrest Ave, Victoria, BC V9A 4W4, Canada.	drsklei@islandnet.com			NHLBI NIH HHS [N01-HB-97077, N01-HB-97079, N01-HB-97078] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097078, N01HB097077, N01HB097079] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown AE, 1997, TRANSFUSION, V37, P926, DOI 10.1046/j.1537-2995.1997.37997454019.x; BUKRINSKY MI, 1988, AIDS, V2, P405, DOI 10.1097/00002030-198810000-00019; Busch M. P., 1996, Transfusion (Bethesda), V36, p41S; CARLSON JR, 1988, JAMA-J AM MED ASSOC, V260, P674; *CDCP, 1995, MMWR-MORBID MORTAL W, V42, P603; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P561; *CDCP, 1991, MMWR-MORBID MORTAL W, V40, P692; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; *CTR BIOL EV RES F, 1992, REV REC PREV HUM IMM; DODD RY, 1990, ARCH PATHOL LAB MED, V114, P240; FENOUILLET E, 1991, AIDS, V5, P770; HAUSLER WJ, 1988, INFECT CONT HOSP EP, V9, P345, DOI 10.1086/645875; HAUSLER WJ, 1989, INFECT CONT HOSP EP, V10, P354, DOI 10.1086/646045; HEALEY DS, 1993, AIDS, V7, P655, DOI 10.1097/00002030-199305000-00007; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; LANGEDIJK JPM, 1992, AIDS, V6, P1547, DOI 10.1097/00002030-199212000-00023; MCFARLAND W, 1997, INF DIS SOC AM 35 AN; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; SABINO EC, 1994, J ACQ IMMUN DEF SYND, V7, P853; Sayre KR, 1996, TRANSFUSION, V36, P45, DOI 10.1046/j.1537-2995.1996.36196190514.x; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; SCHWARTZ DH, 1995, CLIN DIAGN LAB IMMUN, V2, P268, DOI 10.1128/CDLI.2.3.268-271.1995; WALLACE EL, 1993, TRANSFUSION, V33, P139, DOI 10.1046/j.1537-2995.1993.33293158046.x; WEINSTOCK HS, 1996, 11 INT C AIDS JUL 7; Zuck TF, 1995, TRANSFUSION, V35, P944, DOI 10.1046/j.1537-2995.1995.351196110900.x	26	92	98	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 30	1998	280	12					1080	1085		10.1001/jama.280.12.1080	http://dx.doi.org/10.1001/jama.280.12.1080			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FJ	9757856	Bronze			2022-12-28	WOS:000076002400037
J	Dolovich, LR; Addis, A; Vaillancourt, JMR; Power, JDB; Koren, G; Einarson, TR				Dolovich, LR; Addis, A; Vaillancourt, JMR; Power, JDB; Koren, G; Einarson, TR			Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MATERNAL DRUG HISTORIES; PRENATAL EXPOSURE; CONGENITAL-MALFORMATIONS; ANTIEPILEPTIC DRUGS; LATE INFANCY; DIAZEPAM USE; ASSOCIATION; TERATOGENICITY; ABNORMALITIES; INUTERO	Objective: To determine if exposure to benzodiazepines during the first trimester of pregnancy increases risk of major malformations or cleft lip or palate. Design: Meta-analysis. Setting: Studies from 1966 to present Subjects: Studies were located with Medline, Embase, Reprotox, and from references of textbooks, reviews, and included articles. Included studies were original, concurrently controlled studies in any language. Interventions: Data extraction and quality assessment were done independently and in duplicate. Main outcome measures: Maternal exposure to benzodiazepines in at least the first trimester; incidence of major malformations or oral cleft alone, measured as odds ratios and 95% confidence intervals with a random effects model. Results: Of over 1400 studies reviewed, 74 were retrieved and 23 included. In the analysis of cohort studies fetal exposure to benzodiazepine was not associated with major malformations (odds ratio 0.90; 95% confidence interval 0.61 to 1.35) or oral cleft (1.19; 0.34 to 4.15). Analysis of case-control studies showed an association between exposure to benzodiazepines and development of major malformations (3.01; 1.32 to 6.84) or oral cleft alone (1.79; 1.13 to 2.82). Conclusions: Pooled data fk om cohort studies showed no association between fetal exposure to benzodiazepines and the risk of major malformations or oral cleft On the basis of pooled data from case-control studies, however, there was a significant increased risk for major malformations or oral cleft alone. Until more research is reported, level 2 ultrasonography should be used to rule out risible forms of cleft lip.	Univ Toronto, Hosp Sick Children, Div Clin Pharmacol & Toxicol, Motherrisk Programme, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Fac Pharm, Toronto, ON M5S 2S2, Canada; Univ Toronto, Fac Pharm, Toronto, ON M5S 2S2, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Koren, G (corresponding author), Univ Toronto, Hosp Sick Children, Div Clin Pharmacol & Toxicol, Motherrisk Programme, Toronto, ON M5G 1X8, Canada.		Addis, Antonio/J-7894-2016; Koren, Gideon/AAG-7726-2019; Addis, Antonio/K-1865-2019	Addis, Antonio/0000-0003-0962-9959; Koren, Gideon/0000-0002-9234-0875; Addis, Antonio/0000-0003-0962-9959; Dolovich, Lisa/0000-0002-0061-6783				Altshuler LL, 1996, AM J PSYCHIAT, V153, P592; BEALL JR, 1972, CAN MED ASSOC J, V106, P1061; BERGMAN U, 1992, LANCET, V340, P694, DOI 10.1016/0140-6736(92)92232-5; BRACKEN MB, 1981, OBSTET GYNECOL, V58, P336; CHESLEY S, 1991, NEUROPHARMACOLOGY, V30, P53, DOI 10.1016/0028-3908(91)90042-A; CORREAVILLASENOR A, 1994, TERATOLOGY, V50, P137, DOI 10.1002/tera.1420500208; CROMBIE DL, 1975, NEW ENGL J MED, V293, P198; Czeizel A, 1987, Reprod Toxicol, V1, P183; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; GREENBERG G, 1977, BRIT MED J, V2, P853, DOI 10.1136/bmj.2.6091.853; GREGROIRE G, 1994, PHARMACOEPIDEM DR S, V3, pS18; HARTZ SC, 1975, NEW ENGL J MED, V292, P726, DOI 10.1056/NEJM197504032921405; Heinonen OP, 1977, BIRTH DEFECTS DRUGS; HORWITZ RI, 1979, AM J MED, V66, P556, DOI 10.1016/0002-9343(79)91164-1; JICK H, 1981, JAMA-J AM MED ASSOC, V246, P343, DOI 10.1001/jama.246.4.343; KULLANDER S, 1976, ACTA OBSTET GYN SCAN, V55, P25, DOI 10.3109/00016347609156779; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LAEGREID L, 1987, LANCET, V1, P108; LAEGREID L, 1989, J PEDIATR-US, V114, P126, DOI 10.1016/S0022-3476(89)80619-5; LAEGREID L, 1992, NEUROPEDIATRICS, V23, P60, DOI 10.1055/s-2008-1071314; LAEGREID L, 1990, DEV MED CHILD NEUROL, V32, P432; LEVINE M, 1994, JAMA-J AM MED ASSOC, V271, P1615, DOI 10.1001/jama.271.20.1615; MCELHATTON PR, 1994, REPROD TOXICOL, V8, P461, DOI 10.1016/0890-6238(94)90029-9; MILKOVICH L, 1974, NEW ENGL J MED, V291, P1268, DOI 10.1056/NEJM197412122912402; MILLER RP, 1975, TOXICOL APPL PHARM, V32, P53, DOI 10.1016/0041-008X(75)90194-5; NAKANE Y, 1980, EPILEPSIA, V21, P663, DOI 10.1111/j.1528-1157.1980.tb04320.x; NOYA CA, 1981, REV CUBANA HIG EPIDE, V19, P200; ORNOY A, 1997, TERATOLOGY, V55, pA102; PASTUSZAK A, 1996, CAN J CLIN PHARM, V3, P167; ROBERT E, 1986, EUR NEUROL, V25, P436, DOI 10.1159/000116048; RODRIGUEZ PE, 1986, MED CLIN, V87, P741; ROSENBERG L, 1983, NEW ENGL J MED, V309, P1282, DOI 10.1056/NEJM198311243092103; SAFRA MJ, 1975, LANCET, V2, P478; Samren EB, 1997, EPILEPSIA, V38, P981, DOI 10.1111/j.1528-1157.1997.tb01480.x; SAXEN I, 1975, LANCET, V2, P498; SAXEN I, 1974, TERATOLOGY, V9, P217, DOI 10.1002/tera.1420090213; SHIONO PH, 1984, NEW ENGL J MED, V311, P919; SKRABANEK P, 1992, LANCET, V340, P1208, DOI 10.1016/0140-6736(92)92902-R; St Clair Sheri M., 1992, Obstetrics and Gynecology, V80, P843; TIKKANEN J, 1992, TERATOLOGY, V46, P447, DOI 10.1002/tera.1420460509; VIGGEDAL G, 1993, J CHILD PSYCHOL PSYC, V34, P295, DOI 10.1111/j.1469-7610.1993.tb00993.x; WALKER BE, 1974, TERATOLOGY, V10, P159, DOI 10.1002/tera.1420100212; WINSHIP KA, 1984, ARCH DIS CHILD, V59, P1052, DOI 10.1136/adc.59.11.1052; WINTER RM, 1987, LANCET, V1, P627	45	171	178	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	1998	317	7162					839	+		10.1136/bmj.317.7162.839	http://dx.doi.org/10.1136/bmj.317.7162.839			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748174	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000076222300014
J	Hibble, A; Kanka, D; Pencheon, D; Pooles, F				Hibble, A; Kanka, D; Pencheon, D; Pooles, F			Guidelines in general practice: the new Tower of Babel?	BRITISH MEDICAL JOURNAL			English	Article									Fulbourne Hosp, NHS Execut Anglia & Oxford, Gen Practice Off, Cambridge CB1 5RB, England; Fulbourne Hosp, Cambridge & Huntingdon Hlth Author, Cambridge CB1 5RB, England; Univ Forvie Site, Inst Publ Hlth, Cambridge CB2 2SR, England	University of Cambridge	Hibble, A (corresponding author), Fulbourne Hosp, NHS Execut Anglia & Oxford, Gen Practice Off, Cambridge CB1 5RB, England.							Field MJ., 1992, GUIDELINES CLIN PRAC; FRY J, 1993, GEN PRACTICE FACTS; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; *U LEEDS NUFF I HL, 1994, B U LEEDS, V8	4	104	105	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1998	317	7162					862	863		10.1136/bmj.317.7162.862	http://dx.doi.org/10.1136/bmj.317.7162.862			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748185	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000076222300022
J	Migliorini, F; Michel, P; Morbidelli, A; Nesvorny, D; Zappala, V				Migliorini, F; Michel, P; Morbidelli, A; Nesvorny, D; Zappala, V			Origin of multikilometer Earth- and Mars-crossing asteroids: A quantitative simulation	SCIENCE			English	Article							LINEAR SECULAR RESONANCES; SEMIMAJOR AXES SMALLER; MAIN BELT; 2 AU; COMETS; REGION	Orbital dynamic simulations show that many asteroids in the main asteroid belt are driven toward Mars-crossing orbits by numerous weak mean motion resonances, which slowly increase the orbital ellipticity of the asteroids. In addition, half of the Mars-crossing asteroids (MCAs) transition to Earth-crossing asteroids (ECAs) in less than 20 million years. This scenario quantitatively explains the observed number of large ECAs and MCAs.	Observ Cote Azur, F-06304 Nice 4, France; Osservatorio Astron Torino, I-10025 Pino Torinese, Italy; Armagh Observ, Coll Hill BT61 9DG, North Ireland	UDICE-French Research Universities; Universite Cote d'Azur; Observatoire de la Cote d'Azur; Istituto Nazionale Astrofisica (INAF)	Morbidelli, A (corresponding author), Observ Cote Azur, BP 4229, F-06304 Nice 4, France.		Michel, Patrick/AGX-0167-2022	Michel, Patrick/0000-0002-0884-1993				BOWELL E, 1994, IAU SYMP, P477; Gladman BJ, 1997, SCIENCE, V277, P197, DOI 10.1126/science.277.5323.197; GREENBERG R, 1989, ASTEROIDS, V2, P778; Jedicke R, 1998, ICARUS, V131, P245, DOI 10.1006/icar.1997.5876; LEVISON HF, 1994, ICARUS, V108, P18, DOI 10.1006/icar.1994.1039; Lupishko DF, 1998, PLANET SPACE SCI, V46, P47, DOI 10.1016/S0032-0633(97)00132-3; Menichella M, 1996, EARTH MOON PLANETS, V72, P133, DOI 10.1007/BF00117512; Michel P, 1997, ICARUS, V128, P230, DOI 10.1006/icar.1997.5727; Michel P, 1997, ICARUS, V129, P348, DOI 10.1006/icar.1997.5780; MILANI A, 1994, ICARUS, V107, P219, DOI 10.1006/icar.1994.1020; MORBIDELLI A, IN PRESS ICARUS; NESVORNY D, IN PRESS ASTRON J; Valsecchi GB, 1997, ASTRON ASTROPHYS, V323, P986; Zappala V, 1996, ASTR SOC P, V107, P29	14	86	86	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					2022	2024		10.1126/science.281.5385.2022	http://dx.doi.org/10.1126/science.281.5385.2022			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748160				2022-12-28	WOS:000076161800054
J	Lees, KR				Lees, KR			Multifactorial approach to stroke investigation and prevention	LANCET			English	Editorial Material									Univ Glasgow, Western Infirm, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Lees, KR (corresponding author), Univ Glasgow, Western Infirm, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland.							Bath P, 1997, BRIT MED J, V315, P1167; Caplan LR, 1998, J NEUROL NEUROSUR PS, V64, P716, DOI 10.1136/jnnp.64.6.716; Curb JD, 1996, ARTERIOSCL THROM VAS, V16, P1495, DOI 10.1161/01.ATV.16.12.1495; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Sandercock P, 1997, LANCET, V349, P1569; WEIR CJ, 1994, LANCET, V344, P999, DOI 10.1016/S0140-6736(94)91648-9; Yamamoto H, 1998, J NEUROL NEUROSUR PS, V64, P771, DOI 10.1136/jnnp.64.6.771	7	6	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 19	1998	352	9132					923	924		10.1016/S0140-6736(05)61509-7	http://dx.doi.org/10.1016/S0140-6736(05)61509-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752812				2022-12-28	WOS:000076002200005
J	Rao, VD; Misra, S; Boronenkov, IV; Anderson, RA; Hurley, JH				Rao, VD; Misra, S; Boronenkov, IV; Anderson, RA; Hurley, JH			Structure of type II beta phosphatidylinositol phosphate kinase: A protein kinase fold flattened for interfacial phosphorylation	CELL			English	Article							MULTIPLE ISOMORPHOUS REPLACEMENT; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; PHOSPHOLIPASE-C; INOSITOL TRISPHOSPHATE; DIFFRACTION DATA; 5-KINASE; FAMILY; 3-KINASE; DOMAIN	Phosphoinositide kinases play central roles in signal transduction by phosphorylating the inositol ring at specific positions. The structure of one such enzyme, type I1 beta phosphatidylinositol phosphate kinase, reveals a protein kinase ATP-binding core and demonstrates that all phosphoinositide kinases belong to one superfamily. The enzyme is a disc-shaped homodimer with a 33 x 48 Angstrom basic flat face that suggests an electrostatic mechanism for plasma membrane targeting. Conserved basic residues form a putative phosphatidylinositol phosphate specificity site. The substrate-binding site is open on one side, consistent with dual specificity for phosphatidylinositol 3- and 5-phosphates. A modeled complex with membrane-bound substrate and ATP shows how a phosphoinositide kinase can phosphorylate its substrate in situ at the membrane interface.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Wisconsin System; University of Wisconsin Madison	Hurley, JH (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.			Anderson, Richard/0000-0001-6265-8359; Misra, Saurav/0000-0002-1385-8554	NIGMS NIH HHS [GM51968, GM57549] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051968] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1996, XPLOR VERSION 3 8; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; *COLL COMP PROJ, 1994, ACTA CRYSTALLOGR D, V50, P670; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hinchliffe K, 1997, NATURE, V390, P123, DOI 10.1038/36458; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Hon WC, 1997, CELL, V89, P887, DOI 10.1016/S0092-8674(00)80274-3; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Hurley JH, 1997, CURR OPIN STRUC BIOL, V7, P557, DOI 10.1016/S0959-440X(97)80122-4; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V24, P946; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEARSON RH, 1979, NATURE, V281, P499, DOI 10.1038/281499a0; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WONG K, 1994, J BIOL CHEM, V269, P2881; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	57	182	188	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					829	839		10.1016/S0092-8674(00)81741-9	http://dx.doi.org/10.1016/S0092-8674(00)81741-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753329	Bronze			2022-12-28	WOS:000076021200015
J	Boyle, P; Horton, R; Radda, G; Sharp, D; Veronesi, U; Walker, AM				Boyle, P; Horton, R; Radda, G; Sharp, D; Veronesi, U; Walker, AM			Open debate on hormone-replacement therapy	LANCET			English	Editorial Material							METAANALYSIS		European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy; The Lancet, London, England; MRC, London, England; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	IRCCS European Institute of Oncology (IEO); Harvard University; Harvard T.H. Chan School of Public Health	Boyle, P (corresponding author), European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy.		Boyle, Peter/A-4380-2014	Boyle, Peter/0000-0001-6251-0610				[Anonymous], 1997, LANCET, V350, P675; Bailar JC, 1997, NEW ENGL J MED, V337, P559, DOI 10.1056/NEJM199708213370810; Naylor CD, 1997, BMJ-BRIT MED J, V315, P617, DOI 10.1136/bmj.315.7109.617; *NIH CONS DEV PAN, 1995, NIH CONS DEV C STAT	4	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					836	836		10.1016/S0140-6736(05)60003-7	http://dx.doi.org/10.1016/S0140-6736(05)60003-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742975				2022-12-28	WOS:000075857300005
J	Turner, RC; Holman, RR; Stratton, IM; Cull, CA; Matthews, DR; Manley, SE; Frighi, V; Wright, D; Neil, A; Kohner, E; McElroy, H; Fox, C; Hadden, D				Turner, RC; Holman, RR; Stratton, IM; Cull, CA; Matthews, DR; Manley, SE; Frighi, V; Wright, D; Neil, A; Kohner, E; McElroy, H; Fox, C; Hadden, D		UK Prospective Diabet Study Grp	Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)	LANCET			English	Article							BIGUANIDES; NIDDM	Background In patients with type 2 diabetes, intensive blood-glucose control with insulin or sulphonylurea therapy decreases progression of microvascular disease and may also reduce the risk of heart attacks. This study investigated whether intensive glucose control with metformin has any specific advantage or disadvantage. Methods Of 4075 patients recruited to UKPDS in 15 centres, 1704 overweight (>120% ideal bodyweight) patients with newly diagnosed type 2 diabetes, mean age 53 years, had raised fasting plasma glucose (FPG; 6.1-15.0 mmol/L) without hyperglycaemic symptoms after 3 months' initial diet. 753 were included in a randomised controlled trial, median duration 10.7 years, of conventional policy, primarily with diet alone (n=411) versus intensive blood-glucose control policy with metformin, aiming for FPG below 6 mmol/L (n=342). A secondary analysis compared the 342 patients allocated metformin with 951 overweight patients allocated intensive blood-glucose control with chlorpropamide (n=265), glibenclamide (n=277), or insulin (n=409). The primary outcome measures were aggregates of any diabetes-related clinical endpoint, diabetes-related death, and all-cause mortality. In a supplementary randomised controlled trial, 537 non-overweight and overweight patients, mean age 59 years, who were already on maximum sulphonylurea therapy but had raised FPG (6.1-15.0 mmol/L), were allocated continuing sulphonylurea therapy alone (n=269) or addition of metformin (n=268). Findings Median glycated haemoglobin (HbA(1c)) was 7.4% in the metformin group compared with 8.0% in the conventional group. Patients allocated metformin, compared with the conventional group, had risk reductions of 32% (95% CI 13-47, p=0.002) for any diabetes-related endpoint, 42% for diabetes-related death (9-63, p=0.017), and 36% for all-cause mortality (9-55, p=0.011). Among patients allocated intensive blood-glucose control, metformin showed a greater effect than chlorpropamide, glibenclamide, or insulin for any diabetes-related endpoint (p=0.0034), all-cause mortality (p=0.021), and stroke (p=0.032). Early addition of metformin in sulphonyl urea-treated patients was associated with an increased risk of diabetes-related death (96% increased risk [95% CI 2-275], p=0.039) compared with continued sulphonylurea alone. A combined analysis of the main and supplementary studies showed fewer metformin-allocated patients having diabetes-related endpoints (risk reduction 19% [2-33], p=0.033). Epidemiological assessment of the possible association of death from diabetes-related causes with the concurrent therapy of diabetes in 4416 patients did not show an increased risk in diabetes-related death in patients treated with a combination of sulphonylurea and metformin (risk reduction 5% [-33 to 32], p=0.78). Interpretation Since intensive glucose control with metformin appears to decrease the risk of diabetes-related endpoints in overweight diabetic patients, and is associated with less weight gain and fewer hypoglycaemic attacks than are insulin and sulphonylureas, it may be the first-line pharmacological therapy of choice in these patients.	Radcliffe Infirm, Diabet Res Labs, UKPDS Grp, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Turner, RC (corresponding author), Radcliffe Infirm, Diabet Res Labs, UKPDS Grp, Woodstock Rd, Oxford OX2 6HE, England.		Frighi, Valeria/AAD-2648-2022; stratton, irene/AAZ-3627-2020	Frighi, Valeria/0000-0001-8177-8778; stratton, irene/0000-0003-1172-7865; Manley, Susan/0000-0002-8298-4511				[Anonymous], 1995, Diabetes, V44, P1249; BAILEY CJ, 1992, DIABETES CARE, V15, P755, DOI 10.2337/diacare.15.6.755; Bailey CJ, 1996, NEW ENGL J MED, V334, P574, DOI 10.1056/NEJM199602293340906; BEISSWENGER P, 1997, DIABETES S1, V46, pA74; Cusi K, 1996, J CLIN ENDOCR METAB, V81, P4059, DOI 10.1210/jc.81.11.4059; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATM EARL BREAST C; MANLEY SE, 1994, DIABETIC MED, V11, P534; Metropolitan Life Foundation New weight standards for men and women, 1959, STAT B, V40, P1; MODAN M, 1986, DIABETOLOGIA, V29, P82, DOI 10.1007/BF00456115; NAGI DK, 1993, DIABETES CARE, V16, P621, DOI 10.2337/diacare.16.4.621; NATTRASS M, 1978, DIABETOLOGIA, V14, P71, DOI 10.1007/BF01263443; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Rothman K, 1986, MODERN EPIDEMIOLOGY; The University Group Diabetes Program, 1975, DIABETES, V24, P65; Turner R, 1996, ANN INTERN MED, V124, P136, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00011; TURNER RC, 1991, DIABETOLOGIA, V34, P877; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Wright A, 1998, ANN INTERN MED, V128, P165, DOI 10.7326/0003-4819-128-3-199802010-00001; Wright AD, 1998, DIABETES CARE, V21, P87; Yki-Jarvinen H., 1996, Diabetologia, V39, pA33	20	6389	6665	17	364	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	1998	352	9131					854	865		10.1016/s0140-6736(98)07037-8	http://dx.doi.org/10.1016/s0140-6736(98)07037-8			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742977				2022-12-28	WOS:000075857300007
J	Robertson, IH; Mattingley, JB; Rorden, C; Driver, J				Robertson, IH; Mattingley, JB; Rorden, C; Driver, J			Phasic alerting of neglect patients overcomes their spatial deficit in visual awareness	NATURE			English	Article							SUSTAINED ATTENTION; UNILATERAL NEGLECT; FRONTAL LESIONS; MECHANISMS; EXTINCTION; ACTIVATION; AROUSAL; SYSTEMS	Patients with extensive damage to the right hemisphere of their brain often exhibit unilateral neglect of the left side of space. The spatial attention of these patients is strongly biased towards the right(1), so their awareness of visual events on the left is impaired(2). Extensive right-hemisphere lesions also impair tonic alertness (the ability to maintain arousal)(3-5). This nonspatial deficit in alertness is often considered to be a different problem from spatial neglect(5,6), but the two impairments may be linked(7,8). If so, then phasically increasing the patients' alertness should temporarily ameliorate their spatial bias in awareness. Here we provide evidence to support this theory. Right-hemisphere-neglect patients judged whether a visual event on the left preceded or followed a comparable event on the right. They became aware of left events half a second later than right events on average. This spatial imbalance in the time course of visual awareness was corrected when a warning sound alerted the patients phasically. Even a warning sound on the right accelerated the perception of left visual events in this way. Nonspatial phasic alerting can thus overcome disabling spatial biases in perceptual awareness after brain injury.	MRC, Cognit & Brain Sci Unit, Cambridge CB2 2EF, England; UCL, Inst Cognit Neurosci, London WC1E 6BT, England	University of London; University College London	Robertson, IH (corresponding author), MRC, Cognit & Brain Sci Unit, 15 Chaucer Rd, Cambridge CB2 2EF, England.		Driver, Jon/A-4779-2010; Mattingley, Jason/J-1537-2014	Mattingley, Jason/0000-0003-0929-9216; Rorden, Chris/0000-0002-7554-6142; Robertson, Ian H/0000-0001-8637-561X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CORBETTA M, 1993, J NEUROSCI, V13, P1202; Damasio Antonio, 1989, LESION ANAL NEUROPSY; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DIPELLEGRINO G, 1995, NEUROPSYCHOLOGIA, V33, P153, DOI 10.1016/0028-3932(94)00111-2; FernandezDuque D, 1997, NEUROPSYCHOLOGIA, V35, P477, DOI 10.1016/S0028-3932(96)00103-0; Hackley SA, 1998, NATURE, V391, P786, DOI 10.1038/35849; HEILMAN KM, 1979, NEUROPSYCHOLOGIA, V17, P315, DOI 10.1016/0028-3932(79)90077-0; HEILMAN KM, 1978, NEUROLOGY, V28, P229, DOI 10.1212/WNL.28.3.229; HEILMAN KM, 1987, HDB PHYSL 1, V5, P461; HOCKEY GRJ, 1970, Q J EXP PSYCHOL, V22, P28, DOI 10.1080/14640747008401898; Kinomura S, 1996, SCIENCE, V271, P512, DOI 10.1126/science.271.5248.512; Kinsbourne M., 1993, UNILATERAL NEGLECT C, DOI DOI 10.4324/9780203765258; MACKWORTH JF, 1968, PSYCHOL REV, V75, P308, DOI 10.1037/h0025896; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; Parasuraman R., 1987, REC RES PSY, P11, DOI 10.1007/978-1-4612-4756-2_2; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Paus T, 1997, J COGNITIVE NEUROSCI, V9, P392, DOI 10.1162/jocn.1997.9.3.392; Posner M.I., 1978, CHRONOMETRIC EXPLORA; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POSNER MI, 1987, PSYCHOBIOLOGY, V15, P107; ROBERTSON IH, 1995, J CLIN EXP NEUROPSYC, V17, P416, DOI 10.1080/01688639508405133; ROBERTSON IH, 1993, UNILATERAL NEGLECT C; ROBERTSON JH, 1997, NEUROPSYCHOLOGIA, V35, P1527; Rorden C, 1997, NEUROPSYCHOLOGIA, V35, P421, DOI 10.1016/S0028-3932(96)00093-0; Rueckert L, 1996, NEUROPSYCHOLOGIA, V34, P953, DOI 10.1016/0028-3932(96)00016-4; TAYLOR MM, 1967, J ACOUST SOC AM, V41, P782, DOI 10.1121/1.1910407; Titchener E. B., 1908, LECT ELEMENTARY PSYC, DOI 10.1037/10867-000; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8; Wilson B., 1988, BEHAV INATTENTION TE	29	411	413	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 10	1998	395	6698					169	172		10.1038/25993	http://dx.doi.org/10.1038/25993			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744274				2022-12-28	WOS:000075829900041
J	Andersen, RE; Franckowiak, SC; Snyder, J; Bartlett, SJ; Fontaine, KR				Andersen, RE; Franckowiak, SC; Snyder, J; Bartlett, SJ; Fontaine, KR			Can inexpensive signs encourage the use of stairs? Results from a community intervention	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICAL-ACTIVITY; HEALTH; EXERCISE	Background: The U.S. Surgeon General advocates the accumulation of moderate-intensity activity throughout the day to improve health. Objective: To test the effectiveness of signs to encourage use of stairs instead of escalators. Design: Community intervention. Setting: Shopping center. Participants: 17 901 shoppers. Intervention: Signs promoting the hearth and weight-control benefits of stair use were placed beside escalators with adjacent stairs. Measurements: The sex, age, race,weight classification, and use of stairs were observed. Results: Overall, stair use increased from 4.8% to 6.9% and 7.2% with the health and weight-control signs, respectively. Younger persons increased their stair use from 4.6% to 6.0% with the health sign and 6.1% with the weight-control sign. Older persons almost doubled their stair use from 5.1% to 8.1% with the health sign and increased use to 8.7% with the weight-control sign. Differential use of stairs was observed between ethnic groups. Among white persons, stair use increased from 5.1% to 7.5% and 7.8% with the health and weight-control signs, respectively. Among black persons, stair use decreased from 4.1% to 3.4% with the health sign and increased to 5.0% with the weight-control sign. At baseline, lean persons used the stairs more often than overweight persons (5.4% and 3.8%, respectively). The health sign increased stair use to 7.2% among normal-weight persons and 6.3% among overweight persons; the weight-control sign prompted stair use to increase to 6.9% among persons of normal weight and to 7.8% among overweight persons. Conclusions: Simple, inexpensive interventions can increase physical activity. Research is needed to identify effective motivators to promote activity among black persons.	Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Div Gastroenterol, Baltimore, MD 21224 USA; Johns Hopkins Weight Management Ctr, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Andersen, RE (corresponding author), Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, 5501 Hopkins Bayview Circle JHAAC SB-81, Baltimore, MD 21224 USA.	andersen@welchlink.welchjhu.edu	Bartlett, Susan J./J-9864-2012; Bartlett, Susan Joan/AAD-4103-2020	Bartlett, Susan Joan/0000-0001-9755-2490				Andersen RE, 1997, ANN INTERN MED, V127, P395, DOI 10.7326/0003-4819-127-5-199709010-00010; Andersen RE, 1998, JAMA-J AM MED ASSOC, V279, P938, DOI 10.1001/jama.279.12.938; ANDERSEN RE, 1995, MED EXERC NUTR HLTH, V4, P57; ANDERSEN RE, 1996, LIFESTYLE WEIGHT MAN, P95; BLACKBURN GL, 1995, EATING DISORDERS OBE, P406; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BLAIR SN, 1992, MED EXERCISE NUTRITI, V1, P54; BLAMEY A, 1995, BRIT MED J, V311, P289, DOI 10.1136/bmj.311.7000.289; BROWNELL KD, 1980, AM J PSYCHIAT, V137, P1540; BROWNELL KD, 1992, J CONSULT CLIN PSYCH, V60, P505, DOI 10.1037/0022-006X.60.4.505; *CDCP, 1994, BRFSS SUMM PREV REP; DUNN AL, IN PRESS AM J PREV M; Fletcher GF, 1996, CIRCULATION, V94, P857, DOI 10.1161/01.CIR.94.4.857; Gordon NF, 1993, J CARDIOPULM REHABIL, V13, P161, DOI DOI 10.1097/00008483-199305000-00001; HASKELL WL, 1994, MED SCI SPORT EXER, V26, P649, DOI 10.1249/00005768-199406000-00001; *INT COUNC SHOPP C, 1997, SCOP SHOPP CENT 1997, P3; KELLY RB, 1987, J FAM PRACTICE, V24, P630; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUTYLA D, 1994, ICSC RES Q, V1, P8; LOGSDON DN, 1989, AM J PREV MED, V5, P249, DOI 10.1016/S0749-3797(18)31065-1; MUTRIE N, 1997, AM COLL SPORTS MED P, P37; NORUSIS MJ, 1992, SPSS PC PLUS ADV STA; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; STAMFORD BA, 1988, EXERCISE SPORT SCI R, P341; STRAKOSCH GR, 1996, ELEVATOR WORLD, V44, P68; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, pR25; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P597; *US PUBL HLTH SERV, 1996, OFF SURG GEN PHYS AC	29	123	126	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1998	129	5					363	369		10.7326/0003-4819-129-5-199809010-00003	http://dx.doi.org/10.7326/0003-4819-129-5-199809010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114RL	9735063				2022-12-28	WOS:000075622600003
J	Bartus, RT; Tracy, MA; Emerich, DF; Zale, SE				Bartus, RT; Tracy, MA; Emerich, DF; Zale, SE			Sustained delivery of proteins for novel therapeutic products	SCIENCE			English	Article							HUMAN GROWTH-HORMONE; RELEASE; MODEL		Alkermes Inc, Cambridge, MA 02139 USA	Alkermes	Bartus, RT (corresponding author), Alkermes Inc, 64 Sidney St, Cambridge, MA 02139 USA.							Bawa R., 1985, J CONTR RELEASE, V1, P259, DOI [10.1016/0168-3659(85)90002-1, DOI 10.1016/0168-3659(85)90002-1]; Emerich DF, 1997, NATURE, V386, P395, DOI 10.1038/386395a0; Johnson OL, 1997, PHARM RES-DORDR, V14, P730, DOI 10.1023/A:1012142204132; Khan A, 1998, Patent No. [US 5 711 968, 5711968]; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; LANGER R, 1976, NATURE, V263, P797, DOI 10.1038/263797a0; Lee HJ, 1997, J PHARMACOL EXP THER, V281, P1431; LEE VHL, 1991, ADV PARENTERAL SCI, V4, P691; NAFFAKH N, 1995, P NATL ACAD SCI USA, V92, P3194, DOI 10.1073/pnas.92.8.3194; Nieforth KA, 1996, CLIN PHARMACOL THER, V59, P636, DOI 10.1016/S0009-9236(96)90003-X; SALTZMAN WM, 1989, BIOPHYS J, V55, P163, DOI 10.1016/S0006-3495(89)82788-2; Tracy MA, 1998, BIOTECHNOL PROGR, V14, P108, DOI 10.1021/bp9701271; Wall D.A., 1995, DRUG DELIV, V2, P1, DOI DOI 10.3109/10717549509031346; WRIGHT JC, 1997, P INT S CONTR REL BI, V24, P59; Zale S. E., 1997, US Patent, Patent No. [5,674,534, 5674534]; Zhang Y, 1997, J BIOMED MATER RES, V34, P531, DOI 10.1002/(SICI)1097-4636(19970315)34:4<531::AID-JBM13>3.0.CO;2-F; [No title captured]	17	94	108	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1161	1162		10.1126/science.281.5380.1161	http://dx.doi.org/10.1126/science.281.5380.1161			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9735031				2022-12-28	WOS:000075531200040
J	Berger, A				Berger, A			Science commentary: Extracorporeal membrane oxygenation	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					916	916						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756808				2022-12-28	WOS:000076409000022
J	Marnellos, G; Stoukides, M				Marnellos, G; Stoukides, M			Ammonia synthesis at atmospheric pressure	SCIENCE			English	Article							METHANE; OXIDE	Ammonia was synthesized from its elements at atmospheric pressure in a solid state proton (H+)-conducting cell-reactor. Hydrogen was flowing over the anode and was converted into protons that were transported through the solid electrolyte and reached the cathode (palladium) over which nitrogen was passing. At 570 degrees C and atmospheric pressure, greater than 78 percent of the electrochemically supplied hydrogen was converted into ammonia. The thermodynamic requirement for a high-pressure process is eliminated.	Aristotelian Univ Salonika, Dept Chem Engn, GR-54006 Salonika, Greece; Aristotelian Univ Salonika, Chem Proc Engn Res Inst, GR-54006 Salonika, Greece	Aristotle University of Thessaloniki; Aristotle University of Thessaloniki	Marnellos, G (corresponding author), Aristotelian Univ Salonika, Dept Chem Engn, GR-54006 Salonika, Greece.							Athanasiou C, 1996, IONICS, V2, P353, DOI 10.1007/BF02375813; CHIANG PH, 1993, SOLID STATE IONICS, V61, P99, DOI 10.1016/0167-2738(93)90340-9; GUR TM, 1983, SCIENCE, V219, P967, DOI 10.1126/science.219.4587.967; HAMAKAWA S, 1993, J ELECTROCHEM SOC, V140, P459, DOI 10.1149/1.2221068; Iwahara H, 1996, SOLID STATE IONICS, V86-8, P9, DOI 10.1016/0167-2738(96)00087-2; JIANG Y, 1994, SCIENCE, V264, P1563, DOI 10.1126/science.264.5165.1563; Panagos E, 1996, CHEM ENG SCI, V51, P3175, DOI 10.1016/0009-2509(96)00216-3; Satterfield C.N., 1980, HETEROGENEOUS CATALY, P301; STOUKIDES M, 1988, IND ENG CHEM RES, V27, P1745, DOI 10.1021/ie00082a002; Vayenas C.G., 1996, MOD ASPECT ELECTROC, V29, P57; VAYENAS CG, 1980, SCIENCE, V208, P593, DOI 10.1126/science.208.4444.593; [No title captured]	12	388	417	5	273	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 2	1998	282	5386					98	100		10.1126/science.282.5386.98	http://dx.doi.org/10.1126/science.282.5386.98			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756486				2022-12-28	WOS:000076294900046
J	Holt, PR; Atillasoy, EO; Gilman, J; Guss, J; Moss, SF; Newmark, H; Fan, KH; Yang, K; Lipkin, M				Holt, PR; Atillasoy, EO; Gilman, J; Guss, J; Moss, SF; Newmark, H; Fan, KH; Yang, K; Lipkin, M			Modulation of abnormal colonic epithelial cell proliferation and differentiation by low-fat dairy foods - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIETARY CALCIUM; FECAL WATER; CYTOLYTIC ACTIVITY; COLORECTAL-CANCER; LARGE-BOWEL; BILE-ACIDS; CARCINOGENESIS; MUCOSA; CHEMOPREVENTION; CYTOTOXICITY	Context.-Before the development of human colonic neoplasms, colonic epithelial cells showed altered growth and differentiation. These alterations characterized mucosa at risk for cancer formation and were termed intermediate biomarkers of risk. Modifications of the mucosa toward more normal features by nutrients or drugs are putative approaches to chemoprevention of colon cancer. Objective.-To determine whether increasing calcium intake via dairy products alters colonic biomarkers toward normal. Design.-Randomized, single-blind, controlled study. Setting.-Outpatient clinic. Participants.-Seventy subjects with a history of polypectomy for colonic adenomatous polyps. Intervention.-low-fat dairy products containing up to 1200 mg/d of calcium. Subjects were randomized to 4 strata by diet (control vs higher calcium) and age (<60 vs greater than or equal to 60 years). Main Outcome Measures.-Changes in total colonic epithelial cells and number and position of thymidine-labeled epithelial cells and changes in the ratio of sulfomucins (predominantly secreted by distal colorectal epithelial cells) to sialomucins and expression of cytokeratin AE1, 2 markers of colonic cell differentiation. Results.-During 6 and 12 months of treatment, reduction of colonic epithelial cell proliferative activity (P<.05), reduction in size of the proliferative compartment (P<.05), and restoration of acidic mucin (P<.02), cytokeratin AE1 distribution (P<.05), and nuclear size (P<.05) toward that of normal cells occurred. Control subjects showed no differences from baseline proliferative values at 6 and 12 months (P>.05). Conclusion.-Increasing the daily intake of calcium by up to 1200 mg via lowfat dairy food in subjects at risk for colonic neoplasia reduces proliferative activity of colonic epithelial cells and restores markers of normal cellular differentiation.	St Lukes Roosevelt Hosp, Dept Med, Gastrointestinal Div, New York, NY 10025 USA; Columbia Univ, New York, NY USA; Strang Canc Prevent Ctr, New York, NY USA; Cornell Univ, Med Ctr, New York Hosp, New York, NY 10021 USA	Mount Sinai St. Luke's; Mount Sinai West; Columbia University; Cornell University; NewYork-Presbyterian Hospital	Holt, PR (corresponding author), St Lukes Roosevelt Hosp, Dept Med, Gastrointestinal Div, 1111 Amsterdam Ave, New York, NY 10025 USA.			holt, peter/0000-0002-8469-2766				ABDELALI H, 1995, MUTAT RES-FUND MOL M, V331, P133, DOI 10.1016/0027-5107(95)00059-R; AMBROS RA, 1990, ANAL QUANT CYTOL, V12, P172; [Anonymous], 1994, NIH Consens Statement, V12, P1; ARENDS JW, 1984, BIOCHIM BIOPHYS ACTA, V780, P1, DOI 10.1016/0304-419X(84)90005-2; Baron JA, 1998, GASTROENTEROLOGY, V114, pA563, DOI 10.1016/S0016-5085(98)82289-0; BOSTICK RM, 1995, JNCI-J NATL CANCER I, V87, P1307, DOI 10.1093/jnci/87.17.1307; COOPER D, 1985, LAB INVEST, V52, P243; DArgenio G, 1996, GASTROENTEROLOGY, V110, P1727, DOI 10.1053/gast.1996.v110.pm8964397; Duris I, 1996, HEPATO-GASTROENTEROL, V43, P152; FILIPE MI, 1974, CANCER-AM CANCER SOC, V34, P282, DOI 10.1002/1097-0142(197408)34:2<282::AID-CNCR2820340211>3.0.CO;2-W; FLEISS J, 1986, DESIGN ANAL CLIN EXP, P49; GARINCHESA P, 1986, AM J SURG PATHOL, V10, P829; GARLAND C, 1985, LANCET, V1, P307, DOI 10.1016/S0140-6736(85)91082-7; Govers MJAP, 1996, CANCER RES, V56, P3270; HANSKI C, 1991, CANCER RES, V51, P5342; Holt PR, 1996, CANCER EPIDEM BIOMAR, V5, P937; LAPRE JA, 1993, CANCER RES, V53, P248; LAPRE JA, 1991, AM J PHYSIOL, V261, pG907, DOI 10.1152/ajpgi.1991.261.6.G907; Liew C, 1995, CARCINOGENESIS, V16, P3037, DOI 10.1093/carcin/16.12.3037; LIPKIN M, 1985, NEW ENGL J MED, V313, P1381, DOI 10.1056/NEJM198511283132203; LIPKIN M, 1995, JNCI-J NATL CANCER I, V87, P1275, DOI 10.1093/jnci/87.17.1275; LIPKIN M, 1991, CALCIUM VITAMIN D CO; MELING GI, 1991, CANCER, V67, P1642, DOI 10.1002/1097-0142(19910315)67:6<1642::AID-CNCR2820670628>3.0.CO;2-R; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MORSON B, 1974, P ROY SOC MED, V67, P451, DOI 10.1177/00359157740676P115; NEWMARK HL, 1995, J CELL BIOCHEM, P247; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PENCE BC, 1988, CARCINOGENESIS, V9, P187, DOI 10.1093/carcin/9.1.187; Pence BC, 1996, NUTR CANCER, V25, P35, DOI 10.1080/01635589609514426; RICHTER F, 1995, CARCINOGENESIS, V16, P2685, DOI 10.1093/carcin/16.11.2685; SAMS JS, 1990, CANCER, V66, P502, DOI 10.1002/1097-0142(19900801)66:3&lt;502::AID-CNCR2820660317&gt;3.0.CO;2-N; Schmelz EM, 1996, CANCER RES, V56, P4936; SLATTERY ML, 1988, AM J EPIDEMIOL, V128, P504, DOI 10.1093/oxfordjournals.aje.a114998; SUN TT, 1994, CANC CELLS TRANSFORM; VERHEST A, 1990, CANCER, V65, P2047, DOI 10.1002/1097-0142(19900501)65:9<2047::AID-CNCR2820650926>3.0.CO;2-4; *VIT HLTH STAT CTR, 1994, 3 NAT HLTH NUT EX SU, P255; WEISBURGER J, 1991, AM CANC SOC TXB CLIN; WELBERG JWM, 1993, EUR J CLIN INVEST, V23, P63, DOI 10.1111/j.1365-2362.1993.tb00719.x; Yang K, 1996, CANCER RES, V56, P4644	39	111	114	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 30	1998	280	12					1074	1079		10.1001/jama.280.12.1074	http://dx.doi.org/10.1001/jama.280.12.1074			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FJ	9757855				2022-12-28	WOS:000076002400036
J	Berger, A				Berger, A			Action on clinical audit: progress report 2	BMJ-BRITISH MEDICAL JOURNAL			English	Article									BMJ, London WC1H 9JR, England		Berger, A (corresponding author), BMJ, London WC1H 9JR, England.							Berger A, 1998, BMJ-BRIT MED J, V316, P1893; Miller E, 1998, BRIT MED J, V316, P875, DOI 10.1136/bmj.316.7135.875	2	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	1998	317	7162					880	881		10.1136/bmj.317.7162.880	http://dx.doi.org/10.1136/bmj.317.7162.880			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748193	Green Published			2022-12-28	WOS:000076222300029
J	Shahidullah, M				Shahidullah, M			Mainuddin Ahmed - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1998	317	7162					889	889		10.1136/bmj.317.7162.889	http://dx.doi.org/10.1136/bmj.317.7162.889			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748198	Green Published			2022-12-28	WOS:000076222300049
J	Kirschenbaum, LA; Astiz, ME; Rackow, EC				Kirschenbaum, LA; Astiz, ME; Rackow, EC			Interpretation of blood lactate concentrations in patients with sepsis	LANCET			English	Editorial Material							SEPTIC SHOCK; OXYGEN DELIVERY; CONSUMPTION; PYRUVATE		New York Med Coll, St Vincent Hosp & Med Ctr, Dept Med, New York, NY 10011 USA	New York Medical College; Saint Vincents Hospital Manhattan	Kirschenbaum, LA (corresponding author), New York Med Coll, St Vincent Hosp & Med Ctr, Dept Med, New York, NY 10011 USA.							ASTIZ M, 1988, CIRC SHOCK, V26, P311; Astiz ME, 1998, LANCET, V351, P1501, DOI 10.1016/S0140-6736(98)01134-9; ASTIZ ME, 1987, CRIT CARE MED, V15, P26, DOI 10.1097/00003246-198701000-00005; BAKKER J, 1991, CHEST, V99, P956, DOI 10.1378/chest.99.4.956; Bakker J, 1996, AM J SURG, V171, P221, DOI 10.1016/S0002-9610(97)89552-9; BRODER G, 1964, SCIENCE, V143, P1457, DOI 10.1126/science.143.3613.1457; FRIEDMAN G, 1995, CRIT CARE MED, V23, P1184, DOI 10.1097/00003246-199507000-00006; Levraut J, 1998, AM J RESP CRIT CARE, V157, P1021, DOI 10.1164/ajrccm.157.4.9705037; RONCO JJ, 1993, AM REV RESPIR DIS, V147, P25, DOI 10.1164/ajrccm/147.1.25; SCHAEFER CF, 1991, J SURG RES, V51, P382, DOI 10.1016/0022-4804(91)90138-C; SIEGEL JH, 1979, SURGERY, V86, P163; VARY TC, 1986, AM J PHYSIOL, V250, pE634, DOI 10.1152/ajpendo.1986.250.6.E634; VINCENT JL, 1983, CRIT CARE MED, V11, P449, DOI 10.1097/00003246-198306000-00012; VITEK V, 1971, ANN SURG, V173, P308, DOI 10.1097/00000658-197102000-00021; WEIL MH, 1970, CIRCULATION, V41, P989, DOI 10.1161/01.CIR.41.6.989	15	17	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 19	1998	352	9132					921	922		10.1016/S0140-6736(05)61507-3	http://dx.doi.org/10.1016/S0140-6736(05)61507-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752810				2022-12-28	WOS:000076002200003
J	Bruijn, LI; Houseweart, MK; Kato, S; Anderson, KL; Anderson, SD; Ohama, E; Reaume, AG; Scott, RW; Cleveland, DW				Bruijn, LI; Houseweart, MK; Kato, S; Anderson, KL; Anderson, SD; Ohama, E; Reaume, AG; Scott, RW; Cleveland, DW			Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1	SCIENCE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CU,ZN SUPEROXIDE-DISMUTASE; OXIDATIVE DAMAGE; MICE; INCLUSIONS; MUTATION; DISEASE; GENE; DEGENERATION; PROPERTY	Analysis of transgenic mice expressing familiar amyotrophic Lateral sclerosis (ALS)-linked mutations in the enzyme superoxide dismutase (SOD1) have shown that motor neuron death arises from a mutant-mediated toxic property or properties. In testing the disease mechanism, both elimination and elevation of wild-type SOD1 were found to have no effect on mutant-mediated disease, which demonstrates that the use of SOD mimetics is unlikely to be an effective therapy and raises the question of whether toxicity arises from superoxide-mediated oxidative stress. Aggregates containing SOD1 were common to disease caused by different mutants, implying that coaggregation of an unidentified essential component or components or aberrant catalysis by misfolded mutants underlies a portion of mutant-mediated toxicity.	Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Tottori Univ, Fac Med, Dept Neuropathol, Inst Neurol Sci, Yonago, Tottori 683, Japan; Cephalon, W Chester, PA 19380 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Tottori University; Teva Pharmaceutical Industries; Cephalon Inc.	Cleveland, DW (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.		Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027036, R37NS027036] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 27036] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEAL MF, 1997, ANN NEUROL, V42, P646; BECHER M, COMMUNICATION; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; Bruijn LI, 1997, P NATL ACAD SCI USA, V94, P7606, DOI 10.1073/pnas.94.14.7606; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Chou SM, 1996, J CHEM NEUROANAT, V10, P249, DOI 10.1016/0891-0618(96)00137-8; Chou SM, 1996, J NEUROL SCI, V139, P16, DOI 10.1016/0022-510X(96)00090-1; Corson LB, 1998, P NATL ACAD SCI USA, V95, P6361, DOI 10.1073/pnas.95.11.6361; DalCanto MC, 1997, ACTA NEUROPATHOL, V93, P537; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DURHAM HD, 1997, J NEUROPATHOL EXP NE, V56, P52; Ferrante RJ, 1997, ANN NEUROL, V42, P326, DOI 10.1002/ana.410420309; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Kato S, 1996, J NEUROPATH EXP NEUR, V55, P1089, DOI 10.1097/00005072-199655100-00009; Kato S, 1997, AM J PATHOL, V151, P611; Liochev SI, 1997, ARCH BIOCHEM BIOPHYS, V346, P263, DOI 10.1006/abbi.1997.0298; OREELL R, 1995, NATURE, V274, P504; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SHIBATA N, 1994, NEUROSCI LETT, V179, P149, DOI 10.1016/0304-3940(94)90956-3; Shibata N, 1996, DEV NEUROSCI-BASEL, V18, P492, DOI 10.1159/000111445; Shibata N, 1996, J NEUROPATH EXP NEUR, V55, P481, DOI 10.1097/00005072-199604000-00011; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P6675, DOI 10.1073/pnas.95.12.6675; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Williamson TL, 1998, P NATL ACAD SCI USA, V95, P9631, DOI 10.1073/pnas.95.16.9631; WILLIAMSON TL, UNPUB; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Yim HS, 1997, J BIOL CHEM, V272, P8861	31	948	986	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1851	1854		10.1126/science.281.5384.1851	http://dx.doi.org/10.1126/science.281.5384.1851			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743498				2022-12-28	WOS:000076007100053
J	Yoshida, H; Kong, YY; Yoshida, R; Elia, AJ; Hakem, A; Hakem, R; Penninger, JM; Mak, TW				Yoshida, H; Kong, YY; Yoshida, R; Elia, AJ; Hakem, A; Hakem, R; Penninger, JM; Mak, TW			Apaf1 is required for mitochondrial pathways of apoptosis and brain development	CELL			English	Article							PROGRAMMED CELL-DEATH; C-ELEGANS; CAENORHABDITIS-ELEGANS; CYTOCHROME-C; PROTEASE ACTIVATION; NEGATIVE SELECTION; SIGNALING COMPLEX; GENE CED-3; BCL-2; SURVIVAL	Apoptosis is essential for the precise regulation of cellular homeostasis and development. The role in vivo of Apaf1, a mammalian homolog of C. elegans CED-4, was investigated in gene-targeted Apaf1(-/-) mice. Apaf1-deficient mice exhibited reduced apoptosis in the brain and striking craniofacial abnormalities with hyperproliferation of neuronal cells. Apaf1-deficient cells were resistant to a variety of apoptotic stimuli, and the processing of Caspases 2, 3, and 8 was impaired. However, both Apaf1(-/-) thymocytes and activated T lymphocytes were sensitive to Fas-induced killing, showing that Fas-mediated apoptosis in these cells is independent of Apaf1. These data indicate that Apaf1 plays a central role in the common events of mitochondria-dependent apoptosis in most death pathways and that this role is critical for normal development.	Amgen Inst, Toronto, ON, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Mak, TW (corresponding author), Amgen Inst, 620 Univ Ave, Toronto, ON, Canada.		Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777; Hakem, Razqallah/0000-0001-5948-7931				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CAVINESS VS, 1995, TRENDS NEUROSCI, V18, P379, DOI 10.1016/0166-2236(95)93933-O; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Clarke PGH, 1996, ANAT EMBRYOL, V193, P81; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FADOK VA, 1992, J IMMUNOL, V148, P2207; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HORVITZ HR, 1983, COLD SPRING HARB SYM, V48, P453, DOI 10.1101/SQB.1983.048.01.050; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Shimizu S, 1996, ONCOGENE, V13, P21; Shortman K, 1990, Semin Immunol, V2, P3; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TAKAHASHI T, 1995, J NEUROSCI, V15, P6046; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Thornberry NA, 1998, CHEM BIOL, V5, pR97, DOI 10.1016/S1074-5521(98)90615-9; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weller M, 1997, J NEURAL TRANSM-SUPP, P115; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	64	958	995	1	46	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1998	94	6					739	750		10.1016/S0092-8674(00)81733-X	http://dx.doi.org/10.1016/S0092-8674(00)81733-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753321	Bronze			2022-12-28	WOS:000076021200007
J	Cook, DJ; Walter, SD; Cook, RJ; Griffith, LE; Guyatt, GH; Leasa, D; Jaeschke, RZ; Brun-Buisson, C				Cook, DJ; Walter, SD; Cook, RJ; Griffith, LE; Guyatt, GH; Leasa, D; Jaeschke, RZ; Brun-Buisson, C		Canadian Critical Care Trials Grp	Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients	ANNALS OF INTERNAL MEDICINE			English	Article						ventilators, mechanical; pneumonia; cross-infection; time factors	NOSOCOMIAL MAXILLARY SINUSITIS; INTENSIVE-CARE UNITS; RECEIVING MECHANICAL VENTILATION; PREVIOUS ANTIMICROBIAL THERAPY; INTUBATED PATIENTS; PSEUDOMONAS-AERUGINOSA; MULTIVARIATE-ANALYSIS; ENTERAL NUTRITION; MORTALITY; INFECTION	Background: Understanding the risk factors for ventilator-associated pneumonia can help to assess prognosis and devise and test preventive strategies. Objective: To examine the baseline and time-dependent risk factors for ventilator-associated pneumonia and to determine the conditional probability and cumulative risk over the duration of stay in the intensive care unit. Design: Prospective cohort study. Setting: 16 intensive care units in Canada. Patients: 1014 mechanically ventilated patients. Measurements: Demographic and time-dependent variables reflecting illness severity, ventilation, nutrition, and drug exposure. Pneumonia was classified by using five methods: adjudication committee, bedside clinician's diagnosis, Centers for Disease Control and Prevention definition, Clinical Pulmonary Infection score, and positive culture from bronchoalveolar lavage or protected specimen brush. Results: 177 of 1014 patients (17.5%) developed ventilator-associated pneumonia 9.0 +/- 5.9 days (median, 7 days [interquartile range, 5 to 10 days]) after admission to the intensive care unit. Although the cumulative risk increased over time, the daily hazard rate decreased after day 5 (3.3% at day 5, 2.3% at day 10, and 1.3% at day 15). independent predictors of ventilator-associated pneumonia in multivariable analysis were a primary admitting diagnosis of burns (risk ratio, 5.09 [95% CI, 1.52 to 17.03]), trauma (risk ratio, 5.00 [CI, 1.91 to 13.11]), central nervous system disease (risk ratio, 3.40 [CI, 1.31 to 8.81]), respiratory disease (risk ratio, 2.79 [CI, 1.04 to 7.51]), cardiac disease (risk ratio, 2.72 [CI, 1.05 to 7.01]), mechanical ventilation in the previous 24 hours (risk ratio, 2.28 [CI, 1.11 to 4.68]), witnessed aspiration (risk ratio, 3.25 [CI, 1.62 to 6.50]), and paralytic agents (risk ratio, 1.57 [CI, 1.03 to 2.39]). Exposure to antibiotics conferred protection (risk ratio, 0.37 [CI, 0.27 to 0.51]). Independent risk factors were the same regardless of the pneumonia definition used. Conclusions: The daily risk for pneumonia decreases with increasing duration of stay in the intensive care unit. Witnessed aspiration and exposure to paralytic agents are potentially modifiable independent risk factors. Exposure to antibiotics was associated with low rates of early ventilator-associated pneumonia, but this effect attenuates over time.	McMaster Univ, Med Ctr, Dept Clin Epidemiol, Hamilton, ON L8N 3Z5, Canada; Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON N2L 3G1, Canada; Univ Paris 12, Hop Henri Mondor, Dept Med Intens Care, F-94010 Creteil, France; Univ Paris 12, Hop Henri Mondor, Infect Control Unit, F-94010 Creteil, France; Univ Western Ontario, London, ON, Canada	McMaster University; University of Waterloo; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Western University (University of Western Ontario)	Cook, DJ (corresponding author), St Josephs Hosp, Dept Med, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	debcook@fhs.csu.mcmaster.ca	Walter, Stephen/AAB-5548-2022	Walter, Stephen/0000-0003-4157-8928; Cook, Richard/0000-0002-1414-4908				Alvarez-lerma F, 1997, CLIN INTENSIVE CARE, V8, P164; [Anonymous], 1989, AM REV RESPIR DIS, V139, P1058; ATHERTON ST, 1978, LANCET, V2, P968; Baraibar J, 1997, CHEST, V112, P1050, DOI 10.1378/chest.112.4.1050; Bonten MJM, 1997, CLIN INFECT DIS, V24, P309, DOI 10.1093/clinids/24.3.309; BRAUN SR, 1986, CRIT CARE MED, V14, P198, DOI 10.1097/00003246-198603000-00006; Brewer C, 1996, CHEST, V109, P1019; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; CHASTRE J, 1994, AM J RESP CRIT CARE, V150, P570, DOI 10.1164/ajrccm.150.2.8049850; CHEVRET S, 1993, INTENS CARE MED, V19, P256, DOI 10.1007/BF01690545; Cook, 1997, Crit Care, V1, P3, DOI 10.1186/cc1; Cook D, 1998, NEW ENGL J MED, V338, P791, DOI 10.1056/NEJM199803193381203; Cook D, 1998, JAMA-J AM MED ASSOC, V279, P781, DOI 10.1001/jama.279.10.781; Cook DJ, 1998, JAMA-J AM MED ASSOC, V279, P1605, DOI 10.1001/jama.279.20.1605; COOK DJ, 1994, AM J RESP CRIT CARE, V149, pA640; CRAVEN DE, 1988, ARCH INTERN MED, V148, P1161, DOI 10.1001/archinte.148.5.1161; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; Cunnion KM, 1996, AM J RESP CRIT CARE, V153, P158, DOI 10.1164/ajrccm.153.1.8542110; Elatrous S, 1996, CLIN INTENSIVE CARE, V7, P276, DOI DOI 10.3109/TCIC.7.6.276.281; Fagon JY, 1996, JAMA-J AM MED ASSOC, V275, P866, DOI 10.1001/jama.275.11.866; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; HANSON LC, 1992, AM J MED, V92, P161, DOI 10.1016/0002-9343(92)90107-M; HEYLAND D, 1992, CHEST, V101, P187, DOI 10.1378/chest.101.1.187; HOLZAPFEL L, 1993, CRIT CARE MED, V21, P1132, DOI 10.1097/00003246-199308000-00010; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; IBANEZ J, 1992, JPEN-PARENTER ENTER, V16, P419, DOI 10.1177/0148607192016005419; JOSHI N, 1992, AM J MED, V93, P135, DOI 10.1016/0002-9343(92)90042-A; KOLLEF MH, 1995, CHEST, V108, P1655, DOI 10.1378/chest.108.6.1655; Kollef MH, 1997, CHEST, V112, P765, DOI 10.1378/chest.112.3.765; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; Kropec A, 1996, INTENS CARE MED, V22, P1155, DOI 10.1007/BF01709329; LANGER M, 1989, AM REV RESPIR DIS, V140, P302, DOI 10.1164/ajrccm/140.2.302; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; LIBERATI A, 1997, ACUTE RESP INFECT MO, V3, P1; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; MICHELSON A, 1991, ANAESTHESIST, V40, P100; MONTECALVO MA, 1992, CRIT CARE MED, V20, P1377, DOI 10.1097/00003246-199210000-00004; MOSCONI P, 1991, EUR J EPIDEMIOL, V7, P320, DOI 10.1007/BF00144995; NIEDERMAN MS, 1994, AM J RESP CRIT CARE, V150, P565, DOI 10.1164/ajrccm.150.2.8049849; OROZCOLEVI M, 1995, AM J RESP CRIT CARE, V152, P1387, DOI 10.1164/ajrccm.152.4.7551400; Papazian L, 1996, AM J RESP CRIT CARE, V154, P91, DOI 10.1164/ajrccm.154.1.8680705; PINGLETON SK, 1986, AM J MED, V80, P827, DOI 10.1016/0002-9343(86)90623-6; PUGIN J, 1991, AM REV RESPIR DIS, V143, P1121, DOI 10.1164/ajrccm/143.5_Pt_1.1121; RELLO J, 1992, CHEST, V102, P1562, DOI 10.1378/chest.102.5.1562; RELLO J, 1994, INTENS CARE MED, V20, P193, DOI 10.1007/BF01704699; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; Rello J, 1996, AM J RESP CRIT CARE, V154, P111, DOI 10.1164/ajrccm.154.1.8680665; ROUBY JJ, 1994, AM J RESP CRIT CARE, V150, P776, DOI 10.1164/ajrccm.150.3.8087352; SALORD F, 1990, INTENS CARE MED, V16, P390, DOI 10.1007/BF01735177; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Timsit JF, 1996, AM J RESP CRIT CARE, V154, P116, DOI 10.1164/ajrccm.154.1.8680666; TIMSIT JF, 1995, CHEST, V108, P1036, DOI 10.1378/chest.108.4.1036; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639	55	588	623	0	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1998	129	6					433	440		10.7326/0003-4819-129-6-199809150-00002	http://dx.doi.org/10.7326/0003-4819-129-6-199809150-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JJ	9735080				2022-12-28	WOS:000075892100001
J	Laramore, GE; Stelzer, KJ				Laramore, GE; Stelzer, KJ			Radiation therapy for benign disease: an old area revisited	LANCET			English	Editorial Material							IRRADIATION; RESTENOSIS; PREVENTION; PARADIGM		Univ Washington, Med Ctr, Dept Radiat Oncol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Laramore, GE (corresponding author), Univ Washington, Med Ctr, Dept Radiat Oncol, Seattle, WA 98195 USA.							Brady LW, 1997, INT J RADIAT ONCOL, V39, P945, DOI 10.1016/S0360-3016(97)00708-6; Brenner DJ, 1996, INT J RADIAT ONCOL, V36, P805, DOI 10.1016/S0360-3016(96)00414-2; BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5; Carter AJ, 1996, INT J RADIAT ONCOL, V36, P797, DOI 10.1016/S0360-3016(96)00410-5; CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265; Fajardo LF, 1998, INT J RADIAT ONCOL, V40, P761; Gregoritch SJ, 1996, INT J RADIAT ONCOL, V36, P981, DOI 10.1016/S0360-3016(96)00442-7; Koh WJ, 1996, INT J RADIAT ONCOL, V36, P829, DOI 10.1016/S0360-3016(96)00408-7; Mazur W, 1996, INT J RADIAT ONCOL, V36, P777, DOI 10.1016/S0360-3016(96)00298-2; OGILVY CS, 1990, NEUROSURGERY, V26, P725, DOI 10.1227/00006123-199005000-00001; ORDER SE, 1990, RAD THERAPY BENIGN D; Popowski Y, 1996, INT J RADIAT ONCOL, V36, P923, DOI 10.1016/S0360-3016(96)00409-9; Rubin P, 1998, INT J RADIAT ONCOL, V40, P929, DOI 10.1016/S0360-3016(97)00937-1; SCHWARTZ RS, 1992, J AM COLL CARDIOL, V20, P1284, DOI 10.1016/0735-1097(92)90389-5; STALMAN SP, 1997, RETINA, V17, P481; WAKSMAN R, 1995, CIRCULATION, V91, P1533, DOI 10.1161/01.CIR.91.5.1533	16	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	1998	352	9131					834	835		10.1016/S0140-6736(05)60001-3	http://dx.doi.org/10.1016/S0140-6736(05)60001-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742973				2022-12-28	WOS:000075857300003
J	Chow, P; Kiat, TC; Choo, TB; Machin, D				Chow, P; Kiat, TC; Choo, TB; Machin, D			Tamoxifen in hepatocellular carcinoma	LANCET			English	Letter							RECEPTOR		Singapore Gen Hosp, Dept Surg, Singapore 169608, Singapore; Singapore Gen Hosp, Dept Gastroenterol, Singapore 169608, Singapore; Minist Hlth, Clin Trials & Epidemiol Res Unit, Singapore, Singapore	Singapore General Hospital; Singapore General Hospital; Ministry of Health-Singapore	Chow, P (corresponding author), Singapore Gen Hosp, Dept Surg, Singapore 169608, Singapore.			pignata, sandro/0000-0002-8836-2633; GALLO, CIRO/0000-0002-7939-3104; Chow, Pierce/0000-0003-0584-2584; Crisanti, Andrea/0000-0002-2406-4426				BOIX L, 1993, J HEPATOL, V17, P187, DOI 10.1016/S0168-8278(05)80036-4; BOIX L, 1995, J HEPATOL, V17, P87; Gallo C, 1998, LANCET, V352, P17; GELMANN EP, 1997, SEMIN ONCOL, V24, pS165; Jiang SY, 1995, J HEPATOL, V23, P712, DOI 10.1016/0168-8278(95)80038-7; Villa E, 1996, CANCER RES, V56, P3883	6	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					819	820		10.1016/S0140-6736(05)60715-5	http://dx.doi.org/10.1016/S0140-6736(05)60715-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737316				2022-12-28	WOS:000075762700055
J	Harmer, M				Harmer, M			One fortunate old man	LANCET			English	Editorial Material									Perrot Wood, Petworth GU28 ONZ, Sussex, England		Harmer, M (corresponding author), Perrot Wood, Petworth GU28 ONZ, Sussex, England.							COOMBE C, 1813, MED T R COLL PHYSICS, V4, P16; CROHN BB, 1932, JAMA-J AM MED ASSOC, P99; DALZEIL TK, 1913, BRIT MED J, V2, P1068; HARMER M, 1986, LANCET, V2, P94; HARMER M, 1956, LANCET, V1, P106; HARMER MH, 1988, BRISTOL MED CHIRURG, P103; 1955, LANCET, V2, P1283	7	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					813	814		10.1016/S0140-6736(98)06442-3	http://dx.doi.org/10.1016/S0140-6736(98)06442-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737305				2022-12-28	WOS:000075762700044
J	Pincus, T; Esther, R; DeWalt, DA; Callahan, LF				Pincus, T; Esther, R; DeWalt, DA; Callahan, LF			Social conditions and self-management are more powerful determinants of health than access to care	ANNALS OF INTERNAL MEDICINE			English	Article							FORMAL EDUCATION LEVEL; CORONARY HEART-DISEASE; BRITISH CIVIL-SERVANTS; RHEUMATOID-ARTHRITIS; UNITED-STATES; ALAMEDA COUNTY; MORTALITY DIFFERENCES; SOCIOECONOMIC-STATUS; INCOME-DISTRIBUTION; CLINICAL STATUS	Professional organizations advocate universal access to medical care as a primary approach to improving health in the population. Access to medical services is critical to outcomes of acute processes managed in an inpatient hospital, the setting of most medical education, research, and training, but seems to be limited in its capacity to affect outcomes of outpatient care, the setting of most medical activities. Persistent and widening disparities in health according to socioeconomic status provide evidence of limitations of access to care. First, job classification, a measure of socioeconomic status, was a better predictor of cardiovascular death than cholesterol level, blood pressure, and smoking combined in employed London civil servants with universal access to the National Health Service. Second, disparities in health according to socioeconomic status widened between 1970 and 1980 in the United Kingdom despite universal access (similar trends were seen in the United States). Third, in the United States, noncompletion of high school is a greater risk factor than biological factors for development of many diseases, an association that is explained only in part by age, ethnicity, sex, or smoking status. Fourth, level of formal education predicted cardiovascular mortality better than random assignment to active drug or placebo over 3 years in a clinical trial that provides optimal access to care. Increased recognition of limitations of universal access by physicians and their professional societies may enhance efforts to improve the health of the population.	Vanderbilt Univ, Sch Med, Div Rheumatol & Immunol, Nashville, TN 37232 USA; Univ N Carolina, Thurston Arthrit Res Ctr, Sheps Ctr Hlth Serv, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Thurston Arthrit Res Ctr, Sheps Ctr Hlth Serv, Dept Epidemiol, Chapel Hill, NC 27599 USA	Vanderbilt University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Pincus, T (corresponding author), Vanderbilt Univ, Sch Med, Div Rheumatol & Immunol, 203 Oxford House,1313 21st Ave S, Nashville, TN 37232 USA.		Callahan, Leigh/X-3799-2018	Callahan, Leigh/0000-0001-6362-7220; DeWalt, Darren/0000-0003-2270-751X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR030701] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR30701] Funding Source: Medline; PHS HHS [21393] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ackerknecht Erwin, 1953, R VIRCHOW DOCTOR STA; ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; *AM COLL PHYS, 1997, ANN INTERN MED, V127, P485; *AM COLL PHYS, 1990, ANN INTERN MED, V112, P641; ANTONOVSKY A, 1968, J CHRON DIS, V21, P65, DOI 10.1016/0021-9681(68)90098-2; ARAKI S, 1986, SOC SCI MED, V23, P1163, DOI 10.1016/0277-9536(86)90335-7; BANDURA A, 1982, AM PSYCHOL, V37, P122, DOI 10.1037/0003-066X.37.2.122; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; BLAXTER M, 1987, LANCET, V2, P30; Callahan L F, 1989, Arthritis Care Res, V2, P122, DOI 10.1002/anr.1790020406; Callahan LF, 1996, ARTHRIT CARE RES, V9, P463, DOI 10.1002/art.1790090608; CALLAHAN LF, 1990, ARTHRITIS RHEUM, V33, P407, DOI 10.1002/art.1780330315; CALLAHAN LF, 1988, ARTHRITIS RHEUM-US, V31, P1346, DOI 10.1002/art.1780311102; DeFriese G., 1994, AGING QUALITY LIFE, P99; DEFRIESE GH, 1989, SOC SCI MED, V29, P195, DOI 10.1016/0277-9536(89)90167-6; DENNIS BH, 1993, INT J EPIDEMIOL, V22, P420, DOI 10.1093/ije/22.3.420; DEVELLIS RF, 1993, J RHEUMATOL, V20, P866; DIDERICHSEN F, 1990, SOC SCI MED, V31, P359, DOI 10.1016/0277-9536(90)90283-X; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; EPSTEIN AM, 1988, NEW ENGL J MED, V318, P1579, DOI 10.1056/NEJM198806163182405; FEIN O, 1995, J GEN INTERN MED, V10, P577, DOI 10.1007/BF02640369; FEINSTEIN JS, 1993, MILBANK Q, V71, P279, DOI 10.2307/3350401; FELDMAN JJ, 1989, AM J EPIDEMIOL, V129, P919, DOI 10.1093/oxfordjournals.aje.a115225; FRUGER JM, 1998, ARCH INTERN MED, V158, P1245; FUCHS VR, 1979, MILBANK FUND Q, V57, P153, DOI 10.2307/3349761; Gillum RF, 1997, ANN INTERN MED, V127, P111, DOI 10.7326/0003-4819-127-2-199707150-00003; GREENBERGER NJ, 1990, ANN INTERN MED, V112, P637, DOI 10.7326/0003-4819-112-9-637; GROSSMAN M, 1975, HOUSEHOLD PRODUCTION; GURALNIK JM, 1989, AM J PUBLIC HEALTH, V79, P703, DOI 10.2105/AJPH.79.6.703; HAAN M, 1987, AM J EPIDEMIOL, V125, P989, DOI 10.1093/oxfordjournals.aje.a114637; HANNAN MT, 1992, J CLIN EPIDEMIOL, V45, P139, DOI 10.1016/0895-4356(92)90006-9; HINKLE LE, 1968, SCIENCE, V161, P238, DOI 10.1126/science.161.3838.238; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; Kaplan GA, 1996, BRIT MED J, V312, P999; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; KITAGAWA WM, 1973, DIFFERENTIAL MORTALI, P1; KOGEVINAS M, 1991, J EPIDEMIOL COMMUN H, V45, P216, DOI 10.1136/jech.45.3.216; KROENKE K, 1989, AM J MED, V86, P262, DOI 10.1016/0002-9343(89)90293-3; KUNST AE, 1994, AM J PUBLIC HEALTH, V84, P932, DOI 10.2105/AJPH.84.6.932; KUNST AE, 1990, SOC SCI MED, V31, P141, DOI 10.1016/0277-9536(90)90055-W; LAGASSE R, 1990, SOC SCI MED, V31, P237, DOI 10.1016/0277-9536(90)90270-3; LAHELMA E, 1990, SOC SCI MED, V31, P257, DOI 10.1016/0277-9536(90)90272-T; LATOUR J, 1991, J CLIN EPIDEMIOL, V44, P889, DOI 10.1016/0895-4356(91)90051-A; LAVECCHIA C, 1987, J EPIDEMIOL COMMUN H, V41, P161, DOI 10.1136/jech.41.2.161; LEBOWITZ MD, 1977, J CHRON DIS, V30, P599, DOI 10.1016/0021-9681(77)90058-3; LEIGH JP, 1994, INT J AGING HUM DEV, V39, P233, DOI 10.2190/XQXR-UTGP-WA8X-9FQJ; LEIGH JP, 1991, J RHEUMATOL, V18, P24; LEVIN LS, 1976, PUBLIC HEALTH REP, V91, P206; LORIG K, 1993, HEALTH EDUC QUART, V20, P17, DOI 10.1177/109019819302000104; LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403; Lynch JW, 1997, NEW ENGL J MED, V337, P1889, DOI 10.1056/NEJM199712253372606; MACINTYRE S, 1993, J SOC POLICY, V22, P213, DOI 10.1017/S0047279400019310; Marmot M., 1995, SOC HLTH, P172; MARMOT MG, 1983, J PSYCHOSOM RES, V27, P377, DOI 10.1016/0022-3999(83)90069-7; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; MARMOT MG, 1986, LANCET, V2, P274; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; MASEIDE P, 1990, SOC SCI MED, V31, P331, DOI 10.1016/0277-9536(90)90280-6; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PEARCE NE, 1985, J EPIDEMIOL COMMUN H, V39, P9, DOI 10.1136/jech.39.1.9; PINCUS T, 1988, J RHEUMATOL, V15, P1457; PINCUS T, 1994, J CLIN EPIDEMIOL, V47, P355, DOI 10.1016/0895-4356(94)90156-2; PINCUS T, 1985, J CHRON DIS, V38, P973, DOI 10.1016/0021-9681(85)90095-5; PINCUS T, 1987, J CHRON DIS, V40, P865, DOI 10.1016/0021-9681(87)90186-X; PINCUS T, 1996, BULLETIN, V40, P5; Pincus T., 1995, ADVANCES, V11, P4; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; *SELF CAR I, 1996, DEM MAN HDB; Seligman M. E., 1975, HELPLESSNESS DEPRESS; SISKIND V, 1987, COMMUNITY HEALTH ST, V11, P15; SOBEL DS, 1995, PSYCHOSOM MED, V57, P234, DOI 10.1097/00006842-199505000-00005; STANSFELD SA, 1993, J PSYCHOSOM RES, V37, P227, DOI 10.1016/0022-3999(93)90031-A; STANSFELD SA, 1992, PSYCHOL MED, V22, P739, DOI 10.1017/S0033291700038186; STARR P, 1992, LOGIC HLTH CARE REFO; Stein CM, 1997, CLIN PHARMACOL THER, V61, P1, DOI 10.1016/S0009-9236(97)90175-2; WHITE L, 1994, J CLIN EPIDEMIOL, V47, P363, DOI 10.1016/0895-4356(94)90157-0; Wilkinson R., 1997, UNHEALTHY SOC AFFLIC; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; WOLFE F, 1994, ARTHRITIS RHEUM-US, V37, P481, DOI 10.1002/art.1780370408; *WORK GROUP IN HLT, 1980, IN HLTH REP RES WORK	80	182	183	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1998	129	5					406	411		10.7326/0003-4819-129-5-199809010-00011	http://dx.doi.org/10.7326/0003-4819-129-5-199809010-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	114RL	9735069				2022-12-28	WOS:000075622600009
J	Adams, JM; Cory, S				Adams, JM; Cory, S			The Bcl-2 protein family: Arbiters of cell survival	SCIENCE			English	Review							MICROSATELLITE MUTATOR PHENOTYPE; RECEPTOR-DEFICIENT MICE; SCHIZOSACCHAROMYCES-POMBE; C-ELEGANS; CAENORHABDITIS-ELEGANS; HEMATOPOIETIC-CELLS; PROMOTING PROTEINS; POLYCYSTIC KIDNEY; CYCLE PROGRESSION; SOMATIC MUTATIONS	Bcl-2 and related cytoplasmic proteins are key regulators of apoptosis, the cell suicide program critical for development, tissue homeostasis, and protection against pathogens. Those most similar to Bcl-2 promote cell survival by inhibiting adapters needed for activation of the proteases (caspases) that dismantle the cell. More distant relatives instead promote apoptosis, apparently through mechanisms that include displacing the adapters from the pro-survival proteins. Thus, for many but not all apoptotic signals, the balance between these competing activities determines cell fate. Bcl-2 family members are essential for maintenance of major organ systems, and mutations affecting them are implicated in cancer.	Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	Walter & Eliza Hall Institute	Adams, JM (corresponding author), Walter & Eliza Hall Inst Med Res, Post Off Royal Melbourne Hosp, Parkville, Vic 3050, Australia.		Adams, Jerry M/E-1199-2013; Cory, Suzanne/E-1642-2013	Cory, Suzanne/0000-0002-6818-3451; Adams, Jerry/0000-0002-4360-8628	NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER; NCI NIH HHS [CA43540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOYD JM, 1995, ONCOGENE, V11, P1921; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Chaudhary D, 1998, J BIOL CHEM, V273, P17708, DOI 10.1074/jbc.273.28.17708; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; CORY S, 1994, COLD SPRING HARB SYM, V59, P365, DOI 10.1101/SQB.1994.059.01.041; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Cory S, 1998, BBA-REV CANCER, V1377, pR25, DOI 10.1016/S0304-419X(98)00003-1; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; delPeso L, 1997, SCIENCE, V278, P687; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Haldar S, 1997, CANCER RES, V57, P229; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; Jurgensmeier JM, 1997, MOL BIOL CELL, V8, P325; KAMADA S, 1995, CANCER RES, V55, P354; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KOZOPAS KM, 1993, P NATL ACAD SC IUS, V903, P516; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lam M, 1998, J BIOL CHEM, V273, P17307, DOI 10.1074/jbc.273.28.17307; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIN EY, 1993, J IMMUNOL, V151, P1979; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Ng FWH, 1998, J BIOL CHEM, V273, P3140, DOI 10.1074/jbc.273.6.3140; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PRINT C, UNPUB; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Ross AJ, 1998, NAT GENET, V18, P251, DOI 10.1038/ng0398-251; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shindler KS, 1997, J NEUROSCI, V17, P3112; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1997, BBA-REV CANCER, V1333, pF151, DOI 10.1016/S0304-419X(97)00019-X; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TANAKA S, 1992, BLOOD, V79, P229; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Uhlmann EJ, 1996, CANCER RES, V56, P2506; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yamamoto H, 1997, CANCER RES, V57, P4420; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	108	4562	4882	4	377	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1322	1326		10.1126/science.281.5381.1322	http://dx.doi.org/10.1126/science.281.5381.1322			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9735050				2022-12-28	WOS:000075666800042
J	Hahn, AF				Hahn, AF			Guillain-Barre syndrome	LANCET			English	Article							CAMPYLOBACTER-JEJUNI INFECTION; MOTOR AXONAL NEUROPATHY; MILLER-FISHER-SYNDROME; ACUTE IDIOPATHIC NEUROPATHY; MYELINATED NERVE-FIBERS; CYTOMEGALOVIRUS-INFECTION; PLASMA-EXCHANGE; SERUM IGG; ANTI-GM1 ANTIBODIES; INFLUENZA VACCINE	Guillain-Barre syndrome (GBS) is viewed as a reactive, self-limited, autoimmune disease triggered by a preceding bacterial or viral infection. Campylobacter jejuni, a major cause of bacterial gastroenteritis worldwide, is the most frequent antecedent pathogen. It is likely that immune responses directed towards the infecting organisms are involved in the pathogenesis of GBS by cross-reaction with neural tissues. The infecting organism induces humoral and cellular immune responses that, because of the sharing of homologous epitopes (molecular mimicry), cross-react with ganglioside surface components of peripheral nerves. Immune reactions against target epitopes in Schwann-cell surface membrane or myelin result in acute inflammatory demyelinating neuropathy (85% of cases); reactions against epitopes contained in the axonal membrane cause the acute axonal forms of GBS (15% of cases). Care for such patients may be challenging, yet the prognosis overall is favourable. Optimal supportive care and anticipation and prevention of complications are the mainstay of therapy. Admission to the intensive-care unit is necessary In 33% of patients who require intubation and assisted ventilation. Immunomodulation with infusions of IgG or plasma exchange treatments foreshorten the disease course.	Univ Western Ontario, London Hlth Sci Ctr, Clin Neurol Sci, London, ON N6A 5A5, Canada	London Health Sciences Centre; Western University (University of Western Ontario)	Hahn, AF (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, Clin Neurol Sci, 339 Windermere Rd, London, ON N6A 5A5, Canada.	angelika.hahn@lhsc.on.ca						Annane D, 1997, ANN NEUROL, V41, P298; [Anonymous], 1978, Ann Neurol, V3, P565; [Anonymous], 1993, Lancet, V341, P586; ARNASON BGW, 1975, PERIPHERAL NEUROPATH, P1437; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; ASBURY AK, 1969, MEDICINE, V48, P173, DOI 10.1097/00005792-196905000-00001; Beghi E, 1996, BRAIN, V119, P2053; BEGHI E, 1985, ARCH NEUROL-CHICAGO, V42, P1053, DOI 10.1001/archneur.1985.04060100035016; Berciano J, 1997, MUSCLE NERVE, V20, P846; BERGER JR, 1987, ANN NEUROL, V22, P393, DOI 10.1002/ana.410220322; Blaser MJ, 1997, J INFECT DIS, V176, pS103, DOI 10.1086/513780; BOS AP, 1987, INTENS CARE MED, V13, P328, DOI 10.1007/BF00255788; BOUCQUEY D, 1991, J NEUROL SCI, V104, P56, DOI 10.1016/0022-510X(91)90216-T; BROWN WF, 1993, MUSCLE NERVE, V16, P200, DOI 10.1002/mus.880160214; BROWN WF, 1984, BRAIN, V107, P219, DOI 10.1093/brain/107.1.219; CHIBA A, 1993, NEUROLOGY, V43, P1911, DOI 10.1212/WNL.43.10.1911; CHIBA A, 1992, ANN NEUROL, V31, P677, DOI 10.1002/ana.410310619; CORNBLATH DR, 1990, ANN NEUROL, V27, pS17, DOI 10.1002/ana.410270706; CORNBLATH DR, 1988, ANN NEUROL, V23, P354, DOI 10.1002/ana.410230407; daSilveira CM, 1997, LANCET, V349, P14, DOI 10.1016/S0140-6736(96)07408-9; FEASBY TE, 1993, J NEUROL SCI, V116, P185, DOI 10.1016/0022-510X(93)90324-R; FEASBY TE, 1986, BRAIN, V109, P1115, DOI 10.1093/brain/109.6.1115; FISHER M, 1956, NEW ENGL J MED, V255, P57, DOI 10.1056/NEJM195607122550201; FULLER GN, 1992, J NEUROL NEUROSUR PS, V55, P1079, DOI 10.1136/jnnp.55.11.1079; GANSER AL, 1984, J NEUROSCI RES, V12, P245, DOI 10.1002/jnr.490120212; Giovannoni G, 1996, CURR OPIN NEUROL, V9, P165, DOI 10.1097/00019052-199606000-00004; Govoni V, 1996, J NEUROL SCI, V137, P62, DOI 10.1016/0022-510X(95)00333-W; GREGSON NA, 1991, J NEUROL, V238, P447, DOI 10.1007/BF00314652; Gregson NA, 1997, J NEUROIMMUNOL, V73, P28, DOI 10.1016/S0165-5728(96)00162-2; GREGSON NA, 1993, Q J MED, V86, P111; GRIFFIN JW, 1995, BRAIN, V118, P577, DOI 10.1093/brain/118.3.577; Griffin JW, 1996, J NEUROCYTOL, V25, P33, DOI 10.1007/BF02284784; Griffin JW, 1996, ANN NEUROL, V39, P17, DOI 10.1002/ana.410390105; HaferMacko C, 1996, ANN NEUROL, V40, P635, DOI 10.1002/ana.410400414; HaferMacko CE, 1996, ANN NEUROL, V39, P627, DOI 10.1002/ana.410390512; HAHN AF, 1996, CRIT CARE NEUROL, V5, P627; HARTUNG HP, 1995, MUSCLE NERVE, V18, P137, DOI 10.1002/mus.880180202; HARTUNG HP, 1995, MUSCLE NERVE, V18, P154, DOI 10.1002/mus.880180203; HEMACHUDHA T, 1988, NEUROLOGY, V38, P375, DOI 10.1212/WNL.38.3.375; Ho TW, 1997, NEUROLOGY, V48, P717, DOI 10.1212/WNL.48.3.717; Ho TW, 1997, NEUROLOGY, V48, P695, DOI 10.1212/WNL.48.3.695; HO TW, 1995, BRAIN, V118, P597, DOI 10.1093/brain/118.3.597; HONAVAR M, 1991, BRAIN, V114, P1245, DOI 10.1093/brain/114.3.1245; Hughes R, 1996, BRIT MED J, V312, P1475; Hughes RAC, 1997, LANCET, V349, P225; Hughes RAC, 1997, J INFECT DIS, V176, pS92, DOI 10.1086/513793; HUGHES RAC, 1990, GUILLAINBARRE SYNDRO; Irie S, 1996, J NEUROIMMUNOL, V68, P19, DOI 10.1016/0165-5728(96)00059-8; Jacobs BC, 1997, J NEUROL NEUROSUR PS, V62, P641, DOI 10.1136/jnnp.62.6.641; JACOBS BC, 1995, ANN NEUROL, V37, P260, DOI 10.1002/ana.410370218; Jacobs BC, 1996, ANN NEUROL, V40, P181, DOI 10.1002/ana.410400209; Jiang GX, 1997, J NEUROL NEUROSUR PS, V62, P447, DOI 10.1136/jnnp.62.5.447; KAPLAN JE, 1983, NEUROLOGY, V33, P633, DOI 10.1212/WNL.33.5.633; Kinnunen E, 1998, AM J EPIDEMIOL, V147, P69; KLEYWEG RP, 1991, J NEUROL NEUROSUR PS, V54, P957, DOI 10.1136/jnnp.54.11.957; Kornberg AJ, 1996, NEUROLOGY, V47, P1317, DOI 10.1212/WNL.47.5.1317; KUROKI S, 1993, ANN NEUROL, V33, P243, DOI 10.1002/ana.410330304; MCKHANN, 1985, NEUROLOGY, V35, P1096; MCKHANN GM, 1988, ANN NEUROL, V23, P347, DOI 10.1002/ana.410230406; MCKHANN GM, 1993, ANN NEUROL, V33, P333, DOI 10.1002/ana.410330402; MISHU B, 1993, ANN INTERN MED, V118, P947, DOI 10.7326/0003-4819-118-12-199306150-00006; NG KKP, 1995, QJM-INT J MED, V88, P243; Nishimura M, 1997, J NEUROL SCI, V153, P91, DOI 10.1016/S0022-510X(97)00170-6; OGAWAGOTO K, 1994, J NEUROIMMUNOL, V55, P55, DOI 10.1016/0165-5728(94)90146-5; Olive JA, 1997, J INFECT DIS, V175, pS160, DOI 10.1093/infdis/175.Supplement_1.S160; OOMES PG, 1995, ANN NEUROL, V38, P170, DOI 10.1002/ana.410380208; Powell HC, 1996, ANN NEUROL, V39, P4, DOI 10.1002/ana.410390103; Prevots DR, 1997, J INFECT DIS, V175, pS151, DOI 10.1093/infdis/175.Supplement_1.S151; PRINEAS JW, 1981, ANN NEUROL, V9, P6, DOI 10.1002/ana.410090704; RAPHAEL JC, 1992, ANN NEUROL, V32, P94; RAPHAEL JC, 1987, ANN NEUROL, V22, P753; REES JH, 1995, NEW ENGL J MED, V333, P1374, DOI 10.1056/NEJM199511233332102; REES JH, 1995, ANN NEUROL, V38, P809, DOI 10.1002/ana.410380516; REES JH, 1996, J NEUROL NEUROSUR PS, V61, P215; ROBERTS M, 1995, ANN NEUROL, V38, P111, DOI 10.1002/ana.410380118; ROBERTS M, 1994, LANCET, V343, P454, DOI 10.1016/S0140-6736(94)92694-8; ROPPER AH, 1992, NEW ENGL J MED, V326, P1130, DOI 10.1056/NEJM199204233261706; ROSCELLI JD, 1991, AM J EPIDEMIOL, V133, P952, DOI 10.1093/oxfordjournals.aje.a115974; RUDNICKI S, 1992, MUSCLE NERVE, V15, P57, DOI 10.1002/mus.880150111; SAFRANEK TJ, 1991, AM J EPIDEMIOL, V133, P940, DOI 10.1093/oxfordjournals.aje.a115973; Salisbury DM, 1998, LANCET, V351, P79, DOI 10.1016/S0140-6736(05)78156-3; SCHLUEP M, 1988, NEUROLOGY, V38, P1890, DOI 10.1212/WNL.38.12.1890; TAKIGAWA T, 1995, ANN NEUROL, V37, P436, DOI 10.1002/ana.410370405; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; VISSER LH, 1994, ANN NEUROL, V35, P749; Visser LH, 1996, NEUROLOGY, V47, P668, DOI 10.1212/WNL.47.3.668; VISSER LH, 1995, BRAIN, V118, P841, DOI 10.1093/brain/118.4.841; WALSH FS, 1991, J NEUROIMMUNOL, V34, P43, DOI 10.1016/0165-5728(91)90097-Q; Willison HJ, 1997, J INFECT DIS, V176, pS144, DOI 10.1086/513799; WILLISON HJ, 1993, J NEUROL NEUROSUR PS, V56, P204, DOI 10.1136/jnnp.56.2.204; WINER JB, 1988, J NEUROL NEUROSUR PS, V51, P613, DOI 10.1136/jnnp.51.5.613; WINER JB, 1988, J NEUROL NEUROSUR PS, V51, P605, DOI 10.1136/jnnp.51.5.605; YUKI N, 1992, MUSCLE NERVE, V15, P899, DOI 10.1002/mus.880150806; YUKI N, 1992, BIOMED RES-TOKYO, V13, P451, DOI 10.2220/biomedres.13.451; Yuki N, 1997, J INFECT DIS, V176, pS150, DOI 10.1086/513800; Yuki N, 1997, ANN NEUROL, V42, P28, DOI 10.1002/ana.410420107; Yuki N, 1996, J NEUROIMMUNOL, V71, P155, DOI 10.1016/S0165-5728(96)00142-7; YUKI N, 1993, J EXP MED, V178, P1771, DOI 10.1084/jem.178.5.1771; YUKI N, 1990, NEUROLOGY, V40, P1900, DOI 10.1212/WNL.40.12.1900	99	287	298	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 22	1998	352	9128					635	641		10.1016/S0140-6736(97)12308-X	http://dx.doi.org/10.1016/S0140-6736(97)12308-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746040				2022-12-28	WOS:000075567400042
J	Sills, ES; Strider, W; Hyde, HJ; Anker, D; Rees, GJ; Davis, OK				Sills, ES; Strider, W; Hyde, HJ; Anker, D; Rees, GJ; Davis, OK			Gynaecology, forced sterilisation, and asylum in the USA	LANCET			English	Article									Cornell Univ, Med Ctr, New York Hosp, Dept Obstet & Gynecol, New York, NY 10021 USA; NYU, Downtown Hosp, Dept Obstet & Gynecol, New York, NY USA; US House Representatives, Judiciary Comm, Washington, DC 20515 USA; Harvard Univ, Sch Law, Cambridge, MA 02138 USA; US House Representatives, Int Relat Comm, Washington, DC 20515 USA	Cornell University; NewYork-Presbyterian Hospital; New York University; Harvard University	Sills, ES (corresponding author), Ctr Reprod Hlth, 326 21st Ave N, Nashville, TN 37203 USA.		Sills, E Scott/AAQ-8463-2020	Sills, E Scott/0000-0001-7334-1031				*AM COLL OBST GYN, 1995, ACOG TECHN B, V209, P1; AUDET AM, 1995, ANN INTERN MED, V122, P607, DOI 10.7326/0003-4819-122-8-199504150-00009; GREENHALGH S, 1994, POPUL DEV REV, V20, P365, DOI 10.2307/2137523; *PEOPL REP CHIN MI, 1988, CHIN STAT HLTH DIG 1, P235; POSTEL E, 1996, POPULATION WOMEN, P81; RASMUSSEN OV, 1990, DAN MED B, V30, P1	6	3	3	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 6	1998	351	9117					1729	1730		10.1016/S0140-6736(98)30023-9	http://dx.doi.org/10.1016/S0140-6736(98)30023-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734907				2022-12-28	WOS:000074088900042
J	Delange, F				Delange, F			Risks and benefits of iodine supplementation	LANCET			English	Editorial Material							THYROTOXICOSIS		Int Council Control Iodine Deficiency Disorders, B-1170 Brussels, Belgium		Delange, F (corresponding author), Int Council Control Iodine Deficiency Disorders, B-1170 Brussels, Belgium.							BALTISBERGER BL, 1995, EUR J ENDOCRINOL, V132, P546, DOI 10.1530/eje.0.1320546; Bourdoux PP, 1996, LANCET, V347, P552, DOI 10.1016/S0140-6736(96)91188-5; CONNOLLY RJ, 1970, LANCET, V1, P500; Delange F, 1996, B WORLD HEALTH ORGAN, V74, P101; Dremier S, 1996, J CLIN ENDOCR METAB, V81, P4187, DOI 10.1210/jc.81.12.4187; Elimination of Iodine Deficiency Disorders in Southeast Asia WHO, 1997, SEANUT138 WHO, P1; HERZEL BS, 1983, LANCET, V2, P1126; Kahaly G, 1997, J CLIN ENDOCR METAB, V82, P4049, DOI 10.1210/jc.82.12.4049; Stanbury JB, 1998, THYROID, V8, P83, DOI 10.1089/thy.1998.8.83; Stanbury JB, 1994, DAMAGED BRAIN IODINE, P1; TODD CH, 1995, LANCET, V346, P1563, DOI 10.1016/S0140-6736(95)92095-1; [WHO UNICEF ICCIDD], 1996, WHONUT9613 UNICEF IC; *WHO UNICEF ICCIDD, 1994, WHONUT946 UNICEF ICC; *WHO UNICEF ICCIDD, 1998, AFRONUT972 WHO UNICE; [No title captured]	15	47	52	3	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 28	1998	351	9107					923	924		10.1016/S0140-6736(05)60596-X	http://dx.doi.org/10.1016/S0140-6736(05)60596-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734932				2022-12-28	WOS:000072770900003
J	van Dissel, JT; van Langevelde, P; Westendorp, RGJ; Kwappenberg, K; Frolich, M				van Dissel, JT; van Langevelde, P; Westendorp, RGJ; Kwappenberg, K; Frolich, M			Anti-inflammatory cytokine profile and mortality in febrile patients	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; SEPTIC SHOCK; TNF-ALPHA; IN-VITRO; SEPSIS; ANTIBODIES; ENDOTOXIN; SERUM; INTERLEUKIN-6	Background An anti-inflammatory cytokine profile on whole-blood stimulation in vitro is associated with fatal outcome of meningococcal disease. We investigated whether an antiinflammatory cytokine profile in the circulation is associated with adverse outcome in other infectious diseases. Methods We enrolled 464 consecutive patients (272 men, 192 women) who presented to hospital with fever (greater than or equal to 38.2 degrees C). On admission we measured plasma interleukin 10 (IL-10) and tumour necrosis factor alpha (TNF alpha), and collected clinical and microbiological data on the febrile illness, then followed up all patients for clinical outcome. Findings In at least 399 of the 464 patients fever was caused by infection. 33 patients died after a median hospital stay of 11 days (interquartile range 3-20). Concentrations of IL-10 were significantly higher in non-survivors (median 169 pg/mL [IQR 83-530]) than in survivors (median 88 pg/mL [42-235], p=0.042). When dichotomised around the median, the mortality risk was two times higher in patients who had high concentrations of IL-10 than in those with low concentrations (relative risk 2.39 [95% CI 1.07-5.33]), in patients with low and high concentrations of TNF alpha. In the 406 patients without haemodynamic deterioration in the first 24 h, IL-10 was higher and TNF alpha lower in patients who died than in those who survived. The ratio of IL-10 to TNF alpha was higher in non-survivors (median 6.9 [3.0-21.0]) than in survivors (median 3.9 [2.0-7.0], p=0.040). This ratio was highest in patients who died without underlying disease (median 21.5 [5.0-25.0]). Age, sex, and duration of fever before admission did not explain the differences in IL-10 and TNF alpha. Interpretation An anti-inflammatory cytokine profile of a high ratio of IL-10 to TNF alpha is associated with fatal outcome in febrile patients with community-acquired infection. Our findings caution against a widespread use of proinflammatory cytokine inhibition in patients with sepsis.	Leiden Univ, Med Ctr, Dept Infect Dis, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Chem, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van Dissel, JT (corresponding author), Leiden Univ, Med Ctr, Dept Infect Dis, POB 9600, NL-2300 RC Leiden, Netherlands.							ALEXANDER HR, 1991, J CLIN INVEST, V88, P34, DOI 10.1172/JCI115298; [Anonymous], J ENDOTOXIN RES; BAGBY GJ, 1991, J INFECT DIS, V163, P83, DOI 10.1093/infdis/163.1.83; Bone RC, 1996, ANN INTERN MED, V125, P680, DOI 10.7326/0003-4819-125-8-199610150-00009; BOTHE J, 1993, NATURE, V364, P782; COHEN J, 1997, CLIN MICROBIOL INFEC, V13, P2; COOPER JF, 1971, J LAB CLIN MED, V78, P138; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; ECHTENACHER B, 1990, J IMMUNOL, V163, P83; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; GOLDIE AS, 1995, JAMA-J AM MED ASSOC, V274, P172, DOI 10.1001/jama.274.2.172; GrossWeege W, 1997, INTENS CARE MED, V23, P16, DOI 10.1007/s001340050285; GUICE KS, 1991, J SURG RES, V51, P494; HAMILTON G, 1992, SCAND J INFECT DIS, V24, P361, DOI 10.3109/00365549209061344; HAVELL EA, 1992, J IMMUNOL, V148, P1486; HEATH DI, 1993, GUT, V34, P41, DOI 10.1136/gut.34.1.41; HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147; LEIBOVICI L, 1991, ARCH INTERN MED, V151, P1801; MALO D, 1994, TRENDS GENET, V10, P365, DOI 10.1016/0168-9525(94)90133-3; MARCHANT A, 1994, LANCET, V343, P707, DOI 10.1016/S0140-6736(94)91584-9; MASTROENI P, 1991, MICROB PATHOGENESIS, V11, P33, DOI 10.1016/0882-4010(91)90091-N; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; Nelson S, 1996, CLIN CHEST MED, V17, P319, DOI 10.1016/S0272-5231(05)70317-8; Newport MJ, 1997, CURR OPIN INFECT DIS, V10, P233, DOI 10.1097/00001432-199706000-00013; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; SKAMENE E, 1982, NATURE, V297, P506, DOI 10.1038/297506a0; Stuber F, 1996, CRIT CARE MED, V24, P381, DOI 10.1097/00003246-199603000-00004; vanderPoll T, 1997, AM J RESP CRIT CARE, V155, P603, DOI 10.1164/ajrccm.155.2.9032201; VANFURTH R, 1994, J INFECT DIS, V170, P234, DOI 10.1093/infdis/170.1.234; WESTENDORP RGJ, 1995, J INFECT DIS, V171, P1057, DOI 10.1093/infdis/171.4.1057; Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6	32	337	345	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 28	1998	351	9107					950	953		10.1016/S0140-6736(05)60606-X	http://dx.doi.org/10.1016/S0140-6736(05)60606-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734942				2022-12-28	WOS:000072770900013
J	Salmon, G; James, A; Smith, DM				Salmon, G; James, A; Smith, DM			Bullying in schools: self reported anxiety, depression, and self esteem in secondary school children	BRITISH MEDICAL JOURNAL			English	Article									Warneford Hosp, Highfield Adolescent Unit, Oxford OX3 7JX, England; Inst Hlth Sci, Ctr Stat Med, Oxford OX3 7LF, England	University of Oxford	James, A (corresponding author), Warneford Hosp, Highfield Adolescent Unit, Oxford OX3 7JX, England.							ANGOLD A, 1995, INT J METHODS PSYCHI, V5, P136; OLWEUS D, 1994, J CHILD PSYCHOL PSYC, V35, P1171, DOI 10.1111/j.1469-7610.1994.tb01229.x; REYNOLDS CR, 1978, J ABNORM CHILD PSYCH, V6, P271, DOI 10.1007/BF00919131; Rosenberg M., 1986, CONCEIVING SELF; Smith PK, 1994, SCH BULLYING INSIGHT	5	210	219	3	84	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					924	925						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	128LV	9756812				2022-12-28	WOS:000076409000026
J	Ristow, M; Muller-Wieland, D; Pfeiffer, A; Krone, W; Kahn, CR				Ristow, M; Muller-Wieland, D; Pfeiffer, A; Krone, W; Kahn, CR			Obesity associated with a mutation in a genetic regulator of adipocyte differentiation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSULIN-RESISTANCE; RECEPTOR; ADIPOGENESIS; PHOSPHORYLATION; CLONING; GAMMA	Background There is increasing evidence of genetic factors leading to obesity, but the exact genes involved have not been defined. Peroxisome-proliferator-activated receptor gamma 2 (PPAR gamma 2) is a transcription factor that has a key role in adipocyte differentiation, and therefore mutations of the gene for this factor might predispose people to obesity. Methods We studied 358 unrelated German subjects, including 121 obese subjects (defined as those with a body-mass index [the weight in kilograms divided by the square of the height in meters] of more than 29). We evaluated these subjects for mutations in the gene for PPAR gamma 2 at or near a site of serine phosphorylation at position 114 that negatively regulates the transcriptional activity of the protein, using a polymerase-chain-reaction-based assay coupled with specific endonuclease digestion. The activity of the mutation identified was analyzed by retroviral transfection and overexpression in murine fibroblasts. Results Four of the 121 obese subjects had a missense mutation in the gene for PPAR gamma 2 that resulted in the conversion of proline to glutamine at position 115, as compared with none of the 237 subjects of normal weight (P=0.01). All the subjects with the mutant allele were markedly obese, with body-mass-index values ranging from 37.9 to 47.3, as compared with a mean of 33.6 in the other obese subjects. Overexpression of the mutant gene in murine fibroblasts led to the production of a protein in which the phosphorylation of serine at position 114 was defective, as well as to accelerated differentiation of the cells into adipocytes and greater cellular accumulation of triglyceride than with the wild-type PPAR gamma 2. These effects were similar to those of an in vitro mutation created directly at the Ser114 phosphorylation site. Conclusions A Pro115Gln mutation in PPAR gamma 2 accelerates the differentiation of adipocytes and may cause obesity. (N Engl J Med 1998;339:953-9.) (C)1998, Massachusetts Medical Society.	Joslin Diabet Ctr, Div Res, Sect Cellular & Mol Physiol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Cologne, Klin & Poliklin Innere Med 2, Cologne, Germany; Ruhr Univ Bochum, Bergmannsheil, Med Klin & Poliklin, D-4630 Bochum, Germany	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; University of Cologne; Ruhr University Bochum	Kahn, CR (corresponding author), Joslin Diabet Ctr, Div Res, Sect Cellular & Mol Physiol, 1 Joslin Pl, Boston, MA 02215 USA.		Ristow, Michael/O-9858-2014; Kahn, Ronald/AAY-2435-2021; Pfeiffer, Andreas F.H./AAJ-2311-2020	Ristow, Michael/0000-0003-2109-2453; Kahn, Ronald/0000-0002-7583-9228; Pfeiffer, Andreas F.H./0000-0002-6887-0016	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK045935] Funding Source: NIH RePORTER; NIDDK NIH HHS [2 P30 DK 36836, DK 45935] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Bouchard C, 1994, GENETICS OBESITY; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092-8674(00)80937-X; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; Knebel B, 1997, BIOCHEM BIOPH RES CO, V234, P626, DOI 10.1006/bbrc.1997.6696; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Latruffe N, 1997, BIOCHIMIE, V79, P81, DOI 10.1016/S0300-9084(97)81496-4; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; *NAT DIAB DAT GROU, 1905, NIH PUBL; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Ristow M, 1998, DIABETES, V47, P851, DOI 10.2337/diabetes.47.5.851; RISTOW M, 1995, LANCET, V346, P502, DOI 10.1016/S0140-6736(95)91351-3; Ristow M, 1997, J CLIN INVEST, V100, P2833, DOI 10.1172/JCI119831; Rosenbaum M, 1997, NEW ENGL J MED, V337, P396, DOI 10.1056/NEJM199708073370606; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Schwartz S, 1998, NEW ENGL J MED, V338, P861, DOI 10.1056/NEJM199803263381302; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TONTONOZ P, 1995, CELL, V80, P957; Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301; Yen CJ, 1997, BIOCHEM BIOPH RES CO, V241, P270, DOI 10.1006/bbrc.1997.7798; ZHANG YY, 1995, NATURE, V374, P479, DOI 10.1038/374479a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	31	434	459	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1998	339	14					953	959		10.1056/NEJM199810013391403	http://dx.doi.org/10.1056/NEJM199810013391403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124MW	9753710				2022-12-28	WOS:000076186900003
J	Ryan, MJ				Ryan, MJ			Sexual selection, receiver biases, and the evolution of sex differences	SCIENCE			English	Review							FEMALE MATE CHOICE; GENE-REGULATION; PHYLOGENETIC TESTS; COURTSHIP; SIGNALS; SONG; COMMUNICATION; PREFERENCES; LEPIDOPTERA; ARCTIIDAE	Recent approaches to analyzing the evolution of female mating preferences emphasize how historical influences on female receiver systems can bias the evolution of male traits that females find attractive. These studies combine animal behavior, sensory biology, phylogenetics, and artificial neural network models. They attempt to understand why specific phenotypes involved in sexual selection have evolved, rather than merely determining whether such traits and preferences are adaptive. It is now clear that traits and preferences often do not coevolve via genetic correlations, that female mating preferences for a given male trait are influenced by adaptations and constraints outside of the context of female responses to that particular trait, and that receiver biases can explain much of the diversity in male signaling phenotypes. It also appears that an understanding of historical effects will prove valuable in investigating why neural and cognitive systems respond to sensory stimuli as they do.	Univ Texas, Dept Zool, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Ryan, MJ (corresponding author), Univ Texas, Dept Zool, Austin, TX 78712 USA.	mryan@mail.utexas.edu						Andersson Malte, 1994; BASOLO AL, 1990, SCIENCE, V250, P808, DOI 10.1126/science.250.4982.808; CHRISTY JH, 1995, AM NAT, V146, P171, DOI 10.1086/285793; Clayton DF, 1997, J NEUROBIOL, V33, P549; Davies NB, 1998, P ROY SOC B-BIOL SCI, V265, P673, DOI 10.1098/rspb.1998.0346; Dugatkin LA, 1996, P NATL ACAD SCI USA, V93, P2770, DOI 10.1073/pnas.93.7.2770; ENDLER JA, 1992, AM NAT, V139, pS125, DOI 10.1086/285308; ENQUIST M, 1993, NATURE, V361, P446, DOI 10.1038/361446a0; GERHARDT HC, 1994, ANIM BEHAV, V47, P959, DOI 10.1006/anbe.1994.1127; Greenfield MD, 1997, P ROY SOC B-BIOL SCI, V264, P1355, DOI 10.1098/rspb.1997.0188; GREENFIELD MD, 1993, NATURE, V364, P618, DOI 10.1038/364618a0; GUILFORD T, 1993, TRENDS NEUROSCI, V16, P430, DOI 10.1016/0166-2236(93)90068-W; HARTSHORNE C, 1956, AUK, V95, P758; Jang YW, 1996, ANIM BEHAV, V51, P1095, DOI 10.1006/anbe.1996.0111; Jarvis ED, 1997, NEUROREPORT, V8, P2073, DOI 10.1097/00001756-199705260-00052; Jones IL, 1998, BEHAV ECOL, V9, P187, DOI 10.1093/beheco/9.2.187; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; KIRKPATRICK M, 1982, EVOLUTION, V36, P1, DOI [10.2307/2407961, 10.1111/j.1558-5646.1982.tb05003.x]; LANGLOIS JH, 1990, PSYCHOL SCI, V1, P115, DOI 10.1111/j.1467-9280.1990.tb00079.x; MARCHETTI K, 1993, NATURE, V362, P149, DOI 10.1038/362149a0; Marler CA, 1997, EVOLUTION, V51, P1244, DOI 10.1111/j.1558-5646.1997.tb03971.x; McClintock WJ, 1996, ANIM BEHAV, V52, P167, DOI 10.1006/anbe.1996.0162; MELLO C, 1995, J NEUROSCI, V15, P6919; MORRIS MR, 1995, BIOL J LINN SOC, V54, P383, DOI 10.1016/0024-4066(95)90017-9; PERRETT DI, 1994, NATURE, V368, P239, DOI 10.1038/368239a0; Phelps SM, 1998, P ROY SOC B-BIOL SCI, V265, P279, DOI 10.1098/rspb.1998.0293; PHELPS SM, UNPUB; POMERANTZ JR, 1986, HDB PERCEPTION, V2; PROCTOR HC, 1992, ANIM BEHAV, V44, P745, DOI 10.1016/S0003-3472(05)80300-8; PROCTOR HC, 1991, ANIM BEHAV, V42, P589, DOI 10.1016/S0003-3472(05)80242-8; Prum RO, 1997, AM NAT, V149, P668, DOI 10.1086/286014; Rosenthal GG, 1998, P NATL ACAD SCI USA, V95, P4431, DOI 10.1073/pnas.95.8.4431; Ryan M.J., 1990, Oxford Surveys in Evolutionary Biology, V7, P157; Ryan Michael J., 1997, P179; RYAN MJ, 1995, SCIENCE, V269, P390, DOI 10.1126/science.269.5222.390; RYAN MJ, 1993, PHILOS T ROY SOC B, V340, P187, DOI 10.1098/rstb.1993.0057; SANDERFORD MV, 1995, J INSECT BEHAV, V8, P19, DOI 10.1007/BF01990967; SEARCY WA, 1992, AM ZOOL, V32, P71; SHAW K, 1995, TRENDS ECOL EVOL, V10, P117, DOI 10.1016/S0169-5347(00)89005-9; Simmons RB, 1996, J INSECT BEHAV, V9, P909, DOI 10.1007/BF02208978; Stripling R, 1997, J NEUROSCI, V17, P3883; WESTEBERHARD MJ, 1979, P AM PHILOS SOC, V123, P222; Williams G. C., 1966, P307; WYTTENBACH RA, 1993, J ACOUST SOC AM, V94, P777, DOI 10.1121/1.408207; ZETNER MR, 1996, NATURE, V383, P29; [No title captured]	46	306	314	1	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1998	281	5385					1999	2003		10.1126/science.281.5385.1999	http://dx.doi.org/10.1126/science.281.5385.1999			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748154				2022-12-28	WOS:000076161800048
J	Singal, PK; Iliskovic, N				Singal, PK; Iliskovic, N			Doxorubicin-induced cardiomyopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HEART-FAILURE; ADRIAMYCIN CARDIOTOXICITY; ANTHRACYCLINE THERAPY; RADIONUCLIDE ANGIOCARDIOGRAPHY; INFUSION REGIMEN; RISK-FACTORS; CHILDREN; TOXICITY; BREAST; CHEMOTHERAPY		St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Fac Med, Dept Physiol, Winnipeg, MB, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	Singal, PK (corresponding author), St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, 351 Tache Ave,Rm R3022, Winnipeg, MB R2H 2A6, Canada.							ALEXANDER J, 1979, NEW ENGL J MED, V300, P278, DOI 10.1056/NEJM197902083000603; ARICO M, 1988, NEW ENGL J MED, V319, P1353; BENJAMIN RS, 1975, CANCER CHEMOTH REP 3, V6, P183; BHATTACHARYA S, 1991, EUR J NUCL MED, V18, P889, DOI 10.1007/BF02258455; BIELACK SS, 1989, EUR J CANCER CLIN ON, V25, P873, DOI 10.1016/0277-5379(89)90135-1; BILLINGHAM ME, 1977, AM J SURG PATHOL, V1, P17, DOI 10.1097/00000478-197701010-00002; BRISTOW MR, 1982, HOSP PRACT, V17, P101; BRISTOW MR, 1978, CANCER TREAT REP, V62, P873; BRISTOW MR, 1981, AM HEART J, V102, P709, DOI 10.1016/0002-8703(81)90096-X; Bristow MR, 1980, DRUG INDUCED HEART D, P191; CURRAN CF, 1991, CANCER TREAT REV, V18, P241, DOI 10.1016/0305-7372(91)90015-R; DOROSHOW JH, 1980, J CLIN INVEST, V65, P128, DOI 10.1172/JCI109642; Ganz WI, 1996, ONCOLOGY, V53, P461; GILLADOGA AC, 1976, CANCER, V37, P1070, DOI 10.1002/1097-0142(197602)37:2+<1070::AID-CNCR2820370814>3.0.CO;2-6; GREEN D, 1994, CANCER RES, V54, P738; HARRISON DT, 1976, ANN INTERN MED, V85, P339, DOI 10.7326/0003-4819-85-3-339; HJALMARSON A, 1994, DRUGS, V47, P31, DOI 10.2165/00003495-199400474-00006; Iliskovic N, 1997, AM J PATHOL, V150, P727; KIM YD, 1979, JAMA-J AM MED ASSOC, V241, P1816, DOI 10.1001/jama.241.17.1816; LEFRAK EA, 1973, CANCER-AM CANCER SOC, V32, P302, DOI 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2; LEGHA SS, 1982, ANN INTERN MED, V96, P133, DOI 10.7326/0003-4819-96-2-133; LEWIS AB, 1981, PEDIATRICS, V68, P67; LUTHY A, 1992, J HEART LUNG TRANSPL, V11, P815; MANCUSO L, 1985, CANCER TREAT REP, V69, P243; MASON JW, 1978, CANCER TREAT REP, V62, P857; MCKILLOP JH, 1983, AM HEART J, V106, P1048, DOI 10.1016/0002-8703(83)90651-8; MINOW RA, 1977, CANCER, V39, P1397, DOI 10.1002/1097-0142(197704)39:4<1397::AID-CNCR2820390407>3.0.CO;2-U; Pihkala J, 1996, EUR J CANCER, V32A, P97, DOI 10.1016/0959-8049(95)00555-2; PIVER MS, 1985, CANCER, V56, P76, DOI 10.1002/1097-0142(19850701)56:1<76::AID-CNCR2820560113>3.0.CO;2-S; PRAGA C, 1979, CANCER TREAT REP, V63, P827; PRICE FV, 1993, GYNECOL ONCOL, V51, P383, DOI 10.1006/gyno.1993.1308; RITCHIE JL, 1980, CANCER, V46, P1109, DOI 10.1002/1097-0142(19800901)46:5<1109::AID-CNCR2820460506>3.0.CO;2-B; ROSEN GM, 1990, METHOD ENZYMOL, V186, P611; SCHLUMBERGER M, 1991, CANCER, V67, P2997, DOI 10.1002/1097-0142(19910615)67:12<2997::AID-CNCR2820671211>3.0.CO;2-#; SEIFERT CF, 1994, ANN PHARMACOTHER, V28, P1413, DOI 10.1177/106002809402801219; SHADDY RE, 1995, AM HEART J, V129, P197, DOI 10.1016/0002-8703(95)90061-6; SHAPIRA J, 1990, CANCER, V65, P870, DOI 10.1002/1097-0142(19900215)65:4<870::AID-CNCR2820650407>3.0.CO;2-D; SINGAL PK, 1995, J MOL CELL CARDIOL, V27, P1055, DOI 10.1016/0022-2828(95)90074-8; Singal PK, 1997, FASEB J, V11, P931, DOI 10.1096/fasebj.11.12.9337145; SINGAL PK, 1987, J MOL CELL CARDIOL, V19, P817, DOI 10.1016/S0022-2828(87)80392-9; SINHA BK, 1987, BIOCHEM PHARMACOL, V36, P793, DOI 10.1016/0006-2952(87)90164-X; SISSON JC, 1987, J NUCL MED, V28, P1620; SIVESKIILISKOVIC N, 1995, CIRCULATION, V91, P10, DOI 10.1161/01.CIR.91.1.10; SPEYER JL, 1985, AM J MED, V78, P555, DOI 10.1016/0002-9343(85)90395-X; STEINHERZ LJ, 1992, PEDIATRICS, V89, P942; STEINHERZ LJ, 1991, JAMA-J AM MED ASSOC, V266, P1672, DOI 10.1001/jama.266.12.1672; STEINHERZ LJ, 1995, MED PEDIATR ONCOL, V24, P352, DOI 10.1002/mpo.2950240604; TAKANO H, 1995, J NUCL MED, V36, P2060; TREAT J, 1990, J NATL CANCER I, V82, P1706, DOI 10.1093/jnci/82.21.1706; VONHOFF DD, 1977, AM J MED, V62, P200, DOI 10.1016/0002-9343(77)90315-1; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; WAKASUGI S, 1995, J NUCL MED, V36, P2069; WEISS RB, 1992, SEMIN ONCOL, V19, P670; WILLIAMS GA, 1992, ADR529 CTR DRUG EV R, P1	54	1419	1478	7	197	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1998	339	13					900	905		10.1056/NEJM199809243391307	http://dx.doi.org/10.1056/NEJM199809243391307			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121VY	9744975				2022-12-28	WOS:000076037400007
J	Petersen, LA				Petersen, LA			Recent advances - General medicine	BRITISH MEDICAL JOURNAL			English	Review							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; RANDOMIZED TRIAL; HIV-1 RNA; CARDIOVASCULAR-DISEASE; POSTMENOPAUSAL WOMEN; ALCOHOL-CONSUMPTION; FOLLOW-UP; RISK; MORTALITY		Dept Vet Affairs Med Ctr, Hlth Serv Res & Dev, Houston, TX 77030 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center	Petersen, LA (corresponding author), Dept Vet Affairs Med Ctr, Hlth Serv Res & Dev, Houston, TX 77030 USA.							Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Black HR, 1997, ARCH INTERN MED, V157, P2413; CARPENTER CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1062; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Gupta S, 1997, CIRCULATION, V96, P404; Gurfinkel E, 1997, LANCET, V350, P404, DOI 10.1016/S0140-6736(97)07201-2; Hall AS, 1997, LANCET, V349, P1493, DOI 10.1016/S0140-6736(97)04442-5; Hein HO, 1996, BRIT MED J, V312, P736, DOI 10.1136/bmj.312.7033.736; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Lepor H, 1996, NEW ENGL J MED, V335, P533, DOI 10.1056/NEJM199608223350801; MacMahon S, 1997, LANCET, V349, P375; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Morrison HI, 1996, JAMA-J AM MED ASSOC, V275, P1893, DOI 10.1001/jama.275.24.1893; Mossad SB, 1996, ANN INTERN MED, V125, P81, DOI 10.7326/0003-4819-125-2-199607150-00001; Muhlestein JB, 1996, J AM COLL CARDIOL, V27, P1555, DOI 10.1016/0735-1097(96)00055-1; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; Pearce KF, 1996, NEW ENGL J MED, V335, P1559, DOI 10.1056/NEJM199611213352103; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	29	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					792	795		10.1136/bmj.317.7161.792	http://dx.doi.org/10.1136/bmj.317.7161.792			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740570	Green Published			2022-12-28	WOS:000076084200034
J	Davidoff, F				Davidoff, F			Intelligence work	LANCET			English	Article									Annals Internal Med, Philadelphia, PA 19106 USA		Davidoff, F (corresponding author), Annals Internal Med, 190 N Independence Mall W, Philadelphia, PA 19106 USA.							Bhopal R, 1997, BRIT MED J, V314, P1009, DOI 10.1136/bmj.314.7086.1009; Schon D.A., 1987, ED REFLECTIVE PRACTI	2	3	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					895	896		10.1016/S0140-6736(05)60034-7	http://dx.doi.org/10.1016/S0140-6736(05)60034-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742999				2022-12-28	WOS:000075857300045
J	Pierce, JP; Gilpin, EA; Emery, SL; White, MM; Rosbrook, B; Berry, CC				Pierce, JP; Gilpin, EA; Emery, SL; White, MM; Rosbrook, B; Berry, CC			Has the California Tobacco Control Program reduced smoking?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTE-SMOKING; CAMPAIGN; CONSUMPTION; TAX; PROPOSITION-99; PREVALENCE; AUSTRALIA; QUIT	Context.-Comprehensive community-wide tobacco control programs are considered appropriate public health approaches to reduce population smoking prevalence. Objective.-To examine trends in smoking behavior before, during, and after the California Tobacco Control Program. Design.-Per capita cigarette consumption data (1983-1997) were derived from tobacco industry sales figures. Adult (greater than or equal to 18 years) smoking prevalence data were obtained from the National Health Interview Surveys (1978-1994), the California Tobacco Surveys (1990-1996), the Current Population Surveys (1992-1996), and the California Behavioral Risk Factor Survey and its supplement (1991-1997). Trends were compared before and after introduction of the program, with the period after the program being divided into 2 parts (early, 1989-1993; late, 1994-1996). Main Outcome Measures.-Change in cigarette consumption and smoking prevalence in California compared with the rest of the United States. Results.-Per capita cigarette consumption declined 52% faster in California in the early period than previously (from 9.7 packs per person per month at the beginning of the program to 6.5 packs per person per month in 1993), and the decline was significantly greater in California than in the rest of the United States (P < .001). In the late period, the decline in California slowed to 28% of the early program so that in 1996 an average of 6.0 packs per person per month were consumed. No decline occurred in the rest of the United States, and in 1996, 10.5 packs per person per month were consumed. Smoking prevalence showed a similar pattern, but in the late period, there was no significant decline in prevalence in either California or the rest of the United States. In 1996, smoking prevalence was 18.0% in California and 22.4% in the rest of the United States. Conclusions.-The initial effect of the program to reduce smoking in California did not persist. Possible reasons include reduced program funding, increased tobacco industry expenditures for advertising and promotion, and industry pricing and political activities. The question remains how the public health community can modify the program to regain its original momentum.	Univ Calif San Diego, Ctr Canc, Canc Prevent & Control Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Family & Prevent Med, Div Hlth Care Sci, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Pierce, JP (corresponding author), Univ Calif San Diego, Ctr Canc, Canc Prevent & Control Program, La Jolla, CA 92093 USA.	JPPierce@ucsd.edu		Pierce, John/0000-0002-0075-7471	NATIONAL CANCER INSTITUTE [P01CA072092] Funding Source: NIH RePORTER; NCI NIH HHS [CA72092] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1908, BIOMETRIKA, V6, P1; [Anonymous], 1995, Am J Public Health, V85, P183; BAL DG, 1990, JAMA-J AM MED ASSOC, V264, P1570, DOI 10.1001/jama.264.12.1570; BALBACH ED, 1997, HOLDING GOVT ACCOUNT; Becker RA, 1988, NEW S LANGUAGE PROGR; *CA DEP HLTH SERV, 1994, CAL AD TOB SURV SAS; CHILCOTE SD, 1990, COMMUNICATION   0418; CLEVELAND WS, 1982, J AM STAT ASSOC, V77, P520, DOI 10.2307/2287705; DWYER T, 1986, MED J AUSTRALIA, V144, P344, DOI 10.5694/j.1326-5377.1986.tb115916.x; EGGER G, 1983, BRIT MED J, V287, P1125, DOI 10.1136/bmj.287.6399.1125; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; FLEWELLING RL, 1992, AM J PUBLIC HEALTH, V82, P867, DOI 10.2105/AJPH.82.6.867; GILPIN EA, 1994, AM J PUBLIC HEALTH, V84, P1576, DOI 10.2105/AJPH.84.10.1576; Giovino Gary A., 1994, Morbidity and Mortality Weekly Report, V43, P1; Goldman LK, 1998, JAMA-J AM MED ASSOC, V279, P772, DOI 10.1001/jama.279.10.772; HANSEN RH, 1995, 40 US DEP COMM BUR C; HARRIS JE, 1996, MMWR-MORBID MORTAL W, V45, P966; Heiser PF, 1997, AM J PUBLIC HEALTH, V87, P968, DOI 10.2105/AJPH.87.6.968; KLAUSNER R, 1998, TAB CONTROL S2, V6, pS1; Lewitt E M, 1982, J Health Econ, V1, P121; LYNCH BS, 1995, GROWING TOBACCO FREE; Manley M, 1997, Tob Control, V6 Suppl 2, pS5, DOI 10.1136/tc.6.suppl_2.S5; Manley M W, 1997, Tob Control, V6 Suppl 2, pS12, DOI 10.1136/tc.6.suppl_2.S12; *NAT CANC I, 1992, NIH PUBL; Neter J, 1985, APPL LINEAR REGRESSI; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P61, DOI 10.1001/jama.261.1.61; PIERCE JP, 1991, JAMA-J AM MED ASSOC, V265, P1257, DOI 10.1001/jama.1991.03460100057019; PIERCE JP, 1990, AM J PUBLIC HEALTH, V80, P565, DOI 10.2105/AJPH.80.5.565; Pierce JP, 1994, TOBACCO USE CALIFORN; Pierce JP., 1998, TOBACCO CONTROL CALI; *SAS I INC, 1991, SAS SYST REGR; SHAPIRO E, 1993, WALL STREET J, pA1; Shopland DR, 1996, J NATL CANCER I, V88, P1748, DOI 10.1093/jnci/88.23.1748; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V267, P2721, DOI 10.1001/jama.267.20.2721; *TOB I, 1997, MONTHL STAT CIG TAX; Traynor MP, 1996, J HEALTH POLIT POLIC, V21, P543, DOI 10.1215/03616878-21-3-543; *US BUR CENS, 1990, RES POP SEL AG GROUP; *US BUR CENS, 1996, RES POP SEL AG GROUP; *US DEP HHS, 1989, PUBL CDC; *US DHEW, 1979, DHEW PUBL; *US FED TRAD COMM, 1997, FED TRAD COMM REP C	41	210	211	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1998	280	10					893	899		10.1001/jama.280.10.893	http://dx.doi.org/10.1001/jama.280.10.893			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	115LN	9739973				2022-12-28	WOS:000075666600035
J	Maron, BJ				Maron, BJ			Cardiovascular risks to young persons on the athletic field	ANNALS OF INTERNAL MEDICINE			English	Article							SUDDEN CARDIAC DEATH; RIGHT-VENTRICULAR CARDIOMYOPATHY; AMERICAN-HEART-ASSOCIATION; MAIN CORONARY-ARTERY; HYPERTROPHIC CARDIOMYOPATHY; ANOMALOUS ORIGIN; CLINICAL MANIFESTATIONS; HEALTH-PROFESSIONALS; PATHO-PHYSIOLOGY; DISEASE	Sudden cardiac deaths of young athletes, which are usually associated with physical exertion, continue to achieve high public visibility and generate considerable concern. Despite broad community participation in sports, such catastrophes are uncommon, occurring in about 1/200 000 high school athletes per academic year. Various unsuspected congenital cardiovascular diseases are usually responsible; the most common lesions are hypertrophic cardiomyopathy and several congenital coronary artery anomalies. Selected reports suggest that arrhythmogenic right ventricular dysplasia may be a more common cause of these deaths than previously suspected. In some trained athletes with borderline increases in thickness of the left ventricular wall, mild morphologic expression of hypertrophic cardiomyopathy can often be distinguished from the physiologic consequences of athlete's heart by noninvasive clinical assessment and testing. In addition, the recognized cardiovascular risks of the athletic field are now extended to include cardiac arrest resulting from relatively modest, nonpenetrating chest blows produced by projectiles (such as baseballs) or bodily contact in the absence of underlying cardiac disease and without structural injury to the chest wall or heart. These uncommon but usually fatal events seem to result when chest impact occurs precisely during the vulnerable phase of repolarization, and they may be reduced by use of softer baseballs. Preparticipation screening for cardiovascular disease, consisting of standard history and physical examination, is customary practice for most high school and college athletes in the United States. Evidence suggests, however, that the present screening process for cardiovascular disease in high school athletes may be largely inadequate, given the content of the approved screening questionnaires (which serve as guidelines for the process) and the use of examiners with little cardiovascular training. This emphasizes the need for national standardization of preparticipation screening. The recommendations of the 26th Bethesda Conference for disqualification from competitive athletics are now a standard for management decisions when cardiovascular abnormalities are identified in trained athletes.	Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA	Minneapolis Heart Institute Foundation	Maron, BJ (corresponding author), Minneapolis Heart Inst Fdn, 920 E 28th St,Suite 40, Minneapolis, MN 55407 USA.							Aretz T., 1986, AM J CARDIOVASC PATH, V1, P3; BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; CECCHI F, 1995, J AM COLL CARDIOL, V26, P1529, DOI 10.1016/0735-1097(95)00353-3; CHEITLIN MD, 1974, CIRCULATION, V50, P780, DOI 10.1161/01.CIR.50.4.780; CORRADO D, 1994, CIRCULATION, V90, P2315, DOI 10.1161/01.CIR.90.5.2315; CORRADO D, 1990, AM J MED, V89, P588, DOI 10.1016/0002-9343(90)90176-E; CORRADO D, 1997, CIRCULATION S1, V96, P152; DALIENTO L, 1995, J AM COLL CARDIOL, V25, P655, DOI 10.1016/0735-1097(94)00433-Q; ESTES NAM, 1995, NEW ENGL J MED, V333, P380, DOI 10.1056/NEJM199508103330611; Fuller CM, 1997, MED SCI SPORT EXER, V29, P1131, DOI 10.1097/00005768-199709000-00003; GAITHER NS, 1991, AM HEART J, V122, P69, DOI 10.1016/0002-8703(91)90760-F; Glover DW, 1998, JAMA-J AM MED ASSOC, V279, P1817, DOI 10.1001/jama.279.22.1817; HUSTON TP, 1985, NEW ENGL J MED, V313, P24, DOI 10.1056/NEJM198507043130106; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; JAMES TN, 1967, ANN INTERN MED, V67, P1013, DOI 10.7326/0003-4819-67-5-1013; JUREIDINI SB, 1994, AM HEART J, V127, P438, DOI 10.1016/0002-8703(94)90136-8; Kerber RE, 1997, CIRCULATION, V95, P1677; KLONER RA, 1992, CIRCULATION, V85, P407, DOI 10.1161/01.CIR.85.2.407; LAMBERT EC, 1974, AM J CARDIOL, V34, P89, DOI 10.1016/0002-9149(74)90098-8; LEWIS JF, 1989, AM J CARDIOL, V64, P1029, DOI 10.1016/0002-9149(89)90802-3; LEWIS JF, 1992, BRIT HEART J, V68, P296; Liberthson RR, 1996, NEW ENGL J MED, V334, P1039, DOI 10.1056/NEJM199604183341607; LINK MS, IN PRESS N ENGL J ME; MARIAN AJ, 1995, CIRCULATION, V91, P532; Maron BJ, 1997, AM J CARDIOL, V79, P840, DOI 10.1016/S0002-9149(96)00887-9; MARON BJ, 1995, NEW ENGL J MED, V333, P337, DOI 10.1056/NEJM199508103330602; MARON BJ, 1994, J AM COLL CARDIOL, V24, P848, DOI 10.1016/0735-1097(94)90837-0; Maron BJ, 1996, J AM COLL CARDIOL, V28, P428, DOI 10.1016/0735-1097(96)00137-4; MARON BJ, 1991, AM J CARDIOL, V68, P140, DOI 10.1016/0002-9149(91)90732-Z; MARON BJ, 1987, J AM COLL CARDIOL, V10, P1214, DOI 10.1016/S0735-1097(87)80121-3; MARON BJ, 1993, NEW ENGL J MED, V329, P55, DOI 10.1056/NEJM199307013290113; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1994, J AM COLL CARDIOL, V24, P880, DOI 10.1016/0735-1097(94)90844-3; MARON BJ, 1986, J AM COLL CARDIOL, V7, P190, DOI 10.1016/S0735-1097(86)80282-0; Maron BJ, 1996, CIRCULATION, V94, P850, DOI 10.1161/01.CIR.94.4.850; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1995, CIRCULATION, V91, P1596, DOI 10.1161/01.CIR.91.5.1596; MARON BJ, 1995, CIRCULATION, V92, P785, DOI 10.1161/01.CIR.92.4.785; MARON BJ, 1994, BRIT HEART J, V72, pS13; MARON BJ, 1981, AM J CARDIOL, V48, P252, DOI 10.1016/0002-9149(81)90604-4; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; Maron BJ, 1996, CIRCULATION, V94, P588; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; Maron BJ, 1997, LANCET, V350, P127, DOI 10.1016/S0140-6736(97)01282-8; Maron BJ, 1997, J AM COLL CARDIOL, V29, P6275; MARON BJ, 1994, J AM COLL CARDIOL, V23, P1405, DOI 10.1016/0735-1097(94)90384-0; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; MARON BJ, IN PRESS CIRCULATION; MARON BJ, 1997, CIRCULATION S1, V96, P755; MARON BJ, 1998, COMPREHENSIVE CARDIO, P1081; MCKENNA WJ, 1981, BRIT HEART J, V46, P168; Niimura H, 1998, NEW ENGL J MED, V338, P1248, DOI 10.1056/NEJM199804303381802; PELLICCIA A, 1991, NEW ENGL J MED, V324, P295, DOI 10.1056/NEJM199101313240504; PELLICCIA A, 1995, AM J CARDIOL, V75, P827, DOI 10.1016/S0002-9149(99)80421-4; Pelliccia A, 1996, JAMA-J AM MED ASSOC, V276, P211, DOI 10.1001/jama.276.3.211; PHILLIPS M, 1986, JAMA-J AM MED ASSOC, V256, P2696, DOI 10.1001/jama.256.19.2696; ROBERTS WC, 1988, AM J CARDIOL, V62, P1263, DOI 10.1016/0002-9149(88)90271-8; SCHLOMKA G, 1932, CHIRURGIE BERLIN, V81, P43; SCHWARTZ K, 1995, CIRCULATION, V91, P532, DOI 10.1161/01.CIR.91.2.532; SISCOVICK DS, 1984, NEW ENGL J MED, V311, P874, DOI 10.1056/NEJM198410043111402; SPIRITO P, 1994, CIRCULATION, V90, P2743, DOI 10.1161/01.CIR.90.6.2743; SPIRITO P, 1989, NEW ENGL J MED, V320, P749, DOI 10.1056/NEJM198903233201201; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; THIENE G, 1983, HUM PATHOL, V14, P704, DOI 10.1016/S0046-8177(83)80143-9; THIENE G, 1988, NEW ENGL J MED, V318, P129, DOI 10.1056/NEJM198801213180301; THOMPSON PD, 1982, JAMA-J AM MED ASSOC, V247, P2535, DOI 10.1001/jama.247.18.2535; TOPAZ O, 1985, CHEST, V87, P476, DOI 10.1378/chest.87.4.476; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641; VIRMANI R, 1988, AM HEART J, V115, P1068, DOI 10.1016/0002-8703(88)90078-6; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6; ZEPPILLI P, 1994, CHEST, V106, P373, DOI 10.1378/chest.106.2.373	72	83	86	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1998	129	5					379	386		10.7326/0003-4819-129-5-199809010-00006	http://dx.doi.org/10.7326/0003-4819-129-5-199809010-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114RL	9735066				2022-12-28	WOS:000075622600006
J	Ridder, GJ; Richter, B; Laszig, R; Sander, A				Ridder, GJ; Richter, B; Laszig, R; Sander, A			A farmer with a lump in his throat	LANCET			English	Article									Univ Freiburg, Dept Otorhinolaryngol, D-79106 Freiburg, Germany; Univ Freiburg, Inst Med Microbiol & Hyg, D-79106 Freiburg, Germany	University of Freiburg; University of Freiburg	Ridder, GJ (corresponding author), Univ Freiburg, Dept Otorhinolaryngol, Hugstetter Str 55, D-79106 Freiburg, Germany.		Richter, Bernhard/D-1406-2010	Ridder, Gerd J./0000-0002-9742-4437				Anderson BE, 1997, CLIN MICROBIOL REV, V10, P203, DOI 10.1128/CMR.10.2.203; Bass JW, 1997, PEDIATR INFECT DIS J, V16, P163, DOI 10.1097/00006454-199702000-00002; Raasveld MHM, 1997, CLIN INFECT DIS, V24, P77, DOI 10.1093/clinids/24.1.77; Zinzindohoue F, 1996, LANCET, V348, P1178, DOI 10.1016/S0140-6736(05)65320-2	4	16	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 28	1998	351	9107					954	954						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734943				2022-12-28	WOS:000072770900014
J	Johnson, H; Bouman, WP; Lawton, J				Johnson, H; Bouman, WP; Lawton, J			Withdrawal reaction associated with venlafaxine	BRITISH MEDICAL JOURNAL			English	Letter									Nottingham Healthcare NHS Trust, Wells Road Ctr, Nottingham NG3 3AA, England		Johnson, H (corresponding author), Nottingham Healthcare NHS Trust, Wells Road Ctr, Nottingham NG3 3AA, England.							Benazzi F, 1996, CAN J PSYCHIAT, V41, P487, DOI 10.1177/070674379604100722; Coupland NJ, 1996, J CLIN PSYCHOPHARM, V16, P356, DOI 10.1097/00004714-199610000-00003; DILSAVER SC, 1994, DRUG SAFETY, V10, P103, DOI 10.2165/00002018-199410020-00002; Farah A, 1996, AM J PSYCHIAT, V153, P576; Louie AK, 1996, AM J PSYCHIAT, V153, P1652	5	12	12	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					787	787		10.1136/bmj.317.7161.787a	http://dx.doi.org/10.1136/bmj.317.7161.787a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740568	Green Published			2022-12-28	WOS:000076084200032
J	Johnston, CM; Nesterova, TB; Formstone, EJ; Newall, AET; Duthie, SM; Sheardown, SA; Brockdorff, N				Johnston, CM; Nesterova, TB; Formstone, EJ; Newall, AET; Duthie, SM; Sheardown, SA; Brockdorff, N		X Inactivation Grp	Developmentally regulated Xist promoter switch mediates initiation of X inactivation	CELL			English	Article							CHROMOSOME INACTIVATION; GENE-EXPRESSION; MOUSE; RNA; METHYLATION; STABILIZATION; CONSERVATION; AUTOSOME; NUCLEUS; EMBRYOS	Developmental regulation of the mouse Xist gene at the onset of X chromosome inactivation is mediated by RNA stabilization. Here, we show that alternate promoter usage gives rise to distinct stable and unstable RNA isoforms. Unstable Xist transcript initiates at a novel upstream promoter, whereas stable Xist RNA is transcribed from the previously identified promoter and from a novel downstream promoter. Analysis of cells undergoing X inactivation indicates that a developmentally regulated promoter switch mediates stabilization and accumulation of Xist RNA on the inactive X chromosome.	Hammersmith Hosp, Imperial Coll Sch Med, MRC,Clin Sci Ctr, Inactivat Grp X, London W12 0NN, England; Russian Acad Sci, Inst Cytol & Genet, Siberian Dept, Novosibirsk 630090, Russia	Imperial College London; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS	Brockdorff, N (corresponding author), Hammersmith Hosp, Imperial Coll Sch Med, MRC,Clin Sci Ctr, Inactivat Grp X, DuCane Rd, London W12 0NN, England.			Nesterova, Tatyana/0000-0001-7740-4386; Brockdorff, Neil/0000-0003-4838-2653				ARIEL M, 1995, NAT GENET, V9, P312, DOI 10.1038/ng0395-312; ATWATER JA, 1990, ANNU REV GENET, V24, P519; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; CIANETTI L, 1990, NUCLEIC ACIDS RES, V18, P4361, DOI 10.1093/nar/18.15.4361; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Clerc P, 1998, NAT GENET, V19, P249, DOI 10.1038/924; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571; HENDRICH BD, 1993, HUM MOL GENET, V2, P663, DOI 10.1093/hmg/2.6.663; Hendrich BD, 1997, NUCLEIC ACIDS RES, V25, P2661, DOI 10.1093/nar/25.13.2661; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Marahrens Y, 1998, CELL, V92, P657, DOI 10.1016/S0092-8674(00)81133-2; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MCMAHON A, 1983, J EMBRYOL EXP MORPH, V46, P53; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; NORRIS DP, 1994, CELL, V77, P41, DOI 10.1016/0092-8674(94)90233-X; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; Sheardown SA, 1997, GENE, V203, P159, DOI 10.1016/S0378-1119(97)00507-6; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; ZUCCOTTI M, 1995, NAT GENET, V9, P316, DOI 10.1038/ng0395-316	38	69	69	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					809	817		10.1016/S0092-8674(00)81739-0	http://dx.doi.org/10.1016/S0092-8674(00)81739-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753327	Bronze			2022-12-28	WOS:000076021200013
J	Malamud, BD; Morein, G; Turcotte, DL				Malamud, BD; Morein, G; Turcotte, DL			Forest fires: An example of self-organized critical behavior	SCIENCE			English	Article							MODEL; LAWS	Despite the many complexities concerning their initiation and propagation, forest fires exhibit power-law frequency-area statistics over many orders of magnitude. A simple forest fire model, which is an example of self-organized criticality, exhibits similar behavior. One practical implication of this result is that the frequency-area distribution of small and medium fires can be used to quantify the risk of Large fires, as is routinely done for earthquakes.	Cornell Univ, Dept Geol Sci, Ithaca, NY 14853 USA	Cornell University	Malamud, BD (corresponding author), Cornell Univ, Dept Geol Sci, Ithaca, NY 14853 USA.		Malamud, Bruce/H-7885-2013	Malamud, Bruce/0000-0001-8164-4825				Aki K., 1982, EARTHQUAKE PREDICTIO, P556, DOI [DOI 10.1029/ME004P0566, 10.1029/ME004p0566]; ALBANO EV, 1995, PHYSICA A, V216, P213, DOI 10.1016/0378-4371(95)00015-Y; BAK P, 1989, J GEOPHYS RES-SOLID, V94, P15635, DOI 10.1029/JB094iB11p15635; BAK P, 1988, PHYS REV A, V38, P364, DOI 10.1103/PhysRevA.38.364; BAK P, 1990, PHYS LETT A, V147, P297, DOI 10.1016/0375-9601(90)90451-S; BURRIDGE R, 1967, B SEISMOL SOC AM, V57, P341; CLAR S, 1994, PHYS REV E, V50, P1009, DOI 10.1103/PhysRevE.50.1009; Clar S, 1996, J PHYS-CONDENS MAT, V8, P6803, DOI 10.1088/0953-8984/8/37/004; DROSSEL B, 1992, PHYS REV LETT, V69, P1629, DOI 10.1103/PhysRevLett.69.1629; FRNAKEL A, 1996, 96532 US GEOL SURV; HENLEY CL, 1993, PHYS REV LETT, V71, P2741, DOI 10.1103/PhysRevLett.71.2741; HEYERDAHL E, FIRE HIST DATABASE W; Honecker A, 1996, PHYSICA A, V229, P478, DOI 10.1016/0378-4371(95)00441-6; JOHANSEN A, 1994, PHYSICA D, V78, P186, DOI 10.1016/0167-2789(94)90114-7; KASISCHKE ES, 1995, REMOTE SENS ENVIRON, V51, P263, DOI 10.1016/0034-4257(93)00074-J; Pyne S.J., 1997, WORLD FIRE CULTURE F; Rhodes CJ, 1996, NATURE, V381, P600, DOI 10.1038/381600a0; TURCOTTE DL, 1989, TECTONOPHYSICS, V167, P171, DOI 10.1016/0040-1951(89)90067-X; *US FISH WILDL SER, UNPUB	19	431	450	5	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1840	1842		10.1126/science.281.5384.1840	http://dx.doi.org/10.1126/science.281.5384.1840			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743494				2022-12-28	WOS:000076007100049
J	Lundberg, GD				Lundberg, GD			Writing is all	LANCET			English	Article							AUTHORSHIP		Journal Amer Med Assoc, Chicago, IL 60610 USA	American Medical Association	Lundberg, GD (corresponding author), Journal Amer Med Assoc, 515 N State St, Chicago, IL 60610 USA.	george_lundberg@ama-assn.org						Davidson F, 1997, JAMA-J AM MED ASSOC, V277, P927; Horton R, 1997, LANCET, V350, P5, DOI 10.1016/S0140-6736(05)66236-8; LUNDBERG GD, 1988, JAMA-J AM MED ASSOC, V259, P1947, DOI 10.1001/jama.1988.03720130024020; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; Smith R, 1997, BRIT MED J, V314, P992, DOI 10.1136/bmj.314.7086.992	5	18	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					898	898		10.1016/S0140-6736(05)60037-2	http://dx.doi.org/10.1016/S0140-6736(05)60037-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9743002				2022-12-28	WOS:000075857300048
J	Harnad, S				Harnad, S			On-line journals and financial fire walls	NATURE			English	Editorial Material									Univ Southampton, Dept Elect & Comp Sci, Southampton SO17 1BJ, Hants, England	University of Southampton	Harnad, S (corresponding author), Univ Southampton, Dept Elect & Comp Sci, Southampton SO17 1BJ, Hants, England.		Harnad, Stevan R/A-1010-2008	Harnad, Stevan/0000-0001-6153-1129					0	15	15	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1998	395	6698					127	+		10.1038/25878	http://dx.doi.org/10.1038/25878			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744269				2022-12-28	WOS:000075829900030
J	Nikolic, M; Chou, MM; Lu, WG; Mayer, BJ; Tsai, LH				Nikolic, M; Chou, MM; Lu, WG; Mayer, BJ; Tsai, LH			The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity	NATURE			English	Article							CYCLIN-DEPENDENT KINASE-5; REGULATORY SUBUNIT; ACTIN ORGANIZATION; FAMILY; RHO; EXPRESSION; ACTIVATOR; GTPASES; CDC42; BRAIN	Cyclin-dependent kinase 5 (Cdk5) and its neuron-specific regulator p35 (refs 1-4) are essential for neuronal migration and for the laminar configuration of the cerebral cortex(5-7). In addition, p35/ Cdk5 kinase concentrates at the leading edges of axonal growth cones and regulates neurite outgrowth in cortical neurons in cultures. The Rho family of small GTPases is implicated in a range of cellular functions, including cell migration and neurite outgrowth(9-13). Here we show that the p35/Cdk5 kinase co-localizes with Raf in neuronal growth cones, Furthermore, p35 associates;: directly with Rac in a GTP-dependent manner. Another Rac effector, Pak1 kinase(14,15), is also present in the Rac-p35/Cdk5 complexes and co-localizes with p35/Cdk5 and Rac at neuronal peripheries. The active p35/Cdk5 kinase causes Pak1 hyperphosphorylation in a Rac-dependent manner, which results in downregulation of Pak1 kinase activity. Because the Rho family of GTPases and the Pak kinases are implicated in actin polymerization(16-18), the modification of Pak1, imposed by the p35/Cdk5 kinase, is likely to have an impact on the dynamics of the reorganization of the actin cytoskeleton in neurons, thus promoting neuronal migration and neurite outgrowth.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Tsai, LH (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, 200 Longwood Ave, Boston, MA 02115 USA.	lhtsai@warren.med.harvard.edu	Chou, Mitch Ming Chi/AAP-7037-2021	Chou, Mitch Ming Chi/0000-0002-6786-6867				Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Delalle I, 1997, J NEUROCYTOL, V26, P283, DOI 10.1023/A:1018500617374; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Kwon YT, 1998, J COMP NEUROL, V395, P510, DOI 10.1002/(SICI)1096-9861(19980615)395:4<510::AID-CNE7>3.0.CO;2-4; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; PATRICK GN, IN PRESS J BIOL CHEM; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; Tomizawa K, 1996, NEUROSCIENCE, V74, P519, DOI 10.1016/0306-4522(96)00136-4; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	30	330	346	0	8	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 10	1998	395	6698					194	198		10.1038/26034	http://dx.doi.org/10.1038/26034			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744280				2022-12-28	WOS:000075829900047
J	Kuroki, K; Masuda, A; Uehara, H; Kuroki, A				Kuroki, K; Masuda, A; Uehara, H; Kuroki, A			A new treatment for toxic megacolon	LANCET			English	Article									Kuroki Gastrointestinal Surg Hosp, Kagoshima 8900034, Japan; Kagoshima Univ, Dept Psychosomat Med, Kagoshima 890, Japan	Kagoshima University	Kuroki, K (corresponding author), Kuroki Gastrointestinal Surg Hosp, Kagoshima 8900034, Japan.							GREENSTEIN AJ, 1985, J CLIN GASTROENTEROL, V7, P137, DOI 10.1097/00004836-198504000-00007; JALAN KN, 1969, GASTROENTEROLOGY, V57, P68, DOI 10.1016/s0016-5085(19)33962-9; KWEICINSKI MG, 1987, J FOOT SURG, V26, P394; PURRMANN J, 1989, HEPATO-GASTROENTEROL, V36, P209; Sheth SG, 1998, LANCET, V351, P509, DOI 10.1016/S0140-6736(97)10475-5	5	21	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					782	782						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737284				2022-12-28	WOS:000075762700013
J	de Bono, M; Bargmann, CI				de Bono, M; Bargmann, CI			Natural variation in a neuropeptide Y receptor homolog modifies social behavior and food response in C-elegans	CELL			English	Article							PROTEIN-COUPLED RECEPTORS; CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; MICE LACKING; AMINO-ACID; GENE; IDENTIFICATION; EVOLUTION; NEMATODE; MULTIPLE	Natural isolates of C. elegans exhibit either solitary or social feeding behavior. Solitary foragers move slowly on a bacterial lawn and disperse across it,while social foragers move rapidly on bacteria and aggregate together. A loss-of-function mutation in the npr-1 gene, which encodes a predicted G protein-coupled receptor similar to neuropeptide Y receptors, causes a solitary strain to take on social behavior. Two isoforms of NPR-1 that differ at a single residue occur in the wild. One isoform, NPR-1 215F, is found exclusively in social strains, while the other isoform, NPR-1 215V, is found exclusively in solitary strains. An NPR-1 215V transgene can induce solitary feeding behavior in a wild social strain. Thus, isoforms of a putative neuropeptide receptor generate natural variation in C. elegans feeding behavior.	Univ Calif San Francisco, Dept Anat, Howard Hughes Med Inst, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Howard Hughes Med Inst, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, Howard Hughes Med Inst, Program Neurosci & Genet, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	de Bono, M (corresponding author), Univ Calif San Francisco, Dept Anat, Howard Hughes Med Inst, Program Dev Biol, San Francisco, CA 94143 USA.			de Bono, Mario/0000-0001-8347-0443; Bargmann, Cornelia/0000-0002-8484-0618				ANDREW PA, 1976, NEMATOLOGICA, V22, P451, DOI 10.1163/187529276X00454; Baraban SC, 1997, J NEUROSCI, V17, P8927, DOI 10.1523/jneurosci.17-23-08927.1997; Bargmann CI, 1998, ANNU REV NEUROSCI, V21, P279, DOI 10.1146/annurev.neuro.21.1.279; Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166-2236(96)01057-0; BLUML K, 1994, J BIOL CHEM, V269, P402; BLUML K, 1994, J BIOL CHEM, V269, P11537; BRENNER S, 1974, GENETICS, V77, P71; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; BROWNLEE DJA, 1994, PARASITOLOGY, V108, P587, DOI 10.1017/S0031182000077453; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; Burstein ES, 1996, J BIOL CHEM, V271, P2882, DOI 10.1074/jbc.271.6.2882; CLARK SG, 1994, GENETICS, V137, P987; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; CROLL NA, 1970, BEHAV NEMATODES, P18; DAINTY RH, 1985, J APPL BACTERIOL, V59, P303, DOI 10.1111/j.1365-2672.1985.tb03324.x; EGILMEZ NK, 1995, J MOL EVOL, V40, P372, DOI 10.1007/BF00164023; Finley KD, 1997, P NATL ACAD SCI USA, V94, P913, DOI 10.1073/pnas.94.3.913; GREWAL P S, 1992, Fundamental and Applied Nematology, V15, P159; Gu T, 1998, MOL CELL BIOL, V18, P4556, DOI 10.1128/MCB.18.8.4556; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; HEILIG M, 1995, CRIT REV NEUROBIOL, V9, P115; Hodgkin J, 1997, GENETICS, V146, P149; HOLLIS JP, 1962, NATURE, V193, P798, DOI 10.1038/193798b0; HOLLIS JP, 1960, PHYTOPATHOLOGY, V50, P639; Karayiorgou M, 1997, P NATL ACAD SCI USA, V94, P4572, DOI 10.1073/pnas.94.9.4572; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; LORENZ KZ, 1950, SYM SOC EXP BIOL, V4, P221; Maule AG, 1996, INT J PARASITOL, V26, P927, DOI 10.1016/S0020-7519(96)80066-X; MCBRIDE JM, 1966, NATURE, V211, P545, DOI 10.1038/211545b0; McGue M, 1998, ANNU REV NEUROSCI, V21, P1, DOI 10.1146/annurev.neuro.21.1.1; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Melo JA, 1996, NAT GENET, V13, P147, DOI 10.1038/ng0696-147; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; Monaghan AP, 1997, NATURE, V390, P515, DOI 10.1038/37364; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; ROSOFF ML, 1993, PEPTIDES, V14, P331, DOI 10.1016/0196-9781(93)90049-M; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; Sambrook J., 2002, MOL CLONING LAB MANU; Sawyer LA, 1997, SCIENCE, V278, P2117, DOI 10.1126/science.278.5346.2117; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; Sokolowski MB, 1997, P NATL ACAD SCI USA, V94, P7373, DOI 10.1073/pnas.94.14.7373; SOKOLOWSKI MB, 1980, BEHAV GENET, V10, P291, DOI 10.1007/BF01067774; Soll DR, 1995, INT REV CYTOL, V163, P43; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Sulston J., 1988, NEMATODE CAENORHABDI, P587; THOMAS JH, 1993, GENETICS, V134, P1105; WAHLESTEDT C, 1993, ANNU REV PHARMACOL, V33, P309, DOI 10.1146/annurev.pa.33.040193.001521; Wehner JM, 1997, NAT GENET, V17, P331, DOI 10.1038/ng1197-331; WILSON EO, SOCIOBIOLOGY; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZECHMAN JM, 1985, CAN J MICROBIOL, V31, P232, DOI 10.1139/m85-045	52	558	572	2	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 4	1998	94	5					679	689		10.1016/S0092-8674(00)81609-8	http://dx.doi.org/10.1016/S0092-8674(00)81609-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741632	Bronze			2022-12-28	WOS:000075851900015
J	Hirose, Y; Manley, JL				Hirose, Y; Manley, JL			RNA polymerase II is an essential mRNA polyadenylation factor	NATURE			English	Article							C-TERMINAL DOMAIN; PRE-MESSENGER-RNAS; POLY(A) POLYMERASE; SPLICING FACTORS; 3'-END CLEAVAGE; SR PROTEINS; IN-VITRO; PHOSPHORYLATION; TRANSCRIPTION; SUBUNIT	Production of messenger RNA in eukaryotic cells is a complex, multistep process. mRNA polyadenylation, or 3' processing, requires several protein factors, including cleavage/polyadenylation-specificity factor (CPSF), cleavage-stimulation factor, two cleavage factors and poly(A) polymerase (reviewed in refs 1, 2). These proteins seem to be unnecessary for other steps in mRNA synthesis such as transcription and splicing, and factors required for these processes were not considered to be essential for polyadenylation. Nonetheless, these reactions may be linked so that they are effectively coordinated in vivo(3-9). For example, the CTD carboxy-terminal domain of the largest subunit of RNA polymerase II (RNAP II) is required for efficient splicing and polyadenylation in vivo(8), and CPSF is brought to a promoter by the transcription factor TFIID and transferred to RNAP II at the time of transcription initiation(9). These findings suggest that polyadenylation factors can be recruited to an RNA 3'-processing signal by RNAP II, where they dissociate from the polymerase and initiate polyadenylation. Here we present results that extend this model by showing that RNAP II is actually required, in the absence of transcription, for 3' processing in vitro.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Manley, JL (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.			Manley, James/0000-0002-8341-1459				Besse Sylvie, 1995, Gene Expression, V4, P143; CANTONEL JC, 1997, NATURE, V389, P399; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; Colgan DF, 1998, EMBO J, V17, P1053, DOI 10.1093/emboj/17.4.1053; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Flaherty SM, 1997, P NATL ACAD SCI USA, V94, P11893, DOI 10.1073/pnas.94.22.11893; GUNDERSON SI, 1994, CELL, V76, P531, DOI 10.1016/0092-8674(94)90116-3; Harlow E., 1988, ANTIBODIES LAB MANUA; Hirose Y, 1997, J BIOL CHEM, V272, P29636, DOI 10.1074/jbc.272.47.29636; Lou H, 1996, GENE DEV, V10, P208, DOI 10.1101/gad.10.2.208; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MATTHEWS HR, 1995, PHARMACOL THERAPEUT, V67, P323, DOI 10.1016/0163-7258(95)00020-8; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; REINBERG D, 1987, J BIOL CHEM, V262, P3310; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	28	295	299	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1998	395	6697					93	96		10.1038/25786	http://dx.doi.org/10.1038/25786			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116JY	9738505				2022-12-28	WOS:000075722200054
J	McGregor, AM				McGregor, AM			Has the target autoantigen for Graves' ophthalmopathy been found?	LANCET			English	Editorial Material							THYROID-ASSOCIATED OPHTHALMOPATHY; AUTOANTIBODIES; TISSUE; MUSCLE		Kings Coll London, Sch Med & Dent, Dept Med, London SE5 9PJ, England	University of London; King's College London	McGregor, AM (corresponding author), Kings Coll London, Sch Med & Dent, Dept Med, London SE5 9PJ, England.							Bahn RS, 1998, J CLIN ENDOCR METAB, V83, P998, DOI 10.1210/jc.83.3.998; Bartalena L, 1998, NEW ENGL J MED, V338, P73, DOI 10.1056/NEJM199801083380201; BURCH HB, 1993, ENDOCR REV, V14, P747, DOI 10.1210/er.14.6.747; Crisp MS, 1997, J CLIN ENDOCR METAB, V82, P2003; ELSHEIKH M, 1994, CURRENT THERAPY ENDO, P90; Gunji K, 1998, THYROID, V8, P553, DOI 10.1089/thy.1998.8.553; Heufelder AE, 1997, BAILLIERE CLIN ENDOC, V11, P499, DOI 10.1016/S0950-351X(97)80723-9; Kubota S, 1998, THYROID, V8, P175, DOI 10.1089/thy.1998.8.175; Kubota S, 1998, J CLIN ENDOCR METAB, V83, P443, DOI 10.1210/jc.83.2.443; Perros P, 1998, THYROID, V8, P423, DOI 10.1089/thy.1998.8.423; PRUMMEL MF, 1993, JAMA-J AM MED ASSOC, V269, P479, DOI 10.1001/jama.269.4.479; Sorisky A, 1996, J CLIN ENDOCR METAB, V81, P3428, DOI 10.1210/jc.81.9.3428; WALL JR, 1995, J CLIN ENDOCR METAB, V80, P1226, DOI 10.1210/jc.80.4.1226; ZHANG ZG, 1992, CLIN IMMUNOL IMMUNOP, V62, P183, DOI 10.1016/0090-1229(92)90071-U	14	26	26	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 22	1998	352	9128					595	596		10.1016/S0140-6736(05)79573-8	http://dx.doi.org/10.1016/S0140-6736(05)79573-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746018				2022-12-28	WOS:000075567400006
J	Haller, H; Hempel, A; Homuth, V; Mandelkow, A; Busjahn, A; Maasch, C; Drab, M; Lindschau, C; Jupner, A; Vetter, K; Dudenhausen, J; Luft, FC				Haller, H; Hempel, A; Homuth, V; Mandelkow, A; Busjahn, A; Maasch, C; Drab, M; Lindschau, C; Jupner, A; Vetter, K; Dudenhausen, J; Luft, FC			Endothelial-cell permeability and protein kinase C in pre-eclampsia	LANCET			English	Article							ALBUMIN PERMEABILITY; BIOCHEMICAL-EVIDENCE; PREECLAMPSIA; FIBRONECTIN; PREGNANCY; HYPERTENSION; DYSFUNCTION; EXPRESSION; ACTIVATION	Background Oedema and vascular leakage play a part in the pathogenesis of pre-eclampsia. We tested the hypothesis that serum from pre-eclamptic increases endothelial-cell permeability and possible signal-transduction pathways. Methods We studied eight patients with pre-eclampsia, eight normotensive pregnant women, eight non-pregnant women, five pregnant patients with pre-existing hypertension, and four hypertensive non-pregnant women, Cultured human umbilical-vein endothelial-cell monolayers were used and permeability was measured by albumin flux, The part played by protein kinase C (PKC) signalling was examined by down-regulation with phorbol ester and with the inhibitors Goe 6976 and staurosporine, PKC isoforms were assessed by western blot and confocal microscopy, Antisense oligodesoxynucleotides (ODN) were used to test for specific PKC isoforms. Findings Serum from pre-eclamptic women increased endothelial permeability significantly (by 100%, p < 0.01). The change in permeability decreased rapidly after delivery, Serum from normotensive pregnant women and non-pregnant women had no effect, Permeability was not influenced by serum from pateints with essential hypertension or pregnant patients with pre-existing hypertension. Serum from pre-eclamptic patients induced a translocation of PKC isoforms alpha and epsilon within the cells, Goe 6976 and staurosporine (10(-8) mol/L) inhibited the increase in permeability induced by serum from preeclamptic patients. Down-regulation of PKC alpha and, to a lesser extent, PKC epsilon by antisense ODN also inhibited the pre-eclampsia-induced permeability increase. Interpretation Serum from pre-eclamptic patients contains a factor or factors that increase endothelial-cell permeability. The effect of pre-eclamptic serum may be mediated by PKC alpha and epsilon.	Franz Volhard Clin, D-13122 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Klinikum Buch, Berlin, Germany; Krankenhaus Neukolln, Dept Obstet & Gynaecol, Berlin, Germany; Humboldt Univ, Virchow Klinikum Charite, Dept Obstet, D-1086 Berlin, Germany	Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Haller, H (corresponding author), Franz Volhard Clin, Wiltberg Str 50, D-13122 Berlin, Germany.		Lindschau, Carsten/AAE-6721-2020; Drab, Marek/J-5196-2013; Busjahn, Andreas/F-9936-2011; Busjahn, Andreas/P-5023-2019; Lindschau, Carsten/G-1798-2011; Drab, Marek/AAQ-1892-2020	Drab, Marek/0000-0002-2771-1692; Busjahn, Andreas/0000-0001-9650-6919; Lindschau, Carsten/0000-0003-1960-099X; Luft, Friedrich/0000-0002-8635-1199				BROWN MA, 1984, CLIN OBSTET GYNAECOL, V8, P287; DAVISON JM, 1997, KIDNEY INT S, V59, pS90; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DEJAGER CA, 1995, J LAB CLIN MED, V125, P522; EDEN TW, 1922, J OBSTET GYN BR COMM, V29, P386; FRIEDMAN SA, 1994, AM J OBSTET GYNECOL, V170, P838, DOI 10.1016/S0002-9378(94)70295-0; FRIEDMAN SA, 1991, CLIN PERINATOL, V18, P661, DOI 10.1016/S0095-5108(18)30490-1; Haller H, 1997, HYPERTENSION, V29, P291, DOI 10.1161/01.HYP.29.1.291; HALLER H, 1994, ANN NY ACAD SCI, V733, P313, DOI 10.1111/j.1749-6632.1994.tb17281.x; Haller H, 1996, J AM SOC NEPHROL, V7, P40; HEMPEL A, IN PRESS CIRC RES; LINDHEIMER MD, 1989, ANNU REV MED, V40, P233; LYNCH JJ, 1990, J CLIN INVEST, V85, P1991, DOI 10.1172/JCI114663; NORTHOVER AM, 1994, INFLAMMATION, V18, P481, DOI 10.1007/BF01560695; PATTERSON CE, 1994, MICROVASC RES, V48, P212, DOI 10.1006/mvre.1994.1050; PERRY KG, 1992, CLIN OBSTET GYNECOL, V35, P338; ROBERTS JM, 1991, AM J HYPERTENS, V4, P700, DOI 10.1093/ajh/4.8.700; ROBERTS JM, 1991, SEMIN PERINATOL, V15, P86; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; ROBERTS JM, 1992, AM J REPROD IMMUNOL, V27, P101, DOI 10.1111/j.1600-0897.1992.tb00735.x; SCHRIER RW, 1991, OBSTET GYNECOL, V77, P632; STASEK JE, 1992, J CELL PHYSIOL, V153, P62, DOI 10.1002/jcp.1041530110; TAYLOR RN, 1991, AM J OBSTET GYNECOL, V165, P895, DOI 10.1016/0002-9378(91)90435-T	23	56	58	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 28	1998	351	9107					945	949						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734941				2022-12-28	WOS:000072770900012
J	Johnson, GJ				Johnson, GJ			Limitations of epidemiology in understanding pathogenesis of cataracts	LANCET			English	Editorial Material									UCL, Inst Ophthalmol, London EC1V 9EL, England	University of London; University College London	Johnson, GJ (corresponding author), UCL, Inst Ophthalmol, London EC1V 9EL, England.							Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; Harding J., 1991, CATARACT BIOCH EPIDE; Jacques PF, 1997, AM J CLIN NUTR, V66, P911, DOI 10.1093/ajcn/66.4.911; Rauf A., 1996, Investigative Ophthalmology and Visual Science, V37, pS237; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115	5	5	5	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 28	1998	351	9107					925	926						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734934				2022-12-28	WOS:000072770900005
J	Woo, P; Wedderburn, LR				Woo, P; Wedderburn, LR			Juvenile chronic arthritis	LANCET			English	Article							RHEUMATOID-ARTHRITIS; PEDIATRIC-RHEUMATOLOGY; EPIDEMIOLOGY; METHOTREXATE; ONSET; POPULATION; ROCHESTER; INFECTION; ADULTHOOD; EFFICACY		UCL, Windeyer Inst Med Sci, Paediat Rheumatol Unit, London W1P 6DB, England	University of London; University College London	Woo, P (corresponding author), UCL, Windeyer Inst Med Sci, Paediat Rheumatol Unit, London W1P 6DB, England.			Wedderburn, Lucy/0000-0002-7495-1429				ARGUEDAS O, 1995, CLIN EXP RHEUMATOL, V13, P119; Brewer E J Jr, 1977, Arthritis Rheum, V20, P195; BROOKS PJ, 1990, ARTHRITIS RHEUM, V33, P91, DOI 10.1002/art.1780330112; Bywaters EGL, 1968, POPULATION STUDIES R, P235; CASSIDY J, 1989, TXB PAEDIAT RHEUMATO; CRAWLEY EM, 1997, BR J RHEUMATOL S1, V36, pS137; DAVID J, 1994, BRIT J RHEUMATOL, V33, P876; DEVERETYNDALL A, 1984, ANN RHEUM DIS, V43, P1, DOI 10.1136/ard.43.1.1; Donn RP, 1996, EUR J IMMUNOGENET, V23, P245, DOI 10.1111/j.1744-313X.1996.tb00121.x; Fishman Daniel, 1997, Arthritis and Rheumatism, V40, pS72; GARE BA, 1995, J RHEUMATOL, V22, P295; Gattorno M, 1997, CLIN EXP IMMUNOL, V109, P4, DOI 10.1046/j.1365-2249.1997.4331330.x; GIANNINI EH, 1993, SEMIN ARTHRITIS RHEU, V23, P34, DOI 10.1016/S0049-0172(05)80025-3; HALLE F, 1991, CLIN EXP RHEUMATOL, V9, P297; HILL R, 1975, ARTHRITIS RHEUM S1, V20, pS162; JUNDT JW, 1993, J RHEUMATOL, V20, P1845; KUNNAMO I, 1986, ARTHRITIS RHEUM, V29, P1232, DOI 10.1002/art.1780291008; LAAKSONEN AL, 1966, ACTA PAEDIAT SC S166, V55, pS9; LEAK AM, 1992, BRIT J RHEUMATOL, V31, P631; LIFE P, 1993, J RHEUMATOL, V20, P1388; MADDISON P, 1997, OXFORD TXB RHEUMATOL; MCDOWELL TL, 1995, ARTHRITIS RHEUM, V38, P221, DOI 10.1002/art.1780380210; Melian A, 1996, CURR OPIN IMMUNOL, V8, P82, DOI 10.1016/S0952-7915(96)80109-9; MILLER LC, 1993, LANCET, V341, P146, DOI 10.1016/0140-6736(93)90006-3; Miossec P, 1996, IMMUNOL TODAY, V17, P170, DOI 10.1016/0167-5699(96)80615-3; Mouy R, 1996, J PEDIATR-US, V129, P750, DOI 10.1016/S0022-3476(96)70160-9; MULLER K, IN PRESS BR J RHEUMA; Munthe E, 1978, CARE RHEUMATIC CHILD, P47; Murray KJ, 1996, J RHEUMATOL, V23, P2116; OEN K, 1995, J RHEUMATOL, V22, P745; PAUL C, 1993, IMMUNOGENETICS, V37, P442; Peterson LS, 1996, ARTHRITIS RHEUM, V39, P1385, DOI 10.1002/art.1780390817; Prakken ABJ, 1997, IMMUNOL LETT, V57, P139, DOI 10.1016/S0165-2478(97)00090-4; PRIEUR AM, 1987, CLIN EXP RHEUMATOL, V5, P217; PRITCHARD MH, 1989, BRIT J RHEUMATOL, V28, P521; PRITCHARD MH, 1988, BRIT J RHEUMATOL, V27, P176; PUGH MT, 1993, BRIT J RHEUMATOL, V32, P838; ROSENBERG AM, 1990, J RHEUMATOL, V17, P827; SILVERMAN ED, 1993, CLIN EXP IMMUNOL, V91, P90; SOUTHWOOD TR, 1997, CONTROVERSIES RHEUMA; SULLIVAN DB, 1975, ARTHRITIS RHEUM, V18, P251, DOI 10.1002/art.1780180309; Symmons DPM, 1996, J RHEUMATOL, V23, P1975; TAUROG JD, 1994, J EXP MED, V180, P2359, DOI 10.1084/jem.180.6.2359; TOWNER SR, 1983, ARTHRITIS RHEUM-US, V26, P1208, DOI 10.1002/art.1780261006; WALLACE CA, 1991, RHEUM DIS CLIN N AM, V17, P891; White PH, 1996, BRIT J RHEUMATOL, V35, P80; Woo P, 1997, ARTHRITIS RHEUM, V40, P97; Woo P, 1997, RHEUM DIS CLIN N AM, V23, P491, DOI 10.1016/S0889-857X(05)70344-6; Woo Patricia, 1997, Arthritis and Rheumatism, V40, pS47; WOO PMM, 1994, CLIN EXP RHEUMATOL, V12, pS87	50	87	94	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 28	1998	351	9107					969	973						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734957				2022-12-28	WOS:000072770900045
J	Parker, RA; Hartman, EE				Parker, RA; Hartman, EE			A 73-year-old man with symptomatic benign prostatic hyperplasia, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Barry MJ, 1997, JAMA-J AM MED ASSOC, V278, P2178	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 30	1998	280	12					1092	1092		10.1001/jama.280.12.1092	http://dx.doi.org/10.1001/jama.280.12.1092			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FJ	9757858				2022-12-28	WOS:000076002400039
J	Gronbaek, M; Becker, U; Johansen, D; Tonnesen, H; Jensen, G; Sorensen, TIA				Gronbaek, M; Becker, U; Johansen, D; Tonnesen, H; Jensen, G; Sorensen, TIA			Population based cohort study of the association between alcohol intake and cancer of the upper digestive tract	BRITISH MEDICAL JOURNAL			English	Article							UPPER AERODIGESTIVE TRACT; ESOPHAGEAL CANCER; RISK-FACTORS; ORAL-CANCER; CONSUMPTION; MORTALITY; DRINKING; BEVERAGE; ETIOLOGY; SMOKING	Objective: To examine the relation between different types of alcoholic drinks and upper digestive tract cancers (oropharyngeal and oesophageal). Design: Population based study with baseline assessment or intake or beer, wine, and spirits, smoking habits, educational level, and 2-19 years' follow up on risk of upper digestive tract cancer. Setting: Denmark. Subjects: 15 117 men and 13 063 women aged 20 to 98 years. Main outcome measure: Number and time of identification of incident upper digestibe tract cancer during follow up. Results: During a mean follow up of 13.5 years, 156 subjects developed upper digestive tract cancer. Compared with non-drinkers (drinkers of <1 drink/week), subjects who drank 7-21 beers or spirits a week but no wine were at a risk of 3.0 (95% confidence interval 1.5 to 6.1), whereas those who had the same total alcohol intake but with wine as greater than or equal to 30% Of their intake had a risk of 0.5 (0.2 to 1.4). Drinkers of >21 beers and spirits but no wine had a relative risk of 5.2 (2.7 to 10.2) compared with non-drinkers, whereas those who drank the same amount, but included wine in their alcohol intake, had a relative risk of 1.7 (0.6 to 4.4). Conclusion: A moderate intake of wine probably does not increase the risk of upper digestive tract cancer, whereas a moderate intake of beer or spirits increases the risk considerably.	Kommunehosp, Inst Prevent Med, Danish Epidemiol Sci Ctr, Copenhagen Ctr Prospect Populat Studies, DK-1399 Copenhagen K, Denmark; Hvidovre Univ Hosp, Dept Med Gastroenterol, Alcohol Unit, DK-2650 Hvidovre, Denmark; Hvidovre Univ Hosp, Dept Surg Gastroenterol, DK-2650 Hvidovre, Denmark; Bispebjerg Univ Hosp, Epidemiol Res Unit, Copenhagen City Heart City, DK-2400 Copenhagen NV, Denmark	Aarhus University; University of Copenhagen; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital	Gronbaek, M (corresponding author), Kommunehosp, Inst Prevent Med, Danish Epidemiol Sci Ctr, Copenhagen Ctr Prospect Populat Studies, DK-1399 Copenhagen K, Denmark.		Becker, Ulrik/D-2657-2012	Becker, Ulrik/0000-0002-1678-7771; Gronbaek, Morten Klocker/0000-0002-8473-6474; Tonnesen, Hanne/0000-0002-7161-3416				Andersen P. K., 2012, STAT MODELS BASED CO; Appleyard M., 1989, SCAND J SOC MED, V41, P1; BLOT WJ, 1988, CANCER RES, V48, P3282; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; DECARLI A, 1987, Nutrition and Cancer, V10, P29; GAO YT, 1994, INT J CANCER, V58, P192, DOI 10.1002/ijc.2910580208; Gronbaek M, 1996, EUR J CLIN NUTR, V50, P487; GRONBAEK M, 1995, BRIT MED J, V310, P1165, DOI 10.1136/bmj.310.6988.1165; HEIN HO, 1993, LANCET, V341, P392, DOI 10.1016/0140-6736(93)92987-5; HEITMANN BL, 1993, INT J OBESITY, V17, P329; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; KABAT GC, 1989, INT J CANCER, V43, P190, DOI 10.1002/ijc.2910430203; KATO I, 1992, CANCER CAUSE CONTROL, V3, P145, DOI 10.1007/BF00051654; Lieber C. S., 1992, MED NUTR COMPLICATIO; Macfarlane GJ, 1996, J EPIDEMIOL COMMUN H, V50, P636, DOI 10.1136/jech.50.6.636; MERLETTI F, 1989, CANCER RES, V49, P4919; OLSEN J, 1985, J EPIDEMIOL COMMUN H, V39, P304, DOI 10.1136/jech.39.4.304; Storm HH, 1989, CANC INCIDENCE DENMA; TAVANI A, 1993, CANCER-AM CANCER SOC, V72, P2531, DOI 10.1002/1097-0142(19931101)72:9<2531::AID-CNCR2820720903>3.0.CO;2-T; TUYNS AJ, 1979, INT J CANCER, V23, P443, DOI 10.1002/ijc.2910230402; Uenobe F, 1997, MUTAT RES-FUND MOL M, V373, P197, DOI 10.1016/S0027-5107(96)00191-1; WINN DM, 1995, AM J CLIN NUTR, V61, p437S, DOI 10.1093/ajcn/61.2.437S	22	140	147	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1998	317	7162					844	847		10.1136/bmj.317.7162.844	http://dx.doi.org/10.1136/bmj.317.7162.844			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748175	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000076222300015
J	Lyons, R; Payne, C; McCabe, M; Fielder, C				Lyons, R; Payne, C; McCabe, M; Fielder, C			Legibility of doctors' handwriting: quantitative comparative study	BRITISH MEDICAL JOURNAL			English	Article									Iechyd Morgannwg Hlth, Dept Publ Hlth, Swansea SA1 1LT, W Glam, Wales; Morriston Hosp NHS Trust, Dept Accid & Emergency, Swansea SA6 6NL, W Glam, Wales; Singleton Hosp, Swansea NHS Trust, Dept Otolaryngol, Swansea SA2 8QA, W Glam, Wales	Morriston Hospital; Singleton Hospital	Payne, C (corresponding author), Iechyd Morgannwg Hlth, Dept Publ Hlth, Swansea SA1 1LT, W Glam, Wales.		Lyons, Ronan/G-7741-2012	Lyons, Ronan/0000-0001-5225-000X				Berwick DM, 1996, BRIT MED J, V313, P1657, DOI 10.1136/bmj.313.7072.1657; *CARD SOFTW, 1996, TEL WIND; Kelly A M, 1993, N Z Med J, V106, P363; MULLAN K, 1989, J ROY COLL GEN PRACT, V39, P347	4	34	35	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1998	317	7162					863	864		10.1136/bmj.317.7162.863	http://dx.doi.org/10.1136/bmj.317.7162.863			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748186	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000076222300023
J	Moser, EI; Krobert, KA; Moser, MB; Morris, RGM				Moser, EI; Krobert, KA; Moser, MB; Morris, RGM			Impaired spatial learning after saturation of long-term potentiation	SCIENCE			English	Article							HIPPOCAMPAL SYNAPTIC TRANSMISSION; SILENT SYNAPSES; MUTANT MICE; WATER-MAZE; MEMORY; ENHANCEMENT; LTP; RATS; ACQUISITION; INFORMATION	If information is stored as activity-driven increases in synaptic weights in the hippocampal formation, saturation of hippocampal long-term potentiation (LTP) should impair learning. Here, rats in which one hippocampus had been lesioned were implanted with a multielectrode stimulating array across and into the angular bundle afferent to the other hippocampus. Repeated cross-bundle tetanization caused cumulative potentiation. Residual synaptic plasticity was assessed by tetanizing a naive test electrode in the center of the bundle. Spatial learning was disrupted in animals with no residual LTP (<10 percent) but not in animals that were capable of further potentiation, Thus, saturation of hippocampal LTP impairs spatial learning.	Norwegian Univ Sci & Technol, Dept Psychol, N-7034 Trondheim, Norway; Univ Oslo, Rikshosp, Inst Surg Res, Cardiovasc Res Ctr, N-0027 Oslo, Norway; Univ Edinburgh, Ctr Neurosci, Edinburgh EH8 9LE, Midlothian, Scotland	Norwegian University of Science & Technology (NTNU); University of Oslo; National Hospital Norway; University of Edinburgh	Moser, EI (corresponding author), Norwegian Univ Sci & Technol, Dept Psychol, N-7034 Trondheim, Norway.		Morris, Richard G M/C-9982-2013					BARNES CA, 1994, J NEUROSCI, V14, P5793; BERGER TW, 1984, SCIENCE, V224, P627, DOI 10.1126/science.6324350; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLISS TVP, 1993, HIPPOCAMPUS, V3, P123, DOI 10.1002/hipo.450030203; CAIN DP, 1993, HIPPOCAMPUS, V3, P153, DOI 10.1002/hipo.450030208; CASTRO CA, 1989, NATURE, V342, P545, DOI 10.1038/342545a0; Errington ML, 1997, NATURE, V387, P666, DOI 10.1038/42625; FREY U, 1995, NEUROSCIENCE, V67, P799, DOI 10.1016/0306-4522(95)00117-2; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JARRARD LE, 1989, J NEUROSCI METH, V29, P251, DOI 10.1016/0165-0270(89)90149-0; JEFFERY KJ, 1993, HIPPOCAMPUS, V3, P141; KOROL DL, 1993, HIPPOCAMPUS, V3, P127, DOI 10.1002/hipo.450030204; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; MCNAUGHTON BL, 1986, J NEUROSCI, V6, P563; MCNAUGHTON BL, 1983, NEUROBIOLOGY HIPPOCA, P233; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1986, Q J EXP PSYCHOL-B, V38, P365; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MOSER E, 1993, J NEUROSCI, V13, P3916; MOSER E, 1993, SCIENCE, V259, P1324, DOI 10.1126/science.8446900; MOSER MB, 1995, P NATL ACAD SCI USA, V92, P9697, DOI 10.1073/pnas.92.21.9697; NostenBertrand M, 1996, NATURE, V379, P826, DOI 10.1038/379826a0; ROBINSON GB, 1992, HIPPOCAMPUS, V2, P389, DOI 10.1002/hipo.450020406; SHORS TJ, 1989, SCIENCE, V244, P224, DOI 10.1126/science.2704997; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; TEYLER TJ, 1987, ANNU REV NEUROSCI, V10, P131, DOI 10.1146/annurev.ne.10.030187.001023; TREVES A, 1994, HIPPOCAMPUS, V4, P374, DOI 10.1002/hipo.450040319; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Yeckel MF, 1998, J NEUROSCI, V18, P438	34	360	372	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					2038	2042		10.1126/science.281.5385.2038	http://dx.doi.org/10.1126/science.281.5385.2038			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748165				2022-12-28	WOS:000076161800059
J	Galimand, M; Gerbaud, G; Guibourdenche, M; Riou, JY; Courvalin, P				Galimand, M; Gerbaud, G; Guibourdenche, M; Riou, JY; Courvalin, P			High-level chloramphenicol resistance in Neisseria meningitidis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLOSTRIDIUM-PERFRINGENS; SULFONAMIDE RESISTANCE; TRANSPOSON TN4451; MUTAGENESIS; SEROGROUP; GENETICS; EXCISES; CLONING; STRAINS	Background Neisseria meningitidis is nearly always susceptible to the penicillins, the cephalosporins, and chloramphenicol. Between 1987 and 1996, however, chloramphenicol-resistant strains were isolated from 11 patients in Vietnam and 1 in France. Methods The minimal inhibitory concentration of chloramphenicol was determined for the 12 isolates. The isolates were analyzed by monoclonal-antibody-based serotyping and subtyping, pulsed-field gel electrophoresis, and multilocus enzyme electrophoresis. Bacterial DNA was analyzed by hybridization, the polymerase chain reaction, and sequencing to identify the resistance gene and determine the origin of the resistance. Results The isolates were resistant to chloramphenicol (minimal inhibitory concentration, greater than or equal to 64 mg per liter) and produced an active chloramphenicol acetyltransferase. All 12 strains belonged to serogroup B but had a high degree of diversity, and 10 could not be typed with the use of monoclonal antibodies. The nucleotide sequence of the resistance gene and the flanking regions was identical to that of an internal portion of transposon Tn4451 that carries the catP gene in Clostridium perfringens. Moreover, this gene was located in the same genomic site in the chloramphenicol-resistant isolates. Conclusions The high-level chloramphenicol resistance that we describe in N. meningitidis isolates is of great concern, since in developing countries, chloramphenicol given intramuscularly is the standard therapy for meningococcal meningitis. The resistance to chloramphenicol is due to the presence of the catP gene on a truncated transposon that has lost mobility because of internal deletions, and the transformation of genetic material between strains of N. meningitidis probably played an important part in the dissemination of the gene. (N Engl J Med 1998;339:868-74.) (C)1998, Massachusetts Medical Society.	Inst Pasteur, Unite Agents Antibacteriens, Natl Reference Ctr Meningococci, F-75724 Paris 15, France; Inst Pasteur, Natl Reference Ctr Antibiotics, F-75724 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Galimand, M (corresponding author), Inst Pasteur, Unite Agents Antibacteriens, Natl Reference Ctr Meningococci, 28 Rue Dr Roux, F-75724 Paris 15, France.							Abadi FJR, 1996, ANTIMICROB AGENTS CH, V40, P646, DOI 10.1128/AAC.40.3.646; ABDILLAHI H, 1987, FEMS MICROBIOL LETT, V48, P367, DOI 10.1016/0378-1097(87)90077-2; ABRAHAM LJ, 1988, PLASMID, V19, P164, DOI 10.1016/0147-619X(88)90055-8; Achtman M, 1995, MENINGOCOCCAL DIS, P159; BANNAM TL, 1995, MOL MICROBIOL, V16, P535, DOI 10.1111/j.1365-2958.1995.tb02417.x; BOWLER LD, 1994, J BACTERIOL, V176, P333, DOI 10.1128/JB.176.2.333-337.1994; CAUGANT DA, 1987, J BACTERIOL, V169, P2781, DOI 10.1128/jb.169.6.2781-2792.1987; CAUGANT DA, 1986, P NATL ACAD SCI USA, V83, P4927, DOI 10.1073/pnas.83.13.4927; FERMER C, 1995, J BACTERIOL, V177, P4669, DOI 10.1128/jb.177.16.4669-4675.1995; FUNATSU G, 1972, J MOL BIOL, V68, P547, DOI 10.1016/0022-2836(72)90108-8; GASCOYNEBINZI DM, 1994, J ANTIMICROB CHEMOTH, V34, P1015, DOI 10.1093/jac/34.6.1015; Haas M J, 1975, Methods Enzymol, V43, P611; HOKE C, 1982, INT J SYST BACTERIOL, V32, P57, DOI 10.1099/00207713-32-1-57; KELLOGG DS, 1963, J BACTERIOL, V85, P1274, DOI 10.1128/JB.85.6.1274-1279.1963; Knapp Joan S., 1995, P324; KRISTIANSEN BE, 1990, ANTIMICROB AGENTS CH, V34, P2277, DOI 10.1128/AAC.34.11.2277; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; NASSIF X, 1991, J BACTERIOL, V173, P2147, DOI 10.1128/JB.173.7.2147-2154.1991; Nolte O, 1997, J ANTIMICROB CHEMOTH, V39, P747, DOI 10.1093/jac/39.6.747; Oppenheim BA, 1997, CLIN INFECT DIS, V24, pS98, DOI 10.1093/clinids/24.Supplement_1.S98; RADSTROM P, 1992, J BACTERIOL, V174, P6386; ROBERTS MC, 1990, ANTIMICROB AGENTS CH, V34, P476, DOI 10.1128/AAC.34.3.476; Sambrok J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shaw W V, 1975, Methods Enzymol, V43, P737; STEFFEN C, 1989, GENE, V75, P349, DOI 10.1016/0378-1119(89)90282-5; SWARTLEY JS, 1993, MOL MICROBIOL, V10, P299, DOI 10.1111/j.1365-2958.1993.tb01956.x; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; VEDROS NA, 1978, METHOD MICROBIOL, V10, P293; WINTERSCHEID KK, 1994, ANTIMICROB AGENTS CH, V38, P1661, DOI 10.1128/AAC.38.7.1661; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	31	81	85	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1998	339	13					868	874		10.1056/NEJM199809243391302	http://dx.doi.org/10.1056/NEJM199809243391302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121VY	9744970				2022-12-28	WOS:000076037400002
J	Bryant, CA; Ouldred, E; Jackson, SHD; Kinirons, MT				Bryant, CA; Ouldred, E; Jackson, SHD; Kinirons, MT			Purpuric rash with donepezil treatment	BRITISH MEDICAL JOURNAL			English	Letter							ALZHEIMERS-DISEASE		Univ London Kings Coll, Sch Med & Dent, Dept Hlth Care Elderly, Clin Age Res Unit, London SE5 9PJ, England; Guys Hosp, Dept Geriatr & Gen Med, London SE1 9RT, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Bryant, CA (corresponding author), Univ London Kings Coll, Sch Med & Dent, Dept Hlth Care Elderly, Clin Age Res Unit, London SE5 9PJ, England.							MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Rogers SL, 1996, DEMENTIA, V7, P293, DOI 10.1159/000106895	2	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					787	787		10.1136/bmj.317.7161.787	http://dx.doi.org/10.1136/bmj.317.7161.787			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740567	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000076084200031
J	Green, DR				Green, DR			Apoptotic pathways: The roads to ruin	CELL			English	Review							CYTOCHROME-C; MITOCHONDRIA; RELEASE; BCL-2		La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Green, DR (corresponding author), La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417				Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STENNICKE HR, 1998, IN PRESS J BIOL CHEM; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	24	1047	1113	0	33	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					695	698		10.1016/S0092-8674(00)81728-6	http://dx.doi.org/10.1016/S0092-8674(00)81728-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753316	Bronze			2022-12-28	WOS:000076021200002
J	Treiman, DM; Meyers, PD; Walton, NY; Collins, JF; Colling, C; Rowan, AJ; Handforth, A; Faught, E; Calabrese, VP; Uthman, BM; Ramsay, RE; Mamdani, MB				Treiman, DM; Meyers, PD; Walton, NY; Collins, JF; Colling, C; Rowan, AJ; Handforth, A; Faught, E; Calabrese, VP; Uthman, BM; Ramsay, RE; Mamdani, MB		Vet Affairs Status Epilepticus Cooperative	A comparison of four treatments for generalized convulsive status epilepticus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENOUS PHENYTOIN; LORAZEPAM; DIAZEPAM; SEIZURES	Background and Methods Although generalized convulsive status epilepticus is a life-threatening emergency, the best initial drug treatment is uncertain. We conducted a five-year randomized, double-blind, multicenter trial of four intravenous regimens: diazepam (0.15 mg per kilogram of body weight) followed by phenytoin (18 mg per kilogram), lorazepam (0.1 mg per kilogram), phenobarbital (15 mg per kilogram), and phenytoin (18 mg per kilogram). Patients were classified as having either overt generalized status epilepticus (defined as easily visible generalized convulsions) or subtle status epilepticus (indicated by coma and ictal discharges on the electroencephalogram, with or without subtle convulsive movements such as rhythmic muscle twitches or tonic eye deviation). Treatment was considered successful when all motor and electroencephalographic seizure activity ceased within 20 minutes after the beginning of the drug infusion and there was no return of seizure activity during the next 40 minutes. Analyses were performed with data on only the 518 patients with verified generalized convulsive status epilepticus as well as with data on all 570 patients who were enrolled. Results Three hundred eighty-four patients had a verified diagnosis of overt generalized convulsive status epilepticus. In this group, lorazepam was successful in 64.9 percent of those assigned to receive it, phenobarbital in 58.2 percent, diazepam and phenytoin in 55.8 percent, and phenytoin in 43.6 percent (P=0.02 for the overall comparison among the four groups). Lorazepam was significantly superior to phenytoin in a pairwise comparison (P=0.002). Among the 134 patients with a verified diagnosis of subtle generalized convulsive status epilepticus, no significant differences among the treatments were detected (range of success rates, 7.7 to 24.2 percent). In an intention-to-treat analysis, the differences among treatment groups were not significant, either among the patients with overt status epilepticus (P=0.12) or among those with subtle status epilepticus (P=0.91). There were no differences among the treatments with respect to recurrence during the 12-hour study period, the incidence of adverse reactions, or the outcome at 30 days. Conclusions As initial intravenous treatment for overt generalized convulsive status epilepticus, lorazepam is more effective than phenytoin. Although lorazepam is no more efficacious than phenobarbital or diazepam and phenytoin, it is easier to use. (N Engl J Med 1998;339:792-8.) (C) 1998, Massachusetts Medical Society.	Vet Affairs Med Ctr, Neurol Serv, W Los Angeles, CA USA; Vet Affairs Med Ctr, Neurol Serv, Bronx, NY USA; Vet Affairs Med Ctr, Neurol Serv, Birmingham, AL USA; Vet Affairs Med Ctr, Neurol Serv, Richmond, VA USA; Vet Affairs Med Ctr, Neurol Serv, Gainesville, FL 32608 USA; Vet Affairs Med Ctr, Neurol Serv, Miami, FL 33125 USA; Hines Vet Affairs Med Ctr, Neurol Serv, Chicago, IL USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA; Mt Sinai Coll Med, Dept Neurol, New York, NY USA; Univ Alabama, Sch Med, Dept Neurol, Birmingham, AL USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurol, Richmond, VA 23298 USA; Univ Florida, Sch Med, Dept Neurol, Gainesville, FL USA; Univ Miami, Sch Med, Dept Neurol, Miami, FL USA; Loyola Univ, Sch Med, Dept Neurol, Chicago, IL 60611 USA; Vet Affairs Cooperat Studies Program, Coordinating Ctr, Dept Neurol, Perry Point, MD USA; Vet Affairs Cooperat Studies Program, Clin Res Pharm Coordinating Ctr, Dept Neurol, Albuquerque, NM USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Hunter Holmes McGuire Veterinary Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Icahn School of Medicine at Mount Sinai; University of Alabama System; University of Alabama Birmingham; Virginia Commonwealth University; State University System of Florida; University of Florida; University of Miami; Loyola University Chicago	Treiman, DM (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, 97 Paterson St, New Brunswick, NJ 08901 USA.		Faught, Raymond Edward/F-7767-2010; Ramsay, R. Eugene/D-4491-2011					AMAND G, 1976, REV EEG NEUROPHYSIOL, V6, P532, DOI 10.1016/S0370-4475(76)80024-X; CARTER CH, 1958, ARCH NEURO PSYCHIATR, V79, P136, DOI 10.1001/archneurpsyc.1958.02340020016003; CRANFORD RE, 1979, NEUROLOGY, V29, P1474, DOI 10.1212/WNL.29.11.1474; CRAWFORD TO, 1988, NEUROLOGY, V38, P1035, DOI 10.1212/WNL.38.7.1035; CRAWFORD TO, 1987, NEUROLOGY, V37, P190, DOI 10.1212/WNL.37.2.190; De Oliveira RSP, 1978, REV BRAS CLIN THER, V7, P295; Delgado-Escueta A V, 1983, Adv Neurol, V34, P477; DELORENZO RJ, 1995, J CLIN NEUROPHYSIOL, V12, P316; DODSON WE, 1993, JAMA-J AM MED ASSOC, V270, P854; Everitt B.S., 1977, ANAL CONTINGENCY TAB; GABOR AJ, 1990, J EPILEPSY, V3, P3, DOI 10.1016/0896-6974(90)90070-F; Goldberg M A, 1983, Adv Neurol, V34, P499; GRIFFITH PA, 1980, ANN NEUROL, V7, P493, DOI 10.1002/ana.410070521; HAUSER WA, 1990, NEUROLOGY, V40, P9; LACEY DJ, 1986, J PEDIATR-US, V108, P771, DOI 10.1016/S0022-3476(86)81065-4; Leppik I E, 1983, Adv Neurol, V34, P447; LEPPIK IE, 1983, JAMA-J AM MED ASSOC, V249, P1452, DOI 10.1001/jama.249.11.1452; LEVY RJ, 1984, ARCH NEUROL-CHICAGO, V41, P605, DOI 10.1001/archneur.1984.04210080013006; MCWILLIAM PKA, 1958, LANCET, V2, P1147; MURPHY JT, 1956, JAMA-J AM MED ASSOC, V160, P385, DOI 10.1001/jama.1956.02960400043010; RAMSAY RE, 1979, ARCH NEUROL-CHICAGO, V36, P535, DOI 10.1001/archneur.1979.00500450029003; *SAS I, 1989, SAS STAT US GUID VER; SHANER DM, 1988, NEUROLOGY, V38, P202, DOI 10.1212/WNL.38.2.202; SOREL L, 1981, CLIN THER, V4, P326; SUTHERLAND JM, 1969, EPIEPSIES MODERN DIA; TREIMAN DM, 1993, EPILEPSIA, V34, pS2, DOI 10.1111/j.1528-1157.1993.tb05902.x; TREIMAN DM, 1990, EPILEPSY RES, V5, P49, DOI 10.1016/0920-1211(90)90065-4; von Albert H H, 1983, Adv Neurol, V34, P453; WALKER JE, 1979, ANN NEUROL, V6, P207, DOI 10.1002/ana.410060305; WALLIS W, 1968, NEUROLOGY, V18, P513, DOI 10.1212/WNL.18.6.513; Waltregny A, 1975, Acta Neurol Belg, V75, P219; Wilder B J, 1983, Adv Neurol, V34, P441; WILDER BJ, 1977, ANN NEUROL, V1, P511, DOI 10.1002/ana.410010602	33	867	891	0	33	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1998	339	12					792	798		10.1056/NEJM199809173391202	http://dx.doi.org/10.1056/NEJM199809173391202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119QT	9738086	Green Published			2022-12-28	WOS:000075909200002
J	Shimon, I; Melmed, S				Shimon, I; Melmed, S			Management of pituitary tumors	ANNALS OF INTERNAL MEDICINE			English	Review							LONG-TERM TREATMENT; PROLACTIN-SECRETING MACROADENOMAS; ANALOG SMS 201-995; SOMATOSTATIN RECEPTOR SUBTYPES; THYROID-STIMULATING HORMONE; SLOW-RELEASE LANREOTIDE; GROWTH-HORMONE; DOPAMINE AGONIST; ACROMEGALIC PATIENTS; CUSHINGS-SYNDROME	Management of pituitary tumors has improved in the past decade since the introduction of novel therapeutic agents. As a result, several treatment options are now available. Dopamine agonists are the preferred treatment for both symptomatic microprolactinomas and macroprolactinomas; these drugs result in normalization of hormone levels and tumor shrinkage in most treated patients. New formulations (such as cabergoline and parenteral bromocriptine) with prolonged duration of action offer improved compliance with treatment and cure rates. For acromegaly and adrenocorticotropin hormone (ACTH)-secreting, thyroid-stimulating hormone (TSH)-secreting, and nonfunctional adenomas, surgery often results in cure. Octreotide and the long-acting, slow-release somatostatin analogues are effective medical alternatives to or adjuvants for transsphenoidal surgery in patients with growth hormone-secreting and TSH-secreting tumors. No drug treatment is available for symptomatic nonfunctional tumors, and patients with ACTH-secreting adenomas may benefit from cortisol-lowering drugs after surgical failure. Pituitary irradiation may be required after surgery for ACTH-secreting, TSH-secreting, and nonfunctioning tumors; it is less commonly required for acromegaly. Although many pituitary tumors are successfully resected, functional adenomas may not be cured by surgery. As more-effective drugs are introduced for the management of pituitary tumors, more patients with hormone-secreting adenomas are being successfully treated medically.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Melmed, S (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Room 2015,8700 Beverly Blvd, Los Angeles, CA 90048 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050238] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-50238] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barkan AL, 1997, J CLIN ENDOCR METAB, V82, P3187, DOI 10.1210/jc.82.10.3187; BATES AS, 1993, Q J MED, V86, P293; BeckPeccoz P, 1996, ENDOCR REV, V17, P610, DOI 10.1210/er.17.6.610; BENGTSSON BA, 1988, ACTA MED SCAND, V223, P327; BEREZIN M, 1995, J ENDOCRINOL INVEST, V18, P436, DOI 10.1007/BF03349742; BEREZIN M, 1984, J CLIN ENDOCR METAB, V59, P1220, DOI 10.1210/jcem-59-6-1220; BESSER GM, 1972, BRIT MED J, V3, P669, DOI 10.1136/bmj.3.5828.669; BEVAN JS, 1992, ENDOCR REV, V13, P220, DOI 10.1210/er.13.2.220; BEVAN JS, 1994, CLIN ENDOCRINOL, V41, P709, DOI 10.1111/j.1365-2265.1994.tb02782.x; Biller BMK, 1996, J CLIN ENDOCR METAB, V81, P2338, DOI 10.1210/jc.81.6.2338; BOULOUX PMG, 1987, BRIT MED J, V294, P1323, DOI 10.1136/bmj.294.6583.1323-a; BRONSTEIN MD, 1987, HORM METAB RES, V19, P271, DOI 10.1055/s-2007-1011796; BRUE T, 1992, J CLIN ENDOCR METAB, V74, P577, DOI 10.1210/jc.74.3.577; Caron P, 1997, J CLIN ENDOCR METAB, V82, P18, DOI 10.1210/jc.82.1.18; CHANSON P, 1993, ANN INTERN MED, V119, P236, DOI 10.7326/0003-4819-119-3-199308010-00010; CHEN WY, 1994, J BIOL CHEM, V269, P15892; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CHIODINI P, 1981, J CLIN ENDOCR METAB, V53, P737, DOI 10.1210/jcem-53-4-737; CICCARELLI E, 1993, J CLIN ENDOCR METAB, V76, P484, DOI 10.1210/jc.76.2.484; Colao A, 1997, J CLIN ENDOCR METAB, V82, P518, DOI 10.1210/jc.82.2.518; Colao A, 1997, J CLIN ENDOCR METAB, V82, P876, DOI 10.1210/jc.82.3.876; COMI RJ, 1987, NEW ENGL J MED, V317, P12, DOI 10.1056/NEJM198707023170103; DEBRUIN TWA, 1992, J CLIN ENDOCR METAB, V75, P1310, DOI 10.1210/jc.75.5.1310; deHerder WW, 1996, CLIN ENDOCRINOL, V45, P755, DOI 10.1046/j.1365-2265.1996.8650876.x; ESIRI MM, 1986, J CLIN ENDOCR METAB, V63, P383, DOI 10.1210/jcem-63-2-383; EZZAT S, 1992, ANN INTERN MED, V117, P711, DOI 10.7326/0003-4819-117-9-711; FAHLBUSCH R, 1992, ENDOCRIN METAB CLIN, V21, P669, DOI 10.1016/S0889-8529(18)30208-1; Feigenbaum SL, 1996, J CLIN ENDOCR METAB, V81, P1711, DOI 10.1210/jc.81.5.1711; FLOGSTAD AK, 1994, J CLIN ENDOCR METAB, V79, P461, DOI 10.1210/jc.79.2.461; Flogstad AK, 1997, J CLIN ENDOCR METAB, V82, P23, DOI 10.1210/jc.82.1.23; FLOGSTAD AK, 1995, J CLIN ENDOCR METAB, V80, P3601, DOI 10.1210/jc.80.12.3601; FRIEDMAN E, 1994, J CLIN ENDOCR METAB, V78, P568, DOI 10.1210/jc.78.3.568; GANCEL A, 1994, CLIN ENDOCRINOL, V40, P421; Giusti M, 1996, J CLIN ENDOCR METAB, V81, P2089, DOI 10.1210/jc.81.6.2089; GOMEZ F, 1977, AM J MED, V62, P648, DOI 10.1016/0002-9343(77)90866-X; GREENMAN Y, 1994, J CLIN ENDOCR METAB, V78, P398, DOI 10.1210/jc.78.2.398; GREENMAN Y, 1994, J CLIN ENDOCR METAB, V79, P724, DOI 10.1210/jc.79.3.724; GRUNSTEIN RR, 1994, ANN INTERN MED, V121, P478, DOI 10.7326/0003-4819-121-7-199410010-00002; HAASE R, 1993, CLIN ENDOCRINOL, V38, P165, DOI 10.1111/j.1365-2265.1993.tb00989.x; HERON I, 1993, J CLIN ENDOCR METAB, V76, P721, DOI 10.1210/jc.76.3.721; HOMBURG R, 1990, CLIN ENDOCRINOL, V32, P565, DOI 10.1111/j.1365-2265.1990.tb00899.x; HOWLETT TA, 1997, P END SOC 79 ANN M M; ITUARTE EA, 1984, ANN INTERN MED, V101, P627, DOI 10.7326/0003-4819-101-5-627; JAFFE CA, 1993, J CLIN INVEST, V92, P695, DOI 10.1172/JCI116639; JAFFE CA, 1992, ENDOCRIN METAB CLIN, V21, P713, DOI 10.1016/S0889-8529(18)30210-X; JOHNSTON DG, 1984, LANCET, V2, P187; KATZ E, 1989, OBSTET GYNECOL, V73, P517; KATZNELSON L, 1992, J CLIN ENDOCR METAB, V75, P1318, DOI 10.1210/jc.75.5.1318; KLEINBERG DL, 1983, NEW ENGL J MED, V309, P704, DOI 10.1056/NEJM198309223091205; KLETZKY OA, 1989, FERTIL STERIL, V51, P269; KLIBANSKI A, 1987, J CLIN ENDOCR METAB, V64, P536, DOI 10.1210/jcem-64-3-536; KLIBANSKI A, 1991, NEW ENGL J MED, V324, P822; Kovacs M, 1996, ENDOCRINOLOGY, V137, P5364, DOI 10.1210/en.137.12.5364; LAMBERTS SWJ, 1985, NEW ENGL J MED, V313, P1576, DOI 10.1056/NEJM198512193132504; LAMBERTS SWJ, 1986, CLIN ENDOCRINOL, V25, P201, DOI 10.1111/j.1365-2265.1986.tb01683.x; LAMBERTS SWJ, 1986, J CLIN ENDOCR METAB, V63, P16, DOI 10.1210/jcem-63-1-16; LANDOLT AM, 1984, J CLIN ENDOCR METAB, V58, P1179, DOI 10.1210/jcem-58-6-1179; LIM MJ, 1992, ANN INTERN MED, V117, P719, DOI 10.7326/0003-4819-117-9-719; LIUZZI A, 1985, NEW ENGL J MED, V313, P656, DOI 10.1056/NEJM198509123131103; LUTON JP, 1979, NEW ENGL J MED, V300, P459, DOI 10.1056/NEJM197903013000903; MAMPALAM TJ, 1988, ANN INTERN MED, V109, P487, DOI 10.7326/0003-4819-109-6-487; MCGRATH GA, 1993, J CLIN ENDOCR METAB, V76, P1363, DOI 10.1210/jc.76.5.1363; MELEN O, 1987, ENDOCRIN METAB CLIN, V16, P585, DOI 10.1016/S0889-8529(18)30465-1; MELMED S, 1995, J CLIN ENDOCR METAB, V80, P3395, DOI 10.1210/jc.80.12.3395; Melmed S, 1998, J CLIN ENDOCR METAB, V83, P2646, DOI 10.1210/jc.83.8.2646; MELMED S, 1994, AM J MED, V97, P468; MILLER GM, 1995, J CLIN ENDOCR METAB, V80, P1386, DOI 10.1210/jc.80.4.1386; MILLER JW, 1993, ENDOCR REV, V14, P443, DOI 10.1210/er.14.4.443; MISBIN RI, 1976, J CLIN PHARMACOL, V16, P645, DOI 10.1002/j.1552-4604.1976.tb01504.x; Molitch Mark E., 1995, P443; MOLITCH ME, 1992, ENDOCRIN METAB CLIN, V21, P597, DOI 10.1016/S0889-8529(18)30204-4; MOLITCH ME, 1985, J CLIN ENDOCR METAB, V60, P698, DOI 10.1210/jcem-60-4-698; Molitch ME, 1997, J CLIN ENDOCR METAB, V82, P996, DOI 10.1210/jc.82.4.996; NABARRO JDN, 1987, CLIN ENDOCRINOL, V26, P481, DOI 10.1111/j.1365-2265.1987.tb00805.x; NEWMAN CB, 1995, J CLIN ENDOCR METAB, V80, P2768, DOI 10.1210/jc.80.9.2768; ORSKOV H, 1991, CLIN ENDOCRINOL, V34, P395, DOI 10.1111/j.1365-2265.1991.tb00311.x; PAKES D, 1979, NEW ENGL J MED, V301, P873; PELLEGRINI I, 1989, J CLIN ENDOCR METAB, V69, P500, DOI 10.1210/jcem-69-3-500; PLOCKINGER U, 1994, J CLIN ENDOCR METAB, V79, P1416, DOI 10.1210/jc.79.5.1416; RIDGWAY EC, 1981, NEW ENGL J MED, V304, P1254, DOI 10.1056/NEJM198105213042102; SCHETTINI G, 1990, CLIN ENDOCRINOL, V33, P161, DOI 10.1111/j.1365-2265.1990.tb00479.x; SCHLECHTE J, 1989, J CLIN ENDOCR METAB, V68, P412, DOI 10.1210/jcem-68-2-412; SCHTEINGART DE, 1980, J CLIN ENDOCR METAB, V51, P1195, DOI 10.1210/jcem-51-5-1195; SCHULTE HM, 1990, J CLIN ENDOCR METAB, V70, P1426, DOI 10.1210/jcem-70-5-1426; Shimon I, 1997, J CLIN INVEST, V99, P789, DOI 10.1172/JCI119225; Shimon I, 1997, J CLIN INVEST, V100, P2386, DOI 10.1172/JCI119779; SNYDER PJ, 1995, PITUITARY, V4, P559; STEWART PM, 1995, J CLIN ENDOCR METAB, V80, P3267, DOI 10.1210/jc.80.11.3267; THORNER MO, 1974, BRIT MED J, V2, P419, DOI 10.1136/bmj.2.5916.419; THORNER MO, 1980, J CLIN ENDOCR METAB, V51, P438, DOI 10.1210/jcem-51-3-438; UR E, 1992, CLIN ENDOCRINOL, V36, P147, DOI 10.1111/j.1365-2265.1992.tb00949.x; VANCE ML, 1990, ANN INTERN MED, V112, P668, DOI 10.7326/0003-4819-112-9-668; VANCE ML, 1989, J CLIN ENDOCR METAB, V68, P336, DOI 10.1210/jcem-68-2-336; VANCE ML, 1991, ARCH INTERN MED, V151, P1573; VANCE ML, 1985, J CLIN ENDOCR METAB, V61, P580, DOI 10.1210/jcem-61-3-580; VANCE ML, 1984, ANN INTERN MED, V100, P78, DOI 10.7326/0003-4819-100-1-78; VANTVERLAAT JW, 1991, CLIN ENDOCRINOL, V34, P175, DOI 10.1111/j.1365-2265.1991.tb00289.x; VERHELST JA, 1991, CLIN ENDOCRINOL, V35, P169, DOI 10.1111/j.1365-2265.1991.tb03517.x; WEBSTER J, 1994, NEW ENGL J MED, V331, P904, DOI 10.1056/NEJM199410063311403; WOOD DF, 1991, CLIN ENDOCRINOL, V35, P455, DOI 10.1111/j.1365-2265.1991.tb00928.x	100	79	85	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1998	129	6					472	483		10.7326/0003-4819-129-6-199809150-00009	http://dx.doi.org/10.7326/0003-4819-129-6-199809150-00009			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JJ	9735086				2022-12-28	WOS:000075892100007
J	Fujimoto, S; Kobayashi, M; Uemura, O; Iwasa, M; Ando, T; Katoh, T; Nakamura, G; Maki, N; Togari, H; Wada, Y				Fujimoto, S; Kobayashi, M; Uemura, O; Iwasa, M; Ando, T; Katoh, T; Nakamura, G; Maki, N; Togari, H; Wada, Y			PCR on cerebrospinal fluid to show influenza-associated acute encephalopathy or encephalitis	LANCET			English	Article							CHILDHOOD; JAPAN	Background Except for Reye's syndrome, influenza-associated acute encephalopathy or encephalitis is not universally recognised. We did a multicentre study of laboratory and clinical data for patients with influenza-associated acute encephalopathy or encephalitis. Methods In Nagoya, Japan, ten patients with acute encephalopathy or encephalitis associated with influenza-like illness were admitted to our hospitals between April, 1996, and March, 1997. We collected clinical, laboratory and serological data and assessed cerebrospinal fluid samples by PCR for influenza A and B. Findings Seven patients, aged 22 months to 4 years, had evidence of recent influenza infection, six with type-A/Hong Kong (H3N2) and one with type B. The first sign in the central nervous system appeared within 2 days of fever in all but one patient. The first sign of involvement of the central nervous system was generalised convulsions in all patients. Two patients died, one had sequelae, and four survived without sequelae. PCR for influenza type A was positive for five patients. Interpretation The results of PCR suggest that at least part of the influenza type A genome existed in the central nervous system. influenza-associated acute encephalopathy or encephalitis in young children deserves wider recognition.	Nagoya City Univ, Sch Med, Dept Paediat, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Med, Dept Lab Med, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Moriyama Municipal Hosp, Dept Pediat, Nagoya, Aichi, Japan; Nagoya Daini Red Cross Hosp, Dept Paediat, Nagoya, Aichi, Japan; Higashi Municipal Hosp, Dept Paediat, Nagoya, Aichi, Japan; Josai Municipal Hosp, Dept Paediat, Nagoya, Aichi, Japan	Nagoya City University; Nagoya City University; Japanese Red Cross Nagoya Daini Hospital	Fujimoto, S (corresponding author), Nagoya City Univ, Sch Med, Dept Paediat, Mizuho Ku, Mizuho Cho, Nagoya, Aichi 4678601, Japan.							Crookshank FG, 1919, LANCET, V1, P79; DELONG GR, 1982, PEDIATRICS, V69, P53; DELORME L, 1979, AM J DIS CHILD, V133, P822, DOI 10.1001/archpedi.1979.02130080062011; DUBOWITZ V, 1958, LANCET, V1, P140; FLEWETT TH, 1958, LANCET, V2, P11; Hirota Y, 1996, NATURE, V380, P18, DOI 10.1038/380018a0; ISHIKAWA T, 1993, BRAIN DEV-JPN, V15, P192, DOI 10.1016/0387-7604(93)90064-F; Jeffery KJM, 1997, LANCET, V349, P313, DOI 10.1016/S0140-6736(96)08107-X; Kamimura N, 1997, Nihon Rinsho, V55, P880; LEHMANN NI, 1971, MED J AUSTRALIA, V2, P1166, DOI 10.5694/j.1326-5377.1971.tb92768.x; MATSUZONO Y, 1996, NIHONSYONIKAGAKKAIZA, V100, P1258; MCCONKEY B, 1958, LANCET, V2, P15; MIZUGUCHI M, 1995, J NEUROL NEUROSUR PS, V58, P555, DOI 10.1136/jnnp.58.5.555; Morishita T, 1992, Kansenshogaku Zasshi, V66, P944; ROSE E, 1982, W INDIAN MED J, V31, P29; YAMADA A, 1991, MICROBIOL IMMUNOL, V35, P259, DOI 10.1111/j.1348-0421.1991.tb01555.x; 1970, BMJ, V1, P311	17	163	173	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					873	875		10.1016/S0140-6736(98)12449-2	http://dx.doi.org/10.1016/S0140-6736(98)12449-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742980				2022-12-28	WOS:000075857300010
J	Kahn, HS; Tatham, LM; Patel, AV; Thun, MJ; Heath, CW				Kahn, HS; Tatham, LM; Patel, AV; Thun, MJ; Heath, CW			Increased cancer mortality following a history of nonmelanoma skin cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NON-HODGKINS-LYMPHOMA; BASAL-CELL CARCINOMA; RENAL-TRANSPLANT RECIPIENTS; ULTRAVIOLET-RADIATION; MALIGNANCIES; SUNLIGHT; ASSOCIATION; EXPOSURE; RISK; DNA	Context.-Cancer registries have reported an increased incidence of melanoma and certain noncutaneous cancers following nonmelanoma skin cancer (NMSC). Whether these findings were attributable to intensified surveillance, shared risk factors, or increased cancer susceptibility remains unclear. Objective.-To determine whether a history of NMSC predicts cancer mortality. Design.-Prospective cohort with Ie-year mortality follow-up adjusted for multiple risk factors. Setting.-Cancer Prevention Study II, United States and Puerto Rico. Participants.-Nearly 1.1 million adult volunteers who completed a baseline questionnaire in 1982. Main Outcome Measure.-Deaths due to all cancers and common cancers. Results.-After adjusting for age, race, education, smoking, obesity, alcohol use, and other conventional risk factors, a baseline history of NMSC was associated with increased total cancer mortality (men's relative risk [RR], 1.30; 95% confidence interval [CI], 1.23-1.36; women's RR, 1.26; 95% CI, 1.17-1.35). Exclusion of deaths due to melanoma reduced these RRs only slightly. Mortality was increased for the following cancers: melanoma (RR, 3.36 in men, 3.52 in women); pharynx (RR, 2.77 in men, 2.81 in women); lung (RR, 1.37 in men, 1.46 in women); non-Hodgkin lymphoma (RR, 1.32 in men, 1.50 in women); in men only, salivary glands (RR, 2.96), prostate (RR, 1.28), testis (RR, 12.7), urinary bladder (RR, 1.41), and leukemia (RR, 1.37); and in women only, breast (RR, 1.34). All-cause mortality was slightly increased (adjusted men's RR, 1.03 [95% CI, 1.00-1.06]; women's RR, 1.04 [95% CI, 1.00-1.09]). Conclusions.-Persons with a history of NMSC are at increased risk of cancer mortality. Although the biological mechanisms are unknown, a history of NMSC should increase the clinician's alertness for certain noncutaneous cancers as well as melanoma.	Amer Canc Soc, Dept Epidemiol & Surveillance Res, Atlanta, GA 30329 USA; Emory Univ, Sch Med, Dept Family & Prevent Med, Atlanta, GA USA	American Cancer Society; Emory University	Thun, MJ (corresponding author), Amer Canc Soc, Dept Epidemiol & Surveillance Res, 1599 Clifton Rd NE, Atlanta, GA 30329 USA.		Kahn, Henry S/A-6946-2009	Kahn, Henry S/0000-0003-2533-1562				ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; Au WW, 1996, ENVIRON HEALTH PERSP, V104, P579, DOI 10.2307/3432826; Black Homer S., 1993, Cancer Bulletin (Houston), V45, P232; Boxman ILA, 1997, J INVEST DERMATOL, V108, P712, DOI 10.1111/1523-1747.ep12292090; CALLE EE, 1993, AM J EPIDEMIOL, V137, P235, DOI 10.1093/oxfordjournals.aje.a116664; CARTWRIGHT R, 1994, LEUKEMIA LYMPHOMA, V14, P387, DOI 10.3109/10428199409049694; COX DR, 1972, J R STAT SOC B, V34, P187; English DR, 1997, CANCER CAUSE CONTROL, V8, P271, DOI 10.1023/A:1018440801577; EUVRARD S, 1993, CANCER, V72, P2198, DOI 10.1002/1097-0142(19931001)72:7<2198::AID-CNCR2820720722>3.0.CO;2-Q; Frankel S, 1998, BMJ-BRIT MED J, V316, P499, DOI 10.1136/bmj.316.7130.499; Freedman DM, 1997, BRIT MED J, V314, P1451, DOI 10.1136/bmj.314.7092.1451; Frisch M, 1996, ANN INTERN MED, V125, P815, DOI 10.7326/0003-4819-125-10-199611150-00005; FRISCH M, 1995, AM J EPIDEMIOL, V141, P916, DOI 10.1093/oxfordjournals.aje.a117358; GARFINKEL L, 1992, STAT B METROP INSUR, V73, P21; Goldberg LH, 1997, LANCET, V349, P664, DOI 10.1016/S0140-6736(05)60130-4; HALL P, 1995, INT J CANCER, V62, P519, DOI 10.1002/ijc.2910620505; KRIPKE ML, 1994, CANCER RES, V54, P6102; Leigh IM, 1996, CANCER SURV, V26, P1; Levi F, 1998, AM J EPIDEMIOL, V147, P722; Levi F, 1997, AM J EPIDEMIOL, V146, P734; LINDELOF B, 1991, J AM ACAD DERMATOL, V25, P245, DOI 10.1016/0190-9622(91)70189-9; McMichael AJ, 1996, BRIT J CANCER, V73, P945, DOI 10.1038/bjc.1996.169; Newton R, 1997, BRIT MED J, V314, P1483, DOI 10.1136/bmj.314.7092.1483b; Payne DA, 1995, ANTICANCER RES, V15, P2213; Schottenfeld D, 1996, ANN INTERN MED, V125, P852, DOI 10.7326/0003-4819-125-10-199611150-00011; SCOTTO J, 1996, CANC EPIDEMIOLOGY PR, P1313; Shisler JL, 1998, SCIENCE, V279, P102, DOI 10.1126/science.279.5347.102; SPITZ MR, 1984, CANCER, V54, P1854, DOI 10.1002/1097-0142(19841101)54:9<1854::AID-CNCR2820540915>3.0.CO;2-1; TEPPO L, 1985, J NATL CANCER I, V75, P207; Tyring Stephen K., 1993, Cancer Bulletin (Houston), V45, P212	30	89	90	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1998	280	10					910	912		10.1001/jama.280.10.910	http://dx.doi.org/10.1001/jama.280.10.910			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115LN	9739976	Bronze			2022-12-28	WOS:000075666600038
J	Peterson, WL; Cook, DJ				Peterson, WL; Cook, DJ			Contempo 1998 - Updates linking evidence and experience - Antisecretory therapy for bleeding peptic ulcer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							UPPER GASTROINTESTINAL HEMORRHAGE; PLACEBO-CONTROLLED MULTICENTER; OMEPRAZOLE; RANITIDINE; INJECTION; INFUSION; ACID		Univ Texas, Hlth Sci Ctr, SW Med Sch, Dept Med, Dallas, TX 75235 USA; McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; McMaster University; McMaster University	Peterson, WL (corresponding author), Dept Vet Affairs Med Ctr, Med Serv, 111B1,4500 S Lancaster, Dallas, TX 75216 USA.	w.peterson@juno.com						COLLINS R, 1985, NEW ENGL J MED, V313, P660, DOI 10.1056/NEJM198509123131104; COOK DJ, 1992, GASTROENTEROLOGY, V102, P139, DOI 10.1016/0016-5085(92)91793-4; DANESHMEND TK, 1992, BRIT MED J, V304, P143, DOI 10.1136/bmj.304.6820.143; DeMuckadell OBS, 1997, SCAND J GASTROENTERO, V32, P320, DOI 10.3109/00365529709007679; FELDMAN M, 1988, GASTROENTEROLOGY, V95, P630, DOI 10.1016/S0016-5085(88)80008-8; GREEN FW, 1978, GASTROENTEROLOGY, V74, P38; GROSSO C, 1995, SCAND J GASTROENTERO, V30, P872, DOI 10.3109/00365529509101593; Hasselgren G, 1997, SCAND J GASTROENTERO, V32, P328, DOI 10.3109/00365529709007680; Khuroo MS, 1997, NEW ENGL J MED, V336, P1054, DOI 10.1056/NEJM199704103361503; LANAS A, 1995, J CLIN GASTROENTEROL, V21, P103, DOI 10.1097/00004836-199509000-00008; Lin HJ, 1998, ARCH INTERN MED, V158, P54, DOI 10.1001/archinte.158.1.54; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; VILLANUEVA C, 1995, ENDOSCOPY, V27, P308, DOI 10.1055/s-2007-1005698; WALT RP, 1992, LANCET, V340, P1058, DOI 10.1016/0140-6736(92)93078-2	14	12	13	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1998	280	10					877	878		10.1001/jama.280.10.877	http://dx.doi.org/10.1001/jama.280.10.877			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115LN	9739959				2022-12-28	WOS:000075666600015
J	Pacini, F; Vorontsova, T; Molinaro, E; Kuchinskaya, E; Agate, L; Shavrova, E; Astachova, L; Chiovato, L; Pinchera, A				Pacini, F; Vorontsova, T; Molinaro, E; Kuchinskaya, E; Agate, L; Shavrova, E; Astachova, L; Chiovato, L; Pinchera, A			Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chernobyl radioactive fallout	LANCET			English	Article							ATOMIC-BOMB SURVIVORS; RADIATION; DISORDERS; DISEASES; CANCER	Background The long-term effects of ionising radiation, including radioiodine, on thyroid function are not well known. We compared thyroid immunity and function in two groups of children from Belarus, one of whom was exposed to the radioactive fallout of Chernobyl. Methods We measured serum free thyroxine 4 (free T4), free T3, and thyrotropin hormone (TSH) and the prevalence of thyroid autoantibodies (antithyroglobulin and antithyroperoxidase), in 287 children or adolescents living in Hoiniki (average caesium contamination of 5.4 Ci/km(2)). We also studied 208 children and adolescents living in Braslav (average contamination <0.1 Ci/km(2)), who were age 12 years or less at the time of the Chernobyl accident. Findings The prevalence of antithyroglobulin or antithyroperoxidase, or both, was significantly higher (p=0.0001) in individuals living in Hoiniki (56 [19.5%] of 287) than in those living in Braslav (eight [3.8%] of 208). In both villages, no sex differences were found in the antibody prevalence before age 13 years. Thereafter, a significantly higher prevalence of thyroid autoantibodies was found in girls from Hoiniki. The increase in the prevalence of circulating antibodies in the contaminated group was already apparent in individuals who, at the time of the accident, were in utero or newborn (15.7%), and was even more pronounced in children of 9 years or more (35.1%). No major alterations of serum FT-4, FT-3, or TSH were found. Interpretation 6-8 years after the Chernobyl accident, a significant increase in thyroid autoimmunity was found in children exposed to radioactive fallout. Pubertal age in girls is a risk factor for increased prevalence of thyroid autoimmunity. The autoimmune phenomena are limited to an increased prevalence of circulating thyroid autoantibodies without evidence of significant thyroid dysfunction, The future development of clinically relevant thyroid autoimmune diseases, especially hypothyroidism, is a possibility.	Univ Pisa, Inst Endocrinol, I-56124 Pisa, Italy; Ctr Thyroid Pathol, Minsk, BELARUS; Inst Radiat Med & Endocrinol, Minsk, BELARUS	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Pisa	Pacini, F (corresponding author), Univ Pisa, Inst Endocrinol, Via Paradisa 2, I-56124 Pisa, Italy.	fpacini@endoc.med.unipi.it	chiovato, luca/AAC-9003-2019; Chiovato, Luca/K-6617-2016	Chiovato, Luca/0000-0001-7457-7353				AKIYAMA M, 1995, INT J RADIAT BIOL, V68, P497, DOI 10.1080/09553009514551491; ASANO M, 1978, Journal of Radiation Research, V19, P306, DOI 10.1269/jrr.19.306; BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; CHIOVATO L, 1993, J ENDOCRINOL INVEST, V16, P384, DOI 10.1007/BF03348863; *COMM EUR COMM, 1993, OFF OFF PUBL EUR COM, P1; CONARD RA, 1980, 51261 BNL, P1; DEGROOT LJ, 1983, AM J MED, V74, P852, DOI 10.1016/0002-9343(83)91077-X; DEMIDCHIK E, 1994, CHERNOBYL UPDATE FUT, P21; Goulko GM, 1998, RADIAT ENVIRON BIOPH, V36, P261, DOI 10.1007/s004110050081; HANCOCK SL, 1991, NEW ENGL J MED, V325, P599, DOI 10.1056/NEJM199108293250902; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; LIKHTAREV IA, 1995, NATURE, V375, P365, DOI 10.1038/375365a0; MARIOTTI S, 1992, LANCET, V339, P1506, DOI 10.1016/0140-6736(92)91265-A; MARIOTTI S, 1997, J ENDOCRINOL INVE S5, V20, P38; MASAHIRO I, 1995, THYROID, V5, P365; MORIMOTO I, 1987, J NUCL MED, V28, P1115; NAGATAKI S, 1994, JAMA-J AM MED ASSOC, V272, P364, DOI 10.1001/jama.272.5.364; NIKIFOROV YE, 1995, CANCER-AM CANCER SOC, V76, P900, DOI 10.1002/1097-0142(19950901)76:5<900::AID-CNCR2820760527>3.0.CO;2-X; Pacini F, 1997, J CLIN ENDOCR METAB, V82, P3563, DOI 10.1210/jc.82.11.3563; Sobolev B., 1996, Radiological Consequences of the Chernobyl Accident. Proceedings of the First International Conference (EUR 16544 EN), P741; SPITALNIK PF, 1978, CANCER, V41, P1098, DOI 10.1002/1097-0142(197803)41:3<1098::AID-CNCR2820410344>3.0.CO;2-#; Tronko N., 1996, Radiological Consequences of the Chernobyl Accident. Proceedings of the First International Conference (EUR 16544 EN), P683; Tsyb A. F., 1996, Radiological Consequences of the Chernobyl Accident. Proceedings of the First International Conference (EUR 16544 EN), P691; Vykhovanets EV, 1997, CLIN IMMUNOL IMMUNOP, V84, P251, DOI 10.1006/clin.1997.4379	24	69	74	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 5	1998	352	9130					763	766		10.1016/S0140-6736(97)11397-6	http://dx.doi.org/10.1016/S0140-6736(97)11397-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737280				2022-12-28	WOS:000075762700009
J	Yule, WL				Yule, WL			In search of a medical artist	LANCET			English	Article											Yule, WL (corresponding author), 20 Hillside Rd, Forfar DD8 2AY, Scotland.							Desmond R, 1994, DICT BRIT IRISH BOT	1	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					806	809		10.1016/S0140-6736(98)03077-3	http://dx.doi.org/10.1016/S0140-6736(98)03077-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737303				2022-12-28	WOS:000075762700042
J	Kawasaki, I; Shim, YH; Kirchner, J; Kaminker, J; Wood, WB; Strome, S				Kawasaki, I; Shim, YH; Kirchner, J; Kaminker, J; Wood, WB; Strome, S			PGL-1, a predicted RNA-binding component of germ granules, is essential for fertility in C-elegans	CELL			English	Article							CAENORHABDITIS-ELEGANS; CELL-FORMATION; P-GRANULE; GENE; PROTEIN; EMBRYOS; DROSOPHILA; LINE; LOCALIZATION; SEGREGATION	Germ cells are distinct from somatic cells in their immortality, totipotency, and ability to undergo meiosis. Candidates for components that guide the unique germline program are the distinctive granules observed in germ cells of many species. We show that a component of germ granules is essential for fertility in C. elegans and that its primary function is in germline proliferation. This role has been revealed by molecular and genetic analyses of pgl-1. PGL-1 is a predicted RNA-binding protein that is present on germ granules at all stages of development. Elimination of PGL-1 results in defective germ granules and sterility. Interestingly, PGL-1 function is required for fertility only at elevated temperatures, suggesting that germline development is inherently sensitive to temperature.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	Indiana University System; Indiana University Bloomington; University of Colorado System; University of Colorado Boulder	Strome, S (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.		Kawasaki, Ichiro/D-6864-2011	Kawasaki, Ichiro/0000-0003-1722-0993	NIGMS NIH HHS [R01 GM034059, GM34059] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034059] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARDSLEY A, 1993, DEVELOPMENT, V119, P207; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BARTON MK, 1987, GENETICS, V115, P107; BEANAN MJ, 1992, DEVELOPMENT, V116, P755; BOURBON HM, 1988, J MOL BIOL, V200, P627, DOI 10.1016/0022-2836(88)90476-7; BRENNER S, 1974, GENETICS, V77, P71; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CZOLOWSKA R, 1972, ROUX ARCH DEV BIOL, V169, P335, DOI 10.1007/BF00580253; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; EDDY EM, 1975, INT REV CYTOL, V43, P229; Edgar LG, 1995, METHOD CELL BIOL, V48, P303; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; Evans D, 1997, P NATL ACAD SCI USA, V94, P9751, DOI 10.1073/pnas.94.18.9751; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Forbes A, 1998, DEVELOPMENT, V125, P679; FRANCIS R, 1995, GENETICS, V139, P579; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GIRARD JP, 1993, NUCLEIC ACIDS RES, V21, P2149, DOI 10.1093/nar/21.9.2149; Gruidl ME, 1996, P NATL ACAD SCI USA, V93, P13837, DOI 10.1073/pnas.93.24.13837; Guedes S, 1997, DEVELOPMENT, V124, P731; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; Hird SN, 1996, DEVELOPMENT, V122, P1303; Holdeman R, 1998, DEVELOPMENT, V125, P2457; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; KEMPHUES KJ, 1988, GENETICS, V120, P977; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KIMBLE J, 1984, DEV BIOL, V105, P234, DOI 10.1016/0012-1606(84)90279-3; Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0; LAPEYRE B, 1990, MOL CELL BIOL, V10, P430, DOI 10.1128/MCB.10.1.430; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; MAHOWALD AP, 1977, AM ZOOL, V17, P551; MARSH J, 1994, CIBA FDN S, V182; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; OLMSTED JB, 1986, METHOD ENZYMOL, P467; PAULSEN JE, 1995, GENETICS, V141, P1383; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Rongo C, 1996, TRENDS GENET, V12, P102, DOI 10.1016/0168-9525(96)81421-1; RUSSELL ID, 1992, J CELL BIOL, V119, P737, DOI 10.1083/jcb.119.4.737; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; STROME S, 1995, DEVELOPMENT, V121, P2961; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STROME S, 1986, GAMETOGENESIS EARLY, P77; Styhler S, 1998, DEVELOPMENT, V125, P1569; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WOLF N, 1983, J EMBRYOL EXP MORPH, V73, P297; Wood W. B., 1984, Molecular biology of development. Proceedings of a CETUS-UCLA Symposium held 1-7 April, 1984, in Steamboat Springs, Colorado. (UCLS Symposia on Molecular and Cellular Biology, New Series, Volume 19.), P37; YAMAGUCHI Y, 1983, DEV GROWTH DIFFER, V25, P121	58	280	286	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 4	1998	94	5					635	645		10.1016/S0092-8674(00)81605-0	http://dx.doi.org/10.1016/S0092-8674(00)81605-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741628	Bronze			2022-12-28	WOS:000075851900011
J	Hall, WJ				Hall, WJ			Update in geriatrics	ANNALS OF INTERNAL MEDICINE			English	Bibliography									Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA	University of Rochester	Hall, WJ (corresponding author), Univ Rochester, Sch Med & Dent, Dept Med, Box MED,601 Elmwood Ave, Rochester, NY 14642 USA.								0	2	2	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1998	129	5					387	393		10.7326/0003-4819-129-5-199809010-00008	http://dx.doi.org/10.7326/0003-4819-129-5-199809010-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114RL	9735067				2022-12-28	WOS:000075622600007
J	Moher, D; Pham, B; Jones, A; Cook, DJ; Jadad, AR; Moher, M; Tugwell, P; Klassen, TP				Moher, D; Pham, B; Jones, A; Cook, DJ; Jadad, AR; Moher, M; Tugwell, P; Klassen, TP			Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?	LANCET			English	Article							CONSORT STATEMENT; ULCERATIVE-COLITIS; METAANALYSIS; READERS; THERAPY; PLACEBO; BIAS	Background Few meta-analyses of randomised trials assess the quality of the studies included. Yet there is increasing evidence that trial quality can affect estimates of intervention efficacy. We investigated whether different methods of quality assessment provide different estimates of intervention efficacy evaluated in randomised controlled trials (RCTs). Methods We randomly selected 11 meta-analyses that involved 127 RCTs on the efficacy of interventions used for circulatory and digestive diseases, mental health, and pregnancy and childbirth. We replicated all the meta-analyses using published data from the primary studies. The quality of reporting of all 127 clinical trials was assessed by means of component and scale approaches. To explore the effects of quality on the quantitative results, we examined the effects of different methods of incorporating quality scores (sensitivity analysis and quality weights) on the results of the meta-analyses, Findings The quality of trials was low. Masked assessments provided significantly higher scores than unmasked assessments (mean 2.74 [SD 1.10] vs 2.55 [1.20]). Low-quality trials (score less than or equal to 2), compared with high-quality trials (score >2), were associated with an increased estimate of benefit of 34% (ratio of odds ratios [ROR] 0.66 [95% CI 0.52-0.83]). Trials that used inadequate allocation concealment, compared with those that used adequate methods, were also associated with an increased estimate of benefit (37%; ROR = 0.63 [0.45-0.88]). The average treatment benefit was 39% (odds ratio [OR] 0.61 [0.57-0.65]) for all trials, 52% (OR 0.48 [0.43-0.54]) for low-quality trials, and 29% (OR 0.71 [0.65-0.77]) for high-quality trials. Use of all the trial scores as quality weights reduced the effects to 35% (OR 0.65 [0.59-0.71]) and resulted in the least statistical heterogeneity, Interpretation Studies of low methodological quality in which the estimate of quality is incorporated into the meta-analyses can alter the interpretation of the benefit of intervention, whether a scale or component approach is used in the assessment of trial quality.	Childrens Hosp Eastern Ontario, Thomas C Chalmers Ctr Systemat Reviews, Res Inst, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Dept Med, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON K1N 6N5, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4L8, Canada; McMaster Univ, Dept Epidemiol & Biostat, Hlth Informat Res Unit, Hamilton, ON L8S 4L8, Canada; Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Oxford, England	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; University of Ottawa; McMaster University; McMaster University; University of Oxford	Moher, D (corresponding author), Childrens Hosp Eastern Ontario, Thomas C Chalmers Ctr Systemat Reviews, Res Inst, Room R226,401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	107656.3375@compuserve.com	Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556; Moher, David/0000-0003-2434-4206				Altman DG, 1996, BRIT MED J, V313, P570; ANDREW E, 1994, JAMA-J AM MED ASSOC, V272, P1926, DOI 10.1001/jama.1994.03520240054041; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Berlin JA, 1997, LANCET, V350, P185, DOI 10.1016/S0140-6736(05)62352-5; CHALMERS TC, 1991, STAT MED, V10, P971, DOI 10.1002/sim.4780100618; COUNSELL C, 1995, COCHRANE LIB; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; DOLANMULLEN P, 1994, AM J OBSTET GYNECOL, V171, P1328, DOI 10.1016/0002-9378(94)90156-2; Fackler ML, 1996, ANN INTERN MED, V124, P741, DOI 10.7326/0003-4819-124-8-199604150-00007; FELSON DT, 1992, J CLIN EPIDEMIOL, V45, P885, DOI 10.1016/0895-4356(92)90072-U; Freemantle N, 1997, ANN INTERN MED, V126, P81, DOI 10.7326/0003-4819-126-1-199701010-00011; GRANT A, 1995, COCHRANE LIBR; HUGHES E, 1995, COCHRANE LIB; JADAD AER, 1998, JAMA-J AM MED ASSOC, V280, P178; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LENSING AWA, 1995, ARCH INTERN MED, V155, P601, DOI 10.1001/archinte.155.6.601; LOONEN AJM, 1991, PHARM WEEKBLAD, V13, P167, DOI 10.1007/BF01957741; LOOSEMORE TM, 1994, INT ANGIOL, V13, P133; MARI JD, 1994, PSYCHOL MED, V24, P565, DOI 10.1017/S0033291700027720; MARSHALL JK, 1995, ALIMENT PHARM THERAP, V9, P293; McNamee D, 1996, LANCET, V348, P562; MCNUTT RA, 1990, JAMA-J AM MED ASSOC, V263, P1371, DOI 10.1001/jama.263.10.1371; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; Moher D, 1996, INT J TECHNOL ASSESS, V12, P195, DOI 10.1017/S0266462300009570; PACE F, 1995, SCAND J GASTROENTERO, V30, P101, DOI 10.3109/00365529509093245; RAMIREZLASSEPAS M, 1988, STROKE, V19, P397, DOI 10.1161/01.STR.19.3.397; Rennie D, 1996, JAMA-J AM MED ASSOC, V276, P649, DOI 10.1001/jama.276.8.649; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SUTHERLAND LR, 1993, ANN INTERN MED, V118, P540, DOI 10.7326/0003-4819-118-7-199304010-00009	30	2370	2493	0	65	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 22	1998	352	9128					609	613		10.1016/S0140-6736(98)01085-X	http://dx.doi.org/10.1016/S0140-6736(98)01085-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746022				2022-12-28	WOS:000075567400010
J	Bryant, P				Bryant, P			Diagnostic dilemma - Car health	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					934	934						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756816				2022-12-28	WOS:000076409000030
J	Laine, L; Estrada, R; Trujillo, M; Knigge, K; Fennerty, MB				Laine, L; Estrada, R; Trujillo, M; Knigge, K; Fennerty, MB			Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori	ANNALS OF INTERNAL MEDICINE			English	Article							UREA BREATH TEST; OMEPRAZOLE; LANSOPRAZOLE; ERADICATION; GASTRITIS; ACCURACY	Background: Proton-pump inhibitor therapy may cause false-negative results on Helicobacter pylori diagnostic testing. Objective: To determine the frequency and duration of conversion of urea breath test results from positive to negative in patients given a proton-pump inhibitor. Setting: Two urban university gastroenterology clinics. Patients: Patients infected with H. pylori who had positive results on urea breath tests. Intervention: Lansoprazole, 30 mg/d for 28 days. Measurements: The urea breath test was repeated at 28 days. If the results were negative, testing was repeated 3, 7, 14, and 28 days after completion of therapy until the results reverted to positive. Results: 31 (33%) of 93 patients in whom H. pylori was not eradicated had a negative breath test result while receiving lansoprazole. The proportions of patients whose breath test results were positive after completion of lansoprazole therapy were 91% (95% CI, 83% to 96%) at 3 days, 97% (CI, 90% to 99%) at 7 days, and 100% (CI, 96% to 100%) at 14 days. Conclusion: Patients should not receive proton-pump inhibitors for 2 weeks before receiving the urea breath test for H. pylori infection.	Univ So Calif, Sch Med, Dept Med, Gastrointestinal Div, Los Angeles, CA 90033 USA	University of Southern California	Laine, L (corresponding author), Univ So Calif, Sch Med, Dept Med, Gastrointestinal Div, 2025 Zonal Ave, Los Angeles, CA 90033 USA.							Atherton JC, 1997, ALIMENT PHARM THER, V11, P11, DOI 10.1046/j.1365-2036.11.s1.3.x; BAYERDORFFER E, 1992, EUR J GASTROEN HEPAT, V4, P697; BIASCO G, 1989, LANCET, V2, P1403; Chey WD, 1997, AM J GASTROENTEROL, V92, P446; Chey WD, 1996, AM J GASTROENTEROL, V91, P89; Cutler AF, 1996, AM J GASTROENTEROL, V91, P85; DAW MA, 1991, ALIMENT PHARM THERAP, V5, P435; HUI WM, 1991, DIGEST DIS SCI, V36, P577, DOI 10.1007/BF01297022; IWAHI T, 1991, ANTIMICROB AGENTS CH, V35, P490, DOI 10.1128/AAC.35.3.490; Kolt SD, 1997, GASTROENTEROLOGY, V112, pA180; LAINE LA, 1996, AM J MED, V100, P525; Malfertheiner P, 1997, GUT, V41, P8; SHARP J, 1991, GUT, V32, pA565; UNGE P, 1989, SCAND J GASTROENTERO, V24, P49, DOI 10.3109/00365528909091311; WEIL J, 1991, ALIMENT PHARM THERAP, V5, P309	15	153	160	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1998	129	7					547	550		10.7326/0003-4819-129-7-199810010-00007	http://dx.doi.org/10.7326/0003-4819-129-7-199810010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123KN	9758575				2022-12-28	WOS:000076124500006
J	Tramer, MR; Reynolds, DJM; Moore, RA; McQuay, HJ				Tramer, MR; Reynolds, DJM; Moore, RA; McQuay, HJ			When placebo controlled trials are essential and equivalence trials are inadequate	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROPHYLACTIC ANTIEMETIC THERAPY; RESEARCH ETHICS COMMITTEES; POSTOPERATIVE NAUSEA; GYNECOLOGICAL LAPAROSCOPY; CLINICAL-TRIALS; ORAL ONDANSETRON; DROPERIDOL; PREVENTION; SURGERY; METOCLOPRAMIDE		Univ Oxford, Oxford Radcliffe Hosp, Pain Res & Nuffield Dept Anaesthet, Oxford OX3 7LJ, England; Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England	University of Oxford; Radcliffe Infirmary; University of Oxford	Tramer, MR (corresponding author), Univ Hosp Geneva, DAPSIG, Div Anaesthesiol, CH-1211 Geneva 14, Switzerland.	martin.tramer@hcuge.ch						ALON E, 1994, ANAESTHESIST, V43, P500, DOI 10.1007/s001010050084; ALON E, 1992, ANESTH ANALG, V75, P561; ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844; BREMNER WGM, 1993, BRIT J ANAESTH, V71, P296, DOI 10.1093/bja/71.2.296; Calamandrei M, 1994, Cah Anesthesiol, V42, P19; CANTANNA R, 1994, MINERVA ANESTESIO S1, V60, P109; CETICA P, 1994, MINERVA ANESTESIO S1, V60, P41; Chen PP, 1996, EUR J ANAESTH, V13, P485, DOI 10.1046/j.1365-2346.1996.d01-392.x; CITRON ML, 1993, ANN INTERN MED, V118, P470, DOI 10.7326/0003-4819-118-6-199303150-00013; COLLIER J, 1995, BMJ-BRIT MED J, V311, P821, DOI 10.1136/bmj.311.7009.821; DARI M, 1994, MINERVA ANESTESIO S1, V60, P85; DAVIS A, 1995, ANAESTH INTENS CARE, V23, P438, DOI 10.1177/0310057X9502300404; DAVIS PJ, 1995, ANESTHESIOLOGY, V83, P956, DOI 10.1097/00000542-199511000-00007; DESILVA PHDP, 1995, ANESTH ANALG, V81, P139, DOI 10.1097/00000539-199507000-00028; EDDY DM, 1994, JAMA-J AM MED ASSOC, V271, P1792, DOI 10.1001/jama.271.22.1792; Eriksson H, 1996, ANESTH ANALG, V82, P533, DOI 10.1097/00000539-199603000-00019; ERNST E, 1995, BMJ-BRIT MED J, V311, P551, DOI 10.1136/bmj.311.7004.551; FURST SR, 1994, ANESTHESIOLOGY, V81, P799, DOI 10.1097/00000542-199410000-00005; GAN TJ, 1994, BRIT J ANAESTH, V72, P544, DOI 10.1093/bja/72.5.544; GILBERT EM, 1995, NEW ENGL J MED, V332, P61; GIORGI L, 1994, MINERVA ANESTESIO S1, V60, P73; GROND S, 1995, ANESTH ANALG, V81, P603, DOI 10.1097/00000539-199509000-00032; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Kalso E, 1997, PAIN, V71, P127, DOI 10.1016/S0304-3959(97)03344-7; KORTTILA K, 1992, BRIT J ANAESTH, V69, pS20, DOI 10.1093/bja/69.supplement_1.20S; LEWIS MA, 1994, AM J HOSP PHARM, V51, P524, DOI 10.1093/ajhp/51.4.524; LITMAN RS, 1995, J CLIN ANESTH, V7, P58, DOI 10.1016/0952-8180(94)00008-R; LopezOlaondo L, 1996, BRIT J ANAESTH, V76, P835, DOI 10.1093/bja/76.6.835; MALINS AF, 1994, BRIT J ANAESTH, V72, P231, DOI 10.1093/bja/72.2.231; MALTEPE F, 1996, TURK ANESTEZIYOLOJI, V24, P180; MARKMAN M, 1994, CANCER INVEST, V12, P654, DOI 10.3109/07357909409023050; McQuay H, 1996, BMJ-BRIT MED J, V313, P1008; McQuay HJ, 1996, PAIN, V68, P217, DOI 10.1016/S0304-3959(96)03140-5; Modesti C., 1995, Acta Anaesthesiologica Italica, V46, P73; MOORE RA, IN PRESS PAIN; Naguib M, 1996, CAN J ANAESTH, V43, P226, DOI 10.1007/BF03011739; PAECH MJ, 1995, ANAESTH INTENS CARE, V23, P548, DOI 10.1177/0310057X9502300503; PAXTON D, 1995, ANAESTHESIA, V50, P1083, DOI 10.1111/j.1365-2044.1995.tb05957.x; PAXTON LD, 1995, ANAESTHESIA, V50, P403, DOI 10.1111/j.1365-2044.1995.tb05993.x; Pueyo FJ, 1996, ANESTH ANALG, V83, P117, DOI 10.1097/00000539-199607000-00021; RAPHAEL JH, 1993, BRIT J ANAESTH, V71, P845, DOI 10.1093/bja/71.6.845; ROCCATAGLIATA DC, 1994, MINERVA ANESTESIO S1, V60, P95; ROSE JB, 1994, ANESTH ANALG, V79, P486; ROSSI N, 1991, WATER AIR SOIL POLL, V60, P1, DOI 10.1007/BF00293961; Rothman KJ, 1996, BMJ-BRIT MED J, V313, P3, DOI 10.1136/bmj.313.7048.3a; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; ROWE L, 1995, J ONE DAY SURG   WIN, P9; RUST M, 1995, ANAESTHESIST, V44, P288, DOI 10.1007/s001010050156; Savulescu J, 1996, BMJ-BRIT MED J, V313, P1390, DOI 10.1136/bmj.313.7069.1390; SPLINTER WM, 1995, CAN J ANAESTH, V42, P848, DOI 10.1007/BF03011029; Stone PG, 1997, BRIT MED J, V315, P60; Talbot D, 1997, BRIT MED J, V315, P1464, DOI 10.1136/bmj.315.7120.1464; Tang J, 1996, ANESTH ANALG, V83, P304, DOI 10.1097/00000539-199608000-00018; TAUBES G, 1995, SCIENCE, V267, P25, DOI 10.1126/science.7809605; Tramer M, 1997, BRIT J ANAESTH, V78, P256, DOI 10.1093/bja/78.3.256; Tramer MR, 1997, ANESTHESIOLOGY, V87, P1277, DOI 10.1097/00000542-199712000-00004; Tramer MR, 1997, BRIT MED J, V314, P1088, DOI 10.1136/bmj.314.7087.1088; vandenBerg AA, 1996, BRIT J ANAESTH, V76, P449, DOI 10.1093/bja/76.3.449	59	73	75	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	1998	317	7162					875	880		10.1136/bmj.317.7162.875	http://dx.doi.org/10.1136/bmj.317.7162.875			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748192	Green Published			2022-12-28	WOS:000076222300028
J	Lin, Z; Hahm, TS; Lee, WW; Tang, WM; White, RB				Lin, Z; Hahm, TS; Lee, WW; Tang, WM; White, RB			Turbulent transport reduction by zonal flows: Massively parallel simulations	SCIENCE			English	Article							PLASMA; GEOMETRY	Three-dimensional gyrokinetic simulations of microturbulence in magnetically confined toroidal plasmas with massively parallel computers showed that, with Linear flow damping, an asymptotic residual flow develops In agreement with analytic calculations. Nonlinear global simulations of instabilities driven by temperature gradients in the ion component of the plasma support the view that turbulence-driven fluctuating zonal flows can substantially reduce turbulent transport. Finally, the outstanding differences in the flow dynamics observed in global and Local simulations are found to be due to profile variations.	Princeton Univ, Princeton Plasma Phys Lab, Princeton, NJ 08543 USA	Princeton University; United States Department of Energy (DOE); Princeton Plasma Physics Laboratory	Lin, Z (corresponding author), Princeton Univ, Princeton Plasma Phys Lab, POB 451, Princeton, NJ 08543 USA.		Tang, William/AHA-7918-2022; White, Roscoe B/D-1773-2013	Tang, William/0000-0002-8211-3636; White, Roscoe B/0000-0002-4239-2685				BOOZER AH, 1981, PHYS FLUIDS, V24, P1999, DOI 10.1063/1.863297; DIAMOND PH, 1991, PHYS FLUIDS B-PLASMA, V3, P1626, DOI 10.1063/1.859681; Dimits AM, 1996, PHYS REV LETT, V77, P71, DOI 10.1103/PhysRevLett.77.71; HAHM TS, 1988, PHYS FLUIDS, V31, P2670, DOI 10.1063/1.866544; HAHM TS, 1995, PHYS PLASMAS, V2, P1648, DOI 10.1063/1.871313; HASEGAWA A, 1987, PHYS REV LETT, V59, P1581, DOI 10.1103/PhysRevLett.59.1581; LEE WW, 1983, PHYS FLUIDS, V26, P556, DOI 10.1063/1.864140; Lin Z, 1997, PHYS REV LETT, V78, P456, DOI 10.1103/PhysRevLett.78.456; LIN Z, 1995, PHYS REV E, V52, P5646, DOI 10.1103/PhysRevE.52.5646; PARKER SE, 1993, PHYS REV LETT, V71, P2042, DOI 10.1103/PhysRevLett.71.2042; White R., 1984, NATL GALLERY TECH B, V8, P5	11	831	849	4	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1835	1837		10.1126/science.281.5384.1835	http://dx.doi.org/10.1126/science.281.5384.1835			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743492	Green Submitted			2022-12-28	WOS:000076007100047
J	Single, S; Borst, A				Single, S; Borst, A			Dendritic integration and its role in computing image velocity	SCIENCE			English	Article							INTRINSIC ELECTROPHYSIOLOGICAL CHARACTERISTICS; BLOWFLY CALLIPHORA-ERYTHROCEPHALA; VISUAL-MOTION DETECTION; PLATE TANGENTIAL CELLS; LOBULA PLATE; CALCIUM ACCUMULATION; MEMBRANE-PROPERTIES; HORIZONTAL CELLS; FLY; INTERNEURONS	The mechanisms underlying visual motion detection can be studied simultaneously in different cell compartments in vivo by using calcium as a reporter of the spatiotemporal activity distribution in single motion-sensitive cells of the fly. As predicted by the Reichardt model, Local dendritic calcium signals are found to indicate the direction and velocity of pattern motion but are corrupted by spatial pattern properties. The latter are canceled out by spatial integration, thus Leading to a purely directional selective output signal in the axon. These;findings attribute a specific computational task to the dendrites of visual interneurons and imply a functional interpretation of dendritic morphology.	Max Planck Soc, Friedrich Miescher Lab, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Max Planck Society	Borst, A (corresponding author), Max Planck Soc, Friedrich Miescher Lab, Spemannstr 37-39, D-72076 Tubingen, Germany.	alexander.borst@tuebingen.mpg.de						BORST A, 1992, P NATL ACAD SCI USA, V89, P4139, DOI 10.1073/pnas.89.9.4139; Borst A, 1996, J COMPUT NEUROSCI, V3, P313, DOI 10.1007/BF00161091; BREER H, 1988, INT CONGR SER, V832, P301; Brotz TM, 1996, J NEUROPHYSIOL, V76, P1786, DOI 10.1152/jn.1996.76.3.1786; BUCHNER E, 1984, J COMP PHYSIOL, V155, P471, DOI 10.1007/BF00611912; DOUGLASS JK, 1995, J NEUROSCI, V15, P5596; ECKERT H, 1983, J INSECT PHYSIOL, V29, P547, DOI 10.1016/0022-1910(83)90020-3; EECKMAN FH, 1994, NEURAL NETWORK SIMUL, P114; EGELHAAF M, 1995, J NEUROPHYSIOL, V73, P2540, DOI 10.1152/jn.1995.73.6.2540; EGELHAAF M, 1989, J OPT SOC AM A, V6, P1070, DOI 10.1364/JOSAA.6.001070; EGELHAAF M, 1992, VISUAL NEUROSCI, V8, P151, DOI 10.1017/S0952523800009317; Haag J, 1997, J NEUROSCI, V17, P4809; Haag J, 1997, J COMPUT NEUROSCI, V4, P349, DOI 10.1023/A:1008804117334; HAUSEN K, 1982, BIOL CYBERN, V46, P67, DOI 10.1007/BF00335352; HAUSEN K, 1982, BIOL CYBERN, V45, P143, DOI 10.1007/BF00335241; HAUSEN K, 1976, Z NATURFORSCH C, V31, P629; Hausen K., 1984, PHOTORECEPTION VISIO, P523, DOI [10.1007/978-1-4613-2743-1_15, DOI 10.1007/978-1-4613-2743-1_15]; HENGSTENBERG R, 1977, NATURE, V270, P338, DOI 10.1038/270338a0; HENGSTENBERG R, 1982, J COMP PHYSIOL, V149, P163, DOI 10.1007/BF00619211; OCarroll DC, 1996, NATURE, V382, P63, DOI 10.1038/382063a0; REICHARDT W, 1987, J COMP PHYSIOL A, V161, P533, DOI 10.1007/BF00603660; Reichardt W, 1961, SENS COMMUN, P303; Single S, 1997, J NEUROSCI, V17, P6023; VERNINO S, 1994, J NEUROSCI, V14, P5514; ZAAGMAN WH, 1978, BIOL CYBERN, V31, P163, DOI 10.1007/BF00337002	25	152	153	3	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1848	1850		10.1126/science.281.5384.1848	http://dx.doi.org/10.1126/science.281.5384.1848			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743497				2022-12-28	WOS:000076007100052
J	Unrau, PJ; Bartel, DP				Unrau, PJ; Bartel, DP			RNA-catalysed nucleotide synthesis	NATURE			English	Article							PREBIOTIC SYNTHESIS; BINDING-SITE; OROTATE PHOSPHORIBOSYLTRANSFERASE; SALMONELLA-TYPHIMURIUM; PURINE NUCLEOSIDES; RIBOZYME; LIGASE	The 'RNA world' hypothesis proposes that early life developed by making use of RNA molecules, rather than proteins, to catalyse the synthesis of important biological molecules'. It is thought, however, that the nucleotides constituting RNA were scarce on early Earth(1-4), RNA-based life must therefore have acquired the ability to synthesize RNA nucleotides from simpler and more readily available precursors, such as sugars and bases. Plausible prebiotic synthesis routes have been proposed for sugars', sugar phosphates(6) and the four RNA bases(7-11), but the coupling of these molecules into nucleotides, specifically pyrimidine nucleotides, poses a challenge to the RNA world hypothesis(1-3). Here we report the application of in vitro selection to isolate RNA molecules that catalyse the synthesis of a pyrimidine nucleotide at their 3' terminus. The finding that RNA can catalyse this type of reaction, which is modelled after pyrimidine synthesis in contemporary metabolism, supports the idea of an RNA world that included nucleotide synthesis and other metabolic pathways mediated by ribozymes.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Bartel, DP (corresponding author), MIT, Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.							BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BHATIA MB, 1990, BIOCHEMISTRY-US, V29, P10480, DOI 10.1021/bi00498a009; EKLAND EH, 1995, NUCLEIC ACIDS RES, V23, P3231, DOI 10.1093/nar/23.16.3231; Ekland EH, 1996, NATURE, V382, P373, DOI 10.1038/382373a0; ENGLAND TE, 1977, P NATL ACAD SCI USA, V74, P4839, DOI 10.1073/pnas.74.11.4839; FERRIS JP, 1968, J MOL BIOL, V33, P693, DOI 10.1016/0022-2836(68)90314-8; FULLER WD, 1972, J MOL EVOL, V1, P249, DOI 10.1007/BF01660244; FULLER WD, 1972, J MOL BIOL, V67, P25, DOI 10.1016/0022-2836(72)90383-X; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; GRAY MW, 1974, BIOCHEMISTRY-US, V13, P5453, DOI 10.1021/bi00724a001; IGLOI GL, 1988, BIOCHEMISTRY-US, V27, P3842, DOI 10.1021/bi00410a048; JAFFE EK, 1979, J BIOL CHEM, V254, P839; Joyce GF., 1993, COLD SPRING HARB MON, V24, P1; LARRALDE R, 1995, P NATL ACAD SCI USA, V92, P8158, DOI 10.1073/pnas.92.18.8158; LOHRMANN R, 1978, TETRAHEDRON, V34, P853, DOI 10.1016/0040-4020(78)88129-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; Mizuno T., 1974, Advances in Carbohydrate Chemistry and Biochemistry, V29, P173; MIZUNO Y, 1962, CHEM PHARM BULL, V10, P647; ORO J, 1961, NATURE, V191, P1193, DOI 10.1038/1911193a0; PITSCH S, 1995, ORIGINS LIFE EVOL B, V25, P297, DOI 10.1007/BF01581773; PSODA A, 1974, J AM CHEM SOC, V96, P6832, DOI 10.1021/ja00829a003; ROBERTSON MP, 1995, NATURE, V375, P772, DOI 10.1038/375772a0; SANCHEZ RA, 1967, J MOL BIOL, V30, P223; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; STOKS PG, 1979, NATURE, V282, P709, DOI 10.1038/282709a0; Tao W, 1996, BIOCHEMISTRY-US, V35, P14, DOI 10.1021/bi951898l; Wecker M, 1996, RNA, V2, P982; WIERZCHOWSKI KL, 1965, J AM CHEM SOC, V87, P4621, DOI 10.1021/ja00948a039	30	195	205	2	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1998	395	6699					260	263		10.1038/26193	http://dx.doi.org/10.1038/26193			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751052				2022-12-28	WOS:000075974600045
J	Starfield, B				Starfield, B			Quality-of-care research - Internal elegance and external relevance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							UNITED-STATES; MORTALITY; PATIENT; INCOME; INEQUALITY		Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA	Johns Hopkins University	Starfield, B (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, 624 N Broadway,Room 452, Baltimore, MD 21205 USA.							Black C, 1998, MED CARE, V36, P3, DOI 10.1097/00005650-199801000-00002; BLACK D, 1980, INEQUITIES HLTH BLAC; Blumenthal D, 1997, JAMA-J AM MED ASSOC, V278, P1622, DOI 10.1001/jama.278.19.1622; BUSHSHUR R, 1967, AM J PUBLIC HEALTH, V57, P1991; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Cleary PD, 1997, JAMA-J AM MED ASSOC, V278, P1608, DOI 10.1001/jama.278.19.1608; CODMAN EA, 1920, STUDY HOSP EFFICIENC; Dick RS, 1997, COMPUTER BASED PATIE; Entwistle VA, 1998, BRIT MED J, V316, P463, DOI 10.1136/bmj.316.7129.463; Fiscella K, 1997, BRIT MED J, V314, P1724, DOI 10.1136/bmj.314.7096.1724; Genel M, 1996, PEDIATR RES, V39, P902, DOI 10.1203/00006450-199605000-00027; Gold M, 1995, Health Care Financ Rev, V16, P155; Kaplan GA, 1996, BRIT MED J, V312, P999; KAPLAN SH, 1995, MED CARE, V33, P1176, DOI 10.1097/00005650-199512000-00002; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; Lantz PM, 1998, JAMA-J AM MED ASSOC, V279, P1703, DOI 10.1001/jama.279.21.1703; Lundberg GD, 1997, JAMA-J AM MED ASSOC, V278, P1615, DOI 10.1001/jama.278.19.1615; Majeed A, 1997, BRIT MED J, V315, P1515, DOI 10.1136/bmj.315.7121.1515; Mushlin A I, 1980, Med Care, V18, P1; *NAT COMM VIT HLTH, 1996, 72267783245 NAT COMM; President's Advisory Commission on Consumer Protection and Quality in the Health Care Industry, 1998, QUAL 1 BETT HLTH CAR; SALTMAN RB, 1994, INT J HEALTH SERV, V24, P201, DOI 10.2190/8WMP-RR2K-ABM7-NVNH; SCHWARTZ S, 1994, AM J PUBLIC HEALTH, V84, P819, DOI 10.2105/AJPH.84.5.819; Smith MA, 1997, JAMA-J AM MED ASSOC, V278, P1573, DOI 10.1001/jama.278.19.1573; Starfield B, 1998, J FAM PRACTICE, V46, P216; STARFIELD B, 1981, AM J PUBLIC HEALTH, V71, P127, DOI 10.2105/AJPH.71.2.127; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; Starfield B, 1993, J Ambul Care Manage, V16, P27; *WHO, 1998, FIN REP M POL OR MON; Zapka J G, 1995, J Ambul Care Manage, V18, P73	30	47	48	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1998	280	11					1006	1008		10.1001/jama.280.11.1006	http://dx.doi.org/10.1001/jama.280.11.1006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	119JC	9749484				2022-12-28	WOS:000075891400035
J	Tulsky, JA; Fischer, GS; Rose, MR; Arnold, RM				Tulsky, JA; Fischer, GS; Rose, MR; Arnold, RM			Opening the black box: How do physicians communicate about advance directives?	ANNALS OF INTERNAL MEDICINE			English	Article						advance directives; physician-patient relations; physician's role; communication; decision making	LIFE-SUSTAINING TREATMENT; NOT-RESUSCITATE ORDERS; TREATMENT PREFERENCES; MEDICAL FUTILITY; OF-LIFE; CARE; PROBABILITY; DECISIONS; DISCUSSIONS; RESIDENTS	Background: The quality of communication that leads to the completion of written advance directives may influence the usefulness of these documents, but the nature of that communication remains relatively unexplored. Objective: To describe how physicians discuss advance directives with patients. Design: Prospective study. Setting: Five outpatient primary care medicine practices in Durham, North Carolina, and Pittsburgh, Pennsylvania. Participants: 56 attending internists and 56 of their established patients. Eligible patients were at least 65 years of age or had a serious medical illness. Measurements: Two raters coded transcripts of audiotaped discussions about advance directives to document how physicians introduced the topic of advance directives, discussed scenarios and treatments, provided information, elicited patient values, and identified surrogate decision makers. Results: Conversations about advance directives averaged 5.6 minutes; physicians spoke for two thirds of this time. In 91 % of cases, physicians discussed dire scenarios in which most patients would not want to be treated, and 48% asked patients about their preferences in reversible scenarios. Fifty-five percent of physicians discussed scenarios involving uncertainty, typically using vague language. Patients' values were rarely explored in detail. In 88% of cases, physicians discussed surrogate decision making and documents to aid in advance care planning. Conclusions: Although they accomplished the goal of introducing patients to advance directives, discussions infrequently dealt with patients' values and attitudes toward uncertainty. Physicians may not have addressed the topic in a way that would be of substantial use in future decision making, and these discussions did not meet the standards proposed in the literature.	Vet Affairs Med Ctr, Durham, NC 27705 USA; Duke Univ, Durham, NC USA; Univ Pittsburgh, Med Ctr, Ctr Med Eth, Div Gen Internal Med,Sect Palliat Care & Med Eth, Pittsburgh, PA 15213 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Tulsky, JA (corresponding author), Vet Affairs Med Ctr, 508 Fulton St, Durham, NC 27705 USA.				NIA NIH HHS [5-P60-AG11268] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P60AG011268] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APPELBAUM P, 1987, INFORMED CONSENT LEG; Braddock CH, 1997, J GEN INTERN MED, V12, P339, DOI 10.1046/j.1525-1497.1997.00057.x; CARRESE JA, 1995, JAMA-J AM MED ASSOC, V274, P826, DOI 10.1001/jama.274.10.826; CHURCHILL LR, 1989, J RELIG HEALTH, V28, P175, DOI 10.1007/BF00987749; Corbin J, 1990, BASICS QUALITATIVE R; DANIS M, 1994, ANN INTERN MED, V120, P567, DOI 10.7326/0003-4819-120-7-199404010-00006; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DOUKAS DJ, 1991, J FAM PRACTICE, V32, P145; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1995, J AM GERIATR SOC, V43, P440, DOI 10.1111/j.1532-5415.1995.tb05821.x; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FORROW L, 1994, HASTINGS CENT REP, V24, pS29, DOI 10.2307/3563481; GORDON GH, 1991, ARCH INTERN MED, V151, P567, DOI 10.1001/archinte.151.3.567; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; *HAST CTR, 1987, GUID TERM LIF SUST T; HIGH DM, 1994, HASTINGS CENT REP, V24, pS16, DOI 10.2307/3563476; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KONG A, 1986, NEW ENGL J MED, V315, P740, DOI 10.1056/NEJM198609183151206; LIDZ CW, 1992, EROSION AUTONOMY LON; LO B, 1994, RESOLVING ETHICAL DI; Lynn J, 1991, Law Med Health Care, V19, P101; MAPES REA, 1979, SOC SCI MED-MED SOC, V13, P277, DOI 10.1016/0271-7123(79)90046-4; MAZUR DJ, 1991, J GEN INTERN MED, V6, P237, DOI 10.1007/BF02598968; MAZUR DJ, 1993, J AM GERIATR SOC, V41, P223, DOI 10.1111/j.1532-5415.1993.tb06696.x; MAZUR DJ, 1990, MED DECIS MAKING, V10, P2, DOI 10.1177/0272989X9001000102; Meier DE, 1996, ARCH INTERN MED, V156, P1227, DOI 10.1001/archinte.156.11.1227; Miles S H, 1990, J Clin Ethics, V1, P108; MILLER A, 1985, WESTERN J MED, V143, P256; MILLER DK, 1992, J GEN INTERN MED, V7, P475, DOI 10.1007/BF02599446; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; NAKAO MA, 1983, AM J MED, V74, P1061, DOI 10.1016/0002-9343(83)90819-7; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; SCHADE SG, 1989, J MED ETHICS, V15, P186, DOI 10.1136/jme.15.4.186; Schneiderman LJ, 1996, ANN INTERN MED, V125, P669, DOI 10.7326/0003-4819-125-8-199610150-00007; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; Schwartz LM, 1997, ANN INTERN MED, V127, P966, DOI 10.7326/0003-4819-127-11-199712010-00003; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; STARR TJ, 1986, J GEN INTERN MED, V1, P373, DOI 10.1007/BF02596420; Teno J, 1997, J AM GERIATR SOC, V45, P513, DOI 10.1111/j.1532-5415.1997.tb05180.x; Teno J, 1997, J AM GERIATR SOC, V45, P500, DOI 10.1111/j.1532-5415.1997.tb05178.x; Teno JM, 1997, J AM GERIATR SOC, V45, P508, DOI 10.1111/j.1532-5415.1997.tb05179.x; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; Tulsky JA, 1996, ARCH INTERN MED, V156, P1285, DOI 10.1001/archinte.156.12.1285; UHLMANN RF, 1991, ARCH INTERN MED, V151, P495, DOI 10.1001/archinte.151.3.495; *US PC, 1993, STUD ETH PROBL MED B; VENTRES W, 1993, J CLIN ETHIC, V4, P134; Ventres W, 1992, Fam Pract Res J, V12, P157	51	246	246	1	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1998	129	6					441	449		10.7326/0003-4819-129-6-199809150-00003	http://dx.doi.org/10.7326/0003-4819-129-6-199809150-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	119JJ	9735081				2022-12-28	WOS:000075892100002
J	Chalmers, I				Chalmers, I			The public interest	LANCET			English	Article									UK Cochrane Ctr, Oxford OX2 7LG, England	Cochrane Centre	Chalmers, I (corresponding author), UK Cochrane Ctr, Summertown Pavil,Middle Way, Oxford OX2 7LG, England.	ichalmers@cochrane.co.uk						DULEY L, 1994, LANCET, V343, P58, DOI 10.1016/S0140-6736(94)90914-8; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579	2	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	1998	352	9131					893	894		10.1016/S0140-6736(05)60032-3	http://dx.doi.org/10.1016/S0140-6736(05)60032-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742997				2022-12-28	WOS:000075857300043
J	Tashima, KT				Tashima, KT			Cerebrospinal fluid levels of antiretroviral medications - Abstract and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ZIDOVUDINE		Brown Univ, Providence, RI 02912 USA	Brown University	Tashima, KT (corresponding author), Brown Univ, Providence, RI 02912 USA.							ARENDT G, 1998, 12 WORLD AIDS C JUN; BUTLER KM, 1991, NEW ENGL J MED, V324, P137, DOI 10.1056/NEJM199101173240301; COLLIER AC, 1997, 35 ANN M INF DIS SOC; FARTHING C, 1997, 37 INT C ANT AG CHEM; Foudraine NA, 1998, LANCET, V351, P1547, DOI 10.1016/S0140-6736(98)07333-4; GISOLF GH, 1998, 12 WORLD AIDS C JUN; Gisslen M, 1997, J INFECT DIS, V175, P434, DOI 10.1093/infdis/175.2.434; SIDTIS JJ, 1993, ANN NEUROL, V33, P343, DOI 10.1002/ana.410330403; Skolnick AA, 1998, JAMA-J AM MED ASSOC, V279, P419, DOI 10.1001/jama.279.6.419; Stahle L, 1997, LANCET, V350, P1823, DOI 10.1016/S0140-6736(05)63640-9; TASHIMA KT, 1998, 12 WORLD AIDS C JUN; YAZDANIAN M, 1997, 4 C RETR OPP INF JAN	12	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1998	280	10					879	880		10.1001/jama.280.10.879	http://dx.doi.org/10.1001/jama.280.10.879			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115LN	9739960				2022-12-28	WOS:000075666600016
J	Andrulis, DP				Andrulis, DP			Access to care is the centerpiece in the elimination of socioeconomic disparities in health	ANNALS OF INTERNAL MEDICINE			English	Article							HOSPITAL PATIENTS; INSURANCE; OUTCOMES; MEDICAID; SERVICES; EMERGENCY; ADMISSION; COST	Many health care professionals have sustained an almost single-minded conviction that disparities in access to health care across socioeconomic groups are the key reason for the major discrepancies in health status between wealthy persons and poor persons. Others, however, have argued that a host of factors work to create major impediments and that reducing or eliminating financial barriers to health care in particular will do little to reduce discrepancies in health status. This paper, while acknowledging the spectrum of contributing factors, argues that the elimination of financially based differences in access is central to any effort to create equity in outcomes across socioeconomic groups. Through selected review of the many studies on health insurance, access, outcomes, and socioeconomic status, it establishes that a core links affected populations, their difficulty in financing health care, and the threat to their well-being. In so doing, it cites findings that strongly associate lack of insurance (especially for persons who live in poverty), inability to obtain services, and adverse health outcomes. It also uses the example of Medicaid and other coverage for HIV-infected persons in particular as an important positive instance in which leveling the discrepancies in health care across socioeconomic groups can move toward creating quality in access and outcomes. The competitive pressures in today's health care environment threaten to drive socioeconomic groups further apart, especially insured and uninsured persons. However, the recent enactment of state actions, especially the State Child Health Insurance Program, represent powerful examples of health insurance expansion that have lessons for policymakers at all levels for the monitoring and reduction of socioeconomic disparities.	New York Acad Med, New York, NY 10029 USA	New York Academy of Medicine	Andrulis, DP (corresponding author), New York Acad Med, 1216 5th Ave, New York, NY 10029 USA.							AHERN M, 1992, INQUIRY-J HEALTH CAR, V29, P67; Anderson GF, 1997, HEALTH AFFAIR, V16, P163, DOI 10.1377/hlthaff.16.6.163; AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; Bodenheimer T, 1997, NEW ENGL J MED, V337, P651, DOI 10.1056/NEJM199708283370923; Bograd H, 1997, JAMA-J AM MED ASSOC, V277, P1067, DOI 10.1001/jama.277.13.1067; BRAVEMAN P, 1993, JAMA-J AM MED ASSOC, V269, P1285, DOI 10.1001/jama.269.10.1285; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; CASANOVA C, 1995, INT J HEALTH SERV, V25, P283, DOI 10.2190/PCF7-ALX9-6CN3-7X9G; *CHILDR DEF FUND, 1997, 14 THINGS SHOULD KNO; Cunningham WE, 1998, MED CARE, V36, P295, DOI 10.1097/00005650-199803000-00007; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; Donelan K, 1996, HEALTH AFFAIR, V15, P254, DOI 10.1377/hlthaff.15.2.254; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P737, DOI 10.1001/jama.270.6.737; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; Marquis MS, 1996, HEALTH SERV RES, V30, P791; Millman M., 1993, ACCESS HLTH CARE AM; *NAT AC AG, 1997, PUBLIC POLICY AGING, P8; *NAT CTR HLTH STAT, 1994, DHHS PUBL; Pappas G, 1997, AM J PUBLIC HEALTH, V87, P811, DOI 10.2105/AJPH.87.5.811; Reichman NE, 1996, J HEALTH ECON, V15, P455, DOI 10.1016/S0167-6296(96)00491-2; SAVER BG, 1993, AM J PUBLIC HEALTH, V83, P1583, DOI 10.2105/AJPH.83.11.1583; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; SPILLMAN BC, 1992, INQUIRY-J HEALTH CAR, V29, P457; STERN RS, 1991, JAMA-J AM MED ASSOC, V266, P2238, DOI 10.1001/jama.266.16.2238; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; 1997, MMWR MORB MORTAL WKL, V46, P861; 1997, WASHINGTON POST 0411, P1; 1997, CTR STUDYING HLTH SY, P1; 1995, MMWR MORB MORTAL WKL, V47, P73	30	263	266	1	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1998	129	5					412	416		10.7326/0003-4819-129-5-199809010-00012	http://dx.doi.org/10.7326/0003-4819-129-5-199809010-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	114RL	9735070				2022-12-28	WOS:000075622600010
J	Reid, TMS				Reid, TMS			Striking a balance in maternal immune response to infection	LANCET			English	Editorial Material							PREGNANCY; CELLS; TH2		Aberdeen Royal Infirm, Dept Med Microbiol, Aberdeen AB25 2ZN, Scotland	University of Aberdeen	Reid, TMS (corresponding author), Aberdeen Royal Infirm, Dept Med Microbiol, Aberdeen AB25 2ZN, Scotland.							DEKOSSODO S, 1992, SERONO SYM, V92, P249; Fievet N, 1997, CLIN EXP IMMUNOL, V107, P462, DOI 10.1046/j.1365-2249.1997.d01-966.x; HART CA, 1988, BAILLIERE CLIN IMMUN, V2, P735; Krishnan L, 1996, J IMMUNOL, V156, P653; KRISHNAN L, 1996, J IMMUNOL, V156, P643; MCGREGOR IA, 1984, AM J TROP MED HYG, V33, P517, DOI 10.4269/ajtmh.1984.33.517; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nahmias AJ, 1997, CLIN PERINATOL, V24, P497, DOI 10.1016/S0095-5108(18)30178-7; Raghupathy R, 1997, IMMUNOL TODAY, V18, P478, DOI 10.1016/S0167-5699(97)01127-4; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; TANIGUCHI T, 1991, AM J OBSTET GYNECOL, V165, P131, DOI 10.1016/0002-9378(91)90241-I; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D	13	13	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 6	1998	351	9117					1670	1672		10.1016/S0140-6736(98)22023-X	http://dx.doi.org/10.1016/S0140-6736(98)22023-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734878				2022-12-28	WOS:000074088900002
J	Anaissie, EJ; Kontoyiannis, DP; O'Brien, S; Kantarjian, H; Robertson, L; Lerner, S; Keating, MJ				Anaissie, EJ; Kontoyiannis, DP; O'Brien, S; Kantarjian, H; Robertson, L; Lerner, S; Keating, MJ			Infections in patients with chronic lymphocytic leukemia treated with fludarabine	ANNALS OF INTERNAL MEDICINE			English	Review							LOW-GRADE LYMPHOMA; PNEUMOCYSTIS PNEUMONIA; PLUS PREDNISONE; PHASE-II; THERAPY; AGENT; MONOPHOSPHATE; LISTERIOSIS; PHOSPHATE; MALIGNANCIES	Background: Fludarabine, a purine analogue with activity in chronic lymphocytic leukemia, is usually well tolerated. Although serious infections after fludarabine therapy have been described, a systematic analysis of the risk factors for such infections in chronic lymphocytic leukemia is lacking. Objective: To determine the risk factors for major infection in patients with chronic lymphocytic leukemia treated with fludarabine. Design: Retrospective review of medical records. Setting: Cancer center. Patients: 402 patients with chronic lymphocytic leukemia not previously treated or treated with chlorambucil (with or without prednisone) who received fludarabine (30 mg/m(2) of body surface area per day for 5 days) with or without prednisone at 4-week intervals. Results: Infections occurred more often in previously treated (144 of 248 [58%]) than in previously untreated (53 of 154 [34%]) patients (P < 0.001). Listeriosis or pneumocystosis occurred in 12 of 170 (7%) previously treated patients receiving fludarabine plus prednisone, 0 of 78 previously treated patients receiving fludarabine alone, and 2 of 154 (1%) previously untreated patients receiving fludarabine plus prednisone (P = 0.003). Univariate analysis identified previous chemotherapy, advanced disease, failure to respond to fludarabine, elevated serum P, microglobulin level (P < 0.001), low serum albumin level (P = 0.024), elevated serum creatinine concentration (P = 0.008), and low granulocyte count (P = 0.003) as risk factors for infection. Multivariate analysis identified Rai stage III or IV (odds ratio, 1.98 [95% CI, 1.17 to 3.94]), previous treatment (odds ratio, 2.24 [CI, 1.43 to 3.51]), and elevated serum creatinine concentration (odds ratio, 1.98 [CI, 1.09 to 3.67]) as statistically significant independent risk factors for major infection. A baseline granulocyte count of more than 1000 cells/mu L was protective (odds ratio, 0.54 [CI, 0.29 to 0.99]). Five (26%) of 19 patients with a CD4 count less than 50 cells/mL developed cutaneous tester compared with 9 (6%) of 139 patients with a CD4 count greater than 50 cells/mL (P = 0.01). Conclusions: Fludarabine used in previously treated patients with chronic lymphocytic leukemia may be associated with infections involving T-cell dysfunction, such as listeriosis, pneumocystosis, mycobacterial infections, and opportunistic fungal and viral infections. Prophylaxis or presumptive therapy should be initiated in the appropriate setting.	Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Anaissie, EJ (corresponding author), Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, 4301 W Markham,Mail Slot 776, Little Rock, AR 72205 USA.							ANAISSIE E, 1992, ANN INTERN MED, V117, P466, DOI 10.7326/0003-4819-117-6-466; Angelopoulou MA, 1996, LEUKEMIA LYMPHOMA, V21, P321, DOI 10.3109/10428199209067614; [Anonymous], 1994, J CLIN ONCOL, V12, P2471; BASTION Y, 1991, EUR J CANCER, V27, P671, DOI 10.1016/0277-5379(91)90247-B; BERGMANN L, 1993, ANN ONCOL, V4, P371, DOI 10.1093/oxfordjournals.annonc.a058515; BOLDT DH, 1984, CANCER RES, V44, P4661; Briones J, 1996, MED CLIN-BARCELONA, V107, P86; BYRD JC, 1995, AM J HEMATOL, V49, P135, DOI 10.1002/ajh.2830490207; CHAPEL HM, 1987, SEMIN HEMATOL, V24, P291; Cheson B D, 1990, Oncology (Williston Park), V4, P71; CHESON BD, 1988, AM J HEMATOL, V29, P152, DOI 10.1002/ajh.2830290307; CHESON BD, 1995, J CLIN ONCOL, V13, P2431, DOI 10.1200/JCO.1995.13.9.2431; DEROSSI G, 1993, HAEMATOLOGICA, V78, P167; DIMOPOULOS MA, 1993, AM J MED, V95, P49, DOI 10.1016/0002-9343(93)90231-D; FAUCI AS, 1976, ANN INTERN MED, V84, P304, DOI 10.7326/0003-4819-84-3-304; FENCHEL K, 1995, LEUKEMIA LYMPHOMA, V18, P485, DOI 10.3109/10428199509059649; GIRMENIA C, 1994, BRIT J HAEMATOL, V87, P407, DOI 10.1111/j.1365-2141.1994.tb04932.x; GREVER MR, 1988, NOUV REV FR HEMATOL, V30, P457; Hequet O, 1997, HEMATOL CELL THER, V39, P89, DOI 10.1007/s00282-997-0089-1; HIDDEMANN W, 1991, ANN HEMATOL, V63, P1, DOI 10.1007/BF01714952; HOCHSTER HS, 1992, J CLIN ONCOL, V10, P28, DOI 10.1200/JCO.1992.10.1.28; KEATING MJ, 1993, BLOOD, V81, P2878; KEATING MJ, 1988, LEUKEMIA, V2, P157; KEATING MJ, 1989, BLOOD, V74, P19; KONTOYIANIS DP, 1993, CHRONIC LYMPHOCYTIC, P399; Montserrat E, 1996, LEUKEMIA LYMPHOMA, V21, P467, DOI 10.3109/10428199609093445; Morrison VA, 1998, SEMIN ONCOL, V25, P98; OBrien S, 1997, LEUKEMIA, V11, P1631, DOI 10.1038/sj.leu.2400816; OBRIEN S, 1993, BLOOD, V82, P1695; Papajik T, 1997, Vnitr Lek, V43, P25; Pillay GS, 1996, S AFR MED J, V86, P949; PUCCIO CA, 1991, J CLIN ONCOL, V9, P1562, DOI 10.1200/JCO.1991.9.9.1562; REDMAN JR, 1992, J CLIN ONCOL, V10, P790, DOI 10.1200/JCO.1992.10.5.790; ROBERTSON LE, 1992, BLOOD, V80, P29; SANDERS C, 1992, AM J HEMATOL, V39, P314, DOI 10.1002/ajh.2830390418; Schilling P J, 1991, Oncology (Williston Park), V5, P12; SCHILLING PJ, 1990, NEW ENGL J MED, V323, P833, DOI 10.1056/NEJM199009203231216; UZUN O, 1995, BLOOD, V86, P2063, DOI 10.1182/blood.V86.6.2063.bloodjournal8662063; WHELAN JS, 1991, BRIT J CANCER, V64, P120, DOI 10.1038/bjc.1991.253; WIJERMANS PW, 1993, EUR J HAEMATOL, V50, P292; YOUNG JL, 1981, NATL CANCER I MONOGR, V57, P10	41	215	231	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1998	129	7					559	566		10.7326/0003-4819-129-7-199810010-00010	http://dx.doi.org/10.7326/0003-4819-129-7-199810010-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123KN	9758577				2022-12-28	WOS:000076124500008
J	Rees, PJ; Dudley, F				Rees, PJ; Dudley, F			ABC of oxygen - Oxygen therapy in chronic lung disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Guys & St Thomas Hosp Trust, London, England; Hurley Clin, London, England	Guy's & St Thomas' NHS Foundation Trust	Rees, PJ (corresponding author), Guys & St Thomas Hosp Trust, London, England.							[Anonymous], 1980, Ann Intern Med, V93, P391; FLENLEY DC, 1981, LANCET, V1, P681	2	8	9	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	1998	317	7162					871	874		10.1136/bmj.317.7162.871	http://dx.doi.org/10.1136/bmj.317.7162.871			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748190	Green Published			2022-12-28	WOS:000076222300026
J	Eccles, M; Clarke, J; Livingstone, M; Freemantle, N; Mason, J				Eccles, M; Clarke, J; Livingstone, M; Freemantle, N; Mason, J		N England Evidence Based Dementia G	North of England evidence based guidelines development project: guideline for the primary care management of dementia	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MENTAL-STATE-EXAMINATION; PRIMARY DEGENERATIVE DEMENTIA; MULTI-INFARCT DEMENTIA; LEWY BODY TYPE; ALZHEIMERS-DISEASE; DOUBLE-BLIND; COGNITIVE IMPAIRMENT; SENILE DEMENTIA; SPOUSE-CAREGIVERS; CONTROLLED TRIAL		Newcastle Univ, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Sch Hlth Sci, Sch Med, Dept Primary Hlth Care, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; N Tyneside Gen Hosp, Psychiat Old Age Serv, N Shields NE29 8NH, England; Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England	Newcastle University - UK; University of York - UK	Eccles, M (corresponding author), Newcastle Univ, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.	Martin.Eccles@ncl.ac.uk	Mason, James M/D-9904-2011; Eccles, Martin P/AAD-4029-2020	Mason, James M/0000-0001-9210-4082; Freemantle, Nick/0000-0001-5807-5740				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Asada T, 1996, AGE AGEING, V25, P22, DOI 10.1093/ageing/25.1.22; ATHER SA, 1986, ACTA PSYCHIAT SCAND, V73, P81, DOI 10.1111/j.1600-0447.1986.tb10541.x; AUTUONO PG, 1995, ARCH INTERN MED, V155, P1766; BALLARD CG, 1993, J AFFECT DISORDERS, V29, P1, DOI 10.1016/0165-0327(93)90111-V; BALLARD CG, 1995, J AFFECT DISORDERS, V35, P59, DOI 10.1016/0165-0327(95)00041-K; BARBERGERGATEAU P, 1992, J AM GERIATR SOC, V40, P1129, DOI 10.1111/j.1532-5415.1992.tb01802.x; BAYER AJ, 1987, DRUGS, V33, P84, DOI 10.2165/00003495-198700332-00016; BOWERS J, 1990, MED J AUSTRALIA, V153, P192, DOI 10.5694/j.1326-5377.1990.tb136858.x; BRAEKHUS A, 1995, J AM GERIATR SOC, V43, P656, DOI 10.1111/j.1532-5415.1995.tb07201.x; BRAVNE C, 1995, BRIT J PSYCHIAT, V17, P255; BRODATY H, 1989, BMJ-BRIT MED J, V299, P1375, DOI 10.1136/bmj.299.6712.1375; BUCHNER DM, 1987, JAMA-J AM MED ASSOC, V20, P1492; Burke W J, 1988, Alzheimer Dis Assoc Disord, V2, P356, DOI 10.1097/00002093-198802040-00004; BURKE WJ, 1994, ALZ DIS ASSOC DIS, V8, P22, DOI 10.1097/00002093-199408010-00005; BURNS A, 1990, BRIT J PSYCHIAT, V157, P81, DOI 10.1192/bjp.157.1.81; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; CHATELLIER G, 1990, BRIT MED J, V300, P495, DOI 10.1136/bmj.300.6723.495; CLARNETTE RM, 1994, J GERIATR PSYCH NEUR, V7, P23, DOI 10.1177/089198879400700105; COLERICK EJ, 1986, J AM GERIATR SOC, V34, P493, DOI 10.1111/j.1532-5415.1986.tb04239.x; Collins C, 1994, West J Nurs Res, V16, P40, DOI 10.1177/019394599401600104; COOPER B, 1992, INT J GERIATR PSYCH, V7, P591, DOI 10.1002/gps.930070809; CRYSTAL HA, 1994, J AM GERIATR SOC, V42, P933, DOI 10.1111/j.1532-5415.1994.tb06583.x; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; DELANEY P, 1982, SOUTHERN MED J, V75, P707, DOI 10.1097/00007611-198206000-00020; DEUTSCH LH, 1991, AM J PSYCHIAT, V148, P1159; DURA JR, 1991, PSYCHOL AGING, V6, P467, DOI 10.1037/0882-7974.6.3.467; Eccles M, 1996, BMJ-BRIT MED J, V312, P760; ENGEDAL K, 1989, Scandinavian Journal of Primary Health Care, V7, P161, DOI 10.3109/02813438909087234; ERKINJUNTTI T, 1987, J AM GERIATR SOC, V35, P412, DOI 10.1111/j.1532-5415.1987.tb04662.x; FAGGER SA, 1994, LANCET, V337, P989; FARLOW M, 1992, JAMA-J AM MED ASSOC, V268, P2523, DOI 10.1001/jama.268.18.2523; FEHER EP, 1994, J GERIATR PSYCH NEUR, V7, P58, DOI 10.1177/089198879400700111; FILLENBAUM GG, 1994, ARCH NEUROL-CHICAGO, V51, P916, DOI 10.1001/archneur.1994.00540210088017; FITZ AG, 1994, J AM GERIATR SOC, V42, P186, DOI 10.1111/j.1532-5415.1994.tb04950.x; FORETTE F, 1995, EUR J NEUROL, V2, P229, DOI 10.1111/j.1468-1331.1995.tb00124.x; FOX JH, 1975, J GERONTOL, V30, P557, DOI 10.1093/geronj/30.5.557; GAGNON M, 1990, NEUROEPIDEMIOLOGY, V9, P143, DOI 10.1159/000110764; GALASKO D, 1990, ARCH NEUROL-CHICAGO, V47, P49, DOI 10.1001/archneur.1990.00530010061020; GALLAGHER D, 1989, GERONTOLOGIST, V29, P449, DOI 10.1093/geront/29.4.449; GAUTHIER S, 1990, NEW ENGL J MED, V322, P1272, DOI 10.1056/NEJM199005033221804; GOODMAN CC, 1990, GERONTOLOGIST, V30, P399, DOI 10.1093/geront/30.3.399; HALEY WE, 1992, GERONTOLOGIST, V32, P219, DOI 10.1093/geront/32.2.219; HALEY WE, 1987, J AM GERIATR SOC, V35, P405, DOI 10.1111/j.1532-5415.1987.tb04661.x; HALEY WE, 1989, PSYCHOL AGING, V4, P389, DOI 10.1037/0882-7974.4.4.389; HALEY WE, 1987, PSYCHOL AGING, V2, P323, DOI 10.1037/0882-7974.2.4.323; HANLEY IG, 1981, BRIT J PSYCHIAT, V138, P10, DOI 10.1192/bjp.138.1.10; HEBERT R, 1995, ARCH GERONTOL GERIAT, V20, P129, DOI 10.1016/0167-4943(94)00590-4; Huang Y, 1994, J S C Med Assoc, V90, P51; HUGHES JR, 1976, J AM GERIATR SOC, V24, P490, DOI 10.1111/j.1532-5415.1976.tb03271.x; HUNTZINGER JA, 1992, GEN HOSP PSYCHIAT, V14, P142, DOI 10.1016/0163-8343(92)90040-H; ILIFFE S, 1994, BRIT J GEN PRACT, V44, P503; JITAPUNKUL S, 1991, AGE AGEING, V20, P332, DOI 10.1093/ageing/20.5.332; KASA M, 1989, NEUROEPIDEMIOLOGY, V8, P254, DOI 10.1159/000110191; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; KNESEVICH JW, 1983, AM J PSYCHIAT, V140, P233; KNOPMAN DS, 1988, J AM GERIATR SOC, V36, P108, DOI 10.1111/j.1532-5415.1988.tb01778.x; KOKMEN E, 1991, NEUROLOGY, V41, P1393, DOI 10.1212/WNL.41.9.1393; KOKMEN E, 1991, ARCH NEUROL-CHICAGO, V48, P725, DOI 10.1001/archneur.1991.00530190071018; KOSS E, 1993, ARCH NEUROL-CHICAGO, V50, P92, DOI 10.1001/archneur.1993.00540010086023; KOTSORIS H, 1987, STROKE, V18, P138, DOI 10.1161/01.STR.18.1.138; LARSON EB, 1986, ARCH INTERN MED, V146, P1917, DOI 10.1001/archinte.146.10.1917; LAWTON MP, 1989, GERONTOLOGIST, V29, P8, DOI 10.1093/geront/29.1.8; LAZARUS LW, 1987, AM J PSYCHIAT, V144, P41; LEVITT AJ, 1992, ACTA PSYCHIAT SCAND, V86, P301, DOI 10.1111/j.1600-0447.1992.tb03270.x; LIVINGSTON G, 1990, PSYCHOL MED, V20, P881, DOI 10.1017/S0033291700036588; LORD TR, 1993, PERCEPT MOTOR SKILL, V76, P451, DOI 10.2466/pms.1993.76.2.451; LOVETT WC, 1987, J CLIN PSYCHIAT, V48, P234; MALONE ML, 1993, J AM GERIATR SOC, V41, P853, DOI 10.1111/j.1532-5415.1993.tb06183.x; MALTBY N, 1994, BMJ-BRIT MED J, V308, P879, DOI 10.1136/bmj.308.6933.879; MCCORMICK A, 1995, MORBIDITY STAT GEN P; MCCORMICK WC, 1994, J AM GERIATR SOC, V42, P517, DOI 10.1111/j.1532-5415.1994.tb04974.x; MCCORMICK WC, 1995, J GEN INTERN MED, V10, P187, DOI 10.1007/BF02600253; MCDONALD RJ, 1979, PHARMAKOPSYCH NEURO, V12, P407, DOI 10.1055/s-0028-1094637; MCGLONE J, 1990, ARCH NEUROL-CHICAGO, V47, P1189, DOI 10.1001/archneur.1990.00530110043015; MCINTYRE L, 1987, J FAM PRACTICE, V24, P399; MCKEITH I, 1992, BRIT MED J, V305, P673, DOI 10.1136/bmj.305.6855.673; MCKEITH IG, 1992, PSYCHOL MED, V22, P911, DOI 10.1017/S0033291700038484; MELTON LJ, 1994, J AM GERIATR SOC, V42, P614, DOI 10.1111/j.1532-5415.1994.tb06859.x; MENDEZ MF, 1992, J AM GERIATR SOC, V40, P1095, DOI 10.1111/j.1532-5415.1992.tb01796.x; MEYER JS, 1989, J AM GERIATR SOC, V37, P549, DOI 10.1111/j.1532-5415.1989.tb05688.x; MITTELMAN MS, 1993, GERONTOLOGIST, V33, P730, DOI 10.1093/geront/33.6.730; MOLLOY DW, 1991, CAN MED ASSOC J, V144, P29; MORRIS LW, 1989, BRIT J MED PSYCHOL, V62, P173, DOI 10.1111/j.2044-8341.1989.tb02824.x; MOWRY BJ, 1998, BRIT J PSYCHIAT, V153, P328; MURPHY MF, 1991, ANN NY ACAD SCI, V640, P253; *N ENGL EV BAS GUI, 1998, EV BAS GUID PRIM CAR; NYBACK H, 1993, ACTA NEUROL SCAND, V88, P36; Nygaard H A, 1991, Scand J Caring Sci, V5, P157; O'Connor D W, 1990, Int Psychogeriatr, V2, P45, DOI 10.1017/S1041610290000291; O'Donnell B F, 1992, J Geriatr Psychiatry Neurol, V5, P45; OCONNOR DW, 1993, BRIT J GEN PRACT, V43, P185; OCONNOR DW, 1990, ACTA PSYCHIAT SCAND, V81, P78, DOI 10.1111/j.1600-0447.1990.tb06453.x; PARKS SH, 1991, AM J ORTHOPSYCHIAT, V61, P501, DOI 10.1037/h0079290; PASSERI M, 1993, AGING-CLIN EXP RES, V5, P63, DOI 10.1007/BF03324128; PEARSON JL, 1989, J AM GERIATR SOC, V37, P1117, DOI 10.1111/j.1532-5415.1989.tb06674.x; RATCLIFFE PJ, 1985, POSTGRAD MED J, V61, P201, DOI 10.1136/pgmj.61.713.201; REDING M, 1985, ARCH NEUROL-CHICAGO, V42, P894, DOI 10.1001/archneur.1985.04060080080019; REIFLER BV, 1986, J AM GERIATR SOC, V34, P855, DOI 10.1111/j.1532-5415.1986.tb07258.x; REISBERG B, 1987, J CLIN PSYCHIAT, V48, P9; RICHARDS M, 1993, NEUROLOGY, V43, P2184, DOI 10.1212/WNL.43.11.2184; Rogers SL, 1998, ARCH INTERN MED, V158, P1021, DOI 10.1001/archinte.158.9.1021; Rogers SL, 1996, DEMENTIA, V7, P293, DOI 10.1159/000106895; ROSEN J, 1991, BIOL PSYCHIAT, V29, P224, DOI 10.1016/0006-3223(91)91284-X; Rovner BW, 1996, J AM GERIATR SOC, V44, P7, DOI 10.1111/j.1532-5415.1996.tb05631.x; RUSSO J, 1995, EXP AGING RES, V21, P273, DOI 10.1080/03610739508253985; SCHNEIDER LS, 1990, J AM GERIATR SOC, V38, P553, DOI 10.1111/j.1532-5415.1990.tb02407.x; SCHULZ R, 1991, PSYCHOL AGING, V6, P569, DOI 10.1037/0882-7974.6.4.569; SHIP JA, 1994, J AM GERIATR SOC, V42, P57, DOI 10.1111/j.1532-5415.1994.tb06074.x; SIU AL, 1991, ANN INTERN MED, V115, P122, DOI 10.7326/0003-4819-115-2-122; SPECK CE, 1995, EPIDEMIOLOGY, V6, P366, DOI 10.1097/00001648-199507000-00006; STEELE C, 1990, AM J PSYCHIAT, V147, P1049; STEPHENS MAP, 1991, GERONTOLOGIST, V31, P217, DOI 10.1093/geront/31.2.217; SUNDERLAND T, 1989, J AM GERIATR SOC, V37, P725, DOI 10.1111/j.1532-5415.1989.tb02233.x; TAPPEN RM, 1994, RES NURS HEALTH, V17, P159, DOI 10.1002/nur.4770170303; TATEMICHI TK, 1992, NEUROLOGY, V42, P1185, DOI 10.1212/wnl.42.6.1185; THOMPSON TL, 1990, NEW ENGL J MED, V323, P691; TOBIANSKY R, 1995, PSYCHOL MED, V25, P779, DOI 10.1017/S0033291700035029; TROISI A, 1993, DEMENTIA, V4, P87, DOI 10.1159/000107302; TROSTER AI, 1994, J NEUROPSYCH CLIN N, V6, P54; UHLMANN RF, 1991, J AM GERIATR SOC, V39, P876, DOI 10.1111/j.1532-5415.1991.tb04454.x; VANLOVERENHUYBEN CMS, 1984, J AM GERIATR SOC, V32, P584, DOI 10.1111/j.1532-5415.1984.tb06137.x; Venn R D, 1980, Adv Biochem Psychopharmacol, V23, P363; VERHEY FRJ, 1995, J GERIATR PSYCH NEUR, V8, P23; VITALIANO PP, 1991, PSYCHOL AGING, V6, P392, DOI 10.1037/0882-7974.6.3.392; WATKINS PB, 1994, JAMA-J AM MED ASSOC, V274, P992; WATSON YI, 1993, J AM GERIATR SOC, V41, P1235, DOI 10.1111/j.1532-5415.1993.tb07308.x; WELLS JC, 1992, ACTA PSYCHIAT SCAND, V86, P23, DOI 10.1111/j.1600-0447.1992.tb03220.x; WILCOCK GK, 1994, BRIT J GEN PRACT, V44, P30; Williams G O, 1995, Arch Fam Med, V4, P512, DOI 10.1001/archfami.4.6.512; Wimo Anders, 1993, Scandinavian Journal of Primary Health Care, V11, P117, DOI 10.3109/02813439308994913; WOOD PC, 1994, INT J GERIATR PSYCH, V9, P649, DOI 10.1002/gps.930090809; YESAVAGE JA, 1979, ARCH GEN PSYCHIAT, V36, P220; YLIKOSKI R, 1992, ACTA NEUROL SCAND, V85, P391; ZARIT SH, 1986, GERONTOLOGIST, V26, P260, DOI 10.1093/geront/26.3.260; ZARIT SH, 1987, PSYCHOL AGING, V2, P225, DOI 10.1037/0882-7974.2.3.225; 1996, 39 WEEK MULTICENTER; 1995, PRELIMINARY MULTICEN; 1996, 1K WEEK MULTICENTER	139	98	99	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 19	1998	317	7161					802	808		10.1136/bmj.317.7161.802	http://dx.doi.org/10.1136/bmj.317.7161.802			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	122RA	9740574	Green Published			2022-12-28	WOS:000076084200038
J	Ganzini, L				Ganzini, L			An independent scientist	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Ganzini L, 1997, NEW ENGL J MED, V336, P1824, DOI 10.1056/NEJM199706193362511	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1998	280	11					950	950		10.1001/jama.280.11.950-a	http://dx.doi.org/10.1001/jama.280.11.950-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JC	9749463				2022-12-28	WOS:000075891400001
J	Mechanic, R; Coleman, K; Dobson, A				Mechanic, R; Coleman, K; Dobson, A			Teaching hospital costs - Implications for academic missions in a competitive market	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARE	Context.-As the managed care environment demands lower prices and a greater focus on primary care, the high cost of teaching hospitals may adversely affect their ability to carry out academic missions. Objective.-To develop a national estimate of total inpatient hospital costs related to graduate medical education (GME). Design.-Using Medicare cost report data for fiscal year 1993, we developed a series of regression models to analyze the relationship between inpatient hospital costs per case and explanatory variables, such as case mix, wage levels, local market characteristics, and teaching intensity (the ratio of interns and residents to beds). Setting and Participants.-A total of 4764 nonfederal, general acute care hospitals, including 1014 teaching hospitals. Major Outcome Measures.-Actual direct GME hospital costs and estimated indirect GME-related hospital costs based on the statistical relationship between teaching intensity and inpatient costs per case. Results.-In 1993, academic medical center (AMC) costs per case were 82.9% higher than those for urban nonteaching hospitals tactual cost per case, $9901 vs $5412, respectively). Non-AMC teaching hospital costs per case were 22.5% higher than those for nonteaching hospitals tactual cost per differences in case, $6630 vs $5412, respectively). After adjustment for case mix, wage levels, and direct GME costs, AMCs were 44% more expensive and other teaching hospitals were 14% more costly than nonteaching hospitals. The majority of this difference is explained by teaching intensity. Total estimated US direct and indirect GME-related costs were between $18.1 billion and $22.8 billion in 1997. These estimates include some indirect costs, not directly educational in nature, related to clinical research activities and specialized service capacity. Conclusions.-The cost of teaching hospitals relative to their nonteaching counterparts justifies concern about the potential financial impact of competitive markets on academic missions. The 1997 GME-related cost estimates provide a starting point as public funding mechanisms for academic missions are debated. The efficiency of residency programs, their consistency with national health workforce needs, financial benefits provided to teaching hospitals, and ability of AMCs to maintain higher payment rates are also important considerations in determining future levels of public financial support.	Lewin Grp, Fairfax, VA USA		Mechanic, R (corresponding author), Massachusetts Hosp Assoc, 5 New England Execut Pk, Burlington, MA 01803 USA.				PHS HHS [282-92-0041] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AM HOSP ASS, 1998, HOSP STAT; ANDERSON GF, 1986, INQUIRY-J HEALTH CAR, V23, P191; *ASS AM MED COLL, 1994, MED ED AMB CAR SETT; Association of American Medical C, 2021, AAMC DAT BOOK STAT I; BLUMENTHAL D, 1996, HLTH AFF MILLWOOD, V15, P201; BREYER F, 1987, J HEALTH ECON, V6, P147, DOI 10.1016/0167-6296(87)90004-X; *COMM FUND TASK FO, 1997, LEV PLAYING FIELD FI; *COUNC GRAD MED ED, 1996, PAT CAR PHYS SUPPL R; DOBSON A, 1994, ANAL TEACHING HOSP C; Dor A, 1996, J HEALTH ECON, V15, P1, DOI 10.1016/0167-6296(95)00029-1; GRANNEMANN TW, 1986, J HEALTH ECON, V5, P107, DOI 10.1016/0167-6296(86)90001-9; *HOUS WAYS MEANS C, 1983, 9825 HOUS WAYS MEANS; *I MED, 1996, NAT WORKF OPT BAL SU; IGLEHART JK, 1995, NEW ENGL J MED, V332, P6; Lave J., 1985, MEDICARE ADJUSTMENT; Mechanic RE, 1996, HEALTH AFFAIR, V15, P72, DOI 10.1377/hlthaff.15.3.72; *NAT ASS CHILDR HO, 1995, MED FUND GRAD MED ED; Pettengill J, 1982, Health Care Financ Rev, V4, P101; Pew Health Professions Commission, 1995, CRIT CHALL REV HLTH; *PROSP PAYM ASS CO, 1995, REP REC C; *PROSP PAYM ASS CO, 1997, REP REC C; *PROSP PAYM ASS CO, 1996, REP REC C; Reuter J, 1997, HEALTH AFFAIR, V16, P242, DOI 10.1377/hlthaff.16.4.242; SALSBERG E, 1997, STATE STRATEGIES FIN; THORPE KE, 1988, INQUIRY-J HEALTH CAR, V25, P219; *US C BUDG OFF, 1997, JAN 1997 BAS EST; *US C BUDG OFF, 1995, MED GRAD MED ED; VITA MG, 1990, J HEALTH ECON, V9, P1, DOI 10.1016/0167-6296(90)90038-5; 1997, MED HLTH PERSPE 0113, P1	29	113	113	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1998	280	11					1015	1019		10.1001/jama.280.11.1015	http://dx.doi.org/10.1001/jama.280.11.1015			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	119JC	9749488				2022-12-28	WOS:000075891400038
J	Schaeffer, HJ; Catling, AD; Eblen, ST; Collier, LS; Krauss, A; Weber, MJ				Schaeffer, HJ; Catling, AD; Eblen, ST; Collier, LS; Krauss, A; Weber, MJ			MP1: A MEK binding partner that enhances enzymatic activation of the MAP kinase cascade	SCIENCE			English	Article							PROTEIN	Signal transduction is controlled both by regulation of enzyme activation and by organization of enzymatic complexes with nonenzymatic adapters, scaffolds, and anchor proteins. The extracellular signal-regulated kinase (ERK) cascade is one of several evolutionarily conserved mitogen-activated protein (MAP) kinase cascades important in the regulation of growth, apoptosis, and differentiation. A two-hybrid screen was conducted to identify nonenzymatic components of this signaling cascade that might be important in regulating its activity. A protein called MP1 (MEK Partner 1) was identified that bound specifically to MEK1 and ERK1 and facilitated their activation. When overexpressed in cultured cells, MP1 enhanced activation of ERK1 and activation of a reporter driven by the transcription factor Elk-1. Expression of MP1 in cells increased binding of ERK1 to MEK1. MP1 apparently functions as an adapter to enhance the efficiency of the MAP kinase cascade.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Weber, MJ (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA.			Schaeffer, Hans-Joerg/0000-0003-2010-9153	NATIONAL CANCER INSTITUTE [R01CA039076, R37CA039076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047332] Funding Source: NIH RePORTER; NCI NIH HHS [CA39076] Funding Source: Medline; NIGMS NIH HHS [GM47332] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CATLING AD, UNPUB; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOI KY, 1994, CELL, V78, P499; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARPER JW, 1993, CELL, V75, P805; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; SCHAEFFER HF, UNPUB	13	377	392	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1668	1671		10.1126/science.281.5383.1668	http://dx.doi.org/10.1126/science.281.5383.1668			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733512				2022-12-28	WOS:000075856500045
J	Robine, JM				Robine, JM			Measuring the burden of disease	LANCET			English	Editorial Material							MORTALITY; HEALTH		INSERM, F-34298 Montpellier 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Robine, JM (corresponding author), INSERM, Val Aurelle, F-34298 Montpellier 5, France.		Robine, Jean-Marie/F-5439-2011; Lopez, Alan D/F-1487-2010	Robine, Jean-Marie/0000-0002-4111-6195; Lopez, Alan D/0000-0001-5818-6512				Anand S, 1997, J HEALTH ECON, V16, P685, DOI 10.1016/S0167-6296(97)00005-2; Bonneux L, 1998, BRIT MED J, V316, P26, DOI 10.1136/bmj.316.7124.26; Hyder AA, 1998, AM J PUBLIC HEALTH, V88, P196, DOI 10.2105/AJPH.88.2.196; Murray CJL, 1997, J HEALTH ECON, V16, P703, DOI 10.1016/S0167-6296(97)00004-0; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; National Center for Health Statistics, 1996, HLTH PEOPL 2000 REV; ROMEDER JM, 1977, INT J EPIDEMIOL, V6, P143, DOI 10.1093/ije/6.2.143; Tsevat J, 1998, JAMA-J AM MED ASSOC, V279, P371, DOI 10.1001/jama.279.5.371; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304	9	7	7	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					757	758		10.1016/S0140-6736(05)60676-9	http://dx.doi.org/10.1016/S0140-6736(05)60676-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737277				2022-12-28	WOS:000075762700006
J	Liu, DJ; Ishima, R; Tong, KI; Bagby, S; Kokubo, T; Muhandiram, DR; Kay, LE; Nakatani, Y; Ikura, M				Liu, DJ; Ishima, R; Tong, KI; Bagby, S; Kokubo, T; Muhandiram, DR; Kay, LE; Nakatani, Y; Ikura, M			Solution structure of a TBP-TAF(II)230 complex: Protein mimicry of the minor groove surface of the TATA box unwound by TBP	CELL			English	Article							RNA-POLYMERASE-II; YEAST TFIIA/TBP/DNA COMPLEX; NUCLEAR-MAGNETIC-RESONANCE; URACIL-DNA GLYCOSYLASE; CRYSTAL-STRUCTURE; BINDING-PROTEIN; TRANSCRIPTION FACTOR; TERNARY COMPLEX; TRANSACTIVATION DOMAIN; PREINITIATION COMPLEX	General transcription factor TFIID consists of TATA box-binding protein (TBP) and TBP-associated factors (TAF(II)s), which together play a central role in both positive and negative regulation of transcription. The N-terminal region of the 230 kDa Drosophaa TAF(II)(dTAF(II)230) binds directly to TBP and inhibits TBP binding to the TATA box. We report here the solution structure of the complex formed by dTAF(II)230 N-terminal region (residues 11-77) and TBP. dTAF(II)230(11-77) comprises three or helices and a beta hairpin, forming a core that occupies the concave DNA-binding surface of TBP. The TBP-binding surface of dTAF(II)230 markedly resembles the minor groove surface of the partially unwound TATA box in the TBP-TATA complex. This protein mimicry of the TATA element surface provides the structural basis of the mechanism by which dTAF(II)230 negatively controls the TATA box-binding activity within the TFIID complex.	Ontario Canc Inst, Div Mol & Struct Biol, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; Univ Toronto, Protein Engn Network Ctr Excellence, Dept Med & Mol Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Protein Engn Network Ctr Excellence, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Protein Engn Network Ctr Excellence, Dept Chem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Toronto; University of Toronto; University of Toronto	Ikura, M (corresponding author), Ontario Canc Inst, Div Mol & Struct Biol, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.			Bagby, Stefan/0000-0003-2302-9511				ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; ASO T, 1994, J BIOL CHEM, V269, P26575; Bagby S, 1997, J BIOMOL NMR, V10, P279, DOI 10.1023/A:1018359305544; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Drysdale CM, 1998, MOL CELL BIOL, V18, P1711, DOI 10.1128/MCB.18.3.1711; Frankel AD, 1998, CELL, V92, P149, DOI 10.1016/S0092-8674(00)80908-3; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; Kay LE, 1997, CURR OPIN STRUC BIOL, V7, P722, DOI 10.1016/S0959-440X(97)80084-X; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; Kosa PF, 1997, P NATL ACAD SCI USA, V94, P6042, DOI 10.1073/pnas.94.12.6042; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEE M, 1995, MOL CELL BIOL, V15, P5461; LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3; MERRITT EA, 1997, METHOD ENZYMOL, V277, P503; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; Nicholls A.J., 1993, GRASP MANUAL; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; NILGES M, 1991, NATO ADV SCI I A-LIF, V225, P451; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Nyborg J, 1996, TRENDS BIOCHEM SCI, V21, P81, DOI 10.1016/0968-0004(96)30008-X; O'Brien T, 1998, MOL CELL, V1, P905, DOI 10.1016/S1097-2765(00)80089-1; Oelgeschlager T, 1998, MOL CELL, V1, P925, DOI 10.1016/S1097-2765(00)80092-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ORENGO CA, 1992, PROTEINS, V14, P139, DOI 10.1002/prot.340140203; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhou P, 1998, CELL, V92, P687, DOI 10.1016/S0092-8674(00)81136-8; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	67	172	181	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 4	1998	94	5					573	583		10.1016/S0092-8674(00)81599-8	http://dx.doi.org/10.1016/S0092-8674(00)81599-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741622	Bronze			2022-12-28	WOS:000075851900005
J	Douglas, C				Douglas, C			Soundings - Going slowly	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					955	955						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756835				2022-12-28	WOS:000076409000082
J	Tsang, SH; Burns, ME; Calvert, PD; Gouras, P; Baylor, DA; Goff, SP; Arshavsky, VY				Tsang, SH; Burns, ME; Calvert, PD; Gouras, P; Baylor, DA; Goff, SP; Arshavsky, VY			Role for the target enzyme in deactivation of photoreceptor G protein in vivo	SCIENCE			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; ROD OUTER SEGMENTS; TRANSDUCIN GTPASE ACTIVITY; CGMP PHOSPHODIESTERASE; RETINAL RODS; VISUAL TRANSDUCTION; ACTIVATION STEPS; GAMMA-SUBUNIT; RGS PROTEINS; FAMILY	Heterotrimeric guanosine 5'-triphosphate (GTP)-binding proteins (C proteins) are deactivated by hydrolysis of the CTP that they bind when activated by transmembrane receptors. Transducin, the C protein that relays visual excitation from rhodopsin to the cyclic guanosine 3',5'-monophosphate phosphodiesterase (PDE) in retinal photoreceptors, must be deactivated for the light response to recover. A point mutation in the gamma subunit of PDE impaired transducin-PDE interactions and slowed the recovery rate of the flash response in transgenic mouse rods. These results indicate that the normal deactivation of transducin in vivo requires the G protein to interact with its target enzyme.	Harvard Univ, Sch Med, Howe Lab Ophthalmol, Boston, MA 02114 USA; Columbia Univ Coll Phys & Surg, Edward S Harkness Eye Inst, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA; Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA; Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA	Harvard University; Harvard Medical School; Columbia University; Columbia University; Stanford University; Harvard University; Massachusetts Eye & Ear Infirmary; Columbia University; Howard Hughes Medical Institute	Arshavsky, VY (corresponding author), Harvard Univ, Sch Med, Howe Lab Ophthalmol, Boston, MA 02114 USA.	varshavsky@meei.harvard.edu	Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547	NEI NIH HHS [EY05750, EY10336, T32 EY07105] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005750, R01EY010336, T32EY007105] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ANTONNY B, 1993, BIOCHEMISTRY-US, V32, P8646, DOI 10.1021/bi00084a036; ARSHAVSKY VY, 1989, FEBS LETT, V250, P353, DOI 10.1016/0014-5793(89)80754-9; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BOURNE HR, 1995, PHILOS T R SOC B, V349, P283, DOI 10.1098/rstb.1995.0114; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BOWNDS MD, 1995, BEHAV BRAIN SCI, V18, P415, DOI 10.1017/S0140525X00039170; BURNS M, UNPUB; Calvert PD, 1998, J GEN PHYSIOL, V111, P39, DOI 10.1085/jgp.111.1.39; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAMB TD, 1981, J PHYSIOL-LONDON, V319, P463, DOI 10.1113/jphysiol.1981.sp013921; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; Lyubarsky AL, 1996, J NEUROSCI, V16, P563, DOI 10.1523/jneurosci.16-02-00563.1996; Natochin M, 1997, J BIOL CHEM, V272, P17444, DOI 10.1074/jbc.272.28.17444; Nekrasova ER, 1997, BIOCHEMISTRY-US, V36, P7638, DOI 10.1021/bi970427r; Nikonov S, 1998, J GEN PHYSIOL, V111, P7, DOI 10.1085/jgp.111.1.7; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; PAGES F, 1992, J BIOL CHEM, V267, P22018; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; SUNG CH, 1994, J NEUROSCI, V14, P5818; Tsang SH, 1996, SCIENCE, V272, P1026, DOI 10.1126/science.272.5264.1026; TUTEJA N, 1988, FEBS LETT, V232, P182, DOI 10.1016/0014-5793(88)80413-7; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; ZIMMERMAN AL, 1986, NATURE, V321, P70, DOI 10.1038/321070a0	47	167	168	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1998	282	5386					117	121		10.1126/science.282.5386.117	http://dx.doi.org/10.1126/science.282.5386.117			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756475				2022-12-28	WOS:000076294900052
J	[Anonymous]				[Anonymous]			Question marks remain over PCGs	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	1998	317	7162					891	891						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748199				2022-12-28	WOS:000076222300061
J	Gonzalez, A; Lawton, JH; Gilbert, FS; Blackburn, TM; Evans-Freke, I				Gonzalez, A; Lawton, JH; Gilbert, FS; Blackburn, TM; Evans-Freke, I			Metapopulation dynamics, abundance, and distribution in a microecosystem	SCIENCE			English	Article							CONSERVATION; MECHANISMS; ARTIFACTS; RANGE; CORE	The experimental fragmentation of landscapes of a natural ecosystem resulted in declines in the abundance and distribution of most species in the multispecies animal community inhabiting the landscapes and the extinction of many species. These declines caused the deterioration of the positive interspecific relation between local population abundance and distributional extent in this community. However, when patches were connected by habitat corridors, an immigration "rescue effect" arrested declines in both abundance and distribution and maintained the observed positive relation between them. These results demonstrate the importance of metapopulation dynamics and landscape connectivity for the persistence of populations in fragmented landscapes.	Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Ascot SL5 7PY, Berks, England; Univ Nottingham, Sch Biol Sci, Nottingham NG7 2RD, England	Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Nottingham	Gonzalez, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Silwood Pk, Ascot SL5 7PY, Berks, England.		Blackburn, Tim M/A-7685-2011; Blackburn, Tim/AAC-3144-2019; Gonzalez, Andrew/F-2247-2010; Gilbert, Francis S/K-3817-2013	Blackburn, Tim/0000-0003-0152-2663; Gonzalez, Andrew/0000-0001-6075-8081; Gilbert, Francis/0000-0002-2727-4103				[Anonymous], 1997, ECOL SOC, DOI DOI 10.5751/ES-00015-010104; BROWN JH, 1984, AM NAT, V124, P255, DOI 10.1086/284267; Burkey TV, 1997, AM NAT, V150, P568, DOI 10.1086/286082; DAVIS RC, 1981, ECOL MONOGR, V5, P125; Gaston K.J., 1994, RARITY, P1; Gaston KJ, 1996, OIKOS, V76, P211, DOI 10.2307/3546192; Gaston KJ, 1997, J ANIM ECOL, V66, P579, DOI 10.2307/5951; GILBERT FS, 1998, P R SOC LONDON B, V265, P1; GONZALEZ A, 1998, THESIS U LONDON; HANSKI I, 1991, OIKOS, V62, P88, DOI 10.2307/3545451; HANSKI I, 1991, BIOL J LINN SOC, V42, P17, DOI 10.1111/j.1095-8312.1991.tb00549.x; Hanski Ilkka, 1993, P108; Holyoak M, 1996, J ANIM ECOL, V65, P640, DOI 10.2307/5743; LAWTON JH, 1993, TRENDS ECOL EVOL, V8, P409, DOI 10.1016/0169-5347(93)90043-O; Lawton JH, 1996, BIRD STUDY, V43, P3, DOI 10.1080/00063659609460991; NEE S, 1991, OIKOS, V62, P83, DOI 10.2307/3545450; SCHENKER R, 1986, B BR ANTARCT SURV, V71, P36; SEYD EL, 1992, ZOOL J LINN SOC-LOND, V106, P115, DOI 10.1111/j.1096-3642.1992.tb01242.x; TAYLOR PD, 1993, OIKOS, V68, P571, DOI 10.2307/3544927; Warren PH, 1997, J ANIM ECOL, V66, P730, DOI 10.2307/5924; Wilson E.O., 1975, P522; WRIGHT DH, 1991, J BIOGEOGR, V18, P463, DOI 10.2307/2845487	22	349	358	5	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					2045	2047		10.1126/science.281.5385.2045	http://dx.doi.org/10.1126/science.281.5385.2045			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748167				2022-12-28	WOS:000076161800061
J	Sokejima, S; Kagamimori, S				Sokejima, S; Kagamimori, S			Working hours as a risk factor for acute myocardial infarction in Japan: case-control study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; ENVIRONMENTAL TOBACCO-SMOKE; CARDIOVASCULAR-DISEASE; RATE-VARIABILITY; BLOOD-PRESSURE; MORTALITY; EXPOSURE; SEVERITY; TERM	Objective: To clarify the extent to which working hours affect the risk of acute myocardial infarction, independent of established risk factors and occupational conditions. Design: Case-control study. Setting: University and general hospitals and routine medical examinations at workplaces in Japan. Subjects: Cases were 195 men aged 30-69 years admitted to hospital with acute myocardial infarction during 1990-3, Controls were 331 men matched at group level fur age and occupations who were judged to be free of coronary heart diseases at routine medical examinations in the workplace. Main outcome measures: Odds ratios for myocardial infarction in relation to previous mean daily working hours in a month and changes in mean working hours during previous year. Results: Compared with men with mean working hours of >7-9 hours, the odds ratio of acute myocardial infarction (adjusted for age and occupation) for men with working hours of >11 hours was 2.44 (95% confidence interval 1.26 to 4.73) and for men with working hours of less than or equal to 7 hours was 3.07 (1.77 to 5.32). Compared with men who experienced an increase of less than or equal to 1 hour in mean working hours, the adjusted odds ratio of myocardial infarction for men who experienced an increase of > 3 hours was 2.53 (1.34 to 4.77). No appreciable change was observed when odds rations were adjusted for established and psychosocial risk factors for myocardial infarction. Conclusion: there was a U shaped relation between the mean working hours and the risk of acute myocardial infarction. There also seemed to be a trend for the risk of infarction to increase with greater increases in mean working hours.	Toyama Med & Pharmaceut Univ, Fac Med, Dept Welfare Promot & Epidemiol, Toyama 9300194, Japan	University of Toyama	Sokejima, S (corresponding author), Toyama Med & Pharmaceut Univ, Fac Med, Dept Welfare Promot & Epidemiol, 2630 Sugitani, Toyama 9300194, Japan.							ALFREDSSON L, 1993, INT J EPIDEMIOL, V22, P57, DOI 10.1093/ije/22.1.57; APPELS A, 1991, BEHAV MED, V17, P53, DOI 10.1080/08964289.1991.9935158; BABA S, 1994, CIRCULATION, V89, P109, DOI 10.1161/01.CIR.89.1.109; Christensen NJ, 1995, ANN NY ACAD SCI, V771, P640, DOI 10.1111/j.1749-6632.1995.tb44716.x; HAMMAR N, 1994, INT J EPIDEMIOL, V23, P277, DOI 10.1093/ije/23.2.277; HAMMOND SK, 1995, JAMA-J AM MED ASSOC, V274, P956, DOI 10.1001/jama.274.12.956; HAVASHI T, 1996, J OCCUP ENVIRON MED, V38, P1007; HAYANO J, 1990, CIRCULATION, V81, P1217, DOI 10.1161/01.CIR.81.4.1217; HAYANO J, 1990, AM J CARDIOL, V65, P84, DOI 10.1016/0002-9149(90)90030-5; HAYANO J, 1991, AM HEART J, V121, P1070, DOI 10.1016/0002-8703(91)90664-4; HOSMER DW, 1989, APPL LOGISTIC REGRES; IUOMILEHTO J, 1987, BRIT MED J, V295, P623; *JAP MIN HLTH WELF, 1991, SPEC REP VIT STAT 19; *JAP MIN HLTH WELF, 1993, NAT SURV CIRC DIS 19; *JAP MIN LAB, 1997, YB LAB STAT 1995; Kageyama T, 1997, LANCET, V350, P639, DOI 10.1016/S0140-6736(05)63328-4; MARMOT MG, 1976, AM J EPIDEMIOL, V104, P225, DOI 10.1093/oxfordjournals.aje.a112296; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; Marmot MG, 1997, LANCET, V350, P235, DOI 10.1016/S0140-6736(97)04244-X; MORRIS JK, 1994, BMJ-BRIT MED J, V308, P1135, DOI 10.1136/bmj.308.6937.1135; MUKAI S, 1995, J APPL PHYSIOL, V78, P212, DOI 10.1152/jappl.1995.78.1.212; MUSCAT JE, 1995, INT J EPIDEMIOL, V24, P715, DOI 10.1093/ije/24.4.715; Naruse Y, 1997, J Epidemiol, V7, P71; OKAYAMA A, 1993, INT J EPIDEMIOL, V22, P1038, DOI 10.1093/ije/22.6.1038; Pais P, 1996, LANCET, V348, P358, DOI 10.1016/S0140-6736(96)02507-X; PIEPER C, 1993, J HYPERTENS, V11, P177, DOI 10.1097/00004872-199302000-00010; REED DM, 1989, AM J EPIDEMIOL, V129, P495, DOI 10.1093/oxfordjournals.aje.a115160; ROBERTSON TL, 1977, AM J CARDIOL, V39, P239, DOI 10.1016/S0002-9149(77)80197-5; *SAS I, 1996, SAS STAT SOFTW HANG; STENDER M, 1993, INT J EPIDEMIOL, V22, P644, DOI 10.1093/ije/22.4.644; Uehata Tetsunojo, 1991, Journal of Human Ergology, V20, P147; UESHIMA H, 1990, ACTA CARDIOL, V45, P311	32	166	173	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					775	780		10.1136/bmj.317.7161.775	http://dx.doi.org/10.1136/bmj.317.7161.775			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740562	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000076084200022
J	Martin, T; Obst, U; Rebek, J				Martin, T; Obst, U; Rebek, J			Molecular assembly and encapsulation directed by hydrogen-bonding preferences and the filling of space	SCIENCE			English	Article							SOLID-STATE; ORGANIC STRUCTURES; DESIGN; TAPES	Multiple copies of a molecule, held together in finite aggregates, give rise to properties and functions that are unique to their assembled states. Because these aggregates are held together by weak forces operating over short distances, a premium is placed on complementarity: The molecular surfaces must facilitate specific interactions that direct the assembly to one aggregate rather than another. Hydrogen-bonding preferences can be combined with molecular curvature to favor the assembly of four self-complementary subunits into a pseudo-spherical capsule. Filling the capsule with smaller, complementary molecules provides the final instruction for the assembly process.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Rebek, J (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Martin, Tomas/J-9222-2014	Martin, Tomas/0000-0002-9504-7287				BARR RG, 1986, J PHYS CHEM-US, V90, P328, DOI 10.1021/j100274a026; BURKE PO, 1984, J CHEM SOC PERK T 2, P1851, DOI 10.1039/p29840001851; CHANG YL, 1993, J AM CHEM SOC, V115, P5991, DOI 10.1021/ja00067a014; CHAPMAN RG, 1995, J AM CHEM SOC, V117, P9081, DOI 10.1021/ja00140a031; Conn MM, 1997, CHEM REV, V97, P1647, DOI 10.1021/cr9603800; CRAM DJ, 1994, CONTIANER MOL THEIR; DRIAN CM, 1993, J CHEM SOC CHEM COMM, P243; GALLANT M, 1991, J ORG CHEM, V56, P2284, DOI 10.1021/jo00007a007; GARCIAS X, 1995, TETRAHEDRON LETT, V36, P8535, DOI 10.1016/0040-4039(95)01829-7; HARRIS KDM, 1989, NATURE, V341, P19, DOI 10.1038/341019a0; LEISEROWITZ L, 1969, J CHEM SOC A, P2372, DOI 10.1039/j19690002372; MacGillivray LR, 1997, NATURE, V389, P469, DOI 10.1038/38985; Mecozzi S, 1998, CHEM-EUR J, V4, P1016, DOI 10.1002/(SICI)1521-3765(19980615)4:6<1016::AID-CHEM1016>3.0.CO;2-B; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; MORAT C, 1979, TETRAHEDRON LETT, V45, P4409; Rudkevich DM, 1997, ANGEW CHEM INT EDIT, V36, P846, DOI 10.1002/anie.199708461; Tokunaga Y, 1998, J AM CHEM SOC, V120, P66, DOI 10.1021/ja972885t; Vreekamp RH, 1996, ANGEW CHEM INT EDIT, V35, P1215, DOI 10.1002/anie.199612151; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; YANG J, 1994, TETRAHEDRON LETT, V35, P3665, DOI 10.1016/S0040-4039(00)73066-8; ZERKOWSKI JA, 1992, J AM CHEM SOC, V114, P5473, DOI 10.1021/ja00039a096; ZERKOWSKI JA, 1990, J AM CHEM SOC, V112, P9025, DOI 10.1021/ja00180a083; ZERKOWSKI JA, 1994, J AM CHEM SOC, V116, P2382, DOI 10.1021/ja00085a018; Zimmerman SC, 1996, SCIENCE, V271, P1095, DOI 10.1126/science.271.5252.1095	24	123	124	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1842	1845		10.1126/science.281.5384.1842	http://dx.doi.org/10.1126/science.281.5384.1842			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743495				2022-12-28	WOS:000076007100050
J	DiPaola, RS; Zhang, HY; Lambert, GH; Meeker, R; Licitra, E; Rafi, MM; Zhu, BT; Spaulding, H; Goodin, S; Toledano, MB; Hait, WN; Gallo, MA				DiPaola, RS; Zhang, HY; Lambert, GH; Meeker, R; Licitra, E; Rafi, MM; Zhu, BT; Spaulding, H; Goodin, S; Toledano, MB; Hait, WN; Gallo, MA			Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIETHYLSTILBESTROL; CELLS; MICE; EXPRESSION; APOPTOSIS; ESTRADIOL; EXTRACTS; GINSENG	Background Herbal mixtures are popular alternatives to demonstrated therapies. PC-SPES, a commercially available combination of eight herbs, is used as a nonestrogenic treatment for cancer of the prostate. Since other herbal medicines have estrogenic effects in vitro, we tested the estrogenic activity of PC-SPES in yeast and mice and in men with prostate cancer. Methods We measured the estrogenic activity of PC-SPES with transcriptional-activation assays in yeast and a biologic assay in mice. We assessed the clinical activity of PC-SPES in eight patients with hormone-sensitive prostate cancer by measuring serum prostate-specific antigen and testosterone concentrations during and after treatment. Results In complementary yeast assays, a 1:200 dilution of an ethanol extract of PC-SPES had estrogenic activity similar to that of 1 nM estradiol, and in ovariectomized CD-1 mice, the herbal mixture increased uterine weights substantially. In six of six men with prostate cancer, PC-SPES decreased serum testosterone concentrations (P<0.05), and in eight of eight patients it decreased serum concentrations of prostate-specific antigen. All eight patients had breast tenderness and loss of libido, and one had venous thrombosis. High-performance liquid chromatography, gas chromatography, and mass spectrometry showed that PC-SPES contains estrogenic organic compounds that are distinct from diethylstilbestrol, estrone, and estradiol. Conclusions PC-SPES has potent estrogenic activity. The use of this unregulated mixture of herbs may confound the results of standard or experimental therapies and may produce clinically significant adverse effects. (N Eng[ J Med 1998;339:785-91.) (C) 1998, Massachusetts Medical Society.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Med, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, New Brunswick, NJ 08901 USA; Canc Inst New Jersey, New Brunswick, NJ USA; Environm & Occupat Hlth Sci Inst, Piscataway, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	DiPaola, RS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Med, 195 Little Albany St, New Brunswick, NJ 08901 USA.				NATIONAL CANCER INSTITUTE [P20CA057142, P30CA072720, R03CA077133] Funding Source: NIH RePORTER; NCI NIH HHS [CA57142, CA72720, R03-CA77133] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APRIKIAN AG, 1994, BRIT J UROL, V74, P630, DOI 10.1111/j.1464-410X.1994.tb09196.x; Carraro JC, 1996, PROSTATE, V29, P231, DOI 10.1002/(SICI)1097-0045(199610)29:4&lt;231::AID-PROS4&gt;3.0.CO;2-E; CITRIN DL, 1985, CANCER, V56, P457, DOI 10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7; Cott JM, 1997, PHARMACOPSYCHIATRY, V30, P108, DOI 10.1055/s-2007-979529; Delos S, 1995, J STEROID BIOCHEM, V55, P375, DOI 10.1016/0960-0760(95)00184-0; DROZ JP, 1908, PROSTATE, V24, P62; Duda RB, 1996, ANN SURG ONCOL, V3, P515, DOI 10.1007/BF02306082; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FAN S, 1995, Patent No. 5417979; Fielden MR, 1997, ENVIRON HEALTH PERSP, V105, P1238, DOI 10.1289/ehp.971051238; GARNICK MB, 1984, NEW ENGL J MED, V311, P1281; Halicka HD, 1997, INT J ONCOL, V11, P437; Hsieh TC, 1997, BIOCHEM MOL BIOL INT, V42, P535; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; PIERRAT B, 1992, GENE, V119, P237, DOI 10.1016/0378-1119(92)90277-V; Risberg T, 1998, J CLIN ONCOL, V16, P6, DOI 10.1200/JCO.1998.16.1.6; Robertson CN, 1996, J NATL CANCER I, V88, P908, DOI 10.1093/jnci/88.13.908; See DM, 1997, IMMUNOPHARMACOLOGY, V35, P229, DOI 10.1016/S0162-3109(96)00125-7; SUCHAR LA, 1995, J PHARMACOL EXP THER, V272, P197; Volz HP, 1997, PHARMACOPSYCHIATRY, V30, P72, DOI 10.1055/s-2007-979522; WALKER BE, 1983, TERATOLOGY, V27, P73, DOI 10.1002/tera.1420270111; WALKER BE, 1983, J NATL CANCER I, V70, P477; Zava DT, 1997, ENVIRON HEALTH PERSP, V105, P637, DOI 10.2307/3433383; Zhu BT, 1997, CANCER RES, V57, P2419	24	257	274	0	27	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1998	339	12					785	791		10.1056/NEJM199809173391201	http://dx.doi.org/10.1056/NEJM199809173391201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119QT	9738085	Bronze			2022-12-28	WOS:000075909200001
J	Topol, EJ				Topol, EJ			Drafter and draftees	LANCET			English	Article									Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Topol, EJ (corresponding author), Cleveland Clin Fdn, Dept Cardiol, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Topol, Eric/0000-0002-1478-4729				Burnett AK, 1998, LANCET, V351, P700, DOI 10.1016/S0140-6736(97)09214-3; Horton R, 1998, LANCET, V351, P688, DOI 10.1016/S0140-6736(98)22010-1; Horton R, 1997, LANCET, V350, P5, DOI 10.1016/S0140-6736(05)66236-8; *MERR WEBST, 1995, MERR WEBST COLL DICT; Smith R, 1997, BRIT MED J, V315, P696, DOI 10.1136/bmj.315.7110.696; Topol EJ, 1997, CIRCULATION, V95, P1072	6	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					897	898		10.1016/S0140-6736(05)60036-0	http://dx.doi.org/10.1016/S0140-6736(05)60036-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9743001				2022-12-28	WOS:000075857300047
J	Amend, JP; Shock, EL				Amend, JP; Shock, EL			Energetics of amino acid synthesis in hydrothermal ecosystems	SCIENCE			English	Article							EUBACTERIUM THERMOTOGA-MARITIMA; MOLAL THERMODYNAMIC PROPERTIES; GEOCHEMICAL CONSTRAINTS; ELEVATED-TEMPERATURES; PYROCOCCUS-FURIOSUS; HIGH-PRESSURES; STANDARD; SEQUENCE; SYSTEMS; 1000-DEGREES-C	Thermodynamic calculations:showed that the autotrophic synthesis of all 20 protein-forming amino acids was energetically favored in hot (100 degrees C), moderately reduced, submarine hydrothermal solutions relative to the synthesis in cold (18 degrees C), oxidized, surface seawater. The net synthesis reactions of 11 amino acids were exergonic in the hydrothermal solution, but all were endergonic in surface seawater. The synthesis of the requisite amino acids of nine thermophilic and hyperthermophilic proteins in a 100 degrees C hydrothermal solution yielded between 600 and 8000 kilojoules per mole of protein, which is energy that is available to drive the intracellular synthesis of enzymes and other biopolymers in hyperthermophiles thriving in these ecosystems.	Washington Univ, Dept Earth & Planetary Sci, Grp Exploring Organ Proc Geochem, St Louis, MO 63130 USA	Washington University (WUSTL)	Amend, JP (corresponding author), Washington Univ, Dept Earth & Planetary Sci, Grp Exploring Organ Proc Geochem, St Louis, MO 63130 USA.			Shock, Everett/0000-0002-4283-0163				Amend JP, 1997, J CHEM SOC FARADAY T, V93, P1927, DOI 10.1039/a608126f; Amend JP, 1997, GEOCHIM COSMOCHIM AC, V61, P11, DOI 10.1016/S0016-7037(96)00306-7; BACHLEITNER M, 1989, FEMS MICROBIOL LETT, V57, P115, DOI 10.1111/j.1574-6968.1989.tb03231.x; BAROSS JA, 1985, ORIGINS LIFE EVOL B, V15, P327, DOI 10.1007/BF01808177; BLAKE PR, 1991, BIOCHEMISTRY-US, V30, P10885, DOI 10.1021/bi00109a012; BUSSE SC, 1992, BIOCHEMISTRY-US, V31, P11952, DOI 10.1021/bi00162a038; ENGEL AM, 1992, EMBO J, V11, P4369, DOI 10.1002/j.1460-2075.1992.tb05537.x; HELGESON HC, 1991, CAN MINERAL, V29, P707; HELGESON HC, 1981, AM J SCI, V281, P1249, DOI 10.2475/ajs.281.10.1249; Huber C, 1997, SCIENCE, V276, P245, DOI 10.1126/science.276.5310.245; INGMANSON DE, 1977, ORIGINS LIFE EVOL B, V8, P221, DOI 10.1007/BF00930683; JAKOSKY BM, IN PRESS J GEOPHYS R; JOHNSON JW, 1992, COMPUT GEOSCI-UK, V18, P899, DOI 10.1016/0098-3004(92)90029-Q; KEIL RG, UNPUB; LILLEY MD, COMMUNICATION; LUTZ RA, 1994, NATURE, V371, P663, DOI 10.1038/371663a0; McCollom TM, 1997, GEOCHIM COSMOCHIM AC, V61, P4375, DOI 10.1016/S0016-7037(97)00241-X; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Pennisi E, 1998, SCIENCE, V280, P672, DOI 10.1126/science.280.5364.672; RUSSELL MJ, 1997, J GEOL SOC LONDON, V154, P337; SANANGELANTONI AM, 1992, J GEN MICROBIOL, V138, P383, DOI 10.1099/00221287-138-2-383; SCHOCK EL, IN PRESS J GEOPHYS R; SCHULTES V, 1990, EUR J BIOCHEM, V192, P25, DOI 10.1111/j.1432-1033.1990.tb19190.x; SHOCK EL, 1992, GEOCHIM COSMOCHIM AC, V56, P3481, DOI 10.1016/0016-7037(92)90392-V; SHOCK EL, 1992, J CHEM SOC FARADAY T, V88, P803, DOI 10.1039/ft9928800803; Shock EL, 1997, GEOCHIM COSMOCHIM AC, V61, P907, DOI 10.1016/S0016-7037(96)00339-0; SHOCK EL, 1995, ORIGINS LIFE EVOL B, V25, P141, DOI 10.1007/BF01581579; SHOCK EL, 1990, ORIGINS LIFE EVOL B, V20, P331, DOI 10.1007/BF01808115; SHOCK EL, 1996, EVOLUTION HYDROTHERM, P40; SHOCK EL, IN PRESS THERMOPHILE; SVERJENSKY DA, 1989, COSMOCHIM ACTA, V53, P2157; TAKAHASHI T, 1980, CU180 LAM GEOL OBS; VONDAMM KL, 1990, ANNU REV EARTH PL SC, V18, P173, DOI 10.1146/annurev.ea.18.050190.001133; WACHTERSHAUSER G, 1988, SYST APPL MICROBIOL, V10, P207; Woese C, 1998, P NATL ACAD SCI USA, V95, P6854, DOI 10.1073/pnas.95.12.6854	35	158	162	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1659	1662		10.1126/science.281.5383.1659	http://dx.doi.org/10.1126/science.281.5383.1659			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733509				2022-12-28	WOS:000075856500042
J	Diez-Gonzalez, F; Callaway, TR; Kizoulis, MG; Russell, JB				Diez-Gonzalez, F; Callaway, TR; Kizoulis, MG; Russell, JB			Grain feeding and the dissemination of acid-resistant Escherichia coli from cattle	SCIENCE			English	Article							FOODBORNE PATHOGENS; O157-H7; DISEASE	The gastric stomach of humans is a barrier to food-borne pathogens, but Escherichia coli can survive at pH 2.0 if it is grown under mildly acidic conditions. Cattle are a natural reservoir for pathogenic E. coli, and cattle fed mostly grain had Lower colonic pH and more acid-resistant E. coli than cattle fed only hay. On the basis of numbers and survival after acid shock, cattle that were fed grain had 10(6)-fold more acid-resistant E. coli than cattle fed hay, but a brief period of hay feeding decreased the acid-resistant count substantially.	Cornell Univ, Div Biol Sci, Microbiol Sect, Ithaca, NY 14853 USA; ARS, USDA, Ithaca, NY 14853 USA	Cornell University; United States Department of Agriculture (USDA)	Russell, JB (corresponding author), Cornell Univ, Div Biol Sci, Microbiol Sect, Ithaca, NY 14853 USA.	jbr8@cornell.edu	Callaway, Todd/AAG-9380-2020; Diez-Gonzalez, Francisco/AAA-8401-2022	Callaway, Todd/0000-0002-3310-4979; Diez-Gonzalez, Francisco/0000-0002-8644-1397				Armstrong GL, 1996, EPIDEMIOL REV, V18, P29, DOI 10.1093/oxfordjournals.epirev.a017914; BENJAMIN MM, 1995, APPL ENVIRON MICROB, V61, P1669, DOI 10.1128/AEM.61.4.1669-1672.1995; Buchanan RL, 1997, FOOD TECHNOL-CHICAGO, V51, P69; CALDWELL DR, 1966, APPL MICROBIOL, V14, P794, DOI 10.1128/AEM.14.5.794-801.1966; Collins JE, 1997, EMERG INFECT DIS, V3, P471, DOI 10.3201/eid0304.970409; CRAY WC, 1995, APPL ENVIRON MICROB, V61, P1586, DOI 10.1128/AEM.61.4.1586-1590.1995; *CTR AGR SCI TECHN, 1994, 122 CAST CTR AGR SCI; GORDEN J, 1993, INFECT IMMUN, V61, P364, DOI 10.1128/IAI.61.1.364-367.1993; Hitchins A. D., 1995, FDA BACTERIOLOGICAL; Lederberg J, 1997, EMERG INFECT DIS, V3, P417, DOI 10.3201/eid0304.970402; LIN ECC, 1996, ESCHERICHIA COLI SAL, V1, pCH20; Ott, 1993, INTRO STAT METHODS D; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; RUSSELL JR, 1981, J ANIM SCI, V52, P1177, DOI 10.2527/jas1981.5251177x; Sokal Robert R., 1969, BIOMETRY; SU CY, 1995, ANN INTERN MED, V123, P698, DOI 10.7326/0003-4819-123-9-199511010-00009; Tauxe RV, 1997, EMERG INFECT DIS, V3, P425, DOI 10.3201/eid0304.970403; WALDO DR, 1973, J ANIM SCI, V37, P1062, DOI 10.2527/jas1973.3741062x; WHIPP SC, 1994, J AM VET MED ASSOC, V204, P1168; Zhao T, 1998, J CLIN MICROBIOL, V36, P641, DOI 10.1128/JCM.36.3.641-647.1998	20	271	280	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1666	1668		10.1126/science.281.5383.1666	http://dx.doi.org/10.1126/science.281.5383.1666			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733511				2022-12-28	WOS:000075856500044
J	Cunningham, PJ; Kemper, P				Cunningham, PJ; Kemper, P			Ability to obtain medical care for the uninsured - How much does it vary across communities?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Association-of-Health-Services-Research	JUN 15-17, 1997	CHICAGO, ILLINOIS	Assoc Hlth Serv Res			HEALTH-INSURANCE; UNITED-STATES; ACCESS	Context.-Communities differ in the way that medical care for medically indigent persons is organized and delivered! which is likely to result in differences across communities in the ability of uninsured persons to obtain medical care. Changes in the health care system, many of which are driven locally, may further exacerbate these differences. Objective.-To examine the extent of variation across US communities in the ability of uninsured persons to obtain medical care and the extent to which health status and other characteristics of the uninsured population account for these differences. Design,Analysis of the 1996-1997 Community Tracking Study Household Survey. Setting.-A nationally representative sample of the US civilian, noninstitutionalized population residing in 60 randomly selected communities. Larger sample sizes were obtained for 12 of these communities, which were randomly selected to represent metropolitan areas in the United States with more than 200000 persons. Participants.-A total of 60 446 individuals and 7200 uninsured persons. Main Outcome Measures.-The percentage of persons who either did not obtain needed medical care in the previous year or postponed receiving needed medical care in the previous year. Results.-Differences between communities with the highest percentage of uninsured persons reporting difficulty obtaining care and communities with the lowest percentage were more than 2-fold (41.4% vs 18.5%, P < .05). Little of the variation across communities is accounted for by differences in health status or sociodemographic characteristics of the uninsured population. The pattern of variation across communities in the ability of uninsured persons to obtain medical care is not correlated with variations in the ability of privately insured persons to obtain care (Pearson r, 0.04). Simulation results indicate that expanding private or public insurance coverage would not only increase the ability of uninsured persons to obtain medical care but would also reduce the variation across communities. Conclusions.-If people are uninsured, where they live is an important factor in determining the difficulty they have in obtaining care. This is likely to persist given that care for uninsured persons is driven largely by state and local policy, and health system changes are constraining clinicians' ability and willingness to serve uninsured persons in many parts of the country.	Ctr Studying Hlth Syst Change, Washington, DC 20024 USA		Cunningham, PJ (corresponding author), Ctr Studying Hlth Syst Change, 600 Maryland Ave SW,Suite 550, Washington, DC 20024 USA.							ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V3, P1; BASHSHUR RL, 1994, MED CARE, V32, P409, DOI 10.1097/00005650-199405000-00001; BERK ML, 1995, HEALTH AFFAIR, V14, P139, DOI 10.1377/hlthaff.14.3.139; Berk ML, 1998, HEALTH AFFAIR, V17, P180, DOI 10.1377/hlthaff.17.1.180; CUNNINGHAM P, 1993, AHCPR PUBL; Cunningham PJ, 1997, HEALTH AFFAIR, V16, P167, DOI 10.1377/hlthaff.16.4.167; Donelan K, 1996, JAMA-J AM MED ASSOC, V276, P1346, DOI 10.1001/jama.276.16.1346; FELDMAN R, 1997, M CTR STUD HLTH SYST; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P737, DOI 10.1001/jama.270.6.737; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HIMMELSTEIN DU, 1995, AM J PUBLIC HEALTH, V85, P341, DOI 10.2105/AJPH.85.3.341; Kemper P, 1996, INQUIRY-J HEALTH CAR, V33, P195; KOHN L, 1997, HLTH SYSTEM CHANGE 1; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; Lipson DJ, 1996, HEALTH AFFAIR, V15, P33, DOI 10.1377/hlthaff.15.2.33; METCALF CE, 1996, CTR STUD HLTH SYST C, V1; PORTES A, 1992, J HEALTH SOC BEHAV, V33, P283, DOI 10.2307/2137309; RASK KJ, 1994, JAMA-J AM MED ASSOC, V271, P1931, DOI 10.1001/jama.271.24.1931; SHAH BV, 1996, SUDAAN US MAN REL 7; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WEINICK RM, 1997, AHCPR PUBL; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388	23	90	90	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1998	280	10					921	927		10.1001/jama.280.10.921	http://dx.doi.org/10.1001/jama.280.10.921			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	115LN	9739978				2022-12-28	WOS:000075666600040
J	Keating, NL; Zaslavsky, AM; Ayanian, JZ				Keating, NL; Zaslavsky, AM; Ayanian, JZ			Physicians' experiences and beliefs regarding informal consultation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUIDELINES; CARE	Context.-Efforts to control medical expenses by emphasizing primary care and limiting specialty care may influence how physicians use informal or "curbside" consultation. Objective.-To understand physicians' use of and beliefs about informal consultation. Design.-Survey mailed in July 1997. Participants.-Of a random sample of Massachusetts general internists, pediatricians, cardiologists, orthopedic surgeons (n = 300 each), and infectious disease specialists (n = 200) surveyed, 1225 were eligible and 705 (58%) responded. Main Outcome Measures.-Self-reported use of and beliefs about informal consultation. Results.-Generalist physicians requested more informal consultations than specialists (median, 3 vs 1 per week; P < .001) and were asked to provide fewer (2 vs 5 per week; P < .001). In multivariate analyses, physicians in a health maintenance organization, multispecialty group, or single-specialty group requested more informal consultations than those in solo practice (82%, 40%, and 28% more, respectively; all P < .001) and were more often asked to provide them (43%, 63%, and 14% more, respectively; all P < .05). Physicians with at least 30% of their income from capitation requested 38% more and were asked to provide 46% more informal consultations than those with little or no income from capitation (both P < .001). Generalists' overall approval of informal consultation was greater than specialists' (mean 5.9 vs 5.1 on a 7-point Likert scale; P < .001), and approval was strongly associated with beliefs about how informal consultation affects quality of care (P < .001). Conclusions.-Use of informal consultation is common, varies by specialty, practice setting, and capitation, and therefore may increase with current trends toward group practice and managed care. Because overall approval of informal consultation is strongly associated with beliefs about how it affects quality of care, this issue should be carefully considered by physicians who participate in informal consultation.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Div Gen Internal Med, Sect Hlth Serv & Policy Res,Dept Med,Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ayanian, JZ (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.		Keating, Nancy L/I-9968-2019	Keating, Nancy L/0000-0002-8274-4681				Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; DWYER C, 1998, ACP OBSERVER     JAN, P11; Findling JW, 1996, ENDOCRINOLOGIST, V6, P328, DOI 10.1097/00019616-199607000-00009; HARTOG M, 1988, J ROY COLL PHYS LOND, V22, P51; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; Huttin C, 1997, INT J QUAL HEALTH C, V9, P207, DOI 10.1093/intqhc/9.3.207; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1151, DOI 10.1056/NEJM199410273311709; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; LILJESTRAND P, 1996, 11 INT C AIDS JUL 7; MAGNUSSEN CR, 1992, INFECT DIS CLIN PRAC, V6, P391; Manian FA, 1996, JAMA-J AM MED ASSOC, V275, P145; Manian FA, 1996, CLIN INFECT DIS, V22, P303, DOI 10.1093/clinids/22.2.303; MYERS JP, 1984, J INFECT DIS, V150, P797, DOI 10.1093/infdis/150.6.797; Pearson SD, 1998, J GEN INTERN MED, V13, P435, DOI 10.1046/j.1525-1497.1998.00131.x; Robinson JC, 1996, HEALTH AFFAIR, V15, P7, DOI 10.1377/hlthaff.15.1.7; WEINBERG AD, 1981, J MED EDUC, V56, P174	17	76	77	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1998	280	10					900	904		10.1001/jama.280.10.900	http://dx.doi.org/10.1001/jama.280.10.900			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115LN	9739974	Bronze			2022-12-28	WOS:000075666600036
J	Rothman, KJ; Adami, HO; Trichopoulos, D				Rothman, KJ; Adami, HO; Trichopoulos, D			Should the mission of epidemiology include the eradication of poverty?	LANCET			English	Editorial Material							VITAMIN-A SUPPLEMENTATION; CHILDHOOD MORTALITY; TRIAL		Boston Univ, Sch Med, Dept Med & Epidemiol, Boston, MA 02118 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden	Boston University; Harvard University; Harvard T.H. Chan School of Public Health; Karolinska Institutet	Rothman, KJ (corresponding author), Boston Univ, Sch Med, Evans Dept Med, Prevent Med & Epidemiol Sect, Boston, MA 02118 USA.			Rothman, Kenneth/0000-0003-2398-1705				Beaglehole R., 1997, PUBLIC HLTH CROSSROA, P120; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; DAULAIRE NMP, 1992, BMJ-BRIT MED J, V304, P207, DOI 10.1136/bmj.304.6821.207; HERRERA MG, 1992, LANCET, V340, P267, DOI 10.1016/0140-6736(92)92357-L; MACKAY AM, 1982, AM J PUBLIC HEALTH, V72, P248, DOI 10.2105/AJPH.72.3.248; Mourino-Perez RR, 1998, EPIDEMIOLOGY, V9, P355, DOI 10.1097/00001648-199805000-00024; Pearce N, 1996, AM J PUBLIC HEALTH, V86, P678, DOI 10.2105/AJPH.86.5.678; Plotnick GD, 1997, JAMA-J AM MED ASSOC, V278, P1682, DOI 10.1001/jama.278.20.1682; Shy CM, 1997, AM J EPIDEMIOL, V145, P479; SOMMER A, 1986, LANCET, V1, P1169; Susser M, 1996, AM J PUBLIC HEALTH, V86, P674, DOI 10.2105/AJPH.86.5.674; SUSSER M, 1989, INT J EPIDEMIOL, V18, P481, DOI 10.1093/ije/18.3.481; Wilcox AJ, 1997, EPIDEMIOLOGY, V8, P684; 1997, LANCET, V350, P229	14	99	109	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					810	813		10.1016/S0140-6736(98)01327-0	http://dx.doi.org/10.1016/S0140-6736(98)01327-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	117CH	9737304	hybrid			2022-12-28	WOS:000075762700043
J	Kors, JA; de Bruyne, MC; Hoes, AW; van Herpen, G; Hofman, A; van Bemmel, JH; Grobbee, DE				Kors, JA; de Bruyne, MC; Hoes, AW; van Herpen, G; Hofman, A; van Bemmel, JH; Grobbee, DE			T axis as an indicator of risk of cardiac events in elderly people	LANCET			English	Article							CORONARY HEART-DISEASE; DEATH; ELECTROCARDIOGRAMS; MORTALITY; PROGRAMS; MEN	Background The T axis was postulated to be a general marker of repolarisation abnormality, indicative of subclinical myocardial damage. The aim of this investigation was to assess the prognostic importance of the T axis for fatal and non-fatal cardiac events, in a prospective cohort study of men and women aged 55 years and older. Methods 2352 men and 3429 women from the population-based Rotterdam Study took part in the study. Electrocardiograms were done, and T axes were categorised as normal, borderline, or abnormal. Data were analysed with Cox's proportional-hazards models; adjustment for age and sex was done where appropriate. Findings During 3-6 (mean 4) years of follow-up of the 5781 participants, 165 (2.9%) fatal and 192 (3.3%) non-fatal cardiac events occurred. Participants with an abnormal T axis (n=609) had an increased risk of cardiac death (hazard ratio 3.9 [95% CI 2.8-5.6]), sudden cardiac death (4.4 [2.6-7.4]), non-fatal cardiac events (2.7 [1.9-3.9]), and combined fatal or non-fatal cardiac events (3.2 [2.5-4.1]); p<0.001 for each. Additional adjustment for established cardiovascular risk factors resulted in lower. but still significant risk for all endpoints. The risk associated with an abnormal T axis was higher than those for any other cardiovascular risk factor. Additional subgroup analyses indicated that the risk of cardiac death was not substantially modified by age, sex, or history of myocardial infarction. Interpretation The T axis is a strong and independent risk indicator of fatal and non-fatal cardiac events in the elderly.	Erasmus Univ, Sch Med, Dept Med Informat, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Univ Utrecht, Julius Ctr Patient Oriented Res, Utrecht, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Utrecht University	Kors, JA (corresponding author), Erasmus Univ, Sch Med, Dept Med Informat, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BRISTOW JD, 1961, AM HEART J, V61, P242, DOI 10.1016/0002-8703(61)90582-8; CEDRES BL, 1982, CIRCULATION, V65, P146, DOI 10.1161/01.CIR.65.1.146; COOKSEY JD, 1977, CLIN VECTORCARDIOGRA; CULLEN K, 1982, BRIT HEART J, V47, P209; CUPPLES LA, 1992, CIRCULATION, V85, P11; de Bruyne MC, 1998, CIRCULATION, V97, P467; deBruyne MC, 1997, AM J CARDIOL, V80, P1300, DOI 10.1016/S0002-9149(97)00669-3; DRAPER HW, 1964, CIRCULATION, V30, P853, DOI 10.1161/01.CIR.30.6.853; EDENBRANDT L, 1988, J ELECTROCARDIOL, V21, P361, DOI 10.1016/0022-0736(88)90113-6; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; KANNEL WB, 1987, AM HEART J, V113, P370, DOI 10.1016/0002-8703(87)90280-8; KNUTSEN R, 1988, J CLIN EPIDEMIOL, V41, P293, DOI 10.1016/0895-4356(88)90134-5; Kors JA, 1996, J ELECTROCARDIOL, V29, P83, DOI 10.1016/S0022-0736(96)80025-2; KORS JA, 1990, EUR HEART J, V11, P1083, DOI 10.1093/oxfordjournals.eurheartj.a059647; LARSON MG, 1995, STAT MED, V14, P1745, DOI 10.1002/sim.4780141604; LIAO YL, 1988, J AM COLL CARDIOL, V12, P1494, DOI 10.1016/S0735-1097(88)80016-0; MYERBURG RJ, 1992, CIRCULATION, V85, P2; Prineas R., 1982, MINNESOTA CODE MANUA; RABKIN SW, 1982, BRIT HEART J, V47, P546; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; Sigurdsson E, 1996, J AM COLL CARDIOL, V27, P1140, DOI 10.1016/0735-1097(95)00614-1; SILVERBE.SM, 1966, AM J CARDIOL, V18, P672, DOI 10.1016/0002-9149(66)90084-1; Tervahauta M, 1996, AM J MED, V100, P641, DOI 10.1016/S0002-9343(96)00042-3; VANBEMMEL JH, 1990, METHOD INFORM MED, V29, P346; WILLEMS JL, 1987, J AM COLL CARDIOL, V10, P1313, DOI 10.1016/S0735-1097(87)80136-5; WILLEMS JL, 1991, NEW ENGL J MED, V325, P1767, DOI 10.1056/NEJM199112193252503; World Health Organization, 2004, ICD 10 INT STAT CLAS, V2nd	28	132	132	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 22	1998	352	9128					601	605		10.1016/S0140-6736(97)10190-8	http://dx.doi.org/10.1016/S0140-6736(97)10190-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746020				2022-12-28	WOS:000075567400008
J	Chan, A; McCaul, KA; Keane, RJ; Haan, EA				Chan, A; McCaul, KA; Keane, RJ; Haan, EA			Effect of parity, gravidity, previous miscarriage, and age on risk of Down's syndrome: population based study	BRITISH MEDICAL JOURNAL			English	Article									Australian Hlth Commiss, Epidemiol Branch, Pregnancy Outcome Unit, Adelaide, SA 5000, Australia; Australian Hlth Commiss, Epidemiol Branch, Hlth Stat Unit, Adelaide, SA 5000, Australia; Womens & Childrens Hosp, Dept Med Genet & Epidemiol, S Australian Birth Defects Register, N Adelaide, SA 5006, Australia		Chan, A (corresponding author), Australian Hlth Commiss, Epidemiol Branch, Pregnancy Outcome Unit, POB 6,Rundle Mall, Adelaide, SA 5000, Australia.		McCaul, Kieran A/B-8751-2008					HALLIDAY J, 1995, LANCET, V345, P704, DOI 10.1016/S0140-6736(95)90872-2; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; *SAS I, 1993, SAS STAT SOFTW GENMO; Schimmel MS, 1997, BRIT MED J, V314, P720, DOI 10.1136/bmj.314.7082.720	4	22	22	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					923	924						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756811				2022-12-28	WOS:000076409000025
J	Wittlinger, G; Tapponnier, P; Poupinet, G; Mei, J; Danian, S; Herquel, G; Masson, F				Wittlinger, G; Tapponnier, P; Poupinet, G; Mei, J; Danian, S; Herquel, G; Masson, F			Tomographic evidence for localized lithospheric shear along the Altyn Tagh fault	SCIENCE			English	Article							SEISMIC TOMOGRAPHY; SOUTHERN TIBET; NORTHERN TIBET; WESTERN TIBET; TECTONICS; CHINA; ASIA; ANOMALIES; EVOLUTION; TARIM	Seismic tomography across the Altyn Tagh fault, at the north edge of the Tibetan Plateau, reveals a Low P-wave velocity anomaly below the fault down to 140 kilometers. This anomaly probably reflects strike-slip shear in the lithosphere. Slip-partitioning may also induce a wedge of crust from the Tarim Basin to plunge into the mantle.	Univ Strasbourg 1, CNRS, Inst Phys Globe, F-67084 Strasbourg, France; Inst Phys Globe Strasbourg, Lab Tecton, F-75205 Paris, France; Univ Grenoble 1, CNRS, Lab Geophys Interne & Tectonophys, F-38041 Grenoble, France; Chinese Acad Geol Sci, Inst Mineral Deposits, Beijing 100037, Peoples R China	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Chinese Academy of Geological Sciences	Wittlinger, G (corresponding author), Univ Strasbourg 1, CNRS, Inst Phys Globe, 5 Rue R Descartes, F-67084 Strasbourg, France.		Tapponnier, .Paul E/B-7033-2011	Tapponnier, .Paul E/0000-0002-7135-1962; Masson, Frederic/0000-0002-0186-7138				AKI K, 1977, J GEOPHYS RES, V82, P277, DOI 10.1029/JB082i002p00277; ARMIJO R, 1989, J GEOPHYS RES-SOLID, V94, P2787, DOI 10.1029/JB094iB03p02787; AVOUAC JP, 1993, GEOPHYS RES LETT, V20, P895, DOI 10.1029/93GL00128; BALLY AW, 1986, 86 US GEOL SURV; BRIAIS A, 1993, J GEOPHYS RES-SOL EA, V98, P6299, DOI 10.1029/92JB02280; BURCHFIEL BC, 1989, GEOLOGY, V17, P478; CHOPIN C, 1984, CONTRIB MINERAL PETR, V86, P107, DOI 10.1007/BF00381838; DEMETS C, 1990, GEOPHYS J INT, V101, P425, DOI 10.1111/j.1365-246X.1990.tb06579.x; FLEITOUT L, 1980, J STRUCT GEOL, V2, P159, DOI 10.1016/0191-8141(80)90046-2; HOUSEMAN GA, 1986, J GEOPHYS RES, V86, P3664; KARATO S, 1993, GEOPHYS RES LETT, V20, P1623, DOI 10.1029/93GL01767; Leloup PH, 1995, TECTONOPHYSICS, V251, P3, DOI 10.1016/0040-1951(95)00070-4; LYONCAEN H, 1984, GEOPHYS RES LETT, V11, P1251, DOI 10.1029/GL011i012p01251; Matte P, 1996, EARTH PLANET SC LETT, V142, P311, DOI 10.1016/0012-821X(96)00086-6; MOLNAR P, 1987, SCIENCE, V235, P299, DOI 10.1126/science.235.4786.299; MOLNAR P, 1989, GEOPHYS J INT, V99, P123, DOI 10.1111/j.1365-246X.1989.tb02020.x; *NAT EARTHQ INF CT, 1995, PREL DET EP; Nelson KD, 1996, SCIENCE, V274, P1684, DOI 10.1126/science.274.5293.1684; PELTZER G, 1989, SCIENCE, V246, P1285, DOI 10.1126/science.246.4935.1285; Peltzer G, 1996, J GEOPHYS RES-SOL EA, V101, P27943, DOI 10.1029/96JB02698; PELTZER G, 1988, J GEOPHYS RES, V93, P15095; Scholz C. H., 1990, MECH EARTHQUAKES FAU; SCLATER JG, 1981, REV GEOPHYS SPACE PH, V18, P269; TAPPONNIER P, 1990, NATURE, V343, P431, DOI 10.1038/343431a0; TAPPONNIER P, 1977, J GEOPHYS RES, V82, P2905, DOI 10.1029/JB082i020p02905; Wittlinger G, 1996, EARTH PLANET SC LETT, V139, P263, DOI 10.1016/0012-821X(95)00235-5	26	206	253	3	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1998	282	5386					74	76		10.1126/science.282.5386.74	http://dx.doi.org/10.1126/science.282.5386.74			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756478				2022-12-28	WOS:000076294900038
J	Giovannucci, E; Stampfer, MJ; Colditz, GA; Hunter, DJ; Fuchs, C; Rosner, BA; Speizer, FE; Willett, WC				Giovannucci, E; Stampfer, MJ; Colditz, GA; Hunter, DJ; Fuchs, C; Rosner, BA; Speizer, FE; Willett, WC			Multivitamin use, folate, and colon cancer in women in the nurses' health study	ANNALS OF INTERNAL MEDICINE			English	Article						folic acid; vitamins; colonic neoplasms; diet; dose-response relationship, drug	METHYLENETETRAHYDROFOLATE REDUCTASE POLYMORPHISM; NEURAL-TUBE DEFECTS; COLORECTAL-CANCER; LOGISTIC-REGRESSION; TRIPHOSPHATE POOLS; ALCOHOL INTAKE; PLASMA FOLATE; FOLIC-ACID; RED-CELL; RISK	Background: High intake of folate may reduce risk for colon cancer, but the dosage and duration relations and the impact of dietary compared with supplementary sources are not well understood. Objective: To evaluate the relation between folate intake and incidence of colon cancer. Design: Prospective cohort study. Setting: 88 756 women from the Nurses' Health Study who were free of cancer in 1980 and provided updated assessments of diet, including multivitamin supplement use, from 1980 to 1994. Patients: 442 women with new cases of colon cancer. Measurements: Multivariate relative risk (RR) and 95% CIs for colon cancer in relation to energy-adjusted folate intake. Results: Higher energy-adjusted folate intake in 1980 was related to a lower risk for colon cancer (RR, 0.69 [95% CI, 0.52 to 0.93] for intake >400 mu g/d compared with intake less than or equal to 200 mu g/d) after controlling for age; family history of colorectal cancer; aspirin use; smoking; body mass; physical activity; and intakes of red meat, alcohol, methionine, and fiber. When intake of vitamins A, C, D, and E and intake of calcium were also controlled for, results were similar. Women who used multivitamins containing folic acid had no benefit with respect to colon cancer after 4 years of use (RR, 1.02) and had only nonsignificant risk reductions after 5 to 9 (RR, 0.83) or 10 to 14 years of use (RR, 0.80). After 15 years of use, however, risk was markedly lower (RR, 0.25 [CI, 0.13 to 0.51]), representing 15 instead of 68 new cases of colon cancer per 10 000 women 55 to 69 years of age. Folate from dietary sources alone was related to a modest reduction in risk for colon cancer, and the benefit of long-term multivitamin use was present across all levels of dietary intakes. Conclusions: Long-term use of multivitamins may substantially reduce risk for colon cancer. This effect may be related to the folic acid contained in multivitamins.	Channing Labs, Boston, MA 02115 USA		Giovannucci, E (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1991, Lancet, V338, P131, DOI 10.1016/0140-6736(91)90133-A; BAILEY LB, 1982, NUTR RES, V2, P397, DOI 10.1016/S0271-5317(82)80048-1; Baron JA, 1998, J NATL CANCER I, V90, P57, DOI 10.1093/jnci/90.1.57; BENITO E, 1993, INT J CANCER, V55, P213, DOI 10.1002/ijc.2910550208; BENITO E, 1991, INT J CANCER, V49, P161, DOI 10.1002/ijc.2910490202; BIRD CL, 1995, CANCER EPIDEM BIOMAR, V4, P709; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Chen J, 1996, CANCER RES, V56, P4862; CHU KC, 1994, JNCI-J NATL CANCER I, V86, P997, DOI 10.1093/jnci/86.13.997; COLDITZ GA, 1987, INT J EPIDEMIOL, V16, P392, DOI 10.1093/ije/16.3.392; Cravo M, 1994, Eur J Cancer Prev, V3, P473, DOI 10.1097/00008469-199411000-00004; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; Cuskelly GJ, 1996, LANCET, V347, P657, DOI 10.1016/S0140-6736(96)91205-2; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1988, CANCER RES, V48, P1159; FENECH M, 1994, CARCINOGENESIS, V15, P1405, DOI 10.1093/carcin/15.7.1405; FERRARONI M, 1994, BRIT J CANCER, V70, P1150, DOI 10.1038/bjc.1994.463; Food and Drug Administration, 1973, FED REGISTER, V38, P20725; FREUDENHEIM JL, 1991, INT J EPIDEMIOL, V20, P368, DOI 10.1093/ije/20.2.368; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; GIOVANNUCCI E, 1995, JNCI-J NATL CANCER I, V87, P265, DOI 10.1093/jnci/87.4.265; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; GLYNN SA, 1994, NUTR CANCER, V22, P101, DOI 10.1080/01635589409514336; Glynn SA, 1996, CANCER EPIDEM BIOMAR, V5, P487; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; Gregory JF, 1997, EUR J CLIN NUTR, V51, pS54; HUNTING DJ, 1985, CARCINOGENESIS, V6, P1525, DOI 10.1093/carcin/6.10.1525; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; JAMES SJ, 1994, CANCER RES, V54, P5075; KIRKE PN, 1993, Q J MED, V86, P703; Ma J, 1997, CANCER RES, V57, P1098; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MEUTH M, 1981, SOMAT CELL GENET, V7, P89, DOI 10.1007/BF01544750; MEYER F, 1993, AM J EPIDEMIOL, V138, P225, DOI 10.1093/oxfordjournals.aje.a116851; Oakley GP, 1997, AM J CLIN NUTR, V65, P1889, DOI 10.1093/ajcn/65.6.1889; PASPATIS GA, 1995, DIS COLON RECTUM, V38, P64, DOI 10.1007/BF02053860; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; SAUBERLICH HE, 1990, FOLIC ACID METABOLIS, P211; SENTI FR, 1985, J NUTR, V115, P1398, DOI 10.1093/jn/115.11.1398; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Sturmer T, 1998, ANN INTERN MED, V128, P713, DOI 10.7326/0003-4819-128-9-199805010-00003; SUBAR AF, 1989, AM J CLIN NUTR, V50, P508, DOI 10.1093/ajcn/50.3.508; SUTHERLAND GR, 1988, MUTAT RES, V200, P207, DOI 10.1016/0027-5107(88)90084-X; Tseng M, 1996, AM J EPIDEMIOL, V144, P1005, DOI 10.1093/oxfordjournals.aje.a008871; *USDA, 1989, AGR HDB SERIES, V8; WEINBERG G, 1981, P NATL ACAD SCI-BIOL, V78, P2447, DOI 10.1073/pnas.78.4.2447; White E, 1997, CANCER EPIDEM BIOMAR, V6, P769; WICKRAMASINGHE SN, 1994, BLOOD, V83, P1656; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	54	543	562	0	32	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1998	129	7					517	+		10.7326/0003-4819-129-7-199810010-00002	http://dx.doi.org/10.7326/0003-4819-129-7-199810010-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123KN	9758570				2022-12-28	WOS:000076124500001
J	Leidig-Bruckner, G; Grauer, A				Leidig-Bruckner, G; Grauer, A			Blue sclerae in osteogenesis imperfecta	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Heidelberg, D-69115 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Leidig-Bruckner, G (corresponding author), Univ Heidelberg, Bergheimer Str 58, D-69115 Heidelberg, Germany.								0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1998	339	14					966	966		10.1056/NEJM199810013391405	http://dx.doi.org/10.1056/NEJM199810013391405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124MW	9753712				2022-12-28	WOS:000076186900005
J	Bartlett, JG				Bartlett, JG			Update in infectious diseases	ANNALS OF INTERNAL MEDICINE			English	Article							CHLAMYDIA; ASSOCIATION		Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Johns Hopkins University	Bartlett, JG (corresponding author), 1830 Monument St,Room 437, Baltimore, MD 21205 USA.							[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P295; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1204; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; DiAlberti L, 1997, LANCET, V350, P1655, DOI 10.1016/S0140-6736(97)10102-7; Hennessy TW, 1996, NEW ENGL J MED, V334, P1281, DOI 10.1056/NEJM199605163342001; Muhlestein JB, 1996, J AM COLL CARDIOL, V27, P1555, DOI 10.1016/0735-1097(96)00055-1; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; O'Brien KL, 1998, PEDIATRICS, V101, P178; O'Brien KL, 1998, PEDIATRICS, V101, P174; ORR PH, 1993, J FAM PRACTICE, V36, P507; *PHS TASK FORC, 1998, MMWR-MORBID MORTAL W, V47, P1; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rosenstein N, 1998, PEDIATRICS, V101, P181; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; Schwartz B, 1998, PEDIATRICS, V101, P171; THOM DH, 1992, JAMA-J AM MED ASSOC, V268, P68, DOI 10.1001/jama.268.1.68; 1994, MMWR MORB MORTAL WKL, V43, P31; 1994, MMWR MORB MORTAL WKL, V43, P23; 1997, MMWR MORB MORTAL WKL, V46, P777; 1997, MMWR MORB MORTAL WKL, V46, P295	22	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1998	129	6					464	471		10.7326/0003-4819-129-6-199809150-00008	http://dx.doi.org/10.7326/0003-4819-129-6-199809150-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JJ	9735085				2022-12-28	WOS:000075892100006
J	Rosenthal, AN; Ryan, A; Al-Jehani, RM; Storey, A; Harwood, CA; Jacobs, IJ				Rosenthal, AN; Ryan, A; Al-Jehani, RM; Storey, A; Harwood, CA; Jacobs, IJ			p53 codon 72 polymorphism and risk of cervical cancer in UK	LANCET			English	Article								Background A polymorphism at codon 72 of the human tumour-suppressor gene, p53, results in translation to either arginine or proline. A recent report suggested that the risk of human-papillomavirus;associated cervical cancer in white women is higher for those homozygous for the arginine allele than for those who are heterozygous. We examined a similar number of cervical cancers and a larger control group for their p53 codon 72 polymorphism status to see if we could confirm this result. Methods Three different groups of UK white women were studied: 96 who had volunteered to take part in a trial of ovarian-cancer screening; 150 attending for routine antenatal care in the Oxford region; and 50 women with cervical cancer. DNA from peripheral blood samples and from archival tissue samples was examined by PCR with allele-specific primers. Findings The proportions of individuals homozygous for the arginine allele, homozygous for the proline allele, and heterozygous for the two alleles were 59%, 4%, and 36% among women screened for ovarian cancer; 65%, 8%, and 27% among the antenatal-care group; and 54%, 6%, and 40% in women with cervical cancer. chi(2) analysis showed no significant differences in these proportions. Interpretation In the population studied, individuals homozyous for the arginine variant of codon 72 of the p53 gene were not at increased risk of cervical cancer.	Univ London Queen Mary & Westfield Coll, St Bartholomews & Royal London Sch Med & Dent, Gynaecol Canc Res Unit, London E1 4NS, England; Univ London Queen Mary & Westfield Coll, St Bartholomews & Royal London Sch Med & Dent, ICRF, Skin Tumour Lab, London E1 4NS, England	University of London; Queen Mary University London; University of London; Queen Mary University London	Rosenthal, AN (corresponding author), St Bartholomews Hosp, Gynaecol Canc Res Unit, London EC1A 7BE, England.		Jacobs, Ian J/F-1743-2013	Jacobs, Ian J/0000-0002-8112-4624; Jacobs, Ian/0000-0002-5005-2672; Rosenthal, Adam/0000-0001-6924-0721; Storey, Alan/0000-0003-2001-9772; Harwood, Catherine/0000-0002-1375-0965				BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228; DELACALLEMARTIN O, 1990, NUCLEIC ACIDS RES, V18, P4963, DOI 10.1093/nar/18.16.4963; KAELBLING M, 1992, LANCET, V340, P140, DOI 10.1016/0140-6736(92)93214-8; SAMSBROOK J, 1989, MOL CLONING; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400	5	176	181	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					871	872		10.1016/S0140-6736(98)07357-7	http://dx.doi.org/10.1016/S0140-6736(98)07357-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742979				2022-12-28	WOS:000075857300009
J	Nusser, Z; Hajos, N; Somogyi, P; Mody, I				Nusser, Z; Hajos, N; Somogyi, P; Mody, I			Increased number of synaptic GABA(A) receptors underlies potentiation at hippocampal inhibitory synapses	NATURE			English	Article							LONG-TERM POTENTIATION; ADULT-RAT BRAIN; RELEASE SITES; DENTATE GYRUS; VISUAL-CORTEX; SUBUNITS; CELLS; HETEROGENEITY; INTERNEURONS; TRANSMISSION	Changes in synaptic efficacy are essential far neuronal development(1), learning and memory formation(2) and for pathological slates of neuronal excitability, including temporal-lobe epilepsy(3), At synapses, where there is a high probability of opening of postsynaptic receptors(4), all of which are occupied by the released transmitter(5-9), the most effective means of augmenting postsynaptic responses is to increase the number of receptors(2,10,11). Here we combine quantal analysis of evoked inhibitory postsynaptic currents with quantitative immunogold localization of synaptic GABA(A) receptors in hippocampal granule cells in order to clarify the basis of inhibitory synaptic plasticity induced by an experimental model of temporal-lobe epilepsy (a process known as kindling)(10). We find that the larger amplitude (66% increase) of elementary synaptic currents (quantal size) after kindling results directly from a 75% increase in the number of GABA(A) receptors at inhibitory synapses on somata and axon initial segments. Receptor density was up by 34-40% and the synaptic junctional area was expanded by 31%. Presynaptic boutons were enlarged, which may account for the 39% decrease in the average number of released transmitter packets (quantal content). Our findings establish the postsynaptic insertion of new GABA(A) receptors and the corresponding increase in postsynaptic responses augmenting the efficacy of mammalian inhibitory synapses.	Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Univ Oxford, Dept Pharmacol, MRC, Anat Neuropharmacol Unit, Oxford OX1 3TH, England; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Oxford; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Nusser, Z (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.	mody@ucla.edu	Nusser, Zoltan/K-8587-2014; Hajos, Norbert/U-2640-2019	Hajos, Norbert/0000-0002-4582-2708; Nusser, Zoltan/0000-0001-7004-4111	NINDS NIH HHS [NS36142] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036142] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Auger C, 1997, NEURON, V19, P139, DOI 10.1016/S0896-6273(00)80354-2; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brussaard AB, 1997, NEURON, V19, P1103, DOI 10.1016/S0896-6273(00)80401-8; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; Buhl EH, 1996, SCIENCE, V271, P369, DOI 10.1126/science.271.5247.369; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; Davis GW, 1998, NATURE, V392, P82, DOI 10.1038/32176; DE KONINCK Y, 1994, J NEUROPHYSIOL, V71, P1318, DOI 10.1152/jn.1994.71.4.1318; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; Hajos N, 1997, J NEUROSCI, V17, P8427; KOMATSU Y, 1994, J NEUROSCI, V14, P6488; KORN H, 1992, P NATL ACAD SCI USA, V89, P440, DOI 10.1073/pnas.89.1.440; Kosaka T, 1996, EXP BRAIN RES, V112, P237; Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; Nusser Z, 1997, NEURON, V19, P697, DOI 10.1016/S0896-6273(00)80382-7; Nusser Z, 1996, P NATL ACAD SCI USA, V93, P11939, DOI 10.1073/pnas.93.21.11939; NUSSER Z, 1995, EUR J NEUROSCI, V7, P630, DOI 10.1111/j.1460-9568.1995.tb00667.x; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; PERSOHN E, 1992, J COMP NEUROL, V326, P193, DOI 10.1002/cne.903260204; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Silver RA, 1996, J PHYSIOL-LONDON, V494, P231, DOI 10.1113/jphysiol.1996.sp021487; SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/science.270.5237.758; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; Stratford KJ, 1996, NATURE, V382, P258, DOI 10.1038/382258a0; Stratford KJ, 1997, J PHYSIOL-LONDON, V505, P425, DOI 10.1111/j.1469-7793.1997.425bb.x; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; ZEZULA J, 1991, BRAIN RES, V563, P325, DOI 10.1016/0006-8993(91)91556-G	30	381	393	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 10	1998	395	6698					172	177		10.1038/25999	http://dx.doi.org/10.1038/25999			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744275				2022-12-28	WOS:000075829900042
J	Eastwood, JB; Fiennes, AGTW; Cappuccio, FP; Maxwell, JD				Eastwood, JB; Fiennes, AGTW; Cappuccio, FP; Maxwell, JD			Registering refugee and asylum-seeking doctors	LANCET			English	Editorial Material									St George Hosp, Sch Med, London SW17 0RE, England	St Georges University London	Eastwood, JB (corresponding author), St George Hosp, Sch Med, Cranmer Terrace, London SW17 0RE, England.		Cappuccio, Francesco/D-3028-2009; Cappuccio, Francesco Paolo/ABF-1094-2020	Cappuccio, Francesco Paolo/0000-0002-7842-5493				Beecham L, 1998, BRIT MED J, V316, P1754; Gibberd FB, 1998, BRIT MED J, V316, P1386, DOI 10.1136/bmj.316.7141.1386a; *MED WORKF STAND A, 1997, 3 DEP0 HLTH MED WORK; PILE H, 1997, ASYLUM TRAP, P8	4	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 22	1998	352	9128					647	648		10.1016/S0140-6736(98)05357-4	http://dx.doi.org/10.1016/S0140-6736(98)05357-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746043				2022-12-28	WOS:000075567400045
J	Li, TS; Tubiana, R; Katlama, C; Calvez, V; Ait Mohand, H; Autran, B				Li, TS; Tubiana, R; Katlama, C; Calvez, V; Ait Mohand, H; Autran, B			Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTED PATIENTS; ZIDOVUDINE	Background Highly active antiretroviral therapy (HAART) decreases viral load and increases CD4 T-cell counts in patients with advanced HIV-1 infection. Whether HAART can improve CD4 T-cell function, and the biological characteristics affecting immune reconstitution, remain unclear. We undertook an open prospective pilot study to address these issues. Both treatment-naive and previously treated patients were included. Methods 20 patients (seven naive, 13 previously treated) were treated with one protease inhibitor and two reverse-transcriptase inhibitors and followed up for 12 months. We measured CD4-cell proliferation in response to cytomegalovirus and tuberculin antigens and counted subsets of CD4 cells at baseline and months 1, 3, 6, 9, and 12, Patients who had no antigen-specific reactivity at baseline but developed it while receiving HAART were classified as immunological responders. Findings Four patients had antigen-specific reactivity at baseline compared with 14 at month 12 (p <0.001). Between month 3 and month 12 viral load fell by a median of 1.5 log copies/mL from baseline (4.6 log copies/mL) and CD4-cell count increased by a median of 63/mu L (from 93/mu L). Ten patients (six of seven naive, four of 13 previously treated) were immunological responders. They differed significantly from the ten non-responders in that their viral-load reduction was sustained for 12 months, the increase in CD4 count was greater, and they showed an early increase in memory CD4 T cells with an increase of naive T cells. Interpretation HAART can induce sustained recovery of CD4 T-cell reactivity against opportunistic pathogens in severely immunosuppressed patients. This recovery depends not on baseline Values but on the amplitude and duration of viral-load reduction and the increase of memory CD4 T cells.	Hop La Pitie Salpetriere, CNRS, URA 625, Lab Immunol Cellulaire, F-75013 Paris, France; Hop La Pitie Salpetriere, Dept Malad Infect, F-75013 Paris, France; Hop La Pitie Salpetriere, Serv Virol, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Autran, B (corresponding author), Hop La Pitie Salpetriere, CNRS, URA 625, Lab Immunol Cellulaire, 83 Blvd Hop, F-75013 Paris, France.							Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; CLERICI M, 1992, J INFECT DIS, V166, P723, DOI 10.1093/infdis/166.4.723; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; DOLAN MJ, 1995, J INFECT DIS, V172, P79, DOI 10.1093/infdis/172.1.79; Emery S, 1997, CURR OPIN IMMUNOL, V9, P568, DOI 10.1016/S0952-7915(97)80112-4; FRENCH MAH, 1992, AIDS, V6, P1293, DOI 10.1097/00002030-199211000-00009; GIORGI JV, 1987, J IMMUNOL, V138, P3725; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; HOY JF, 1988, J INFECT DIS, V158, P1971; Jacobson MA, 1997, LANCET, V349, P1443, DOI 10.1016/S0140-6736(96)11431-8; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; Mathez D, 1997, Antivir Ther, V2, P175; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Reed JB, 1997, AM J OPHTHALMOL, V124, P199, DOI 10.1016/S0002-9394(14)70784-6; RINALDO C, 1991, J INFECT DIS, V164, P638, DOI 10.1093/infdis/164.4.638	20	461	495	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 6	1998	351	9117					1682	1686		10.1016/S0140-6736(97)10291-4	http://dx.doi.org/10.1016/S0140-6736(97)10291-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734884				2022-12-28	WOS:000074088900008
J	Rudikoff, D; Lebwohl, M				Rudikoff, D; Lebwohl, M			Atopic dermatitis	LANCET			English	Article							HOUSE-DUST MITE; ETIOLOGIC FACTOR; CONTROLLED TRIAL; T-CELLS; IN-SITU; SKIN; EXPRESSION; ECZEMA; ANTIGEN; HYPERSENSITIVITY		CUNY, Mt Sinai Med Ctr, Dept Dermatol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Rudikoff, D (corresponding author), CUNY, Mt Sinai Med Ctr, Dept Dermatol, 1 Gustave L Levy Pl, New York, NY 10029 USA.							AaltoKorte K, 1997, BRIT J DERMATOL, V136, P172; ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; Absolon CM, 1997, BRIT J DERMATOL, V137, P241, DOI 10.1046/j.1365-2133.1997.18121896.x; Akdis M, 1997, J IMMUNOL, V159, P4611; Alaiti S, 1998, J AM ACAD DERMATOL, V38, P69, DOI 10.1016/S0190-9622(98)70541-9; ALY R, 1977, ARCH DERMATOL, V113, P780, DOI 10.1001/archderm.113.6.780; Babi LFS, 1995, IMMUNOL RES, V14, P317, DOI 10.1007/BF02935627; Bengtsson A, 1997, CLIN EXP IMMUNOL, V109, P533, DOI 10.1046/j.1365-2249.1997.4731373.x; BerthJones J, 1996, J AM ACAD DERMATOL, V34, P1016, DOI 10.1016/S0190-9622(96)90281-9; BerthJones J, 1997, BRIT J DERMATOL, V136, P76, DOI 10.1046/j.1365-2133.1997.d01-1146.x; BORKOWSKI TA, 1996, DERMATOL THER, V1, P38; BOS JD, 1992, ARCH DERMATOL, V128, P1509, DOI 10.1001/archderm.128.11.1509; Buckley C, 1996, CLIN EXP ALLERGY, V26, P1057, DOI 10.1111/j.1365-2222.1996.tb00644.x; Cameron MM, 1997, BRIT J DERMATOL, V137, P1, DOI 10.1111/j.1365-2133.1997.tb03693.x; Campbell DE, 1997, CLIN EXP IMMUNOL, V107, P392, DOI 10.1111/j.1365-2249.1997.278-ce1172.x; CASTELAIN M, 1995, CLIN REV ALLERG IMMU, V13, P161; Cheng JF, 1997, J ALLERGY CLIN IMMUN, V99, P683, DOI 10.1016/S0091-6749(97)70031-9; CLARK RAF, 1989, CLIN IMMUNOL IMMUNOP, V53, pS132, DOI 10.1016/0090-1229(89)90078-0; Coleman R, 1997, BRIT J DERMATOL, V136, P1; COOPER KD, 1994, J INVEST DERMATOL, V102, P128, DOI 10.1111/1523-1747.ep12371746; Cox HE, 1998, BRIT J DERMATOL, V138, P182; DAHL RE, 1995, ARCH PEDIAT ADOL MED, V149, P856, DOI 10.1001/archpedi.1995.02170210030005; DEVRIES JE, 1993, RES IMMUNOL, V144, P597, DOI 10.1016/S0923-2494(05)80009-4; GELMETTI C, 1992, PEDIATR DERMATOL, V9, P380, DOI 10.1111/j.1525-1470.1992.tb00637.x; GREWE SR, 1982, J ALLERGY CLIN IMMUN, V70, P452, DOI 10.1016/0091-6749(82)90008-2; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1991, PEDIATR CLIN N AM, V38, P763; Hanifin JM, 1996, ARCH DERMATOL, V132, P1230, DOI 10.1001/archderm.132.10.1230; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HANIFIN JM, 1993, ALLERGY PRINCIPLES P, P1581; HEBERT AA, 1996, DERMATOL THER, V1, P61; Herd RM, 1996, BRIT J DERMATOL, V135, P20; IMOKAWA G, 1991, J INVEST DERMATOL, V96, P523, DOI 10.1111/1523-1747.ep12470233; Jung K, 1997, INT ARCH ALLERGY IMM, V113, P495, DOI 10.1159/000237628; KANWAR AJ, 1991, PEDIATR DERMATOL, V8, P114, DOI 10.1111/j.1525-1470.1991.tb00297.x; Katagiri K, 1997, CLIN EXP IMMUNOL, V108, P289, DOI 10.1046/j.1365-2249.1997.d01-1015.x; KAY J, 1994, J AM ACAD DERMATOL, V30, P35, DOI 10.1016/S0190-9622(94)70004-4; Koide Masayo, 1997, Journal of Dermatology (Tokyo), V24, P88; KRUTMANN J, 1996, DERMATOLOGICAL THERA, V1, P24; LangeveldWildschut EG, 1996, J ALLERGY CLIN IMMUN, V98, P1019, DOI 10.1016/S0091-6749(96)80186-2; Lear JT, 1996, J AM ACAD DERMATOL, V35, P642, DOI 10.1016/S0190-9622(96)90701-X; LEIFERMAN KM, 1994, J ALLERGY CLIN IMMUN, V94, P1310, DOI 10.1016/0091-6749(94)90347-6; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; Leung DYM, 1997, CLIN EXP IMMUNOL, V107, P25; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; Lever R, 1996, DERMATOL THER, V1, P32; MABIN DC, 1995, ARCH DIS CHILD, V73, P202, DOI 10.1136/adc.73.3.202; MCHENRY PM, 1995, BMJ-BRIT MED J, V314, P843; MORREN MA, 1994, J AM ACAD DERMATOL, V31, P467, DOI 10.1016/S0190-9622(94)70213-6; Murata Y, 1996, J INVEST DERMATOL, V106, P1242, DOI 10.1111/1523-1747.ep12348937; Nakazawa M, 1997, J ALLERGY CLIN IMMUN, V99, P673, DOI 10.1016/S0091-6749(97)70030-7; NEUBER K, 1995, INT ARCH ALLERGY IMM, V107, P179, DOI 10.1159/000236970; Neumann C, 1996, J MOL MED, V74, P401, DOI 10.1007/BF00210634; Ohki O, 1997, BRIT J DERMATOL, V136, P838, DOI 10.1111/j.1365-2133.1997.tb03922.x; Patel L, 1997, ARCH DIS CHILD, V76, P505, DOI 10.1136/adc.76.6.505; Reekers R, 1996, BRIT J DERMATOL, V135, P935, DOI 10.1046/j.1365-2133.1996.d01-1098.x; Resnick SD, 1996, ARCH DERMATOL, V132, P1047, DOI 10.1001/archderm.132.9.1047; Reynolds NJ, 1997, J ROY COLL PHYS LOND, V31, P241; RING J, 1996, DERMATOL THER, V1, P51; Rothe MJ, 1996, J AM ACAD DERMATOL, V35, P1, DOI 10.1016/S0190-9622(96)90486-7; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; SAMPSON HA, 1992, PEDIATR DERMATOL, V9, P376, DOI 10.1111/j.1525-1470.1992.tb00636.x; Sampson HA, 1997, J ROY SOC MED, V90, P2, DOI 10.1177/0141076897090030S02; Seguchi T, 1996, ARCH DERMATOL RES, V288, P442, DOI 10.1007/s004030050080; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Tan BB, 1997, BRIT J DERMATOL, V136, P351, DOI 10.1111/j.1365-2133.1997.tb14942.x; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; ThestrupPedersen K, 1997, ACTA DERM-VENEREOL, V77, P20; Tupker RA, 1996, J ALLERGY CLIN IMMUN, V97, P1064, DOI 10.1016/S0091-6749(96)70259-2; Valenta R, 1996, J INVEST DERMATOL, V107, P203, DOI 10.1111/1523-1747.ep12329617; VanderPloeg I, 1997, CLIN EXP IMMUNOL, V109, P526, DOI 10.1046/j.1365-2249.1997.4671365.x; Werfel T, 1996, J INVEST DERMATOL, V107, P871, DOI 10.1111/1523-1747.ep12331164; Werfel T, 1997, J ALLERGY CLIN IMMUN, V99, P124, DOI 10.1016/S0091-6749(97)81053-6; WILLIAMS HC, 1995, DERMATOL CLIN, V13, P649, DOI 10.1016/S0733-8635(18)30070-6; YONEDA K, 1995, BRIT J DERMATOL, V133, P586, DOI 10.1111/j.1365-2133.1995.tb02710.x	76	203	207	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 6	1998	351	9117					1715	1721		10.1016/S0140-6736(97)12082-7	http://dx.doi.org/10.1016/S0140-6736(97)12082-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734903				2022-12-28	WOS:000074088900038
J	Short, RV				Short, RV			Malthus, a prophet without honour	LANCET			English	Editorial Material									Royal Hosp Women, Dept Perinatal Med, Carlton, Vic 3053, Australia		Short, RV (corresponding author), Royal Hosp Women, Dept Perinatal Med, Carlton, Vic 3053, Australia.							[Anonymous], 1798, ESSAY PRINCIPLE POPU, V1; DARWIN C, 1958, AUTOBIOGRAPHY; FLEUR AGN, 1982, TR MALTHUS ESSAY PRI; Keynes John Maynard, 1951, ESSAYS IN BIOGRAPHY; MALTHUS TR, 1798, ESSSAY PRINCIPLE POP; Wallace Alfred Russel, 1905, MY LIFE	6	6	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 6	1998	351	9117					1676	1676		10.1016/S0140-6736(05)77738-2	http://dx.doi.org/10.1016/S0140-6736(05)77738-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734882				2022-12-28	WOS:000074088900006
J	Weisfuse, IB				Weisfuse, IB			Gonorrhoea control and antimicrobial resistance	LANCET			English	Editorial Material									New York City Dept Hlth, Bur Sexually Transmitted Dis, New York, NY 10013 USA	New York City Department of Health & Mental Hygiene	Weisfuse, IB (corresponding author), New York City Dept Hlth, Bur Sexually Transmitted Dis, New York, NY 10013 USA.							[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P761; DILLON JR, 1977, 12 M INT SOC SEX TRA; Fox KK, 1997, J INFECT DIS, V175, P1396, DOI 10.1086/516472; Jones RB, 1998, AM J MED, V104, P28, DOI 10.1016/S0002-9343(97)00277-5; SIEGEL JE, 1997, HIDDEN EPIDEMIC CONF, P330; *US DEP HHS, 1997, SEX TRANSM DIS SURV, P1	7	4	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 28	1998	351	9107					928	928						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734937				2022-12-28	WOS:000072770900008
J	Dolk, H; Busby, A; Armstrong, BG; Walls, PH				Dolk, H; Busby, A; Armstrong, BG; Walls, PH			Geographical variation in anophthalmia and microphthalmia in England, 1988-94	BRITISH MEDICAL JOURNAL			English	Article							INHOMOGENEOUS POPULATIONS; MATERNAL FEVER; TERATOGENICITY; MALFORMATIONS; ANOMALIES; EXPOSURE; COLOBOMA; UPDATE	Objective: To investigate the geographical variation and clustering of congenital anophthalmia and microphthalmia in England, in response to media reports of clusters. Design: Comparison of pattern of residence at birth of cases of anophthalmia and microphthalmia in England in 1988-94, notified to a special register, with pattern of residence of all births. Three groups studied included all cases, all severe cases, and all severe cases of unknown aetiology. Outcome measures: Prevalence rates of anophthalmia and microphthalmia by region and district and by ward population density and socioeconomic deprivation index of enumeration district grouped into fifths. Clustering expressed as the tendency for the three nearest neighbours of a case to be more likely to be cases than expected by chance, or for there to be more cases within circles of fixed radius of a case than expected by chance. Results: The overall prevalence of anophthalmia and microphthalmia was 1.0 per 10 000 births. Regional and district variation in prevalence did not reach statistical significance. Prevalence was higher in rural than urban areas: the relative risk in the group of wards of lowest population density compared with the most densely populated group was 1.79 (95% confidence interval 1.15 to 2.81) for all cases and 2.37 (1.38 to 4.08) for severe cases. There was no evidence of a trend in risk with socioeconomic deprivation. There was very little evidence of localised clustering. Conclusions: There is very little evidence to support the presence of strongly localised environmental exposures causing clusters of children to be born with anophthalmia or microphthalmia The excess risk in rural areas requires further investigation.	Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Environm Epidemiol Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Dolk, H (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Environm Epidemiol Unit, London WC1E 7HT, England.	h.dolk@lshtm.ac.uk		armstrong, benedict/0000-0003-4407-0409				ALXEANDER FE, 1992, GEOGRAPHICAL ENV EPI, P238; BUSBY A, 1998, IN PRESS ARCH DIS CH; BUYS ML, 1990, EYE BIRTH DEFECTS EN; Carstairs V., 1991, DEPRIVATION HLTH SCO; CUZICK J, 1990, J ROY STAT SOC B MET, V52, P73; DIGGLE PJ, 1991, BIOMETRICS, V47, P1155, DOI 10.2307/2532668; DOLK H, 1993, BRIT MED J, V307, P203, DOI 10.1136/bmj.307.6897.203-b; DONALD JM, 1991, ENVIRON HEALTH PERSP, V94, P237, DOI 10.2307/3431317; EDWARDS MJ, 1986, TERATOGEN CARCIN MUT, V6, P563, DOI 10.1002/tcm.1770060610; FRASER FC, 1978, LANCET, V2, P634; HARTWIG NG, 1989, TERATOLOGY, V39, P295, DOI 10.1002/tera.1420390311; HOOGENBOOM ER, 1991, CURR EYE RES, V10, P601, DOI 10.3109/02713689109013852; *INT PROGR CHEM SA, 1993, ENV HLTH CRIT, V148; KNOX EG, 1991, EPIDEMIOLOGY CONGENI; KRISTENSEN P, 1994, BRIT MED J, V308, P205, DOI 10.1136/bmj.308.6922.205c; LAMBERT S, 1990, PEDIATRIC OPHTHALMOL, P91; Lyons Jones K., 1988, SMITHS RECOGNIZABLE; MARTUZZI M, 1995, AM J EPIDEMIOL, V141, P369, DOI 10.1093/aje/141.4.369; *MIN AGR, 1992, FISH FOOD PEST SAF D; PADUANO M, 1993, OBSERVER        0117, P3; ROMERO P, 1989, ENVIRON RES, V50, P256, DOI 10.1016/S0013-9351(89)80006-4; *SCOTT OFF, 1988, REP WORK PART MICR F; Sherman JD, 1996, ARCH ENVIRON HEALTH, V51, P5, DOI 10.1080/00039896.1996.9935986; SPAGNOLO A, 1994, REPROD TOXICOL, V8, P397, DOI 10.1016/0890-6238(94)90079-5; SPRAGGETT K, 1982, TERATOLOGY, V25, pA78; SULIK KK, 1988, DEVELOPMENT, V103, P213; VONHERZEN JL, 1976, OBSTET GYNECOL, V50, P728; WARBURG M, 1992, OPHTHALMIC PAED GEN, V13, P111, DOI 10.3109/13816819209087611; WARBURG M, 1991, OPHTHALMIC PAED GEN, V12, P57, DOI 10.3109/13816819109023675; WEILAND HT, 1987, LANCET, V1, P682; *WELSH OFF, 1985, INC CONG MALF WAL SP	31	66	70	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					905	909						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756803	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000076409000016
J	Worrall, D; Elias, L; Ashford, D; Smallwood, M; Sidebottom, C; Lillford, P; Telford, J; Holt, C; Bowles, D				Worrall, D; Elias, L; Ashford, D; Smallwood, M; Sidebottom, C; Lillford, P; Telford, J; Holt, C; Bowles, D			A carrot leucine-rich-repeat protein that inhibits ice recrystallization	SCIENCE			English	Article							THERMAL HYSTERESIS PROTEIN; ANTIFREEZE PROTEINS; CRYSTAL-STRUCTURE; PLANTS; ELECTROPHORESIS; PATHOGENESIS; EXPRESSION; BINDING; TOMATO	Many organisms adapted to live at subzero temperatures express antifreeze proteins that improve their tolerance to freezing. Although structurally diverse, all antifreeze proteins interact with ice surfaces, depress the freezing temperature of aqueous solutions, and inhibit ice crystal growth. A protein purified from carrot shares these functional features with antifreeze proteins of fish. Expression of the carrot complementary DNA in tobacco resulted in the accumulation of antifreeze activity in the apoplast of plants grown at greenhouse temperatures. The sequence of carrot antifreeze protein is similar to that of polygalacturonase inhibitor proteins and contains leucine-rich repeats.	Univ York, Dept Biol, Plant Lab, York YO1 5YW, N Yorkshire, England; Unilever Res, Bedford MK44 1LO, England	University of York - UK; Unilever	Smallwood, M (corresponding author), Univ York, Dept Biol, Plant Lab, POB 373, York YO1 5YW, N Yorkshire, England.			Worrall, Dawn/0000-0002-9062-7987				Bertrand JA, 1996, EMBO J, V15, P2678, DOI 10.1002/j.1460-2075.1996.tb00628.x; COLLMER A, 1986, ANNU REV PHYTOPATHOL, V24, P383, DOI 10.1146/annurev.py.24.090186.002123; Davies PL, 1997, CURR OPIN STRUC BIOL, V7, P828, DOI 10.1016/S0959-440X(97)80154-6; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DEVRIES AL, 1986, METHOD ENZYMOL, V127, P293; DEVRIES AL, 1971, SCIENCE, V172, P1152, DOI 10.1126/science.172.3988.1152; Draper J., 1988, PLANT GENETIC TRANSF, P69; DUMAN JG, 1994, BBA-PROTEIN STRUCT M, V1206, P129, DOI 10.1016/0167-4838(94)90081-7; DUMAN JG, 1993, CRYOBIOLOGY, V30, P322, DOI 10.1006/cryo.1993.1031; Duman John G., 1993, Advances in Low-Temperature Biology, V2, P131; GRIFFITH M, 1995, BIOTECHNOL ADV, V13, P375, DOI 10.1016/0734-9750(95)02001-J; GROSS KC, 1982, HORTSCIENCE, V17, P933; HIGHTOWER R, 1991, PLANT MOL BIOL, V17, P1013, DOI 10.1007/BF00037141; HON WC, 1995, PLANT PHYSIOL, V109, P879, DOI 10.1104/pp.109.3.879; Huang T., 1995, Cryobiology, V32, P577; Jia ZC, 1996, NATURE, V384, P285, DOI 10.1038/384285a0; KENWARD KD, 1993, PLANT MOL BIOL, V23, P377, DOI 10.1007/BF00029012; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Logsdon JM, 1997, P NATL ACAD SCI USA, V94, P3485, DOI 10.1073/pnas.94.8.3485; MCMANUS MT, 1988, PLANTA, V175, P56; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PORWAL BL, 1989, INDIAN J AGRON, V34, P293; RAJESHEKAR CB, 1996, PLANT PHYSIOL, V111, P605; ROHRINGER R, 1983, J EXP BOT, V34, P1589, DOI 10.1093/jxb/34.12.1589; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SMALLWOOD M, UNPUB; SONNICHSEN FD, 1993, SCIENCE, V259, P1154, DOI 10.1126/science.8438165; SONNICHSEN FD, 1995, PROTEIN SCI, V4, P460; STOTZ HU, 1994, PLANT MOL BIOL, V25, P607, DOI 10.1007/BF00029600; URRUTIA ME, 1992, BIOCHIM BIOPHYS ACTA, V1121, P199, DOI 10.1016/0167-4838(92)90355-H; WISNIEWSKI M, 1987, PROTOPLASMA, V141, P160, DOI 10.1007/BF01272898; Yeh Y, 1996, CHEM REV, V96, P601, DOI 10.1021/cr950260c; ZHENG LS, 1992, PLANT CELL, V4, P1147, DOI 10.1105/tpc.4.9.1147	35	205	271	1	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 2	1998	282	5386					115	117		10.1126/science.282.5386.115	http://dx.doi.org/10.1126/science.282.5386.115			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756474				2022-12-28	WOS:000076294900051
J	Rodrigues, LC				Rodrigues, LC			A compliment - Having your research ideas stolen	BRITISH MEDICAL JOURNAL			English	Article									Univ London, London WC1E 7HU, England	University of London	Rodrigues, LC (corresponding author), Univ London, London WC1E 7HU, England.		RODRIGUES, LAURA CUNHA/AAO-4130-2021	Rodrigues, Laura Cunha/0000-0001-9008-660X					0	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1998	317	7162					857	857		10.1136/bmj.317.7162.857	http://dx.doi.org/10.1136/bmj.317.7162.857			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748182	Green Published			2022-12-28	WOS:000076222300020
J	Papayannopoulos, V; Tomlinson, A; Panin, VM; Rauskolb, C; Irvine, KD				Papayannopoulos, V; Tomlinson, A; Panin, VM; Rauskolb, C; Irvine, KD			Dorsal-ventral signaling in the Drosophila eye	SCIENCE			English	Article							PATTERN-FORMATION; LIMB DEVELOPMENT; NOTCH; FRINGE; GENES; CELLS; EXPRESSION; DELTA; AXIS; DISC	The development of the Drosophila eye has served as a model system for investigations of tissue patterning and cell-cell communication; however, early eye development-has not been well understood. The results presented here indicate that specialized cells are established along the dorsal-ventral midline of the developing eye by Notch-mediated signaling between dorsal and ventral cells, and that Notch activation at the midline plays an essential role both in promoting the growth of the eye primordia and in regulating eye patterning. These observations imply that the developmental homology between Drosophila wings and vertebrate limbs extends to Drosophila eyes.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Columbia University; Columbia University	Irvine, KD (corresponding author), Rutgers State Univ, Waksman Inst, POB 759, Piscataway, NJ 08854 USA.		Panin, Vlad/G-1583-2016	Panin, Vlad/0000-0001-9126-1481; Papayannopoulos, Venizelos/0000-0002-3741-8190	NIGMS NIH HHS [GM-R01-54594] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054594] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brodsky MH, 1996, DEV BIOL, V173, P428, DOI 10.1006/dbio.1996.0038; Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161; CAMPOSORTEGA JA, 1978, ROUX ARCH DEV BIOL, V184, P155, DOI 10.1007/BF00848224; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; Heberlein U, 1998, DEVELOPMENT, V125, P567; HIGASHIJIMA SI, 1992, GENE DEV, V6, P50, DOI 10.1101/gad.6.1.50; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Irvine KD, 1997, CURR OPIN CELL BIOL, V9, P867, DOI 10.1016/S0955-0674(97)80090-7; Ito K, 1997, DEVELOPMENT, V124, P761; Jarman AP, 1996, TRENDS GENET, V12, P121, DOI 10.1016/0168-9525(96)30015-2; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; McNeill H, 1997, GENE DEV, V11, P1073, DOI 10.1101/gad.11.8.1073; MCNEILL H, UNPUB; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; PARODY TR, 1993, GENETICS, V135, P527; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; RAUSKOLB C, UNPUB; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; SPEICHER SA, 1994, DEVELOPMENT, V120, P535; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; STRUHL G, UNPUB; Sun X, 1996, DEVELOPMENT, V122, P2465; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; Treisman JE, 1998, CURR TOP DEV BIOL, V39, P119, DOI 10.1016/S0070-2153(08)60454-8; VILLANO JL, 1995, DEVELOPMENT, V121, P2767; Wehrli M, 1998, DEVELOPMENT, V125, P1421; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; ZHENG L, 1995, DEVELOPMENT, V121, P3045	31	184	186	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					2031	2034		10.1126/science.281.5385.2031	http://dx.doi.org/10.1126/science.281.5385.2031			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748163				2022-12-28	WOS:000076161800057
J	Duneau, G				Duneau, G			Evaluation and management guidelines	BRITISH MEDICAL JOURNAL			English	Editorial Material									Cook Cty Hosp, Chicago, IL 60612 USA	John H Stroger Junior Hospital Cook County	Duneau, G (corresponding author), Cook Cty Hosp, Chicago, IL 60612 USA.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					822	822		10.1136/bmj.317.7161.822	http://dx.doi.org/10.1136/bmj.317.7161.822			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740586	Green Published			2022-12-28	WOS:000076084200083
J	Dirick, L; Goetsch, L; Ammerer, C; Byers, B				Dirick, L; Goetsch, L; Ammerer, C; Byers, B			Regulation of meiotic S phase by Ime2 and a Clb5,6-associated kinase in Saccharomyces cerevisiae	SCIENCE			English	Article							CELL-CYCLE; PROTEIN-KINASE; DNA-REPLICATION; BUDDING YEAST; START; G1; INHIBITOR; MEIOSIS; TRANSITION; ARREST	Cyclin-dependent kinase (Cdk) mutations that prevent entry into the mitotic cell cycle of budding yeast fail to block meiotic DNA replication, suggesting there may be fundamental differences between these pathways. However, 5 phase in meiosis was found to depend on the same B-type cyclins (Clb5 and Clb6) as it does in mitosis. Meiosis differs instead in the mechanism that controls removal of the Cdk inhibitor Sic1. Destruction of Sic1 and activation of a Clb5-dependent kinase in meiotic cells required the action of the meiosis-specific protein kinase Ime2, thereby coupling early meiotic gene expression to control of DNA replication for meiosis.	Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Vienna, Ludwig Boltzmann Inst, Dept Biochem & Mol Cell Biol, A-1030 Vienna, Austria	University of Washington; University of Washington Seattle; Ludwig Boltzmann Institute; University of Vienna	Byers, B (corresponding author), Univ Washington, Dept Genet, Box 357360, Seattle, WA 98195 USA.				NIGMS NIH HHS [GM 18541] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018541, R01GM118541, R37GM018541] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Chu S, 1998, MOL CELL, V1, P685, DOI 10.1016/S1097-2765(00)80068-4; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; DIRICK L, UNPUB; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; Foiani M, 1996, MOL GEN GENET, V253, P278, DOI 10.1007/s004380050323; IINO Y, 1995, GENETICS, V140, P1235; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KOMINAMI K, 1993, BIOSCI BIOTECH BIOCH, V57, P1731, DOI 10.1271/bbb.57.1731; KUHNE C, 1993, EMBO J, V12, P3437, DOI 10.1002/j.1460-2075.1993.tb06018.x; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; Murray A, 1993, CELL CYCLE INTRO; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHUSTER EO, 1989, GENETICS, V123, P29; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; YOSHIDA M, 1990, MOL GEN GENET, V221, P176, DOI 10.1007/BF00261718	24	112	113	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1854	1857		10.1126/science.281.5384.1854	http://dx.doi.org/10.1126/science.281.5384.1854			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743499				2022-12-28	WOS:000076007100054
J	Mastroberardino, L; Spindler, B; Pfeiffer, R; Skelly, PJ; Loffing, J; Shoemaker, CB; Verrey, F				Mastroberardino, L; Spindler, B; Pfeiffer, R; Skelly, PJ; Loffing, J; Shoemaker, CB; Verrey, F			Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family	NATURE			English	Article							INTERLEUKIN-1-DEPENDENT INTERLEUKIN-2 PRODUCTION; MONOCLONAL-ANTIBODY 4F2; XENOPUS-LAEVIS OOCYTES; EL4 THYMOMA CELLS; SURFACE-ANTIGEN; HEAVY-CHAIN; STIMULATION; EXPRESSION; PROTEIN; CLONING	Amino-acid transport across cellular plasma membranes depends on several parallel-functioning (co-)transporters and exchangers'. The widespread transport system L accounts for a sodium-independent exchange of large, neutral amino acids, whereas the system y(+)L exchanges positively charged amino acids and/or neutral amino acids together with sodium(2,3). The molecular nature of these transporters remains unknown, although expression of the human cell-surface glycoprotein 4F2 heavy chain (h4F2hc; CD98 in the mouse)(4,5) is known to induce low levels of L- and/or y(+)L-type transport(6-9). This glycoprotein is found in activated lymphocytes, together with an uncharacterized, disulphide-linked lipophilic light chain with an apparent relative molecular mass of 40,000 (M-r 40 K)(10,11). Here we identify the permease-related protein E16 (ref. 12) as the first light chain of h4F2hc and show that the resulting heterodimeric complex mediates L-type amino-acid transport. The homologous protein from Schistosoma mansoni, SPRM1, also associates covalently with coexpressed h4F2hc glycoprotein, although it induces amino-acid transport of different substrate specificity. The coexpression of h4F2hc is required for surface expression of these permease-related light chains, which belong to a new family of amino-acid transporters that form heterodimers with cell-surface glycoproteins.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Anat, CH-8057 Zurich, Switzerland; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	University of Zurich; University of Zurich; Harvard University; Harvard T.H. Chan School of Public Health	Verrey, F (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Loffing, Johannes/ABG-9973-2020	Verrey, Francois/0000-0003-3250-9824; Loffing, Johannes/0000-0002-9415-6588				BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Broer S, 1995, BIOCHEM J, V312, P863, DOI 10.1042/bj3120863; Broer S, 1997, BIOCHEM J, V324, P535, DOI 10.1042/bj3240535; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; EISENBARTH GS, 1980, J IMMUNOL, V124, P1237; GAUGITSCH HW, 1992, J BIOL CHEM, V267, P11267; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HEMLER ME, 1982, J IMMUNOL, V129, P623; HOFMANN K, 1992, COMPUT APPL BIOSCI, V8, P331; Isnard AD, 1996, J MOL BIOL, V262, P473, DOI 10.1006/jmbi.1996.0529; LUSCHER B, 1985, J IMMUNOL, V135, P3951; MACDONALD HR, 1985, J IMMUNOL, V135, P3944; OXENDER DL, 1963, J BIOL CHEM, V238, P3686; PALACIN M, 1994, J EXP BIOL, V196, P123; Spindler B, 1997, PFLUG ARCH EUR J PHY, V434, P323, DOI 10.1007/s004240050403; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596	20	442	480	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1998	395	6699					288	291		10.1038/26246	http://dx.doi.org/10.1038/26246			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751058				2022-12-28	WOS:000075974600054
J	Biagioli, M				Biagioli, M			Long live the deans!	LANCET			English	Article									Harvard Univ, Dept Hist Sci, Cambridge, MA 02138 USA	Harvard University	Biagioli, M (corresponding author), Harvard Univ, Dept Hist Sci, Cambridge, MA 02138 USA.							RENNIE D, 1997, JAMA-J AM MED ASSOC, V278, P583	1	1	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					899	900		10.1016/S0140-6736(05)60039-6	http://dx.doi.org/10.1016/S0140-6736(05)60039-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9743004				2022-12-28	WOS:000075857300050
J	Horton, R				Horton, R			A fair reward	LANCET			English	Article									The Lancet, London, England		Horton, R (corresponding author), The Lancet, London, England.							*BOYER COMM, 1998, REINV UND ED BLUEPR; Gadamer H.-G., 1996, ENIGMA HLTH	2	16	16	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					892	892		10.1016/S0140-6736(05)60030-X	http://dx.doi.org/10.1016/S0140-6736(05)60030-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742995				2022-12-28	WOS:000075857300041
J	McDermott, DH; Zimmerman, PA; Guignard, F; Kleeberger, CA; Leitman, SF; Murphy, PM				McDermott, DH; Zimmerman, PA; Guignard, F; Kleeberger, CA; Leitman, SF; Murphy, PM		Multicenter AIDS Cohort Study MACS	CCR5 promoter polymorphism and HIV-1 disease progression	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR; PLASMODIUM-VIVAX; INFECTION; GENE; TRANSMISSION; RESISTANCE; CCR5-DELTA-32; DELETION; ALLELE	Background The rate of progression to AIDS varies among individuals infected with HIV-1. Factors responsible include two inherited human alleles, CCR5 Delta 32 and CCR2-641, which alter the protein-coding regions for the HIV-1 coreceptors/chemokine receptors CCR5 and CCR2b. We tested the hypothesis that polymorphisms of the CCR5 promoter might affect the rate of progression of HIV-1 infected people to AIDS. Methods We used directed heteroduplex analysis to identify polymorphism in the CCR5 promoter. Promoter-variants were compared in vitro with a chloramphenicol acetyltransferase reporter gene, and in vivo by genotyping HIV-1 seroconvertors discordant at polymorphous loci, Findings An A/G polymorphism was identified at basepair 59029 (Genbank U95626) in the CCR5 promoter. Both promoter alleles were common (43-68% allelic frequency for 59029-A depending on race). When in-vitro promoter activity was measured, 59029-G had 45% lower activity than 59029-A (p=0.05). In a cohort of HIV-1 seroconvertors lacking both CCR5 Delta 32 and CCR2-641, 59029-G/G individuals progressed to AIDS on average 3.8 years more slowly than 59029-A/A individuals (p=0.004). 59029-G/A discordance did not correlate with discordant rates of infection. Interpretation Our results are consistent with the hypothesis that CCR5 is important in HIV-1 pathogenesis, CCR5 59029-G/G appears to be protective relative to CCR5 59029-A/A, and about twice as protective relative to CCR5 Delta 32 or CCR2-641. This effect may be the result of reduced CCR5 mRNA production. These results identify the first site in the CCR5 promoter that may be a useful target for treatment of HIV-1 infection.	NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; NIH, Div Transfus Med, Warren Grant Magnuson Clin Ctr, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; Johns Hopkins University	Murphy, PM (corresponding author), NIAID, Host Def Lab, NIH, Bldg 10,Rm 11N113, Bethesda, MD 20892 USA.	pmm@nih.gov	McDermott, David/AAP-2459-2021	McDermott, David/0000-0001-6978-0867	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052] Funding Source: NIH RePORTER; NCRR NIH HHS [5-M01-RR-00052] Funding Source: Medline; PHS HHS [UO1-A1-35042, UO1-A1-35043] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AnsariLari MA, 1997, NAT GENET, V16, P221, DOI 10.1038/ng0797-221; Berger EA, 1997, AIDS, V11, pS3; Carrington M, 1997, AM J HUM GENET, V61, P1261, DOI 10.1086/301645; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; Edelstein RE, 1997, J ACQ IMMUN DEF SYND, V16, P243, DOI 10.1097/00042560-199712010-00004; Guignard F, 1998, J IMMUNOL, V160, P985; Hoffman TL, 1997, J INFECT DIS, V176, P1093, DOI 10.1086/516519; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kostrikis LG, 1998, NAT MED, V4, P350, DOI 10.1038/nm0398-350; LUI R, 1996, CELL, V86, P367; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; Moriuchi H, 1997, J IMMUNOL, V159, P5441; Mummidi S, 1997, J BIOL CHEM, V272, P30662, DOI 10.1074/jbc.272.49.30662; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; Quillent C, 1998, LANCET, V351, P14, DOI 10.1016/S0140-6736(97)09185-X; Rousseau CM, 1997, J ACQ IMMUN DEF SYND, V16, P239, DOI 10.1097/00042560-199712010-00003; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Smith MW, 1997, LANCET, V350, P741, DOI 10.1016/S0140-6736(05)63551-9; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; ZIMMERMAN PA, 1995, HUM IMMUNOL, V42, P233, DOI 10.1016/0198-8859(94)00107-2; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	26	326	337	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	1998	352	9131					866	870		10.1016/S0140-6736(98)04158-0	http://dx.doi.org/10.1016/S0140-6736(98)04158-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742978	hybrid			2022-12-28	WOS:000075857300008
J	Sussman, MA; Lim, HW; Gude, N; Taigen, T; Olson, EN; Robbins, J; Colbert, MC; Gualberto, A; Wieczorek, DF; Molkentin, JD				Sussman, MA; Lim, HW; Gude, N; Taigen, T; Olson, EN; Robbins, J; Colbert, MC; Gualberto, A; Wieczorek, DF; Molkentin, JD			Prevention of cardiac hypertrophy in mice by calcineurin inhibition	SCIENCE			English	Article							TRANSCRIPTION FACTORS; BETA-TROPOMYOSIN; TRANSGENIC MICE; CYCLOSPORINE-A; HEART-FAILURE; CARDIOMYOPATHY; CA2+; TRANSPLANTATION; MECHANISMS; MUTATIONS	Hypertrophic cardiomyopathy (HCM) is an inherited form of heart disease that affects 1 in 500 individuals. Here it is shown that calcineurin, a calcium-regulated phosphatase, plays a critical role in the pathogenesis of HCM. Administration of the calcineurin inhibitors cyclosporin and FK506 prevented disease in mice that were genetically predisposed to develop HCM as a result of aberrant expression of tropomodulin, myosin Light chain-2, or fetal beta-tropomyosin in the heart. Cyclosporin had a similar effect in a rat model of pressure-overload hypertrophy. These results suggest that calcineurin inhibitors merit investigation as potential therapeutics for certain forms of human heart disease.	Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Univ Cincinnati, Dept Mol Genet, Cincinnati, OH 45267 USA	Cincinnati Children's Hospital Medical Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Case Western Reserve University; University System of Ohio; University of Cincinnati	Molkentin, JD (corresponding author), Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.			Gualberto, Antonio/0000-0002-6590-839X; Molkentin, Jeffery/0000-0002-3558-6529	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058224, R01HL058224] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58224-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham WT, 1997, CIRCULATION, V96, P2755, DOI 10.1161/01.CIR.96.9.2755; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; Colbert MC, 1997, J CLIN INVEST, V100, P1958, DOI 10.1172/JCI119727; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; FEWELL JG, UNPUB; Gualberto A, 1998, J BIOL CHEM, V273, P7088, DOI 10.1074/jbc.273.12.7088; HAVERICH A, 1994, TRANSPLANT P, V26, P2713; HONGO K, 1995, AM J PHYSIOL-CELL PH, V269, pC690, DOI 10.1152/ajpcell.1995.269.3.C690; HUSI H, 1994, J BIOL CHEM, V269, P14199; James J, 1997, AM J PHYSIOL-HEART C, V273, pH2105, DOI 10.1152/ajpheart.1997.273.5.H2105; LEGUENNEC JY, 1991, EXP PHYSIOL, V76, P975, DOI 10.1113/expphysiol.1991.sp003560; Lim H. J., UNPUB; Maier LS, 1998, AM J PHYSIOL-HEART C, V274, pH1361, DOI 10.1152/ajpheart.1998.274.4.H1361; MARON BJ, 1995, CIRCULATION, V92, P785, DOI 10.1161/01.CIR.92.4.785; Maron BJ, 1997, LANCET, V350, P127, DOI 10.1016/S0140-6736(97)01282-8; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Muthuchamy M, 1995, J BIOL CHEM, V270, P30593, DOI 10.1074/jbc.270.51.30593; MUTHUCHAMY M, IN PRESS J MOL CELL; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Palmiter KA, 1997, BASIC RES CARDIOL, V92, P63, DOI 10.1007/BF00794070; Palmiter KA, 1996, J BIOL CHEM, V271, P11611, DOI 10.1074/jbc.271.20.11611; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Schaub MC, 1997, J MOL MED, V75, P901, DOI 10.1007/s001090050182; Sussman MA, 1998, CIRC RES, V82, P94; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167; Ventura HO, 1997, CURR OPIN CARDIOL, V12, P375, DOI 10.1097/00001573-199707000-00005; Vikstrom KL, 1996, CURR OPIN CELL BIOL, V8, P97, DOI 10.1016/S0955-0674(96)80053-6; WATKINS H, 1995, HUM MOL GENET, V4, P1721, DOI 10.1093/hmg/4.suppl_1.1721; WIEDERRECHT G, 1993, ANN NY ACAD SCI, V696, P9, DOI 10.1111/j.1749-6632.1993.tb17137.x	29	391	410	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1690	1693		10.1126/science.281.5383.1690	http://dx.doi.org/10.1126/science.281.5383.1690			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733519				2022-12-28	WOS:000075856500052
J	Wang, CY; Mayo, MW; Korneluk, RG; Goeddel, DV; Baldwin, AS				Wang, CY; Mayo, MW; Korneluk, RG; Goeddel, DV; Baldwin, AS			NF-kappa B antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation	SCIENCE			English	Article							INDUCED CELL-DEATH; RECEPTOR-1 SIGNALING COMPLEX; INDUCED APOPTOSIS; CYTOCHROME-C; POLY(ADP-RIBOSE) POLYMERASE; CAENORHABDITIS-ELEGANS; ALPHA PROTEOLYSIS; CD95 FAS/APO-1; KINASE COMPLEX; PROTEIN	Tumor necrosis factor alpha (TNF-alpha) binding to the TNF receptor (TNFR) potentially initiates apoptosis and activates the transcription factor nuclear factor kappa B (NF-kappa B), which suppresses apoptosis by an unknown mechanism. The activation of NF-kappa B was found to block the activation of caspase-8. TRAF1 (TNFR-associated factor 1), TRAF2, and the inhibitor-of-apoptosis (IAP) proteins c-IAP1 and c-IAP2 were identified as gene targets of NF-kappa B transcriptional activity. in cells in which NF-kappa B was inactive, all of these proteins were required to fully suppress TNF-induced apoptosis, whereas c-IAP1 and c-IAP2 were sufficient to suppress etoposide-induced apoptosis. Thus, NF-kappa B activates a group of gene products that function cooperatively at the earliest checkpoint to suppress TNF-alpha-mediated apoptosis and that function more distally to suppress genotoxic agent-mediated apoptosis.	Univ N Carolina, Sch Dent, Lineberger Comprehens Canc Ctr, Dept Endodont, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Childrens Hosp Eastern Ontario, Mol Genet Res Lab, Ottawa, ON K1H 8M5, Canada; Tularik, S San Francisco, CA 94080 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Ottawa; Children's Hospital of Eastern Ontario; University of North Carolina; University of North Carolina Chapel Hill	Wang, CY (corresponding author), Univ N Carolina, Sch Dent, Lineberger Comprehens Canc Ctr, Dept Endodont, Chapel Hill, NC 27599 USA.				NCI NIH HHS [CA 75080, CA73756] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073756, R01CA075080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1998, MOL CELL, V1, P782; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1997, CELL, V88, P335; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Speiser DE, 1997, J EXP MED, V185, P1777, DOI 10.1084/jem.185.10.1777; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang C.-W., UNPUB; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wu BY, 1997, J VIROL, V71, P3161, DOI 10.1128/JVI.71.4.3161-3167.1997; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	58	2445	2571	0	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1680	1683		10.1126/science.281.5383.1680	http://dx.doi.org/10.1126/science.281.5383.1680			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733516	Green Submitted			2022-12-28	WOS:000075856500049
J	Miles, SH				Miles, SH			A challenge to licensing boards: The stigma of mental illness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		COLEMAN R, 1994, J LEGISLATION, V20, P145; Miles S, 1997, Minn Med, V80, P42; 1997, MINN MED, V80, P6; 1984, AM J PSYCHIAT, V141, P331	4	23	23	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1998	280	10					865	865		10.1001/jama.280.10.865	http://dx.doi.org/10.1001/jama.280.10.865			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	115LN	9739951				2022-12-28	WOS:000075666600001
J	Giovannucci, E				Giovannucci, E			Selenium and risk of prostate cancer	LANCET			English	Editorial Material							SERUM		Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Giovannucci, E (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA.							Clark LC, 1998, BRIT J UROL, V81, P730; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; COMSTOCK GW, 1992, AM J EPIDEMIOL, V135, P115, DOI 10.1093/oxfordjournals.aje.a116264; GRIFFIN AC, 1982, MOL INTERRELATIONS N, P401; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Longnecker MP, 1996, EPIDEMIOLOGY, V7, P384, DOI 10.1097/00001648-199607000-00008; MAJEED FA, 1994, BRIT J UROL, V73, P377, DOI 10.1111/j.1464-410X.1994.tb07600.x; Rayman MP, 1997, BRIT MED J, V314, P387, DOI 10.1136/bmj.314.7078.387; SHAMBERGER RJ, 1969, CAN MED ASSOC J, V100, P682; Yoshizawa K, 1998, JNCI-J NATL CANCER I, V90, P1219, DOI 10.1093/jnci/90.16.1219	10	27	27	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 5	1998	352	9130					755	756		10.1016/S0140-6736(05)60674-5	http://dx.doi.org/10.1016/S0140-6736(05)60674-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737275				2022-12-28	WOS:000075762700004
J	Wolf, F; Geisel, T				Wolf, F; Geisel, T			Spontaneous pinwheel annihilation during visual development	NATURE			English	Article							OCULAR DOMINANCE COLUMNS; ORIENTATION SELECTIVITY; STRIATE CORTEX; MAPS; ORGANIZATION; ARRANGEMENT; PREFERENCE; DOMAINS; MODELS	Neurons in the visual cortex respond preferentially to edge-like stimuli of a particular orientation(1). It is a long-standing hypothesis that orientation selectivity arises during development through the activity-dependent refinement of cortical circuitry(2-4). Unambiguous evidence far such a process has, however, remained elusive(5-7). Here we argue that, if orientation preferences arise through activity-dependent refinement of initially unselective patterns of synaptic connections, this process should leave distinct signatures in the emerging spatial pattern of preferred orientations. Preferred orientations typically change smoothly and progressively across the cortex(1). This smooth progression is disrupted at the centres of so-called pinwheels(8,9), where neurons exhibiting the whole range of orientation preferences are located in close vicinity(10). Assuming that orientation selectivity develops through a set of rules that we do not specify, we demonstrate mathematically that the spatial density of pinwheels is rigidly constrained by basic symmetry principles. In particular, the spatial density of pinwheels, which emerge when orientation selectivity is first established, is larger than a model-independent minimal value. As a consequence, lower densities, if observed in adult animals, are predicted to develop through the motion and annihilation of pinwheel pairs.	Max Planck Inst Stromungsforsch, D-37018 Gottingen, Germany; Univ Frankfurt, SFB Nichtlineare Dynam, D-6000 Frankfurt, Germany	Max Planck Society; Goethe University Frankfurt	Wolf, F (corresponding author), Max Planck Inst Stromungsforsch, Postfach 2853, D-37018 Gottingen, Germany.		Wolf, Fred/D-5771-2011	Wolf, Fred/0000-0002-7068-3762				ALBUS K, 1984, J PHYSIOL-LONDON, V348, P153, DOI 10.1113/jphysiol.1984.sp015104; [Anonymous], 1995, TURBULENCE; BOCK GR, 1995, DEV CEREBRAL CORTEX; BONHOEFFER T, 1995, EUR J NEUROSCI, V7, P1973, DOI 10.1111/j.1460-9568.1995.tb00720.x; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Bosking WH, 1997, J NEUROSCI, V17, P2112; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; Chapman B, 1996, J NEUROSCI, V16, P6443; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; DURBIN R, 1990, NATURE, V343, P644, DOI 10.1038/343644a0; ERWIN E, 1995, NEURAL COMPUT, V7, P425, DOI 10.1162/neco.1995.7.3.425; GERMAN S, 1997, SIAM J APPL MATH, V36, P86; Godecke I, 1996, NATURE, V379, P251, DOI 10.1038/379251a0; Halperin B., 1981, PHYSICS DEFECTS, P813; Horton JC, 1996, J NEUROSCI, V16, P5510; Hubel DH, 1962, J PHYSL, V160, P215; LEVAY S, 1991, VISION VISUAL DYSFUN, P266; LOWEL S, 1987, J COMP NEUROL, V255, P401, DOI 10.1002/cne.902550307; Maldonado PE, 1997, SCIENCE, V276, P1551, DOI 10.1126/science.276.5318.1551; Miller AB, 1996, J PUBLIC HEALTH POL, V17, P367, DOI 10.2307/3343273; MILLER KD, 1994, J NEUROSCI, V14, P409; MOVSHON JA, 1981, ANNU REV PSYCHOL, V32, P447; NIEBUR E, 1994, NEURAL COMPUT, V6, P602, DOI 10.1162/neco.1994.6.4.602; Obermayer K, 1997, NEURAL COMPUT, V9, P555, DOI 10.1162/neco.1997.9.3.555; Rao SC, 1997, J COMP NEUROL, V387, P358; Renyi A., 1970, PROBABILITY THEORY; Sompolinsky H, 1997, CURR OPIN NEUROBIOL, V7, P514, DOI 10.1016/S0959-4388(97)80031-1; Swindale NV, 1996, NETWORK-COMP NEURAL, V7, P161, DOI 10.1088/0954-898X/7/2/002; SWINDALE NV, 1987, J NEUROSCI, V7, P1414; von der Malsburg C, 1973, Kybernetik, V14, P85	30	83	83	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1998	395	6697					73	78		10.1038/25736	http://dx.doi.org/10.1038/25736			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116JY	9738500				2022-12-28	WOS:000075722200049
J	Ayres, JG; Frost, CD; Holmes, WF; Williams, DRR; Ward, SM				Ayres, JG; Frost, CD; Holmes, WF; Williams, DRR; Ward, SM			Postmarketing surveillance study of a non-chlorofluorocarbon inhaler according to the safety assessment of marketed medicines guidelines	BRITISH MEDICAL JOURNAL			English	Article							METERED-DOSE INHALER; ASTHMA	Objective To evaluate the safety of a non-chlorofluorocarbon metered dose salbutamol inhaler. Design This was a postmarketing surveillance study, conducted under formal guidelines for company sponsored safety assessment of marketed medicines (SAMM). A non-randomised, non-interventional, observational design compared patients prescribed metered doses of salbutamol delivered by inhalers using either hydrofluoroalkane or chlorofluorocarbon as the propellant. Follow up was three months. Setting 646 general practices throughout the United Kingdom. Subjects 6614 patients with obstructive airways disease (1667 patient years of exposure). Main outcome measures Proportions of patients who were: admitted to hospital for respiratory diseases, reported adverse side effects, or withdrew because of adverse affects. Results There were no significant differences between the hydrofluoroalkane (HFA 134a) and chlorofluorocarbon inhaler groups in relation to the proportions of patients admitted to hospital for respiratory diseases (odds ratio 0.75; 95% confidence interval 0.51 to 1.08) or the proportions who reported adverse events (1.01; 0.88 to 1.17). However, more patients using the hydrofluoroalkane inhaler than the chlorofluorocarbon inhaler withdrew because of adverse events (3.8% and 0.9% respectively). Conclusion The hydrofluoroalkane inhaler was as safe as the chlorofluorocarbon inhaler when judged by hospital admissions and adverse affects. The study design successfully fulfilled the recommendations of the guidelines. Differences between postmarketing surveillance studies and randomised clinical trials in assessing safety were identified. These may lead to difficulties in the design of postmarketing surveillance studies.	Birmingham Heartlands Hosp, Dept Resp Med, Birmingham B9 5SS, W Midlands, England; Univ London London Sch Hyg & Trop Med, Med Stat Unit, London WC1 7HT, England; Sherrington Pk Med Practice, Nottingham NG5 2EJ, England; Nuffield Inst Hlth, Div Publ Hlth, Leeds LS2 9PL, W Yorkshire, England; 3M Hlth Care, Loughborough LE1 11EP, Leics, England	Heart of England NHS Foundation Trust; University of Birmingham; University of London; London School of Hygiene & Tropical Medicine; University of Leeds; 3M	Ayres, JG (corresponding author), Birmingham Heartlands Hosp, Dept Resp Med, Birmingham B9 5SS, W Midlands, England.							*ASS BRIT PHARM IN, 1996, ABPI COMP DAT SHEETS; Bleecker ER, 1998, CHEST, V113, P283, DOI 10.1378/chest.113.2.283; DOCKHORN R, 1995, J ALLERGY CLIN IMMUN, V96, P50, DOI 10.1016/S0091-6749(95)70032-3; *EUR AG EV MED PRO, 1995, CPMP18095 EAEMP; Kleerup EC, 1996, CHEST, V109, P702, DOI 10.1378/chest.109.3.702; RAWLINS MD, 1991, BRIT MED J, V302, P223, DOI 10.1136/bmj.302.6770.223; Tinkelman DC, 1998, CHEST, V113, P290, DOI 10.1378/chest.113.2.290; WALLER PC, 1992, BRIT MED J, V304, P1470, DOI 10.1136/bmj.304.6840.1470; WELLS F, 1988, BRIT MED J, V296, P399	9	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					926	930						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756813				2022-12-28	WOS:000076409000027
J	[Anonymous]				[Anonymous]			BMA and health minister will discuss review body remit	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 3	1998	317	7163					954	954						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756834				2022-12-28	WOS:000076409000079
J	Chen, J; Hamon, MA; Hu, H; Chen, YS; Rao, AM; Eklund, PC; Haddon, RC				Chen, J; Hamon, MA; Hu, H; Chen, YS; Rao, AM; Eklund, PC; Haddon, RC			Solution properties of single-walled carbon nanotubes	SCIENCE			English	Article							RAMAN-SCATTERING; ALLOTROPES; BUNDLES	Naked metallic and semiconducting single-walled carbon nanotubes (SWNTs) were dissolved in organic solutions by derivatization with thionychloride and octadecylamine. Both ionic (charge transfer) and covalent solution-phase chemistry with concomitant modulation of the SWNT band structure were demonstrated. Solution-phase near-infrared spectroscopy was used to study the effects of chemical modifications on the band gaps of the SWNTs. Reaction of soluble SWNTs with dichlorocarbene led to functionalization of the nanotube walls.	Univ Kentucky, Dept Chem, Ctr Appl Energy Res, Lexington, KY 40506 USA; Univ Kentucky, Dept Phys, Ctr Appl Energy Res, Lexington, KY 40506 USA; Univ Kentucky, Adv Carbon Mat Ctr, Lexington, KY 40506 USA	University of Kentucky; University of Kentucky; University of Kentucky	Haddon, RC (corresponding author), Univ Kentucky, Dept Chem, Ctr Appl Energy Res, Lexington, KY 40506 USA.		Haddon, Robert C/A-2528-2008; Chen, Jian/A-5486-2008; Chen, Yongsheng/D-3256-2011	Haddon, Robert C/0000-0002-7903-5139; Chen, Yongsheng/0000-0003-1448-8177				Bandow S, 1998, PHYS REV LETT, V80, P3779, DOI 10.1103/PhysRevLett.80.3779; Chen Y, 1998, J MATER RES, V13, P2423, DOI 10.1557/JMR.1998.0337; Crespi VH, 1997, PHYS REV LETT, V79, P2093, DOI 10.1103/PhysRevLett.79.2093; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; Grigorian L, 1998, PHYS REV LETT, V80, P5560, DOI 10.1103/PhysRevLett.80.5560; Haddon RC, 1997, NATURE, V388, P31, DOI 10.1038/40302; HADDON RC, 1995, NATURE, V378, P249, DOI 10.1038/378249a0; HADDON RC, 1987, J ORG CHEM, V52, P711, DOI 10.1021/jo00380a052; Journet C, 1997, NATURE, V388, P756, DOI 10.1038/41972; Lee RS, 1997, NATURE, V388, P255, DOI 10.1038/40822; Liu J, 1998, SCIENCE, V280, P1253, DOI 10.1126/science.280.5367.1253; Odom TW, 1998, NATURE, V391, P62, DOI 10.1038/34145; Osterodt J, 1996, CHEM COMMUN, P547, DOI 10.1039/cc9960000547; Pichler T, 1998, PHYS REV LETT, V80, P4729, DOI 10.1103/PhysRevLett.80.4729; PREDA DV, 1998, CHEM ENG NEWS, V46, P46; Rao AM, 1997, NATURE, V388, P257, DOI 10.1038/40827; Rao AM, 1997, SCIENCE, V275, P187, DOI 10.1126/science.275.5297.187; SEYFERTH D, 1972, ACCOUNTS CHEM RES, V5, P65, DOI 10.1021/ar50050a004; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; TSUDA M, 1993, TETRAHEDRON LETT, V34, P6911, DOI 10.1016/S0040-4039(00)91828-8; Wildoer JWG, 1998, NATURE, V391, P59, DOI 10.1038/34139; Yakobson BI, 1997, AM SCI, V85, P324	22	2441	2630	10	725	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 2	1998	282	5386					95	98		10.1126/science.282.5386.95	http://dx.doi.org/10.1126/science.282.5386.95			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756485				2022-12-28	WOS:000076294900045
J	Lyons, WA; Nelson, TE; Williams, ER; Cramer, JA; Turner, TR				Lyons, WA; Nelson, TE; Williams, ER; Cramer, JA; Turner, TR			Enhanced positive cloud-to-ground lightning in thunderstorms ingesting smoke from fires	SCIENCE			English	Article							AMAZON RIVER; ELECTRIFICATION; MICROPHYSICS; DISCHARGE; SPRITES; FLASHES; DENSITY; STORMS; RIME	Smoke from forest fires in southern Mexico was advected into the U.S. southern plains from April to lune 1998. Cloud-to-ground lightning (CG) flash data from the National Lightning Detection Network matched against satellite-mapped aerosol plumes imply that thunderstorms forming in smoke-contaminated air masses generated Large amounts of Lightning with positive polarity (+CGs). During 2 months, nearly half a million flashes in the southern plains exhibited +CG percentages that were triple the climatological norm. The peak currents in these +CGs were double the expected value. These thunderstorms also produced abnormally high numbers of mesospheric optical sprites.	FMA Res Inc, Yucca Ridge Field Stn, Ft Collins, CO 80524 USA; MIT, Ralph M Parsons Lab, Cambridge, MA 02139 USA; Global Atmospher Inc, Tucson, AZ 85706 USA	Massachusetts Institute of Technology (MIT)	Lyons, WA (corresponding author), FMA Res Inc, Yucca Ridge Field Stn, Ft Collins, CO 80524 USA.							BOCCIPPIO DJ, 1995, SCIENCE, V269, P1088, DOI 10.1126/science.269.5227.1088; Brooks IM, 1997, ATMOS RES, V43, P277, DOI 10.1016/S0169-8095(96)00043-9; Cerveny RS, 1998, NATURE, V394, P561, DOI 10.1038/29043; Cummins KL, 1998, J GEOPHYS RES-ATMOS, V103, P9035, DOI 10.1029/98JD00153; CUMMINS KL, COMMUNICATION; FRANZ RC, 1990, SCIENCE, V249, P48, DOI 10.1126/science.249.4964.48; Hobbs P.V., 1969, J APPL METEOR, V8, P833, DOI [10.1175/1520-0450(1969)0082.0.CO;2, DOI 10.1175/1520-0450(1969)0082.0.CO;2, DOI 10.1175/1520-0450(1969)008<0833:INFANF>2.0.CO;2]; HOBBS PV, 1969, SCIENCE, V163, P279, DOI 10.1126/science.163.3864.279; HOLLE RL, 1993, NSSL102 NOAA; ISRAELSSON S, 1987, J GEOPHYS RES-ATMOS, V92, P10996, DOI 10.1029/JD092iD09p10996; JAYARATNE ER, 1985, J GEOPHYS RES-ATMOS, V90, P3063, DOI 10.1029/JD090iD07p13063; KAUFMAN YJ, 1993, J APPL METEOROL, V32, P729, DOI [10.1175/1520-0450(1993)032<0729:EOASOC>2.0.CO;2, 10.1175/1520-0450(1993)032&lt;0729:EOASOC&gt;2.0.CO;2]; LATHAM D, 1991, J GEOPHYS RES-ATMOS, V96, P17151, DOI 10.1029/91JD01808; LYONS WA, 1986, J CLIM APPL METEOROL, V25, P1518, DOI 10.1175/1520-0450(1986)025<1518:TIOMCS>2.0.CO;2; Lyons WA, 1996, J GEOPHYS RES-ATMOS, V101, P29641, DOI 10.1029/96JD01866; Lyons WA, 1998, MON WEATHER REV, V126, P2217, DOI 10.1175/1520-0493(1998)126<2217:LPCCTG>2.0.CO;2; LYONS WA, 1994, GEOPHYS RES LETT, V21, P875, DOI 10.1029/94GL00560; MACGORMAN DR, 1994, MON WEATHER REV, V122, P1671, DOI 10.1175/1520-0493(1994)122<1671:PCTGLI>2.0.CO;2; Maddox RA, 1997, J APPL METEOROL, V36, P302, DOI 10.1175/1520-0450(1997)036<0302:ICSWLO>2.0.CO;2; MOORE CB, 1986, SCIENCE, V233, P1413, DOI 10.1126/science.233.4771.1413; MOORE CB, 1989, J GEOPHYS RES-ATMOS, V94, P13127, DOI 10.1029/JD094iD11p13127; Orville RE, 1997, MON WEATHER REV, V125, P631, DOI 10.1175/1520-0493(1997)125<0631:LGFDIT>2.0.CO;2; Pueschel R. F., 1973, J APPL METEOROL, V12, P549, DOI DOI 10.1175/1520-0450(1973)012<0549:SCFAAS>2.0.CO;2; RICHEY JE, 1989, SCIENCE, V246, P101, DOI 10.1126/science.246.4926.101; SENTMAN DD, 1995, GEOPHYS RES LETT, V22, P1205, DOI 10.1029/95GL00583; STERNBERG HO, 1987, GEOGR ANN A, V69, P201, DOI 10.2307/521378; STOLZENBURG M, 1994, MON WEATHER REV, V122, P1740, DOI 10.1175/1520-0493(1994)122<1740:OOHGFD>2.0.CO;2; VONNEGUT B, 1995, J GEOPHYS RES-ATMOS, V100, P5037, DOI 10.1029/94JD02956; WESTCOTT NE, 1995, J APPL METEOROL, V34, P1633, DOI 10.1175/1520-0450-34.7.1633; Williams ER, 1996, J GEOPHYS RES-ATMOS, V101, P29715, DOI 10.1029/96JD03216; WILLIAMS ER, 1995, J GEOPHYS RES-ATMOS, V100, P1503, DOI 10.1029/94JD01103	31	145	150	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 2	1998	282	5386					77	80		10.1126/science.282.5386.77	http://dx.doi.org/10.1126/science.282.5386.77			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756479				2022-12-28	WOS:000076294900039
J	Glorieux, FH; Bishop, NJ; Plotkin, H; Chabot, G; Lanoue, G; Travers, R				Glorieux, FH; Bishop, NJ; Plotkin, H; Chabot, G; Lanoue, G; Travers, R			Cyclic administration of pamidronate in children with severe osteogenesis imperfecta	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENOUS PAMIDRONATE; BONE; BISPHOSPHONATES; DENSITY	Background Severe osteogenesis imperfecta is a disorder characterized by osteopenia, frequent fractures, progressive deformity, loss of mobility, and chronic bone pain. There is no effective therapy for the disorder. We assessed the effects of treatment with a bisphosphonate on bone resorption. Methods In an uncontrolled observational study involving 30 children who were 3 to 16 years old and had severe osteogenesis imperfecta, we administered pamidronate intravenously (mean [+/-SD] close, 6.8+/-1.1 mg per kilogram of body weight per year) at 4-to-6-month intervals for 1.3 to 5.0 years. Clinical status, biochemical characteristics reflecting bone turnover, the bone mineral density of the lumbar spine, and radiologic changes were assessed regularly during treatment. Results Administration of pamidronate resulted in sustained reductions in serum alkaline phosphatase concentrations and in the urinary excretion of calcium and type I collagen N-telopeptide. There was a mean annualized increase of 41.9+/-29.0 percent in bone mineral density, and the deviation of bone mineral density from normal, as indicated by the z score, improved from -5.3+/-1.2 to -3.4+/-1.5. The cortical width of the metacarpals increased by 27.0+/-20.2 percent per year. The increases in the size of the vertebral bodies suggested that new bone had formed. The mean incidence of radiologically confirmed fractures decreased by 1.7 per year (P<0.001). Treatment with pamidronate did not alter the rate of fracture healing, the growth rate, or the appearance of the growth plates. Mobility and ambulation improved in 16 children and remained unchanged in the other 14. AII the children reported substantial relief of chronic pain and fatigue. Conclusions In children with severe osteogenesis imperfecta, cyclic administration of intravenous pamidronate improved clinical outcomes, reduced bone resorption, and increased bone density. (N Engl J Med 1998;339:947-52.) (C)1998, Massachusetts Medical Society.	Shriners Hosp Crippled Children, Genet Unit, Montreal, PQ H3G 1A6, Canada; McGill Univ, Dept Surg, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada	McGill University; McGill University; McGill University	Glorieux, FH (corresponding author), Shriners Hosp Crippled Children, Genet Unit, 1529 Cedar Ave, Montreal, PQ H3G 1A6, Canada.							Adami S, 1996, DRUG SAFETY, V14, P158, DOI 10.2165/00002018-199614030-00003; ALBRIGHT JA, 1971, J BONE JOINT SURG AM, VA 53, P1415, DOI 10.2106/00004623-197153070-00020; BARON R, 1983, PEDIATR RES, V17, P204, DOI 10.1203/00006450-198303000-00007; Bembi B, 1997, J PEDIATR-US, V131, P622, DOI 10.1016/S0022-3476(97)70074-X; BLECK EE, 1981, CLIN ORTHOP RELAT R, V159, P111; BRENNER RE, 1994, J BONE MINER RES, V9, P993; Brumsen C, 1997, MEDICINE, V76, P266, DOI 10.1097/00005792-199707000-00005; CASTELLS S, 1973, CLIN ORTHOP RELAT R, V93, P239; CATTELL HS, 1968, J BONE JOINT SURG AM, VA 50, P123, DOI 10.2106/00004623-196850010-00008; DAVIE MWJ, 1994, ARCH DIS CHILD, V70, P331, DOI 10.1136/adc.70.4.331; DEVOGELAER JP, 1987, SKELETAL RADIOL, V16, P360, DOI 10.1007/BF00350961; FROST HM, 1988, CALCIFIED TISSUE INT, V42, P145, DOI 10.1007/BF02556327; Garn SM, 1976, P 1 WORKSH BON MORPH, P367; GLORIEUX FH, 1997, J BONE MINER RES  S1, V12, pS389; GLORIEUX FH, 1994, J BONE MINER RES  S1, V9, pS226; Greulich WW., 1959, CALIF MED, V91, P53; HARINCK HIJ, 1987, CLIN ORTHOP RELAT R, P79; HUAUX JP, 1988, J PEDIATR ORTHOPED, V8, P71, DOI 10.1097/01241398-198801000-00017; LIENS D, 1994, LANCET, V343, P953, DOI 10.1016/S0140-6736(94)90069-8; OLIVERI M B, 1991, Henry Ford Hospital Medical Journal, V39, P45; PEDERSEN U, 1985, ACTA ORTHOP SCAND, V56, P260, DOI 10.3109/17453678508993009; Plotkin H, 1996, CALCIFIED TISSUE INT, V58, P144, DOI 10.1007/s002239900025; Reinus WR, 1998, CALCIFIED TISSUE INT, V62, P17, DOI 10.1007/s002239900387; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; SYKES B, 1990, AM J HUM GENET, V46, P293; UNDERWOOD LE, 1992, WILLIAMS TXB ENDOCRI, P1079; VETTER U, 1992, CALCIFIED TISSUE INT, V50, P36, DOI 10.1007/BF00297295; WIMALAWANSA SJ, 1993, CALCIFIED TISSUE INT, V53, P237, DOI 10.1007/BF01320908	28	656	684	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1998	339	14					947	952		10.1056/NEJM199810013391402	http://dx.doi.org/10.1056/NEJM199810013391402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124MW	9753709	Bronze			2022-12-28	WOS:000076186900002
J	Partridge, L; Hurst, LD				Partridge, L; Hurst, LD			Sex and conflict	SCIENCE			English	Review						a	CYTOPLASMIC MALE-STERILITY; FEMALE DROSOPHILA-MELANOGASTER; PLANTAGO-LANCEOLATA L; MEIOTIC DRIVE; POSITIVE SELECTION; TRANSPOSABLE ELEMENTS; MOLECULAR EVOLUTION; GENETIC INCOMPATIBILITY; SEGREGATION DISTORTERS; REPRODUCTIVE-BEHAVIOR	Evolutionary conflict occurs when the deterministic spread of an allele lowers the fitness either of its bearer or of other individuals in the population, Leading to selection for suppressors. Sex promotes conflict because associations between alleles are temporary. Differing selection on males and females, sexual selection, and differences in transmission patterns between classes of nuclear and cytoplasmic genes can all give rise to conflict. Inert Y chromosomes, uniparental inheritance of cytoplasmic genes, mating strains and sexes. and many features of sexual behavior may have evolved in part as a result of evolutionary conflict. Estimates of its quantitative importance, however, are still needed.	Univ London Univ Coll, Galton Lab, Dept Biol, London NW1 2HE, England; Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	University of London; University College London; University of Bath	Partridge, L (corresponding author), Univ London Univ Coll, Galton Lab, Dept Biol, London NW1 2HE, England.		Partridge, Linda/E-7342-2015; Partridge, Linda/A-5501-2010; Hurst, Laurence/F-9215-2010	Partridge, Linda/0000-0001-9615-0094; Hurst, Laurence/0000-0002-1002-1054				AIGAKI T, 1991, NEURON, V7, P557, DOI 10.1016/0896-6273(91)90368-A; ALATALO RV, 1981, AM NAT, V117, P738, DOI 10.1086/283756; Atlan A, 1997, EVOLUTION, V51, P1886, DOI 10.1111/j.1558-5646.1997.tb05111.x; Badge RM, 1997, J THEOR BIOL, V187, P261, DOI 10.1006/jtbi.1997.0432; BATEMAN AJ, 1948, HEREDITY, V2, P349, DOI 10.1038/hdy.1948.21; Bird A, 1997, TRENDS GENET, V13, P469, DOI 10.1016/S0168-9525(97)01310-3; BIRKY CW, 1995, P NATL ACAD SCI USA, V92, P11331, DOI 10.1073/pnas.92.25.11331; Brookfield JFY, 1997, GENETICA, V100, P281, DOI 10.1023/A:1018310418744; BROOKS LD, 1988, EVOLUTION SEX; BRUCK D, 1957, P NATL ACAD SCI USA, V43, P152, DOI 10.1073/pnas.43.1.152; Bull J.J., 1983, EVOLUTION SEX DETERM; BULMER MG, 1986, EVOLUTIONARY PROCESS, P743; Burt A, 1998, P ROY SOC B-BIOL SCI, V265, P141, DOI 10.1098/rspb.1998.0275; BURT AS, UNPUB; Chapman T, 1996, P ROY SOC B-BIOL SCI, V263, P755, DOI 10.1098/rspb.1996.0113; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; CHARLESWORTH B, 1978, GENETICS, V89, P171; CHARLESWORTH B, 1978, AM NAT, V112, P975, DOI 10.1086/283342; CHARLESWORTH B, 1991, GENET RES, V57, P127, DOI 10.1017/S0016672300029190; CHARLESWORTH B, 1994, GENET RES, V64, P183, DOI 10.1017/S0016672300032845; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; CHARLESWORTH B, 1994, P ROY SOC B-BIOL SCI, V258, P101, DOI 10.1098/rspb.1994.0149; CHARLESWORTH B, 1978, P NATL ACAD SCI USA, V75, P5618, DOI 10.1073/pnas.75.11.5618; CHEN PS, 1988, CELL, V54, P291, DOI 10.1016/0092-8674(88)90192-4; CLARK AG, 1995, GENETICS, V139, P189; CLARKWALKER GD, 1992, INT REV CYTOL, V141, P89, DOI 10.1016/S0074-7696(08)62064-1; CLUTTONBROCK TH, 1995, ANIM BEHAV, V49, P1345, DOI 10.1006/anbe.1995.0166; CluttonBrock TH, 1997, PHILOS T R SOC B, V352, P839, DOI 10.1098/rstb.1997.0064; CLUTTONBROCK TH, 1992, BEHAV ECOL, V3, P234, DOI 10.1093/beheco/3.3.234; CLUTTONBROCK TH, 1995, NATURE, V373, P209, DOI 10.1038/373209a0; Cordts R, 1996, ANIM BEHAV, V52, P269, DOI 10.1006/anbe.1996.0172; COSMIDES LM, 1981, J THEOR BIOL, V89, P83, DOI 10.1016/0022-5193(81)90181-8; Darwin C., 1874, DESCENT MAN SELECTIO; Davies N. B., 1992, DUNNOCK BEHAV SOCIAL; Davies NB, 1996, ANIM BEHAV, V51, P27, DOI 10.1006/anbe.1996.0003; deHaan AA, 1997, GENETICS, V147, P1317; DeHaan AA, 1997, HEREDITY, V79, P453, DOI 10.1038/hdy.1997.184; DELANNAY X, 1978, Naturalistes Belges, V59, P223; Endo T, 1996, MOL BIOL EVOL, V13, P685, DOI 10.1093/oxfordjournals.molbev.a025629; FELDMAN MW, 1991, AM NAT, V137, P443, DOI 10.1086/285176; Fisher R.A., 1930, GENETICAL THEORY NAT; Frank SA, 1996, P ROY SOC B-BIOL SCI, V263, P339, DOI 10.1098/rspb.1996.0052; Frank SA, 1996, NATURE, V383, P224, DOI 10.1038/383224a0; Gershenson S, 1928, GENETICS, V13, P488; GOODENOUGH UW, 1995, ANNU REV PLANT PHYS, V46, P21; Goodrich J, 1998, CURR BIOL, V8, pR480, DOI 10.1016/S0960-9822(98)70312-4; Guttman DS, 1998, NATURE, V393, P263, DOI 10.1038/30492; HAIG D, 1991, CELL, V64, P1045; HAIG D, 1989, AM NAT, V134, P147, DOI 10.1086/284971; Haldane JB., 1990, CAUSES EVOLUTION; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; HARDY RW, 1984, GENETICS, V107, P591; HARTL DL, 1972, THEOR APPL GENET, V42, P81, DOI 10.1007/BF00277948; HARTL DL, 1975, THEOR POPUL BIOL, V7, P168, DOI 10.1016/0040-5809(75)90012-X; HASTINGS IM, 1992, GENET RES, V59, P215, DOI 10.1017/S0016672300030500; HERNDON LA, 1995, P NATL ACAD SCI USA, V92, P10114, DOI 10.1073/pnas.92.22.10114; HICKEY DA, 1982, GENETICS, V101, P519; Hoekstra R F, 1987, Experientia Suppl, V55, P59; Hoekstra RF., 1990, ORG CONSTRAINTS DYNA; Holland B, 1998, EVOLUTION, V52, P1, DOI 10.1111/j.1558-5646.1998.tb05132.x; HOUDE AE, 1992, HEREDITY, V69, P229, DOI 10.1038/hdy.1992.120; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; Hughes AL, 1997, BIOESSAYS, V19, P777, DOI 10.1002/bies.950190907; Hughes AL, 1997, MOL BIOL EVOL, V14, P1, DOI 10.1093/oxfordjournals.molbev.a025694; HUGHES AL, 1992, MOL BIOL EVOL, V9, P381; HUGHES AL, 1990, MOL BIOL EVOL, V7, P515; Hurst CDD, 1997, INFLUENTIAL PASSENGERS, P125; Hurst GDD, 1998, HEREDITY, V80, P2, DOI 10.1046/j.1365-2540.1998.00337.x; Hurst LD, 1997, TRENDS GENET, V13, P436, DOI 10.1016/S0168-9525(97)01273-0; Hurst LD, 1996, TRENDS ECOL EVOL, V11, P310; HURST LD, 1991, GENETICS, V128, P841; HURST LD, 1993, BIOL REV, V68, P121, DOI 10.1111/j.1469-185X.1993.tb00733.x; HURST LD, 1992, P ROY SOC B-BIOL SCI, V247, P189, DOI 10.1098/rspb.1992.0027; HURST LD, 1992, GENETICS, V130, P229; Hurst LD, 1996, GENETICS, V142, P641; HURST LD, 1994, NATURE, V368, P811, DOI 10.1038/368811a0; Hurst LD, 1996, Q REV BIOL, V71, P317, DOI 10.1086/419442; HURST LD, 1995, PHILOS T R SOC B, V349, P321, DOI 10.1098/rstb.1995.0120; HURST LD, 1990, J THEOR BIOL, V144, P429, DOI 10.1016/S0022-5193(05)80085-2; Hurst LD, 1996, P ROY SOC B-BIOL SCI, V263, P415, DOI 10.1098/rspb.1996.0063; HURST LD, 1994, P ROY SOC B-BIOL SCI, V258, P287, DOI 10.1098/rspb.1994.0175; HURST LD, IN PRESS CURR OPIN G; HUTSON V, 1993, P ROY SOC B-BIOL SCI, V253, P43, DOI 10.1098/rspb.1993.0080; IWASA Y, 1987, EVOLUTION, V41, P49, DOI 10.1111/j.1558-5646.1987.tb05770.x; JAMES AC, 1992, ANIM BEHAV, V44, P168, DOI 10.1016/S0003-3472(05)80767-5; Jones RN, 1982, B CHROMOSOMES; KNOWLTON N, 1979, NATURE, V279, P419, DOI 10.1038/279419a0; KNOWLTON N, 1974, J THEOR BIOL, V46, P283, DOI 10.1016/0022-5193(74)90153-2; LANDE R, 1987, SEXUAL SELECTION TES, P83; LAW R, 1984, PROC R SOC SER B-BIO, V221, P53, DOI 10.1098/rspb.1984.0022; LAW R, 1992, P ROY SOC B-BIOL SCI, V248, P69, DOI 10.1098/rspb.1992.0044; LENINGTON S, 1991, ADV STUD BEHAV, V20, P51; LEVIN BR, 1969, AM NAT, V103, P647, DOI 10.1086/282631; Lewis D, 1941, NEW PHYTOL, V40, P158; LEWONTIN RC, 1962, AM NAT, V96, P65, DOI 10.1086/282208; LEWONTIN RC, 1960, GENETICS, V45, P705; LIBERMAN U, 1975, THEOR POPUL BIOL, V7, P127; Lockhart AB, 1996, BIOL REV, V71, P415, DOI 10.1111/j.1469-185X.1996.tb01281.x; LOPEZLEON MD, 1992, EVOLUTION, V46, P529, DOI [10.2307/2409869, 10.1111/j.1558-5646.1992.tb02056.x]; LYTTLE TW, 1991, ANNU REV GENET, V25, P511, DOI 10.1146/annurev.ge.25.120191.002455; Marin I, 1998, SCIENCE, V281, P1990, DOI 10.1126/science.281.5385.1990; MAYNARD SMITH J., 1978, EVOLUTION SEX; McVean GT, 1997, P ROY SOC B-BIOL SCI, V264, P739, DOI 10.1098/rspb.1997.0105; MERCOT H, 1995, J EVOLUTION BIOL, V8, P283, DOI 10.1046/j.1420-9101.1995.8030283.x; MIAO VPW, 1991, MOL GEN GENET, V226, P214, DOI 10.1007/BF00273606; MONEGER F, 1994, EMBO J, V13, P8, DOI 10.1002/j.1460-2075.1994.tb06230.x; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; NAUTA MJ, 1993, GENETICS, V135, P923; NUNNEY L, 1993, EVOLUTION, V47, P1342, DOI 10.1111/j.1558-5646.1993.tb02159.x; NUNNEY L, 1989, EVOLUTION, V43, P245, DOI 10.1111/j.1558-5646.1989.tb04225.x; NUR U, 1985, GENETICS, V110, P73; OSTERGREN G., 1945, Botaniska Notiser, P157; PACKER C, 1982, NATURE, V296, P740, DOI 10.1038/296740a0; PALUMBO G, 1994, GENETICS, V138, P1181; Parker G.A., 1983, P141; PARKER GA, 1972, J THEOR BIOL, V36, P529, DOI 10.1016/0022-5193(72)90007-0; Parker GA, 1998, PHILOS T R SOC B, V353, P261, DOI 10.1098/rstb.1998.0208; PARTRIDGE L, 1981, NATURE, V294, P580, DOI 10.1038/294580a0; POLICANSKY D, 1970, SCIENCE, V169, P888, DOI 10.1126/science.169.3948.888; Poot P, 1997, AM J BOT, V84, P1256, DOI 10.2307/2446050; PRICE GR, 1970, NATURE, V227, P520, DOI 10.1038/227520a0; Queller D. C., 1989, Oxford Surveys in Evolutionary Biology, V6, P73; QUELLER DC, 1994, AM NAT, V144, pS84, DOI 10.1086/285654; RATNIEKS FLW, 1989, NATURE, V342, P796, DOI 10.1038/342796a0; REBOUD X, 1994, HEREDITY, V72, P132, DOI 10.1038/hdy.1994.19; Regev A, 1998, MOL BIOL EVOL, V15, P880, DOI 10.1093/oxfordjournals.molbev.a025992; RICE WR, 1994, SCIENCE, V263, P230, DOI 10.1126/science.8284674; Rice WR, 1998, P NATL ACAD SCI USA, V95, P6217, DOI 10.1073/pnas.95.11.6217; Rice WR, 1997, BEHAV ECOL SOCIOBIOL, V41, P1, DOI 10.1007/s002650050357; RICE WR, 1984, EVOLUTION, V38, P735, DOI 10.1111/j.1558-5646.1984.tb00346.x; RICE WR, 1987, GENETICS, V116, P161; RICE WR, 1987, EVOLUTION, V41, P911, DOI 10.1111/j.1558-5646.1987.tb05864.x; Rice WR, 1996, BIOSCIENCE, V46, P331, DOI 10.2307/1312947; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; Rigaud T, 1997, BIOESSAYS, V19, P409, DOI 10.1002/bies.950190508; ROWE L, 1994, TRENDS ECOL EVOL, V9, P289, DOI 10.1016/0169-5347(94)90032-9; Ryan MJ, 1998, SCIENCE, V281, P1999, DOI 10.1126/science.281.5385.1999; SAUMITOULAPRADE P, 1994, TRENDS ECOL EVOL, V9, P431, DOI 10.1016/0169-5347(94)90126-0; Schnable PS, 1998, TRENDS PLANT SCI, V3, P175, DOI 10.1016/S1360-1385(98)01235-7; SEARS BB, 1980, PLASMID, V4, P233, DOI 10.1016/0147-619X(80)90063-3; Selker EU, 1997, TRENDS GENET, V13, P296, DOI 10.1016/S0168-9525(97)01201-8; SKIBINSKI DOF, 1994, GENETICS, V138, P801; SNIEGOWSKI PD, 1994, GENETICS, V137, P815; STEINEMANN M, 1993, P NATL ACAD SCI USA, V90, P5737, DOI 10.1073/pnas.90.12.5737; Szathmary E, 1995, MAJOR TRANSITIONS EV; Tan Y, 1997, TRENDS ECOL EVOL, V12, P348, DOI 10.1016/S0169-5347(97)01127-0; THOMSON GJ, 1976, THEOR POPUL BIOL, V10, P10, DOI 10.1016/0040-5809(76)90003-4; THOMSON GJ, 1975, THEOR POPUL BIOL, V8, P202, DOI 10.1016/0040-5809(75)90032-5; Tram U, 1998, P NATL ACAD SCI USA, V95, P4051, DOI 10.1073/pnas.95.7.4051; Trivers R. L., 1972, SEXUAL SELECTION DES, P136, DOI DOI 10.1002/AJPA.1330400226; Tsaur SC, 1997, MOL BIOL EVOL, V14, P544, DOI 10.1093/oxfordjournals.molbev.a025791; vanBoven M, 1996, EVOLUTION, V50, P2488, DOI [10.2307/2410715, 10.1111/j.1558-5646.1996.tb03634.x]; VANDAMME JMM, 1983, THESIS U GRONINGEN; WERREN JH, 1987, J THEOR BIOL, V124, P317, DOI 10.1016/S0022-5193(87)80119-4; Wilkinson GS, 1998, NATURE, V391, P276, DOI 10.1038/34640; Winge O, 1927, J GENET, V18, P1, DOI 10.1007/BF03052599; WU CI, 1983, GENETICS, V105, P651; WU CI, 1983, THEOR POPUL BIOL, V24, P107, DOI 10.1016/0040-5809(83)90035-7; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zeh JA, 1997, P ROY SOC B-BIOL SCI, V264, P69, DOI 10.1098/rspb.1997.0010; Zeh JA, 1996, P ROY SOC B-BIOL SCI, V263, P1711, DOI 10.1098/rspb.1996.0250; Zeh JA, 1997, BEHAV ECOL SOCIOBIOL, V40, P111, DOI 10.1007/s002650050323; ZOUROS E, 1994, P NATL ACAD SCI USA, V91, P7463, DOI 10.1073/pnas.91.16.7463; [No title captured]	164	152	157	2	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1998	281	5385					2003	2008		10.1126/science.281.5385.2003	http://dx.doi.org/10.1126/science.281.5385.2003			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748155				2022-12-28	WOS:000076161800049
J	Gordon, PN; Williamson, S; Lawler, PG				Gordon, PN; Williamson, S; Lawler, PG			As seen on TV: observational study of cardiopulmonary resuscitation in British television medical dramas	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PATIENTS PREFERENCES; ELDERLY PATIENTS; SURVIVAL; RELATIVES; DECISION; VIEWS	Objective: To determine the frequency and accuracy with which cardiopulmonary resuscitation is portrayed in British television medical dramas. design: Observational study. Subjects: 64 episodes of three major British television medical dramas: Casualty, Cardiac Arrest, and Medics. Main outcome measures: Frequency of cardiopulmonary resuscitation shown on television; age, sex, and diagnosis of the patients undergoing resuscitation; rate of survival through resuscitation. Results: Overall 52 patients had a cardiorespiratory arrest on screen and 3 had a respiratory arrest alone, all the arrests occurring in 40 of the 64 episodes. Of the 52 patients having cardiorespiratory arrest, 32 (62%) underwent an attempt at cardiopulmonary resuscitation; 8 attempts were successful. Al 3 of the patients having respiratory arrests alone received ventilatory support and survived. On 48% of occasions, victims of cardiac arrest seemed to be less than 35 years old. Conclusions: Cardiorespiratory resuscitation is often depicted in British television medical dramas. Patients portrayed receiving resuscitation are likely to be in a younger age group than in real life. Though the reasons for resuscitation are more varied and more often associated with trauma than in reality, the overall success rate is nevertheless realistic. Widespread overoptimism of patients for survival after resuscitation cannot necessarily be blamed on British television medical dramas.	S Cleveland Hosp, Dept Obstet & Gynaecol, Middlesbrough TS4 3BW, Cleveland, England		Gordon, PN (corresponding author), S Cleveland Hosp, Dept Obstet & Gynaecol, Middlesbrough TS4 3BW, Cleveland, England.	patrickg@globalnet.co.uk						Ballew KA, 1995, RESUSCITATION, V30, P203, DOI 10.1016/0300-9572(95)00894-2; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; Diem SJ, 1996, NEW ENGL J MED, V334, P1578, DOI 10.1056/NEJM199606133342406; EKSTROM L, 1994, RESUSCITATION, V27, P181, DOI 10.1016/0300-9572(94)90031-0; FLORIN D, 1993, J ROY COLL PHYS LOND, V27, P135; HEAP MJ, 1993, ANAESTHESIA, V48, P1027; HILL ME, 1994, BRIT MED J, V308, P1677, DOI 10.1136/bmj.308.6945.1677; JUDE JR, 1961, JAMA-J AM MED ASSOC, V178, P1063, DOI 10.1001/jama.1961.03040500005002; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; LIDDLE J, 1994, J ROY COLL PHYS LOND, V28, P228; Markert RJ, 1996, NEW ENGL J MED, V335, P1605; MEAD GE, 1995, J MED ETHICS, V21, P39, DOI 10.1136/jme.21.1.39; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; SCHONWETTER RS, 1993, J GEN INTERN MED, V8, P295, DOI 10.1007/BF02600139; SCHONWETTER RS, 1991, J AM GERIATR SOC, V39, P372, DOI 10.1111/j.1532-5415.1991.tb02902.x; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; Turow J, 1996, LANCET, V347, P1240, DOI 10.1016/S0140-6736(96)90747-3; Valentin A, 1995, RESUSCITATION, V30, P217, DOI 10.1016/0300-9572(95)00898-5; WAGG A, 1995, J ROY COLL PHYS LOND, V29, P20	21	40	42	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 19	1998	317	7161					780	783		10.1136/bmj.317.7161.780	http://dx.doi.org/10.1136/bmj.317.7161.780			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740563	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000076084200023
J	O'Reilly, D; Steele, K; Merriman, B; Gilliland, D; Brown, S				O'Reilly, D; Steele, K; Merriman, B; Gilliland, D; Brown, S			Effect of fundholding on removing patients from general practitioners' lists: retrospective study	BRITISH MEDICAL JOURNAL			English	Article									Queens Univ Belfast, Hlth & Social Care Res Unit, Belfast BT12 6BJ, Antrim, North Ireland; Queens Univ Belfast, Dept Gen Practice, Belfast, Antrim, North Ireland; Royal Coll Gen Physicians Res Practice, Coleraine BT52 1JB, Londonderry, North Ireland	Queens University Belfast; Queens University Belfast	O'Reilly, D (corresponding author), Queens Univ Belfast, Hlth & Social Care Res Unit, Belfast BT12 6BJ, Antrim, North Ireland.	d.oreilly@qub.ac.uk						DIXON J, 1995, BRIT MED J, V311, P727, DOI 10.1136/bmj.311.7007.727; LAURANCE J, 1996, TIMES           0925, P10; MATSAGANIS M, 1994, J HEALTH ECON, V13, P31, DOI 10.1016/0167-6296(94)90003-5; OREILLY D, IN PRESS BR J GEN PR; SCHEFFLER R, 1989, LANCET, V1, P950	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					785	786		10.1136/bmj.317.7161.785	http://dx.doi.org/10.1136/bmj.317.7161.785			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740566	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000076084200026
J	Chang, HY; Nishitoh, H; Yang, XL; Ichijo, H; Baltimore, D				Chang, HY; Nishitoh, H; Yang, XL; Ichijo, H; Baltimore, D			Activation of apoptosis signal regulating kinase 1 (ASK1) by the adapter protein Daxx	SCIENCE			English	Article							CELL-DEATH; RECEPTOR; CLEAVAGE; SAPK/JNK; PATHWAYS; MAPKKK; MICE	The Fas death receptor can activate the Jun NH2-terminal kinase (JNK) pathway through the receptor-associated protein Daxx. Daxx was found to activate the JNK kinase kinase ASK1, and overexpression of a kinase-deficient ASK1 mutant inhibited Fas- and Daxx-induced apoptosis and JNK activation. Fas activation induced Daxx to interact with ASK1, which consequently relieved an inhibitory intramolecular interaction between the amino- and carboxyl-termini of ASK1, activating its kinase activity. The Daxx-ASK1 connection completes a signaling pathway from a cell surface death receptor to kinase cascades that modulate nuclear transcription factors.	Tokyo Med & Dent Univ, Fac Dent, Dept Biomat Sci, Bunkyo Ku, Tokyo 1138549, Japan; MIT, Dept Biol, Cambridge, MA 02138 USA; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 170, Japan; CALTECH, Pasadena, CA 91125 USA	Tokyo Medical & Dental University (TMDU); Massachusetts Institute of Technology (MIT); Japanese Foundation for Cancer Research; California Institute of Technology	Baltimore, D (corresponding author), Tokyo Med & Dent Univ, Fac Dent, Dept Biomat Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.			Nishitoh, Hideki/0000-0002-8652-4109; Ichijo, Hidenori/0000-0002-5005-6438	NATIONAL CANCER INSTITUTE [R01CA051462] Funding Source: NIH RePORTER; NCI NIH HHS [CA51462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cahill MA, 1996, ONCOGENE, V13, P2087; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tobiume K, 1997, BIOCHEM BIOPH RES CO, V239, P905, DOI 10.1006/bbrc.1997.7580; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	22	503	525	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1860	1863		10.1126/science.281.5384.1860	http://dx.doi.org/10.1126/science.281.5384.1860			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743501				2022-12-28	WOS:000076007100056
J	Beigel, Y; Ostfeld, I; Schoenfeld, N				Beigel, Y; Ostfeld, I; Schoenfeld, N			A leading question	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HERBAL MEDICINE; REMEDIES; INTOXICATION; PREVALENCE		Rabin Med Ctr, Dept Internal Med A, IL-49100 Petah Tiqwa, Israel; Rabin Med Ctr, Porphyria Reference Lab, IL-49100 Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Rabin Medical Center; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Beigel, Y (corresponding author), Rabin Med Ctr, Dept Internal Med A, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.							Abbot NC, 1996, NATURE, V381, P361, DOI 10.1038/381361a0; BAYLY GR, 1995, HUM EXP TOXICOL, V14, P24, DOI 10.1177/096032719501400106; CULLEN MR, 1983, MEDICINE, V62, P221, DOI 10.1097/00005792-198307000-00003; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Kappas A., 1995, METABOLIC MOL BASES, V2, P2103; KEEN RW, 1994, POSTGRAD MED J, V70, P113, DOI 10.1136/pgmj.70.820.113; KEW J, 1993, BRIT MED J, V306, P506, DOI 10.1136/bmj.306.6876.506; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; MARKOWITZ SB, 1994, JAMA-J AM MED ASSOC, V271, P932, DOI 10.1001/jama.271.12.932; MITCHELLHEGGS CAW, 1990, HUM EXP TOXICOL, V9, P195, DOI 10.1177/096032719000900314; PONTIFEX AH, 1985, CAN MED ASSOC J, V133, P1227; SMITHERMAN J, 1991, AM J IND MED, V20, P795, DOI 10.1002/ajim.4700200611; TEFFERI A, 1994, MAYO CLIN PROC, V69, P991, DOI 10.1016/S0025-6196(12)61827-8; WOOLF GM, 1994, ANN INTERN MED, V121, P729, DOI 10.7326/0003-4819-121-10-199411150-00001	14	29	31	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1998	339	12					827	830		10.1056/NEJM199809173391208	http://dx.doi.org/10.1056/NEJM199809173391208			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119QT	9738092				2022-12-28	WOS:000075909200008
J	Herzog, CA; Ma, JZ; Collins, AJ				Herzog, CA; Ma, JZ; Collins, AJ			Poor long-term survival after acute myocardial infarction among patients on long-term dialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MINNESOTA HEART SURVEY; DIABETES-MELLITUS; TRENDS; HEMODIALYSIS; MORBIDITY; MORTALITY	Background Cardiovascular disease is common in patients on long-term dialysis, and it accounts for 44 percent of overall mortality in this group. We undertook a study to assess long-term survival after acute myocardial infarction among patients in the United States who were receiving long-term dialysis, Methods Patients on dialysis who were hospitalized during the period from 1977 to 1995 for a first myocardial infarction after the initiation of renal-replacement therapy were retrospectively identified from the U.S. Renal Data System data base. Overall mortality and mortality from cardiac causes (including all in-hospital deaths) were estimated by the life-table method. The effect of independent predictors on survival was examined in a Cox regression model with adjustment for existing illnesses. Results The overall mortality (+/-SE) after acute myocardial infarction among 34,189 patients on long term dialysis was 59.3+/-0.3 percent at one year, 73.0+/-0.3 percent at two years, and 89.9+/-0.2 percent at five years. The mortality from cardiac causes was 40.8+/-0.3 percent at one year, 51.8+/-0.3 percent at two years, and 70.2+/-0.4 percent at five years. Patients who were older or had diabetes had higher mortality than patients without these characteristics. Adverse outcomes occurred even in patients who had acute myocardial infarction in 1990 through 1995. Also, the mortality rate after myocardial infarction was considerably higher for patients on long-term dialysis than for renal-transplant recipients. Conclusions Patients on dialysis who have acute myocardial infarction have high mortality from cardiac causes and poor long-term survival. (N Engl J Med 1998;339:799-805.) (C) 1998, Massachusetts Medical Society.	Hennepin Cty Med Ctr, Dept Internal Med, Minneapolis, MN 55415 USA; Univ Minnesota, Minneapolis, MN USA	Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities	Herzog, CA (corresponding author), Hennepin Cty Med Ctr, Dept Internal Med, 701 Pk Ave, Minneapolis, MN 55415 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049540] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 RO1 DK 49540] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOEMBERGEN WE, 1994, J AM SOC NEPHROL, V5, P1231; COLLINS AJ, 1990, AM J KIDNEY DIS, V15, P422, DOI 10.1016/S0272-6386(12)70360-8; COX DR, 1972, J R STAT SOC B, V34, P187; DONAHUE RP, 1993, J CLIN EPIDEMIOL, V46, P245, DOI 10.1016/0895-4356(93)90072-9; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; HELD P J, 1991, Journal of the American Society of Nephrology, V2, P328; HERZOG CA, 1997, CIRCULATION S1, V96, P202; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEANE WF, 1994, AM J KIDNEY DIS, V24, P1010, DOI 10.1016/S0272-6386(12)81076-6; KONG TQ, 1993, CIRCULATION, V88, P49; Malacrida R, 1998, NEW ENGL J MED, V338, P8, DOI 10.1056/NEJM199801013380102; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; NICOD P, 1989, CIRCULATION, V79, P528, DOI 10.1161/01.CIR.79.3.528; PUCKETT CD, 1997, ED ANNOTATION ICD9CM, V3; PUCKETT CD, 1997, ED ANNOTATION ICD9CM, V2; PUCKETT CD, 1997, ED ANNOTATION ICD9CM, V1; Rubin Timothy A., 1996, Journal of the American College of Cardiology, V27, p67A; SMITH JW, 1984, AM J CARDIOL, V54, P718, DOI 10.1016/S0002-9149(84)80196-4; SPRAFKA JM, 1991, DIABETES CARE, V14, P537, DOI 10.2337/diacare.14.7.537; *USRDS, 1992, USRDS NIH PUBL, P61; *USRDS, 1997, USRDS NIH PUBL, pD1; *USRDS, 1997, USRDS NIH PUBL, P35; *USRDS, 1997, USRDS NIH PUBL, P21; *USRDS, 1997, USRDS NIH PUBL, pC1; *USRDS, 1997, USRDS NIH PUBL, P69; *USRDS, 1997, USRDS NIH PUBL, P91	28	715	749	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1998	339	12					799	805		10.1056/NEJM199809173391203	http://dx.doi.org/10.1056/NEJM199809173391203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119QT	9738087	Bronze			2022-12-28	WOS:000075909200003
J	Teret, SP; Webster, DW; Vernick, JS; Smith, TW; Leff, D; Wintemute, GJ; Cook, PJ; Hawkins, DF; Kellermann, AL; Sorenson, SB; DeFrancesco, S				Teret, SP; Webster, DW; Vernick, JS; Smith, TW; Leff, D; Wintemute, GJ; Cook, PJ; Hawkins, DF; Kellermann, AL; Sorenson, SB; DeFrancesco, S			Support for new policies to regulate firearms	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GUN POLICY; INJURIES; VIOLENCE; HOMICIDE; HANDGUNS; CRIME	Background New policy options are emerging in the debate regarding the regulation of firearms in the United States. These options include the treatment of firearms as consumer products, the design of which can be regulated for safety; denial of gun ownership to those convicted of misdemeanors; and strategies to curtail the illegal sale of guns. The public's opinion of these innovative gun-policy options has not been thoroughly assessed. Methods We conducted two telephone surveys of 1200 adults each in the United States in 1996 and 1997-1998. Cognitive interviews and pretests were used in the development of the survey instruments. Potential participants were then contacted by random-digit dialing of telephone numbers. Results A majority of the respondents favored safety standards for new handguns. These standards included childproofing (favored by 88 percent of respondents), personalization (devices that permit firing only by an authorized person; 71 percent), magazine safeties (devices that prevent firing after the magazine or clip is removed; 82 percent), and loaded-chamber indicators (devices that show whether the handgun is loaded; 73 percent). There was strong support for policies prohibiting persons convicted of specific misdemeanors from purchasing a firearm. Support for such prohibitions was strongest for crimes involving violence or the illegal use of a firearm (83 to 95 percent) or substance abuse (71 to 92 percent). There was also widespread support for policies designed to reduce the illegal sale of guns, such as mandatory tamper-resistant serial numbers (90 percent), a limit of one handgun purchase per customer per month (81 percent), and mandatory registration of handguns (82 percent). Even among the subgroup of respondents who were gun owners, a majority were in favor of stricter gun regulations with regard to 20 of the 22 proposals covered in the poll. Conclusions Strong public support, even among gun owners, for innovative strategies to regulate firearms suggests that these proposals warrant serious consideration by policy makers. (N Engl J Med 1998; 339:813-8.) (C) 1998, Massachusetts Medical Society.	Johns Hopkins Sch Publ Hlth, Johns Hopkins Ctr Gun Policy & Res, Baltimore, MD 21205 USA; Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA; Joyce Fdn, Chicago, IL USA; Univ Calif Davis, Violence Prevent Res Program, Sacramento, CA 95817 USA; Duke Univ, Sanford Inst Publ Policy, Durham, NC USA; Univ Illinois, African Amer Studies Dept, Chicago, IL USA; Emory Univ, Rollins Sch Publ Hlth, Ctr Injury Control, Atlanta, GA 30322 USA; Univ Calif Los Angeles, Sch Publ Hlth, Violence Prevent Res Grp, Los Angeles, CA 90024 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Chicago; University of California System; University of California Davis; Duke University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Emory University; Rollins School Public Health; University of California System; University of California Los Angeles	Teret, SP (corresponding author), Johns Hopkins Sch Publ Hlth, Johns Hopkins Ctr Gun Policy & Res, 624 N Broadway, Baltimore, MD 21205 USA.			Cook, Philip/0000-0001-5094-9052				Baker S P, 1980, J Public Health Policy, V1, P224, DOI 10.2307/3342086; BOGUS CT, 1998, UC DAVIS L REV, V31, P309; Britt CL, 1996, LAW SOC REV, V30, P361, DOI 10.2307/3053963; Cook PJ, 1996, JAMA-J AM MED ASSOC, V275, P1765, DOI 10.1001/jama.275.22.1765; HAGGERTY CC, 1997, NATL GUN POLICY SURV; Hemenway D, 1997, J CRIM LAW CRIM, V87, P1430, DOI 10.2307/1144020; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; KELLERMANN AL, 1991, ANNU REV PUBL HEALTH, V12, P17; Kleck G, 1995, J CRIM LAW CRIM, V86, P150, DOI 10.2307/1144004; LOFTIN C, 1991, NEW ENGL J MED, V325, P1615, DOI 10.1056/NEJM199112053252305; LOTT J, 1997, J LEGAL STUD, V26, P16; Malcolm Joyce Lee, 1994, KEEP BEAR ARMS ORIGI; MCDOWALL D, 1994, AM J PUBLIC HEALTH, V84, P1982, DOI 10.2105/AJPH.84.12.1982; ROBINSON KD, 1996, PERSONALIZED GUNS RE; SUGARMANN J, 1977, CEASE FIRE COMPREHEN; Teret S P, 1995, Inj Prev, V1, P139, DOI 10.1136/ip.1.3.139; TERET SP, 1993, HEALTH AFFAIR, V12, P96, DOI 10.1377/hlthaff.12.4.96; VERNICK JS, 1993, AM J PUBLIC HEALTH, V83, P1773, DOI 10.2105/AJPH.83.12.1773; VERNICK JS, 1993, HEALTH AFFAIR, V12, P198, DOI 10.1377/hlthaff.12.4.198; WEBSTER DW, 1991, ISSUES SCI TECHNOL, V7, P73; Webster DW, 1997, AM J PUBLIC HEALTH, V87, P918, DOI 10.2105/AJPH.87.6.918; Weil DS, 1996, JAMA-J AM MED ASSOC, V275, P1759, DOI 10.1001/jama.275.22.1759; Wintemute GJ, 1998, J TRAUMA, V44, P155, DOI 10.1097/00005373-199801000-00021; Wintemute GJ, 1996, JAMA-J AM MED ASSOC, V275, P1749, DOI 10.1001/jama.275.22.1749; WINTEMUTE GJ, 1987, JAMA-J AM MED ASSOC, V257, P3107, DOI 10.1001/jama.257.22.3107	25	62	62	0	27	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1998	339	12					813	818		10.1056/NEJM199809173391206	http://dx.doi.org/10.1056/NEJM199809173391206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	119QT	9738090				2022-12-28	WOS:000075909200006
J	Huang, MX; Zhou, Z; Elledge, SJ				Huang, MX; Zhou, Z; Elledge, SJ			The DNA replication and damage checkpoint pathways induce transcription by inhibition of the Crt1 repressor	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; RIBONUCLEOTIDE REDUCTASE; COREPRESSOR COMPLEX; PROTEIN-KINASE; YEAST; P53; IDENTIFICATION; FAMILY; DOMAIN; REPAIR	We have identified the yeast CRT1 gene as an effector of the DNA damage and replication checkpoint pathway. CRT1 encodes a DNA-binding protein that recruits the general repressors Ssn6 and Tupl to the promoters of damage-inducible genes. Derepression of the Crt1 regulon suppresses the lethality of mec1 and rad53 null alleles and is essential for cell viability during replicative stress. In response to DNA damage and replication blocks, Crt1 becomes hyperphosphorylated and no longer binds DNA, resulting in transcriptional induction. CRT1 is autoregulated and is itself induced by DNA damage, indicating the existence of a negative feedback pathway that facilitates return to the repressed state after elimination of damage. The inhibition of an autoregulatory repressor in response to DNA damage is a strategy conserved throughout prokaryotic and eukaryotic evolution.	Baylor Coll Med, Howard Hughes Med Inst, Verna & Marrs Mclean Dept Biochem, Dept Human & Mol Genet, Houston, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute	Elledge, SJ (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, Verna & Marrs Mclean Dept Biochem, Dept Human & Mol Genet, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044664, R37GM044664] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44664] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ALLEN JB, 1994, YEAST, V10, P1267, DOI 10.1002/yea.320101003; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DESANY BA, 1998, IN PRESS GENES DEV; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P5373, DOI 10.1128/MCB.9.12.5373; Flaggs G, 1997, CURR BIOL, V7, P977, DOI 10.1016/S0960-9822(06)00417-9; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GUARENTE L, 1984, P NATL ACAD SCI-BIOL, V81, P7860, DOI 10.1073/pnas.81.24.7860; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Ho Y, 1997, P NATL ACAD SCI USA, V94, P581, DOI 10.1073/pnas.94.2.581; Huang MX, 1997, MOL CELL BIOL, V17, P6105, DOI 10.1128/MCB.17.10.6105; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; Varanasi US, 1996, MOL CELL BIOL, V16, P6707; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHOU Z, 1992, GENETICS, V131, P851; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	30	412	423	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 4	1998	94	5					595	605		10.1016/S0092-8674(00)81601-3	http://dx.doi.org/10.1016/S0092-8674(00)81601-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741624	Bronze			2022-12-28	WOS:000075851900007
J	Thorns, A				Thorns, A			White lies	BRITISH MEDICAL JOURNAL			English	Editorial Material									Trinity Hospice, London SW4 0RN, England		Thorns, A (corresponding author), 4 Ashley Cottages,Crampshaw Lane, Surrey KT21 2TZ, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					939	939						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756819				2022-12-28	WOS:000076409000034
J	Clarke, AD; Davis, D; Kapustin, VN; Eisele, F; Chen, G; Paluch, I; Lenschow, D; Bandy, AR; Thornton, D; Moore, K; Mauldin, L; Tanner, D; Litchy, M; Carroll, MA; Collins, J; Albercook, C				Clarke, AD; Davis, D; Kapustin, VN; Eisele, F; Chen, G; Paluch, I; Lenschow, D; Bandy, AR; Thornton, D; Moore, K; Mauldin, L; Tanner, D; Litchy, M; Carroll, MA; Collins, J; Albercook, C			Particle nucleation in the tropical boundary layer and its coupling to marine sulfur sources	SCIENCE			English	Article							CLOUD CONDENSATION NUCLEI; AEROSOL-SIZE DISTRIBUTION; DIMETHYL SULFIDE; ATMOSPHERIC SULFUR; PACIFIC; SULFATE; CYCLES; ENTRAINMENT; SAGA-3; OCEAN	New particle formation in a tropical marine boundary Layer setting was characterized during NASA's Pacific Exploratory Mission-Tropics A program. It represents the clearest demonstration to date of aerosol nucleation and growth being Linked to the natural marine sulfur cycle. This conclusion was based on real-time observations of dimethylsulfide, sulfur dioxide, sulfuric acid (gas), hydroxide, ozone, temperature, relative humidity, aerosol size and number distribution, and total aerosol surface area. Classic binary nucleation theory predicts no nucleation under the observed marine boundary layer conditions.	Univ Hawaii, Sch Ocean & Earth Sci & Technol, Honolulu, HI 96822 USA; Georgia Inst Technol, Sch Earth & Atmospher Sci, Atlanta, GA 30332 USA; Natl Ctr Atmospher Res, Div Atmospher Chem, Boulder, CO 80307 USA; Drexel Univ, Dept Chem, Philadelphia, PA 19104 USA; Univ Michigan, Ann Arbor, MI 48109 USA; NASA, Langley Res Ctr, Hampton, VA 23665 USA	University of Hawaii System; University System of Georgia; Georgia Institute of Technology; National Center Atmospheric Research (NCAR) - USA; Drexel University; University of Michigan System; University of Michigan; National Aeronautics & Space Administration (NASA); NASA Langley Research Center	Clarke, AD (corresponding author), Univ Hawaii, Sch Ocean & Earth Sci & Technol, Honolulu, HI 96822 USA.			LENSCHOW, DONALD/0000-0003-4353-0098				ANDREAE MO, 1983, SCIENCE, V221, P744, DOI 10.1126/science.221.4612.744; ANDREAE MO, 1995, J GEOPHYS RES-ATMOS, V100, P11335, DOI 10.1029/94JD02828; AYERS GP, 1991, NATURE, V349, P404, DOI 10.1038/349404a0; Bandy A, 1996, GEOPHYS RES LETT, V23, P741, DOI 10.1029/96GL00779; BANDY AR, 1993, J GEOPHYS RES-ATMOS, V98, P23423, DOI 10.1029/93JD02407; BATES TS, 1987, J GEOPHYS RES-OCEANS, V92, P2930, DOI 10.1029/JC092iC03p02930; BONSANG B, 1980, J GEOPHYS RES-OCEANS, V85, P7410, DOI 10.1029/JC085iC12p07410; CHARLSON RJ, 1987, NATURE, V326, P655, DOI 10.1038/326655a0; CHEN G, IN PRESS J GEOPHYS R; CLARKE AD, 1987, J GEOPHYS RES-ATMOS, V92, P4179, DOI 10.1029/JD092iD04p04179; Clarke AD, 1996, GEOPHYS RES LETT, V23, P733, DOI 10.1029/96GL00778; CLARKE AD, 1993, J GEOPHYS RES-ATMOS, V98, P16997, DOI 10.1029/92JD02481; CLARKE AD, 1993, J GEOPHYS RES-ATMOS, V98, P20633, DOI 10.1029/93JD00797; Covert DS, 1996, J GEOPHYS RES-ATMOS, V101, P6919, DOI 10.1029/95JD03068; COVERT DS, 1992, J GEOPHYS RES-ATMOS, V97, P20581, DOI 10.1029/92JD02074; Crawford JH, 1997, J GEOPHYS RES-ATMOS, V102, P28447, DOI 10.1029/97JD00011; Davis D, 1998, J GEOPHYS RES-ATMOS, V103, P1657, DOI 10.1029/97JD03452; DAVIS D, 1997, FALL M AM GEOPH UN S; DAVIS D, IN PRESS J GEOPHYS R; DAVIS D, 1996, J GEOPHYS RES, V101, P211; EISELE FL, 1993, J GEOPHYS RES-ATMOS, V98, P9001, DOI 10.1029/93JD00031; EISELE FL, 1991, J GEOPHYS RES-ATMOS, V96, P9295, DOI 10.1029/91JD00198; HEGG DA, 1990, J GEOPHYS RES-ATMOS, V95, P13917, DOI 10.1029/JD095iD09p13917; HOPPEL WA, 1986, GEOPHYS RES LETT, V13, P125, DOI 10.1029/GL013i002p00125; HOPPEL WA, 1994, J GEOPHYS RES-ATMOS, V99, P14443, DOI 10.1029/94JD00797; HUEBERT BJ, 1993, J GEOPHYS RES-ATMOS, V98, P16985, DOI 10.1029/92JD02818; KERMINEN VM, 1994, J GEOPHYS RES-ATMOS, V99, P25607, DOI 10.1029/94JD01988; LIN X, 1992, J GEOPHYS RES-ATMOS, V97, P18161, DOI 10.1029/92JD01673; Mauldin RL, 1998, J GEOPHYS RES-ATMOS, V103, P16713, DOI 10.1029/98JD00882; *NAT RES COUNC, 1996, AER RAD FORC CLIM CH, P48; QUINN PK, 1990, J GEOPHYS RES-ATMOS, V95, P16405, DOI 10.1029/JD095iD10p16405; RAES F, 1995, J GEOPHYS RES-ATMOS, V100, P2893, DOI 10.1029/94JD02832; RUSSELL LM, 1994, J GEOPHYS RES-ATMOS, V99, P20989, DOI 10.1029/94JD01932; SHAW GE, 1989, ATMOS ENVIRON, V23, P2053; Weber RJ, 1996, CHEM ENG COMMUN, V151, P53, DOI 10.1080/00986449608936541; WEXLER AS, 1994, ATMOS ENVIRON, V28, P531, DOI 10.1016/1352-2310(94)90129-5; Yvon SA, 1996, J GEOPHYS RES-ATMOS, V101, P6899, DOI 10.1029/95JD03356	37	173	178	3	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 2	1998	282	5386					89	92		10.1126/science.282.5386.89	http://dx.doi.org/10.1126/science.282.5386.89			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756483				2022-12-28	WOS:000076294900043
J	Mueller, UG; Rehner, SA; Schultz, TR				Mueller, UG; Rehner, SA; Schultz, TR			The evolution of agriculture in ants	SCIENCE			English	Article							FUNGUS-GROWING ANTS	Cultivation of fungi for food by fungus-growing ants (Attini: Formicidae) originated about 50 million years ago, The subsequent evolutionary history of this agricultural symbiosis was inferred from phylogenetic and population-genetic patterns of 553 cultivars isolated from gardens of "primitive" fungus-growing ants. These patterns indicate that fungus-growing ants succeeded at domesticating multiple cultivars, that the ants are capable of switching to novel cultivars, that single ant species farm a diversity of cultivars, and that cultivars are shared occasionally between distantly related ant species, probably by lateral transfer between ant colonies.	Univ Maryland, Dept Biol, College Pk, MD 20742 USA; Smithsonian Trop Res Inst, Balboa, Panama; Univ Puerto Rico, Dept Biol, Rio Piedras, PR 00931 USA; Smithsonian Inst, Natl Museum Nat Hist, Washington, DC 20560 USA	University System of Maryland; University of Maryland College Park; Smithsonian Institution; Smithsonian Tropical Research Institute; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico Rio Piedras; Smithsonian Institution; Smithsonian National Museum of Natural History	Mueller, UG (corresponding author), Univ Maryland, Dept Biol, College Pk, MD 20742 USA.	um3@umail.umd.edu; schultz@onyx.si.edu						[Anonymous], 1971, INSECT SOC; CHAPELA IH, 1994, SCIENCE, V266, P1691, DOI 10.1126/science.266.5191.1691; HERVEY A, 1977, BRITTONIA, V29, P226, DOI 10.2307/2805856; Holldobler B., 1990, pi; JOHNSON J, 1997, THESIS DUKE U DURHAM; Judson OP, 1996, TRENDS ECOL EVOL, V11, pA41; LYNCH M, 1993, J HERED, V84, P339, DOI 10.1093/oxfordjournals.jhered.a111354; Martin M. M., 1987, INVERTEBRATE MICROBI; Mueller UG, 1996, MOL ECOL, V5, P119, DOI 10.1111/j.1365-294X.1996.tb00297.x; REHNER SA, UNPUB; Rindos D, 1984, ORIGINS AGR; Schultz TR, 1995, SYST ENTOMOL, V20, P337, DOI 10.1111/j.1365-3113.1995.tb00100.x; SNELLING RR, 1992, INSECTS PANAMA MESOA, P481; Weber NA., 1972, GARDENING ANTS; White T.J., 1990, STRUCTURE FUNCTION F, V56	15	385	399	0	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1998	281	5385					2034	2038		10.1126/science.281.5385.2034	http://dx.doi.org/10.1126/science.281.5385.2034			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748164				2022-12-28	WOS:000076161800058
J	Butz, S; Okamoto, M; Sudhof, TC				Butz, S; Okamoto, M; Sudhof, TC			A tripartite protein complex with the potential to couple synaptic vesicle exocytosis to cell adhesion in brain	CELL			English	Article							TUMOR-SUPPRESSOR PROTEIN; ELEGANS VULVAR INDUCTION; POSTSYNAPTIC DENSITY; RECEPTOR LOCALIZATION; EPITHELIAL-CELLS; NERVOUS-SYSTEM; NEUREXINS; JUNCTION; MEMBRANE; HOMOLOG	We identify a complex of three proteins in brain that has the potential to couple synaptic vesicle exocytosis to neuronal cell adhesion. The three proteins are: (1) CASK, a protein related to MAGUKs (membrane-associated guanylate kinases); (2) Mint1, a putative vesicular trafficking protein; and (3) Veli1, -2, and -3, vertebrate homologs of C. elegans LIN-7. CASK, Mint1, and Velis form a tight, salt-resistant complex that can be readily isolated. CASK, Mint1, and Velis contain PDZ domains in addition to other modules. However, no PDZ domains are involved in complex formation, leaving them free to recruit cell adhesion molecules, receptors, and channels to the complex. We propose that the tripartite complex acts as a nucleation site for the assembly of proteins involved in synaptic vesicle exocytosis and synaptic junctions.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet,Ctr Basic Neurosci, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet,Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NIMH NIH HHS [R01-MH52804] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COHEN AR, 1998, IN PRESS J CELL BIOL; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; DUCLOS F, 1995, MAMM GENOME, V6, P57, DOI 10.1007/BF00350899; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hata Y, 1996, J NEUROSCI, V16, P2488; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hunt CA, 1996, J NEUROSCI, V16, P1380; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Martin JR, 1996, EMBO J, V15, P1865, DOI 10.1002/j.1460-2075.1996.tb00537.x; MAZOYER S, 1995, GENOMICS, V28, P25, DOI 10.1006/geno.1995.1101; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; OKAMOTO M, 1998, IN PRESS EUR J CELL; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sambrook J., 2002, MOL CLONING LAB MANU; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Smith KV, 1996, NURS ETHICS, V3, P17, DOI 10.1177/096973309600300104; Tsukita S, 1997, SOC GEN PHY, V52, P69; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; WEINBERG RJ, 1998, IN PRESS J CELL BIOL; Woods D F, 1993, J Cell Sci Suppl, V17, P171; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141	41	439	464	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					773	782		10.1016/S0092-8674(00)81736-5	http://dx.doi.org/10.1016/S0092-8674(00)81736-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753324	Bronze			2022-12-28	WOS:000076021200010
J	Clayton, NS; Dickinson, A				Clayton, NS; Dickinson, A			Episodic-like memory during cache recovery by scrub jays	NATURE			English	Article							NUTCRACKERS NUCIFRAGA-COLUMBIANA; BLACK-CAPPED CHICKADEES; FOOD PERISHABILITY; SPATIAL MEMORY; MARSH TITS; SITES	The recollection of past experiences allows us to recall what a particular event was, and where and when it occurred(1,2), a form of memory that is thought to be unique to humans(3). It is known, however, that food-storing birds remember the spatial location(4-6) and contents(6-9) of their caches. Furthermore, food-storing animals adapt their caching and recovery strategies to the perishability of food stores(10-13), which suggests that they are sensitive to temporal factors. Here we show that scrub jays (Aphelocoma coerulescens) remember 'when' food items are stored by allowing them to recover perishable 'wax worms' (wax-moth larvae) and non-perishable peanuts which they had previously cached in visuospatially distinct sites, Jays searched preferentially for fresh wax worms, their favoured food, when allowed to recover them shortly after caching. However, they rapidly learned to avoid searching for worms after a longer interval during which the worms had decayed. The recovery preference of jays demonstrates memory of where and when particular food items were cached, thereby fulfilling the behavioural criteria for episodic-like memory in non-human animals.	Univ Calif Davis, Sect Neurobiol Physiol & Behav, Davis, CA 95616 USA; Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England	University of California System; University of California Davis; University of Cambridge	Clayton, NS (corresponding author), Univ Calif Davis, Sect Neurobiol Physiol & Behav, Davis, CA 95616 USA.	nsclayton@ucdavis.edu	Clayton, Nicola s/A-2891-2010	Clayton, Nicola/0000-0003-1835-423X				[Anonymous], 1983, CANADIAN PSYCHOL; BAKER MC, 1995, ANIM BEHAV, V49, P1599, DOI 10.1016/0003-3472(95)90081-0; Clayton NS, 1996, IBIS, V138, P250, DOI 10.1111/j.1474-919X.1996.tb04336.x; CLAYTON NS, IN PRESS J EXP PSYCH; CLAYTON NS, IN PRESS ANIM BEHAV; GENDRON RP, 1995, AM NAT, V145, P948, DOI 10.1086/285778; HadjChikh LZ, 1996, ANIM BEHAV, V52, P941, DOI 10.1006/anbe.1996.0242; HAMPTON RR, 1994, BEHAV ECOL, V5, P44, DOI 10.1093/beheco/5.1.44; KAMIL AC, 1993, ANIM BEHAV, V45, P241, DOI 10.1006/anbe.1993.1030; KAMIL AC, 1985, J EXP PSYCHOL ANIM B, V11, P95, DOI 10.1037/0097-7403.11.1.95; KAMIL AC, 1990, J EXP PSYCHOL ANIM B, V16, P162, DOI 10.1037/0097-7403.16.2.162; REICHMAN OJ, 1988, ANIM BEHAV, V36, P1525, DOI 10.1016/S0003-3472(88)80223-9; SHERRY DF, 1982, ANIM BEHAV, V30, P631, DOI 10.1016/S0003-3472(82)80080-8; Shettleworth S. J., 1995, P NATO ADV STUDY I S, P158; SHETTLEWORTH SJ, 1982, J EXP PSYCHOL ANIM B, V8, P354, DOI 10.1037/0097-7403.8.4.354; STEVENS TA, 1986, IBIS, V128, P513, DOI 10.1111/j.1474-919X.1986.tb02703.x; Tulving E., 1972, ORG MEMORY, P382, DOI DOI 10.1007/978-1-4419-0463-8_37; TULVING E, IN PRESS HIPPOCAMPUS	18	860	879	6	336	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1998	395	6699					272	274		10.1038/26216	http://dx.doi.org/10.1038/26216			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751053				2022-12-28	WOS:000075974600049
J	Fukuda, K; Nisenbaum, R; Stewart, G; Thompson, WW; Robin, L; Washko, RM; Noah, DL; Barrett, DH; Randall, B; Herwaldt, BL; Mawle, AC; Reeves, WC				Fukuda, K; Nisenbaum, R; Stewart, G; Thompson, WW; Robin, L; Washko, RM; Noah, DL; Barrett, DH; Randall, B; Herwaldt, BL; Mawle, AC; Reeves, WC			Chronic multisymptom illness affecting Air Force veterans of the Gulf War	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OPERATION-DESERT-SHIELD; PERSIAN-GULF; US VETERANS; HEALTH; STORM; MISSISSIPPI; INFECTION; MORTALITY; PERSONNEL; DISEASES	Context.-Gulf War (GW) veterans report nonspecific symptoms significantly more often than their nondeployed peers. However, no specific disorder has been identified, and the etiologic basis and clinical significance of their symptoms remain unclear. Objectives.-To organize symptoms reported by US Air Force GW veterans into a case definition, to characterize clinical features, and to evaluate risk factors. Design.-Cross-sectional population survey of individual characteristics and symptoms and clinical evaluation (including a structured interview, the Medical Outcomes Study Short Form 36, psychiatric screening, physical examination, clinical laboratory tests, and serologic assays for antibodies against viruses, rickettsia, parasites, and bacteria) conducted in 1995, Participants and Setting.-The cross-sectional questionnaire survey included 3723 currently active volunteers, irrespective of health status or GW participation, from 4 air force populations,The cross-sectional clinical evaluation included 158 GW veterans from one unit, irrespective of health status. Main Outcome Measures.-Symptom-based case definition; case prevalence rate for GW veterans and nondeployed personnel; clinical and laboratory findings among veterans who met the case definition. Results.-We defined a case as having 1 or more chronic symptoms from at least 2 of 3 categories (fatigue, mood-cognition, and musculoskeletal). The prevalence of mild-to-moderate and severe cases was 39% and 6%, respectively, among 1155 GW veterans compared with 14% and 0.7% among 2520 nondeployed personnel. Illness was not associated with time or place of deployment or with duties during the war. Fifty-nine clinically evaluated GW veterans (37%) were noncases, 86 (54%) mild-to-moderate cases, and 13 (8%) severe cases, Although no physical examination, laboratory, or serologic findings identified cases, veterans who met the case definition had significantly diminished functioning and well-being. Conclusions.-Among currently active members of 4 Air Force populations, a chronic multisymptom condition was significantly associated with deployment to the GW. The condition was not associated with specific GW exposures and also affected nondeployed personnel.	Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30333 USA; ABT Associates Inc, Cambridge, MA 02138 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; ABT Associates	Reeves, WC (corresponding author), Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Mail Stop A-15,1600 Clifton Rd, Atlanta, GA 30333 USA.	wcr1@cdc.gov		Fukuda, Keiji/0000-0002-9598-9565				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ASH LR, 1987, PARASITES GUIDE LAB, P51; BASILEVSKI A, 1994, STAT FACTOR ANAL REL; CAMARGO MARIO E., 1966, REV INST MED TROP SAO PAULO, V8, P227; *CDCP, 1992, MMWR-MORBID MORTAL W, V41, P131; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P443; DEFRAITES RF, 1992, INVESTIGATION SUSPEC; *DEP DEF, 1996, COMPR CLIN EV PROGR; Floyd FJ, 1995, PSYCHOL ASSESSMENT, V7, P286, DOI 10.1037/1040-3590.7.3.286; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Gorsuch R., 1983, FACTOR ANAL; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; Gray GC, 1996, NEW ENGL J MED, V335, P1505, DOI 10.1056/NEJM199611143352007; GREEN GM, 1994, JAMA-J AM MED ASSOC, V272, P391, DOI 10.1001/jama.1994.03520050071033; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P231, DOI 10.1001/jama.277.3.231; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P215, DOI 10.1001/jama.277.3.215; HARMAN HH, 1976, MODERN FACTOR ANAL, P268; HYAMS KC, 1995, CLIN INFECT DIS, V20, P1497, DOI 10.1093/clinids/20.6.1497; HYAMS KC, 1991, NEW ENGL J MED, V325, P1423, DOI 10.1056/NEJM199111143252006; Hyams KC, 1996, ANN INTERN MED, V125, P398, DOI 10.7326/0003-4819-125-5-199609010-00007; HYAMS KC, 1993, J INFECT DIS, V167, P986, DOI 10.1093/infdis/167.4.986; Institute of Medicine, 1996, HLTH CONS SERV PERS; Kang HK, 1996, NEW ENGL J MED, V335, P1498, DOI 10.1056/NEJM199611143352006; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MAGILL AJ, 1993, NEW ENGL J MED, V328, P1383, DOI 10.1056/NEJM199305133281904; MCHORNEY CA, 1992, MED CARE, V30, pMS253, DOI 10.1097/00005650-199205001-00025; MELVIN DM, 1982, PUBL CDC; MURRAYLEISURE KA, 1994, 34 INT C ANT AG CHEM; NEWHOUSE VF, 1979, AM J TROP MED HYG, V28, P387, DOI 10.4269/ajtmh.1979.28.387; Nisenbaum R, 1998, AM J EPIDEMIOL, V148, P72, DOI 10.1093/oxfordjournals.aje.a009562; Penman AD, 1996, MIL MED, V161, P1; RONALD MG, 1995, ARCH INTERN MED, V155, P262; Schwartz DA, 1997, JAMA-J AM MED ASSOC, V277, P238, DOI 10.1001/jama.277.3.238; *STAT AN SYST I, 1990, SAS STAT US GUID, V1; *STAT AN SYST I, 1990, SAS STAT US GUID, V2; STRETCH RH, 1995, MIL MED, V160, P131, DOI 10.1093/milmed/160.3.131; Tabachnick B.G., 1983, USING MULTIVARIATE S; Tsai Theodore F., 1995, P980; TSANG VCW, 1991, CLIN LAB MED, V11, P1029, DOI 10.1016/S0272-2712(18)30533-X; *UN SPEC COMM IR, 1995, REP SECR GEN STAT IM; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEBER R, 1992, NEW ENGL J MED, V326, P161, DOI 10.1056/NEJM199201163260304; Writer JV, 1996, JAMA-J AM MED ASSOC, V275, P118, DOI 10.1001/jama.275.2.118	45	506	515	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1998	280	11					981	988		10.1001/jama.280.11.981	http://dx.doi.org/10.1001/jama.280.11.981			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JC	9749480				2022-12-28	WOS:000075891400031
J	Rostykus, PS; Cummings, P; Mueller, BA				Rostykus, PS; Cummings, P; Mueller, BA			Risk factors for pilot fatalities in general aviation airplane crash landings	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIRCRAFT	Context.-Most pilots survive airplane crash landings in small airplanes. Factors associated with pilot death have not been well studied. Objective.-To identify factors associated with fatalities in general aviation airplane crash landings. Design.-Case-control study. Setting.-The United States. Subjects.-All pilots in general aviation crash landings of airplanes with 10 seats or fewer, from 1983 through 1992. Main Outcome Measure.-Pilot death. Results.-Pilots died in 437 (5.2%) of 8411 crash landings. A fire or explosion on the ground was strongly associated with pilot death (relative risk [RR], 20.4; 95% confidence interval [CI], 15.5-26.9), adjusted for pilot age, pilot flight hours, type of landing gear, and the filing of an instrument flight plan. Pilots who failed to use both lap belt and shoulder harness were more likely to die (adjusted RR, 6.8; 95% CI, 1.8-25.5), as were those who used only the lap belt (adjusted RR, 1.7, 95% CI, 1.3-2.2), compared with pilots who used both restraints. Conclusion.-Pilots may be able to reduce their risk of death in a crash landing by using lap and shoulder restraints.	Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Rostykus, PS (corresponding author), 132 8th St, Ashland, OR 97520 USA.							*AIRCR OWN PIL ASS, 1994, AOPAS 1994 AV FACT C; BAKER SP, 1984, INJURY FACT BOOK; *GEN AV MAN ASS, 1997, GEN AV STAT DAT; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; LI GH, 1993, J OCCUP ENVIRON MED, V35, P1244; LI GH, 1994, AVIAT SPACE ENVIR MD, V65, P944; *NAT TRANSP SAF BO, 1994, NTSBARG9402; *NAT TRANSP SAF BO, 1993, 61204 NTSB	8	15	16	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1998	280	11					997	999		10.1001/jama.280.11.997	http://dx.doi.org/10.1001/jama.280.11.997			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JC	9749482				2022-12-28	WOS:000075891400033
J	Bachrach, S; Berry, RS; Blume, M; von Foerster, T; Fowler, A; Ginsparg, P; Heller, S; Kestner, N; Odlyzko, A; Okerson, A; Wigington, R; Fowler, A				Bachrach, S; Berry, RS; Blume, M; von Foerster, T; Fowler, A; Ginsparg, P; Heller, S; Kestner, N; Odlyzko, A; Okerson, A; Wigington, R; Fowler, A			Who should own scientific papers?	SCIENCE			English	Editorial Material									No Illinois Univ, Dept Chem, De Kalb, IL 60115 USA; Univ Chicago, Searle Chem Dept, Chicago, IL 60637 USA; Brookhaven Natl Lab, Upton, NY 11973 USA; Springer Verlag, New York, NY 10010 USA; Elect Frontier Fdn, San Francisco, CA 94103 USA; Univ Calif Los Alamos Natl Lab, Theory Div Dept, Los Alamos, NM 87545 USA; USDA, Natl Agr Lib, Beltsville, MD 20705 USA; Louisiana State Univ, Dept Chem, Baton Rouge, LA 70803 USA; AT&T Labs Res, Florham Park, NJ 07932 USA; Yale Univ Lib, New Haven, CT 06502 USA; Amer Chem Soc, Columbus, OH 43220 USA; Amer Acad Arts & Sci, Chicago, IL 60637 USA	Northern Illinois University; University of Chicago; United States Department of Energy (DOE); Brookhaven National Laboratory; Springer Nature; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Agriculture (USDA); Louisiana State University System; Louisiana State University; AT&T; Yale University; American Chemical Society; American Academy of Arts & Sciences	Bachrach, S (corresponding author), No Illinois Univ, Dept Chem, De Kalb, IL 60115 USA.		Berry, R Stephen/A-2236-2012	Bachrach, Steven/0000-0002-7628-7947				Edelson AM, 1998, SCIENCE, V280, P359; *HARV U, 1975, INTR STAT POL REG IN	2	45	45	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1459	1460		10.1126/science.281.5382.1459	http://dx.doi.org/10.1126/science.281.5382.1459			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9750115				2022-12-28	WOS:000075738100023
J	Cook, P				Cook, P			Duplicating a tangled genome	SCIENCE			English	Editorial Material							RNA-POLYMERASE-II; DNA-REPLICATION; NUCLEAR MATRIX; RAT-LIVER; TRANSCRIPTION; DOMAINS; SITES; VISUALIZATION; PHASE		Univ Oxford, Sir William Dunn Sch Pathol, Dept Cell Biol, Oxford OX1 3RE, England	University of Oxford	Cook, P (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, Dept Cell Biol, S Parks Rd, Oxford OX1 3RE, England.			Cook, Peter/0000-0002-6639-188X				BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; FOX MH, 1991, J CELL SCI, V99, P247; HASSAN AB, 1994, J CELL SCI, V107, P1381; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; Jackson DA, 1998, MOL BIOL CELL, V9, P1523, DOI 10.1091/mbc.9.6.1523; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Pederson T, 1998, J MOL BIOL, V277, P147, DOI 10.1006/jmbi.1997.1618; TUBO RA, 1987, J BIOL CHEM, V262, P5857; WANSINK DG, 1994, J CELL SCI, V107, P1449; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; Wei XY, 1998, SCIENCE, V281, P1502, DOI 10.1126/science.281.5382.1502; Zink D, 1998, HUM GENET, V102, P241, DOI 10.1007/s004390050686	17	14	14	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1466	1467		10.1126/science.281.5382.1466	http://dx.doi.org/10.1126/science.281.5382.1466			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9750117				2022-12-28	WOS:000075738100028
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Tissue cork borer	SCIENCE			English	Article																		Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844	1	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1163	1163						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9735032				2022-12-28	WOS:000075531200042
J	Lipian, MS				Lipian, MS			Fading reveries: repressed-memory madness in the UK	LANCET			English	Editorial Material									Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Lipian, MS (corresponding author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.							American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Bartlett F. C., 1932, REMEMBERING; Brandon S, 1998, BRIT J PSYCHIAT, V172, P296, DOI 10.1192/bjp.172.4.296; GOLDSTEIN E, 1993, TRUE STORIES FALSE M; Loftus EF, 1997, APPL COGNITIVE PSYCH, V11, P25, DOI 10.1002/(SICI)1099-0720(199702)11:1<25::AID-ACP452>3.0.CO;2-J; LOFTUS EF, 1993, AM PSYCHOL, V48, P517; Loftus Elisabeth F., 1994, MYTH REPRESSED MEMOR; Neisser U., 1992, AFFECT ACCURACY RECA; Ofshe Richard, 1994, MAKING MONSTERS FALS; POPE HG, 1995, PSYCHOL MED, V25, P121, DOI 10.1017/S0033291700028142; *ROYAL COLL PSYCH, 1997, PSYCHIAT B, V21, P663; [No title captured]	12	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 6	1998	351	9117					1673	1674		10.1016/S0140-6736(05)77736-9	http://dx.doi.org/10.1016/S0140-6736(05)77736-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZT448	9734880				2022-12-28	WOS:000074088900004
J	Steig, EJ; Brook, EJ; White, JWC; Sucher, CM; Bender, ML; Lehman, SJ; Morse, DL; Waddington, ED; Clow, GD				Steig, EJ; Brook, EJ; White, JWC; Sucher, CM; Bender, ML; Lehman, SJ; Morse, DL; Waddington, ED; Clow, GD			Synchronous climate changes in Antarctica and the North Atlantic	SCIENCE			English	Article							YOUNGER DRYAS EVENT; ICE-CORE RECORD; LAST DEGLACIATION; TEMPERATURE-CHANGE; SOLAR MODULATION; POLAR ICE; GREENLAND; MODEL; FIRN; AIR	Central Greenland ice cores provide evidence of abrupt changes in climate over the past 100,000 years. Many of these changes have also been identified in sedimentary and geochemical signatures in deep-sea sediment cores from the North Atlantic, confirming the Link between millennial-scale climate variability and ocean thermohaline circulation. It is shown here that two of the mast prominent North Atlantic events-the rapid warming that marks the end of the Last glacial period and the Bolling/Allerod-Younger Dryas oscillation-are also recorded in an ice core from Taylor Dome, in the western Ross Sea sector of Antarctica. This result contrasts with evidence from ice cores in other regions of Antarctica, which show an asynchronous response between the Northern and Southern Hemispheres.	Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA; Washington State Univ, Dept Geol, Vancouver, WA 98686 USA; Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA; Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA; Univ Texas, Inst Geophys, Austin, TX 78759 USA; Univ Washington, Geophys Program, Seattle, WA 98195 USA; US Geol Survey, Denver Fed Ctr, Englewood, CO 80225 USA	University of Colorado System; University of Colorado Boulder; Washington State University; University of Rhode Island; Princeton University; University of Texas System; University of Texas Austin; University of Washington; University of Washington Seattle; United States Department of the Interior; United States Geological Survey	Steig, EJ (corresponding author), Univ Penn, Dept Earth & Environm Sci, Philadelphia, PA 19104 USA.	steig@colorado.edu	Brook, Edward/AAB-7807-2021; White, James W.C./A-7845-2009; Steig, Eric J/G-9088-2015	White, James W.C./0000-0001-6041-4684; Steig, Eric J/0000-0002-8191-5549				ALLEY RB, 1995, J GLACIOL, V41, P503, DOI 10.3189/S0022143000034845; ALLEY RB, 1993, NATURE, V362, P527, DOI 10.1038/362527a0; Bard E, 1997, EARTH PLANET SC LETT, V150, P453, DOI 10.1016/S0012-821X(97)00082-4; Battle M, 1996, NATURE, V383, P231, DOI 10.1038/383231a0; BENDER M, 1994, NATURE, V372, P663, DOI 10.1038/372663a0; Blunier T, 1997, GEOPHYS RES LETT, V24, P2683, DOI 10.1029/97GL02658; BROECKER WS, 1989, GEOCHIM COSMOCHIM AC, V53, P2465, DOI 10.1016/0016-7037(89)90123-3; Brook EJ, 1996, SCIENCE, V273, P1087, DOI 10.1126/science.273.5278.1087; CAVALIERI DJ, 1985, ANTARCT RES SER, V43, P227; CHARLES CD, 1992, NATURE, V355, P416, DOI 10.1038/355416a0; Charles CD, 1996, EARTH PLANET SC LETT, V142, P19, DOI 10.1016/0012-821X(96)00083-0; CRAIG H, 1988, SCIENCE, V242, P1675, DOI 10.1126/science.242.4886.1675; Crowley TJ, 1992, PALEOCEANOGRAPHY, V7, P489, DOI 10.1029/92PA01058; CROWLEY TJ, 1988, CLIM DYN, V3; CUFFEY KM, 1995, SCIENCE, V270, P455, DOI 10.1126/science.270.5235.455; Finkel RC, 1997, J GEOPHYS RES-OCEANS, V102, P26699, DOI 10.1029/97JC01282; Grootes P. M., 1994, EOS, V75, P225; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; HERRON MM, 1980, J GLACIOL, V25, P373, DOI 10.3189/S0022143000015239; Imbrie J, 1992, PALEOCEANOGRAPHY, V7, P701, DOI 10.1029/92PA02253; JACOBS SS, 1985, ANTARCT RES SER, V43, P203; JOHNSEN SJ, 1992, NATURE, V359, P311, DOI 10.1038/359311a0; JOUZEL J, 1989, QUATERNARY RES, V31, P135, DOI 10.1016/0033-5894(89)90003-3; JOUZEL J, 1993, NATURE, V364, P407, DOI 10.1038/364407a0; JOUZEL J, 1995, CLIM DYNAM, V11, P151, DOI 10.1007/BF00223498; JOUZEL J, 1992, NATO ASI SER, V12, P229; Kurtz D. D., 1985, ANTARCT RES SER, V43, P177, DOI [DOI 10.1029/AR043P0177, 10.1029/AR043p0177]; LEHMAN SJ, 1992, NATURE, V356, P757, DOI 10.1038/356757a0; Licht KJ, 1996, GEOLOGY, V24, P223, DOI 10.1130/0091-7613(1996)024<0223:COLWIR>2.3.CO;2; Mayewski PA, 1996, SCIENCE, V272, P1636, DOI 10.1126/science.272.5268.1636; Mikolajewicz U, 1997, NATURE, V387, P384, DOI 10.1038/387384a0; Morse DL, 1998, GEOPHYS RES LETT, V25, P3383, DOI 10.1029/98GL52486; MORSE DL, 1997, THESIS U WASHINGTON; Raisbeck G.M., 1985, ANN GLACIOL, V7, P138; ROBIN GDQ, 1977, PHILOS T ROY SOC B, V280, P143, DOI 10.1098/rstb.1977.0103; Schiller A, 1997, CLIM DYNAM, V13, P325, DOI 10.1007/s003820050169; Schwander J, 1997, J GEOPHYS RES-ATMOS, V102, P19483, DOI 10.1029/97JD01309; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; SOWERS T, 1992, J GEOPHYS RES-ATMOS, V97, P15683, DOI 10.1029/92JD01297; SOWERS T, 1989, J GEOPHYS RES-ATMOS, V94, P5137, DOI 10.1029/JD094iD04p05137; Stager JC, 1997, SCIENCE, V276, P1834, DOI 10.1126/science.276.5320.1834; STEIG E, 1996, THESIS U WASHINGTON; Steig EJ, 1996, GEOPHYS RES LETT, V23, P523, DOI 10.1029/96GL00255; Steig EJ, 1998, GEOPHYS RES LETT, V25, P163, DOI 10.1029/97GL03566; Steig EJ, 1997, ANN GLACIOL, V25, P418, DOI 10.3189/S0260305500014385; STEIG EJ, IN PRESS ANN GLACIOL; Stuiver, 1995, ANTARCT J US, V30, P95; SUCHER CM, 1997, THESIS U RHODE ISLAN; Waddington E, 1997, EOS T, V78, pF41; WADDINGTON ED, 1994, ANN GLACIOL, V20, P219, DOI 10.3189/172756494794587014; WADDINGTON ED, 1993, NATO ASI SER, V112, P499; Zwally H.J., 1985, OCEANOLOGY ANTARCTIC, V43, P203, DOI DOI 10.1029/AR043P0203	52	254	262	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 2	1998	282	5386					92	95		10.1126/science.282.5386.92	http://dx.doi.org/10.1126/science.282.5386.92			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756484				2022-12-28	WOS:000076294900044
J	McMasters, KM; Giuliano, AE; Ross, MI; Reintgen, DS; Hunt, KK; Byrd, DR; Klimberg, VS; Whitworth, PW; Tafra, LC; Edwards, MJ				McMasters, KM; Giuliano, AE; Ross, MI; Reintgen, DS; Hunt, KK; Byrd, DR; Klimberg, VS; Whitworth, PW; Tafra, LC; Edwards, MJ			Sentinel-lymph-node biopsy for breast cancer - Not yet the standard of care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EARLY-STAGE MELANOMA; AXILLARY DISSECTION; PROGNOSTIC-SIGNIFICANCE; MALIGNANT-MELANOMA; GAMMA-PROBE; INTRAOPERATIVE RADIOLYMPHOSCINTIGRAPHY; PREMENOPAUSAL WOMEN; CUTANEOUS MELANOMA; OCCULT METASTASES; BLUE-DYE		Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40202 USA; John Wayne Canc Ctr, Santa Monica, CA 90404 USA; Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA; H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA; Univ Washington, Sch Med, Seattle, WA 98195 USA; Univ Arkansas Med Sci, Little Rock, AR 72205 USA; Nashville Surg Associates, Nashville, TN 37203 USA; E Carolina Univ, Sch Med, Greenville, NC 27858 USA	University of Louisville; John Wayne Cancer Institute; University of Texas System; UTMD Anderson Cancer Center; H Lee Moffitt Cancer Center & Research Institute; University of Washington; University of Washington Seattle; University of Arkansas System; University of Arkansas Medical Sciences; University of North Carolina; East Carolina University	McMasters, KM (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, 529 S Jackson St, Louisville, KY 40202 USA.							Albertini JJ, 1996, ANN SURG, V223, P217, DOI 10.1097/00000658-199602000-00016; Albertini JJ, 1996, JAMA-J AM MED ASSOC, V276, P1818, DOI 10.1001/jama.276.22.1818; Alex J C, 1996, Surg Oncol Clin N Am, V5, P33; ATKINS H, 1972, BRIT MED J, V2, P423, DOI 10.1136/bmj.2.5811.423; Balch CM, 1996, ANN SURG, V224, P255, DOI 10.1097/00000658-199609000-00002; Barnwell JM, 1998, ANN SURG ONCOL, V5, P126, DOI 10.1007/BF02303845; Borgstein P, 1998, J AM COLL SURGEONS, V186, P275, DOI 10.1016/S1072-7515(98)00011-8; Borgstein PJ, 1997, LANCET, V349, P1668, DOI 10.1016/S0140-6736(05)62634-7; BYRNE J, 1992, EUR J CANCER, V28A, P658; CABANES PA, 1992, LANCET, V339, P1245, DOI 10.1016/0140-6736(92)91591-U; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; Chadha M, 1997, Oncology (Williston Park), V11, P1463; CHEN ZL, 1991, DIS MARKERS, V9, P239; Clare SE, 1997, ANN SURG ONCOL, V4, P447, DOI 10.1007/BF02303667; CLAYTON F, 1993, CANCER-AM CANCER SOC, V71, P1780, DOI 10.1002/1097-0142(19930301)71:5<1780::AID-CNCR2820710512>3.0.CO;2-2; Cox CE, 1998, ANN SURG, V227, P645, DOI 10.1097/00000658-199805000-00005; Crossin JA, 1998, AM SURGEON, V64, P666; DeCicco C, 1997, TUMORI, V83, P539, DOI 10.1177/030089169708300210; Dees EC, 1997, ANN SURG, V226, P279, DOI 10.1097/00000658-199709000-00007; DEMASCAREL I, 1992, BRIT J CANCER, V66, P523, DOI 10.1038/bjc.1992.306; Diab SG, 1998, J CLIN ONCOL, V16, P1655, DOI 10.1200/JCO.1998.16.5.1655; Dowlatshahi K, 1997, CANCER, V80, P1188, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1188::AID-CNCR2>3.0.CO;2-H; ELSON CE, 1993, ANAL QUANT CYTOL, V15, P171; FISHER B, 1981, SURG GYNECOL OBSTET, V152, P765; Gershenwald JE, 1998, J CLIN ONCOL, V16, P2253, DOI 10.1200/JCO.1998.16.6.2253; Giuliano AE, 1996, J SURG ONCOL, V62, P75, DOI 10.1002/(SICI)1096-9098(199606)62:2<75::AID-JSO1>3.0.CO;2-N; GIULIANO AE, 1995, ANN SURG, V222, P394, DOI 10.1097/00000658-199509000-00016; Giuliano AE, 1997, J CLIN ONCOL, V15, P2345, DOI 10.1200/JCO.1997.15.6.2345; GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015; Glass LF, 1996, DERMATOL SURG, V22, P715, DOI 10.1111/j.1524-4725.1996.tb00623.x; GOLDHIRSCH A, 1990, LANCET, V335, P1565; Guenther JM, 1997, CANCER J SCI AM, V3, P336; Haffty BG, 1997, CANCER J SCI AM, V3, P2; HAINSWORTH PJ, 1993, BRIT J SURG, V80, P459, DOI 10.1002/bjs.1800800417; HAYWARD J, 1987, ARCH SURG-CHICAGO, V122, P1244; Kapteijn BAE, 1997, ANN SURG ONCOL, V4, P156, DOI 10.1007/BF02303799; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; KJAERGAARD J, 1985, BRIT J SURG, V72, P365, DOI 10.1002/bjs.1800720511; Krag D, 1998, NEW ENGL J MED, V339, P941, DOI 10.1056/NEJM199810013391401; KRAG DN, 1995, ARCH SURG-CHICAGO, V130, P654; Leong SPL, 1997, ARCH SURG-CHICAGO, V132, P666; MCCREADY DR, 1989, ARCH SURG-CHICAGO, V124, P21; McGuckin MA, 1996, BRIT J CANCER, V73, P88, DOI 10.1038/bjc.1996.16; Miliotes G, 1996, AM SURGEON, V62, P81; Morris AD, 1997, CANCER J, V3, P6; MORTON DL, 1993, J CLIN ONCOL, V11, P1751, DOI 10.1200/JCO.1993.11.9.1751; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; Mudun A, 1996, RADIOLOGY, V199, P171, DOI 10.1148/radiology.199.1.8633142; Mustafa IA, 1998, ANN SURG ONCOL, V5, P4, DOI 10.1007/BF02303756; NASSER IA, 1993, HUM PATHOL, V24, P950, DOI 10.1016/0046-8177(93)90108-S; NEMOTO T, 1980, CANCER, V45, P2917, DOI 10.1002/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M; NEVILLE AM, 1991, LANCET, V337, P1110, DOI 10.1016/0140-6736(91)91768-P; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Pijpers R, 1997, J NUCL MED, V38, P366; Ragaz J, 1997, NEW ENGL J MED, V337, P956, DOI 10.1056/NEJM199710023371402; RAMNATH EM, 1997, J MOFFITT CANC CTR, V4, P483; REINTGEN D, 1994, ANN SURG, V220, P759, DOI 10.1097/00000658-199412000-00009; Reintgen DS, 1996, ANN SURG ONCOL, V3, P327, DOI 10.1007/BF02305660; ROSEN PP, 1983, ANN SURG, V197, P276, DOI 10.1097/00000658-198303000-00006; ROSS MI, 1993, SEMIN SURG ONCOL, V9, P219; SIM FH, 1978, CANCER-AM CANCER SOC, V41, P948, DOI 10.1002/1097-0142(197803)41:3<948::AID-CNCR2820410324>3.0.CO;2-Z; Sosa JA, 1998, ANN SURG ONCOL, V5, P140, DOI 10.1007/BF02303847; Statman R, 1996, Adv Surg, V30, P209; THOMPSON W, 1996, SOC SURG ONC ATL MAR; Turner RR, 1997, ANN SURG, V226, P271, DOI 10.1097/00000658-199709000-00006; UREN RF, 1995, J NUCL MED, V36, P1775; VANDERVEEN H, 1994, BRIT J SURG, V81, P1769, DOI 10.1002/bjs.1800811220; VANLANCKER M, 1995, AM J CLIN ONCOL-CANC, V18, P267; VERONESI U, 1982, CANCER-AM CANCER SOC, V49, P2420, DOI 10.1002/1097-0142(19820601)49:11<2420::AID-CNCR2820491133>3.0.CO;2-2; Veronesi U, 1997, LANCET, V349, P1864, DOI 10.1016/S0140-6736(97)01004-0	70	250	263	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1998	339	14					990	995		10.1056/NEJM199810013391410	http://dx.doi.org/10.1056/NEJM199810013391410			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124MW	9753717				2022-12-28	WOS:000076186900010
J	Hutchison, G				Hutchison, G			The white album	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					797	797		10.1136/bmj.317.7161.797	http://dx.doi.org/10.1136/bmj.317.7161.797			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740572	Green Published			2022-12-28	WOS:000076084200036
J	Marsh, K				Marsh, K			Malaria disaster in Africa	LANCET			English	Editorial Material									Kenya Med Res Inst, Ctr Geog Med Res Coast, Kilifi, Kenya	Kenya Medical Research Institute	Marsh, K (corresponding author), Kenya Med Res Inst, Ctr Geog Med Res Coast, Kilifi, Kenya.							Trape JF, 1998, CR ACAD SCI III-VIE, V321, P689, DOI 10.1016/S0764-4469(98)80009-7	1	136	143	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 19	1998	352	9132					924	924		10.1016/S0140-6736(05)61510-3	http://dx.doi.org/10.1016/S0140-6736(05)61510-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752813				2022-12-28	WOS:000076002200006
J	Silvestri, G; Pritchard, R; Welch, HG				Silvestri, G; Pritchard, R; Welch, HG			Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews	BRITISH MEDICAL JOURNAL			English	Article							LIFE YEARS; METAANALYSIS; ADJUSTMENT	Objective: To determine how patients with lung cancer value the trade off between the survival benefit of chemotherapy and its toxicities. Design: Scripted interviews that included three hypothetical scenarios. Each scenario described the same patient with metastic non-small cell lung cancer with an expected survival of 4 months without treatment. Subjects were asked to indicate the minimum survival benefit required to accept the side effects of chemotherapy in the first two scenarios (mild toxicity and severe toxicity). In the third scenario, subjects were asked to choose between chemotherapy and supportive care when the benefit of chemotherapy was either to prolong life by 3 months or to palliate symptoms. Subjects: 81 patients previously treated with cis-platinum based chemotherapy for advanced non-small cell lung cancer. Main outcome measure: Survival threshold for accepting chemotherapy. Results: The minimum survival threshold for accepting the toxicity of chemotherapy varied widely in patients. Several patients would accept chemotherapy fur a survival benefit of 1 week, while others Many would not choose chemotherapy even for a survival benefit of 24 months. The median survival threshold for accepting chemotherapy was 4.5 months for mild toxicity and 9 months for severe toxicity. When given the choice between supportive care and chemotherapy only 18 (22%) patients chose chemotherapy for a survival benefit of 3 months; 55 (68%) patients chose chemotherapy if it substantially reduced symptoms without prolonging life. Conclusions: Patients' willingness to accept chemotherapy for the treatment of metastatic lung cancer varies widely Many would not choose chemotherapy for its likely survival benefit of 3 months but would if it improved quality of life. The conflict between these patients' preferences and the care they previously received has several explanations, one being that some patients had not received the treatment they would have chosen had they been fully informed.	Med Univ S Carolina, Div Pulm & Crit Care Med, Charleston, SC 29425 USA; Dept Vet Affairs Med Ctr, Hematol Oncol Sect, White River Junction, VT 05009 USA; Dept Vet Affairs Med Ctr, VA Outcomes Grp 111B, White River Junction, VT 05009 USA	Medical University of South Carolina; VA Outcomes Group	Silvestri, G (corresponding author), Med Univ S Carolina, Div Pulm & Crit Care Med, Charleston, SC 29425 USA.							Brundage MD, 1997, J CLIN ONCOL, V15, P330, DOI 10.1200/JCO.1997.15.1.330; GINSBERG RJ, 1993, CANC PRINCIPLES PRAC, P673; GRILLI R, 1993, J CLIN ONCOL, V11, P1866, DOI 10.1200/JCO.1993.11.10.1866; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1895, DOI 10.1056/NEJM199406303302611; MARINO P, 1994, CHEST, V106, P861, DOI 10.1378/chest.106.3.861; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; MCQUELLON RP, 1995, J CLIN ONCOL, V13, P858, DOI 10.1200/JCO.1995.13.4.858; NORD E, 1992, SOC SCI MED, V34, P559, DOI 10.1016/0277-9536(92)90211-8; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; READ JL, 1984, MED DECIS MAKING, V4, P315, DOI 10.1177/0272989X8400400307; RICHARDS MA, 1995, EUR J CANCER, V31A, P112, DOI 10.1016/0959-8049(94)00478-N; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; SOUQUET PJ, 1993, LANCET, V342, P19; Sox HC, 1988, MED DECISION MAKING; STIGGELBOUT AM, 1994, MED DECIS MAKING, V14, P82, DOI 10.1177/0272989X9401400110; YELLEN SB, 1994, J NATL CANCER I, V86, P1766, DOI 10.1093/jnci/86.23.1766	16	273	275	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					771	775		10.1136/bmj.317.7161.771	http://dx.doi.org/10.1136/bmj.317.7161.771			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740561	Green Published, Bronze			2022-12-28	WOS:000076084200021
J	Cho, CH; Bunch, DO; Faure, JE; Goulding, EH; Eddy, EM; Primakoff, P; Myles, DG				Cho, CH; Bunch, DO; Faure, JE; Goulding, EH; Eddy, EM; Primakoff, P; Myles, DG			Fertilization defects in sperm from mice lacking fertilin beta	SCIENCE			English	Article							DISINTEGRIN DOMAIN; EGG FUSION; SURFACE PROTEIN; POTENTIAL ROLE; CELL-ADHESION; MOUSE EGG; METALLOPROTEASE; MOTILITY; IDENTIFICATION; TRANSPORT	Fertilin, a member of the ADAM family, is found on the plasma membrane of mammalian sperm. Sperm from mice tacking fertilin beta were shown to be deficient in sperm-egg membrane adhesion, sperm-egg fusion, migration from the uterus into the oviduct, and binding to the egg zona pellucida. Egg activation was unaffected. The results are consistent with a direct role of fertilin in sperm-egg plasma membrane interaction. Fertilin could also have a direct role in sperm-zona binding or oviduct migration; alternatively, the effects on these functions could result from the absence of fertilin activity during spermatogenesis.	Univ Calif Davis, Sect Mol & Cellular Biol, Livermore, CA 95616 USA; NIEHS, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA	University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Myles, DG (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, Livermore, CA 95616 USA.	dgmyles@ucdavis.edu		Bunch, Donna/0000-0002-3638-0522	NICHD NIH HHS [U54HD29125, HD16580] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016580, U54HD029125, R01HD016580] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; CHO CL, UNPUB; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; Lum L, 1997, DEV BIOL, V191, P131, DOI 10.1006/dbio.1997.8609; MYLES DG, 1993, DEV BIOL, V158, P35, DOI 10.1006/dbio.1993.1166; Myles DG, 1997, BIOL REPROD, V56, P320, DOI 10.1095/biolreprod56.2.320; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; OLDSCLARKE P, 1986, BIOL REPROD, V34, P453, DOI 10.1095/biolreprod34.3.453; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PHELPS BM, 1990, J CELL BIOL, V111, P1839, DOI 10.1083/jcb.111.5.1839; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Seed J, 1996, REPROD TOXICOL, V10, P237, DOI 10.1016/0890-6238(96)00028-7; SMITH TT, 1990, BIOL REPROD, V42, P450, DOI 10.1095/biolreprod42.3.450; Snell WJ, 1996, CELL, V85, P629, DOI 10.1016/S0092-8674(00)81230-1; SUAREZ SS, 1987, BIOL REPROD, V36, P203, DOI 10.1095/biolreprod36.1.203; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Yanagimachi R., 1994, P189; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105	24	416	441	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1857	1859		10.1126/science.281.5384.1857	http://dx.doi.org/10.1126/science.281.5384.1857			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743500				2022-12-28	WOS:000076007100055
J	Fernandez, I; Ubach, J; Dulubova, I; Zhang, XY; Sudhof, TC; Rizo, J				Fernandez, I; Ubach, J; Dulubova, I; Zhang, XY; Sudhof, TC; Rizo, J			Three-dimensional structure of an evolutionarily conserved N-terminal domain of syntaxin 1A	CELL			English	Article							PROTEIN-PROTEIN INTERACTIONS; SYNAPTOTAGMIN-I; VESICLE FUSION; NEUROTRANSMITTER RELEASE; CAENORHABDITIS-ELEGANS; RESONANCE SPECTROSCOPY; SECONDARY STRUCTURE; CALCIUM-FREE; C-2 DOMAIN; NMR	Syntaxin 1A plays a central role in neurotransmitter release through multiple protein-protein interactions. We have used NMR spectroscopy to identify an autonomously folded N-terminal domain in syntaxin 1A and to elucidate its three-dimensional structure. This 120-residue N-terminal domain is conserved in plasma membrane syntaxins but not in other syntaxins, indicating a specific role in exocytosis. The domain contains three long or helices that form an up-and-down bundle with a left-handed twist. A striking residue conservation is observed throughout a long groove that is likely to provide a specific surface for protein-protein interactions. A highly acidic region binds to the C(2)A domain of synaptotagmin I in a Ca2+-dependent interaction that may serve as an electrostatic switch in neurotransmitter release.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rizo, J (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037200] Funding Source: NIH RePORTER; NINDS NIH HHS [NS37200] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Betz A, 1997, J BIOL CHEM, V272, P2520; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; BRENNER S, 1974, GENETICS, V77, P71; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOSONO R, 1991, NEUROSCI LETT, V128, P243, DOI 10.1016/0304-3940(91)90270-4; INOUE A, 1992, J BIOL CHEM, V267, P10613; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1993, J AM CHEM SOC, V115, P2055, DOI 10.1021/ja00058a072; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Kee Y, 1996, J NEUROSCI, V16, P1975; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; KUMAR A, 1981, J AM CHEM SOC, V103, P3654, DOI 10.1021/ja00403a008; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LOGAN TM, 1993, J BIOMOL NMR, V3, P225; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; RIZO J, 1994, J BIOMOL NMR, V4, P741, DOI 10.1007/BF00398406; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; Shao XG, 1997, J BIOMOL NMR, V10, P307, DOI 10.1023/A:1018349601965; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; SUTTON RB, 1998, IN PRESS NATURE; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Wong SH, 1998, J BIOL CHEM, V273, P375, DOI 10.1074/jbc.273.1.375; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; ZHANG L, 1994, CHIN J PHARMACOEPIDE, V3, P4	55	260	268	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					841	849		10.1016/S0092-8674(00)81742-0	http://dx.doi.org/10.1016/S0092-8674(00)81742-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753330	Bronze			2022-12-28	WOS:000076021200016
J	Fukumura, D; Xavier, R; Sugiura, T; Chen, Y; Park, EC; Lu, NF; Selig, M; Nielsen, G; Taksir, T; Jain, RK; Seed, B				Fukumura, D; Xavier, R; Sugiura, T; Chen, Y; Park, EC; Lu, NF; Selig, M; Nielsen, G; Taksir, T; Jain, RK; Seed, B			Tumor induction of VEGF promoter activity in stromal cells	CELL			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY; ANTIANGIOGENIC THERAPY; FACTOR EXPRESSION; TRANSGENIC MICE; MESSENGER-RNA; UP-REGULATION; ANGIOGENESIS; HYPOXIA; MECHANISMS	We have established a line of transgenic mice expressing the A. victoria green fluorescent protein (GFP) under the control of the promoter for vascular endothelial growth factor (VEGF). Mice bearing the transgene show green cellular fluorescence around the healing margins and throughout the granulation tissue of superficial ulcerative wounds. Implantation of solid tumors in the transgenic mice leads to an accumulation of green fluorescence resulting from tumor induction of host VEGF promoter activity. With time, the fluorescent cells invade the tumor and can be seen throughout the tumor mass. Spontaneous mammary tumors induced by oncogene expression in the VEGF-GFP mouse show strong stromal, but not tumor, expression of GFP. In both wound and tumor models the predominant GFP-positive cells are fibroblasts. The finding that the VEGF promoter of nontransformed cells is strongly activated by the tumor microenvironment points to a need to analyze and understand stromal cell collaboration in tumor angiogenesis.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Melvin B & Barbara K Nessel Gene Therapy Ctr, Boston, MA 02114 USA; Massachusetts Gen Hosp, Gastroenterol Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Jain, RK (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.		Jain, Rakesh K/I-1384-2017	Jain, Rakesh K/0000-0001-7571-3548	NATIONAL CANCER INSTITUTE [R35CA056591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI027849, R01AI027849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043031] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA-56591] Funding Source: Medline; NIAID NIH HHS [AI27849] Funding Source: Medline; NIDDK NIH HHS [DK43031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BONDAR I, 1991, RES EXP MED, V191, P379, DOI 10.1007/BF02576693; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; CERFBENSUSSAN N, 1983, J IMMUNOL, V130, P2615; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Damert A, 1997, CANCER RES, V57, P3860; DETMAR M, 1998, IN PRESS INVEST DERM; DVORAK HF, 1995, AM J PATHOL, V146, P1029; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FIDLER IJ, 1995, J NATL CANCER I, V87, P1588, DOI 10.1093/jnci/87.21.1588; FLEENOR DE, 1993, BLOOD, V81, P2781; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Fukumura D, 1997, AM J PATHOL, V150, P713; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Helm R., 1996, CURR BIOL, V6, P178; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; HLATKY L, 1994, CANCER RES, V54, P6083; HOLLANDER GA, 1995, IMMUNITY, V3, P27, DOI 10.1016/1074-7613(95)90156-6; JAIN R, 1997, IEEE MULTIMEDIA, V4, P1; KERBEL RS, 1991, BIOESSAYS, V13, P31, DOI 10.1002/bies.950130106; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LEUNIG M, 1992, CANCER RES, V52, P6553; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; MILSTONE DS, 1998, IN PRESS MICROCIRCUL; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEIN I, 1995, MOL CELL BIOL, V15, P5363; TISCHER E, 1991, J BIOL CHEM, V266, P11947	38	782	839	1	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					715	725		10.1016/S0092-8674(00)81731-6	http://dx.doi.org/10.1016/S0092-8674(00)81731-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753319	Bronze			2022-12-28	WOS:000076021200005
J	Russo, AA; Tong, L; Lee, JO; Jeffrey, PD; Pavletich, NP				Russo, AA; Tong, L; Lee, JO; Jeffrey, PD; Pavletich, NP			Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16(INK4a)	NATURE			English	Article							FAMILIAL MELANOMA; CRYSTAL-STRUCTURE; PROTEIN-KINASE; CELLULAR-TRANSFORMATION; RETINOBLASTOMA-PROTEIN; GENE-PRODUCT; TGF-BETA; P16; MUTATIONS; BINDING	The cyclin-dependent kinases 4 and 6 (Cdk4/6) that control the G1 phase of the cell cycle and their inhibitor, the p16(INK4a) tumour suppressor, have a central role in cell proliferation and in tumorigenesis. The structures of Cdk6 bound to p16(INK4a) and to the related p19(INK4d) reveal that the INK4 inhibitors bind next to the ATP-binding site of the catalytic cleft, opposite where the activating cyclin subunit binds. They prevent cyclin binding indirectly by causing structural changes that propagate to the cyclin-binding site. The INK4 inhibitors also distort the kinase catalytic cleft and interfere with ATP binding, which explains how they can inhibit the preassembled Cdk4/6-cyclin D complexes as well. Ttrmour-derived mutations in INK4a and Cdk4 map to interface contacts, solidifying the role of CDK binding and inhibition in the tumour suppressor activity of p16(INK4a).	Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA.	Nikola@xray2.mskcc.org	Lee, Jie-Oh/AAG-4302-2020; Lee, Jie-Oh/C-1581-2011	Jeffrey, Philip/0000-0002-4351-5341; Lee, Jie-Oh/0000-0001-6519-6049				Arap W, 1997, ONCOGENE, V14, P603, DOI 10.1038/sj.onc.1200870; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Coleman KG, 1997, J BIOL CHEM, V272, P18869, DOI 10.1074/jbc.272.30.18869; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LI Y, 1994, CANCER RES, V54, P6078; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Parry D, 1996, MOL CELL BIOL, V16, P3844; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Stephen DB, 1996, STRUCT ENG MECH, V4, P1; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wolf SS, 1995, MOL BIOTECHNOL, V4, P269, DOI 10.1007/BF02779020; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YANG R, 1995, CANCER RES, V55, P2503; Zhang B, 1996, J BIOL CHEM, V271, P28734, DOI 10.1074/jbc.271.46.28734; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	51	390	408	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	1998	395	6699					237	243		10.1038/26155	http://dx.doi.org/10.1038/26155			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751050				2022-12-28	WOS:000075974600040
J	Yang, RB; Mark, MR; Gray, A; Huang, A; Xie, MH; Zhang, M; Goddard, A; Wood, WI; Gurney, AL; Godowski, PJ				Yang, RB; Mark, MR; Gray, A; Huang, A; Xie, MH; Zhang, M; Goddard, A; Wood, WI; Gurney, AL; Godowski, PJ			Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling	NATURE			English	Article							NF-KAPPA-B; DROSOPHILA TOLL; TYROSINE KINASE; IL-1 RECEPTOR; UP-REGULATION; ACTIVATION; PROTEIN; DORSAL; ENDOTOXIN; IMMUNITY	Vertebrates and invertebrates initiate a series of defence mechanisms following infection by Gram-negative bacteria by sensing the presence of lipopolysaccharide (LPS), a major component of the cell wall of the invading pathogen(1), In humans, monocytes and macrophages respond to LPS by inducing the expression of cytokines, cell-adhesion proteins, and enzymes involved in the production of small proinflammatory mediators. Under pathophysiological conditions, LPS exposure can lead to an often fatal syndrome known as septic shock(2). Sensitive responses of myeloid cells to LPS require a plasma protein called LPS-binding protein and the glycosylphosphatidylinositol-anchored membrane protein CD14. However, the mechanism by which the LPS signal is transduced across the plasma membrane remains unknown(3). Here we show that Toll-like receptor 2 (TLR2) is a signalling receptor that is activated by LPS in a response that depends on LPS-binding protein and is enhanced by CD14. A region in the intracellular domain of TLR2. with homology to a portion of the interleukin (IL)-1 receptor that is implicated in the activation of the IL-1-receptor-associated kinase is required for this response. Our results indicate that TLR2 is a direct mediator of signalling by LPS.	Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA	Roche Holding; Genentech	Godowski, PJ (corresponding author), Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA.	ski@gene.com	Yang, Ruey-Bing/O-1494-2018	Yang, Ruey-Bing/0000-0003-3017-3714				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; Dangl J, 1997, CELL, V91, P17, DOI 10.1016/S0092-8674(01)80005-2; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; HammondKosack KE, 1997, ANNU REV PLANT PHYS, V48, P575, DOI 10.1146/annurev.arplant.48.1.575; HEGUY A, 1992, J BIOL CHEM, V267, P2605; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LEMAITRE B, 1995, EMBO J, V14, P536, DOI 10.1002/j.1460-2075.1995.tb07029.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Luoh SM, 1997, J MOL ENDOCRINOL, V18, P77, DOI 10.1677/jme.0.0180077; MARCHANT A, 1992, EUR J IMMUNOL, V22, P1663, DOI 10.1002/eji.1830220650; MARK MR, 1994, J BIOL CHEM, V269, P10720; MATSUURA K, 1994, J EXP MED, V179, P1671, DOI 10.1084/jem.179.5.1671; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, P NATL ACAD SCI USA, V95, P429, DOI 10.1073/pnas.95.2.429; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253	26	1072	1144	0	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	1998	395	6699					284	288		10.1038/26239	http://dx.doi.org/10.1038/26239			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751057				2022-12-28	WOS:000075974600053
J	Horowitz, HW; Aguero-Rosenfeld, M; Dumler, JS; McKenna, DF; Hsieh, TC; Wu, J; Schwartz, I; Wormser, GP				Horowitz, HW; Aguero-Rosenfeld, M; Dumler, JS; McKenna, DF; Hsieh, TC; Wu, J; Schwartz, I; Wormser, GP			Reinfection with the agent of human granulocytic ehrlichiosis	ANNALS OF INTERNAL MEDICINE			English	Article							BORRELIA-BURGDORFERI; HUMAN-DISEASE; LYME-DISEASE; CULTURE		Johns Hopkins Med Inst, Dept Pathol, Div Med Microbiol, Baltimore, MD 21201 USA; New York Med Coll, Valhalla, NY 10595 USA	Johns Hopkins University; Johns Hopkins Medicine; New York Medical College	Horowitz, HW (corresponding author), Westchester Cty Med Ctr, Div Infect Dis, Room 209,Macy Pavil, Valhalla, NY 10595 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041213] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041511] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI41213-01] Funding Source: Medline; NIAMS NIH HHS [R01-AR41511] Funding Source: Medline; PHS HHS [U50/CCU 210280] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AgueroRosenfeld ME, 1996, ANN INTERN MED, V125, P904, DOI 10.7326/0003-4819-125-11-199612010-00006; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P590; Bakken JS, 1996, JAMA-J AM MED ASSOC, V275, P199, DOI 10.1001/jama.275.3.199; CHEN SM, 1994, J CLIN MICROBIOL, V32, P589, DOI 10.1128/JCM.32.3.589-595.1994; CHIAO JW, 1994, FEMS IMMUNOL MED MIC, V8, P151, DOI 10.1111/j.1574-695X.1994.tb00437.x; Goodman JL, 1996, NEW ENGL J MED, V334, P209, DOI 10.1056/NEJM199601253340401; Nadelman RB, 1997, NEW ENGL J MED, V337, P27, DOI 10.1056/NEJM199707033370105; Nowakowski J, 1997, ANN INTERN MED, V127, P130, DOI 10.7326/0003-4819-127-2-199707150-00006; NYINDO MBA, 1978, AM J VET RES, V39, P15; PANCHOLI P, 1995, J INFECT DIS, V172, P1007, DOI 10.1093/infdis/172.4.1007; Petrovec M, 1997, J CLIN MICROBIOL, V35, P1556, DOI 10.1128/JCM.35.6.1556-1559.1997; SCHWARTZ I, 1992, J CLIN MICROBIOL, V30, P3082, DOI 10.1128/JCM.30.12.3082-3088.1992; STAMP J T, 1950, Vet Rec, V62, P465; Telford SR, 1996, P NATL ACAD SCI USA, V93, P6209, DOI 10.1073/pnas.93.12.6209; TUOMI J, 1967, ACTA PATHOL MIC SC, V70, P429; Zhi N, 1997, J CLIN MICROBIOL, V35, P2606, DOI 10.1128/JCM.35.10.2606-2611.1997	16	28	29	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1998	129	6					461	463		10.7326/0003-4819-129-6-199809150-00007	http://dx.doi.org/10.7326/0003-4819-129-6-199809150-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JJ	9735084				2022-12-28	WOS:000075892100005
J	Erikssen, G; Liestol, K; Bjornholt, J; Thaulow, E; Sandvik, L; Erikssen, J				Erikssen, G; Liestol, K; Bjornholt, J; Thaulow, E; Sandvik, L; Erikssen, J			Changes in physical fitness and changes in mortality	LANCET			English	Article							ALL-CAUSE MORTALITY; CORONARY HEART-DISEASE; AGED NORWEGIAN MEN; FOLLOW-UP; CARDIOVASCULAR MORTALITY; HEALTHY-MEN; EXERCISE; RISK; PREDICTOR; WOMEN	Background Point estimates of physical fitness give important information on the risk of death in healthy people, but there is little information available on effects of sequential changes in physical fitness on mortality. We studied this latter aspect in healthy middle-aged men over a total follow-up period of 22 years. Methods 2014 healthy men aged 40-60 years had a bicycle exercise test and clinical examination, and completed a questionnaire in 1972-75 (survey 1). This was repeated for 1756 (91%) of 1932 men still alive by Dec 31, 1982 (survey 2). The exercise scores were adjusted for age, The change in exercise scores between surveys was divided into quartiles (Q1=least fit, Q4=fittest). An adjusted Cox's proportional hazards model was used to study the association between changes in physical fitness and mortality, with the Q1 men used as controls. Findings By Dec 31, 1994, 238 (17%) of the 1428 men had died, 120 from cardiovascular causes. There were 37 deaths in the Q4 group (19 cardiovascular); their relative risks of death were 0.45 (95% Cl 0.29-0.69) for any cause and 0.47 (0.26-0.86) for cardiovascular causes. There was a graded, inverse relation between changes in physical fitness and mortality irrespective of physical fitness status at survey 1. Interpretation Change in physical fitness in healthy middle-aged men is a strong predictor of mortality. Even smalt improvements in physical fitness are associated with a significantly lowered risk of death. If confirmed, these findings should be used to influence public health policy.	Cent Hosp Akershus, Dept Med, N-1474 Nordbyhagen, Norway; Univ Oslo, Inst Informat, Blindern, Norway; Univ Oslo, Natl Hosp, Dept Med B, Oslo, Norway; Medstat Res AS, Lillestrom, Norway	University of Oslo; University of Oslo; University of Oslo; National Hospital Norway	Erikssen, G (corresponding author), Cent Hosp Akershus, Dept Med, N-1474 Nordbyhagen, Norway.			Bjornholt, Jorgen Vildershoj/0000-0002-0079-8062				Barinaga M, 1997, SCIENCE, V276, P1324, DOI 10.1126/science.276.5317.1324; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BOUCHARD C, 1986, MED SCI SPORT EXER, V18, P639; EICHNER ER, 1994, MED CLIN N AM, V78, P377; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; ELLESTAD MH, 1975, CIRCULATION, V51, P363, DOI 10.1161/01.CIR.51.2.363; ERIKSSEN J, 1977, SCAND J CLIN LAB INV, V37, P243, DOI 10.3109/00365517709091489; ERIKSSEN J, 1986, ACTA MED SCAND, P189; ERIKSSEN J, 1978, THESIS U HOSP OSLO; Hardman A, 1995, J Cardiovasc Risk, V2, P285, DOI 10.1097/00043798-199508000-00001; LEMAITRE RN, 1995, ARCH INTERN MED, V155, P2302, DOI 10.1001/archinte.155.21.2302; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; MUNDAL R, 1987, EUR J APPL PHYSIOL O, V56, P245, DOI 10.1007/BF00690888; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; OCONNOR GT, 1995, AM J EPIDEMIOL, V142, P1147, DOI 10.1093/oxfordjournals.aje.a117573; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SANDVIK L, 1995, CORONARY ARTERY DIS, V6, P667, DOI 10.1097/00019501-199508000-00012; SANDVIK L, 1995, BRIT MED J, V311, P715, DOI 10.1136/bmj.311.7007.715; SLATTERY ML, 1988, AM J EPIDEMIOL, V127, P571, DOI 10.1093/oxfordjournals.aje.a114832; THOMPSON WG, 1994, SOUTH MED J, V87, P567; Thune I, 1997, NEW ENGL J MED, V336, P1269, DOI 10.1056/NEJM199705013361801	27	341	352	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 5	1998	352	9130					759	762		10.1016/S0140-6736(98)02268-5	http://dx.doi.org/10.1016/S0140-6736(98)02268-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737279				2022-12-28	WOS:000075762700008
J	Meluh, PB; Yang, PR; Glowczewski, L; Koshland, D; Smith, MM				Meluh, PB; Yang, PR; Glowczewski, L; Koshland, D; Smith, MM			Cse4p is a component of the core centromere of Saccharomyces cerevisiae	CELL			English	Article							INNER KINETOCHORE PLATE; BUDDING YEAST; CENP-C; CHROMATIN STRUCTURE; PROTEIN; DNA; CHROMOSOME; ANAPHASE; MITOSIS; COMPLEX	Histones are fundamental structural components of chromatin and are expected to play important roles in chromosome dynamics. Here, we present direct evidence that Cse4p, a histone H3 variant, is a structural component of the core centromere of S. cerevisiae. In histone H4 and Cse4p mutants, the core centromere chromatin structure is disrupted at restrictive temperature. Overexpression of Cse4p suppresses this defect in the H4 mutant, implying that the two proteins act together in centromere structure. We show by chromatin immunoprecipitation experiments that Cse4p is specifically cross-linked to centromeric DNA. Furthermore, by immunofluorescence microscopy, Cse4p is found in discrete foci consistent with that expected for centromeres. These results suggest the kinetochore is assembled on a specialized centromeric nucleosome containing Cse4p.	Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Canc, Charlottesville, VA 22908 USA; Carnegie Inst Washington, Howard Hughes Med Inst, Dept Embryol, Baltimore, MD 21210 USA	University of Virginia; University of Virginia; Carnegie Institution for Science; Howard Hughes Medical Institute	Smith, MM (corresponding author), Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041718, R01GM028920] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41718, GM28920] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allshire RC, 1997, CURR OPIN GENET DEV, V7, P264, DOI 10.1016/S0959-437X(97)80137-2; Baker RE, 1998, GENETICS, V149, P73; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; CUMBERLEDGE S, 1987, GENETICS, V117, P203; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; Espelin CW, 1997, J CELL BIOL, V139, P1383, DOI 10.1083/jcb.139.6.1383; FUNK M, 1989, MOL GEN GENET, V219, P153, DOI 10.1007/BF00261171; GAUDET A, 1987, MOL CELL BIOL, V7, P68, DOI 10.1128/MCB.7.1.68; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; Guacci V, 1997, MOL BIOL CELL, V8, P957, DOI 10.1091/mbc.8.6.957; GUACCI V, 1993, COLD SPRING HARB SYM, V58, P677, DOI 10.1101/SQB.1993.058.01.075; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; Hyman AA, 1995, ANNU REV CELL DEV BI, V11, P471, DOI 10.1146/annurev.cb.11.110195.002351; Jannink G, 1996, BIOPHYS J, V71, P451, DOI 10.1016/S0006-3495(96)79247-0; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LECHNER J, 1994, EMBO J, V13, P5203, DOI 10.1002/j.1460-2075.1994.tb06851.x; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; MURPHY MR, 1991, CHROMOSOMA, V101, P189, DOI 10.1007/BF00355368; NICKLAS RB, 1983, J CELL BIOL, V97, P542, DOI 10.1083/jcb.97.2.542; NIEDENTHAL R, 1991, MOL CELL BIOL, V11, P3545, DOI 10.1128/MCB.11.7.3545; NIEDENTHAL RK, 1993, NUCLEIC ACIDS RES, V21, P4726, DOI 10.1093/nar/21.20.4726; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; Rose MD., 1990, METHODS YEAST GENETI; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; Sambrook J., 2002, MOL CLONING LAB MANU; SAUNDERS M, 1988, P NATL ACAD SCI USA, V85, P175, DOI 10.1073/pnas.85.1.175; SAUNDERS MJ, 1990, MOL CELL BIOL, V10, P5721, DOI 10.1128/MCB.10.11.5721; SCHULMAN I, 1991, ANNU REV CELL BIOL, V7, P311, DOI 10.1146/annurev.cellbio.7.1.311; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; Smith MM, 1996, MOL CELL BIOL, V16, P1017; SORGER PK, 1994, J CELL BIOL, V127, P995, DOI 10.1083/jcb.127.4.995; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; STRUNNIKOV AV, 1995, J CELL BIOL, V128, P749, DOI 10.1083/jcb.128.5.749; SULLIVAN BA, 1995, HUM MOL GENET, V4, P2189, DOI 10.1093/hmg/4.12.2189; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; Warburton PE, 1997, CURR BIOL, V7, P901, DOI 10.1016/S0960-9822(06)00382-4; Wiens GR, 1998, CELL, V93, P313, DOI 10.1016/S0092-8674(00)81157-5	42	303	310	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 4	1998	94	5					607	613		10.1016/S0092-8674(00)81602-5	http://dx.doi.org/10.1016/S0092-8674(00)81602-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741625	Bronze			2022-12-28	WOS:000075851900008
J	Sharis, PJ; Cannon, CP; Loscalzo, J				Sharis, PJ; Cannon, CP; Loscalzo, J			The antiplatelet effects of ticlopidine and clopidogrel	ANNALS OF INTERNAL MEDICINE			English	Review							THROMBOTIC THROMBOCYTOPENIC PURPURA; ACUTE MYOCARDIAL-INFARCTION; INTRAVASCULAR ULTRASOUND GUIDANCE; HIGH-RISK PATIENTS; INTRACORONARY STENT IMPLANTATION; INDUCED PLATELET-AGGREGATION; CORONARY-ARTERY DISEASE; SAPHENOUS-VEIN GRAFTS; DOUBLE-BLIND; INTERMITTENT CLAUDICATION	Ticlopidine and clopidogrel achieve antiplatelet effects by inhibiting the binding of adenosine 5'-disphosphate to its platelet receptor. Ticlopidine was first shown to decrease major events compared with placebo or aspirin in patients with stroke or recent transient ischemic attack. Randomized studies in patients undergoing coronary artery stenting have shown that ticlopidine reduces the risk for subacute stent thrombosis compared with warfarin-based regimens. Smaller studies have also shown this drug to have benefit during follow-up in patients with unstable angina, peripheral arterial disease, saphenous vein coronary bypass grafts, and diabetic retinopathy. Clopidogrel was recently approved by the U.S. Food and Drug Administration for the reduction of ischemic events in patients with recent myocardial infarction, stroke, or peripheral arterial disease (incidence, 5.32% per year compared with 5.83% per year for aspirin; P = 0.043) with no added risk for neutropenia. The combination of clopidogrel and aspirin, as well as the utility of clopidogrel in other patient populations and in stenting, requires further study. Ticlopidine and clopidogrel seem to have beneficial effects compared with aspirin (the current standard) in a broad range of patients. These observations highlight the importance of antiplatelet therapy in cardiovascular disease.	Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA	Boston University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Loscalzo, J (corresponding author), Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst, 88 E Newton St, Boston, MA 02118 USA.	jloscalz@bu.edu	Loscalzo, Joseph/ABD-8980-2021					Albiero R, 1997, CIRCULATION, V95, P1145; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ARCAN JC, 1988, ANGIOLOGY, V39, P802, DOI 10.1177/000331978803900904; Ariyoshi K, 1997, AM J HEMATOL, V54, P175; AUKLAND A, 1982, J CLIN PATHOL, V35, P740, DOI 10.1136/jcp.35.7.740; BAILEY SR, 1995, CURR PROB CARDIOLOGY, V20, P618; BALSANO F, 1990, CIRCULATION, V82, P17, DOI 10.1161/01.CIR.82.1.17; Barragan P, 1997, CATHETER CARDIO DIAG, V42, P367, DOI 10.1002/(SICI)1097-0304(199712)42:4<367::AID-CCD1>3.0.CO;2-9; Becquemin JP, 1997, NEW ENGL J MED, V337, P1726, DOI 10.1056/NEJM199712113372404; BELLAVANCE A, 1993, STROKE, V24, P1452, DOI 10.1161/01.STR.24.10.1452; Bennett CL, 1998, ANN INTERN MED, V128, P541, DOI 10.7326/0003-4819-128-7-199804010-00004; Bergamasco B, 1997, FUNCT NEUROL, V12, P33; BERGER PB, 1996, CIRCULATION S1, V94, P256; BERGLUND U, 1985, THROMB HAEMOSTASIS, V54, P808; BIRMELE B, 1991, NEPHROL DIAL TRANSPL, V6, P150, DOI 10.1093/ndt/6.2.150-a; Bittl JA, 1996, NEW ENGL J MED, V335, P1290, DOI 10.1056/NEJM199610243351707; BLANCHARD J, 1993, NOUV REV FR HEMATOL, V35, P523; Boissonnat P, 1997, EUR J CLIN PHARMACOL, V53, P39, DOI 10.1007/s002280050334; Brown RIG, 1997, CAN J CARDIOL, V13, P853; Cannon CP, 1998, CIRCULATION, V97, P340; CARRIERI P, 1984, J INT MED RES, V12, P286, DOI 10.1177/030006058401200504; CATTANEO M, 1993, ARTERIOSCLER THROMB, V13, P393, DOI 10.1161/01.ATV.13.3.393; Cerisier A., 1997, Journal of the American College of Cardiology, V29, p395A; CHEVIGNE M, 1984, ANN THORAC SURG, V37, P370, DOI 10.1016/S0003-4975(10)60757-6; Chotinaiwattarakul Chunhakasem, 1997, Journal of the Medical Association of Thailand, V80, P76; COLLI A, 1987, CLIN PHARMACOL THER, V41, P358, DOI 10.1038/clpt.1987.39; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; Coukell AJ, 1997, DRUGS, V54, P745, DOI 10.2165/00003495-199754050-00006; DAVID JL, 1979, THROMB RES, V14, P35, DOI 10.1016/0049-3848(79)90022-7; DEFREYN G, 1991, THROMB HAEMOSTASIS, V65, P186; DEFREYN G, 1989, SEMIN THROMB HEMOST, V15, P159, DOI 10.1055/s-2007-1002699; deJaegere PP, 1996, J AM COLL CARDIOL, V28, P89, DOI 10.1016/0735-1097(96)00104-0; DESAGER JP, 1994, CLIN PHARMACOKINET, V26, P347, DOI 10.2165/00003088-199426050-00003; DIMINNO G, 1985, J CLIN INVEST, V75, P328, DOI 10.1172/JCI111705; DIRSCHLINGER J, 1997, CIRCULATION S1, V94, P257; Eeckhout E, 1996, J AM COLL CARDIOL, V27, P757, DOI 10.1016/0735-1097(95)00548-4; ELLIE E, 1992, STROKE, V23, P922, DOI 10.1161/01.STR.23.6.922; Elsman P, 1996, LANCET, V348, P273, DOI 10.1016/S0140-6736(05)65589-4; FAGHER B, 1993, ANGIOLOGY, V44, P300, DOI 10.1177/000331979304400406; FELISTE R, 1987, THROMB RES, V48, P403, DOI 10.1016/0049-3848(87)90398-7; Ferguson JJ, 1997, CIRCULATION, V95, P761; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; GACHET C, 1990, BIOCHEM PHARMACOL, V40, P2683, DOI 10.1016/0006-2952(90)90587-B; GACHET C, 1990, BIOCHEM PHARMACOL, V40, P229, DOI 10.1016/0006-2952(90)90683-C; GACHET C, 1995, BRIT J HAEMATOL, V91, P434, DOI 10.1111/j.1365-2141.1995.tb05319.x; GarciaCantu E, 1996, AM J CARDIOL, V77, P451, DOI 10.1016/S0002-9149(97)89336-8; Gawaz M, 1996, CIRCULATION, V94, P279, DOI 10.1161/01.CIR.94.3.279; GENT M, 1989, LANCET, V1, P1215, DOI 10.1016/S0140-6736(89)92327-1; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; GENT M, 1997, CIRCULATION S1, V96, P467; GOLDBERG SL, 1995, J AM COLL CARDIOL, V26, P713, DOI 10.1016/0735-1097(95)00219-T; Goods CM, 1996, AM J CARDIOL, V78, P1042, DOI 10.1016/S0002-9149(96)00532-2; Gregorini L, 1997, J AM COLL CARDIOL, V29, P13, DOI 10.1016/S0735-1097(96)00428-7; GRIMM IS, 1994, AM J GASTROENTEROL, V89, P279; Gryglewski RJ, 1996, EUR J PHARMACOL, V308, P61, DOI 10.1016/0014-2999(96)00256-7; Hall P, 1996, CIRCULATION, V93, P215, DOI 10.1161/01.CIR.93.2.215; HARBISON JW, 1996, CARDIOVASCULAR DRUG, P1465; HARDISTY RM, 1990, THROMB HAEMOSTASIS, V64, P150; HARKER LA, 1993, TICLOPIDINE PLATELET, P41; Hasdai D, 1996, J AM COLL CARDIOL, V28, P361, DOI 10.1016/0735-1097(96)00136-2; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; HERBERT JM, 1993, CARDIOVASC DRUG REV, V11, P180, DOI 10.1111/j.1527-3466.1993.tb00275.x; HOURANI SMO, 1994, TRENDS PHARMACOL SCI, V15, P103, DOI 10.1016/0165-6147(94)90045-0; Humbert M, 1996, ARTERIOSCL THROM VAS, V16, P1532, DOI 10.1161/01.ATV.16.12.1532; Itoh A, 1997, MAYO CLIN PROC, V72, P101, DOI 10.4065/72.2.101; JANZON L, 1990, J INTERN MED, V227, P301, DOI 10.1111/j.1365-2796.1990.tb00164.x; Kao TW, 1997, ACTA HAEMATOL-BASEL, V98, P211; Karrillon GJ, 1996, CIRCULATION, V94, P1519, DOI 10.1161/01.CIR.94.7.1519; Kataoka K, 1996, CIRCULATION, V94, P3997; Kereiakes DJ, 1996, J AM COLL CARDIOL, V27, P536; Kereiakes DJ, 1997, CIRCULATION, V96, P1117, DOI 10.1161/01.CIR.96.4.1117; Kereiakes DJ, 1996, CIRCULATION, V94, P906, DOI 10.1161/01.CIR.94.5.906; KIRSTEIN P, 1980, ATHEROSCLEROSIS, V36, P471, DOI 10.1016/0021-9150(80)90240-3; Kleiman NS, 1993, J AM COLL CARDIOL, V22, P381, DOI 10.1016/0735-1097(93)90041-X; KOVACS MJ, 1993, ANN PHARMACOTHER, V27, P1060, DOI 10.1177/106002809302700910; Kupfer Y, 1997, NEW ENGL J MED, V337, P1245, DOI 10.1056/NEJM199710233371717; LABLANCHE JM, 1996, CIRCULATION S1, V94, P684; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; LeMay MR, 1996, AM J CARDIOL, V78, P148, DOI 10.1016/S0002-9149(96)90387-2; LEON MB, 1997, J AM COLL CARDIOL  S, V29, pA683; LIMET R, 1987, J THORAC CARDIOV SUR, V94, P773; MACHRAOUI A, 1997, CIRCULATION, V96, P593; MACHRAOUI A, 1997, CIRCULATION S1, V94, P256; Mak KH, 1996, J AM COLL CARDIOL, V27, P494, DOI 10.1016/0735-1097(95)00466-1; Makkar R., 1997, Journal of the American College of Cardiology, V29, p353A; Makkar R., 1997, Journal of the American College of Cardiology, V29, p354A; Manolis AS, 1997, AM J CARDIOL, V79, P494, DOI 10.1016/S0002-9149(96)00792-8; MATCHAR DB, 1994, ANN INTERN MED, V121, P54; MCTAVISH D, 1990, DRUGS, V40, P238, DOI 10.2165/00003495-199040020-00006; MEYER D, 1991, MAYO CLIN PROC, V66, P516, DOI 10.1016/S0025-6196(12)62394-5; MILLS DCB, 1992, ARTERIOSCLER THROMB, V12, P430, DOI 10.1161/01.ATV.12.4.430; MIROUZE J, 1990, ARCH OPHTHALMOL-CHIC, V108, P1577; MOLITERNO DJ, 1997, CIRCULATION S1, V96, P475; Moloney BA, 1993, TICLOPIDINE PLATELET, P117; More RS, 1997, LANCET, V349, P146, DOI 10.1016/S0140-6736(97)22003-9; Moussa I, 1997, J AM COLL CARDIOL, V29, P6, DOI 10.1016/S0735-1097(96)00452-4; Nakamura S, 1997, J AM COLL CARDIOL, V29, P21, DOI 10.1016/S0735-1097(96)00431-7; NASCHITZ JE, 1995, J TOXICOL-CLIN TOXIC, V33, P379, DOI 10.3109/15563659509028930; PAGE Y, 1991, LANCET, V337, P774, DOI 10.1016/0140-6736(91)91383-6; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; PIANA RN, 1994, J AM COLL CARDIOL, V23, P1296, DOI 10.1016/0735-1097(94)90370-0; PREISS JP, 1996, CIRCULATION S1, V94, P685; RANDI ML, 1985, DRUG RES, V35, P1847; Rindone JP, 1996, ARCH INTERN MED, V156, P1113, DOI 10.1001/archinte.1996.00040041113012; Riva R, 1996, NEUROLOGY, V46, P1172, DOI 10.1212/WNL.46.4.1172; ROALD HE, 1994, THROMB HAEMOSTASIS, V71, P655; ROSEN H, 1995, AM J KIDNEY DIS, V25, P934, DOI 10.1016/0272-6386(95)90578-2; Roy PR, 1996, AM J CARDIOL, V77, P1105, DOI 10.1016/S0002-9149(96)00141-5; RUIZVALVERDE P, 1995, ANN PHARMACOTHER, V29, P633, DOI 10.1177/106002809502900618; Rupprecht HJ, 1996, CIRCULATION, V94, P1502; RUSSO RJ, 1997, CIRCULATION S1, V94, P654; SALTIEL E, 1987, DRUGS, V34, P222, DOI 10.2165/00003495-198734020-00003; Savage MP, 1997, NEW ENGL J MED, V337, P740, DOI 10.1056/NEJM199709113371103; Savi P, 1998, FEBS LETT, V422, P291, DOI 10.1016/S0014-5793(98)00025-8; Schafer AI, 1996, AM J MED, V101, P199, DOI 10.1016/S0002-9343(96)80077-5; SCHATZ RA, 1991, CIRCULATION, V83, P148, DOI 10.1161/01.CIR.83.1.148; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Schomig A, 1997, J AM COLL CARDIOL, V29, P28, DOI 10.1016/S0735-1097(96)00450-0; SCHUHLEN H, 1996, CIRCULATION S1, V94, P257; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; Serruys PW, 1996, CIRCULATION, V93, P412, DOI 10.1161/01.CIR.93.3.412; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SHAH J, 1990, J CLIN PHARMACOL, V30, P733, DOI 10.1002/j.1552-4604.1990.tb03635.x; SHEAR NH, 1995, NEW ENGL J MED, V333, P460; Sheffield JVL, 1998, NEW ENGL J MED, V338, P548; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; Sirnes PA, 1996, J AM COLL CARDIOL, V28, P1444, DOI 10.1016/S0735-1097(96)00349-X; Steffenino G, 1996, AM HEART J, V132, P1115, DOI 10.1016/S0002-8703(96)90453-6; Stone GW, 1998, J AM COLL CARDIOL, V31, P23, DOI 10.1016/S0735-1097(97)00439-7; TAKISHITA S, 1990, NEW ENGL J MED, V323, P1487; TANAHASHI N, 1993, STROKE, V24, P1083, DOI 10.1161/01.STR.24.7.1083; Teirstein PS, 1997, NEW ENGL J MED, V336, P1697, DOI 10.1056/NEJM199706123362402; TEITELBAUM P, 1993, TICLOPIDINE PLATELET, P27; THEBAULT JJ, 1977, J INT MED RES, V5, P405; TOHGI H, 1994, STROKE, V25, P2017, DOI 10.1161/01.STR.25.10.2017; UCHIYAMA S, 1989, STROKE, V20, P1643, DOI 10.1161/01.STR.20.12.1643; Valeix BH, 1996, CIRCULATION, V94, P3377; VERSTRAETE M, 1995, DRUGS, V49, P856, DOI 10.2165/00003495-199549060-00002; Vom Dahl J., 1997, Journal of the American College of Cardiology, V29, p98A; WONG SC, 1995, J AM COLL CARDIOL, V26, P704, DOI 10.1016/0735-1097(95)00217-R; Wysowksi DK, 1996, JAMA-J AM MED ASSOC, V276, P952, DOI 10.1001/jama.1996.03540120030022; Yeh SP, 1998, ANN HEMATOL, V76, P87, DOI 10.1007/s002770050369	142	236	243	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1998	129	5					394	405		10.7326/0003-4819-129-5-199809010-00009	http://dx.doi.org/10.7326/0003-4819-129-5-199809010-00009			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114RL	9735068				2022-12-28	WOS:000075622600008
J	Ioannidis, JPA; Lau, J				Ioannidis, JPA; Lau, J			Can quality of clinical trials and meta-analyses be quantified?	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED TRIALS		NIAID, Therapeut Res Program, DAIDS, NIH, Rockville, MD 20852 USA; Tufts Univ, Sch Med, New England Med Ctr Hosp, Div Clin Care Res, Boston, MA 02111 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Tufts Medical Center; Tufts University	Ioannidis, JPA (corresponding author), NIAID, Therapeut Res Program, DAIDS, NIH, Rockville, MD 20852 USA.		Ioannidis, John P. A./G-9836-2011					Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P281, DOI 10.1001/jama.279.4.281; Ioannidis JPA, 1997, J CLIN EPIDEMIOL, V50, P1089, DOI 10.1016/S0895-4356(97)00149-2; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; Moher D, 1996, INT J TECHNOL ASSESS, V12, P195, DOI 10.1017/S0266462300009570; SCHMID CH, IN PRESS STAT MED; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408	7	57	58	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 22	1998	352	9128					590	591		10.1016/S0140-6736(98)22034-4	http://dx.doi.org/10.1016/S0140-6736(98)22034-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746014				2022-12-28	WOS:000075567400002
J	Abraham, E; Anzueto, A; Gutierrez, G; Tessler, S; San Pedro, G; Wunderink, R; Dal Nogare, A; Nasraway, S; Berman, S; Cooney, R; Levy, H; Baughman, R; Rumbak, M; Light, RB; Poole, L; Allred, R; Constant, J; Pennington, J; Porter, S				Abraham, E; Anzueto, A; Gutierrez, G; Tessler, S; San Pedro, G; Wunderink, R; Dal Nogare, A; Nasraway, S; Berman, S; Cooney, R; Levy, H; Baughman, R; Rumbak, M; Light, RB; Poole, L; Allred, R; Constant, J; Pennington, J; Porter, S		NORASEPT II Study Grp	Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock	LANCET			English	Article							LETHAL BACTEREMIA; SEPSIS SYNDROME; CLINICAL-TRIAL; FACTOR-ALPHA; TNF-ALPHA; MULTICENTER; EFFICACY; PRIMATES; THERAPY; DISEASE	Background Despite the availability of potent antibiotics and intensive care, mortality rates from septic shock are 40-70%, We assessed the safety and efficacy of murine monoclonal antibody to human tumour necrosis factor alpha (TNF alpha MAb) in the treatment of septic shock. Methods In a randomised, multicentre, double-blind, placebo-controlled clinical trial in 105 hospitals in the USA and Canada, we randomly assigned 1879 patients a single infusion of 7.5 mg/kg TNF alpha MAb (n=949) or placebo (0.25% human serum albumin n=930). Our main outcome measurement was the rate of all-cause mortality at 28 days. Findings 382 (40.3%) of 948 patients who received TNF alpha MAb and 398 (42.8%) of 930 who received placebo had died at 28 days (95% CI -0.02 to 0.07, p=0.27). We found no association between therapy with TNF alpha MAb and increased rapidity in reversal of initial shock or prevention of subsequent shock. Similarly, baseline plasma interleukin-6 concentrations of more than 1000 pg/mL or detectable circulating TNF concentrations were not associated with improvement in survival after TNF alpha MAb therapy. Coagulopathy but not other organ or system failures, was significantly decreased in the TNF alpha MAb group compared with placebo (day 7, p < 0.001; day 28, p = 0.005). Serious adverse events were reported in 55.2% of patients given placebo and 54.1% in the TNF alpha M4b group. Interpretation We did not find an improvement in survival after septic shock with TNF alpha MAb. Therapy not solely dependent on TNF alpha blockade may be required to improve survival.	Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; S Texas Hlth Care Syst, Audie L Murphy Mem VA Hosp Div, San Antonio, TX USA; Hermann Hosp, Houston, TX USA; Maimonides Med Ctr, Brooklyn, NY 11219 USA; Louisiana State Univ, Med Ctr, Shreveport, LA USA; Univ Tennessee, Memphis, TN USA; Univ Texas, SW Med Ctr, Dallas, TX USA; New England Med Ctr, Boston, MA 02111 USA; Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA; Milton S Hershey Med Ctr, Hershey, PA USA; Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA; Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA; Univ S Florida, Hlth Sci Ctr, Tampa, FL USA; Univ Manitoba, Winnipeg, MB, Canada; Bayer Corp, Berkeley, CA USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Texas System; University of Texas Health San Antonio; Maimonides Medical Center; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Tennessee System; University of Tennessee Health Science Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tufts Medical Center; University of Hawaii System; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of New Mexico; University of New Mexico's Health Sciences Center; University System of Ohio; University of Cincinnati; State University System of Florida; University of South Florida; University of Manitoba; Bayer AG	Abraham, E (corresponding author), Univ Colorado, Hlth Sci Ctr, Box C272,4200 E 9th Ave, Denver, CO 80262 USA.		Gutierrez, Guillermo/ABC-1894-2020	Gutierrez, Guillermo/0000-0001-7754-5816; Wunderink, Richard/0000-0002-8527-4195				ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; Abraham E, 1997, JAMA-J AM MED ASSOC, V277, P1531, DOI 10.1001/jama.277.19.1531; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; Cohen J, 1996, CRIT CARE MED, V24, P1431, DOI 10.1097/00003246-199609000-00002; FONG YM, 1989, J EXP MED, V170, P1627, DOI 10.1084/jem.170.5.1627; GALLOWAY CJ, 1991, J IMMUNOL METHODS, V140, P37, DOI 10.1016/0022-1759(91)90124-X; HINSHAW LB, 1992, J TRAUMA, V33, P568, DOI 10.1097/00005373-199210000-00013; HINSHAW LB, 1990, CIRC SHOCK, V30, P279; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; OPAL SM, 1990, J INFECT DIS, V161, P1148, DOI 10.1093/infdis/161.6.1148; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; PARRILLO JE, 1991, ANN INTERN MED, V115, P491, DOI 10.7326/0003-4819-115-6-491; PAULI U, 1994, J IMMUNOL METHODS, V171, P263, DOI 10.1016/0022-1759(94)90047-7; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; Reinhart K, 1996, CRIT CARE MED, V24, P733, DOI 10.1097/00003246-199605000-00003; Sands KE, 1997, JAMA-J AM MED ASSOC, V278, P234, DOI 10.1001/jama.278.3.234; SHERMAN ML, 1988, J CLIN ONCOL, V6, P344, DOI 10.1200/JCO.1988.6.2.344; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302; WENZEL RP, 1992, NEW ENGL J MED, V326, P1151, DOI 10.1056/NEJM199204233261710; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	25	494	521	1	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 28	1998	351	9107					929	933						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734938				2022-12-28	WOS:000072770900009
J	Nightingale, SL				Nightingale, SL			Thalidomide approved for erythema nodosum leprosum	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	17	19	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1998	280	10					872	872		10.1001/jama.280.10.872	http://dx.doi.org/10.1001/jama.280.10.872			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115LN	9739956				2022-12-28	WOS:000075666600006
J	Nightingale, SL				Nightingale, SL			FDA seeks input from stakeholders	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	17	19	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1998	280	10					872	872		10.1001/jama.280.10.872	http://dx.doi.org/10.1001/jama.280.10.872			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115LN	9739956				2022-12-28	WOS:000075666600045
J	Widdecombe, A				Widdecombe, A			Living wills might make patients at risk of death by starvation and dehydration	BRITISH MEDICAL JOURNAL			English	Letter									House Commons, London SW1A 0AA, England		Widdecombe, A (corresponding author), House Commons, London SW1A 0AA, England.							Dyer C, 1998, BRIT MED J, V316, P959; Gadd E, 1998, BRIT MED J, V316, P90	2	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					819	819		10.1136/bmj.317.7161.819a	http://dx.doi.org/10.1136/bmj.317.7161.819a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9786687	Green Published			2022-12-28	WOS:000076084200074
J	Heymann, T				Heymann, T			If devolved facilities are used, processes may be streamlined	BRITISH MEDICAL JOURNAL			English	Letter									Kingston Gen Hosp, Kingston upon Thames KT2 7QB, Surrey, England		Heymann, T (corresponding author), Kingston Gen Hosp, Kingston upon Thames KT2 7QB, Surrey, England.							BLACK A, 1994, HLTH SERVICE J  0623; Kendall J, 1998, BRIT MED J, V316, P1052	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					818	819		10.1136/bmj.317.7161.818b	http://dx.doi.org/10.1136/bmj.317.7161.818b			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740580	Green Published			2022-12-28	WOS:000076084200071
J	Armstrong, E				Armstrong, E			Safety of patients participating in drug trials - Use of placebo in trials of drugs for mental illness should be debated	BRITISH MEDICAL JOURNAL			English	Letter											Armstrong, E (corresponding author), Hyde Pk Gate, London SW7 5DZ, England.							Baldessarini RJ, 1996, J CLIN PSYCHIAT, V57, P441, DOI 10.4088/JCP.v57n1001; POST R, 1997, BIPOLAR DISORDER BIO, P120	2	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					818	818		10.1136/bmj.317.7161.818a	http://dx.doi.org/10.1136/bmj.317.7161.818a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740579				2022-12-28	WOS:000076084200069
J	Kandela, P				Kandela, P			Khartoum - Heat and dust in Sudan	LANCET			English	News Item																			0	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1497	1497		10.1016/S0140-6736(05)78885-1	http://dx.doi.org/10.1016/S0140-6736(05)78885-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605817				2022-12-28	WOS:000073707300032
